<?xml version = '1.0' encoding = 'utf-8'?>
<!--Generated by Oracle BI Publisher 11.1.1.7.1-->
<DATA_DS>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4728815.36</REVENUE>
<PREV_YEAR_REV>3653090.4</PREV_YEAR_REV>
<BUDGET>4634239.05</BUDGET>
<GROSS_PROFIT>3696543.36</GROSS_PROFIT>
<EXPENSES>4091833.9</EXPENSES>
<NET_INCOME>636981.46</NET_INCOME>
<REVENUE_M>4.72881536</REVENUE_M>
<PROFIT_M>3.69654336</PROFIT_M>
<INCOME_M>0.63698146</INCOME_M>
<PHARMA_REV_M>4.72881536</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.69654336</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.63698146</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>5024637.36</REVENUE>
<PREV_YEAR_REV>4172355.44</PREV_YEAR_REV>
<BUDGET>4924144.61</BUDGET>
<GROSS_PROFIT>4115635.07</GROSS_PROFIT>
<EXPENSES>4356809.43</EXPENSES>
<NET_INCOME>667827.93</NET_INCOME>
<REVENUE_M>5.02463736</REVENUE_M>
<PROFIT_M>4.11563507</PROFIT_M>
<INCOME_M>0.66782793</INCOME_M>
<PHARMA_REV_M>5.02463736</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.11563507</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.66782793</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2451308</REVENUE>
<PREV_YEAR_REV>2076464.61</PREV_YEAR_REV>
<BUDGET>2402281.84</BUDGET>
<GROSS_PROFIT>1923541.39</GROSS_PROFIT>
<EXPENSES>2029683.02</EXPENSES>
<NET_INCOME>421624.98</NET_INCOME>
<REVENUE_M>2.451308</REVENUE_M>
<PROFIT_M>1.92354139</PROFIT_M>
<INCOME_M>0.42162498</INCOME_M>
<PHARMA_REV_M>2.451308</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.92354139</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42162498</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>8093856.2</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>7446347.7</BUDGET>
<GROSS_PROFIT>6440251.828</GROSS_PROFIT>
<EXPENSES>7203785.53</EXPENSES>
<NET_INCOME>890070.66</NET_INCOME>
<REVENUE_M>8.0938562</REVENUE_M>
<PROFIT_M>6.440251828</PROFIT_M>
<INCOME_M>0.89007066</INCOME_M>
<PHARMA_REV_M>8.0938562</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.440251828</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.89007066</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>2.288071213E7</REVENUE>
<PREV_YEAR_REV>1.874998204E7</PREV_YEAR_REV>
<BUDGET>2.105025516E7</BUDGET>
<GROSS_PROFIT>1.853004883E7</GROSS_PROFIT>
<EXPENSES>2.035682612E7</EXPENSES>
<NET_INCOME>2523886.01</NET_INCOME>
<REVENUE_M>22.88071213</REVENUE_M>
<PROFIT_M>18.53004883</PROFIT_M>
<INCOME_M>2.52388601</INCOME_M>
<PHARMA_REV_M>22.88071213</PHARMA_REV_M>
<PHARMA_PROFIT_M>18.53004883</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.52388601</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.501758465E7</REVENUE>
<PREV_YEAR_REV>1.251504258E7</PREV_YEAR_REV>
<BUDGET>1.381617788E7</BUDGET>
<GROSS_PROFIT>1.228552087E7</GROSS_PROFIT>
<EXPENSES>1.341124757E7</EXPENSES>
<NET_INCOME>1606337.08</NET_INCOME>
<REVENUE_M>15.01758465</REVENUE_M>
<PROFIT_M>12.28552087</PROFIT_M>
<INCOME_M>1.60633708</INCOME_M>
<PHARMA_REV_M>15.01758465</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.28552087</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.60633708</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>9415354.13</REVENUE>
<PREV_YEAR_REV>7524698.4</PREV_YEAR_REV>
<BUDGET>8662125.8</BUDGET>
<GROSS_PROFIT>8216214.62</GROSS_PROFIT>
<EXPENSES>8172527.38</EXPENSES>
<NET_INCOME>1242826.74</NET_INCOME>
<REVENUE_M>9.41535413</REVENUE_M>
<PROFIT_M>8.21621462</PROFIT_M>
<INCOME_M>1.24282674</INCOME_M>
<PHARMA_REV_M>9.41535413</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.21621462</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.24282674</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>2.467098255E7</REVENUE>
<PREV_YEAR_REV>20127060</PREV_YEAR_REV>
<BUDGET>2.269730395E7</BUDGET>
<GROSS_PROFIT>2.101167571E7</GROSS_PROFIT>
<EXPENSES>2.139032532E7</EXPENSES>
<NET_INCOME>3280657.23</NET_INCOME>
<REVENUE_M>24.67098255</REVENUE_M>
<PROFIT_M>21.01167571</PROFIT_M>
<INCOME_M>3.28065723</INCOME_M>
<PHARMA_REV_M>24.67098255</PHARMA_REV_M>
<PHARMA_PROFIT_M>21.01167571</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>3.28065723</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>3.430397738E7</REVENUE>
<PREV_YEAR_REV>2.606805003E7</PREV_YEAR_REV>
<BUDGET>2.879965919E7</BUDGET>
<GROSS_PROFIT>2.717564687E7</GROSS_PROFIT>
<EXPENSES>2.828486174E7</EXPENSES>
<NET_INCOME>3019115.64</NET_INCOME>
<REVENUE_M>34.30397738</REVENUE_M>
<PROFIT_M>27.17564687</PROFIT_M>
<INCOME_M>3.01911564</INCOME_M>
<PHARMA_REV_M>34.30397738</PHARMA_REV_M>
<PHARMA_PROFIT_M>27.17564687</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>3.01911564</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>4972287.25</REVENUE>
<PREV_YEAR_REV>7626207.44</PREV_YEAR_REV>
<BUDGET>4574504.27</BUDGET>
<GROSS_PROFIT>4166776.72</GROSS_PROFIT>
<EXPENSES>4609310.28</EXPENSES>
<NET_INCOME>362976.97</NET_INCOME>
<REVENUE_M>4.97228725</REVENUE_M>
<PROFIT_M>4.16677672</PROFIT_M>
<INCOME_M>0.36297697</INCOME_M>
<PHARMA_REV_M>4.97228725</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.16677672</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36297697</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.09957795E7</REVENUE>
<PREV_YEAR_REV>1.09799673E7</PREV_YEAR_REV>
<BUDGET>1.195611714E7</BUDGET>
<GROSS_PROFIT>1.008667426E7</GROSS_PROFIT>
<EXPENSES>1.167020999E7</EXPENSES>
<NET_INCOME>1325569.51</NET_INCOME>
<REVENUE_M>10.9957795</REVENUE_M>
<PROFIT_M>10.08667426</PROFIT_M>
<INCOME_M>1.32556951</INCOME_M>
<PHARMA_REV_M>10.9957795</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.08667426</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.32556951</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.173079788E7</REVENUE>
<PREV_YEAR_REV>1.059425456E7</PREV_YEAR_REV>
<BUDGET>1.171233405E7</BUDGET>
<GROSS_PROFIT>9327269.989</GROSS_PROFIT>
<EXPENSES>1.101214016E7</EXPENSES>
<NET_INCOME>1718657.71</NET_INCOME>
<REVENUE_M>11.73079788</REVENUE_M>
<PROFIT_M>9.327269989</PROFIT_M>
<INCOME_M>1.71865771</INCOME_M>
<PHARMA_REV_M>11.73079788</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.327269989</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.71865771</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>4498934.22</REVENUE>
<PREV_YEAR_REV>1.048702615E7</PREV_YEAR_REV>
<BUDGET>4139019.48</BUDGET>
<GROSS_PROFIT>3598697.48</GROSS_PROFIT>
<EXPENSES>4040042.93</EXPENSES>
<NET_INCOME>458891.29</NET_INCOME>
<REVENUE_M>4.49893422</REVENUE_M>
<PROFIT_M>3.59869748</PROFIT_M>
<INCOME_M>0.45889129</INCOME_M>
<PHARMA_REV_M>4.49893422</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.59869748</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45889129</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>1.421151772E7</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>1.36265963E7</BUDGET>
<GROSS_PROFIT>1.215898269E7</GROSS_PROFIT>
<EXPENSES>1.288729377E7</EXPENSES>
<NET_INCOME>1924223.94</NET_INCOME>
<REVENUE_M>14.21151772</REVENUE_M>
<PROFIT_M>12.15898269</PROFIT_M>
<INCOME_M>1.92422394</INCOME_M>
<PHARMA_REV_M>14.21151772</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.15898269</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.92422394</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3409834.42</REVENUE>
<PREV_YEAR_REV>2923181.19</PREV_YEAR_REV>
<BUDGET>3339937.5</BUDGET>
<GROSS_PROFIT>2854197.357</GROSS_PROFIT>
<EXPENSES>3046536.28</EXPENSES>
<NET_INCOME>463298.14</NET_INCOME>
<REVENUE_M>3.40983442</REVENUE_M>
<PROFIT_M>2.854197357</PROFIT_M>
<INCOME_M>0.46329814</INCOME_M>
<PHARMA_REV_M>3.40983442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.854197357</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46329814</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1.097509076E7</REVENUE>
<PREV_YEAR_REV>8893392.05</PREV_YEAR_REV>
<BUDGET>1.025066476E7</BUDGET>
<GROSS_PROFIT>8753702.715</GROSS_PROFIT>
<EXPENSES>9730891.62</EXPENSES>
<NET_INCOME>1044199.15</NET_INCOME>
<REVENUE_M>10.97509076</REVENUE_M>
<PROFIT_M>8.753702715</PROFIT_M>
<INCOME_M>1.04419915</INCOME_M>
<PHARMA_REV_M>10.97509076</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.753702715</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.04419915</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1231487.07</REVENUE>
<PREV_YEAR_REV>1158686.78</PREV_YEAR_REV>
<BUDGET>984433.86</BUDGET>
<GROSS_PROFIT>1060310.37</GROSS_PROFIT>
<EXPENSES>1068930.78</EXPENSES>
<NET_INCOME>162556.29</NET_INCOME>
<REVENUE_M>1.23148707</REVENUE_M>
<PROFIT_M>1.06031037</PROFIT_M>
<INCOME_M>0.16255629</INCOME_M>
<PHARMA_REV_M>1.23148707</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.06031037</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16255629</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2682367.07</REVENUE>
<PREV_YEAR_REV>2499840.61</PREV_YEAR_REV>
<BUDGET>2214658.25</BUDGET>
<GROSS_PROFIT>1993078.395</GROSS_PROFIT>
<EXPENSES>2355379.96</EXPENSES>
<NET_INCOME>326987.1</NET_INCOME>
<REVENUE_M>2.68236707</REVENUE_M>
<PROFIT_M>1.993078395</PROFIT_M>
<INCOME_M>0.3269871</INCOME_M>
<PHARMA_REV_M>2.68236707</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.993078395</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3269871</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2048961.48</REVENUE>
<PREV_YEAR_REV>1904211.45</PREV_YEAR_REV>
<BUDGET>1713764.45</BUDGET>
<GROSS_PROFIT>1632144.375</GROSS_PROFIT>
<EXPENSES>1774747.87</EXPENSES>
<NET_INCOME>274213.61</NET_INCOME>
<REVENUE_M>2.04896148</REVENUE_M>
<PROFIT_M>1.632144375</PROFIT_M>
<INCOME_M>0.27421361</INCOME_M>
<PHARMA_REV_M>2.04896148</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.632144375</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27421361</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1166305.89</REVENUE>
<PREV_YEAR_REV>1078444.98</PREV_YEAR_REV>
<BUDGET>1010030.43</BUDGET>
<GROSS_PROFIT>895755.0038</GROSS_PROFIT>
<EXPENSES>1047342.69</EXPENSES>
<NET_INCOME>118963.2</NET_INCOME>
<REVENUE_M>1.16630589</REVENUE_M>
<PROFIT_M>0.895755004</PROFIT_M>
<INCOME_M>0.1189632</INCOME_M>
<PHARMA_REV_M>1.16630589</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.895755004</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1189632</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.488451489E7</REVENUE>
<PREV_YEAR_REV>1.40020371E7</PREV_YEAR_REV>
<BUDGET>7297515.1</BUDGET>
<GROSS_PROFIT>1.09806913E7</GROSS_PROFIT>
<EXPENSES>6864225.14</EXPENSES>
<NET_INCOME>1640437.24</NET_INCOME>
<REVENUE_M>14.88451489</REVENUE_M>
<PROFIT_M>10.9806913</PROFIT_M>
<INCOME_M>1.64043724</INCOME_M>
<PHARMA_REV_M>14.88451489</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.9806913</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.64043724</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8811018.87</REVENUE>
<PREV_YEAR_REV>8348115.84</PREV_YEAR_REV>
<BUDGET>8458578.11</BUDGET>
<GROSS_PROFIT>6652319.24</GROSS_PROFIT>
<EXPENSES>7647964.38</EXPENSES>
<NET_INCOME>1163054.49</NET_INCOME>
<REVENUE_M>8.81101887</REVENUE_M>
<PROFIT_M>6.65231924</PROFIT_M>
<INCOME_M>1.16305449</INCOME_M>
<PHARMA_REV_M>8.81101887</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.65231924</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.16305449</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7618135.36</REVENUE>
<PREV_YEAR_REV>7184615.65</PREV_YEAR_REV>
<BUDGET>7313409.94</BUDGET>
<GROSS_PROFIT>5265655.164</GROSS_PROFIT>
<EXPENSES>6635395.9</EXPENSES>
<NET_INCOME>982739.46</NET_INCOME>
<REVENUE_M>7.61813536</REVENUE_M>
<PROFIT_M>5.265655164</PROFIT_M>
<INCOME_M>0.98273946</INCOME_M>
<PHARMA_REV_M>7.61813536</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.265655164</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.98273946</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6531012.58</REVENUE>
<PREV_YEAR_REV>6057385.6</PREV_YEAR_REV>
<BUDGET>6269772.07</BUDGET>
<GROSS_PROFIT>4894471.443</GROSS_PROFIT>
<EXPENSES>6054248.66</EXPENSES>
<NET_INCOME>476763.92</NET_INCOME>
<REVENUE_M>6.53101258</REVENUE_M>
<PROFIT_M>4.894471443</PROFIT_M>
<INCOME_M>0.47676392</INCOME_M>
<PHARMA_REV_M>6.53101258</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.894471443</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47676392</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5297173.7</REVENUE>
<PREV_YEAR_REV>4967668.27</PREV_YEAR_REV>
<BUDGET>5085286.76</BUDGET>
<GROSS_PROFIT>3914611.37</GROSS_PROFIT>
<EXPENSES>4910480.02</EXPENSES>
<NET_INCOME>386693.68</NET_INCOME>
<REVENUE_M>5.2971737</REVENUE_M>
<PROFIT_M>3.91461137</PROFIT_M>
<INCOME_M>0.38669368</INCOME_M>
<PHARMA_REV_M>5.2971737</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.91461137</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38669368</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.52892648E7</REVENUE>
<PREV_YEAR_REV>1.439313944E7</PREV_YEAR_REV>
<BUDGET>1.46776942E7</BUDGET>
<GROSS_PROFIT>1.011391024E7</GROSS_PROFIT>
<EXPENSES>1.326596198E7</EXPENSES>
<NET_INCOME>2023302.82</NET_INCOME>
<REVENUE_M>15.2892648</REVENUE_M>
<PROFIT_M>10.11391024</PROFIT_M>
<INCOME_M>2.02330282</INCOME_M>
<PHARMA_REV_M>15.2892648</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.11391024</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.02330282</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3928617.9</REVENUE>
<PREV_YEAR_REV>3666257.45</PREV_YEAR_REV>
<BUDGET>3743182.17</BUDGET>
<GROSS_PROFIT>2594482.9</GROSS_PROFIT>
<EXPENSES>3456065.51</EXPENSES>
<NET_INCOME>472552.39</NET_INCOME>
<REVENUE_M>3.9286179</REVENUE_M>
<PROFIT_M>2.5944829</PROFIT_M>
<INCOME_M>0.47255239</INCOME_M>
<PHARMA_REV_M>3.9286179</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.5944829</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47255239</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3445707</REVENUE>
<PREV_YEAR_REV>3221404.3</PREV_YEAR_REV>
<BUDGET>3270665.04</BUDGET>
<GROSS_PROFIT>2202459.068</GROSS_PROFIT>
<EXPENSES>2939249.1</EXPENSES>
<NET_INCOME>506457.9</NET_INCOME>
<REVENUE_M>3.445707</REVENUE_M>
<PROFIT_M>2.202459068</PROFIT_M>
<INCOME_M>0.5064579</INCOME_M>
<PHARMA_REV_M>3.445707</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.202459068</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5064579</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2079109.77</REVENUE>
<PREV_YEAR_REV>1919290.45</PREV_YEAR_REV>
<BUDGET>1967796.63</BUDGET>
<GROSS_PROFIT>1547626.939</GROSS_PROFIT>
<EXPENSES>1706949.12</EXPENSES>
<NET_INCOME>372160.65</NET_INCOME>
<REVENUE_M>2.07910977</REVENUE_M>
<PROFIT_M>1.547626939</PROFIT_M>
<INCOME_M>0.37216065</INCOME_M>
<PHARMA_REV_M>2.07910977</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.547626939</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37216065</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4216939.26</REVENUE>
<PREV_YEAR_REV>3944793.61</PREV_YEAR_REV>
<BUDGET>3874423.63</BUDGET>
<GROSS_PROFIT>2726694.627</GROSS_PROFIT>
<EXPENSES>3660826.57</EXPENSES>
<NET_INCOME>556112.69</NET_INCOME>
<REVENUE_M>4.21693926</REVENUE_M>
<PROFIT_M>2.726694627</PROFIT_M>
<INCOME_M>0.55611269</INCOME_M>
<PHARMA_REV_M>4.21693926</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.726694627</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55611269</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2082248.86</REVENUE>
<PREV_YEAR_REV>1953237.52</PREV_YEAR_REV>
<BUDGET>1865378.01</BUDGET>
<GROSS_PROFIT>1271937.548</GROSS_PROFIT>
<EXPENSES>1801145.26</EXPENSES>
<NET_INCOME>281103.6</NET_INCOME>
<REVENUE_M>2.08224886</REVENUE_M>
<PROFIT_M>1.271937548</PROFIT_M>
<INCOME_M>0.2811036</INCOME_M>
<PHARMA_REV_M>2.08224886</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.271937548</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2811036</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2055004.28</REVENUE>
<PREV_YEAR_REV>1932284.87</PREV_YEAR_REV>
<BUDGET>1894210.55</BUDGET>
<GROSS_PROFIT>1415573.256</GROSS_PROFIT>
<EXPENSES>1777578.7</EXPENSES>
<NET_INCOME>277425.58</NET_INCOME>
<REVENUE_M>2.05500428</REVENUE_M>
<PROFIT_M>1.415573256</PROFIT_M>
<INCOME_M>0.27742558</INCOME_M>
<PHARMA_REV_M>2.05500428</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.415573256</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27742558</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4272543.79</REVENUE>
<PREV_YEAR_REV>4017606.18</PREV_YEAR_REV>
<BUDGET>3879083.43</BUDGET>
<GROSS_PROFIT>2817169.74</GROSS_PROFIT>
<EXPENSES>3704702.96</EXPENSES>
<NET_INCOME>567840.82</NET_INCOME>
<REVENUE_M>4.27254379</REVENUE_M>
<PROFIT_M>2.81716974</PROFIT_M>
<INCOME_M>0.56784082</INCOME_M>
<PHARMA_REV_M>4.27254379</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.81716974</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56784082</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2116324.57</REVENUE>
<PREV_YEAR_REV>1966277.9</PREV_YEAR_REV>
<BUDGET>1972650.6</BUDGET>
<GROSS_PROFIT>1516092.595</GROSS_PROFIT>
<EXPENSES>1885645.19</EXPENSES>
<NET_INCOME>230679.38</NET_INCOME>
<REVENUE_M>2.11632457</REVENUE_M>
<PROFIT_M>1.516092595</PROFIT_M>
<INCOME_M>0.23067938</INCOME_M>
<PHARMA_REV_M>2.11632457</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.516092595</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23067938</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2858204.7</REVENUE>
<PREV_YEAR_REV>2650498.8</PREV_YEAR_REV>
<BUDGET>3353441.3</BUDGET>
<GROSS_PROFIT>1937416.9</GROSS_PROFIT>
<EXPENSES>2474041.21</EXPENSES>
<NET_INCOME>384163.5</NET_INCOME>
<REVENUE_M>2.8582047</REVENUE_M>
<PROFIT_M>1.9374169</PROFIT_M>
<INCOME_M>0.3841635</INCOME_M>
<PHARMA_REV_M>2.8582047</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.9374169</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3841635</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.430185902E7</REVENUE>
<PREV_YEAR_REV>1.28753225E7</PREV_YEAR_REV>
<BUDGET>1.573204493E7</BUDGET>
<GROSS_PROFIT>1.17974477E7</GROSS_PROFIT>
<EXPENSES>1.269631646E7</EXPENSES>
<NET_INCOME>1605542.56</NET_INCOME>
<REVENUE_M>14.30185902</REVENUE_M>
<PROFIT_M>11.7974477</PROFIT_M>
<INCOME_M>1.60554256</INCOME_M>
<PHARMA_REV_M>14.30185902</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.7974477</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.60554256</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8235845.71</REVENUE>
<PREV_YEAR_REV>7544954.25</PREV_YEAR_REV>
<BUDGET>9059430.28</BUDGET>
<GROSS_PROFIT>6975761.32</GROSS_PROFIT>
<EXPENSES>7148714.08</EXPENSES>
<NET_INCOME>1087131.63</NET_INCOME>
<REVENUE_M>8.23584571</REVENUE_M>
<PROFIT_M>6.97576132</PROFIT_M>
<INCOME_M>1.08713163</INCOME_M>
<PHARMA_REV_M>8.23584571</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.97576132</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.08713163</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.197686171E7</REVENUE>
<PREV_YEAR_REV>1.087976323E7</PREV_YEAR_REV>
<BUDGET>1.317454788E7</BUDGET>
<GROSS_PROFIT>9432425.781</GROSS_PROFIT>
<EXPENSES>1.019218544E7</EXPENSES>
<NET_INCOME>1784676.27</NET_INCOME>
<REVENUE_M>11.97686171</REVENUE_M>
<PROFIT_M>9.432425781</PROFIT_M>
<INCOME_M>1.78467627</INCOME_M>
<PHARMA_REV_M>11.97686171</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.432425781</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.78467627</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4388981.94</REVENUE>
<PREV_YEAR_REV>4085159.87</PREV_YEAR_REV>
<BUDGET>5095488.4</BUDGET>
<GROSS_PROFIT>2960218.65</GROSS_PROFIT>
<EXPENSES>3964993.95</EXPENSES>
<NET_INCOME>423987.97</NET_INCOME>
<REVENUE_M>4.38898194</REVENUE_M>
<PROFIT_M>2.96021865</PROFIT_M>
<INCOME_M>0.42398797</INCOME_M>
<PHARMA_REV_M>4.38898194</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.96021865</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42398797</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1295264.67</REVENUE>
<PREV_YEAR_REV>1213612.81</PREV_YEAR_REV>
<BUDGET>1536061.24</BUDGET>
<GROSS_PROFIT>918601.704</GROSS_PROFIT>
<EXPENSES>1120403.94</EXPENSES>
<NET_INCOME>174860.73</NET_INCOME>
<REVENUE_M>1.29526467</REVENUE_M>
<PROFIT_M>0.918601704</PROFIT_M>
<INCOME_M>0.17486073</INCOME_M>
<PHARMA_REV_M>1.29526467</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.918601704</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17486073</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8561207.59</REVENUE>
<PREV_YEAR_REV>7689316.04</PREV_YEAR_REV>
<BUDGET>8218759.29</BUDGET>
<GROSS_PROFIT>5971442.292</GROSS_PROFIT>
<EXPENSES>7456811.81</EXPENSES>
<NET_INCOME>1104395.78</NET_INCOME>
<REVENUE_M>8.56120759</REVENUE_M>
<PROFIT_M>5.971442292</PROFIT_M>
<INCOME_M>1.10439578</INCOME_M>
<PHARMA_REV_M>8.56120759</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.971442292</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.10439578</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5492071.86</REVENUE>
<PREV_YEAR_REV>4994154.65</PREV_YEAR_REV>
<BUDGET>5272388.99</BUDGET>
<GROSS_PROFIT>4124545.97</GROSS_PROFIT>
<EXPENSES>5091150.62</EXPENSES>
<NET_INCOME>400921.25</NET_INCOME>
<REVENUE_M>5.49207186</REVENUE_M>
<PROFIT_M>4.12454597</PROFIT_M>
<INCOME_M>0.40092125</INCOME_M>
<PHARMA_REV_M>5.49207186</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.12454597</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40092125</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1043336.81</REVENUE>
<PREV_YEAR_REV>958517.59</PREV_YEAR_REV>
<BUDGET>1092549.93</BUDGET>
<GROSS_PROFIT>702937.7456</GROSS_PROFIT>
<EXPENSES>902486.34</EXPENSES>
<NET_INCOME>140850.47</NET_INCOME>
<REVENUE_M>1.04333681</REVENUE_M>
<PROFIT_M>0.702937746</PROFIT_M>
<INCOME_M>0.14085047</INCOME_M>
<PHARMA_REV_M>1.04333681</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.702937746</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14085047</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1068810.5</REVENUE>
<PREV_YEAR_REV>989309.58</PREV_YEAR_REV>
<BUDGET>1083348.28</BUDGET>
<GROSS_PROFIT>762810.048</GROSS_PROFIT>
<EXPENSES>924521.08</EXPENSES>
<NET_INCOME>144289.42</NET_INCOME>
<REVENUE_M>1.0688105</REVENUE_M>
<PROFIT_M>0.762810048</PROFIT_M>
<INCOME_M>0.14428942</INCOME_M>
<PHARMA_REV_M>1.0688105</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.762810048</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14428942</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2493472.52</REVENUE>
<PREV_YEAR_REV>2322419.02</PREV_YEAR_REV>
<BUDGET>2328666.27</BUDGET>
<GROSS_PROFIT>1778290.3</GROSS_PROFIT>
<EXPENSES>2161265.4</EXPENSES>
<NET_INCOME>332207.11</NET_INCOME>
<REVENUE_M>2.49347252</REVENUE_M>
<PROFIT_M>1.7782903</PROFIT_M>
<INCOME_M>0.33220711</INCOME_M>
<PHARMA_REV_M>2.49347252</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.7782903</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33220711</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6937313.75</REVENUE>
<PREV_YEAR_REV>6218404.06</PREV_YEAR_REV>
<BUDGET>6659821.2</BUDGET>
<GROSS_PROFIT>4550877.82</GROSS_PROFIT>
<EXPENSES>6021588.34</EXPENSES>
<NET_INCOME>915725.42</NET_INCOME>
<REVENUE_M>6.93731375</REVENUE_M>
<PROFIT_M>4.55087782</PROFIT_M>
<INCOME_M>0.91572542</INCOME_M>
<PHARMA_REV_M>6.93731375</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.55087782</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.91572542</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.602079256E7</REVENUE>
<PREV_YEAR_REV>1.471543053E7</PREV_YEAR_REV>
<BUDGET>1.537996085E7</BUDGET>
<GROSS_PROFIT>1.165836898E7</GROSS_PROFIT>
<EXPENSES>1.447557438E7</EXPENSES>
<NET_INCOME>1545218.2</NET_INCOME>
<REVENUE_M>16.02079256</REVENUE_M>
<PROFIT_M>11.65836898</PROFIT_M>
<INCOME_M>1.5452182</INCOME_M>
<PHARMA_REV_M>16.02079256</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.65836898</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.5452182</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6330993.87</REVENUE>
<PREV_YEAR_REV>5663038.48</PREV_YEAR_REV>
<BUDGET>6077754.11</BUDGET>
<GROSS_PROFIT>4405675.318</GROSS_PROFIT>
<EXPENSES>5868831.31</EXPENSES>
<NET_INCOME>462162.55</NET_INCOME>
<REVENUE_M>6.33099387</REVENUE_M>
<PROFIT_M>4.405675318</PROFIT_M>
<INCOME_M>0.46216255</INCOME_M>
<PHARMA_REV_M>6.33099387</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.405675318</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46216255</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6013238.62</REVENUE>
<PREV_YEAR_REV>5372368.75</PREV_YEAR_REV>
<BUDGET>5772709.07</BUDGET>
<GROSS_PROFIT>3929050.116</GROSS_PROFIT>
<EXPENSES>5201451.4</EXPENSES>
<NET_INCOME>811787.21</NET_INCOME>
<REVENUE_M>6.01323862</REVENUE_M>
<PROFIT_M>3.929050116</PROFIT_M>
<INCOME_M>0.81178721</INCOME_M>
<PHARMA_REV_M>6.01323862</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.929050116</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.81178721</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6104747.16</REVENUE>
<PREV_YEAR_REV>5654166.63</PREV_YEAR_REV>
<BUDGET>5860557.28</BUDGET>
<GROSS_PROFIT>4558414.707</GROSS_PROFIT>
<EXPENSES>5482062.95</EXPENSES>
<NET_INCOME>622684.21</NET_INCOME>
<REVENUE_M>6.10474716</REVENUE_M>
<PROFIT_M>4.558414707</PROFIT_M>
<INCOME_M>0.62268421</INCOME_M>
<PHARMA_REV_M>6.10474716</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.558414707</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62268421</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.466139865E7</REVENUE>
<PREV_YEAR_REV>1.339818893E7</PREV_YEAR_REV>
<BUDGET>1.40749427E7</BUDGET>
<GROSS_PROFIT>1.02185159E7</GROSS_PROFIT>
<EXPENSES>1.272401243E7</EXPENSES>
<NET_INCOME>1937386.21</NET_INCOME>
<REVENUE_M>14.66139865</REVENUE_M>
<PROFIT_M>10.2185159</PROFIT_M>
<INCOME_M>1.93738621</INCOME_M>
<PHARMA_REV_M>14.66139865</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.2185159</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.93738621</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2191384.91</REVENUE>
<PREV_YEAR_REV>2042221.08</PREV_YEAR_REV>
<BUDGET>2115910.36</BUDGET>
<GROSS_PROFIT>1677680.458</GROSS_PROFIT>
<EXPENSES>1799127.01</EXPENSES>
<NET_INCOME>392257.9</NET_INCOME>
<REVENUE_M>2.19138491</REVENUE_M>
<PROFIT_M>1.677680458</PROFIT_M>
<INCOME_M>0.3922579</INCOME_M>
<PHARMA_REV_M>2.19138491</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.677680458</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3922579</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1888511.7</REVENUE>
<PREV_YEAR_REV>1699891.72</PREV_YEAR_REV>
<BUDGET>2044927.67</BUDGET>
<GROSS_PROFIT>1253159.712</GROSS_PROFIT>
<EXPENSES>1682663.93</EXPENSES>
<NET_INCOME>205847.78</NET_INCOME>
<REVENUE_M>1.8885117</REVENUE_M>
<PROFIT_M>1.253159712</PROFIT_M>
<INCOME_M>0.20584778</INCOME_M>
<PHARMA_REV_M>1.8885117</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.253159712</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20584778</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2030354.22</REVENUE>
<PREV_YEAR_REV>1851414.96</PREV_YEAR_REV>
<BUDGET>2121129.67</BUDGET>
<GROSS_PROFIT>1402771.726</GROSS_PROFIT>
<EXPENSES>1809045.61</EXPENSES>
<NET_INCOME>221308.61</NET_INCOME>
<REVENUE_M>2.03035422</REVENUE_M>
<PROFIT_M>1.402771726</PROFIT_M>
<INCOME_M>0.22130861</INCOME_M>
<PHARMA_REV_M>2.03035422</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.402771726</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22130861</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1469352.82</REVENUE>
<PREV_YEAR_REV>1351216.01</PREV_YEAR_REV>
<BUDGET>1887168.2</BUDGET>
<GROSS_PROFIT>977119.63</GROSS_PROFIT>
<EXPENSES>1275398.25</EXPENSES>
<NET_INCOME>193954.57</NET_INCOME>
<REVENUE_M>1.46935282</REVENUE_M>
<PROFIT_M>0.97711963</PROFIT_M>
<INCOME_M>0.19395457</INCOME_M>
<PHARMA_REV_M>1.46935282</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.97711963</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19395457</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1440910.03</REVENUE>
<PREV_YEAR_REV>1314051.5</PREV_YEAR_REV>
<BUDGET>1781783.42</BUDGET>
<GROSS_PROFIT>922751.5851</GROSS_PROFIT>
<EXPENSES>1255032.64</EXPENSES>
<NET_INCOME>185877.39</NET_INCOME>
<REVENUE_M>1.44091003</REVENUE_M>
<PROFIT_M>0.922751585</PROFIT_M>
<INCOME_M>0.18587739</INCOME_M>
<PHARMA_REV_M>1.44091003</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.922751585</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18587739</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2906769.37</REVENUE>
<PREV_YEAR_REV>2667031.36</PREV_YEAR_REV>
<BUDGET>3648121.86</BUDGET>
<GROSS_PROFIT>1905873.939</GROSS_PROFIT>
<EXPENSES>2555021.23</EXPENSES>
<NET_INCOME>351748.14</NET_INCOME>
<REVENUE_M>2.90676937</REVENUE_M>
<PROFIT_M>1.905873939</PROFIT_M>
<INCOME_M>0.35174814</INCOME_M>
<PHARMA_REV_M>2.90676937</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.905873939</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35174814</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2980879.97</REVENUE>
<PREV_YEAR_REV>2738001.07</PREV_YEAR_REV>
<BUDGET>3623733.74</BUDGET>
<GROSS_PROFIT>2121287.3</GROSS_PROFIT>
<EXPENSES>2579803.23</EXPENSES>
<NET_INCOME>401076.74</NET_INCOME>
<REVENUE_M>2.98087997</REVENUE_M>
<PROFIT_M>2.1212873</PROFIT_M>
<INCOME_M>0.40107674</INCOME_M>
<PHARMA_REV_M>2.98087997</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.1212873</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40107674</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2871241.9</REVENUE>
<PREV_YEAR_REV>2641682.49</PREV_YEAR_REV>
<BUDGET>3649559.52</BUDGET>
<GROSS_PROFIT>2134606.77</GROSS_PROFIT>
<EXPENSES>2484660.56</EXPENSES>
<NET_INCOME>386581.34</NET_INCOME>
<REVENUE_M>2.8712419</REVENUE_M>
<PROFIT_M>2.13460677</PROFIT_M>
<INCOME_M>0.38658134</INCOME_M>
<PHARMA_REV_M>2.8712419</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.13460677</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38658134</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2632380.76</REVENUE>
<PREV_YEAR_REV>2352169.28</PREV_YEAR_REV>
<BUDGET>3612356.09</BUDGET>
<GROSS_PROFIT>1709748.459</GROSS_PROFIT>
<EXPENSES>2241414.56</EXPENSES>
<NET_INCOME>390966.19</NET_INCOME>
<REVENUE_M>2.63238076</REVENUE_M>
<PROFIT_M>1.709748459</PROFIT_M>
<INCOME_M>0.39096619</INCOME_M>
<PHARMA_REV_M>2.63238076</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.709748459</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39096619</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1470138.26</REVENUE>
<PREV_YEAR_REV>1359300.87</PREV_YEAR_REV>
<BUDGET>1820808.31</BUDGET>
<GROSS_PROFIT>1031998.837</GROSS_PROFIT>
<EXPENSES>1217274.48</EXPENSES>
<NET_INCOME>252863.78</NET_INCOME>
<REVENUE_M>1.47013826</REVENUE_M>
<PROFIT_M>1.031998837</PROFIT_M>
<INCOME_M>0.25286378</INCOME_M>
<PHARMA_REV_M>1.47013826</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.031998837</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25286378</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1406116.11</REVENUE>
<PREV_YEAR_REV>1295971.5</PREV_YEAR_REV>
<BUDGET>1822245.97</BUDGET>
<GROSS_PROFIT>897242.688</GROSS_PROFIT>
<EXPENSES>1216290.44</EXPENSES>
<NET_INCOME>189825.68</NET_INCOME>
<REVENUE_M>1.40611611</REVENUE_M>
<PROFIT_M>0.897242688</PROFIT_M>
<INCOME_M>0.18982568</INCOME_M>
<PHARMA_REV_M>1.40611611</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.897242688</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18982568</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1382407.84</REVENUE>
<PREV_YEAR_REV>1277275.31</PREV_YEAR_REV>
<BUDGET>1802925.43</BUDGET>
<GROSS_PROFIT>932434.0915</GROSS_PROFIT>
<EXPENSES>1144633.69</EXPENSES>
<NET_INCOME>237774.15</NET_INCOME>
<REVENUE_M>1.38240784</REVENUE_M>
<PROFIT_M>0.932434092</PROFIT_M>
<INCOME_M>0.23777415</INCOME_M>
<PHARMA_REV_M>1.38240784</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.932434092</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23777415</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1234080.11</REVENUE>
<PREV_YEAR_REV>1145317.97</PREV_YEAR_REV>
<BUDGET>1651678.75</BUDGET>
<GROSS_PROFIT>886069.52</GROSS_PROFIT>
<EXPENSES>1099565.38</EXPENSES>
<NET_INCOME>134514.73</NET_INCOME>
<REVENUE_M>1.23408011</REVENUE_M>
<PROFIT_M>0.88606952</PROFIT_M>
<INCOME_M>0.13451473</INCOME_M>
<PHARMA_REV_M>1.23408011</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.88606952</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13451473</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1295289.56</REVENUE>
<PREV_YEAR_REV>1164368.02</PREV_YEAR_REV>
<BUDGET>1769345.41</BUDGET>
<GROSS_PROFIT>831158.1692</GROSS_PROFIT>
<EXPENSES>1163170.02</EXPENSES>
<NET_INCOME>132119.54</NET_INCOME>
<REVENUE_M>1.29528956</REVENUE_M>
<PROFIT_M>0.831158169</PROFIT_M>
<INCOME_M>0.13211954</INCOME_M>
<PHARMA_REV_M>1.29528956</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.831158169</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13211954</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1393033.82</REVENUE>
<PREV_YEAR_REV>1250962.06</PREV_YEAR_REV>
<BUDGET>1837403.16</BUDGET>
<GROSS_PROFIT>894606.317</GROSS_PROFIT>
<EXPENSES>1241193.13</EXPENSES>
<NET_INCOME>151840.69</NET_INCOME>
<REVENUE_M>1.39303382</REVENUE_M>
<PROFIT_M>0.894606317</PROFIT_M>
<INCOME_M>0.15184069</INCOME_M>
<PHARMA_REV_M>1.39303382</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.894606317</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15184069</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1078371.02</REVENUE>
<PREV_YEAR_REV>966429.49</PREV_YEAR_REV>
<BUDGET>1203498.43</BUDGET>
<GROSS_PROFIT>741703.589</GROSS_PROFIT>
<EXPENSES>905831.66</EXPENSES>
<NET_INCOME>172539.36</NET_INCOME>
<REVENUE_M>1.07837102</REVENUE_M>
<PROFIT_M>0.741703589</PROFIT_M>
<INCOME_M>0.17253936</INCOME_M>
<PHARMA_REV_M>1.07837102</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.741703589</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17253936</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2446926.78</REVENUE>
<PREV_YEAR_REV>2204580.85</PREV_YEAR_REV>
<BUDGET>2628792.04</BUDGET>
<GROSS_PROFIT>1623369.023</GROSS_PROFIT>
<EXPENSES>2176594.47</EXPENSES>
<NET_INCOME>270332.31</NET_INCOME>
<REVENUE_M>2.44692678</REVENUE_M>
<PROFIT_M>1.623369023</PROFIT_M>
<INCOME_M>0.27033231</INCOME_M>
<PHARMA_REV_M>2.44692678</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.623369023</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27033231</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6922424.41</REVENUE>
<PREV_YEAR_REV>6446180.59</PREV_YEAR_REV>
<BUDGET>7614666.86</BUDGET>
<GROSS_PROFIT>5994819.54</GROSS_PROFIT>
<EXPENSES>6008664.39</EXPENSES>
<NET_INCOME>913760.02</NET_INCOME>
<REVENUE_M>6.92242441</REVENUE_M>
<PROFIT_M>5.99481954</PROFIT_M>
<INCOME_M>0.91376002</INCOME_M>
<PHARMA_REV_M>6.92242441</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.99481954</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.91376002</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>9018130.24</REVENUE>
<PREV_YEAR_REV>8583136.86</PREV_YEAR_REV>
<BUDGET>8657405.03</BUDGET>
<GROSS_PROFIT>7575229.4</GROSS_PROFIT>
<EXPENSES>7575229.4</EXPENSES>
<NET_INCOME>1442900.84</NET_INCOME>
<REVENUE_M>9.01813024</REVENUE_M>
<PROFIT_M>7.5752294</PROFIT_M>
<INCOME_M>1.44290084</INCOME_M>
<PHARMA_REV_M>9.01813024</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.5752294</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.44290084</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7535899.56</REVENUE>
<PREV_YEAR_REV>7074633.46</PREV_YEAR_REV>
<BUDGET>7234463.58</BUDGET>
<GROSS_PROFIT>6254796.63</GROSS_PROFIT>
<EXPENSES>6541160.82</EXPENSES>
<NET_INCOME>994738.74</NET_INCOME>
<REVENUE_M>7.53589956</REVENUE_M>
<PROFIT_M>6.25479663</PROFIT_M>
<INCOME_M>0.99473874</INCOME_M>
<PHARMA_REV_M>7.53589956</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.25479663</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.99473874</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5160307.14</REVENUE>
<PREV_YEAR_REV>4856165.49</PREV_YEAR_REV>
<BUDGET>4953894.85</BUDGET>
<GROSS_PROFIT>4350138.92</GROSS_PROFIT>
<EXPENSES>4236612.16</EXPENSES>
<NET_INCOME>923694.98</NET_INCOME>
<REVENUE_M>5.16030714</REVENUE_M>
<PROFIT_M>4.35013892</PROFIT_M>
<INCOME_M>0.92369498</INCOME_M>
<PHARMA_REV_M>5.16030714</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.35013892</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.92369498</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6104214.75</REVENUE>
<PREV_YEAR_REV>5663219.82</PREV_YEAR_REV>
<BUDGET>5860046.16</BUDGET>
<GROSS_PROFIT>5176374.11</GROSS_PROFIT>
<EXPENSES>5658607.07</EXPENSES>
<NET_INCOME>445607.68</NET_INCOME>
<REVENUE_M>6.10421475</REVENUE_M>
<PROFIT_M>5.17637411</PROFIT_M>
<INCOME_M>0.44560768</INCOME_M>
<PHARMA_REV_M>6.10421475</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.17637411</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44560768</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5995689.07</REVENUE>
<PREV_YEAR_REV>5705561.28</PREV_YEAR_REV>
<BUDGET>5755861.51</BUDGET>
<GROSS_PROFIT>4909869.781</GROSS_PROFIT>
<EXPENSES>4964430.55</EXPENSES>
<NET_INCOME>1031258.52</NET_INCOME>
<REVENUE_M>5.99568907</REVENUE_M>
<PROFIT_M>4.909869781</PROFIT_M>
<INCOME_M>1.03125852</INCOME_M>
<PHARMA_REV_M>5.99568907</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.909869781</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03125852</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2167469.9</REVENUE>
<PREV_YEAR_REV>2000932.3</PREV_YEAR_REV>
<BUDGET>1709055.08</BUDGET>
<GROSS_PROFIT>1696695.44</GROSS_PROFIT>
<EXPENSES>1820674.72</EXPENSES>
<NET_INCOME>346795.18</NET_INCOME>
<REVENUE_M>2.1674699</REVENUE_M>
<PROFIT_M>1.69669544</PROFIT_M>
<INCOME_M>0.34679518</INCOME_M>
<PHARMA_REV_M>2.1674699</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.69669544</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34679518</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4536829.89</REVENUE>
<PREV_YEAR_REV>4231935.67</PREV_YEAR_REV>
<BUDGET>3472286.04</BUDGET>
<GROSS_PROFIT>3537752.631</GROSS_PROFIT>
<EXPENSES>4034035.03</EXPENSES>
<NET_INCOME>502794.86</NET_INCOME>
<REVENUE_M>4.53682989</REVENUE_M>
<PROFIT_M>3.537752631</PROFIT_M>
<INCOME_M>0.50279486</INCOME_M>
<PHARMA_REV_M>4.53682989</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.537752631</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50279486</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2324139.57</REVENUE>
<PREV_YEAR_REV>2151084.8</PREV_YEAR_REV>
<BUDGET>1763330.48</BUDGET>
<GROSS_PROFIT>1784009.541</GROSS_PROFIT>
<EXPENSES>2070808.36</EXPENSES>
<NET_INCOME>253331.21</NET_INCOME>
<REVENUE_M>2.32413957</REVENUE_M>
<PROFIT_M>1.784009541</PROFIT_M>
<INCOME_M>0.25333121</INCOME_M>
<PHARMA_REV_M>2.32413957</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.784009541</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25333121</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2362811.07</REVENUE>
<PREV_YEAR_REV>2205987.42</PREV_YEAR_REV>
<BUDGET>1855623.07</BUDGET>
<GROSS_PROFIT>1834614.104</GROSS_PROFIT>
<EXPENSES>1956407.56</EXPENSES>
<NET_INCOME>406403.5</NET_INCOME>
<REVENUE_M>2.36281107</REVENUE_M>
<PROFIT_M>1.834614104</PROFIT_M>
<INCOME_M>0.4064035</INCOME_M>
<PHARMA_REV_M>2.36281107</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.834614104</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4064035</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3453727.07</REVENUE>
<PREV_YEAR_REV>3182661.98</PREV_YEAR_REV>
<BUDGET>3130914.02</BUDGET>
<GROSS_PROFIT>2729724.036</GROSS_PROFIT>
<EXPENSES>3071685.53</EXPENSES>
<NET_INCOME>382041.54</NET_INCOME>
<REVENUE_M>3.45372707</REVENUE_M>
<PROFIT_M>2.729724036</PROFIT_M>
<INCOME_M>0.38204154</INCOME_M>
<PHARMA_REV_M>3.45372707</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.729724036</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38204154</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1683263.92</REVENUE>
<PREV_YEAR_REV>1583831.01</PREV_YEAR_REV>
<BUDGET>1583775.65</BUDGET>
<GROSS_PROFIT>1346611.14</GROSS_PROFIT>
<EXPENSES>1461073.09</EXPENSES>
<NET_INCOME>222190.84</NET_INCOME>
<REVENUE_M>1.68326392</REVENUE_M>
<PROFIT_M>1.34661114</PROFIT_M>
<INCOME_M>0.22219084</INCOME_M>
<PHARMA_REV_M>1.68326392</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.34661114</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22219084</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5013912.16</REVENUE>
<PREV_YEAR_REV>4699934.39</PREV_YEAR_REV>
<BUDGET>4748795.38</BUDGET>
<GROSS_PROFIT>4169656.6</GROSS_PROFIT>
<EXPENSES>4527929.21</EXPENSES>
<NET_INCOME>485982.95</NET_INCOME>
<REVENUE_M>5.01391216</REVENUE_M>
<PROFIT_M>4.1696566</PROFIT_M>
<INCOME_M>0.48598295</INCOME_M>
<PHARMA_REV_M>5.01391216</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.1696566</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48598295</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1522890.69</REVENUE>
<PREV_YEAR_REV>1436987.57</PREV_YEAR_REV>
<BUDGET>1431548.84</BUDGET>
<GROSS_PROFIT>1175976.189</GROSS_PROFIT>
<EXPENSES>1317300.44</EXPENSES>
<NET_INCOME>205590.24</NET_INCOME>
<REVENUE_M>1.52289069</REVENUE_M>
<PROFIT_M>1.175976189</PROFIT_M>
<INCOME_M>0.20559024</INCOME_M>
<PHARMA_REV_M>1.52289069</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.175976189</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20559024</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1633449.57</REVENUE>
<PREV_YEAR_REV>1519685.89</PREV_YEAR_REV>
<BUDGET>1558973.03</BUDGET>
<GROSS_PROFIT>1362460.294</GROSS_PROFIT>
<EXPENSES>1352496.25</EXPENSES>
<NET_INCOME>280953.33</NET_INCOME>
<REVENUE_M>1.63344957</REVENUE_M>
<PROFIT_M>1.362460294</PROFIT_M>
<INCOME_M>0.28095333</INCOME_M>
<PHARMA_REV_M>1.63344957</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.362460294</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28095333</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1942742.98</REVENUE>
<PREV_YEAR_REV>1785560.12</PREV_YEAR_REV>
<BUDGET>1614547.45</BUDGET>
<GROSS_PROFIT>1690186.39</GROSS_PROFIT>
<EXPENSES>1730983.99</EXPENSES>
<NET_INCOME>211758.98</NET_INCOME>
<REVENUE_M>1.94274298</REVENUE_M>
<PROFIT_M>1.69018639</PROFIT_M>
<INCOME_M>0.21175898</INCOME_M>
<PHARMA_REV_M>1.94274298</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.69018639</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21175898</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.334397113E7</REVENUE>
<PREV_YEAR_REV>1.267677258E7</PREV_YEAR_REV>
<BUDGET>12943652</BUDGET>
<GROSS_PROFIT>1.005201346E7</GROSS_PROFIT>
<EXPENSES>1.127529876E7</EXPENSES>
<NET_INCOME>1761404.19</NET_INCOME>
<REVENUE_M>13.34397113</REVENUE_M>
<PROFIT_M>10.05201346</PROFIT_M>
<INCOME_M>1.76140419</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.703497747E7</REVENUE>
<PREV_YEAR_REV>2.568322859E7</PREV_YEAR_REV>
<BUDGET>2.622392814E7</BUDGET>
<GROSS_PROFIT>1.832890367E7</GROSS_PROFIT>
<EXPENSES>2.327790787E7</EXPENSES>
<NET_INCOME>4012222.29</NET_INCOME>
<REVENUE_M>27.03497747</REVENUE_M>
<PROFIT_M>18.32890367</PROFIT_M>
<INCOME_M>4.01222229</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>7520706.49</REVENUE>
<PREV_YEAR_REV>7144671.16</PREV_YEAR_REV>
<BUDGET>7295085.29</BUDGET>
<GROSS_PROFIT>5665348.193</GROSS_PROFIT>
<EXPENSES>6354795.86</EXPENSES>
<NET_INCOME>549011.57</NET_INCOME>
<REVENUE_M>7.52070649</REVENUE_M>
<PROFIT_M>5.665348193</PROFIT_M>
<INCOME_M>0.54901157</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.813797563E7</REVENUE>
<PREV_YEAR_REV>1.723107684E7</PREV_YEAR_REV>
<BUDGET>1.759383636E7</BUDGET>
<GROSS_PROFIT>1.229700334E7</GROSS_PROFIT>
<EXPENSES>2.332025438E7</EXPENSES>
<NET_INCOME>2696040.7</NET_INCOME>
<REVENUE_M>18.13797563</REVENUE_M>
<PROFIT_M>12.29700334</PROFIT_M>
<INCOME_M>2.6960407</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.914508329E7</REVENUE>
<PREV_YEAR_REV>2.768782913E7</PREV_YEAR_REV>
<BUDGET>2.827073079E7</BUDGET>
<GROSS_PROFIT>2.195499124E7</GROSS_PROFIT>
<EXPENSES>3.747224994E7</EXPENSES>
<NET_INCOME>3856618.95</NET_INCOME>
<REVENUE_M>29.14508329</REVENUE_M>
<PROFIT_M>21.95499124</PROFIT_M>
<INCOME_M>3.85661895</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.924912334E7</REVENUE>
<PREV_YEAR_REV>1.828666718E7</PREV_YEAR_REV>
<BUDGET>1.867164964E7</BUDGET>
<GROSS_PROFIT>1.305032815E7</GROSS_PROFIT>
<EXPENSES>2.357035512E7</EXPENSES>
<NET_INCOME>2328568.97</NET_INCOME>
<REVENUE_M>19.24912334</REVENUE_M>
<PROFIT_M>13.05032815</PROFIT_M>
<INCOME_M>2.32856897</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.545201158E7</REVENUE>
<PREV_YEAR_REV>14679411</PREV_YEAR_REV>
<BUDGET>1.498845123E7</BUDGET>
<GROSS_PROFIT>1.164000032E7</GROSS_PROFIT>
<EXPENSES>1.89208305E7</EXPENSES>
<NET_INCOME>2765910.07</NET_INCOME>
<REVENUE_M>15.45201158</REVENUE_M>
<PROFIT_M>11.64000032</PROFIT_M>
<INCOME_M>2.76591007</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.010967511E7</REVENUE>
<PREV_YEAR_REV>1.709322384E7</PREV_YEAR_REV>
<BUDGET>1.950638485E7</BUDGET>
<GROSS_PROFIT>1.514861826E7</GROSS_PROFIT>
<EXPENSES>1.571274528E7</EXPENSES>
<NET_INCOME>3217548.02</NET_INCOME>
<REVENUE_M>20.10967511</REVENUE_M>
<PROFIT_M>15.14861826</PROFIT_M>
<INCOME_M>3.21754802</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.020667309E7</REVENUE>
<PREV_YEAR_REV>1.717567213E7</PREV_YEAR_REV>
<BUDGET>1.96004729E7</BUDGET>
<GROSS_PROFIT>1.522168684E7</GROSS_PROFIT>
<EXPENSES>1.908393905E7</EXPENSES>
<NET_INCOME>1475087.14</NET_INCOME>
<REVENUE_M>20.20667309</REVENUE_M>
<PROFIT_M>15.22168684</PROFIT_M>
<INCOME_M>1.47508714</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.865844184E7</REVENUE>
<PREV_YEAR_REV>2.435967557E7</PREV_YEAR_REV>
<BUDGET>2.779868859E7</BUDGET>
<GROSS_PROFIT>2.158840425E7</GROSS_PROFIT>
<EXPENSES>2.550601324E7</EXPENSES>
<NET_INCOME>3798006.5</NET_INCOME>
<REVENUE_M>28.65844184</REVENUE_M>
<PROFIT_M>21.58840425</PROFIT_M>
<INCOME_M>3.7980065</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.513820185E7</REVENUE>
<PREV_YEAR_REV>1.286747157E7</PREV_YEAR_REV>
<BUDGET>1.468405579E7</BUDGET>
<GROSS_PROFIT>1.026324671E7</GROSS_PROFIT>
<EXPENSES>1.349542357E7</EXPENSES>
<NET_INCOME>2043657.25</NET_INCOME>
<REVENUE_M>15.13820185</REVENUE_M>
<PROFIT_M>10.26324671</PROFIT_M>
<INCOME_M>2.04365725</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.679890088E7</REVENUE>
<PREV_YEAR_REV>1.427906575E7</PREV_YEAR_REV>
<BUDGET>1.629493386E7</BUDGET>
<GROSS_PROFIT>1.202188144E7</GROSS_PROFIT>
<EXPENSES>1.497590567E7</EXPENSES>
<NET_INCOME>2889410.95</NET_INCOME>
<REVENUE_M>16.79890088</REVENUE_M>
<PROFIT_M>12.02188144</PROFIT_M>
<INCOME_M>2.88941095</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.75802613E7</REVENUE>
<PREV_YEAR_REV>4.044322211E7</PREV_YEAR_REV>
<BUDGET>4.615285346E7</BUDGET>
<GROSS_PROFIT>3.106324939E7</GROSS_PROFIT>
<EXPENSES>4.282223517E7</EXPENSES>
<NET_INCOME>5758872.23</NET_INCOME>
<REVENUE_M>47.5802613</REVENUE_M>
<PROFIT_M>31.06324939</PROFIT_M>
<INCOME_M>5.75887223</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.769705541E7</REVENUE>
<PREV_YEAR_REV>3.20424971E7</PREV_YEAR_REV>
<BUDGET>3.656614375E7</BUDGET>
<GROSS_PROFIT>27345444</GROSS_PROFIT>
<EXPENSES>3.392734988E7</EXPENSES>
<NET_INCOME>3672529</NET_INCOME>
<REVENUE_M>37.69705541</REVENUE_M>
<PROFIT_M>27.345444</PROFIT_M>
<INCOME_M>3.672529</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.90628159E7</REVENUE>
<PREV_YEAR_REV>1.620339352E7</PREV_YEAR_REV>
<BUDGET>1.849093143E7</BUDGET>
<GROSS_PROFIT>1.436001922E7</GROSS_PROFIT>
<EXPENSES>1.699414353E7</EXPENSES>
<NET_INCOME>2516291.7</NET_INCOME>
<REVENUE_M>19.0628159</REVENUE_M>
<PROFIT_M>14.36001922</PROFIT_M>
<INCOME_M>2.5162917</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.112129475E7</REVENUE>
<PREV_YEAR_REV>3.783159117E7</PREV_YEAR_REV>
<BUDGET>4.194372065E7</BUDGET>
<GROSS_PROFIT>2.942783777E7</GROSS_PROFIT>
<EXPENSES>3.659795233E7</EXPENSES>
<NET_INCOME>3988765.59</NET_INCOME>
<REVENUE_M>41.12129475</REVENUE_M>
<PROFIT_M>29.42783777</PROFIT_M>
<INCOME_M>3.98876559</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.840418671E7</REVENUE>
<PREV_YEAR_REV>1.693185177E7</PREV_YEAR_REV>
<BUDGET>1.877227045E7</BUDGET>
<GROSS_PROFIT>1.386387385E7</GROSS_PROFIT>
<EXPENSES>1.637972617E7</EXPENSES>
<NET_INCOME>3294349.42</NET_INCOME>
<REVENUE_M>18.40418671</REVENUE_M>
<PROFIT_M>13.86387385</PROFIT_M>
<INCOME_M>3.29434942</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.431064942E7</REVENUE>
<PREV_YEAR_REV>1.316579747E7</PREV_YEAR_REV>
<BUDGET>1.459686241E7</BUDGET>
<GROSS_PROFIT>1.078021221E7</GROSS_PROFIT>
<EXPENSES>1.273647799E7</EXPENSES>
<NET_INCOME>1559860.79</NET_INCOME>
<REVENUE_M>14.31064942</REVENUE_M>
<PROFIT_M>10.78021221</PROFIT_M>
<INCOME_M>1.55986079</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.840418671E7</REVENUE>
<PREV_YEAR_REV>1.693185177E7</PREV_YEAR_REV>
<BUDGET>1.877227045E7</BUDGET>
<GROSS_PROFIT>1.317068016E7</GROSS_PROFIT>
<EXPENSES>1.637972617E7</EXPENSES>
<NET_INCOME>1877227.04</NET_INCOME>
<REVENUE_M>18.40418671</REVENUE_M>
<PROFIT_M>13.17068016</PROFIT_M>
<INCOME_M>1.87722704</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.507588352E7</REVENUE>
<PREV_YEAR_REV>4.146981283E7</PREV_YEAR_REV>
<BUDGET>4.291740119E7</BUDGET>
<GROSS_PROFIT>3.395566305E7</GROSS_PROFIT>
<EXPENSES>4.050986252E7</EXPENSES>
<NET_INCOME>7212141.36</NET_INCOME>
<REVENUE_M>45.07588352</REVENUE_M>
<PROFIT_M>33.95566305</PROFIT_M>
<INCOME_M>7.21214136</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.513820185E7</REVENUE>
<PREV_YEAR_REV>1.39271457E7</PREV_YEAR_REV>
<BUDGET>1.544096589E7</BUDGET>
<GROSS_PROFIT>1.026324671E7</GROSS_PROFIT>
<EXPENSES>1.349542357E7</EXPENSES>
<NET_INCOME>2043657.25</NET_INCOME>
<REVENUE_M>15.13820185</REVENUE_M>
<PROFIT_M>10.26324671</PROFIT_M>
<INCOME_M>2.04365725</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.951841786E7</REVENUE>
<PREV_YEAR_REV>1.795694443E7</PREV_YEAR_REV>
<BUDGET>1.990878621E7</BUDGET>
<GROSS_PROFIT>1.323290175E7</GROSS_PROFIT>
<EXPENSES>1.740030414E7</EXPENSES>
<NET_INCOME>2634986.41</NET_INCOME>
<REVENUE_M>19.51841786</REVENUE_M>
<PROFIT_M>13.23290175</PROFIT_M>
<INCOME_M>2.63498641</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.836742036E7</REVENUE>
<PREV_YEAR_REV>3.529802673E7</PREV_YEAR_REV>
<BUDGET>3.913476876E7</BUDGET>
<GROSS_PROFIT>2.890217776E7</GROSS_PROFIT>
<EXPENSES>3.420383703E7</EXPENSES>
<NET_INCOME>5076963.38</NET_INCOME>
<REVENUE_M>38.36742036</REVENUE_M>
<PROFIT_M>28.90217776</PROFIT_M>
<INCOME_M>5.07696338</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.782722497E7</REVENUE>
<PREV_YEAR_REV>4.400104697E7</PREV_YEAR_REV>
<BUDGET>4.46243025E7</BUDGET>
<GROSS_PROFIT>3.422683615E7</GROSS_PROFIT>
<EXPENSES>4.318798415E7</EXPENSES>
<NET_INCOME>4639240.82</NET_INCOME>
<REVENUE_M>47.82722497</REVENUE_M>
<PROFIT_M>34.22683615</PROFIT_M>
<INCOME_M>4.63924082</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.928881124E7</REVENUE>
<PREV_YEAR_REV>4.534570634E7</PREV_YEAR_REV>
<BUDGET>4.520124824E7</BUDGET>
<GROSS_PROFIT>3.341633536E7</GROSS_PROFIT>
<EXPENSES>4.332320446E7</EXPENSES>
<NET_INCOME>5965606.78</NET_INCOME>
<REVENUE_M>49.28881124</REVENUE_M>
<PROFIT_M>33.41633536</PROFIT_M>
<INCOME_M>5.96560678</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.643294065E7</REVENUE>
<PREV_YEAR_REV>2.06383054E7</PREV_YEAR_REV>
<BUDGET>2.04997324E7</BUDGET>
<GROSS_PROFIT>1.605379749E7</GROSS_PROFIT>
<EXPENSES>2.025694541E7</EXPENSES>
<NET_INCOME>2175995.24</NET_INCOME>
<REVENUE_M>26.43294065</REVENUE_M>
<PROFIT_M>16.05379749</PROFIT_M>
<INCOME_M>2.17599524</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>7.101226453E7</REVENUE>
<PREV_YEAR_REV>6.533128337E7</PREV_YEAR_REV>
<BUDGET>5.552696764E7</BUDGET>
<GROSS_PROFIT>5.349353888E7</GROSS_PROFIT>
<EXPENSES>6.401260844E7</EXPENSES>
<NET_INCOME>6999656.09</NET_INCOME>
<REVENUE_M>71.01226453</REVENUE_M>
<PROFIT_M>53.49353888</PROFIT_M>
<INCOME_M>6.99965609</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.324383387E7</REVENUE>
<PREV_YEAR_REV>1.586432716E7</PREV_YEAR_REV>
<BUDGET>1.557008096E7</BUDGET>
<GROSS_PROFIT>1.234029106E7</GROSS_PROFIT>
<EXPENSES>1.548496282E7</EXPENSES>
<NET_INCOME>1758871.05</NET_INCOME>
<REVENUE_M>13.24383387</REVENUE_M>
<PROFIT_M>12.34029106</PROFIT_M>
<INCOME_M>1.75887105</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.120136287E7</REVENUE>
<PREV_YEAR_REV>1.582525384E7</PREV_YEAR_REV>
<BUDGET>1.552973351E7</BUDGET>
<GROSS_PROFIT>1.295778665E7</GROSS_PROFIT>
<EXPENSES>1.532641432E7</EXPENSES>
<NET_INCOME>1874948.55</NET_INCOME>
<REVENUE_M>21.20136287</REVENUE_M>
<PROFIT_M>12.95778665</PROFIT_M>
<INCOME_M>1.87494855</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.00842271E7</REVENUE>
<PREV_YEAR_REV>1.755748893E7</PREV_YEAR_REV>
<BUDGET>1.731845452E7</BUDGET>
<GROSS_PROFIT>1.437297586E7</GROSS_PROFIT>
<EXPENSES>1.662974003E7</EXPENSES>
<NET_INCOME>3454487.06</NET_INCOME>
<REVENUE_M>20.0842271</REVENUE_M>
<PROFIT_M>14.37297586</PROFIT_M>
<INCOME_M>3.45448706</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7457290.43</REVENUE>
<PREV_YEAR_REV>6803476.36</PREV_YEAR_REV>
<BUDGET>8203019.48</BUDGET>
<GROSS_PROFIT>6071353.005</GROSS_PROFIT>
<EXPENSES>6696646.81</EXPENSES>
<NET_INCOME>760643.62</NET_INCOME>
<REVENUE_M>7.45729043</REVENUE_M>
<PROFIT_M>6.071353005</PROFIT_M>
<INCOME_M>0.76064362</INCOME_M>
<PHARMA_REV_M>7.45729043</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.071353005</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76064362</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5339877.3</REVENUE>
<PREV_YEAR_REV>4984251</PREV_YEAR_REV>
<BUDGET>5873865.03</BUDGET>
<GROSS_PROFIT>4469210.305</GROSS_PROFIT>
<EXPENSES>4795209.82</EXPENSES>
<NET_INCOME>544667.48</NET_INCOME>
<REVENUE_M>5.3398773</REVENUE_M>
<PROFIT_M>4.469210305</PROFIT_M>
<INCOME_M>0.54466748</INCOME_M>
<PHARMA_REV_M>5.3398773</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.469210305</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54466748</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2554067.2</REVENUE>
<PREV_YEAR_REV>2293584.78</PREV_YEAR_REV>
<BUDGET>1929489.43</BUDGET>
<GROSS_PROFIT>1975060.165</GROSS_PROFIT>
<EXPENSES>2216930.33</EXPENSES>
<NET_INCOME>337136.87</NET_INCOME>
<REVENUE_M>2.5540672</REVENUE_M>
<PROFIT_M>1.975060165</PROFIT_M>
<INCOME_M>0.33713687</INCOME_M>
<PHARMA_REV_M>2.5540672</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.975060165</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33713687</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5613548.33</REVENUE>
<PREV_YEAR_REV>5117026.28</PREV_YEAR_REV>
<BUDGET>3998258.46</BUDGET>
<GROSS_PROFIT>4769304.015</GROSS_PROFIT>
<EXPENSES>4857427.34</EXPENSES>
<NET_INCOME>756120.98</NET_INCOME>
<REVENUE_M>5.61354833</REVENUE_M>
<PROFIT_M>4.769304015</PROFIT_M>
<INCOME_M>0.75612098</INCOME_M>
<PHARMA_REV_M>5.61354833</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.769304015</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75612098</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5185440.72</REVENUE>
<PREV_YEAR_REV>4045445.59</PREV_YEAR_REV>
<BUDGET>4955700.57</BUDGET>
<GROSS_PROFIT>4315004.15</GROSS_PROFIT>
<EXPENSES>4497879.55</EXPENSES>
<NET_INCOME>687561.17</NET_INCOME>
<REVENUE_M>5.18544072</REVENUE_M>
<PROFIT_M>4.31500415</PROFIT_M>
<INCOME_M>0.68756117</INCOME_M>
<PHARMA_REV_M>5.18544072</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.31500415</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68756117</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4103887.59</REVENUE>
<PREV_YEAR_REV>4069260.59</PREV_YEAR_REV>
<BUDGET>4879040.63</BUDGET>
<GROSS_PROFIT>3345690.589</GROSS_PROFIT>
<EXPENSES>4427497.57</EXPENSES>
<NET_INCOME>676390.03</NET_INCOME>
<REVENUE_M>4.10388759</REVENUE_M>
<PROFIT_M>3.345690589</PROFIT_M>
<INCOME_M>0.67639003</INCOME_M>
<PHARMA_REV_M>4.10388759</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.345690589</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67639003</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5105181.34</REVENUE>
<PREV_YEAR_REV>4136558.83</PREV_YEAR_REV>
<BUDGET>4880256.75</BUDGET>
<GROSS_PROFIT>4293526.56</GROSS_PROFIT>
<EXPENSES>4426859.08</EXPENSES>
<NET_INCOME>678322.28</NET_INCOME>
<REVENUE_M>5.10518134</REVENUE_M>
<PROFIT_M>4.29352656</PROFIT_M>
<INCOME_M>0.67832228</INCOME_M>
<PHARMA_REV_M>5.10518134</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.29352656</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67832228</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3692834.92</REVENUE>
<PREV_YEAR_REV>2943977.64</PREV_YEAR_REV>
<BUDGET>3552651.12</BUDGET>
<GROSS_PROFIT>2961905.317</GROSS_PROFIT>
<EXPENSES>3284156.43</EXPENSES>
<NET_INCOME>408678.5</NET_INCOME>
<REVENUE_M>3.69283492</REVENUE_M>
<PROFIT_M>2.961905317</PROFIT_M>
<INCOME_M>0.4086785</INCOME_M>
<PHARMA_REV_M>3.69283492</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.961905317</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4086785</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3180922.84</REVENUE>
<PREV_YEAR_REV>2596395.41</PREV_YEAR_REV>
<BUDGET>3071453.76</BUDGET>
<GROSS_PROFIT>2500412.892</GROSS_PROFIT>
<EXPENSES>2754181.15</EXPENSES>
<NET_INCOME>426741.69</NET_INCOME>
<REVENUE_M>3.18092284</REVENUE_M>
<PROFIT_M>2.500412892</PROFIT_M>
<INCOME_M>0.42674169</INCOME_M>
<PHARMA_REV_M>3.18092284</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.500412892</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42674169</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2114909.42</REVENUE>
<PREV_YEAR_REV>1702578.87</PREV_YEAR_REV>
<BUDGET>2028708</BUDGET>
<GROSS_PROFIT>1635459.457</GROSS_PROFIT>
<EXPENSES>1736340.64</EXPENSES>
<NET_INCOME>378568.79</NET_INCOME>
<REVENUE_M>2.11490942</REVENUE_M>
<PROFIT_M>1.635459457</PROFIT_M>
<INCOME_M>0.37856879</INCOME_M>
<PHARMA_REV_M>2.11490942</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.635459457</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37856879</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1898059.82</REVENUE>
<PREV_YEAR_REV>1590677.34</PREV_YEAR_REV>
<BUDGET>1824869.38</BUDGET>
<GROSS_PROFIT>1311255.651</GROSS_PROFIT>
<EXPENSES>1641821.75</EXPENSES>
<NET_INCOME>256238.08</NET_INCOME>
<REVENUE_M>1.89805982</REVENUE_M>
<PROFIT_M>1.311255651</PROFIT_M>
<INCOME_M>0.25623808</INCOME_M>
<PHARMA_REV_M>1.89805982</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.311255651</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25623808</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1897000</REVENUE>
<PREV_YEAR_REV>1489911.48</PREV_YEAR_REV>
<BUDGET>1824540</BUDGET>
<GROSS_PROFIT>1490378.05</GROSS_PROFIT>
<EXPENSES>1690227</EXPENSES>
<NET_INCOME>206773</NET_INCOME>
<REVENUE_M>1.897</REVENUE_M>
<PROFIT_M>1.49037805</PROFIT_M>
<INCOME_M>0.206773</INCOME_M>
<PHARMA_REV_M>1.897</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.49037805</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.206773</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.178195146E7</REVENUE>
<PREV_YEAR_REV>1.060375632E7</PREV_YEAR_REV>
<BUDGET>1.119285389E7</BUDGET>
<GROSS_PROFIT>8431576.831</GROSS_PROFIT>
<EXPENSES>1.942079911E7</EXPENSES>
<NET_INCOME>1142849.29</NET_INCOME>
<REVENUE_M>11.78195146</REVENUE_M>
<PROFIT_M>8.431576831</PROFIT_M>
<INCOME_M>1.14284929</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.191339403E7</REVENUE>
<PREV_YEAR_REV>2.872205462E7</PREV_YEAR_REV>
<BUDGET>3.031772433E7</BUDGET>
<GROSS_PROFIT>2.404035972E7</GROSS_PROFIT>
<EXPENSES>5.260449566E7</EXPENSES>
<NET_INCOME>3041799.9</NET_INCOME>
<REVENUE_M>31.91339403</REVENUE_M>
<PROFIT_M>24.04035972</PROFIT_M>
<INCOME_M>3.0417999</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.787418596E7</REVENUE>
<PREV_YEAR_REV>1.608676736E7</PREV_YEAR_REV>
<BUDGET>1.698047666E7</BUDGET>
<GROSS_PROFIT>1.346462429E7</GROSS_PROFIT>
<EXPENSES>2.94629439E7</EXPENSES>
<NET_INCOME>2368805.49</NET_INCOME>
<REVENUE_M>17.87418596</REVENUE_M>
<PROFIT_M>13.46462429</PROFIT_M>
<INCOME_M>2.36880549</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.273316496E7</REVENUE>
<PREV_YEAR_REV>2.045984846E7</PREV_YEAR_REV>
<BUDGET>2.159650672E7</BUDGET>
<GROSS_PROFIT>1.712489317E7</GROSS_PROFIT>
<EXPENSES>3.747224994E7</EXPENSES>
<NET_INCOME>3008162.79</NET_INCOME>
<REVENUE_M>22.73316496</REVENUE_M>
<PROFIT_M>17.12489317</PROFIT_M>
<INCOME_M>3.00816279</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.550800392E7</REVENUE>
<PREV_YEAR_REV>1.473260373E7</PREV_YEAR_REV>
<BUDGET>1.504276381E7</BUDGET>
<GROSS_PROFIT>1.109807039E7</GROSS_PROFIT>
<EXPENSES>1.09846615E7</EXPENSES>
<NET_INCOME>1504276.38</NET_INCOME>
<REVENUE_M>15.50800392</REVENUE_M>
<PROFIT_M>11.09807039</PROFIT_M>
<INCOME_M>1.50427638</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.462335238E7</REVENUE>
<PREV_YEAR_REV>1.389218476E7</PREV_YEAR_REV>
<BUDGET>1.418465181E7</BUDGET>
<GROSS_PROFIT>1.046498278E7</GROSS_PROFIT>
<EXPENSES>1.254539701E7</EXPENSES>
<NET_INCOME>1418465.18</NET_INCOME>
<REVENUE_M>14.62335238</REVENUE_M>
<PROFIT_M>10.46498278</PROFIT_M>
<INCOME_M>1.41846518</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.931767048E7</REVENUE>
<PREV_YEAR_REV>3.735178695E7</PREV_YEAR_REV>
<BUDGET>3.813814036E7</BUDGET>
<GROSS_PROFIT>2.961800117E7</GROSS_PROFIT>
<EXPENSES>3.36891794E7</EXPENSES>
<NET_INCOME>3826932.91</NET_INCOME>
<REVENUE_M>39.31767048</REVENUE_M>
<PROFIT_M>29.61800117</PROFIT_M>
<INCOME_M>3.82693291</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4336517.4</REVENUE>
<PREV_YEAR_REV>3955684.96</PREV_YEAR_REV>
<BUDGET>3282687.31</BUDGET>
<GROSS_PROFIT>3484603.734</GROSS_PROFIT>
<EXPENSES>3857290.66</EXPENSES>
<NET_INCOME>479226.75</NET_INCOME>
<REVENUE_M>4.3365174</REVENUE_M>
<PROFIT_M>3.484603734</PROFIT_M>
<INCOME_M>0.47922675</INCOME_M>
<PHARMA_REV_M>4.3365174</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.484603734</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47922675</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5340255.05</REVENUE>
<PREV_YEAR_REV>4847096.92</PREV_YEAR_REV>
<BUDGET>3836157.97</BUDGET>
<GROSS_PROFIT>3642067.859</GROSS_PROFIT>
<EXPENSES>4546444.21</EXPENSES>
<NET_INCOME>793810.85</NET_INCOME>
<REVENUE_M>5.34025505</REVENUE_M>
<PROFIT_M>3.642067859</PROFIT_M>
<INCOME_M>0.79381085</INCOME_M>
<PHARMA_REV_M>5.34025505</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.642067859</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.79381085</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5303267.22</REVENUE>
<PREV_YEAR_REV>4758605.71</PREV_YEAR_REV>
<BUDGET>3907336.65</BUDGET>
<GROSS_PROFIT>4323132.192</GROSS_PROFIT>
<EXPENSES>4601561.78</EXPENSES>
<NET_INCOME>701705.43</NET_INCOME>
<REVENUE_M>5.30326722</REVENUE_M>
<PROFIT_M>4.323132192</PROFIT_M>
<INCOME_M>0.70170543</INCOME_M>
<PHARMA_REV_M>5.30326722</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.323132192</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.70170543</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1883891.14</REVENUE>
<PREV_YEAR_REV>1733222.14</PREV_YEAR_REV>
<BUDGET>1707031.98</BUDGET>
<GROSS_PROFIT>1410691.598</GROSS_PROFIT>
<EXPENSES>1640869.18</EXPENSES>
<NET_INCOME>243021.96</NET_INCOME>
<REVENUE_M>1.88389114</REVENUE_M>
<PROFIT_M>1.410691598</PROFIT_M>
<INCOME_M>0.24302196</INCOME_M>
<PHARMA_REV_M>1.88389114</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.410691598</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24302196</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2011401.73</REVENUE>
<PREV_YEAR_REV>1861082.13</PREV_YEAR_REV>
<BUDGET>1753223.98</BUDGET>
<GROSS_PROFIT>1637281.01</GROSS_PROFIT>
<EXPENSES>1689577.45</EXPENSES>
<NET_INCOME>321824.28</NET_INCOME>
<REVENUE_M>2.01140173</REVENUE_M>
<PROFIT_M>1.63728101</PROFIT_M>
<INCOME_M>0.32182428</INCOME_M>
<PHARMA_REV_M>2.01140173</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.63728101</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32182428</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1717276.99</REVENUE>
<PREV_YEAR_REV>1534625.83</PREV_YEAR_REV>
<BUDGET>1687403.43</BUDGET>
<GROSS_PROFIT>1475140.94</GROSS_PROFIT>
<EXPENSES>1442512.67</EXPENSES>
<NET_INCOME>274764.32</NET_INCOME>
<REVENUE_M>1.71727699</REVENUE_M>
<PROFIT_M>1.47514094</PROFIT_M>
<INCOME_M>0.27476432</INCOME_M>
<PHARMA_REV_M>1.71727699</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.47514094</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27476432</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3558676.97</REVENUE>
<PREV_YEAR_REV>3285129.59</PREV_YEAR_REV>
<BUDGET>3426916.06</BUDGET>
<GROSS_PROFIT>2953073.803</GROSS_PROFIT>
<EXPENSES>3165449.2</EXPENSES>
<NET_INCOME>393227.76</NET_INCOME>
<REVENUE_M>3.55867697</REVENUE_M>
<PROFIT_M>2.953073803</PROFIT_M>
<INCOME_M>0.39322776</INCOME_M>
<PHARMA_REV_M>3.55867697</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.953073803</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39322776</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1836926.61</REVENUE>
<PREV_YEAR_REV>1681412.75</PREV_YEAR_REV>
<BUDGET>1688933.01</BUDGET>
<GROSS_PROFIT>1383756.813</GROSS_PROFIT>
<EXPENSES>1599963.08</EXPENSES>
<NET_INCOME>236963.53</NET_INCOME>
<REVENUE_M>1.83692661</REVENUE_M>
<PROFIT_M>1.383756813</PROFIT_M>
<INCOME_M>0.23696353</INCOME_M>
<PHARMA_REV_M>1.83692661</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.383756813</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23696353</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3649443.89</REVENUE>
<PREV_YEAR_REV>3323805.91</PREV_YEAR_REV>
<BUDGET>3377866.02</BUDGET>
<GROSS_PROFIT>2953802.453</GROSS_PROFIT>
<EXPENSES>3158606.98</EXPENSES>
<NET_INCOME>490836.9</NET_INCOME>
<REVENUE_M>3.64944389</REVENUE_M>
<PROFIT_M>2.953802453</PROFIT_M>
<INCOME_M>0.4908369</INCOME_M>
<PHARMA_REV_M>3.64944389</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.953802453</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4908369</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3624507.14</REVENUE>
<PREV_YEAR_REV>3292148.41</PREV_YEAR_REV>
<BUDGET>3383959.95</BUDGET>
<GROSS_PROFIT>2787244.128</GROSS_PROFIT>
<EXPENSES>3084849.33</EXPENSES>
<NET_INCOME>539657.8</NET_INCOME>
<REVENUE_M>3.62450714</REVENUE_M>
<PROFIT_M>2.787244128</PROFIT_M>
<INCOME_M>0.5396578</INCOME_M>
<PHARMA_REV_M>3.62450714</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.787244128</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5396578</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1706031.39</REVENUE>
<PREV_YEAR_REV>1576738.81</PREV_YEAR_REV>
<BUDGET>1649621.06</BUDGET>
<GROSS_PROFIT>1178594.723</GROSS_PROFIT>
<EXPENSES>1475717.15</EXPENSES>
<NET_INCOME>230314.24</NET_INCOME>
<REVENUE_M>1.70603139</REVENUE_M>
<PROFIT_M>1.178594723</PROFIT_M>
<INCOME_M>0.23031424</INCOME_M>
<PHARMA_REV_M>1.70603139</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.178594723</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23031424</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3052615.78</REVENUE>
<PREV_YEAR_REV>2779445.42</PREV_YEAR_REV>
<BUDGET>2462583.07</BUDGET>
<GROSS_PROFIT>2229967.07</GROSS_PROFIT>
<EXPENSES>2715450.47</EXPENSES>
<NET_INCOME>337165.31</NET_INCOME>
<REVENUE_M>3.05261578</REVENUE_M>
<PROFIT_M>2.22996707</PROFIT_M>
<INCOME_M>0.33716531</INCOME_M>
<PHARMA_REV_M>3.05261578</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.22996707</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33716531</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1426780.3</REVENUE>
<PREV_YEAR_REV>1288777.96</PREV_YEAR_REV>
<BUDGET>1223434.61</BUDGET>
<GROSS_PROFIT>1190077.445</GROSS_PROFIT>
<EXPENSES>1238445.3</EXPENSES>
<NET_INCOME>188335</NET_INCOME>
<REVENUE_M>1.4267803</REVENUE_M>
<PROFIT_M>1.190077445</PROFIT_M>
<INCOME_M>0.188335</INCOME_M>
<PHARMA_REV_M>1.4267803</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.190077445</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.188335</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2572743.26</REVENUE>
<PREV_YEAR_REV>2293465.41</PREV_YEAR_REV>
<BUDGET>2142465.23</BUDGET>
<GROSS_PROFIT>2033500.232</GROSS_PROFIT>
<EXPENSES>2289224.46</EXPENSES>
<NET_INCOME>283518.81</NET_INCOME>
<REVENUE_M>2.57274326</REVENUE_M>
<PROFIT_M>2.033500232</PROFIT_M>
<INCOME_M>0.28351881</INCOME_M>
<PHARMA_REV_M>2.57274326</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.033500232</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28351881</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4207242.99</REVENUE>
<PREV_YEAR_REV>3768205.75</PREV_YEAR_REV>
<BUDGET>3427183.81</BUDGET>
<GROSS_PROFIT>3555680.91</GROSS_PROFIT>
<EXPENSES>3800536.93</EXPENSES>
<NET_INCOME>406706.05</NET_INCOME>
<REVENUE_M>4.20724299</REVENUE_M>
<PROFIT_M>3.55568091</PROFIT_M>
<INCOME_M>0.40670605</INCOME_M>
<PHARMA_REV_M>4.20724299</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.55568091</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40670605</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.892742616E7</REVENUE>
<PREV_YEAR_REV>1.714381189E7</PREV_YEAR_REV>
<BUDGET>1.703468354E7</BUDGET>
<GROSS_PROFIT>1.454971957E7</GROSS_PROFIT>
<EXPENSES>1.663899634E7</EXPENSES>
<NET_INCOME>2288429.82</NET_INCOME>
<REVENUE_M>18.92742616</REVENUE_M>
<PROFIT_M>14.54971957</PROFIT_M>
<INCOME_M>2.28842982</INCOME_M>
<PHARMA_REV_M>18.92742616</PHARMA_REV_M>
<PHARMA_PROFIT_M>14.54971957</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.28842982</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.133726674E7</REVENUE>
<PREV_YEAR_REV>1.013982646E7</PREV_YEAR_REV>
<BUDGET>1.020354007E7</BUDGET>
<GROSS_PROFIT>9259782.52</GROSS_PROFIT>
<EXPENSES>9813434.9</EXPENSES>
<NET_INCOME>1523831.84</NET_INCOME>
<REVENUE_M>11.33726674</REVENUE_M>
<PROFIT_M>9.25978252</PROFIT_M>
<INCOME_M>1.52383184</INCOME_M>
<PHARMA_REV_M>11.33726674</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.25978252</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.52383184</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>6920860.65</REVENUE>
<PREV_YEAR_REV>6045150.3</PREV_YEAR_REV>
<BUDGET>7022812.56</BUDGET>
<GROSS_PROFIT>5730771.764</GROSS_PROFIT>
<EXPENSES>6249242.21</EXPENSES>
<NET_INCOME>671618.45</NET_INCOME>
<REVENUE_M>6.92086065</REVENUE_M>
<PROFIT_M>5.730771764</PROFIT_M>
<INCOME_M>0.67161845</INCOME_M>
<PHARMA_REV_M>6.92086065</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.730771764</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67161845</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1778159.67</REVENUE>
<PREV_YEAR_REV>1548987.04</PREV_YEAR_REV>
<BUDGET>1781485.18</BUDGET>
<GROSS_PROFIT>1420238.357</GROSS_PROFIT>
<EXPENSES>1596787.38</EXPENSES>
<NET_INCOME>181372.29</NET_INCOME>
<REVENUE_M>1.77815967</REVENUE_M>
<PROFIT_M>1.420238357</PROFIT_M>
<INCOME_M>0.18137229</INCOME_M>
<PHARMA_REV_M>1.77815967</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.420238357</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18137229</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3109992.1</REVENUE>
<PREV_YEAR_REV>2745743.27</PREV_YEAR_REV>
<BUDGET>4127390.52</BUDGET>
<GROSS_PROFIT>2440738.265</GROSS_PROFIT>
<EXPENSES>2766650.35</EXPENSES>
<NET_INCOME>343341.76</NET_INCOME>
<REVENUE_M>3.1099921</REVENUE_M>
<PROFIT_M>2.440738265</PROFIT_M>
<INCOME_M>0.34334176</INCOME_M>
<PHARMA_REV_M>3.1099921</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.440738265</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34334176</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1589266.53</REVENUE>
<PREV_YEAR_REV>1394435.94</PREV_YEAR_REV>
<BUDGET>2058113.29</BUDGET>
<GROSS_PROFIT>1303198.55</GROSS_PROFIT>
<EXPENSES>1334983.88</EXPENSES>
<NET_INCOME>254282.64</NET_INCOME>
<REVENUE_M>1.58926653</REVENUE_M>
<PROFIT_M>1.30319855</PROFIT_M>
<INCOME_M>0.25428264</INCOME_M>
<PHARMA_REV_M>1.58926653</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.30319855</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25428264</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3338120.57</REVENUE>
<PREV_YEAR_REV>2906769.37</PREV_YEAR_REV>
<BUDGET>4168255.64</BUDGET>
<GROSS_PROFIT>2395685.25</GROSS_PROFIT>
<EXPENSES>2934882.62</EXPENSES>
<NET_INCOME>403237.95</NET_INCOME>
<REVENUE_M>3.33812057</REVENUE_M>
<PROFIT_M>2.39568525</PROFIT_M>
<INCOME_M>0.40323795</INCOME_M>
<PHARMA_REV_M>3.33812057</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.39568525</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40323795</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4713905.06</REVENUE>
<PREV_YEAR_REV>4130831.04</PREV_YEAR_REV>
<BUDGET>6256099.82</BUDGET>
<GROSS_PROFIT>3822495.508</GROSS_PROFIT>
<EXPENSES>4256642.15</EXPENSES>
<NET_INCOME>457262.91</NET_INCOME>
<REVENUE_M>4.71390506</REVENUE_M>
<PROFIT_M>3.822495508</PROFIT_M>
<INCOME_M>0.45726291</INCOME_M>
<PHARMA_REV_M>4.71390506</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.822495508</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45726291</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3310167.15</REVENUE>
<PREV_YEAR_REV>2980879.97</PREV_YEAR_REV>
<BUDGET>4140390.36</BUDGET>
<GROSS_PROFIT>2893500.79</GROSS_PROFIT>
<EXPENSES>2864664.56</EXPENSES>
<NET_INCOME>445502.58</NET_INCOME>
<REVENUE_M>3.31016715</REVENUE_M>
<PROFIT_M>2.89350079</PROFIT_M>
<INCOME_M>0.44550258</INCOME_M>
<PHARMA_REV_M>3.31016715</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.89350079</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44550258</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7920915.53</REVENUE>
<PREV_YEAR_REV>7260833.19</PREV_YEAR_REV>
<BUDGET>7128823.98</BUDGET>
<GROSS_PROFIT>6554161.559</GROSS_PROFIT>
<EXPENSES>6558518.06</EXPENSES>
<NET_INCOME>1362397.47</NET_INCOME>
<REVENUE_M>7.92091553</REVENUE_M>
<PROFIT_M>6.554161559</PROFIT_M>
<INCOME_M>1.36239747</INCOME_M>
<PHARMA_REV_M>7.92091553</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.554161559</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.36239747</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2149891.67</REVENUE>
<PREV_YEAR_REV>1933112.44</PREV_YEAR_REV>
<BUDGET>2103768.19</BUDGET>
<GROSS_PROFIT>1607366.513</GROSS_PROFIT>
<EXPENSES>1866105.97</EXPENSES>
<NET_INCOME>283785.7</NET_INCOME>
<REVENUE_M>2.14989167</REVENUE_M>
<PROFIT_M>1.607366513</PROFIT_M>
<INCOME_M>0.2837857</INCOME_M>
<PHARMA_REV_M>2.14989167</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.607366513</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2837857</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4534959.78</REVENUE>
<PREV_YEAR_REV>4085235.46</PREV_YEAR_REV>
<BUDGET>4370731.06</BUDGET>
<GROSS_PROFIT>3307689.648</GROSS_PROFIT>
<EXPENSES>3861796.93</EXPENSES>
<NET_INCOME>673162.85</NET_INCOME>
<REVENUE_M>4.53495978</REVENUE_M>
<PROFIT_M>3.307689648</PROFIT_M>
<INCOME_M>0.67316285</INCOME_M>
<PHARMA_REV_M>4.53495978</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.307689648</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67316285</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1669405.19</REVENUE>
<PREV_YEAR_REV>1487750.82</PREV_YEAR_REV>
<BUDGET>1658220.8</BUDGET>
<GROSS_PROFIT>1190244.165</GROSS_PROFIT>
<EXPENSES>1499125.86</EXPENSES>
<NET_INCOME>170279.33</NET_INCOME>
<REVENUE_M>1.66940519</REVENUE_M>
<PROFIT_M>1.190244165</PROFIT_M>
<INCOME_M>0.17027933</INCOME_M>
<PHARMA_REV_M>1.66940519</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.190244165</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17027933</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4691727.1</REVENUE>
<PREV_YEAR_REV>4243192.79</PREV_YEAR_REV>
<BUDGET>4461764.83</BUDGET>
<GROSS_PROFIT>3977549.599</GROSS_PROFIT>
<EXPENSES>4074634.46</EXPENSES>
<NET_INCOME>617092.63</NET_INCOME>
<REVENUE_M>4.6917271</REVENUE_M>
<PROFIT_M>3.977549599</PROFIT_M>
<INCOME_M>0.61709263</INCOME_M>
<PHARMA_REV_M>4.6917271</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.977549599</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61709263</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1339655.7</REVENUE>
<PREV_YEAR_REV>1218134.59</PREV_YEAR_REV>
<BUDGET>1585129.38</BUDGET>
<GROSS_PROFIT>1050290.069</GROSS_PROFIT>
<EXPENSES>1125310.79</EXPENSES>
<NET_INCOME>214344.91</NET_INCOME>
<REVENUE_M>1.3396557</REVENUE_M>
<PROFIT_M>1.050290069</PROFIT_M>
<INCOME_M>0.21434491</INCOME_M>
<PHARMA_REV_M>1.3396557</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.050290069</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21434491</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3281678.35</REVENUE>
<PREV_YEAR_REV>2987467.11</PREV_YEAR_REV>
<BUDGET>3841808.46</BUDGET>
<GROSS_PROFIT>2665596.216</GROSS_PROFIT>
<EXPENSES>2918626.57</EXPENSES>
<NET_INCOME>363051.78</NET_INCOME>
<REVENUE_M>3.28167835</REVENUE_M>
<PROFIT_M>2.665596216</PROFIT_M>
<INCOME_M>0.36305178</INCOME_M>
<PHARMA_REV_M>3.28167835</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.665596216</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36305178</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3252487.96</REVENUE>
<PREV_YEAR_REV>2991879.37</PREV_YEAR_REV>
<BUDGET>3897494.96</BUDGET>
<GROSS_PROFIT>2551233.717</GROSS_PROFIT>
<EXPENSES>2859506.18</EXPENSES>
<NET_INCOME>392981.78</NET_INCOME>
<REVENUE_M>3.25248796</REVENUE_M>
<PROFIT_M>2.551233717</PROFIT_M>
<INCOME_M>0.39298178</INCOME_M>
<PHARMA_REV_M>3.25248796</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.551233717</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39298178</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3220040.19</REVENUE>
<PREV_YEAR_REV>2878664.68</PREV_YEAR_REV>
<BUDGET>3906834.85</BUDGET>
<GROSS_PROFIT>2183347.853</GROSS_PROFIT>
<EXPENSES>2829408.35</EXPENSES>
<NET_INCOME>390631.84</NET_INCOME>
<REVENUE_M>3.22004019</REVENUE_M>
<PROFIT_M>2.183347853</PROFIT_M>
<INCOME_M>0.39063184</INCOME_M>
<PHARMA_REV_M>3.22004019</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.183347853</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39063184</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4869831.33</REVENUE>
<PREV_YEAR_REV>4409797.88</PREV_YEAR_REV>
<BUDGET>5823228.25</BUDGET>
<GROSS_PROFIT>4090639.991</GROSS_PROFIT>
<EXPENSES>4397353.74</EXPENSES>
<NET_INCOME>472477.59</NET_INCOME>
<REVENUE_M>4.86983133</REVENUE_M>
<PROFIT_M>4.090639991</PROFIT_M>
<INCOME_M>0.47247759</INCOME_M>
<PHARMA_REV_M>4.86983133</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.090639991</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47247759</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1569049.06</REVENUE>
<PREV_YEAR_REV>1401161.85</PREV_YEAR_REV>
<BUDGET>1936463.79</BUDGET>
<GROSS_PROFIT>1223779.816</GROSS_PROFIT>
<EXPENSES>1454508.48</EXPENSES>
<NET_INCOME>114540.58</NET_INCOME>
<REVENUE_M>1.56904906</REVENUE_M>
<PROFIT_M>1.223779816</PROFIT_M>
<INCOME_M>0.11454058</INCOME_M>
<PHARMA_REV_M>1.56904906</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.223779816</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11454058</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1571513.88</REVENUE>
<PREV_YEAR_REV>1394942.11</PREV_YEAR_REV>
<BUDGET>1924363.45</BUDGET>
<GROSS_PROFIT>1312214.09</GROSS_PROFIT>
<EXPENSES>1290212.9</EXPENSES>
<NET_INCOME>281300.99</NET_INCOME>
<REVENUE_M>1.57151388</REVENUE_M>
<PROFIT_M>1.31221409</PROFIT_M>
<INCOME_M>0.28130099</INCOME_M>
<PHARMA_REV_M>1.57151388</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.31221409</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28130099</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1434479.72</REVENUE>
<PREV_YEAR_REV>1295264.67</PREV_YEAR_REV>
<BUDGET>1756591.33</BUDGET>
<GROSS_PROFIT>1030243.338</GROSS_PROFIT>
<EXPENSES>1240824.96</EXPENSES>
<NET_INCOME>193654.76</NET_INCOME>
<REVENUE_M>1.43447972</REVENUE_M>
<PROFIT_M>1.030243338</PROFIT_M>
<INCOME_M>0.19365476</INCOME_M>
<PHARMA_REV_M>1.43447972</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.030243338</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19365476</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1179403.23</REVENUE>
<PREV_YEAR_REV>1045737.11</PREV_YEAR_REV>
<BUDGET>1239364.42</BUDGET>
<GROSS_PROFIT>872817.3616</GROSS_PROFIT>
<EXPENSES>1059104.1</EXPENSES>
<NET_INCOME>120299.13</NET_INCOME>
<REVENUE_M>1.17940323</REVENUE_M>
<PROFIT_M>0.872817362</PROFIT_M>
<INCOME_M>0.12029913</INCOME_M>
<PHARMA_REV_M>1.17940323</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.872817362</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12029913</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1182467.8</REVENUE>
<PREV_YEAR_REV>1068810.5</PREV_YEAR_REV>
<BUDGET>1238883.03</BUDGET>
<GROSS_PROFIT>853505.262</GROSS_PROFIT>
<EXPENSES>1022834.65</EXPENSES>
<NET_INCOME>159633.15</NET_INCOME>
<REVENUE_M>1.1824678</REVENUE_M>
<PROFIT_M>0.853505262</PROFIT_M>
<INCOME_M>0.15963315</INCOME_M>
<PHARMA_REV_M>1.1824678</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.853505262</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15963315</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.783533232E7</REVENUE>
<PREV_YEAR_REV>1.54655968E7</PREV_YEAR_REV>
<BUDGET>1.819203897E7</BUDGET>
<GROSS_PROFIT>1.450317016E7</GROSS_PROFIT>
<EXPENSES>1.589183065E7</EXPENSES>
<NET_INCOME>1943501.66</NET_INCOME>
<REVENUE_M>17.83533232</REVENUE_M>
<PROFIT_M>14.50317016</PROFIT_M>
<INCOME_M>1.94350166</INCOME_M>
<PHARMA_REV_M>17.83533232</PHARMA_REV_M>
<PHARMA_PROFIT_M>14.50317016</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.94350166</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5738973.86</REVENUE>
<PREV_YEAR_REV>5155986.47</PREV_YEAR_REV>
<BUDGET>5853753.33</BUDGET>
<GROSS_PROFIT>5118189.049</GROSS_PROFIT>
<EXPENSES>4981429.31</EXPENSES>
<NET_INCOME>757544.55</NET_INCOME>
<REVENUE_M>5.73897386</REVENUE_M>
<PROFIT_M>5.118189049</PROFIT_M>
<INCOME_M>0.75754455</INCOME_M>
<PHARMA_REV_M>5.73897386</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.118189049</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75754455</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8321083.61</REVENUE>
<PREV_YEAR_REV>7443695.25</PREV_YEAR_REV>
<BUDGET>8487505.28</BUDGET>
<GROSS_PROFIT>6889857.23</GROSS_PROFIT>
<EXPENSES>6989710.23</EXPENSES>
<NET_INCOME>1331373.38</NET_INCOME>
<REVENUE_M>8.32108361</REVENUE_M>
<PROFIT_M>6.88985723</PROFIT_M>
<INCOME_M>1.33137338</INCOME_M>
<PHARMA_REV_M>8.32108361</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.88985723</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.33137338</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>4941501.39</REVENUE>
<PREV_YEAR_REV>4404307.95</PREV_YEAR_REV>
<BUDGET>5040331.41</BUDGET>
<GROSS_PROFIT>4134475.147</GROSS_PROFIT>
<EXPENSES>4091563.15</EXPENSES>
<NET_INCOME>849938.24</NET_INCOME>
<REVENUE_M>4.94150139</REVENUE_M>
<PROFIT_M>4.134475147</PROFIT_M>
<INCOME_M>0.84993824</INCOME_M>
<PHARMA_REV_M>4.94150139</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.134475147</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.84993824</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7758389.85</REVENUE>
<PREV_YEAR_REV>6939153.4</PREV_YEAR_REV>
<BUDGET>7913557.65</BUDGET>
<GROSS_PROFIT>5999562.873</GROSS_PROFIT>
<EXPENSES>6423946.8</EXPENSES>
<NET_INCOME>1334443.05</NET_INCOME>
<REVENUE_M>7.75838985</REVENUE_M>
<PROFIT_M>5.999562873</PROFIT_M>
<INCOME_M>1.33444305</INCOME_M>
<PHARMA_REV_M>7.75838985</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.999562873</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.33444305</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2301215.33</REVENUE>
<PREV_YEAR_REV>1972515.37</PREV_YEAR_REV>
<BUDGET>2369880.2</BUDGET>
<GROSS_PROFIT>1777992.604</GROSS_PROFIT>
<EXPENSES>2004358.55</EXPENSES>
<NET_INCOME>296856.78</NET_INCOME>
<REVENUE_M>2.30121533</REVENUE_M>
<PROFIT_M>1.777992604</PROFIT_M>
<INCOME_M>0.29685678</INCOME_M>
<PHARMA_REV_M>2.30121533</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.777992604</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29685678</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2493307.17</REVENUE>
<PREV_YEAR_REV>2277200.81</PREV_YEAR_REV>
<BUDGET>1966653.74</BUDGET>
<GROSS_PROFIT>2069594.547</GROSS_PROFIT>
<EXPENSES>2047005.19</EXPENSES>
<NET_INCOME>446301.98</NET_INCOME>
<REVENUE_M>2.49330717</REVENUE_M>
<PROFIT_M>2.069594547</PROFIT_M>
<INCOME_M>0.44630198</INCOME_M>
<PHARMA_REV_M>2.49330717</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.069594547</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44630198</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2717092.38</REVENUE>
<PREV_YEAR_REV>2427470.84</PREV_YEAR_REV>
<BUDGET>1984462.06</BUDGET>
<GROSS_PROFIT>2286976.658</GROSS_PROFIT>
<EXPENSES>2420929.31</EXPENSES>
<NET_INCOME>296163.07</NET_INCOME>
<REVENUE_M>2.71709238</REVENUE_M>
<PROFIT_M>2.286976658</PROFIT_M>
<INCOME_M>0.29616307</INCOME_M>
<PHARMA_REV_M>2.71709238</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.286976658</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29616307</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2682304.33</REVENUE>
<PREV_YEAR_REV>2452101.08</PREV_YEAR_REV>
<BUDGET>2004622.42</BUDGET>
<GROSS_PROFIT>2030626.426</GROSS_PROFIT>
<EXPENSES>2408709.29</EXPENSES>
<NET_INCOME>273595.04</NET_INCOME>
<REVENUE_M>2.68230433</REVENUE_M>
<PROFIT_M>2.030626426</PROFIT_M>
<INCOME_M>0.27359504</INCOME_M>
<PHARMA_REV_M>2.68230433</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.030626426</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27359504</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1648153.02</REVENUE>
<PREV_YEAR_REV>1476098.93</PREV_YEAR_REV>
<BUDGET>1453815.31</BUDGET>
<GROSS_PROFIT>1266308.931</GROSS_PROFIT>
<EXPENSES>1384448.54</EXPENSES>
<NET_INCOME>263704.48</NET_INCOME>
<REVENUE_M>1.64815302</REVENUE_M>
<PROFIT_M>1.266308931</PROFIT_M>
<INCOME_M>0.26370448</INCOME_M>
<PHARMA_REV_M>1.64815302</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.266308931</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26370448</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3923341.91</REVENUE>
<PREV_YEAR_REV>3640898.25</PREV_YEAR_REV>
<BUDGET>3518895.07</BUDGET>
<GROSS_PROFIT>3045056.537</GROSS_PROFIT>
<EXPENSES>3487453.84</EXPENSES>
<NET_INCOME>435888.06</NET_INCOME>
<REVENUE_M>3.92334191</REVENUE_M>
<PROFIT_M>3.045056537</PROFIT_M>
<INCOME_M>0.43588806</INCOME_M>
<PHARMA_REV_M>3.92334191</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.045056537</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43588806</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4067333.36</REVENUE>
<PREV_YEAR_REV>3726355.19</PREV_YEAR_REV>
<BUDGET>3568276.35</BUDGET>
<GROSS_PROFIT>3253570.859</GROSS_PROFIT>
<EXPENSES>3616680.9</EXPENSES>
<NET_INCOME>450652.44</NET_INCOME>
<REVENUE_M>4.06733336</REVENUE_M>
<PROFIT_M>3.253570859</PROFIT_M>
<INCOME_M>0.45065244</INCOME_M>
<PHARMA_REV_M>4.06733336</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.253570859</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45065244</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2005401.23</REVENUE>
<PREV_YEAR_REV>1847223.49</PREV_YEAR_REV>
<BUDGET>1764946.8</BUDGET>
<GROSS_PROFIT>1612342.59</GROSS_PROFIT>
<EXPENSES>1646434.41</EXPENSES>
<NET_INCOME>358966.82</NET_INCOME>
<REVENUE_M>2.00540123</REVENUE_M>
<PROFIT_M>1.61234259</PROFIT_M>
<INCOME_M>0.35896682</INCOME_M>
<PHARMA_REV_M>2.00540123</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.61234259</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35896682</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1801097.49</REVENUE>
<PREV_YEAR_REV>1629760.75</PREV_YEAR_REV>
<BUDGET>1611073.13</BUDGET>
<GROSS_PROFIT>1449883.48</GROSS_PROFIT>
<EXPENSES>1604777.87</EXPENSES>
<NET_INCOME>196319.63</NET_INCOME>
<REVENUE_M>1.80109749</REVENUE_M>
<PROFIT_M>1.44988348</PROFIT_M>
<INCOME_M>0.19631963</INCOME_M>
<PHARMA_REV_M>1.80109749</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.44988348</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19631963</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1978454.52</REVENUE>
<PREV_YEAR_REV>1811506.12</PREV_YEAR_REV>
<BUDGET>1717667.92</BUDGET>
<GROSS_PROFIT>1429383.93</GROSS_PROFIT>
<EXPENSES>1711363.16</EXPENSES>
<NET_INCOME>267091.36</NET_INCOME>
<REVENUE_M>1.97845452</REVENUE_M>
<PROFIT_M>1.42938393</PROFIT_M>
<INCOME_M>0.26709136</INCOME_M>
<PHARMA_REV_M>1.97845452</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.42938393</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26709136</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3202316.11</REVENUE>
<PREV_YEAR_REV>2942509.69</PREV_YEAR_REV>
<BUDGET>2268713.02</BUDGET>
<GROSS_PROFIT>2455366.968</GROSS_PROFIT>
<EXPENSES>2727225.5</EXPENSES>
<NET_INCOME>475090.6</NET_INCOME>
<REVENUE_M>3.20231611</REVENUE_M>
<PROFIT_M>2.455366968</PROFIT_M>
<INCOME_M>0.4750906</INCOME_M>
<PHARMA_REV_M>3.20231611</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.455366968</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4750906</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1664517.24</REVENUE>
<PREV_YEAR_REV>1492492.55</PREV_YEAR_REV>
<BUDGET>1266888.99</BUDGET>
<GROSS_PROFIT>1321959.591</GROSS_PROFIT>
<EXPENSES>1378220.27</EXPENSES>
<NET_INCOME>286296.96</NET_INCOME>
<REVENUE_M>1.66451724</REVENUE_M>
<PROFIT_M>1.321959591</PROFIT_M>
<INCOME_M>0.28629696</INCOME_M>
<PHARMA_REV_M>1.66451724</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.321959591</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28629696</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6593404.24</REVENUE>
<PREV_YEAR_REV>6102856.63</PREV_YEAR_REV>
<BUDGET>5934063.82</BUDGET>
<GROSS_PROFIT>5274195.922</GROSS_PROFIT>
<EXPENSES>5538459.56</EXPENSES>
<NET_INCOME>1054944.68</NET_INCOME>
<REVENUE_M>6.59340424</REVENUE_M>
<PROFIT_M>5.274195922</PROFIT_M>
<INCOME_M>1.05494468</INCOME_M>
<PHARMA_REV_M>6.59340424</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.274195922</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.05494468</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6302479.52</REVENUE>
<PREV_YEAR_REV>5796662.73</PREV_YEAR_REV>
<BUDGET>5672231.57</BUDGET>
<GROSS_PROFIT>4531602.522</GROSS_PROFIT>
<EXPENSES>5489459.66</EXPENSES>
<NET_INCOME>813019.86</NET_INCOME>
<REVENUE_M>6.30247952</REVENUE_M>
<PROFIT_M>4.531602522</PROFIT_M>
<INCOME_M>0.81301986</INCOME_M>
<PHARMA_REV_M>6.30247952</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.531602522</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.81301986</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>2.739407828E7</REVENUE>
<PREV_YEAR_REV>2.49341957E7</PREV_YEAR_REV>
<BUDGET>2.465467045E7</BUDGET>
<GROSS_PROFIT>2.046394201E7</GROSS_PROFIT>
<EXPENSES>2.385372803E7</EXPENSES>
<NET_INCOME>3540350.25</NET_INCOME>
<REVENUE_M>27.39407828</REVENUE_M>
<PROFIT_M>20.46394201</PROFIT_M>
<INCOME_M>3.54035025</INCOME_M>
<PHARMA_REV_M>27.39407828</PHARMA_REV_M>
<PHARMA_PROFIT_M>20.46394201</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>3.54035025</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.329433232E7</REVENUE>
<PREV_YEAR_REV>1.203067547E7</PREV_YEAR_REV>
<BUDGET>1.196489909E7</BUDGET>
<GROSS_PROFIT>1.116894245E7</GROSS_PROFIT>
<EXPENSES>1.156956417E7</EXPENSES>
<NET_INCOME>1724768.15</NET_INCOME>
<REVENUE_M>13.29433232</REVENUE_M>
<PROFIT_M>11.16894245</PROFIT_M>
<INCOME_M>1.72476815</INCOME_M>
<PHARMA_REV_M>13.29433232</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.16894245</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.72476815</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2400250.91</REVENUE>
<PREV_YEAR_REV>2181947.1</PREV_YEAR_REV>
<BUDGET>2146447.51</BUDGET>
<GROSS_PROFIT>1742308.533</GROSS_PROFIT>
<EXPENSES>2090618.54</EXPENSES>
<NET_INCOME>309632.37</NET_INCOME>
<REVENUE_M>2.40025091</REVENUE_M>
<PROFIT_M>1.742308533</PROFIT_M>
<INCOME_M>0.30963237</INCOME_M>
<PHARMA_REV_M>2.40025091</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.742308533</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30963237</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4636919.21</REVENUE>
<PREV_YEAR_REV>3936636.59</PREV_YEAR_REV>
<BUDGET>4382846.29</BUDGET>
<GROSS_PROFIT>3435463.224</GROSS_PROFIT>
<EXPENSES>4075308.51</EXPENSES>
<NET_INCOME>561610.7</NET_INCOME>
<REVENUE_M>4.63691921</REVENUE_M>
<PROFIT_M>3.435463224</PROFIT_M>
<INCOME_M>0.5616107</INCOME_M>
<PHARMA_REV_M>4.63691921</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.435463224</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5616107</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4713833</REVENUE>
<PREV_YEAR_REV>4153557.07</PREV_YEAR_REV>
<BUDGET>4327062.56</BUDGET>
<GROSS_PROFIT>3229557.3</GROSS_PROFIT>
<EXPENSES>4147713.56</EXPENSES>
<NET_INCOME>566119.44</NET_INCOME>
<REVENUE_M>4.713833</REVENUE_M>
<PROFIT_M>3.2295573</PROFIT_M>
<INCOME_M>0.56611944</INCOME_M>
<PHARMA_REV_M>4.713833</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.2295573</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56611944</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2400049.46</REVENUE>
<PREV_YEAR_REV>2091874.51</PREV_YEAR_REV>
<BUDGET>2123689.59</BUDGET>
<GROSS_PROFIT>1697794.992</GROSS_PROFIT>
<EXPENSES>2090443.08</EXPENSES>
<NET_INCOME>309606.38</NET_INCOME>
<REVENUE_M>2.40004946</REVENUE_M>
<PROFIT_M>1.697794992</PROFIT_M>
<INCOME_M>0.30960638</INCOME_M>
<PHARMA_REV_M>2.40004946</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.697794992</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30960638</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4626730.41</REVENUE>
<PREV_YEAR_REV>4132210.2</PREV_YEAR_REV>
<BUDGET>4268443.67</BUDGET>
<GROSS_PROFIT>3714239.602</GROSS_PROFIT>
<EXPENSES>4005026</EXPENSES>
<NET_INCOME>621704.41</NET_INCOME>
<REVENUE_M>4.62673041</REVENUE_M>
<PROFIT_M>3.714239602</PROFIT_M>
<INCOME_M>0.62170441</INCOME_M>
<PHARMA_REV_M>4.62673041</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.714239602</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62170441</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>7125135.29</REVENUE>
<PREV_YEAR_REV>6262964.49</PREV_YEAR_REV>
<BUDGET>6449270.12</BUDGET>
<GROSS_PROFIT>5961235.33</GROSS_PROFIT>
<EXPENSES>6436402.2</EXPENSES>
<NET_INCOME>688733.09</NET_INCOME>
<REVENUE_M>7.12513529</REVENUE_M>
<PROFIT_M>5.96123533</PROFIT_M>
<INCOME_M>0.68873309</INCOME_M>
<PHARMA_REV_M>7.12513529</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.96123533</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68873309</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2322819.11</REVENUE>
<PREV_YEAR_REV>2102384.13</PREV_YEAR_REV>
<BUDGET>2146447.51</BUDGET>
<GROSS_PROFIT>1999947.25</GROSS_PROFIT>
<EXPENSES>2153253.31</EXPENSES>
<NET_INCOME>169565.79</NET_INCOME>
<REVENUE_M>2.32281911</REVENUE_M>
<PROFIT_M>1.99994725</PROFIT_M>
<INCOME_M>0.16956579</INCOME_M>
<PHARMA_REV_M>2.32281911</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.99994725</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16956579</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2326727.41</REVENUE>
<PREV_YEAR_REV>1975351.83</PREV_YEAR_REV>
<BUDGET>2118708.9</BUDGET>
<GROSS_PROFIT>1947354.508</GROSS_PROFIT>
<EXPENSES>1926530.29</EXPENSES>
<NET_INCOME>400197.11</NET_INCOME>
<REVENUE_M>2.32672741</REVENUE_M>
<PROFIT_M>1.947354508</PROFIT_M>
<INCOME_M>0.40019711</INCOME_M>
<PHARMA_REV_M>2.32672741</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.947354508</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40019711</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2692378.94</REVENUE>
<PREV_YEAR_REV>2437645.03</PREV_YEAR_REV>
<BUDGET>2194236.83</BUDGET>
<GROSS_PROFIT>2320830.65</GROSS_PROFIT>
<EXPENSES>2398909.64</EXPENSES>
<NET_INCOME>293469.3</NET_INCOME>
<REVENUE_M>2.69237894</REVENUE_M>
<PROFIT_M>2.32083065</PROFIT_M>
<INCOME_M>0.2934693</INCOME_M>
<PHARMA_REV_M>2.69237894</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.32083065</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2934693</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1800659.66</REVENUE>
<PREV_YEAR_REV>1583470.81</PREV_YEAR_REV>
<BUDGET>1417616.64</BUDGET>
<GROSS_PROFIT>1462585.81</GROSS_PROFIT>
<EXPENSES>1512554.12</EXPENSES>
<NET_INCOME>288105.55</NET_INCOME>
<REVENUE_M>1.80065966</REVENUE_M>
<PROFIT_M>1.46258581</PROFIT_M>
<INCOME_M>0.28810555</INCOME_M>
<PHARMA_REV_M>1.80065966</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.46258581</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28810555</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4037977.26</REVENUE>
<PREV_YEAR_REV>3619747.37</PREV_YEAR_REV>
<BUDGET>3096488.74</BUDGET>
<GROSS_PROFIT>3084425.046</GROSS_PROFIT>
<EXPENSES>3592057.53</EXPENSES>
<NET_INCOME>445919.73</NET_INCOME>
<REVENUE_M>4.03797726</REVENUE_M>
<PROFIT_M>3.084425046</PROFIT_M>
<INCOME_M>0.44591973</INCOME_M>
<PHARMA_REV_M>4.03797726</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.084425046</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44591973</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1985802.86</REVENUE>
<PREV_YEAR_REV>1714603.95</PREV_YEAR_REV>
<BUDGET>1538364.96</BUDGET>
<GROSS_PROFIT>1535621.344</GROSS_PROFIT>
<EXPENSES>1723676.88</EXPENSES>
<NET_INCOME>262125.98</NET_INCOME>
<REVENUE_M>1.98580286</REVENUE_M>
<PROFIT_M>1.535621344</PROFIT_M>
<INCOME_M>0.26212598</INCOME_M>
<PHARMA_REV_M>1.98580286</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.535621344</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26212598</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1952759.72</REVENUE>
<PREV_YEAR_REV>1764568.49</PREV_YEAR_REV>
<BUDGET>1538364.96</BUDGET>
<GROSS_PROFIT>1552736.896</GROSS_PROFIT>
<EXPENSES>1603215.73</EXPENSES>
<NET_INCOME>349543.99</NET_INCOME>
<REVENUE_M>1.95275972</REVENUE_M>
<PROFIT_M>1.552736896</PROFIT_M>
<INCOME_M>0.34954399</INCOME_M>
<PHARMA_REV_M>1.95275972</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.552736896</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34954399</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3653090.4</REVENUE>
<PREV_YEAR_REV>3190927.68</PREV_YEAR_REV>
<BUDGET>2905223.4</BUDGET>
<GROSS_PROFIT>3022183.48</GROSS_PROFIT>
<EXPENSES>3161000.92</EXPENSES>
<NET_INCOME>492089.49</NET_INCOME>
<REVENUE_M>3.6530904</REVENUE_M>
<PROFIT_M>3.02218348</PROFIT_M>
<INCOME_M>0.49208949</INCOME_M>
<PHARMA_REV_M>3.6530904</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.02218348</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49208949</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>5552235.13</REVENUE>
<PREV_YEAR_REV>4884159.92</PREV_YEAR_REV>
<BUDGET>4309392.13</BUDGET>
<GROSS_PROFIT>4723277.94</GROSS_PROFIT>
<EXPENSES>5015071.16</EXPENSES>
<NET_INCOME>537163.97</NET_INCOME>
<REVENUE_M>5.55223513</REVENUE_M>
<PROFIT_M>4.72327794</PROFIT_M>
<INCOME_M>0.53716397</INCOME_M>
<PHARMA_REV_M>5.55223513</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.72327794</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53716397</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1900695.59</REVENUE>
<PREV_YEAR_REV>1664517.24</PREV_YEAR_REV>
<BUDGET>1529896.9</BUDGET>
<GROSS_PROFIT>1367156.078</GROSS_PROFIT>
<EXPENSES>1573775.95</EXPENSES>
<NET_INCOME>326919.64</NET_INCOME>
<REVENUE_M>1.90069559</REVENUE_M>
<PROFIT_M>1.367156078</PROFIT_M>
<INCOME_M>0.32691964</INCOME_M>
<PHARMA_REV_M>1.90069559</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.367156078</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32691964</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4172355.44</REVENUE>
<PREV_YEAR_REV>3675227.62</PREV_YEAR_REV>
<BUDGET>2949426.51</BUDGET>
<GROSS_PROFIT>3586537.17</GROSS_PROFIT>
<EXPENSES>3617189.19</EXPENSES>
<NET_INCOME>555166.25</NET_INCOME>
<REVENUE_M>4.17235544</REVENUE_M>
<PROFIT_M>3.58653717</PROFIT_M>
<INCOME_M>0.55516625</INCOME_M>
<PHARMA_REV_M>4.17235544</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.58653717</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55516625</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.116618306E7</REVENUE>
<PREV_YEAR_REV>1.006152791E7</PREV_YEAR_REV>
<BUDGET>1.09428594E7</BUDGET>
<GROSS_PROFIT>9524754.15</GROSS_PROFIT>
<EXPENSES>9379593.77</EXPENSES>
<NET_INCOME>1786589.29</NET_INCOME>
<REVENUE_M>11.16618306</REVENUE_M>
<PROFIT_M>9.52475415</PROFIT_M>
<INCOME_M>1.78658929</INCOME_M>
<PHARMA_REV_M>11.16618306</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.52475415</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.78658929</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7372217.15</REVENUE>
<PREV_YEAR_REV>6593404.24</PREV_YEAR_REV>
<BUDGET>7224772.81</BUDGET>
<GROSS_PROFIT>6425845.634</GROSS_PROFIT>
<EXPENSES>6192662.41</EXPENSES>
<NET_INCOME>1179554.74</NET_INCOME>
<REVENUE_M>7.37221715</REVENUE_M>
<PROFIT_M>6.425845634</PROFIT_M>
<INCOME_M>1.17955474</INCOME_M>
<PHARMA_REV_M>7.37221715</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.425845634</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.17955474</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7119469.94</REVENUE>
<PREV_YEAR_REV>6302479.52</PREV_YEAR_REV>
<BUDGET>6977080.54</BUDGET>
<GROSS_PROFIT>5332596.896</GROSS_PROFIT>
<EXPENSES>6201058.32</EXPENSES>
<NET_INCOME>918411.62</NET_INCOME>
<REVENUE_M>7.11946994</REVENUE_M>
<PROFIT_M>5.332596896</PROFIT_M>
<INCOME_M>0.91841162</INCOME_M>
<PHARMA_REV_M>7.11946994</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.332596896</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.91841162</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1826799.58</REVENUE>
<PREV_YEAR_REV>1606881.75</PREV_YEAR_REV>
<BUDGET>1771995.59</BUDGET>
<GROSS_PROFIT>1443171.67</GROSS_PROFIT>
<EXPENSES>1499802.46</EXPENSES>
<NET_INCOME>326997.13</NET_INCOME>
<REVENUE_M>1.82679958</REVENUE_M>
<PROFIT_M>1.44317167</PROFIT_M>
<INCOME_M>0.32699713</INCOME_M>
<PHARMA_REV_M>1.82679958</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.44317167</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32699713</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3678310.23</REVENUE>
<PREV_YEAR_REV>3251676.08</PREV_YEAR_REV>
<BUDGET>3567960.92</BUDGET>
<GROSS_PROFIT>2659998.298</GROSS_PROFIT>
<EXPENSES>3131871.11</EXPENSES>
<NET_INCOME>546439.11</NET_INCOME>
<REVENUE_M>3.67831023</REVENUE_M>
<PROFIT_M>2.659998298</PROFIT_M>
<INCOME_M>0.54643911</INCOME_M>
<PHARMA_REV_M>3.67831023</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.659998298</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54643911</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5558163.79</REVENUE>
<PREV_YEAR_REV>4927682.58</PREV_YEAR_REV>
<BUDGET>5391418.87</BUDGET>
<GROSS_PROFIT>4419143.149</GROSS_PROFIT>
<EXPENSES>5019221.66</EXPENSES>
<NET_INCOME>538942.12</NET_INCOME>
<REVENUE_M>5.55816379</REVENUE_M>
<PROFIT_M>4.419143149</PROFIT_M>
<INCOME_M>0.53894212</INCOME_M>
<PHARMA_REV_M>5.55816379</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.419143149</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53894212</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3697886.62</REVENUE>
<PREV_YEAR_REV>3311841.88</PREV_YEAR_REV>
<BUDGET>3586950.02</BUDGET>
<GROSS_PROFIT>3195076.72</GROSS_PROFIT>
<EXPENSES>3200492.63</EXPENSES>
<NET_INCOME>497393.99</NET_INCOME>
<REVENUE_M>3.69788662</REVENUE_M>
<PROFIT_M>3.19507672</PROFIT_M>
<INCOME_M>0.49739399</INCOME_M>
<PHARMA_REV_M>3.69788662</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.19507672</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49739399</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1833390.96</REVENUE>
<PREV_YEAR_REV>1571513.88</PREV_YEAR_REV>
<BUDGET>1778389.23</BUDGET>
<GROSS_PROFIT>1602383.7</GROSS_PROFIT>
<EXPENSES>1505213.98</EXPENSES>
<NET_INCOME>328176.98</NET_INCOME>
<REVENUE_M>1.83339096</REVENUE_M>
<PROFIT_M>1.6023837</PROFIT_M>
<INCOME_M>0.32817698</INCOME_M>
<PHARMA_REV_M>1.83339096</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.6023837</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32817698</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1861733.87</REVENUE>
<PREV_YEAR_REV>1608242.66</PREV_YEAR_REV>
<BUDGET>1805881.85</BUDGET>
<GROSS_PROFIT>1480357.688</GROSS_PROFIT>
<EXPENSES>1658804.88</EXPENSES>
<NET_INCOME>202928.99</NET_INCOME>
<REVENUE_M>1.86173387</REVENUE_M>
<PROFIT_M>1.480357688</PROFIT_M>
<INCOME_M>0.20292899</INCOME_M>
<PHARMA_REV_M>1.86173387</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.480357688</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20292899</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1398285.5</REVENUE>
<PREV_YEAR_REV>1193728.23</PREV_YEAR_REV>
<BUDGET>1356336.94</BUDGET>
<GROSS_PROFIT>1085279.297</GROSS_PROFIT>
<EXPENSES>1174559.82</EXPENSES>
<NET_INCOME>223725.68</NET_INCOME>
<REVENUE_M>1.3982855</REVENUE_M>
<PROFIT_M>1.085279297</PROFIT_M>
<INCOME_M>0.22372568</INCOME_M>
<PHARMA_REV_M>1.3982855</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.085279297</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22372568</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4305098.62</REVENUE>
<PREV_YEAR_REV>3787239.65</PREV_YEAR_REV>
<BUDGET>4700961.56</BUDGET>
<GROSS_PROFIT>3487131.2</GROSS_PROFIT>
<EXPENSES>3829239.69</EXPENSES>
<NET_INCOME>475858.93</NET_INCOME>
<REVENUE_M>4.30509862</REVENUE_M>
<PROFIT_M>3.4871312</PROFIT_M>
<INCOME_M>0.47585893</INCOME_M>
<PHARMA_REV_M>4.30509862</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.4871312</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47585893</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4317247.73</REVENUE>
<PREV_YEAR_REV>3758893.84</PREV_YEAR_REV>
<BUDGET>4842159.72</BUDGET>
<GROSS_PROFIT>3088405.573</GROSS_PROFIT>
<EXPENSES>3793688.82</EXPENSES>
<NET_INCOME>523558.9</NET_INCOME>
<REVENUE_M>4.31724773</REVENUE_M>
<PROFIT_M>3.088405573</PROFIT_M>
<INCOME_M>0.5235589</INCOME_M>
<PHARMA_REV_M>4.31724773</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.088405573</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5235589</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2246856.42</REVENUE>
<PREV_YEAR_REV>2011401.73</PREV_YEAR_REV>
<BUDGET>2435560.31</BUDGET>
<GROSS_PROFIT>1790744.56</GROSS_PROFIT>
<EXPENSES>1887359.39</EXPENSES>
<NET_INCOME>359497.03</NET_INCOME>
<REVENUE_M>2.24685642</REVENUE_M>
<PROFIT_M>1.79074456</PROFIT_M>
<INCOME_M>0.35949703</INCOME_M>
<PHARMA_REV_M>2.24685642</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.79074456</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35949703</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2159633.93</REVENUE>
<PREV_YEAR_REV>1917305.67</PREV_YEAR_REV>
<BUDGET>2369519.97</BUDGET>
<GROSS_PROFIT>1608495.35</GROSS_PROFIT>
<EXPENSES>1814092.5</EXPENSES>
<NET_INCOME>345541.43</NET_INCOME>
<REVENUE_M>2.15963393</REVENUE_M>
<PROFIT_M>1.60849535</PROFIT_M>
<INCOME_M>0.34554143</INCOME_M>
<PHARMA_REV_M>2.15963393</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.60849535</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34554143</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4065491.35</REVENUE>
<PREV_YEAR_REV>3558676.97</PREV_YEAR_REV>
<BUDGET>4760635.75</BUDGET>
<GROSS_PROFIT>3228059.397</GROSS_PROFIT>
<EXPENSES>3616841.56</EXPENSES>
<NET_INCOME>448649.79</NET_INCOME>
<REVENUE_M>4.06549135</REVENUE_M>
<PROFIT_M>3.228059397</PROFIT_M>
<INCOME_M>0.44864979</INCOME_M>
<PHARMA_REV_M>4.06549135</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.228059397</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44864979</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2104913</REVENUE>
<PREV_YEAR_REV>1887780.49</PREV_YEAR_REV>
<BUDGET>2377985.6</BUDGET>
<GROSS_PROFIT>1827064.49</GROSS_PROFIT>
<EXPENSES>1827064.49</EXPENSES>
<NET_INCOME>277848.52</NET_INCOME>
<REVENUE_M>2.104913</REVENUE_M>
<PROFIT_M>1.82706449</PROFIT_M>
<INCOME_M>0.27784852</INCOME_M>
<PHARMA_REV_M>2.104913</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.82706449</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27784852</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1836068.89</REVENUE>
<PREV_YEAR_REV>1665262.88</PREV_YEAR_REV>
<BUDGET>2149422.19</BUDGET>
<GROSS_PROFIT>1613904.55</GROSS_PROFIT>
<EXPENSES>1635937.38</EXPENSES>
<NET_INCOME>200131.51</NET_INCOME>
<REVENUE_M>1.83606889</REVENUE_M>
<PROFIT_M>1.61390455</PROFIT_M>
<INCOME_M>0.20013151</INCOME_M>
<PHARMA_REV_M>1.83606889</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.61390455</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20013151</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2081610.97</REVENUE>
<PREV_YEAR_REV>1799331.8</PREV_YEAR_REV>
<BUDGET>2391115.78</BUDGET>
<GROSS_PROFIT>1556316.439</GROSS_PROFIT>
<EXPENSES>1854715.37</EXPENSES>
<NET_INCOME>226895.6</NET_INCOME>
<REVENUE_M>2.08161097</REVENUE_M>
<PROFIT_M>1.556316439</PROFIT_M>
<INCOME_M>0.2268956</INCOME_M>
<PHARMA_REV_M>2.08161097</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.556316439</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2268956</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1510456.37</REVENUE>
<PREV_YEAR_REV>1347406.69</PREV_YEAR_REV>
<BUDGET>1470054.66</BUDGET>
<GROSS_PROFIT>1291440.19</GROSS_PROFIT>
<EXPENSES>1240084.68</EXPENSES>
<NET_INCOME>270371.69</NET_INCOME>
<REVENUE_M>1.51045637</REVENUE_M>
<PROFIT_M>1.29144019</PROFIT_M>
<INCOME_M>0.27037169</INCOME_M>
<PHARMA_REV_M>1.51045637</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.29144019</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27037169</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1471151.82</REVENUE>
<PREV_YEAR_REV>1282317.71</PREV_YEAR_REV>
<BUDGET>1515937.5</BUDGET>
<GROSS_PROFIT>1040692.797</GROSS_PROFIT>
<EXPENSES>1272546.32</EXPENSES>
<NET_INCOME>198605.5</NET_INCOME>
<REVENUE_M>1.47115182</REVENUE_M>
<PROFIT_M>1.040692797</PROFIT_M>
<INCOME_M>0.1986055</INCOME_M>
<PHARMA_REV_M>1.47115182</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.040692797</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1986055</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7332219.38</REVENUE>
<PREV_YEAR_REV>6258509.49</PREV_YEAR_REV>
<BUDGET>6745641.83</BUDGET>
<GROSS_PROFIT>5902216.639</GROSS_PROFIT>
<EXPENSES>6364366.42</EXPENSES>
<NET_INCOME>967852.96</NET_INCOME>
<REVENUE_M>7.33221938</REVENUE_M>
<PROFIT_M>5.902216639</PROFIT_M>
<INCOME_M>0.96785296</INCOME_M>
<PHARMA_REV_M>7.33221938</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.902216639</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.96785296</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.948568967E7</REVENUE>
<PREV_YEAR_REV>1.677022804E7</PREV_YEAR_REV>
<BUDGET>1.79268345E7</BUDGET>
<GROSS_PROFIT>1.54379707E7</GROSS_PROFIT>
<EXPENSES>1.729512454E7</EXPENSES>
<NET_INCOME>2190565.13</NET_INCOME>
<REVENUE_M>19.48568967</REVENUE_M>
<PROFIT_M>15.4379707</PROFIT_M>
<INCOME_M>2.19056513</INCOME_M>
<PHARMA_REV_M>19.48568967</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.4379707</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.19056513</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.93408933E7</REVENUE>
<PREV_YEAR_REV>1.719388036E7</PREV_YEAR_REV>
<BUDGET>1.779362184E7</BUDGET>
<GROSS_PROFIT>1.592277355E7</GROSS_PROFIT>
<EXPENSES>1.746608537E7</EXPENSES>
<NET_INCOME>1874807.93</NET_INCOME>
<REVENUE_M>19.3408933</REVENUE_M>
<PROFIT_M>15.92277355</PROFIT_M>
<INCOME_M>1.87480793</INCOME_M>
<PHARMA_REV_M>19.3408933</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.92277355</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.87480793</PHARMA_INCOME_M>
<FRANCE_REV_M>19.3408933</FRANCE_REV_M>
<FRANCE_PROFIT_M>15.92277355</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>1.87480793</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.675576644E7</REVENUE>
<PREV_YEAR_REV>1.498786743E7</PREV_YEAR_REV>
<BUDGET>1.541530512E7</BUDGET>
<GROSS_PROFIT>1.460884343E7</GROSS_PROFIT>
<EXPENSES>1.450357335E7</EXPENSES>
<NET_INCOME>2252193.09</NET_INCOME>
<REVENUE_M>16.75576644</REVENUE_M>
<PROFIT_M>14.60884343</PROFIT_M>
<INCOME_M>2.25219309</INCOME_M>
<PHARMA_REV_M>16.75576644</PHARMA_REV_M>
<PHARMA_PROFIT_M>14.60884343</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.25219309</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6190726.97</REVENUE>
<PREV_YEAR_REV>5577281.75</PREV_YEAR_REV>
<BUDGET>5695468.81</BUDGET>
<GROSS_PROFIT>4763764.408</GROSS_PROFIT>
<EXPENSES>5559272.82</EXPENSES>
<NET_INCOME>631454.15</NET_INCOME>
<REVENUE_M>6.19072697</REVENUE_M>
<PROFIT_M>4.763764408</PROFIT_M>
<INCOME_M>0.63145415</INCOME_M>
<PHARMA_REV_M>6.19072697</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.763764408</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.63145415</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.890413101E7</REVENUE>
<PREV_YEAR_REV>1.686970624E7</PREV_YEAR_REV>
<BUDGET>1.739180053E7</BUDGET>
<GROSS_PROFIT>1.618202501E7</GROSS_PROFIT>
<EXPENSES>1.63988782E7</EXPENSES>
<NET_INCOME>2505252.8</NET_INCOME>
<REVENUE_M>18.90413101</REVENUE_M>
<PROFIT_M>16.18202501</PROFIT_M>
<INCOME_M>2.5052528</INCOME_M>
<PHARMA_REV_M>18.90413101</PHARMA_REV_M>
<PHARMA_PROFIT_M>16.18202501</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.5052528</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5186080.67</REVENUE>
<PREV_YEAR_REV>4613814.53</PREV_YEAR_REV>
<BUDGET>5030498.25</BUDGET>
<GROSS_PROFIT>3953129.436</GROSS_PROFIT>
<EXPENSES>4488813.91</EXPENSES>
<NET_INCOME>697266.76</NET_INCOME>
<REVENUE_M>5.18608067</REVENUE_M>
<PROFIT_M>3.953129436</PROFIT_M>
<INCOME_M>0.69726676</INCOME_M>
<PHARMA_REV_M>5.18608067</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.953129436</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69726676</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5166978.86</REVENUE>
<PREV_YEAR_REV>4483589.87</PREV_YEAR_REV>
<BUDGET>5011969.5</BUDGET>
<GROSS_PROFIT>4355216.94</GROSS_PROFIT>
<EXPENSES>4471465.54</EXPENSES>
<NET_INCOME>695513.32</NET_INCOME>
<REVENUE_M>5.16697886</REVENUE_M>
<PROFIT_M>4.35521694</PROFIT_M>
<INCOME_M>0.69551332</INCOME_M>
<PHARMA_REV_M>5.16697886</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.35521694</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69551332</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2533065.41</REVENUE>
<PREV_YEAR_REV>2301322.26</PREV_YEAR_REV>
<BUDGET>2457073.45</BUDGET>
<GROSS_PROFIT>1970988.327</GROSS_PROFIT>
<EXPENSES>2191101.58</EXPENSES>
<NET_INCOME>341963.83</NET_INCOME>
<REVENUE_M>2.53306541</REVENUE_M>
<PROFIT_M>1.970988327</PROFIT_M>
<INCOME_M>0.34196383</INCOME_M>
<PHARMA_REV_M>2.53306541</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.970988327</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34196383</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2572218.18</REVENUE>
<PREV_YEAR_REV>2290610.52</PREV_YEAR_REV>
<BUDGET>2495051.63</BUDGET>
<GROSS_PROFIT>1801344.965</GROSS_PROFIT>
<EXPENSES>2224968.73</EXPENSES>
<NET_INCOME>347249.45</NET_INCOME>
<REVENUE_M>2.57221818</REVENUE_M>
<PROFIT_M>1.801344965</PROFIT_M>
<INCOME_M>0.34724945</INCOME_M>
<PHARMA_REV_M>2.57221818</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.801344965</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34724945</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3660190.54</REVENUE>
<PREV_YEAR_REV>3281678.35</PREV_YEAR_REV>
<BUDGET>3550384.82</BUDGET>
<GROSS_PROFIT>2872656.732</GROSS_PROFIT>
<EXPENSES>3255650.5</EXPENSES>
<NET_INCOME>404540.04</NET_INCOME>
<REVENUE_M>3.66019054</REVENUE_M>
<PROFIT_M>2.872656732</PROFIT_M>
<INCOME_M>0.40454004</INCOME_M>
<PHARMA_REV_M>3.66019054</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.872656732</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40454004</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1899634.28</REVENUE>
<PREV_YEAR_REV>1663311.04</PREV_YEAR_REV>
<BUDGET>1842645.25</BUDGET>
<GROSS_PROFIT>1478865.285</GROSS_PROFIT>
<EXPENSES>1654581.45</EXPENSES>
<NET_INCOME>245052.82</NET_INCOME>
<REVENUE_M>1.89963428</REVENUE_M>
<PROFIT_M>1.478865285</PROFIT_M>
<INCOME_M>0.24505282</INCOME_M>
<PHARMA_REV_M>1.89963428</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.478865285</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24505282</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1851510.65</REVENUE>
<PREV_YEAR_REV>1642502.24</PREV_YEAR_REV>
<BUDGET>1795965.33</BUDGET>
<GROSS_PROFIT>1571932.54</GROSS_PROFIT>
<EXPENSES>1607111.24</EXPENSES>
<NET_INCOME>244399.41</NET_INCOME>
<REVENUE_M>1.85151065</REVENUE_M>
<PROFIT_M>1.57193254</PROFIT_M>
<INCOME_M>0.24439941</INCOME_M>
<PHARMA_REV_M>1.85151065</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.57193254</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24439941</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1844919.27</REVENUE>
<PREV_YEAR_REV>1627257.33</PREV_YEAR_REV>
<BUDGET>1789571.69</BUDGET>
<GROSS_PROFIT>1488849.85</GROSS_PROFIT>
<EXPENSES>1710240.16</EXPENSES>
<NET_INCOME>134679.11</NET_INCOME>
<REVENUE_M>1.8449192700000001</REVENUE_M>
<PROFIT_M>1.48884985</PROFIT_M>
<INCOME_M>0.13467911</INCOME_M>
<PHARMA_REV_M>1.8449192700000001</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.48884985</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13467911</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1631723.5</REVENUE>
<PREV_YEAR_REV>1447705.64</PREV_YEAR_REV>
<BUDGET>2080411.46</BUDGET>
<GROSS_PROFIT>1326591.21</GROSS_PROFIT>
<EXPENSES>1512607.68</EXPENSES>
<NET_INCOME>119115.82</NET_INCOME>
<REVENUE_M>1.6317235</REVENUE_M>
<PROFIT_M>1.32659121</PROFIT_M>
<INCOME_M>0.11911582</INCOME_M>
<PHARMA_REV_M>1.6317235</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.32659121</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11911582</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3250702.87</REVENUE>
<PREV_YEAR_REV>2871241.9</PREV_YEAR_REV>
<BUDGET>4169898.27</BUDGET>
<GROSS_PROFIT>2638882.88</GROSS_PROFIT>
<EXPENSES>2813062.98</EXPENSES>
<NET_INCOME>437639.89</NET_INCOME>
<REVENUE_M>3.25070287</REVENUE_M>
<PROFIT_M>2.63888288</PROFIT_M>
<INCOME_M>0.43763989</INCOME_M>
<PHARMA_REV_M>3.25070287</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.63888288</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43763989</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1664489.08</REVENUE>
<PREV_YEAR_REV>1427141.23</PREV_YEAR_REV>
<BUDGET>2099372.33</BUDGET>
<GROSS_PROFIT>1349001.821</GROSS_PROFIT>
<EXPENSES>1483059.77</EXPENSES>
<NET_INCOME>181429.31</NET_INCOME>
<REVENUE_M>1.66448908</REVENUE_M>
<PROFIT_M>1.349001821</PROFIT_M>
<INCOME_M>0.18142931</INCOME_M>
<PHARMA_REV_M>1.66448908</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.349001821</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18142931</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1199094.66</REVENUE>
<PREV_YEAR_REV>1078371.02</PREV_YEAR_REV>
<BUDGET>1375088.14</BUDGET>
<GROSS_PROFIT>944346.9965</GROSS_PROFIT>
<EXPENSES>1007239.51</EXPENSES>
<NET_INCOME>191855.15</NET_INCOME>
<REVENUE_M>1.19909466</REVENUE_M>
<PROFIT_M>0.944346997</PROFIT_M>
<INCOME_M>0.19185515</INCOME_M>
<PHARMA_REV_M>1.19909466</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.944346997</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19185515</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1377214</REVENUE>
<PREV_YEAR_REV>1248845.2</PREV_YEAR_REV>
<BUDGET>1492214.01</BUDGET>
<GROSS_PROFIT>1142192.429</GROSS_PROFIT>
<EXPENSES>1195421.75</EXPENSES>
<NET_INCOME>181792.25</NET_INCOME>
<REVENUE_M>1.377214</REVENUE_M>
<PROFIT_M>1.142192429</PROFIT_M>
<INCOME_M>0.18179225</INCOME_M>
<PHARMA_REV_M>1.377214</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.142192429</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18179225</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2592669.83</REVENUE>
<PREV_YEAR_REV>2258912</PREV_YEAR_REV>
<BUDGET>2929667.87</BUDGET>
<GROSS_PROFIT>1799832.49</GROSS_PROFIT>
<EXPENSES>2277571.69</EXPENSES>
<NET_INCOME>315098.13</NET_INCOME>
<REVENUE_M>2.59266983</REVENUE_M>
<PROFIT_M>1.79983249</PROFIT_M>
<INCOME_M>0.31509813</INCOME_M>
<PHARMA_REV_M>2.59266983</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.79983249</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31509813</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2597128.63</REVENUE>
<PREV_YEAR_REV>2257888.98</PREV_YEAR_REV>
<BUDGET>2870413.52</BUDGET>
<GROSS_PROFIT>1824620.308</GROSS_PROFIT>
<EXPENSES>2213232.21</EXPENSES>
<NET_INCOME>383896.42</NET_INCOME>
<REVENUE_M>2.59712863</REVENUE_M>
<PROFIT_M>1.824620308</PROFIT_M>
<INCOME_M>0.38389642</INCOME_M>
<PHARMA_REV_M>2.59712863</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.824620308</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38389642</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1163701.95</REVENUE>
<PREV_YEAR_REV>1002655.44</PREV_YEAR_REV>
<BUDGET>1342280.73</BUDGET>
<GROSS_PROFIT>839750.6048</GROSS_PROFIT>
<EXPENSES>1006602.19</EXPENSES>
<NET_INCOME>157099.76</NET_INCOME>
<REVENUE_M>1.16370195</REVENUE_M>
<PROFIT_M>0.839750605</PROFIT_M>
<INCOME_M>0.15709976</INCOME_M>
<PHARMA_REV_M>1.16370195</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.839750605</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15709976</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1164612.68</REVENUE>
<PREV_YEAR_REV>992621.2</PREV_YEAR_REV>
<BUDGET>1330975.8</BUDGET>
<GROSS_PROFIT>866821.212</GROSS_PROFIT>
<EXPENSES>1007389.96</EXPENSES>
<NET_INCOME>157222.71</NET_INCOME>
<REVENUE_M>1.16461268</REVENUE_M>
<PROFIT_M>0.866821212</PROFIT_M>
<INCOME_M>0.15722271</INCOME_M>
<PHARMA_REV_M>1.16461268</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.866821212</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15722271</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2604157.97</REVENUE>
<PREV_YEAR_REV>2263051.53</PREV_YEAR_REV>
<BUDGET>2860943.71</BUDGET>
<GROSS_PROFIT>2078444.95</GROSS_PROFIT>
<EXPENSES>2258269.37</EXPENSES>
<NET_INCOME>345888.59</NET_INCOME>
<REVENUE_M>2.60415797</REVENUE_M>
<PROFIT_M>2.07844495</PROFIT_M>
<INCOME_M>0.34588859</INCOME_M>
<PHARMA_REV_M>2.60415797</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.07844495</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34588859</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6215809.05</REVENUE>
<PREV_YEAR_REV>5346840.53</PREV_YEAR_REV>
<BUDGET>6029334.78</BUDGET>
<GROSS_PROFIT>4671180.504</GROSS_PROFIT>
<EXPENSES>5413969.69</EXPENSES>
<NET_INCOME>801839.37</NET_INCOME>
<REVENUE_M>6.21580905</REVENUE_M>
<PROFIT_M>4.671180504</PROFIT_M>
<INCOME_M>0.80183937</INCOME_M>
<PHARMA_REV_M>6.21580905</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.671180504</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.80183937</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6868779.48</REVENUE>
<PREV_YEAR_REV>6066218.74</PREV_YEAR_REV>
<BUDGET>6662716.1</BUDGET>
<GROSS_PROFIT>5460679.69</GROSS_PROFIT>
<EXPENSES>5769774.76</EXPENSES>
<NET_INCOME>1099004.72</NET_INCOME>
<REVENUE_M>6.86877948</REVENUE_M>
<PROFIT_M>5.46067969</PROFIT_M>
<INCOME_M>1.09900472</INCOME_M>
<PHARMA_REV_M>6.86877948</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.46067969</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.09900472</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9688618.57</REVENUE>
<PREV_YEAR_REV>8752376.82</PREV_YEAR_REV>
<BUDGET>9397960.02</BUDGET>
<GROSS_PROFIT>7655946.399</GROSS_PROFIT>
<EXPENSES>8438786.78</EXPENSES>
<NET_INCOME>1249831.8</NET_INCOME>
<REVENUE_M>9.68861857</REVENUE_M>
<PROFIT_M>7.655946399</PROFIT_M>
<INCOME_M>1.2498318</INCOME_M>
<PHARMA_REV_M>9.68861857</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.655946399</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.2498318</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.556103951E7</REVENUE>
<PREV_YEAR_REV>1.345903601E7</PREV_YEAR_REV>
<BUDGET>1.509420832E7</BUDGET>
<GROSS_PROFIT>1.216071223E7</GROSS_PROFIT>
<EXPENSES>1.326908873E7</EXPENSES>
<NET_INCOME>2291950.77</NET_INCOME>
<REVENUE_M>15.56103951</REVENUE_M>
<PROFIT_M>12.16071223</PROFIT_M>
<INCOME_M>2.29195077</INCOME_M>
<PHARMA_REV_M>15.56103951</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.16071223</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.29195077</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.279396718E7</REVENUE>
<PREV_YEAR_REV>1.113834012E7</PREV_YEAR_REV>
<BUDGET>1.241014816E7</BUDGET>
<GROSS_PROFIT>9474340.05</GROSS_PROFIT>
<EXPENSES>1.088953617E7</EXPENSES>
<NET_INCOME>1904431.01</NET_INCOME>
<REVENUE_M>12.79396718</REVENUE_M>
<PROFIT_M>9.47434005</PROFIT_M>
<INCOME_M>1.90443101</INCOME_M>
<PHARMA_REV_M>12.79396718</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.47434005</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.90443101</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.892575075E7</REVENUE>
<PREV_YEAR_REV>1.653964679E7</PREV_YEAR_REV>
<BUDGET>1.835797823E7</BUDGET>
<GROSS_PROFIT>1.57673808E7</GROSS_PROFIT>
<EXPENSES>1.708877441E7</EXPENSES>
<NET_INCOME>1836976.33</NET_INCOME>
<REVENUE_M>18.92575075</REVENUE_M>
<PROFIT_M>15.7673808</PROFIT_M>
<INCOME_M>1.83697633</INCOME_M>
<PHARMA_REV_M>18.92575075</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.7673808</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.83697633</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8767139.54</REVENUE>
<PREV_YEAR_REV>7509262.91</PREV_YEAR_REV>
<BUDGET>8504125.36</BUDGET>
<GROSS_PROFIT>6209764.938</GROSS_PROFIT>
<EXPENSES>7583575.7</EXPENSES>
<NET_INCOME>1183563.84</NET_INCOME>
<REVENUE_M>8.76713954</REVENUE_M>
<PROFIT_M>6.209764938</PROFIT_M>
<INCOME_M>1.18356384</INCOME_M>
<PHARMA_REV_M>8.76713954</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.209764938</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.18356384</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8582297.27</REVENUE>
<PREV_YEAR_REV>7457290.43</PREV_YEAR_REV>
<BUDGET>8324828.35</BUDGET>
<GROSS_PROFIT>6726375.488</GROSS_PROFIT>
<EXPENSES>7706902.95</EXPENSES>
<NET_INCOME>875394.32</NET_INCOME>
<REVENUE_M>8.58229727</REVENUE_M>
<PROFIT_M>6.726375488</PROFIT_M>
<INCOME_M>0.87539432</INCOME_M>
<PHARMA_REV_M>8.58229727</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.726375488</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.87539432</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.690539642E7</REVENUE>
<PREV_YEAR_REV>1.484092096E7</PREV_YEAR_REV>
<BUDGET>1.639823452E7</BUDGET>
<GROSS_PROFIT>1.471551914E7</GROSS_PROFIT>
<EXPENSES>1.467612454E7</EXPENSES>
<NET_INCOME>2229271.88</NET_INCOME>
<REVENUE_M>16.90539642</REVENUE_M>
<PROFIT_M>14.71551914</PROFIT_M>
<INCOME_M>2.22927188</INCOME_M>
<PHARMA_REV_M>16.90539642</PHARMA_REV_M>
<PHARMA_PROFIT_M>14.71551914</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.22927188</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5740750.57</REVENUE>
<PREV_YEAR_REV>5049965.75</PREV_YEAR_REV>
<BUDGET>5568528.05</BUDGET>
<GROSS_PROFIT>4472699.137</GROSS_PROFIT>
<EXPENSES>4753341.47</EXPENSES>
<NET_INCOME>987409.1</NET_INCOME>
<REVENUE_M>5.74075057</REVENUE_M>
<PROFIT_M>4.472699137</PROFIT_M>
<INCOME_M>0.9874091</INCOME_M>
<PHARMA_REV_M>5.74075057</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.472699137</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.9874091</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>6173815.65</REVENUE>
<PREV_YEAR_REV>5432657.32</PREV_YEAR_REV>
<BUDGET>4768298.94</BUDGET>
<GROSS_PROFIT>4385700.073</GROSS_PROFIT>
<EXPENSES>5429419.48</EXPENSES>
<NET_INCOME>744396.19</NET_INCOME>
<REVENUE_M>6.17381565</REVENUE_M>
<PROFIT_M>4.385700073</PROFIT_M>
<INCOME_M>0.74439619</INCOME_M>
<PHARMA_REV_M>6.17381565</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.385700073</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74439619</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2649037.53</REVENUE>
<PREV_YEAR_REV>2324104.49</PREV_YEAR_REV>
<BUDGET>2053251.05</BUDGET>
<GROSS_PROFIT>2089587.293</GROSS_PROFIT>
<EXPENSES>2299364.58</EXPENSES>
<NET_INCOME>349672.95</NET_INCOME>
<REVENUE_M>2.64903753</REVENUE_M>
<PROFIT_M>2.089587293</PROFIT_M>
<INCOME_M>0.34967295</INCOME_M>
<PHARMA_REV_M>2.64903753</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.089587293</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34967295</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>6111398.8</REVENUE>
<PREV_YEAR_REV>5253903.74</PREV_YEAR_REV>
<BUDGET>4718980.49</BUDGET>
<GROSS_PROFIT>4939655.652</GROSS_PROFIT>
<EXPENSES>5434303.16</EXPENSES>
<NET_INCOME>677095.64</NET_INCOME>
<REVENUE_M>6.1113988</REVENUE_M>
<PROFIT_M>4.939655652</PROFIT_M>
<INCOME_M>0.67709564</INCOME_M>
<PHARMA_REV_M>6.1113988</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.939655652</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67709564</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6224329.15</REVENUE>
<PREV_YEAR_REV>5448765.06</PREV_YEAR_REV>
<BUDGET>4819338.81</BUDGET>
<GROSS_PROFIT>5419020.761</GROSS_PROFIT>
<EXPENSES>5387163.27</EXPENSES>
<NET_INCOME>837165.89</NET_INCOME>
<REVENUE_M>6.22432915</REVENUE_M>
<PROFIT_M>5.419020761</PROFIT_M>
<INCOME_M>0.83716589</INCOME_M>
<PHARMA_REV_M>6.22432915</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.419020761</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83716589</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2981812.51</REVENUE>
<PREV_YEAR_REV>2692819.16</PREV_YEAR_REV>
<BUDGET>2399156.5</BUDGET>
<GROSS_PROFIT>2422484.119</GROSS_PROFIT>
<EXPENSES>2764140.2</EXPENSES>
<NET_INCOME>217672.31</NET_INCOME>
<REVENUE_M>2.98181251</REVENUE_M>
<PROFIT_M>2.422484119</PROFIT_M>
<INCOME_M>0.21767231</INCOME_M>
<PHARMA_REV_M>2.98181251</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.422484119</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21767231</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2980324.78</REVENUE>
<PREV_YEAR_REV>2535065.82</PREV_YEAR_REV>
<BUDGET>2399156.5</BUDGET>
<GROSS_PROFIT>2089773.932</GROSS_PROFIT>
<EXPENSES>2577980.93</EXPENSES>
<NET_INCOME>402343.84</NET_INCOME>
<REVENUE_M>2.98032478</REVENUE_M>
<PROFIT_M>2.089773932</PROFIT_M>
<INCOME_M>0.40234384</INCOME_M>
<PHARMA_REV_M>2.98032478</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.089773932</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40234384</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1500682.08</REVENUE>
<PREV_YEAR_REV>1278471.03</PREV_YEAR_REV>
<BUDGET>1455661.61</BUDGET>
<GROSS_PROFIT>1186139.116</GROSS_PROFIT>
<EXPENSES>1242564.76</EXPENSES>
<NET_INCOME>258117.32</NET_INCOME>
<REVENUE_M>1.50068208</REVENUE_M>
<PROFIT_M>1.186139116</PROFIT_M>
<INCOME_M>0.25811732</INCOME_M>
<PHARMA_REV_M>1.50068208</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.186139116</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25811732</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>2.192027058E7</REVENUE>
<PREV_YEAR_REV>1.783533232E7</PREV_YEAR_REV>
<BUDGET>2.082425705E7</BUDGET>
<GROSS_PROFIT>1.750421657E7</GROSS_PROFIT>
<EXPENSES>1.953749773E7</EXPENSES>
<NET_INCOME>2382772.85</NET_INCOME>
<REVENUE_M>21.92027058</REVENUE_M>
<PROFIT_M>17.50421657</PROFIT_M>
<INCOME_M>2.38277285</INCOME_M>
<PHARMA_REV_M>21.92027058</PHARMA_REV_M>
<PHARMA_PROFIT_M>17.50421657</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.38277285</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7429560.77</REVENUE>
<PREV_YEAR_REV>5738973.86</PREV_YEAR_REV>
<BUDGET>7058082.73</BUDGET>
<GROSS_PROFIT>5860511.83</GROSS_PROFIT>
<EXPENSES>6448858.75</EXPENSES>
<NET_INCOME>980702.02</NET_INCOME>
<REVENUE_M>7.42956077</REVENUE_M>
<PROFIT_M>5.86051183</PROFIT_M>
<INCOME_M>0.98070202</INCOME_M>
<PHARMA_REV_M>7.42956077</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.86051183</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.98070202</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.47129571E7</REVENUE>
<PREV_YEAR_REV>1.185600031E7</PREV_YEAR_REV>
<BUDGET>1.397730924E7</BUDGET>
<GROSS_PROFIT>1.074493724E7</GROSS_PROFIT>
<EXPENSES>1.252793386E7</EXPENSES>
<NET_INCOME>2185023.23</NET_INCOME>
<REVENUE_M>14.7129571</REVENUE_M>
<PROFIT_M>10.74493724</PROFIT_M>
<INCOME_M>2.18502323</INCOME_M>
<PHARMA_REV_M>14.7129571</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.74493724</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.18502323</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7469095.38</REVENUE>
<PREV_YEAR_REV>6128438.23</PREV_YEAR_REV>
<BUDGET>7095640.61</BUDGET>
<GROSS_PROFIT>5624228.82</GROSS_PROFIT>
<EXPENSES>6923851.42</EXPENSES>
<NET_INCOME>545243.96</NET_INCOME>
<REVENUE_M>7.46909538</REVENUE_M>
<PROFIT_M>5.62422882</PROFIT_M>
<INCOME_M>0.54524396</INCOME_M>
<PHARMA_REV_M>7.46909538</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.62422882</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54524396</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2686162.5</REVENUE>
<PREV_YEAR_REV>2117155.73</PREV_YEAR_REV>
<BUDGET>2659300.88</BUDGET>
<GROSS_PROFIT>2181835.493</GROSS_PROFIT>
<EXPENSES>2331589.05</EXPENSES>
<NET_INCOME>354573.45</NET_INCOME>
<REVENUE_M>2.6861625</REVENUE_M>
<PROFIT_M>2.181835493</PROFIT_M>
<INCOME_M>0.35457345</INCOME_M>
<PHARMA_REV_M>2.6861625</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.181835493</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35457345</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3615209.42</REVENUE>
<PREV_YEAR_REV>2862489.25</PREV_YEAR_REV>
<BUDGET>3438990</BUDGET>
<GROSS_PROFIT>2848495.812</GROSS_PROFIT>
<EXPENSES>3351299.14</EXPENSES>
<NET_INCOME>263910.29</NET_INCOME>
<REVENUE_M>3.61520942</REVENUE_M>
<PROFIT_M>2.848495812</PROFIT_M>
<INCOME_M>0.26391029</INCOME_M>
<PHARMA_REV_M>3.61520942</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.848495812</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26391029</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3559521.92</REVENUE>
<PREV_YEAR_REV>2854903.25</PREV_YEAR_REV>
<BUDGET>3386643.75</BUDGET>
<GROSS_PROFIT>2649960.85</GROSS_PROFIT>
<EXPENSES>3078986.46</EXPENSES>
<NET_INCOME>480535.46</NET_INCOME>
<REVENUE_M>3.55952192</REVENUE_M>
<PROFIT_M>2.64996085</PROFIT_M>
<INCOME_M>0.48053546</INCOME_M>
<PHARMA_REV_M>3.55952192</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.64996085</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48053546</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2676396.92</REVENUE>
<PREV_YEAR_REV>2179724.83</PREV_YEAR_REV>
<BUDGET>2556506.25</BUDGET>
<GROSS_PROFIT>2250849.81</GROSS_PROFIT>
<EXPENSES>2323112.53</EXPENSES>
<NET_INCOME>353284.39</NET_INCOME>
<REVENUE_M>2.67639692</REVENUE_M>
<PROFIT_M>2.25084981</PROFIT_M>
<INCOME_M>0.35328439</INCOME_M>
<PHARMA_REV_M>2.67639692</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.25084981</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35328439</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5170900.1</REVENUE>
<PREV_YEAR_REV>4084805.06</PREV_YEAR_REV>
<BUDGET>4942032.38</BUDGET>
<GROSS_PROFIT>3964944.942</GROSS_PROFIT>
<EXPENSES>4545436.81</EXPENSES>
<NET_INCOME>625463.29</NET_INCOME>
<REVENUE_M>5.1709001</REVENUE_M>
<PROFIT_M>3.964944942</PROFIT_M>
<INCOME_M>0.62546329</INCOME_M>
<PHARMA_REV_M>5.1709001</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.964944942</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62546329</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4759638.98</REVENUE>
<PREV_YEAR_REV>3736013.75</PREV_YEAR_REV>
<BUDGET>4712042.59</BUDGET>
<GROSS_PROFIT>3423691.215</GROSS_PROFIT>
<EXPENSES>4183063.11</EXPENSES>
<NET_INCOME>576575.86</NET_INCOME>
<REVENUE_M>4.75963898</REVENUE_M>
<PROFIT_M>3.423691215</PROFIT_M>
<INCOME_M>0.57657586</INCOME_M>
<PHARMA_REV_M>4.75963898</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.423691215</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57657586</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2816572.5</REVENUE>
<PREV_YEAR_REV>2301215.33</PREV_YEAR_REV>
<BUDGET>2788406.78</BUDGET>
<GROSS_PROFIT>2106615.969</GROSS_PROFIT>
<EXPENSES>2453234.65</EXPENSES>
<NET_INCOME>363337.85</NET_INCOME>
<REVENUE_M>2.8165725</REVENUE_M>
<PROFIT_M>2.106615969</PROFIT_M>
<INCOME_M>0.36333785</INCOME_M>
<PHARMA_REV_M>2.8165725</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.106615969</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36333785</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5566224.83</REVENUE>
<PREV_YEAR_REV>4525367.01</PREV_YEAR_REV>
<BUDGET>5510562.58</BUDGET>
<GROSS_PROFIT>4314451.441</GROSS_PROFIT>
<EXPENSES>4817483.47</EXPENSES>
<NET_INCOME>748741.37</NET_INCOME>
<REVENUE_M>5.56622483</REVENUE_M>
<PROFIT_M>4.314451441</PROFIT_M>
<INCOME_M>0.74874137</INCOME_M>
<PHARMA_REV_M>5.56622483</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.314451441</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74874137</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5580697.5</REVENUE>
<PREV_YEAR_REV>4450652.5</PREV_YEAR_REV>
<BUDGET>5524890.53</BUDGET>
<GROSS_PROFIT>3972230.387</GROSS_PROFIT>
<EXPENSES>4751951.87</EXPENSES>
<NET_INCOME>828745.63</NET_INCOME>
<REVENUE_M>5.5806975</REVENUE_M>
<PROFIT_M>3.972230387</PROFIT_M>
<INCOME_M>0.82874563</INCOME_M>
<PHARMA_REV_M>5.5806975</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.972230387</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.82874563</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2798853.75</REVENUE>
<PREV_YEAR_REV>2173866.99</PREV_YEAR_REV>
<BUDGET>2770865.21</BUDGET>
<GROSS_PROFIT>2081395.58</GROSS_PROFIT>
<EXPENSES>2317450.91</EXPENSES>
<NET_INCOME>481402.85</NET_INCOME>
<REVENUE_M>2.79885375</REVENUE_M>
<PROFIT_M>2.08139558</PROFIT_M>
<INCOME_M>0.48140285</INCOME_M>
<PHARMA_REV_M>2.79885375</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.08139558</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48140285</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3992736.04</REVENUE>
<PREV_YEAR_REV>3141084.41</PREV_YEAR_REV>
<BUDGET>3952808.68</BUDGET>
<GROSS_PROFIT>2905289.649</GROSS_PROFIT>
<EXPENSES>3509867.81</EXPENSES>
<NET_INCOME>482868.23</NET_INCOME>
<REVENUE_M>3.99273604</REVENUE_M>
<PROFIT_M>2.905289649</PROFIT_M>
<INCOME_M>0.48286823</INCOME_M>
<PHARMA_REV_M>3.99273604</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.905289649</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48286823</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1941266.25</REVENUE>
<PREV_YEAR_REV>1623444.52</PREV_YEAR_REV>
<BUDGET>1921853.59</BUDGET>
<GROSS_PROFIT>1258115.246</GROSS_PROFIT>
<EXPENSES>1690842.9</EXPENSES>
<NET_INCOME>250423.35</NET_INCOME>
<REVENUE_M>1.94126625</REVENUE_M>
<PROFIT_M>1.258115246</PROFIT_M>
<INCOME_M>0.25042335</INCOME_M>
<PHARMA_REV_M>1.94126625</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.258115246</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25042335</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1964300.63</REVENUE>
<PREV_YEAR_REV>1620335.75</PREV_YEAR_REV>
<BUDGET>1944657.62</BUDGET>
<GROSS_PROFIT>1442582.379</GROSS_PROFIT>
<EXPENSES>1710905.84</EXPENSES>
<NET_INCOME>253394.78</NET_INCOME>
<REVENUE_M>1.96430063</REVENUE_M>
<PROFIT_M>1.442582379</PROFIT_M>
<INCOME_M>0.25339478</INCOME_M>
<PHARMA_REV_M>1.96430063</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.442582379</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25339478</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1985350.5</REVENUE>
<PREV_YEAR_REV>1581889.57</PREV_YEAR_REV>
<BUDGET>1965497</BUDGET>
<GROSS_PROFIT>1588280.4</GROSS_PROFIT>
<EXPENSES>1840419.91</EXPENSES>
<NET_INCOME>144930.59</NET_INCOME>
<REVENUE_M>1.9853505</REVENUE_M>
<PROFIT_M>1.5882804</PROFIT_M>
<INCOME_M>0.14493059</INCOME_M>
<PHARMA_REV_M>1.9853505</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.5882804</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14493059</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1971388.13</REVENUE>
<PREV_YEAR_REV>1657729.19</PREV_YEAR_REV>
<BUDGET>1951674.24</BUDGET>
<GROSS_PROFIT>1616538.26</GROSS_PROFIT>
<EXPENSES>1618509.65</EXPENSES>
<NET_INCOME>352878.47</NET_INCOME>
<REVENUE_M>1.97138813</REVENUE_M>
<PROFIT_M>1.61653826</PROFIT_M>
<INCOME_M>0.35287847</INCOME_M>
<PHARMA_REV_M>1.97138813</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.61653826</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35287847</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2001864.38</REVENUE>
<PREV_YEAR_REV>1630727.18</PREV_YEAR_REV>
<BUDGET>1981845.73</BUDGET>
<GROSS_PROFIT>1468167.335</GROSS_PROFIT>
<EXPENSES>1783661.16</EXPENSES>
<NET_INCOME>218203.22</NET_INCOME>
<REVENUE_M>2.00186438</REVENUE_M>
<PROFIT_M>1.468167335</PROFIT_M>
<INCOME_M>0.21820322</INCOME_M>
<PHARMA_REV_M>2.00186438</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.468167335</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21820322</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1455865.49</REVENUE>
<PREV_YEAR_REV>1230177.18</PREV_YEAR_REV>
<BUDGET>1441306.83</BUDGET>
<GROSS_PROFIT>1011717.328</GROSS_PROFIT>
<EXPENSES>1307367.21</EXPENSES>
<NET_INCOME>148498.28</NET_INCOME>
<REVENUE_M>1.45586549</REVENUE_M>
<PROFIT_M>1.011717328</PROFIT_M>
<INCOME_M>0.14849828</INCOME_M>
<PHARMA_REV_M>1.45586549</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.011717328</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14849828</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1539183.82</REVENUE>
<PREV_YEAR_REV>1223711.1</PREV_YEAR_REV>
<BUDGET>1523791.99</BUDGET>
<GROSS_PROFIT>1240582.16</GROSS_PROFIT>
<EXPENSES>1371412.79</EXPENSES>
<NET_INCOME>167771.04</NET_INCOME>
<REVENUE_M>1.53918382</REVENUE_M>
<PROFIT_M>1.24058216</PROFIT_M>
<INCOME_M>0.16777104</INCOME_M>
<PHARMA_REV_M>1.53918382</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.24058216</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16777104</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7816939.31</REVENUE>
<PREV_YEAR_REV>6215809.05</PREV_YEAR_REV>
<BUDGET>7738769.92</BUDGET>
<GROSS_PROFIT>5853324.159</GROSS_PROFIT>
<EXPENSES>6808554.14</EXPENSES>
<NET_INCOME>1008385.17</NET_INCOME>
<REVENUE_M>7.81693931</REVENUE_M>
<PROFIT_M>5.853324159</PROFIT_M>
<INCOME_M>1.00838517</INCOME_M>
<PHARMA_REV_M>7.81693931</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.853324159</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.00838517</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6448464.73</REVENUE>
<PREV_YEAR_REV>5098850.1</PREV_YEAR_REV>
<BUDGET>6383980.08</BUDGET>
<GROSS_PROFIT>5457851.574</GROSS_PROFIT>
<EXPENSES>5416710.37</EXPENSES>
<NET_INCOME>1031754.36</NET_INCOME>
<REVENUE_M>6.44846473</REVENUE_M>
<PROFIT_M>5.457851574</PROFIT_M>
<INCOME_M>1.03175436</INCOME_M>
<PHARMA_REV_M>6.44846473</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.457851574</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03175436</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>9092507.23</REVENUE>
<PREV_YEAR_REV>7329061.69</PREV_YEAR_REV>
<BUDGET>9001582.16</BUDGET>
<GROSS_PROFIT>7493680.759</GROSS_PROFIT>
<EXPENSES>7892296.27</EXPENSES>
<NET_INCOME>1200210.95</NET_INCOME>
<REVENUE_M>9.09250723</REVENUE_M>
<PROFIT_M>7.493680759</PROFIT_M>
<INCOME_M>1.20021095</INCOME_M>
<PHARMA_REV_M>9.09250723</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.493680759</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.20021095</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.185834366E7</REVENUE>
<PREV_YEAR_REV>9354097</PREV_YEAR_REV>
<BUDGET>1.173976022E7</BUDGET>
<GROSS_PROFIT>8834569.573</GROSS_PROFIT>
<EXPENSES>1.042015429E7</EXPENSES>
<NET_INCOME>1438189.37</NET_INCOME>
<REVENUE_M>11.85834366</REVENUE_M>
<PROFIT_M>8.834569573</PROFIT_M>
<INCOME_M>1.43818937</INCOME_M>
<PHARMA_REV_M>11.85834366</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.834569573</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.43818937</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.586170732E7</REVENUE>
<PREV_YEAR_REV>1.259089048E7</PREV_YEAR_REV>
<BUDGET>1.570309025E7</BUDGET>
<GROSS_PROFIT>1.298450591E7</GROSS_PROFIT>
<EXPENSES>1.37280014E7</EXPENSES>
<NET_INCOME>2133705.92</NET_INCOME>
<REVENUE_M>15.86170732</REVENUE_M>
<PROFIT_M>12.98450591</PROFIT_M>
<INCOME_M>2.13370592</INCOME_M>
<PHARMA_REV_M>15.86170732</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.98450591</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.13370592</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7456103.8</REVENUE>
<PREV_YEAR_REV>6147285.29</PREV_YEAR_REV>
<BUDGET>7381542.76</BUDGET>
<GROSS_PROFIT>5912690.31</GROSS_PROFIT>
<EXPENSES>6121461.22</EXPENSES>
<NET_INCOME>1334642.58</NET_INCOME>
<REVENUE_M>7.4561038</REVENUE_M>
<PROFIT_M>5.91269031</PROFIT_M>
<INCOME_M>1.33464258</INCOME_M>
<PHARMA_REV_M>7.4561038</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.91269031</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.33464258</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3346739.5</REVENUE>
<PREV_YEAR_REV>2662884.21</PREV_YEAR_REV>
<BUDGET>3179402.53</BUDGET>
<GROSS_PROFIT>2369863.054</GROSS_PROFIT>
<EXPENSES>2915010.1</EXPENSES>
<NET_INCOME>431729.4</NET_INCOME>
<REVENUE_M>3.3467395</REVENUE_M>
<PROFIT_M>2.369863054</PROFIT_M>
<INCOME_M>0.4317294</INCOME_M>
<PHARMA_REV_M>3.3467395</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.369863054</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4317294</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3761864.5</REVENUE>
<PREV_YEAR_REV>3087595.41</PREV_YEAR_REV>
<BUDGET>3573771.28</BUDGET>
<GROSS_PROFIT>3030407.568</GROSS_PROFIT>
<EXPENSES>3265298.39</EXPENSES>
<NET_INCOME>496566.11</NET_INCOME>
<REVENUE_M>3.7618645</REVENUE_M>
<PROFIT_M>3.030407568</PROFIT_M>
<INCOME_M>0.49656611</INCOME_M>
<PHARMA_REV_M>3.7618645</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.030407568</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49656611</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7567266.5</REVENUE>
<PREV_YEAR_REV>6001479.2</PREV_YEAR_REV>
<BUDGET>7188903.18</BUDGET>
<GROSS_PROFIT>5590265.032</GROSS_PROFIT>
<EXPENSES>6656913.51</EXPENSES>
<NET_INCOME>910352.99</NET_INCOME>
<REVENUE_M>7.5672665</REVENUE_M>
<PROFIT_M>5.590265032</PROFIT_M>
<INCOME_M>0.91035299</INCOME_M>
<PHARMA_REV_M>7.5672665</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.590265032</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.91035299</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1.160164538E7</REVENUE>
<PREV_YEAR_REV>9552352.05</PREV_YEAR_REV>
<BUDGET>1.102156311E7</BUDGET>
<GROSS_PROFIT>9465846.593</GROSS_PROFIT>
<EXPENSES>1.047824724E7</EXPENSES>
<NET_INCOME>1123398.13</NET_INCOME>
<REVENUE_M>11.60164538</REVENUE_M>
<PROFIT_M>9.465846593</PROFIT_M>
<INCOME_M>1.12339813</INCOME_M>
<PHARMA_REV_M>11.60164538</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.465846593</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.12339813</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3950864.5</REVENUE>
<PREV_YEAR_REV>3258256.84</PREV_YEAR_REV>
<BUDGET>3753321.28</BUDGET>
<GROSS_PROFIT>3176337.021</GROSS_PROFIT>
<EXPENSES>3243659.75</EXPENSES>
<NET_INCOME>707204.75</NET_INCOME>
<REVENUE_M>3.9508645</REVENUE_M>
<PROFIT_M>3.176337021</PROFIT_M>
<INCOME_M>0.70720475</INCOME_M>
<PHARMA_REV_M>3.9508645</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.176337021</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.70720475</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3819222.63</REVENUE>
<PREV_YEAR_REV>3182367.28</PREV_YEAR_REV>
<BUDGET>3628261.49</BUDGET>
<GROSS_PROFIT>3018713.559</GROSS_PROFIT>
<EXPENSES>3402927.36</EXPENSES>
<NET_INCOME>416295.27</NET_INCOME>
<REVENUE_M>3.81922263</REVENUE_M>
<PROFIT_M>3.018713559</PROFIT_M>
<INCOME_M>0.41629527</INCOME_M>
<PHARMA_REV_M>3.81922263</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.018713559</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41629527</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3852635.13</REVENUE>
<PREV_YEAR_REV>2998252.96</PREV_YEAR_REV>
<BUDGET>3660003.37</BUDGET>
<GROSS_PROFIT>3049697.809</GROSS_PROFIT>
<EXPENSES>3459666.34</EXPENSES>
<NET_INCOME>392968.78</NET_INCOME>
<REVENUE_M>3.85263513</REVENUE_M>
<PROFIT_M>3.049697809</PROFIT_M>
<INCOME_M>0.39296878</INCOME_M>
<PHARMA_REV_M>3.85263513</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.049697809</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39296878</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3991364.5</REVENUE>
<PREV_YEAR_REV>3220998.33</PREV_YEAR_REV>
<BUDGET>3791796.28</BUDGET>
<GROSS_PROFIT>2969052.323</GROSS_PROFIT>
<EXPENSES>3304849.81</EXPENSES>
<NET_INCOME>686514.69</NET_INCOME>
<REVENUE_M>3.9913645</REVENUE_M>
<PROFIT_M>2.969052323</PROFIT_M>
<INCOME_M>0.68651469</INCOME_M>
<PHARMA_REV_M>3.9913645</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.969052323</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68651469</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2463473.88</REVENUE>
<PREV_YEAR_REV>1918384.19</PREV_YEAR_REV>
<BUDGET>2217126.49</BUDGET>
<GROSS_PROFIT>1977233.398</GROSS_PROFIT>
<EXPENSES>2069318.06</EXPENSES>
<NET_INCOME>394155.82</NET_INCOME>
<REVENUE_M>2.46347388</REVENUE_M>
<PROFIT_M>1.977233398</PROFIT_M>
<INCOME_M>0.39415582</INCOME_M>
<PHARMA_REV_M>2.46347388</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.977233398</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39415582</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2893814.5</REVENUE>
<PREV_YEAR_REV>2259856.86</PREV_YEAR_REV>
<BUDGET>2604433.05</BUDGET>
<GROSS_PROFIT>2274422.445</GROSS_PROFIT>
<EXPENSES>2511830.99</EXPENSES>
<NET_INCOME>381983.51</NET_INCOME>
<REVENUE_M>2.8938145</REVENUE_M>
<PROFIT_M>2.274422445</PROFIT_M>
<INCOME_M>0.38198351</INCOME_M>
<PHARMA_REV_M>2.8938145</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.274422445</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38198351</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2891949.81</REVENUE>
<PREV_YEAR_REV>2290435.61</PREV_YEAR_REV>
<BUDGET>2602754.83</BUDGET>
<GROSS_PROFIT>2255952.209</GROSS_PROFIT>
<EXPENSES>2680837.48</EXPENSES>
<NET_INCOME>211112.34</NET_INCOME>
<REVENUE_M>2.89194981</REVENUE_M>
<PROFIT_M>2.255952209</PROFIT_M>
<INCOME_M>0.21111234</INCOME_M>
<PHARMA_REV_M>2.89194981</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.255952209</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21111234</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2868755.13</REVENUE>
<PREV_YEAR_REV>2394600.32</PREV_YEAR_REV>
<BUDGET>2581879.61</BUDGET>
<GROSS_PROFIT>2358747.839</GROSS_PROFIT>
<EXPENSES>2355247.96</EXPENSES>
<NET_INCOME>513507.17</NET_INCOME>
<REVENUE_M>2.86875513</REVENUE_M>
<PROFIT_M>2.358747839</PROFIT_M>
<INCOME_M>0.51350717</INCOME_M>
<PHARMA_REV_M>2.86875513</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.358747839</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51350717</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>8692724.43</REVENUE>
<PREV_YEAR_REV>7125135.29</PREV_YEAR_REV>
<BUDGET>7823451.99</BUDGET>
<GROSS_PROFIT>7212263.4</GROSS_PROFIT>
<EXPENSES>7849707.35</EXPENSES>
<NET_INCOME>843017.09</NET_INCOME>
<REVENUE_M>8.69272443</REVENUE_M>
<PROFIT_M>7.2122634</PROFIT_M>
<INCOME_M>0.84301709</INCOME_M>
<PHARMA_REV_M>8.69272443</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.2122634</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.84301709</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5745947.76</REVENUE>
<PREV_YEAR_REV>4724433.37</PREV_YEAR_REV>
<BUDGET>5171352.97</BUDGET>
<GROSS_PROFIT>4183389.153</GROSS_PROFIT>
<EXPENSES>4892602.79</EXPENSES>
<NET_INCOME>853344.96</NET_INCOME>
<REVENUE_M>5.74594776</REVENUE_M>
<PROFIT_M>4.183389153</PROFIT_M>
<INCOME_M>0.85334496</INCOME_M>
<PHARMA_REV_M>5.74594776</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.183389153</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.85334496</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2893814.5</REVENUE>
<PREV_YEAR_REV>2251627.75</PREV_YEAR_REV>
<BUDGET>2604433.05</BUDGET>
<GROSS_PROFIT>2221581.393</GROSS_PROFIT>
<EXPENSES>2503149.54</EXPENSES>
<NET_INCOME>390664.96</NET_INCOME>
<REVENUE_M>2.8938145</REVENUE_M>
<PROFIT_M>2.221581393</PROFIT_M>
<INCOME_M>0.39066496</INCOME_M>
<PHARMA_REV_M>2.8938145</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.221581393</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39066496</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5805423.69</REVENUE>
<PREV_YEAR_REV>4625156.56</PREV_YEAR_REV>
<BUDGET>5224881.32</BUDGET>
<GROSS_PROFIT>4536777.18</GROSS_PROFIT>
<EXPENSES>5035763.8</EXPENSES>
<NET_INCOME>769659.88</NET_INCOME>
<REVENUE_M>5.80542369</REVENUE_M>
<PROFIT_M>4.53677718</PROFIT_M>
<INCOME_M>0.76965988</INCOME_M>
<PHARMA_REV_M>5.80542369</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.53677718</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76965988</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2672583.25</REVENUE>
<PREV_YEAR_REV>2070325.55</PREV_YEAR_REV>
<BUDGET>2405324.93</BUDGET>
<GROSS_PROFIT>2263678.01</GROSS_PROFIT>
<EXPENSES>2381271.68</EXPENSES>
<NET_INCOME>291311.57</NET_INCOME>
<REVENUE_M>2.67258325</REVENUE_M>
<PROFIT_M>2.26367801</PROFIT_M>
<INCOME_M>0.29131157</INCOME_M>
<PHARMA_REV_M>2.67258325</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.26367801</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29131157</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2913473.88</REVENUE>
<PREV_YEAR_REV>2396973.93</PREV_YEAR_REV>
<BUDGET>2622126.49</BUDGET>
<GROSS_PROFIT>2145045.138</GROSS_PROFIT>
<EXPENSES>2595905.22</EXPENSES>
<NET_INCOME>317568.65</NET_INCOME>
<REVENUE_M>2.91347388</REVENUE_M>
<PROFIT_M>2.145045138</PROFIT_M>
<INCOME_M>0.31756865</INCOME_M>
<PHARMA_REV_M>2.91347388</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.145045138</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31756865</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3260390.13</REVENUE>
<PREV_YEAR_REV>2692378.94</PREV_YEAR_REV>
<BUDGET>2934351.11</BUDGET>
<GROSS_PROFIT>2637655.61</GROSS_PROFIT>
<EXPENSES>2905007.6</EXPENSES>
<NET_INCOME>355382.52</NET_INCOME>
<REVENUE_M>3.26039013</REVENUE_M>
<PROFIT_M>2.63765561</PROFIT_M>
<INCOME_M>0.35538252</INCOME_M>
<PHARMA_REV_M>3.26039013</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.63765561</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35538252</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2219552.46</REVENUE>
<PREV_YEAR_REV>1815198.78</PREV_YEAR_REV>
<BUDGET>2175161.41</BUDGET>
<GROSS_PROFIT>1751226.89</GROSS_PROFIT>
<EXPENSES>1926571.54</EXPENSES>
<NET_INCOME>292980.93</NET_INCOME>
<REVENUE_M>2.21955246</REVENUE_M>
<PROFIT_M>1.75122689</PROFIT_M>
<INCOME_M>0.29298093</INCOME_M>
<PHARMA_REV_M>2.21955246</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.75122689</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29298093</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4001357.6</REVENUE>
<PREV_YEAR_REV>3304779.42</PREV_YEAR_REV>
<BUDGET>3921330.45</BUDGET>
<GROSS_PROFIT>3186042.579</GROSS_PROFIT>
<EXPENSES>3464158.19</EXPENSES>
<NET_INCOME>537199.41</NET_INCOME>
<REVENUE_M>4.0013576</REVENUE_M>
<PROFIT_M>3.186042579</PROFIT_M>
<INCOME_M>0.53719941</INCOME_M>
<PHARMA_REV_M>4.0013576</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.186042579</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53719941</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>7032057.67</REVENUE>
<PREV_YEAR_REV>5552235.13</PREV_YEAR_REV>
<BUDGET>6891416.52</BUDGET>
<GROSS_PROFIT>5897947.78</GROSS_PROFIT>
<EXPENSES>6351337.12</EXPENSES>
<NET_INCOME>680720.55</NET_INCOME>
<REVENUE_M>7.03205767</REVENUE_M>
<PROFIT_M>5.89794778</PROFIT_M>
<INCOME_M>0.68072055</INCOME_M>
<PHARMA_REV_M>7.03205767</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.89794778</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68072055</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2461990</REVENUE>
<PREV_YEAR_REV>1900695.59</PREV_YEAR_REV>
<BUDGET>2412750.2</BUDGET>
<GROSS_PROFIT>1790888.456</GROSS_PROFIT>
<EXPENSES>2038527.72</EXPENSES>
<NET_INCOME>423462.28</NET_INCOME>
<REVENUE_M>2.46199</REVENUE_M>
<PROFIT_M>1.790888456</PROFIT_M>
<INCOME_M>0.42346228</INCOME_M>
<PHARMA_REV_M>2.46199</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.790888456</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42346228</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2005942.07</REVENUE>
<PREV_YEAR_REV>1581150.25</PREV_YEAR_REV>
<BUDGET>1965823.23</BUDGET>
<GROSS_PROFIT>1495931.304</GROSS_PROFIT>
<EXPENSES>1801335.98</EXPENSES>
<NET_INCOME>204606.09</NET_INCOME>
<REVENUE_M>2.00594207</REVENUE_M>
<PROFIT_M>1.495931304</PROFIT_M>
<INCOME_M>0.20460609</INCOME_M>
<PHARMA_REV_M>2.00594207</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.495931304</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20460609</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.808776025E7</REVENUE>
<PREV_YEAR_REV>1.479652291E7</PREV_YEAR_REV>
<BUDGET>1.664073943E7</BUDGET>
<GROSS_PROFIT>1.363346469E7</GROSS_PROFIT>
<EXPENSES>1.589851224E7</EXPENSES>
<NET_INCOME>2189248.01</NET_INCOME>
<REVENUE_M>18.08776025</REVENUE_M>
<PROFIT_M>13.63346469</PROFIT_M>
<INCOME_M>2.18924801</INCOME_M>
<PHARMA_REV_M>18.08776025</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.63346469</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.18924801</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>7879855.88</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>7249467.41</BUDGET>
<GROSS_PROFIT>5950107.648</GROSS_PROFIT>
<EXPENSES>6725316.69</EXPENSES>
<NET_INCOME>1154539.18</NET_INCOME>
<REVENUE_M>7.87985588</REVENUE_M>
<PROFIT_M>5.950107648</PROFIT_M>
<INCOME_M>1.15453918</INCOME_M>
<PHARMA_REV_M>7.87985588</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.950107648</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.15453918</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>38068420</REVENUE>
<PREV_YEAR_REV>2.477158538E7</PREV_YEAR_REV>
<BUDGET>2.95029464E7</BUDGET>
<GROSS_PROFIT>2.851457943E7</GROSS_PROFIT>
<EXPENSES>2.887865393E7</EXPENSES>
<NET_INCOME>3189766.08</NET_INCOME>
<REVENUE_M>38.06842</REVENUE_M>
<PROFIT_M>28.51457943</PROFIT_M>
<INCOME_M>3.18976608</INCOME_M>
<PHARMA_REV_M>38.06842</PHARMA_REV_M>
<PHARMA_PROFIT_M>28.51457943</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>3.18976608</PHARMA_INCOME_M>
<FRANCE_REV_M>38.06842</FRANCE_REV_M>
<FRANCE_PROFIT_M>28.51457943</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>3.18976608</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.362251663E7</REVENUE>
<PREV_YEAR_REV>9067976.86</PREV_YEAR_REV>
<BUDGET>1.06927153E7</BUDGET>
<GROSS_PROFIT>9660984.492</GROSS_PROFIT>
<EXPENSES>1.035566231E7</EXPENSES>
<NET_INCOME>1266854.31</NET_INCOME>
<REVENUE_M>13.62251663</REVENUE_M>
<PROFIT_M>9.660984492</PROFIT_M>
<INCOME_M>1.26685431</INCOME_M>
<PHARMA_REV_M>13.62251663</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.660984492</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.26685431</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3498584.42</REVENUE>
<PREV_YEAR_REV>2735448.89</PREV_YEAR_REV>
<BUDGET>3329362.5</BUDGET>
<GROSS_PROFIT>2698808.023</GROSS_PROFIT>
<EXPENSES>2938810.92</EXPENSES>
<NET_INCOME>559773.51</NET_INCOME>
<REVENUE_M>3.49858442</REVENUE_M>
<PROFIT_M>2.698808023</PROFIT_M>
<INCOME_M>0.55977351</INCOME_M>
<PHARMA_REV_M>3.49858442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.698808023</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55977351</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7184650.09</REVENUE>
<PREV_YEAR_REV>5670287.46</PREV_YEAR_REV>
<BUDGET>6834957.38</BUDGET>
<GROSS_PROFIT>5053060.576</GROSS_PROFIT>
<EXPENSES>6317032.87</EXPENSES>
<NET_INCOME>867617.23</NET_INCOME>
<REVENUE_M>7.18465009</REVENUE_M>
<PROFIT_M>5.053060576</PROFIT_M>
<INCOME_M>0.86761723</INCOME_M>
<PHARMA_REV_M>7.18465009</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.053060576</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.86761723</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3682334.42</REVENUE>
<PREV_YEAR_REV>3006281.78</PREV_YEAR_REV>
<BUDGET>3502087.5</BUDGET>
<GROSS_PROFIT>2835345.952</GROSS_PROFIT>
<EXPENSES>3207313.28</EXPENSES>
<NET_INCOME>475021.14</NET_INCOME>
<REVENUE_M>3.68233442</REVENUE_M>
<PROFIT_M>2.835345952</PROFIT_M>
<INCOME_M>0.47502114</INCOME_M>
<PHARMA_REV_M>3.68233442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.835345952</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47502114</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7269043.84</REVENUE>
<PREV_YEAR_REV>6010536.21</PREV_YEAR_REV>
<BUDGET>6914287.5</BUDGET>
<GROSS_PROFIT>5272219.854</GROSS_PROFIT>
<EXPENSES>6188523.02</EXPENSES>
<NET_INCOME>1080520.82</NET_INCOME>
<REVENUE_M>7.26904384</REVENUE_M>
<PROFIT_M>5.272219854</PROFIT_M>
<INCOME_M>1.08052082</INCOME_M>
<PHARMA_REV_M>7.26904384</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.272219854</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.08052082</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3802334.42</REVENUE>
<PREV_YEAR_REV>3028807.32</PREV_YEAR_REV>
<BUDGET>3614887.5</BUDGET>
<GROSS_PROFIT>3344951.613</GROSS_PROFIT>
<EXPENSES>3524764.01</EXPENSES>
<NET_INCOME>277570.41</NET_INCOME>
<REVENUE_M>3.80233442</REVENUE_M>
<PROFIT_M>3.344951613</PROFIT_M>
<INCOME_M>0.27757041</INCOME_M>
<PHARMA_REV_M>3.80233442</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.344951613</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27757041</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>700992.06</REVENUE>
<PREV_YEAR_REV>667509.77</PREV_YEAR_REV>
<BUDGET>1067833.89</BUDGET>
<GROSS_PROFIT>616172.02</GROSS_PROFIT>
<EXPENSES>624583.93</EXPENSES>
<NET_INCOME>76408.13</NET_INCOME>
<REVENUE_M>0.70099206</REVENUE_M>
<PROFIT_M>0.61617202</PROFIT_M>
<INCOME_M>0.07640813</INCOME_M>
<PHARMA_REV_M>0.70099206</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.61617202</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.07640813</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.163708495E7</REVENUE>
<PREV_YEAR_REV>1.086979065E7</PREV_YEAR_REV>
<BUDGET>1.117160155E7</BUDGET>
<GROSS_PROFIT>7875578.124</GROSS_PROFIT>
<EXPENSES>1.02277168E7</EXPENSES>
<NET_INCOME>1409368.15</NET_INCOME>
<REVENUE_M>11.63708495</REVENUE_M>
<PROFIT_M>7.875578124</PROFIT_M>
<INCOME_M>1.40936815</INCOME_M>
<PHARMA_REV_M>11.63708495</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.875578124</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.40936815</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.178226831E7</REVENUE>
<PREV_YEAR_REV>1.096247488E7</PREV_YEAR_REV>
<BUDGET>1.131097758E7</BUDGET>
<GROSS_PROFIT>8778231.38</GROSS_PROFIT>
<EXPENSES>1.019741039E7</EXPENSES>
<NET_INCOME>1584857.92</NET_INCOME>
<REVENUE_M>11.78226831</REVENUE_M>
<PROFIT_M>8.77823138</PROFIT_M>
<INCOME_M>1.58485792</INCOME_M>
<PHARMA_REV_M>11.78226831</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.77823138</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.58485792</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3526894.61</REVENUE>
<PREV_YEAR_REV>3304755.41</PREV_YEAR_REV>
<BUDGET>3258950.81</BUDGET>
<GROSS_PROFIT>2478279.482</GROSS_PROFIT>
<EXPENSES>3135427.23</EXPENSES>
<NET_INCOME>391467.38</NET_INCOME>
<REVENUE_M>3.52689461</REVENUE_M>
<PROFIT_M>2.478279482</PROFIT_M>
<INCOME_M>0.39146738</INCOME_M>
<PHARMA_REV_M>3.52689461</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.478279482</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39146738</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1720803.05</REVENUE>
<PREV_YEAR_REV>1628715.48</PREV_YEAR_REV>
<BUDGET>1620252.88</BUDGET>
<GROSS_PROFIT>1102768.03</GROSS_PROFIT>
<EXPENSES>1498819.46</EXPENSES>
<NET_INCOME>221983.59</NET_INCOME>
<REVENUE_M>1.72080305</REVENUE_M>
<PROFIT_M>1.10276803</PROFIT_M>
<INCOME_M>0.22198359</INCOME_M>
<PHARMA_REV_M>1.72080305</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.10276803</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22198359</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3509909.06</REVENUE>
<PREV_YEAR_REV>3235300.27</PREV_YEAR_REV>
<BUDGET>3259698.32</BUDGET>
<GROSS_PROFIT>2386956.853</GROSS_PROFIT>
<EXPENSES>3083352.55</EXPENSES>
<NET_INCOME>426556.52</NET_INCOME>
<REVENUE_M>3.50990906</REVENUE_M>
<PROFIT_M>2.386956853</PROFIT_M>
<INCOME_M>0.42655652</INCOME_M>
<PHARMA_REV_M>3.50990906</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.386956853</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42655652</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2112753.61</REVENUE>
<PREV_YEAR_REV>1945015.47</PREV_YEAR_REV>
<BUDGET>1916830.02</BUDGET>
<GROSS_PROFIT>1569564.654</GROSS_PROFIT>
<EXPENSES>1734570.71</EXPENSES>
<NET_INCOME>378182.9</NET_INCOME>
<REVENUE_M>2.11275361</REVENUE_M>
<PROFIT_M>1.569564654</PROFIT_M>
<INCOME_M>0.3781829</INCOME_M>
<PHARMA_REV_M>2.11275361</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.569564654</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3781829</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4047659.34</REVENUE>
<PREV_YEAR_REV>3758369.58</PREV_YEAR_REV>
<BUDGET>3805021.66</BUDGET>
<GROSS_PROFIT>2738141.724</GROSS_PROFIT>
<EXPENSES>3502541.74</EXPENSES>
<NET_INCOME>545117.6</NET_INCOME>
<REVENUE_M>4.04765934</REVENUE_M>
<PROFIT_M>2.738141724</PROFIT_M>
<INCOME_M>0.5451176</INCOME_M>
<PHARMA_REV_M>4.04765934</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.738141724</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5451176</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>1931350.98</REVENUE>
<PREV_YEAR_REV>1802575.02</PREV_YEAR_REV>
<BUDGET>1875085.94</BUDGET>
<GROSS_PROFIT>1370332.148</GROSS_PROFIT>
<EXPENSES>1585639.15</EXPENSES>
<NET_INCOME>345711.82</NET_INCOME>
<REVENUE_M>1.93135098</REVENUE_M>
<PROFIT_M>1.370332148</PROFIT_M>
<INCOME_M>0.34571182</INCOME_M>
<PHARMA_REV_M>1.93135098</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.370332148</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34571182</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4243192.79</REVENUE>
<PREV_YEAR_REV>3930600.99</PREV_YEAR_REV>
<BUDGET>3901615.53</BUDGET>
<GROSS_PROFIT>3076383.179</GROSS_PROFIT>
<EXPENSES>3683524.43</EXPENSES>
<NET_INCOME>559668.36</NET_INCOME>
<REVENUE_M>4.24319279</REVENUE_M>
<PROFIT_M>3.076383179</PROFIT_M>
<INCOME_M>0.55966836</INCOME_M>
<PHARMA_REV_M>4.24319279</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.076383179</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55966836</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2048038.53</REVENUE>
<PREV_YEAR_REV>1908009.7</PREV_YEAR_REV>
<BUDGET>1875085.94</BUDGET>
<GROSS_PROFIT>1323266.367</GROSS_PROFIT>
<EXPENSES>1839138.6</EXPENSES>
<NET_INCOME>208899.93</NET_INCOME>
<REVENUE_M>2.04803853</REVENUE_M>
<PROFIT_M>1.323266367</PROFIT_M>
<INCOME_M>0.20889993</INCOME_M>
<PHARMA_REV_M>2.04803853</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.323266367</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20889993</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2804661.49</REVENUE>
<PREV_YEAR_REV>2600299.17</PREV_YEAR_REV>
<BUDGET>3376122.25</BUDGET>
<GROSS_PROFIT>1889021.815</GROSS_PROFIT>
<EXPENSES>2388271.01</EXPENSES>
<NET_INCOME>416390.48</NET_INCOME>
<REVENUE_M>2.80466149</REVENUE_M>
<PROFIT_M>1.889021815</PROFIT_M>
<INCOME_M>0.41639048</INCOME_M>
<PHARMA_REV_M>2.80466149</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.889021815</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41639048</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1418492.09</REVENUE>
<PREV_YEAR_REV>1328711.08</PREV_YEAR_REV>
<BUDGET>1676720.65</BUDGET>
<GROSS_PROFIT>1109317.556</GROSS_PROFIT>
<EXPENSES>1164582.01</EXPENSES>
<NET_INCOME>253910.08</NET_INCOME>
<REVENUE_M>1.41849209</REVENUE_M>
<PROFIT_M>1.109317556</PROFIT_M>
<INCOME_M>0.25391008</INCOME_M>
<PHARMA_REV_M>1.41849209</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.109317556</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25391008</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2885652.15</REVENUE>
<PREV_YEAR_REV>2670827.9</PREV_YEAR_REV>
<BUDGET>3370072.38</BUDGET>
<GROSS_PROFIT>2135013.41</GROSS_PROFIT>
<EXPENSES>2497964.45</EXPENSES>
<NET_INCOME>387687.69</NET_INCOME>
<REVENUE_M>2.88565215</REVENUE_M>
<PROFIT_M>2.13501341</PROFIT_M>
<INCOME_M>0.38768769</INCOME_M>
<PHARMA_REV_M>2.88565215</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.13501341</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38768769</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.442079731E7</REVENUE>
<PREV_YEAR_REV>1.308544024E7</PREV_YEAR_REV>
<BUDGET>1.586287705E7</BUDGET>
<GROSS_PROFIT>1.180850537E7</GROSS_PROFIT>
<EXPENSES>1.283279062E7</EXPENSES>
<NET_INCOME>1588006.7</NET_INCOME>
<REVENUE_M>14.42079731</REVENUE_M>
<PROFIT_M>11.80850537</PROFIT_M>
<INCOME_M>1.5880067</INCOME_M>
<PHARMA_REV_M>14.42079731</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.80850537</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.5880067</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>9700857.33</REVENUE>
<PREV_YEAR_REV>8853534.11</PREV_YEAR_REV>
<BUDGET>1.067094306E7</BUDGET>
<GROSS_PROFIT>7814977.895</GROSS_PROFIT>
<EXPENSES>8642018.36</EXPENSES>
<NET_INCOME>1058838.97</NET_INCOME>
<REVENUE_M>9.70085733</REVENUE_M>
<PROFIT_M>7.814977895</PROFIT_M>
<INCOME_M>1.05883897</INCOME_M>
<PHARMA_REV_M>9.70085733</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.814977895</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.05883897</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.838093415E7</REVENUE>
<PREV_YEAR_REV>1.689339596E7</PREV_YEAR_REV>
<BUDGET>2.021902756E7</BUDGET>
<GROSS_PROFIT>1.546908329E7</GROSS_PROFIT>
<EXPENSES>1.654703739E7</EXPENSES>
<NET_INCOME>1833896.76</NET_INCOME>
<REVENUE_M>18.38093415</REVENUE_M>
<PROFIT_M>15.46908329</PROFIT_M>
<INCOME_M>1.83389676</INCOME_M>
<PHARMA_REV_M>18.38093415</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.46908329</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.83389676</PHARMA_INCOME_M>
<FRANCE_REV_M>18.38093415</FRANCE_REV_M>
<FRANCE_PROFIT_M>15.46908329</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>1.83389676</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5546066.29</REVENUE>
<PREV_YEAR_REV>5135626.98</PREV_YEAR_REV>
<BUDGET>6100672.92</BUDGET>
<GROSS_PROFIT>4632462.788</GROSS_PROFIT>
<EXPENSES>5141203.45</EXPENSES>
<NET_INCOME>404862.84</NET_INCOME>
<REVENUE_M>5.54606629</REVENUE_M>
<PROFIT_M>4.632462788</PROFIT_M>
<INCOME_M>0.40486284</INCOME_M>
<PHARMA_REV_M>5.54606629</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.632462788</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40486284</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5799476.69</REVENUE>
<PREV_YEAR_REV>5370383.08</PREV_YEAR_REV>
<BUDGET>6379424.36</BUDGET>
<GROSS_PROFIT>4935354.66</GROSS_PROFIT>
<EXPENSES>4761370.36</EXPENSES>
<NET_INCOME>1038106.33</NET_INCOME>
<REVENUE_M>5.79947669</REVENUE_M>
<PROFIT_M>4.93535466</PROFIT_M>
<INCOME_M>1.03810633</INCOME_M>
<PHARMA_REV_M>5.79947669</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.93535466</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03810633</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2891828.71</REVENUE>
<PREV_YEAR_REV>2677694.16</PREV_YEAR_REV>
<BUDGET>3376122.25</BUDGET>
<GROSS_PROFIT>1951779.27</GROSS_PROFIT>
<EXPENSES>2509708.57</EXPENSES>
<NET_INCOME>382120.14</NET_INCOME>
<REVENUE_M>2.89182871</REVENUE_M>
<PROFIT_M>1.95177927</PROFIT_M>
<INCOME_M>0.38212014</INCOME_M>
<PHARMA_REV_M>2.89182871</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.95177927</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38212014</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1412795.93</REVENUE>
<PREV_YEAR_REV>1333593.79</PREV_YEAR_REV>
<BUDGET>1682770.51</BUDGET>
<GROSS_PROFIT>924745.5705</GROSS_PROFIT>
<EXPENSES>1268690.74</EXPENSES>
<NET_INCOME>144105.18</NET_INCOME>
<REVENUE_M>1.41279593</REVENUE_M>
<PROFIT_M>0.924745571</PROFIT_M>
<INCOME_M>0.14410518</INCOME_M>
<PHARMA_REV_M>1.41279593</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.924745571</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14410518</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1473450.67</REVENUE>
<PREV_YEAR_REV>1381407.49</PREV_YEAR_REV>
<BUDGET>1637692.96</BUDGET>
<GROSS_PROFIT>822649.613</GROSS_PROFIT>
<EXPENSES>1274534.83</EXPENSES>
<NET_INCOME>198915.84</NET_INCOME>
<REVENUE_M>1.47345067</REVENUE_M>
<PROFIT_M>0.822649613</PROFIT_M>
<INCOME_M>0.19891584</INCOME_M>
<PHARMA_REV_M>1.47345067</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.822649613</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19891584</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1470413.54</REVENUE>
<PREV_YEAR_REV>1400220.49</PREV_YEAR_REV>
<BUDGET>1637692.96</BUDGET>
<GROSS_PROFIT>976428.1165</GROSS_PROFIT>
<EXPENSES>1320431.36</EXPENSES>
<NET_INCOME>149982.18</NET_INCOME>
<REVENUE_M>1.47041354</REVENUE_M>
<PROFIT_M>0.976428117</PROFIT_M>
<INCOME_M>0.14998218</INCOME_M>
<PHARMA_REV_M>1.47041354</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.976428117</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14998218</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2385272.41</REVENUE>
<PREV_YEAR_REV>2233855.91</PREV_YEAR_REV>
<BUDGET>2384604.33</BUDGET>
<GROSS_PROFIT>1399688.096</GROSS_PROFIT>
<EXPENSES>2095868.02</EXPENSES>
<NET_INCOME>289404.39</NET_INCOME>
<REVENUE_M>2.38527241</REVENUE_M>
<PROFIT_M>1.399688096</PROFIT_M>
<INCOME_M>0.28940439</INCOME_M>
<PHARMA_REV_M>2.38527241</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.399688096</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28940439</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>847889.26</REVENUE>
<PREV_YEAR_REV>786904.18</PREV_YEAR_REV>
<BUDGET>874926.7</BUDGET>
<GROSS_PROFIT>566220.447</GROSS_PROFIT>
<EXPENSES>738511.54</EXPENSES>
<NET_INCOME>109377.71</NET_INCOME>
<REVENUE_M>0.84788926</REVENUE_M>
<PROFIT_M>0.566220447</PROFIT_M>
<INCOME_M>0.10937771</INCOME_M>
<PHARMA_REV_M>0.84788926</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.566220447</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10937771</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1765512.72</REVENUE>
<PREV_YEAR_REV>1657673.06</PREV_YEAR_REV>
<BUDGET>1838880.44</BUDGET>
<GROSS_PROFIT>1318742.69</GROSS_PROFIT>
<EXPENSES>1528571.4</EXPENSES>
<NET_INCOME>236941.33</NET_INCOME>
<REVENUE_M>1.76551272</REVENUE_M>
<PROFIT_M>1.31874269</PROFIT_M>
<INCOME_M>0.23694133</INCOME_M>
<PHARMA_REV_M>1.76551272</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.31874269</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23694133</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2308669.96</REVENUE>
<PREV_YEAR_REV>2184117.75</PREV_YEAR_REV>
<BUDGET>2336374.23</BUDGET>
<GROSS_PROFIT>1454282.821</GROSS_PROFIT>
<EXPENSES>1967564.97</EXPENSES>
<NET_INCOME>341104.99</NET_INCOME>
<REVENUE_M>2.30866996</REVENUE_M>
<PROFIT_M>1.454282821</PROFIT_M>
<INCOME_M>0.34110499</INCOME_M>
<PHARMA_REV_M>2.30866996</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.454282821</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34110499</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2265595.4</REVENUE>
<PREV_YEAR_REV>2114869.68</PREV_YEAR_REV>
<BUDGET>2293766.51</BUDGET>
<GROSS_PROFIT>1527983.04</GROSS_PROFIT>
<EXPENSES>1960252.04</EXPENSES>
<NET_INCOME>305343.35</NET_INCOME>
<REVENUE_M>2.2655954</REVENUE_M>
<PROFIT_M>1.52798304</PROFIT_M>
<INCOME_M>0.30534335</INCOME_M>
<PHARMA_REV_M>2.2655954</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.52798304</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30534335</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.194520098E7</REVENUE>
<PREV_YEAR_REV>1.092739838E7</PREV_YEAR_REV>
<BUDGET>1.146739293E7</BUDGET>
<GROSS_PROFIT>8102903.503</GROSS_PROFIT>
<EXPENSES>1.062480508E7</EXPENSES>
<NET_INCOME>1320395.89</NET_INCOME>
<REVENUE_M>11.94520098</REVENUE_M>
<PROFIT_M>8.102903503</PROFIT_M>
<INCOME_M>1.32039589</INCOME_M>
<PHARMA_REV_M>11.94520098</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.102903503</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.32039589</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1019772.77</REVENUE>
<PREV_YEAR_REV>938749.31</PREV_YEAR_REV>
<BUDGET>1050558.61</BUDGET>
<GROSS_PROFIT>680188.44</GROSS_PROFIT>
<EXPENSES>837233.44</EXPENSES>
<NET_INCOME>182539.33</NET_INCOME>
<REVENUE_M>1.01977277</REVENUE_M>
<PROFIT_M>0.68018844</PROFIT_M>
<INCOME_M>0.18253933</INCOME_M>
<PHARMA_REV_M>1.01977277</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.68018844</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18253933</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1154015.3</REVENUE>
<PREV_YEAR_REV>1076617.28</PREV_YEAR_REV>
<BUDGET>1207902.38</BUDGET>
<GROSS_PROFIT>680098.721</GROSS_PROFIT>
<EXPENSES>955524.67</EXPENSES>
<NET_INCOME>198490.63</NET_INCOME>
<REVENUE_M>1.1540153</REVENUE_M>
<PROFIT_M>0.680098721</PROFIT_M>
<INCOME_M>0.19849063</INCOME_M>
<PHARMA_REV_M>1.1540153</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.680098721</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19849063</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.20587117E7</REVENUE>
<PREV_YEAR_REV>1.088633273E7</PREV_YEAR_REV>
<BUDGET>1.157636323E7</BUDGET>
<GROSS_PROFIT>7704323.658</GROSS_PROFIT>
<EXPENSES>1.059742968E7</EXPENSES>
<NET_INCOME>1461282.04</NET_INCOME>
<REVENUE_M>12.0587117</REVENUE_M>
<PROFIT_M>7.704323658</PROFIT_M>
<INCOME_M>1.46128204</INCOME_M>
<PHARMA_REV_M>12.0587117</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.704323658</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.46128204</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.014060944E7</REVENUE>
<PREV_YEAR_REV>9103014.46</PREV_YEAR_REV>
<BUDGET>9734985.07</BUDGET>
<GROSS_PROFIT>6974434.678</GROSS_PROFIT>
<EXPENSES>8635427.79</EXPENSES>
<NET_INCOME>1505181.66</NET_INCOME>
<REVENUE_M>10.14060944</REVENUE_M>
<PROFIT_M>6.974434678</PROFIT_M>
<INCOME_M>1.50518166</INCOME_M>
<PHARMA_REV_M>10.14060944</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.974434678</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.50518166</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.108312107E7</REVENUE>
<PREV_YEAR_REV>1.032829696E7</PREV_YEAR_REV>
<BUDGET>1.063979623E7</BUDGET>
<GROSS_PROFIT>7863855.59</GROSS_PROFIT>
<EXPENSES>9594302.51</EXPENSES>
<NET_INCOME>1488818.55</NET_INCOME>
<REVENUE_M>11.08312107</REVENUE_M>
<PROFIT_M>7.86385559</PROFIT_M>
<INCOME_M>1.48881855</INCOME_M>
<PHARMA_REV_M>11.08312107</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.86385559</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.48881855</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3369943.6</REVENUE>
<PREV_YEAR_REV>3056469.95</PREV_YEAR_REV>
<BUDGET>3504248.18</BUDGET>
<GROSS_PROFIT>2508081.705</GROSS_PROFIT>
<EXPENSES>2997231.67</EXPENSES>
<NET_INCOME>372711.93</NET_INCOME>
<REVENUE_M>3.3699436</REVENUE_M>
<PROFIT_M>2.508081705</PROFIT_M>
<INCOME_M>0.37271193</INCOME_M>
<PHARMA_REV_M>3.3699436</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.508081705</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37271193</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1597895.41</REVENUE>
<PREV_YEAR_REV>1474386.08</PREV_YEAR_REV>
<BUDGET>1743125.99</BUDGET>
<GROSS_PROFIT>1060315.453</GROSS_PROFIT>
<EXPENSES>1386973.21</EXPENSES>
<NET_INCOME>210922.19</NET_INCOME>
<REVENUE_M>1.59789541</REVENUE_M>
<PROFIT_M>1.060315453</PROFIT_M>
<INCOME_M>0.21092219</INCOME_M>
<PHARMA_REV_M>1.59789541</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.060315453</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21092219</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5845212.64</REVENUE>
<PREV_YEAR_REV>5336141.3</PREV_YEAR_REV>
<BUDGET>6071086.49</BUDGET>
<GROSS_PROFIT>4118893.255</GROSS_PROFIT>
<EXPENSES>5278743.42</EXPENSES>
<NET_INCOME>566469.22</NET_INCOME>
<REVENUE_M>5.84521264</REVENUE_M>
<PROFIT_M>4.118893255</PROFIT_M>
<INCOME_M>0.56646922</INCOME_M>
<PHARMA_REV_M>5.84521264</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.118893255</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56646922</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2009449.27</REVENUE>
<PREV_YEAR_REV>1806896.21</PREV_YEAR_REV>
<BUDGET>2061107.55</BUDGET>
<GROSS_PROFIT>1517636.562</GROSS_PROFIT>
<EXPENSES>1649757.85</EXPENSES>
<NET_INCOME>359691.42</NET_INCOME>
<REVENUE_M>2.00944927</REVENUE_M>
<PROFIT_M>1.517636562</PROFIT_M>
<INCOME_M>0.35969142</INCOME_M>
<PHARMA_REV_M>2.00944927</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.517636562</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35969142</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3862916.73</REVENUE>
<PREV_YEAR_REV>3549444.32</PREV_YEAR_REV>
<BUDGET>4091421.14</BUDGET>
<GROSS_PROFIT>2769913.86</GROSS_PROFIT>
<EXPENSES>3342189.58</EXPENSES>
<NET_INCOME>520727.15</NET_INCOME>
<REVENUE_M>3.86291673</REVENUE_M>
<PROFIT_M>2.76991386</PROFIT_M>
<INCOME_M>0.52072715</INCOME_M>
<PHARMA_REV_M>3.86291673</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.76991386</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52072715</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4026851.67</REVENUE>
<PREV_YEAR_REV>3678632.76</PREV_YEAR_REV>
<BUDGET>4099030.9</BUDGET>
<GROSS_PROFIT>2917571.994</GROSS_PROFIT>
<EXPENSES>3485058.62</EXPENSES>
<NET_INCOME>541793.06</NET_INCOME>
<REVENUE_M>4.02685167</REVENUE_M>
<PROFIT_M>2.917571994</PROFIT_M>
<INCOME_M>0.54179306</INCOME_M>
<PHARMA_REV_M>4.02685167</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.917571994</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54179306</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3929778.25</REVENUE>
<PREV_YEAR_REV>3542379.4</PREV_YEAR_REV>
<BUDGET>4109688.74</BUDGET>
<GROSS_PROFIT>2518042.906</GROSS_PROFIT>
<EXPENSES>3344551.89</EXPENSES>
<NET_INCOME>585226.35</NET_INCOME>
<REVENUE_M>3.92977825</REVENUE_M>
<PROFIT_M>2.518042906</PROFIT_M>
<INCOME_M>0.58522635</INCOME_M>
<PHARMA_REV_M>3.92977825</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.518042906</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58522635</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1826146.66</REVENUE>
<PREV_YEAR_REV>1702716.73</PREV_YEAR_REV>
<BUDGET>2034478.6</BUDGET>
<GROSS_PROFIT>1249084.32</GROSS_PROFIT>
<EXPENSES>1627096.68</EXPENSES>
<NET_INCOME>199049.99</NET_INCOME>
<REVENUE_M>1.82614666</REVENUE_M>
<PROFIT_M>1.24908432</PROFIT_M>
<INCOME_M>0.19904999</INCOME_M>
<PHARMA_REV_M>1.82614666</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.24908432</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19904999</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2828172.8</REVENUE>
<PREV_YEAR_REV>2594441.58</PREV_YEAR_REV>
<BUDGET>3673498.77</BUDGET>
<GROSS_PROFIT>1679460.888</GROSS_PROFIT>
<EXPENSES>2484899.14</EXPENSES>
<NET_INCOME>343273.65</NET_INCOME>
<REVENUE_M>2.8281728</REVENUE_M>
<PROFIT_M>1.679460888</PROFIT_M>
<INCOME_M>0.34327365</INCOME_M>
<PHARMA_REV_M>2.8281728</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.679460888</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34327365</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1394435.94</REVENUE>
<PREV_YEAR_REV>1288412.47</PREV_YEAR_REV>
<BUDGET>1801292.61</BUDGET>
<GROSS_PROFIT>964949.67</GROSS_PROFIT>
<EXPENSES>1171326.19</EXPENSES>
<NET_INCOME>223109.75</NET_INCOME>
<REVENUE_M>1.39443594</REVENUE_M>
<PROFIT_M>0.96494967</PROFIT_M>
<INCOME_M>0.22310975</INCOME_M>
<PHARMA_REV_M>1.39443594</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.96494967</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22310975</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1439484.59</REVENUE>
<PREV_YEAR_REV>1328109.35</PREV_YEAR_REV>
<BUDGET>1820808.31</BUDGET>
<GROSS_PROFIT>916951.6902</GROSS_PROFIT>
<EXPENSES>1334402.22</EXPENSES>
<NET_INCOME>105082.38</NET_INCOME>
<REVENUE_M>1.43948459</REVENUE_M>
<PROFIT_M>0.91695169</PROFIT_M>
<INCOME_M>0.10508238</INCOME_M>
<PHARMA_REV_M>1.43948459</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.91695169</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10508238</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1433911.48</REVENUE>
<PREV_YEAR_REV>1301013</PREV_YEAR_REV>
<BUDGET>1809430.66</BUDGET>
<GROSS_PROFIT>892251.419</GROSS_PROFIT>
<EXPENSES>1287652.51</EXPENSES>
<NET_INCOME>146258.97</NET_INCOME>
<REVENUE_M>1.43391148</REVENUE_M>
<PROFIT_M>0.892251419</PROFIT_M>
<INCOME_M>0.14625897</INCOME_M>
<PHARMA_REV_M>1.43391148</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.892251419</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14625897</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2044844.5</REVENUE>
<PREV_YEAR_REV>1871808.42</PREV_YEAR_REV>
<BUDGET>2325893.85</BUDGET>
<GROSS_PROFIT>1291999.923</GROSS_PROFIT>
<EXPENSES>1741549.16</EXPENSES>
<NET_INCOME>303295.35</NET_INCOME>
<REVENUE_M>2.0448445</REVENUE_M>
<PROFIT_M>1.291999923</PROFIT_M>
<INCOME_M>0.30329535</INCOME_M>
<PHARMA_REV_M>2.0448445</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.291999923</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30329535</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3086744.42</REVENUE>
<PREV_YEAR_REV>2812548.94</PREV_YEAR_REV>
<BUDGET>3658497.31</BUDGET>
<GROSS_PROFIT>2220899.8</GROSS_PROFIT>
<EXPENSES>2786951.27</EXPENSES>
<NET_INCOME>299793.14</NET_INCOME>
<REVENUE_M>3.08674442</REVENUE_M>
<PROFIT_M>2.2208998</PROFIT_M>
<INCOME_M>0.29979314</INCOME_M>
<PHARMA_REV_M>3.08674442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.2208998</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29979314</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>992621.2</REVENUE>
<PREV_YEAR_REV>892492.47</PREV_YEAR_REV>
<BUDGET>1164890.63</BUDGET>
<GROSS_PROFIT>610164.252</GROSS_PROFIT>
<EXPENSES>858617.34</EXPENSES>
<NET_INCOME>134003.86</NET_INCOME>
<REVENUE_M>0.9926212</REVENUE_M>
<PROFIT_M>0.610164252</PROFIT_M>
<INCOME_M>0.13400386</INCOME_M>
<PHARMA_REV_M>0.9926212</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.610164252</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13400386</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1108647.05</REVENUE>
<PREV_YEAR_REV>994703.74</PREV_YEAR_REV>
<BUDGET>1291630.73</BUDGET>
<GROSS_PROFIT>841518.5405</GROSS_PROFIT>
<EXPENSES>917959.76</EXPENSES>
<NET_INCOME>190687.29</NET_INCOME>
<REVENUE_M>1.10864705</REVENUE_M>
<PROFIT_M>0.841518541</PROFIT_M>
<INCOME_M>0.19068729</INCOME_M>
<PHARMA_REV_M>1.10864705</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.841518541</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19068729</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.48564058E7</REVENUE>
<PREV_YEAR_REV>1.403744601E7</PREV_YEAR_REV>
<BUDGET>6024979.25</BUDGET>
<GROSS_PROFIT>1.156596745E7</GROSS_PROFIT>
<EXPENSES>5667246.11</EXPENSES>
<NET_INCOME>1672741.78</NET_INCOME>
<REVENUE_M>14.8564058</REVENUE_M>
<PROFIT_M>11.56596745</PROFIT_M>
<INCOME_M>1.67274178</INCOME_M>
<PHARMA_REV_M>14.8564058</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.56596745</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.67274178</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5948306.31</REVENUE>
<PREV_YEAR_REV>5596509.71</PREV_YEAR_REV>
<BUDGET>5710374.06</BUDGET>
<GROSS_PROFIT>5106620.974</GROSS_PROFIT>
<EXPENSES>5514079.95</EXPENSES>
<NET_INCOME>434226.36</NET_INCOME>
<REVENUE_M>5.94830631</REVENUE_M>
<PROFIT_M>5.106620974</PROFIT_M>
<INCOME_M>0.43422636</INCOME_M>
<PHARMA_REV_M>5.94830631</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.106620974</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43422636</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8585452.58</REVENUE>
<PREV_YEAR_REV>7974228</PREV_YEAR_REV>
<BUDGET>8242034.48</BUDGET>
<GROSS_PROFIT>6555508.175</GROSS_PROFIT>
<EXPENSES>7426416.48</EXPENSES>
<NET_INCOME>1159036.1</NET_INCOME>
<REVENUE_M>8.58545258</REVENUE_M>
<PROFIT_M>6.555508175</PROFIT_M>
<INCOME_M>1.1590361</INCOME_M>
<PHARMA_REV_M>8.58545258</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.555508175</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.1590361</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7717209.06</REVENUE>
<PREV_YEAR_REV>7190571.59</PREV_YEAR_REV>
<BUDGET>7408520.69</BUDGET>
<GROSS_PROFIT>6153274.2</GROSS_PROFIT>
<EXPENSES>6389849.1</EXPENSES>
<NET_INCOME>1327359.96</NET_INCOME>
<REVENUE_M>7.71720906</REVENUE_M>
<PROFIT_M>6.1532742</PROFIT_M>
<INCOME_M>1.32735996</INCOME_M>
<PHARMA_REV_M>7.71720906</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.1532742</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.32735996</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4470726.62</REVENUE>
<PREV_YEAR_REV>4218555.76</PREV_YEAR_REV>
<BUDGET>3441633.42</BUDGET>
<GROSS_PROFIT>3309994.786</GROSS_PROFIT>
<EXPENSES>3979774.72</EXPENSES>
<NET_INCOME>490951.91</NET_INCOME>
<REVENUE_M>4.47072662</REVENUE_M>
<PROFIT_M>3.309994786</PROFIT_M>
<INCOME_M>0.49095191</INCOME_M>
<PHARMA_REV_M>4.47072662</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.309994786</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49095191</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2290466.8</REVENUE>
<PREV_YEAR_REV>2145314.8</PREV_YEAR_REV>
<BUDGET>1714483.53</BUDGET>
<GROSS_PROFIT>1869135.431</GROSS_PROFIT>
<EXPENSES>1988125.18</EXPENSES>
<NET_INCOME>302341.62</NET_INCOME>
<REVENUE_M>2.2904668</REVENUE_M>
<PROFIT_M>1.869135431</PROFIT_M>
<INCOME_M>0.30234162</INCOME_M>
<PHARMA_REV_M>2.2904668</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.869135431</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30234162</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2281461.91</REVENUE>
<PREV_YEAR_REV>2139485.64</PREV_YEAR_REV>
<BUDGET>1798615.36</BUDGET>
<GROSS_PROFIT>1673657.644</GROSS_PROFIT>
<EXPENSES>1987153.32</EXPENSES>
<NET_INCOME>294308.59</NET_INCOME>
<REVENUE_M>2.28146191</REVENUE_M>
<PROFIT_M>1.673657644</PROFIT_M>
<INCOME_M>0.29430859</INCOME_M>
<PHARMA_REV_M>2.28146191</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.673657644</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29430859</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1932409.73</REVENUE>
<PREV_YEAR_REV>1803394.86</PREV_YEAR_REV>
<BUDGET>1510808.31</BUDGET>
<GROSS_PROFIT>1645311.614</GROSS_PROFIT>
<EXPENSES>1677331.64</EXPENSES>
<NET_INCOME>255078.08</NET_INCOME>
<REVENUE_M>1.93240973</REVENUE_M>
<PROFIT_M>1.645311614</PROFIT_M>
<INCOME_M>0.25507808</INCOME_M>
<PHARMA_REV_M>1.93240973</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.645311614</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25507808</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2443467.66</REVENUE>
<PREV_YEAR_REV>2258308.92</PREV_YEAR_REV>
<BUDGET>1732578.34</BUDGET>
<GROSS_PROFIT>2100062.717</GROSS_PROFIT>
<EXPENSES>2120929.93</EXPENSES>
<NET_INCOME>322537.73</NET_INCOME>
<REVENUE_M>2.44346766</REVENUE_M>
<PROFIT_M>2.100062717</PROFIT_M>
<INCOME_M>0.32253773</INCOME_M>
<PHARMA_REV_M>2.44346766</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.100062717</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32253773</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>6923173.8</REVENUE>
<PREV_YEAR_REV>6532817.31</PREV_YEAR_REV>
<BUDGET>5327293.88</BUDGET>
<GROSS_PROFIT>5812621.795</GROSS_PROFIT>
<EXPENSES>6253793.7</EXPENSES>
<NET_INCOME>669380.1</NET_INCOME>
<REVENUE_M>6.9231738</REVENUE_M>
<PROFIT_M>5.812621795</PROFIT_M>
<INCOME_M>0.6693801</INCOME_M>
<PHARMA_REV_M>6.9231738</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.812621795</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6693801</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1733222.14</REVENUE>
<PREV_YEAR_REV>1644189.29</PREV_YEAR_REV>
<BUDGET>1579383.46</BUDGET>
<GROSS_PROFIT>1297867.939</GROSS_PROFIT>
<EXPENSES>1509636.48</EXPENSES>
<NET_INCOME>223585.66</NET_INCOME>
<REVENUE_M>1.73322214</REVENUE_M>
<PROFIT_M>1.297867939</PROFIT_M>
<INCOME_M>0.22358566</INCOME_M>
<PHARMA_REV_M>1.73322214</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.297867939</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22358566</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3289121.39</REVENUE>
<PREV_YEAR_REV>3027337.26</PREV_YEAR_REV>
<BUDGET>3126779.31</BUDGET>
<GROSS_PROFIT>2656978.25</GROSS_PROFIT>
<EXPENSES>2924754.64</EXPENSES>
<NET_INCOME>364366.76</NET_INCOME>
<REVENUE_M>3.28912139</REVENUE_M>
<PROFIT_M>2.65697825</PROFIT_M>
<INCOME_M>0.36436676</INCOME_M>
<PHARMA_REV_M>3.28912139</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.65697825</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36436676</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1565592.7</REVENUE>
<PREV_YEAR_REV>1486933.89</PREV_YEAR_REV>
<BUDGET>1578137.41</BUDGET>
<GROSS_PROFIT>1246368.346</GROSS_PROFIT>
<EXPENSES>1451304.43</EXPENSES>
<NET_INCOME>114288.27</NET_INCOME>
<REVENUE_M>1.5655927</REVENUE_M>
<PROFIT_M>1.246368346</PROFIT_M>
<INCOME_M>0.11428827</INCOME_M>
<PHARMA_REV_M>1.5655927</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.246368346</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11428827</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1576738.81</REVENUE>
<PREV_YEAR_REV>1471222.71</PREV_YEAR_REV>
<BUDGET>1526265.61</BUDGET>
<GROSS_PROFIT>1172857.16</GROSS_PROFIT>
<EXPENSES>1363879.07</EXPENSES>
<NET_INCOME>212859.74</NET_INCOME>
<REVENUE_M>1.57673881</REVENUE_M>
<PROFIT_M>1.17285716</PROFIT_M>
<INCOME_M>0.21285974</INCOME_M>
<PHARMA_REV_M>1.57673881</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.17285716</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21285974</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1632802.29</REVENUE>
<PREV_YEAR_REV>1512666.33</PREV_YEAR_REV>
<BUDGET>1592520.56</BUDGET>
<GROSS_PROFIT>1289015.765</GROSS_PROFIT>
<EXPENSES>1454826.84</EXPENSES>
<NET_INCOME>177975.45</NET_INCOME>
<REVENUE_M>1.63280229</REVENUE_M>
<PROFIT_M>1.289015765</PROFIT_M>
<INCOME_M>0.17797545</INCOME_M>
<PHARMA_REV_M>1.63280229</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.289015765</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17797545</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.006090929E7</REVENUE>
<PREV_YEAR_REV>1.905786382E7</PREV_YEAR_REV>
<BUDGET>1.945908201E7</BUDGET>
<GROSS_PROFIT>1.511188296E7</GROSS_PROFIT>
<EXPENSES>1.690848068E7</EXPENSES>
<NET_INCOME>2658604.55</NET_INCOME>
<REVENUE_M>20.06090929</REVENUE_M>
<PROFIT_M>15.11188296</PROFIT_M>
<INCOME_M>2.65860455</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.057208497E7</REVENUE>
<PREV_YEAR_REV>1.004348072E7</PREV_YEAR_REV>
<BUDGET>1.025492242E7</BUDGET>
<GROSS_PROFIT>7565754.022</GROSS_PROFIT>
<EXPENSES>8933129.08</EXPENSES>
<NET_INCOME>1078352.67</NET_INCOME>
<REVENUE_M>10.57208497</REVENUE_M>
<PROFIT_M>7.565754022</PROFIT_M>
<INCOME_M>1.07835267</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.356097968E7</REVENUE>
<PREV_YEAR_REV>1.28829307E7</PREV_YEAR_REV>
<BUDGET>1.315415029E7</BUDGET>
<GROSS_PROFIT>9704711.693</GROSS_PROFIT>
<EXPENSES>1.145866518E7</EXPENSES>
<NET_INCOME>1383219.93</NET_INCOME>
<REVENUE_M>13.56097968</REVENUE_M>
<PROFIT_M>9.704711693</PROFIT_M>
<INCOME_M>1.38321993</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.175923062E7</REVENUE>
<PREV_YEAR_REV>1.117126909E7</PREV_YEAR_REV>
<BUDGET>1.14064537E7</BUDGET>
<GROSS_PROFIT>8415317.003</GROSS_PROFIT>
<EXPENSES>9936235.41</EXPENSES>
<NET_INCOME>2022587.67</NET_INCOME>
<REVENUE_M>11.75923062</REVENUE_M>
<PROFIT_M>8.415317003</PROFIT_M>
<INCOME_M>2.02258767</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.091460773E7</REVENUE>
<PREV_YEAR_REV>3.886887735E7</PREV_YEAR_REV>
<BUDGET>3.96871695E7</BUDGET>
<GROSS_PROFIT>3.082097401E7</GROSS_PROFIT>
<EXPENSES>5.260449566E7</EXPENSES>
<NET_INCOME>3899743.45</NET_INCOME>
<REVENUE_M>40.91460773</REVENUE_M>
<PROFIT_M>30.82097401</PROFIT_M>
<INCOME_M>3.89974345</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.469704368E7</REVENUE>
<PREV_YEAR_REV>1.39621915E7</PREV_YEAR_REV>
<BUDGET>1.425613237E7</BUDGET>
<GROSS_PROFIT>11071283</GROSS_PROFIT>
<EXPENSES>1.889619902E7</EXPENSES>
<NET_INCOME>1072884.19</NET_INCOME>
<REVENUE_M>14.69704368</REVENUE_M>
<PROFIT_M>11.071283</PROFIT_M>
<INCOME_M>1.07288419</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.40426863E7</REVENUE>
<PREV_YEAR_REV>3.234055199E7</PREV_YEAR_REV>
<BUDGET>3.302140571E7</BUDGET>
<GROSS_PROFIT>2.564435559E7</GROSS_PROFIT>
<EXPENSES>41684922</EXPENSES>
<NET_INCOME>4493634.59</NET_INCOME>
<REVENUE_M>34.0426863</REVENUE_M>
<PROFIT_M>25.64435559</PROFIT_M>
<INCOME_M>4.49363459</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.586031927E7</REVENUE>
<PREV_YEAR_REV>1.506730331E7</PREV_YEAR_REV>
<BUDGET>1.53845097E7</BUDGET>
<GROSS_PROFIT>1.135019958E7</GROSS_PROFIT>
<EXPENSES>1.942079911E7</EXPENSES>
<NET_INCOME>1538450.97</NET_INCOME>
<REVENUE_M>15.86031927</REVENUE_M>
<PROFIT_M>11.35019958</PROFIT_M>
<INCOME_M>1.53845097</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.762757237E7</REVENUE>
<PREV_YEAR_REV>2.624619375E7</PREV_YEAR_REV>
<BUDGET>2.67987452E7</BUDGET>
<GROSS_PROFIT>2.081185027E7</GROSS_PROFIT>
<EXPENSES>3.382968046E7</EXPENSES>
<NET_INCOME>3735041.51</NET_INCOME>
<REVENUE_M>27.62757237</REVENUE_M>
<PROFIT_M>20.81185027</PROFIT_M>
<INCOME_M>3.73504151</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.204632579E7</REVENUE>
<PREV_YEAR_REV>1.14440095E7</PREV_YEAR_REV>
<BUDGET>1.168493602E7</BUDGET>
<GROSS_PROFIT>8620772.357</GROSS_PROFIT>
<EXPENSES>1.475060301E7</EXPENSES>
<NET_INCOME>1228725.23</NET_INCOME>
<REVENUE_M>12.04632579</REVENUE_M>
<PROFIT_M>8.620772357</PROFIT_M>
<INCOME_M>1.22872523</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.207442036E7</REVENUE>
<PREV_YEAR_REV>1.147069934E7</PREV_YEAR_REV>
<BUDGET>1.171218775E7</BUDGET>
<GROSS_PROFIT>8640877.813</GROSS_PROFIT>
<EXPENSES>1.478500452E7</EXPENSES>
<NET_INCOME>2076800.3</NET_INCOME>
<REVENUE_M>12.07442036</REVENUE_M>
<PROFIT_M>8.640877813</PROFIT_M>
<INCOME_M>2.0768003</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.556813578E7</REVENUE>
<PREV_YEAR_REV>1.478972899E7</PREV_YEAR_REV>
<BUDGET>1.510109171E7</BUDGET>
<GROSS_PROFIT>1.055472901E7</GROSS_PROFIT>
<EXPENSES>1.906302341E7</EXPENSES>
<NET_INCOME>2101698.33</NET_INCOME>
<REVENUE_M>15.56813578</REVENUE_M>
<PROFIT_M>10.55472901</PROFIT_M>
<INCOME_M>2.10169833</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.545201158E7</REVENUE>
<PREV_YEAR_REV>14679411</PREV_YEAR_REV>
<BUDGET>1.498845123E7</BUDGET>
<GROSS_PROFIT>1.105800031E7</GROSS_PROFIT>
<EXPENSES>1.89208305E7</EXPENSES>
<NET_INCOME>1576105.18</NET_INCOME>
<REVENUE_M>15.45201158</REVENUE_M>
<PROFIT_M>11.05800031</PROFIT_M>
<INCOME_M>1.57610518</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.692675348E7</REVENUE>
<PREV_YEAR_REV>2.288774046E7</PREV_YEAR_REV>
<BUDGET>2.611895087E7</BUDGET>
<GROSS_PROFIT>1.825553105E7</GROSS_PROFIT>
<EXPENSES>2.44048106E7</EXPENSES>
<NET_INCOME>3165452.37</NET_INCOME>
<REVENUE_M>26.92675348</REVENUE_M>
<PROFIT_M>18.25553105</PROFIT_M>
<INCOME_M>3.16545237</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>5.616810067E7</REVENUE>
<PREV_YEAR_REV>4.774288557E7</PREV_YEAR_REV>
<BUDGET>5.448305766E7</BUDGET>
<GROSS_PROFIT>4.231143024E7</GROSS_PROFIT>
<EXPENSES>5.05396096E7</EXPENSES>
<NET_INCOME>5467047.01</NET_INCOME>
<REVENUE_M>56.16810067</REVENUE_M>
<PROFIT_M>42.31143024</PROFIT_M>
<INCOME_M>5.46704701</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>5.100094473E7</REVENUE>
<PREV_YEAR_REV>4.335080302E7</PREV_YEAR_REV>
<BUDGET>4.947091639E7</BUDGET>
<GROSS_PROFIT>3.841901166E7</GROSS_PROFIT>
<EXPENSES>4.737084082E7</EXPENSES>
<NET_INCOME>4979023.69</NET_INCOME>
<REVENUE_M>51.00094473</REVENUE_M>
<PROFIT_M>38.41901166</PROFIT_M>
<INCOME_M>4.97902369</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.057843909E7</REVENUE>
<PREV_YEAR_REV>8991673.23</PREV_YEAR_REV>
<BUDGET>1.026108592E7</BUDGET>
<GROSS_PROFIT>7968738.164</GROSS_PROFIT>
<EXPENSES>9414810.79</EXPENSES>
<NET_INCOME>1893540.6</NET_INCOME>
<REVENUE_M>10.57843909</REVENUE_M>
<PROFIT_M>7.968738164</PROFIT_M>
<INCOME_M>1.8935406</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.431064942E7</REVENUE>
<PREV_YEAR_REV>1.216405201E7</PREV_YEAR_REV>
<BUDGET>1.388132994E7</BUDGET>
<GROSS_PROFIT>1.078021221E7</GROSS_PROFIT>
<EXPENSES>1.273647799E7</EXPENSES>
<NET_INCOME>1559860.79</NET_INCOME>
<REVENUE_M>14.31064942</REVENUE_M>
<PROFIT_M>10.78021221</PROFIT_M>
<INCOME_M>1.55986079</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.328557343E7</REVENUE>
<PREV_YEAR_REV>3.679273741E7</PREV_YEAR_REV>
<BUDGET>4.198700622E7</BUDGET>
<GROSS_PROFIT>3.097667133E7</GROSS_PROFIT>
<EXPENSES>3.858827843E7</EXPENSES>
<NET_INCOME>4198700.62</NET_INCOME>
<REVENUE_M>43.28557343</REVENUE_M>
<PROFIT_M>30.97667133</PROFIT_M>
<INCOME_M>4.19870062</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.510297853E7</REVENUE>
<PREV_YEAR_REV>1.283753175E7</PREV_YEAR_REV>
<BUDGET>1.464988917E7</BUDGET>
<GROSS_PROFIT>1.080822004E7</GROSS_PROFIT>
<EXPENSES>1.346402264E7</EXPENSES>
<NET_INCOME>1540503.81</NET_INCOME>
<REVENUE_M>15.10297853</REVENUE_M>
<PROFIT_M>10.80822004</PROFIT_M>
<INCOME_M>1.54050381</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.099577669E7</REVENUE>
<PREV_YEAR_REV>1.784641018E7</PREV_YEAR_REV>
<BUDGET>2.036590339E7</BUDGET>
<GROSS_PROFIT>1.523033641E7</GROSS_PROFIT>
<EXPENSES>1.889619902E7</EXPENSES>
<NET_INCOME>1532691.7</NET_INCOME>
<REVENUE_M>20.99577669</REVENUE_M>
<PROFIT_M>15.23033641</PROFIT_M>
<INCOME_M>1.5326917</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.071990206E7</REVENUE>
<PREV_YEAR_REV>1.761191675E7</PREV_YEAR_REV>
<BUDGET>20098305</BUDGET>
<GROSS_PROFIT>1.503021696E7</GROSS_PROFIT>
<EXPENSES>1.864791185E7</EXPENSES>
<NET_INCOME>2258469.32</NET_INCOME>
<REVENUE_M>20.71990206</REVENUE_M>
<PROFIT_M>15.03021696</PROFIT_M>
<INCOME_M>2.25846932</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.268072847E7</REVENUE>
<PREV_YEAR_REV>3.62786192E7</PREV_YEAR_REV>
<BUDGET>4.140030662E7</BUDGET>
<GROSS_PROFIT>3.215139276E7</GROSS_PROFIT>
<EXPENSES>3.804907047E7</EXPENSES>
<NET_INCOME>5633856.16</NET_INCOME>
<REVENUE_M>42.68072847</REVENUE_M>
<PROFIT_M>32.15139276</PROFIT_M>
<INCOME_M>5.63385616</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>5.616810067E7</REVENUE>
<PREV_YEAR_REV>5.167465262E7</PREV_YEAR_REV>
<BUDGET>5.219146269E7</BUDGET>
<GROSS_PROFIT>4.231143024E7</GROSS_PROFIT>
<EXPENSES>5.05396096E7</EXPENSES>
<NET_INCOME>5467047.01</NET_INCOME>
<REVENUE_M>56.16810067</REVENUE_M>
<PROFIT_M>42.31143024</PROFIT_M>
<INCOME_M>5.46704701</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.438129176E7</REVENUE>
<PREV_YEAR_REV>1.323078842E7</PREV_YEAR_REV>
<BUDGET>1.466891759E7</BUDGET>
<GROSS_PROFIT>1.029175572E7</GROSS_PROFIT>
<EXPENSES>1.279934966E7</EXPENSES>
<NET_INCOME>2473582.18</NET_INCOME>
<REVENUE_M>14.38129176</REVENUE_M>
<PROFIT_M>10.29175572</PROFIT_M>
<INCOME_M>2.47358218</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.510297853E7</REVENUE>
<PREV_YEAR_REV>1.389474024E7</PREV_YEAR_REV>
<BUDGET>1.54050381E7</BUDGET>
<GROSS_PROFIT>1.080822004E7</GROSS_PROFIT>
<EXPENSES>1.346402264E7</EXPENSES>
<NET_INCOME>1540503.81</NET_INCOME>
<REVENUE_M>15.10297853</REVENUE_M>
<PROFIT_M>10.80822004</PROFIT_M>
<INCOME_M>1.54050381</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.513820185E7</REVENUE>
<PREV_YEAR_REV>1.39271457E7</PREV_YEAR_REV>
<BUDGET>1.544096589E7</BUDGET>
<GROSS_PROFIT>1.083342708E7</GROSS_PROFIT>
<EXPENSES>1.349542357E7</EXPENSES>
<NET_INCOME>2603770.72</NET_INCOME>
<REVENUE_M>15.13820185</REVENUE_M>
<PROFIT_M>10.83342708</PROFIT_M>
<INCOME_M>2.60377072</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.157417703E7</REVENUE>
<PREV_YEAR_REV>1.984824287E7</PREV_YEAR_REV>
<BUDGET>1.968390696E7</BUDGET>
<GROSS_PROFIT>1.625182755E7</GROSS_PROFIT>
<EXPENSES>1.922259173E7</EXPENSES>
<NET_INCOME>2351585.3</NET_INCOME>
<REVENUE_M>21.57417703</REVENUE_M>
<PROFIT_M>16.25182755</PROFIT_M>
<INCOME_M>2.3515853</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.484092096E7</REVENUE>
<PREV_YEAR_REV>1.334734064E7</PREV_YEAR_REV>
<BUDGET>1.632501306E7</BUDGET>
<GROSS_PROFIT>1.245669617E7</GROSS_PROFIT>
<EXPENSES>1.287699991E7</EXPENSES>
<NET_INCOME>1963921.06</NET_INCOME>
<REVENUE_M>14.84092096</REVENUE_M>
<PROFIT_M>12.45669617</PROFIT_M>
<INCOME_M>1.96392106</INCOME_M>
<PHARMA_REV_M>14.84092096</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.45669617</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.96392106</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5311651.21</REVENUE>
<PREV_YEAR_REV>4860086.99</PREV_YEAR_REV>
<BUDGET>4005589.51</BUDGET>
<GROSS_PROFIT>4153255.097</GROSS_PROFIT>
<EXPENSES>4597307.15</EXPENSES>
<NET_INCOME>714344.05</NET_INCOME>
<REVENUE_M>5.31165121</REVENUE_M>
<PROFIT_M>4.153255097</PROFIT_M>
<INCOME_M>0.71434405</INCOME_M>
<PHARMA_REV_M>5.31165121</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.153255097</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.71434405</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2829133.82</REVENUE>
<PREV_YEAR_REV>2530757.51</PREV_YEAR_REV>
<BUDGET>2063891.86</BUDGET>
<GROSS_PROFIT>2257365.877</GROSS_PROFIT>
<EXPENSES>2322718.87</EXPENSES>
<NET_INCOME>506414.95</NET_INCOME>
<REVENUE_M>2.82913382</REVENUE_M>
<PROFIT_M>2.257365877</PROFIT_M>
<INCOME_M>0.50641495</INCOME_M>
<PHARMA_REV_M>2.82913382</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.257365877</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50641495</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2554990.67</REVENUE>
<PREV_YEAR_REV>2043502.1</PREV_YEAR_REV>
<BUDGET>2442384.38</BUDGET>
<GROSS_PROFIT>2141082.19</GROSS_PROFIT>
<EXPENSES>2097647.34</EXPENSES>
<NET_INCOME>457343.33</NET_INCOME>
<REVENUE_M>2.55499067</REVENUE_M>
<PROFIT_M>2.14108219</PROFIT_M>
<INCOME_M>0.45734333</INCOME_M>
<PHARMA_REV_M>2.55499067</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.14108219</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45734333</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2580762.55</REVENUE>
<PREV_YEAR_REV>2067073.99</PREV_YEAR_REV>
<BUDGET>2466609.94</BUDGET>
<GROSS_PROFIT>1882444.336</GROSS_PROFIT>
<EXPENSES>2232359.61</EXPENSES>
<NET_INCOME>348402.94</NET_INCOME>
<REVENUE_M>2.58076255</REVENUE_M>
<PROFIT_M>1.882444336</PROFIT_M>
<INCOME_M>0.34840294</INCOME_M>
<PHARMA_REV_M>2.58076255</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.882444336</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34840294</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>6044610.98</REVENUE>
<PREV_YEAR_REV>4829510.75</PREV_YEAR_REV>
<BUDGET>5804013.76</BUDGET>
<GROSS_PROFIT>4775705.727</GROSS_PROFIT>
<EXPENSES>5462500.09</EXPENSES>
<NET_INCOME>582110.91</NET_INCOME>
<REVENUE_M>6.04461098</REVENUE_M>
<PROFIT_M>4.775705727</PROFIT_M>
<INCOME_M>0.58211091</INCOME_M>
<PHARMA_REV_M>6.04461098</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.775705727</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58211091</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1881000</REVENUE>
<PREV_YEAR_REV>1471151.82</PREV_YEAR_REV>
<BUDGET>1809500</BUDGET>
<GROSS_PROFIT>1459279.8</GROSS_PROFIT>
<EXPENSES>1627065</EXPENSES>
<NET_INCOME>253935</NET_INCOME>
<REVENUE_M>1.881</REVENUE_M>
<PROFIT_M>1.4592798</PROFIT_M>
<INCOME_M>0.253935</INCOME_M>
<PHARMA_REV_M>1.881</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.4592798</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.253935</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1596309.5</REVENUE>
<PREV_YEAR_REV>1313683.61</PREV_YEAR_REV>
<BUDGET>1541224.08</BUDGET>
<GROSS_PROFIT>1310250.84</GROSS_PROFIT>
<EXPENSES>1433485.93</EXPENSES>
<NET_INCOME>162823.57</NET_INCOME>
<REVENUE_M>1.5963095</REVENUE_M>
<PROFIT_M>1.31025084</PROFIT_M>
<INCOME_M>0.16282357</INCOME_M>
<PHARMA_REV_M>1.5963095</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.31025084</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16282357</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.058259226E7</REVENUE>
<PREV_YEAR_REV>1.852433303E7</PREV_YEAR_REV>
<BUDGET>1.955346265E7</BUDGET>
<GROSS_PROFIT>1.550486674E7</GROSS_PROFIT>
<EXPENSES>3.392734988E7</EXPENSES>
<NET_INCOME>2005200.83</NET_INCOME>
<REVENUE_M>20.58259226</REVENUE_M>
<PROFIT_M>15.50486674</PROFIT_M>
<INCOME_M>2.00520083</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.254777831E7</REVENUE>
<PREV_YEAR_REV>1.129300048E7</PREV_YEAR_REV>
<BUDGET>1.119285389E7</BUDGET>
<GROSS_PROFIT>8979629.33</GROSS_PROFIT>
<EXPENSES>1.942079911E7</EXPENSES>
<NET_INCOME>1217134.5</NET_INCOME>
<REVENUE_M>12.54777831</REVENUE_M>
<PROFIT_M>8.97962933</PROFIT_M>
<INCOME_M>1.2171345</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.414467116E7</REVENUE>
<PREV_YEAR_REV>1.34374376E7</PREV_YEAR_REV>
<BUDGET>1.372033103E7</BUDGET>
<GROSS_PROFIT>1.065518079E7</GROSS_PROFIT>
<EXPENSES>1.302193712E7</EXPENSES>
<NET_INCOME>1032560.99</NET_INCOME>
<REVENUE_M>14.14467116</REVENUE_M>
<PROFIT_M>10.65518079</PROFIT_M>
<INCOME_M>1.03256099</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2356256.53</REVENUE>
<PREV_YEAR_REV>2167469.9</PREV_YEAR_REV>
<BUDGET>1847183.89</BUDGET>
<GROSS_PROFIT>1940730.69</GROSS_PROFIT>
<EXPENSES>1979255.48</EXPENSES>
<NET_INCOME>377001.04</NET_INCOME>
<REVENUE_M>2.35625653</REVENUE_M>
<PROFIT_M>1.94073069</PROFIT_M>
<INCOME_M>0.37700104</INCOME_M>
<PHARMA_REV_M>2.35625653</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.94073069</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37700104</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2094847.13</REVENUE>
<PREV_YEAR_REV>1907423.68</PREV_YEAR_REV>
<BUDGET>1632053.95</BUDGET>
<GROSS_PROFIT>1620487.853</GROSS_PROFIT>
<EXPENSES>1824611.85</EXPENSES>
<NET_INCOME>270235.28</NET_INCOME>
<REVENUE_M>2.09484713</REVENUE_M>
<PROFIT_M>1.620487853</PROFIT_M>
<INCOME_M>0.27023528</INCOME_M>
<PHARMA_REV_M>2.09484713</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.620487853</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27023528</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>7825097.11</REVENUE>
<PREV_YEAR_REV>7145165.98</PREV_YEAR_REV>
<BUDGET>5800969.05</BUDGET>
<GROSS_PROFIT>6563593.424</GROSS_PROFIT>
<EXPENSES>7068868.86</EXPENSES>
<NET_INCOME>756228.26</NET_INCOME>
<REVENUE_M>7.82509711</REVENUE_M>
<PROFIT_M>6.563593424</PROFIT_M>
<INCOME_M>0.75622826</INCOME_M>
<PHARMA_REV_M>7.82509711</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.563593424</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75622826</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2515366.02</REVENUE>
<PREV_YEAR_REV>2269448.58</PREV_YEAR_REV>
<BUDGET>1925207.61</BUDGET>
<GROSS_PROFIT>2111806.987</GROSS_PROFIT>
<EXPENSES>2258798.69</EXPENSES>
<NET_INCOME>256567.33</NET_INCOME>
<REVENUE_M>2.51536602</REVENUE_M>
<PROFIT_M>2.111806987</PROFIT_M>
<INCOME_M>0.25656733</INCOME_M>
<PHARMA_REV_M>2.51536602</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.111806987</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25656733</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2813165.76</REVENUE>
<PREV_YEAR_REV>2587509.09</PREV_YEAR_REV>
<BUDGET>1982129.04</BUDGET>
<GROSS_PROFIT>2345633.078</GROSS_PROFIT>
<EXPENSES>2329301.25</EXPENSES>
<NET_INCOME>483864.51</NET_INCOME>
<REVENUE_M>2.81316576</REVENUE_M>
<PROFIT_M>2.345633078</PROFIT_M>
<INCOME_M>0.48386451</INCOME_M>
<PHARMA_REV_M>2.81316576</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.345633078</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48386451</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1884517.25</REVENUE>
<PREV_YEAR_REV>1677840.82</PREV_YEAR_REV>
<BUDGET>1695026.94</BUDGET>
<GROSS_PROFIT>1605608.7</GROSS_PROFIT>
<EXPENSES>1547188.67</EXPENSES>
<NET_INCOME>337328.59</NET_INCOME>
<REVENUE_M>1.88451725</REVENUE_M>
<PROFIT_M>1.6056087</PROFIT_M>
<INCOME_M>0.33732859</INCOME_M>
<PHARMA_REV_M>1.88451725</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.6056087</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33732859</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1708502.44</REVENUE>
<PREV_YEAR_REV>1546841.98</PREV_YEAR_REV>
<BUDGET>1688933.01</BUDGET>
<GROSS_PROFIT>1391788.796</GROSS_PROFIT>
<EXPENSES>1534235.19</EXPENSES>
<NET_INCOME>174267.25</NET_INCOME>
<REVENUE_M>1.70850244</REVENUE_M>
<PROFIT_M>1.391788796</PROFIT_M>
<INCOME_M>0.17426725</INCOME_M>
<PHARMA_REV_M>1.70850244</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.391788796</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17426725</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1901927.31</REVENUE>
<PREV_YEAR_REV>1737237.22</PREV_YEAR_REV>
<BUDGET>1705685.22</BUDGET>
<GROSS_PROFIT>1535191.982</GROSS_PROFIT>
<EXPENSES>1574795.81</EXPENSES>
<NET_INCOME>327131.5</NET_INCOME>
<REVENUE_M>1.90192731</REVENUE_M>
<PROFIT_M>1.535191982</PROFIT_M>
<INCOME_M>0.3271315</INCOME_M>
<PHARMA_REV_M>1.90192731</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.535191982</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3271315</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1665262.88</REVENUE>
<PREV_YEAR_REV>1516508.55</PREV_YEAR_REV>
<BUDGET>1547249.11</BUDGET>
<GROSS_PROFIT>1317222.93</GROSS_PROFIT>
<EXPENSES>1483749.22</EXPENSES>
<NET_INCOME>181513.65</NET_INCOME>
<REVENUE_M>1.66526288</REVENUE_M>
<PROFIT_M>1.31722293</PROFIT_M>
<INCOME_M>0.18151365</INCOME_M>
<PHARMA_REV_M>1.66526288</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.31722293</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18151365</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1799331.8</REVENUE>
<PREV_YEAR_REV>1632802.29</PREV_YEAR_REV>
<BUDGET>1721230.84</BUDGET>
<GROSS_PROFIT>1507660.118</GROSS_PROFIT>
<EXPENSES>1603204.63</EXPENSES>
<NET_INCOME>196127.17</NET_INCOME>
<REVENUE_M>1.7993318</REVENUE_M>
<PROFIT_M>1.507660118</PROFIT_M>
<INCOME_M>0.19612717</INCOME_M>
<PHARMA_REV_M>1.7993318</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.507660118</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19612717</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1590020.15</REVENUE>
<PREV_YEAR_REV>1453706.12</PREV_YEAR_REV>
<BUDGET>1209965.61</BUDGET>
<GROSS_PROFIT>1173220.218</GROSS_PROFIT>
<EXPENSES>1384907.55</EXPENSES>
<NET_INCOME>205112.6</NET_INCOME>
<REVENUE_M>1.59002015</REVENUE_M>
<PROFIT_M>1.173220218</PROFIT_M>
<INCOME_M>0.2051126</INCOME_M>
<PHARMA_REV_M>1.59002015</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.173220218</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2051126</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2790665.51</REVENUE>
<PREV_YEAR_REV>2530404.77</PREV_YEAR_REV>
<BUDGET>2309480.89</BUDGET>
<GROSS_PROFIT>2206979.571</GROSS_PROFIT>
<EXPENSES>2417545.79</EXPENSES>
<NET_INCOME>373119.73</NET_INCOME>
<REVENUE_M>2.79066551</REVENUE_M>
<PROFIT_M>2.206979571</PROFIT_M>
<INCOME_M>0.37311973</INCOME_M>
<PHARMA_REV_M>2.79066551</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.206979571</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37311973</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3058939.94</REVENUE>
<PREV_YEAR_REV>2747760.32</PREV_YEAR_REV>
<BUDGET>2345627.06</BUDGET>
<GROSS_PROFIT>2491744.01</GROSS_PROFIT>
<EXPENSES>2651259.32</EXPENSES>
<NET_INCOME>407680.62</NET_INCOME>
<REVENUE_M>3.05893994</REVENUE_M>
<PROFIT_M>2.49174401</PROFIT_M>
<INCOME_M>0.40768062</INCOME_M>
<PHARMA_REV_M>3.05893994</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.49174401</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40768062</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7369418.48</REVENUE>
<PREV_YEAR_REV>6649839.36</PREV_YEAR_REV>
<BUDGET>6632476.63</BUDGET>
<GROSS_PROFIT>5626993.172</GROSS_PROFIT>
<EXPENSES>6418763.5</EXPENSES>
<NET_INCOME>950654.98</NET_INCOME>
<REVENUE_M>7.36941848</REVENUE_M>
<PROFIT_M>5.626993172</PROFIT_M>
<INCOME_M>0.95065498</INCOME_M>
<PHARMA_REV_M>7.36941848</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.626993172</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.95065498</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.498786743E7</REVENUE>
<PREV_YEAR_REV>1.359791551E7</PREV_YEAR_REV>
<BUDGET>1.348908069E7</BUDGET>
<GROSS_PROFIT>1.249162461E7</GROSS_PROFIT>
<EXPENSES>1.297281784E7</EXPENSES>
<NET_INCOME>2015049.59</NET_INCOME>
<REVENUE_M>14.98786743</REVENUE_M>
<PROFIT_M>12.49162461</PROFIT_M>
<INCOME_M>2.01504959</INCOME_M>
<PHARMA_REV_M>14.98786743</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.49162461</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.01504959</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7197241.17</REVENUE>
<PREV_YEAR_REV>6531012.58</PREV_YEAR_REV>
<BUDGET>6477517.05</BUDGET>
<GROSS_PROFIT>6316946.606</GROSS_PROFIT>
<EXPENSES>6671842.56</EXPENSES>
<NET_INCOME>525398.61</NET_INCOME>
<REVENUE_M>7.19724117</REVENUE_M>
<PROFIT_M>6.316946606</PROFIT_M>
<INCOME_M>0.52539861</INCOME_M>
<PHARMA_REV_M>7.19724117</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.316946606</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52539861</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2333487.84</REVENUE>
<PREV_YEAR_REV>1997113.94</PREV_YEAR_REV>
<BUDGET>2446212.52</BUDGET>
<GROSS_PROFIT>1853123.036</GROSS_PROFIT>
<EXPENSES>1932127.93</EXPENSES>
<NET_INCOME>401359.91</NET_INCOME>
<REVENUE_M>2.33348784</REVENUE_M>
<PROFIT_M>1.853123036</PROFIT_M>
<INCOME_M>0.40135991</INCOME_M>
<PHARMA_REV_M>2.33348784</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.853123036</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40135991</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3121762.05</REVENUE>
<PREV_YEAR_REV>2790406.98</PREV_YEAR_REV>
<BUDGET>4100261.09</BUDGET>
<GROSS_PROFIT>2342712.749</GROSS_PROFIT>
<EXPENSES>2777333.45</EXPENSES>
<NET_INCOME>344428.6</NET_INCOME>
<REVENUE_M>3.12176205</REVENUE_M>
<PROFIT_M>2.342712749</PROFIT_M>
<INCOME_M>0.3444286</INCOME_M>
<PHARMA_REV_M>3.12176205</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.342712749</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3444286</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1629525.35</REVENUE>
<PREV_YEAR_REV>1439484.59</PREV_YEAR_REV>
<BUDGET>2080411.46</BUDGET>
<GROSS_PROFIT>1365379.296</GROSS_PROFIT>
<EXPENSES>1510570</EXPENSES>
<NET_INCOME>118955.35</NET_INCOME>
<REVENUE_M>1.62952535</REVENUE_M>
<PROFIT_M>1.365379296</PROFIT_M>
<INCOME_M>0.11895535</INCOME_M>
<PHARMA_REV_M>1.62952535</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.365379296</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11895535</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5489707.03</REVENUE>
<PREV_YEAR_REV>5002466.77</PREV_YEAR_REV>
<BUDGET>4940736.33</BUDGET>
<GROSS_PROFIT>4189744.413</GROSS_PROFIT>
<EXPENSES>4748596.58</EXPENSES>
<NET_INCOME>741110.45</NET_INCOME>
<REVENUE_M>5.48970703</REVENUE_M>
<PROFIT_M>4.189744413</PROFIT_M>
<INCOME_M>0.74111045</INCOME_M>
<PHARMA_REV_M>5.48970703</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.189744413</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74111045</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.103465034E7</REVENUE>
<PREV_YEAR_REV>9870214.31</PREV_YEAR_REV>
<BUDGET>9931185.29</BUDGET>
<GROSS_PROFIT>8674046.53</GROSS_PROFIT>
<EXPENSES>9576717.43</EXPENSES>
<NET_INCOME>1457932.9</NET_INCOME>
<REVENUE_M>11.03465034</REVENUE_M>
<PROFIT_M>8.67404653</PROFIT_M>
<INCOME_M>1.4579329</INCOME_M>
<PHARMA_REV_M>11.03465034</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.67404653</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.4579329</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6726502.55</REVENUE>
<PREV_YEAR_REV>6064446.88</PREV_YEAR_REV>
<BUDGET>6053852.29</BUDGET>
<GROSS_PROFIT>5260074.547</GROSS_PROFIT>
<EXPENSES>6040399.29</EXPENSES>
<NET_INCOME>686103.26</NET_INCOME>
<REVENUE_M>6.72650255</REVENUE_M>
<PROFIT_M>5.260074547</PROFIT_M>
<INCOME_M>0.68610326</INCOME_M>
<PHARMA_REV_M>6.72650255</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.260074547</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68610326</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7038125.45</REVENUE>
<PREV_YEAR_REV>6310013.05</PREV_YEAR_REV>
<BUDGET>6334312.91</BUDGET>
<GROSS_PROFIT>5726613</GROSS_PROFIT>
<EXPENSES>5827567.87</EXPENSES>
<NET_INCOME>1210557.58</NET_INCOME>
<REVENUE_M>7.03812545</REVENUE_M>
<PROFIT_M>5.726613</PROFIT_M>
<INCOME_M>1.21055758</INCOME_M>
<PHARMA_REV_M>7.03812545</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.726613</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.21055758</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2162983.67</REVENUE>
<PREV_YEAR_REV>1946722.3</PREV_YEAR_REV>
<BUDGET>2097107.18</BUDGET>
<GROSS_PROFIT>1684964.28</GROSS_PROFIT>
<EXPENSES>1816906.29</EXPENSES>
<NET_INCOME>346077.39</NET_INCOME>
<REVENUE_M>2.16298367</REVENUE_M>
<PROFIT_M>1.68496428</PROFIT_M>
<INCOME_M>0.34607739</INCOME_M>
<PHARMA_REV_M>2.16298367</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.68496428</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34607739</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4451448.47</REVENUE>
<PREV_YEAR_REV>3989298.94</PREV_YEAR_REV>
<BUDGET>4223078.73</BUDGET>
<GROSS_PROFIT>3437263.522</GROSS_PROFIT>
<EXPENSES>3960727.63</EXPENSES>
<NET_INCOME>490720.84</NET_INCOME>
<REVENUE_M>4.45144847</REVENUE_M>
<PROFIT_M>3.437263522</PROFIT_M>
<INCOME_M>0.49072084</INCOME_M>
<PHARMA_REV_M>4.45144847</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.437263522</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49072084</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1933987.31</REVENUE>
<PREV_YEAR_REV>1774707.33</PREV_YEAR_REV>
<BUDGET>1853847.19</BUDGET>
<GROSS_PROFIT>1709161.289</GROSS_PROFIT>
<EXPENSES>1678700.99</EXPENSES>
<NET_INCOME>255286.33</NET_INCOME>
<REVENUE_M>1.93398731</REVENUE_M>
<PROFIT_M>1.709161289</PROFIT_M>
<INCOME_M>0.25528633</INCOME_M>
<PHARMA_REV_M>1.93398731</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.709161289</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25528633</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2323944.46</REVENUE>
<PREV_YEAR_REV>2112753.61</PREV_YEAR_REV>
<BUDGET>2192026.54</BUDGET>
<GROSS_PROFIT>1750743.553</GROSS_PROFIT>
<EXPENSES>1907958.4</EXPENSES>
<NET_INCOME>415986.06</NET_INCOME>
<REVENUE_M>2.32394446</REVENUE_M>
<PROFIT_M>1.750743553</PROFIT_M>
<INCOME_M>0.41598606</INCOME_M>
<PHARMA_REV_M>2.32394446</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.750743553</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41598606</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1625588.53</REVENUE>
<PREV_YEAR_REV>1451547.93</PREV_YEAR_REV>
<BUDGET>1937992.77</BUDGET>
<GROSS_PROFIT>1387569.858</GROSS_PROFIT>
<EXPENSES>1411010.84</EXPENSES>
<NET_INCOME>214577.69</NET_INCOME>
<REVENUE_M>1.62558853</REVENUE_M>
<PROFIT_M>1.387569858</PROFIT_M>
<INCOME_M>0.21457769</INCOME_M>
<PHARMA_REV_M>1.62558853</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.387569858</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21457769</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1617181.64</REVENUE>
<PREV_YEAR_REV>1486544.14</PREV_YEAR_REV>
<BUDGET>1912948.02</BUDGET>
<GROSS_PROFIT>1201404.238</GROSS_PROFIT>
<EXPENSES>1403713.66</EXPENSES>
<NET_INCOME>213467.98</NET_INCOME>
<REVENUE_M>1.61718164</REVENUE_M>
<PROFIT_M>1.201404238</PROFIT_M>
<INCOME_M>0.21346798</INCOME_M>
<PHARMA_REV_M>1.61718164</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.201404238</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21346798</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1625139.26</REVENUE>
<PREV_YEAR_REV>1484877.71</PREV_YEAR_REV>
<BUDGET>1915708.48</BUDGET>
<GROSS_PROFIT>1356991.28</GROSS_PROFIT>
<EXPENSES>1365116.98</EXPENSES>
<NET_INCOME>260022.28</NET_INCOME>
<REVENUE_M>1.62513926</REVENUE_M>
<PROFIT_M>1.35699128</PROFIT_M>
<INCOME_M>0.26002228</INCOME_M>
<PHARMA_REV_M>1.62513926</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.35699128</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26002228</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4934319.12</REVENUE>
<PREV_YEAR_REV>4443170.2</PREV_YEAR_REV>
<BUDGET>5822941.76</BUDGET>
<GROSS_PROFIT>4357247.68</GROSS_PROFIT>
<EXPENSES>4455010.09</EXPENSES>
<NET_INCOME>479309.05</NET_INCOME>
<REVENUE_M>4.93431912</REVENUE_M>
<PROFIT_M>4.35724768</PROFIT_M>
<INCOME_M>0.47930905</INCOME_M>
<PHARMA_REV_M>4.93431912</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.35724768</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47930905</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1606488.53</REVENUE>
<PREV_YEAR_REV>1473450.67</PREV_YEAR_REV>
<BUDGET>1872814.17</BUDGET>
<GROSS_PROFIT>1152406.517</GROSS_PROFIT>
<EXPENSES>1389612.58</EXPENSES>
<NET_INCOME>216875.95</NET_INCOME>
<REVENUE_M>1.60648853</REVENUE_M>
<PROFIT_M>1.152406517</PROFIT_M>
<INCOME_M>0.21687595</INCOME_M>
<PHARMA_REV_M>1.60648853</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.152406517</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21687595</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2597073.01</REVENUE>
<PREV_YEAR_REV>2352194.67</PREV_YEAR_REV>
<BUDGET>2795769.63</BUDGET>
<GROSS_PROFIT>1872466.487</GROSS_PROFIT>
<EXPENSES>2310509.84</EXPENSES>
<NET_INCOME>286563.17</NET_INCOME>
<REVENUE_M>2.59707301</REVENUE_M>
<PROFIT_M>1.872466487</PROFIT_M>
<INCOME_M>0.28656317</INCOME_M>
<PHARMA_REV_M>2.59707301</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.872466487</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28656317</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3820768.85</REVENUE>
<PREV_YEAR_REV>3450974.5</PREV_YEAR_REV>
<BUDGET>3973746.42</BUDGET>
<GROSS_PROFIT>3014475.296</GROSS_PROFIT>
<EXPENSES>3452934.6</EXPENSES>
<NET_INCOME>367834.25</NET_INCOME>
<REVENUE_M>3.82076885</REVENUE_M>
<PROFIT_M>3.014475296</PROFIT_M>
<INCOME_M>0.36783425</INCOME_M>
<PHARMA_REV_M>3.82076885</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.014475296</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36783425</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1162350.24</REVENUE>
<PREV_YEAR_REV>1043336.81</PREV_YEAR_REV>
<BUDGET>1249405.75</BUDGET>
<GROSS_PROFIT>780140.4237</GROSS_PROFIT>
<EXPENSES>1005432.96</EXPENSES>
<NET_INCOME>156917.28</NET_INCOME>
<REVENUE_M>1.16235024</REVENUE_M>
<PROFIT_M>0.780140424</PROFIT_M>
<INCOME_M>0.15691728</INCOME_M>
<PHARMA_REV_M>1.16235024</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.780140424</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15691728</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1236121.63</REVENUE>
<PREV_YEAR_REV>1123491.6</PREV_YEAR_REV>
<BUDGET>1249180.24</BUDGET>
<GROSS_PROFIT>965287.381</GROSS_PROFIT>
<EXPENSES>1101384.37</EXPENSES>
<NET_INCOME>134737.26</NET_INCOME>
<REVENUE_M>1.23612163</REVENUE_M>
<PROFIT_M>0.965287381</PROFIT_M>
<INCOME_M>0.13473726</INCOME_M>
<PHARMA_REV_M>1.23612163</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.965287381</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13473726</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.383408669E7</REVENUE>
<PREV_YEAR_REV>1.20587117E7</PREV_YEAR_REV>
<BUDGET>1.411076843E7</BUDGET>
<GROSS_PROFIT>1.061735351E7</GROSS_PROFIT>
<EXPENSES>1.215492358E7</EXPENSES>
<NET_INCOME>1679163.11</NET_INCOME>
<REVENUE_M>13.83408669</REVENUE_M>
<PROFIT_M>10.61735351</PROFIT_M>
<INCOME_M>1.67916311</INCOME_M>
<PHARMA_REV_M>13.83408669</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.61735351</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.67916311</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.614926313E7</REVENUE>
<PREV_YEAR_REV>1.446508513E7</PREV_YEAR_REV>
<BUDGET>1.64722484E7</BUDGET>
<GROSS_PROFIT>1.254309424E7</GROSS_PROFIT>
<EXPENSES>1.42778521E7</EXPENSES>
<NET_INCOME>1871411.04</NET_INCOME>
<REVENUE_M>16.14926313</REVENUE_M>
<PROFIT_M>12.54309424</PROFIT_M>
<INCOME_M>1.87141104</INCOME_M>
<PHARMA_REV_M>16.14926313</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.54309424</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.87141104</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.185600031E7</REVENUE>
<PREV_YEAR_REV>1.014449995E7</PREV_YEAR_REV>
<BUDGET>6185398.6</BUDGET>
<GROSS_PROFIT>8428636.179</GROSS_PROFIT>
<EXPENSES>1.009769824E7</EXPENSES>
<NET_INCOME>1758302.07</NET_INCOME>
<REVENUE_M>11.85600031</REVENUE_M>
<PROFIT_M>8.428636179</PROFIT_M>
<INCOME_M>1.75830207</INCOME_M>
<PHARMA_REV_M>11.85600031</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.428636179</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.75830207</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7060383.99</REVENUE>
<PREV_YEAR_REV>6013238.62</PREV_YEAR_REV>
<BUDGET>7201591.67</BUDGET>
<GROSS_PROFIT>5070767.778</GROSS_PROFIT>
<EXPENSES>6107232.15</EXPENSES>
<NET_INCOME>953151.84</NET_INCOME>
<REVENUE_M>7.06038399</REVENUE_M>
<PROFIT_M>5.070767778</PROFIT_M>
<INCOME_M>0.95315184</INCOME_M>
<PHARMA_REV_M>7.06038399</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.070767778</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.95315184</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>4943700.91</REVENUE>
<PREV_YEAR_REV>4413506.39</PREV_YEAR_REV>
<BUDGET>5042574.93</BUDGET>
<GROSS_PROFIT>3613034.597</GROSS_PROFIT>
<EXPENSES>4276301.29</EXPENSES>
<NET_INCOME>667399.62</NET_INCOME>
<REVENUE_M>4.94370091</REVENUE_M>
<PROFIT_M>3.613034597</PROFIT_M>
<INCOME_M>0.66739962</INCOME_M>
<PHARMA_REV_M>4.94370091</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.613034597</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.66739962</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8170840.53</REVENUE>
<PREV_YEAR_REV>7048141.99</PREV_YEAR_REV>
<BUDGET>8334257.34</BUDGET>
<GROSS_PROFIT>5809467.618</GROSS_PROFIT>
<EXPENSES>7067777.06</EXPENSES>
<NET_INCOME>1103063.47</NET_INCOME>
<REVENUE_M>8.17084053</REVENUE_M>
<PROFIT_M>5.809467618</PROFIT_M>
<INCOME_M>1.10306347</INCOME_M>
<PHARMA_REV_M>8.17084053</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.809467618</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.10306347</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6763834.55</REVENUE>
<PREV_YEAR_REV>5969324.12</PREV_YEAR_REV>
<BUDGET>7075398.38</BUDGET>
<GROSS_PROFIT>5612853.517</GROSS_PROFIT>
<EXPENSES>6107074.48</EXPENSES>
<NET_INCOME>656760.06</NET_INCOME>
<REVENUE_M>6.76383455</REVENUE_M>
<PROFIT_M>5.612853517</PROFIT_M>
<INCOME_M>0.65676006</INCOME_M>
<PHARMA_REV_M>6.76383455</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.612853517</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65676006</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2183996.83</REVENUE>
<PREV_YEAR_REV>1977648.94</PREV_YEAR_REV>
<BUDGET>1520851.74</BUDGET>
<GROSS_PROFIT>1543337.742</GROSS_PROFIT>
<EXPENSES>1961229.15</EXPENSES>
<NET_INCOME>222767.68</NET_INCOME>
<REVENUE_M>2.18399683</REVENUE_M>
<PROFIT_M>1.543337742</PROFIT_M>
<INCOME_M>0.22276768</INCOME_M>
<PHARMA_REV_M>2.18399683</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.543337742</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22276768</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2873812.98</REVENUE>
<PREV_YEAR_REV>2577711.29</PREV_YEAR_REV>
<BUDGET>2088328.67</BUDGET>
<GROSS_PROFIT>2223357.027</GROSS_PROFIT>
<EXPENSES>2379517.15</EXPENSES>
<NET_INCOME>494295.83</NET_INCOME>
<REVENUE_M>2.87381298</REVENUE_M>
<PROFIT_M>2.223357027</PROFIT_M>
<INCOME_M>0.49429583</INCOME_M>
<PHARMA_REV_M>2.87381298</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.223357027</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49429583</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2181947.1</REVENUE>
<PREV_YEAR_REV>2006314.34</PREV_YEAR_REV>
<BUDGET>1777447.05</BUDGET>
<GROSS_PROFIT>1689691.103</GROSS_PROFIT>
<EXPENSES>1900475.92</EXPENSES>
<NET_INCOME>281471.18</NET_INCOME>
<REVENUE_M>2.1819471</REVENUE_M>
<PROFIT_M>1.689691103</PROFIT_M>
<INCOME_M>0.28147118</INCOME_M>
<PHARMA_REV_M>2.1819471</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.689691103</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28147118</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2091874.51</REVENUE>
<PREV_YEAR_REV>1871622.03</PREV_YEAR_REV>
<BUDGET>1758601.49</BUDGET>
<GROSS_PROFIT>1611580.122</GROSS_PROFIT>
<EXPENSES>1822022.7</EXPENSES>
<NET_INCOME>269851.81</NET_INCOME>
<REVENUE_M>2.09187451</REVENUE_M>
<PROFIT_M>1.611580122</PROFIT_M>
<INCOME_M>0.26985181</INCOME_M>
<PHARMA_REV_M>2.09187451</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.611580122</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26985181</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2155726.3</REVENUE>
<PREV_YEAR_REV>1988677.4</PREV_YEAR_REV>
<BUDGET>1776044.74</BUDGET>
<GROSS_PROFIT>1869014.7</GROSS_PROFIT>
<EXPENSES>1998358.28</EXPENSES>
<NET_INCOME>157368.02</NET_INCOME>
<REVENUE_M>2.1557263</REVENUE_M>
<PROFIT_M>1.8690147</PROFIT_M>
<INCOME_M>0.15736802</INCOME_M>
<PHARMA_REV_M>2.1557263</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.8690147</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15736802</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4183372.61</REVENUE>
<PREV_YEAR_REV>3764420.04</PREV_YEAR_REV>
<BUDGET>3523548.29</BUDGET>
<GROSS_PROFIT>3245230.764</GROSS_PROFIT>
<EXPENSES>3561900.74</EXPENSES>
<NET_INCOME>621471.88</NET_INCOME>
<REVENUE_M>4.18337261</REVENUE_M>
<PROFIT_M>3.245230764</PROFIT_M>
<INCOME_M>0.62147188</INCOME_M>
<PHARMA_REV_M>4.18337261</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.245230764</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62147188</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2091185.75</REVENUE>
<PREV_YEAR_REV>1882628.19</PREV_YEAR_REV>
<BUDGET>1792231.61</BUDGET>
<GROSS_PROFIT>1776796.879</GROSS_PROFIT>
<EXPENSES>1863246.5</EXPENSES>
<NET_INCOME>227939.25</NET_INCOME>
<REVENUE_M>2.09118575</REVENUE_M>
<PROFIT_M>1.776796879</PROFIT_M>
<INCOME_M>0.22793925</INCOME_M>
<PHARMA_REV_M>2.09118575</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.776796879</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22793925</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1973484.8</REVENUE>
<PREV_YEAR_REV>1779148.42</PREV_YEAR_REV>
<BUDGET>1777447.05</BUDGET>
<GROSS_PROFIT>1408476.105</GROSS_PROFIT>
<EXPENSES>1707064.35</EXPENSES>
<NET_INCOME>266420.45</NET_INCOME>
<REVENUE_M>1.9734848</REVENUE_M>
<PROFIT_M>1.408476105</PROFIT_M>
<INCOME_M>0.26642045</INCOME_M>
<PHARMA_REV_M>1.9734848</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.408476105</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26642045</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1627442.65</REVENUE>
<PREV_YEAR_REV>1454476.32</PREV_YEAR_REV>
<BUDGET>1136252.43</BUDGET>
<GROSS_PROFIT>1157111.721</GROSS_PROFIT>
<EXPENSES>1407737.89</EXPENSES>
<NET_INCOME>219704.76</NET_INCOME>
<REVENUE_M>1.62744265</REVENUE_M>
<PROFIT_M>1.157111721</PROFIT_M>
<INCOME_M>0.21970476</INCOME_M>
<PHARMA_REV_M>1.62744265</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.157111721</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21970476</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1404530.53</REVENUE>
<PREV_YEAR_REV>1274852.53</PREV_YEAR_REV>
<BUDGET>967791.98</BUDGET>
<GROSS_PROFIT>1080786.244</GROSS_PROFIT>
<EXPENSES>1261268.42</EXPENSES>
<NET_INCOME>143262.11</NET_INCOME>
<REVENUE_M>1.40453053</REVENUE_M>
<PROFIT_M>1.080786244</PROFIT_M>
<INCOME_M>0.14326211</INCOME_M>
<PHARMA_REV_M>1.40453053</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.080786244</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14326211</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.637467255E7</REVENUE>
<PREV_YEAR_REV>1.50066461E7</PREV_YEAR_REV>
<BUDGET>1.473720529E7</BUDGET>
<GROSS_PROFIT>1.353365886E7</GROSS_PROFIT>
<EXPENSES>1.456526525E7</EXPENSES>
<NET_INCOME>1809407.3</NET_INCOME>
<REVENUE_M>16.37467255</REVENUE_M>
<PROFIT_M>13.53365886</PROFIT_M>
<INCOME_M>1.8094073</INCOME_M>
<PHARMA_REV_M>16.37467255</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.53365886</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.8094073</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.337982338E7</REVENUE>
<PREV_YEAR_REV>1.208495168E7</PREV_YEAR_REV>
<BUDGET>1.204184104E7</BUDGET>
<GROSS_PROFIT>1.14660895E7</GROSS_PROFIT>
<EXPENSES>1.158313341E7</EXPENSES>
<NET_INCOME>1796689.96</NET_INCOME>
<REVENUE_M>13.37982338</REVENUE_M>
<PROFIT_M>11.4660895</PROFIT_M>
<INCOME_M>1.79668996</INCOME_M>
<PHARMA_REV_M>13.37982338</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.4660895</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.79668996</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>2.297331493E7</REVENUE>
<PREV_YEAR_REV>2.085287609E7</PREV_YEAR_REV>
<BUDGET>2.067598344E7</BUDGET>
<GROSS_PROFIT>1.906113706E7</GROSS_PROFIT>
<EXPENSES>2.076453423E7</EXPENSES>
<NET_INCOME>2208780.7</NET_INCOME>
<REVENUE_M>22.97331493</REVENUE_M>
<PROFIT_M>19.06113706</PROFIT_M>
<INCOME_M>2.2087807</INCOME_M>
<PHARMA_REV_M>22.97331493</PHARMA_REV_M>
<PHARMA_PROFIT_M>19.06113706</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.2087807</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6525232.54</REVENUE>
<PREV_YEAR_REV>5948306.31</PREV_YEAR_REV>
<BUDGET>5872709.29</BUDGET>
<GROSS_PROFIT>5410788.079</GROSS_PROFIT>
<EXPENSES>6048890.57</EXPENSES>
<NET_INCOME>476341.98</NET_INCOME>
<REVENUE_M>6.52523254</REVENUE_M>
<PROFIT_M>5.410788079</PROFIT_M>
<INCOME_M>0.47634198</INCOME_M>
<PHARMA_REV_M>6.52523254</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.410788079</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47634198</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.382037436E7</REVENUE>
<PREV_YEAR_REV>1.251600402E7</PREV_YEAR_REV>
<BUDGET>1.243833693E7</BUDGET>
<GROSS_PROFIT>1.118165073E7</GROSS_PROFIT>
<EXPENSES>1.197820254E7</EXPENSES>
<NET_INCOME>1842171.82</NET_INCOME>
<REVENUE_M>13.82037436</REVENUE_M>
<PROFIT_M>11.18165073</PROFIT_M>
<INCOME_M>1.84217182</INCOME_M>
<PHARMA_REV_M>13.82037436</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.18165073</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.84217182</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.872693618E7</REVENUE>
<PREV_YEAR_REV>1.698833466E7</PREV_YEAR_REV>
<BUDGET>1.685424256E7</BUDGET>
<GROSS_PROFIT>1.546802089E7</GROSS_PROFIT>
<EXPENSES>1.685730574E7</EXPENSES>
<NET_INCOME>1869630.42</NET_INCOME>
<REVENUE_M>18.72693618</REVENUE_M>
<PROFIT_M>15.46802089</PROFIT_M>
<INCOME_M>1.86963042</INCOME_M>
<PHARMA_REV_M>18.72693618</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.46802089</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.86963042</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8644296.51</REVENUE>
<PREV_YEAR_REV>7736703.79</PREV_YEAR_REV>
<BUDGET>7779866.86</BUDGET>
<GROSS_PROFIT>7174766.1</GROSS_PROFIT>
<EXPENSES>7702068.19</EXPENSES>
<NET_INCOME>942228.32</NET_INCOME>
<REVENUE_M>8.64429651</REVENUE_M>
<PROFIT_M>7.1747661</PROFIT_M>
<INCOME_M>0.94222832</INCOME_M>
<PHARMA_REV_M>8.64429651</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.1747661</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.94222832</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.324874512E7</REVENUE>
<PREV_YEAR_REV>1.21069578E7</PREV_YEAR_REV>
<BUDGET>1.192387061E7</BUDGET>
<GROSS_PROFIT>1.085718528E7</GROSS_PROFIT>
<EXPENSES>1.156168541E7</EXPENSES>
<NET_INCOME>1687059.7</NET_INCOME>
<REVENUE_M>13.24874512</REVENUE_M>
<PROFIT_M>10.85718528</PROFIT_M>
<INCOME_M>1.6870597</INCOME_M>
<PHARMA_REV_M>13.24874512</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.85718528</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.6870597</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7853712.42</REVENUE>
<PREV_YEAR_REV>6990460.46</PREV_YEAR_REV>
<BUDGET>7068341.18</BUDGET>
<GROSS_PROFIT>5894996.544</GROSS_PROFIT>
<EXPENSES>6793461.24</EXPENSES>
<NET_INCOME>1060251.18</NET_INCOME>
<REVENUE_M>7.85371242</REVENUE_M>
<PROFIT_M>5.894996544</PROFIT_M>
<INCOME_M>1.06025118</INCOME_M>
<PHARMA_REV_M>7.85371242</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.894996544</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.06025118</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2259856.86</REVENUE>
<PREV_YEAR_REV>1941207.62</PREV_YEAR_REV>
<BUDGET>2146447.51</BUDGET>
<GROSS_PROFIT>1793874.369</GROSS_PROFIT>
<EXPENSES>1961555.75</EXPENSES>
<NET_INCOME>298301.11</NET_INCOME>
<REVENUE_M>2.25985686</REVENUE_M>
<PROFIT_M>1.793874369</PROFIT_M>
<INCOME_M>0.29830111</INCOME_M>
<PHARMA_REV_M>2.25985686</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.793874369</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29830111</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4659446.43</REVENUE>
<PREV_YEAR_REV>3970758.55</PREV_YEAR_REV>
<BUDGET>4227073.29</BUDGET>
<GROSS_PROFIT>3404274.791</GROSS_PROFIT>
<EXPENSES>4146016.17</EXPENSES>
<NET_INCOME>513430.25</NET_INCOME>
<REVENUE_M>4.65944643</REVENUE_M>
<PROFIT_M>3.404274791</PROFIT_M>
<INCOME_M>0.51343025</INCOME_M>
<PHARMA_REV_M>4.65944643</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.404274791</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51343025</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>7103831.25</REVENUE>
<PREV_YEAR_REV>6275233.72</PREV_YEAR_REV>
<BUDGET>6449587.44</BUDGET>
<GROSS_PROFIT>5623057.103</GROSS_PROFIT>
<EXPENSES>6412047.73</EXPENSES>
<NET_INCOME>691783.51</NET_INCOME>
<REVENUE_M>7.10383125</REVENUE_M>
<PROFIT_M>5.623057103</PROFIT_M>
<INCOME_M>0.69178351</INCOME_M>
<PHARMA_REV_M>7.10383125</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.623057103</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69178351</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>6961207.67</REVENUE>
<PREV_YEAR_REV>6039302.88</PREV_YEAR_REV>
<BUDGET>6461472.13</BUDGET>
<GROSS_PROFIT>5600337.258</GROSS_PROFIT>
<EXPENSES>6286545.18</EXPENSES>
<NET_INCOME>674662.5</NET_INCOME>
<REVENUE_M>6.96120767</REVENUE_M>
<PROFIT_M>5.600337258</PROFIT_M>
<INCOME_M>0.6746625</INCOME_M>
<PHARMA_REV_M>6.96120767</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.600337258</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6746625</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2070325.55</REVENUE>
<PREV_YEAR_REV>1801097.49</PREV_YEAR_REV>
<BUDGET>1945534.14</BUDGET>
<GROSS_PROFIT>1794972.25</GROSS_PROFIT>
<EXPENSES>1844660.06</EXPENSES>
<NET_INCOME>225665.48</NET_INCOME>
<REVENUE_M>2.07032555</REVENUE_M>
<PROFIT_M>1.79497225</PROFIT_M>
<INCOME_M>0.22566548</INCOME_M>
<PHARMA_REV_M>2.07032555</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.79497225</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22566548</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2230687.69</REVENUE>
<PREV_YEAR_REV>1978454.52</PREV_YEAR_REV>
<BUDGET>2074258.16</BUDGET>
<GROSS_PROFIT>1607801.611</GROSS_PROFIT>
<EXPENSES>1929544.85</EXPENSES>
<NET_INCOME>301142.84</NET_INCOME>
<REVENUE_M>2.23068769</REVENUE_M>
<PROFIT_M>1.607801611</PROFIT_M>
<INCOME_M>0.30114284</INCOME_M>
<PHARMA_REV_M>2.23068769</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.607801611</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30114284</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2174033.82</REVENUE>
<PREV_YEAR_REV>1966597.15</PREV_YEAR_REV>
<BUDGET>1945534.14</BUDGET>
<GROSS_PROFIT>1533998.259</GROSS_PROFIT>
<EXPENSES>1880539.25</EXPENSES>
<NET_INCOME>293494.57</NET_INCOME>
<REVENUE_M>2.17403382</REVENUE_M>
<PROFIT_M>1.533998259</PROFIT_M>
<INCOME_M>0.29349457</INCOME_M>
<PHARMA_REV_M>2.17403382</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.533998259</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29349457</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3864949.51</REVENUE>
<PREV_YEAR_REV>3327060.24</PREV_YEAR_REV>
<BUDGET>3009812.26</BUDGET>
<GROSS_PROFIT>2993461.551</GROSS_PROFIT>
<EXPENSES>3399126.27</EXPENSES>
<NET_INCOME>465823.24</NET_INCOME>
<REVENUE_M>3.86494951</REVENUE_M>
<PROFIT_M>2.993461551</PROFIT_M>
<INCOME_M>0.46582324</INCOME_M>
<PHARMA_REV_M>3.86494951</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.993461551</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46582324</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>9310787.36</REVENUE>
<PREV_YEAR_REV>8436740.99</PREV_YEAR_REV>
<BUDGET>9124571.61</BUDGET>
<GROSS_PROFIT>7262414.14</GROSS_PROFIT>
<EXPENSES>8081763.43</EXPENSES>
<NET_INCOME>1229023.93</NET_INCOME>
<REVENUE_M>9.31078736</REVENUE_M>
<PROFIT_M>7.26241414</PROFIT_M>
<INCOME_M>1.22902393</INCOME_M>
<PHARMA_REV_M>9.31078736</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.26241414</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.22902393</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.479652291E7</REVENUE>
<PREV_YEAR_REV>1.281957161E7</PREV_YEAR_REV>
<BUDGET>1.450059246E7</BUDGET>
<GROSS_PROFIT>1.128551393E7</GROSS_PROFIT>
<EXPENSES>1.301154071E7</EXPENSES>
<NET_INCOME>1784982.2</NET_INCOME>
<REVENUE_M>14.79652291</REVENUE_M>
<PROFIT_M>11.28551393</PROFIT_M>
<INCOME_M>1.7849822</INCOME_M>
<PHARMA_REV_M>14.79652291</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.28551393</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.7849822</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9413395.1</REVENUE>
<PREV_YEAR_REV>8159238.54</PREV_YEAR_REV>
<BUDGET>9225127.2</BUDGET>
<GROSS_PROFIT>8312027.87</GROSS_PROFIT>
<EXPENSES>8170826.95</EXPENSES>
<NET_INCOME>1242568.15</NET_INCOME>
<REVENUE_M>9.4133951</REVENUE_M>
<PROFIT_M>8.31202787</PROFIT_M>
<INCOME_M>1.24256815</INCOME_M>
<PHARMA_REV_M>9.4133951</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.31202787</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.24256815</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.342326989E7</REVENUE>
<PREV_YEAR_REV>1.189012424E7</PREV_YEAR_REV>
<BUDGET>1.315480449E7</BUDGET>
<GROSS_PROFIT>1.051070141E7</GROSS_PROFIT>
<EXPENSES>1.142725967E7</EXPENSES>
<NET_INCOME>1996010.23</NET_INCOME>
<REVENUE_M>13.42326989</REVENUE_M>
<PROFIT_M>10.51070141</PROFIT_M>
<INCOME_M>1.99601023</INCOME_M>
<PHARMA_REV_M>13.42326989</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.51070141</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.99601023</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>2.097752029E7</REVENUE>
<PREV_YEAR_REV>1.872693618E7</PREV_YEAR_REV>
<BUDGET>2.055796988E7</BUDGET>
<GROSS_PROFIT>1.771515296E7</GROSS_PROFIT>
<EXPENSES>1.888510879E7</EXPENSES>
<NET_INCOME>2092411.5</NET_INCOME>
<REVENUE_M>20.97752029</REVENUE_M>
<PROFIT_M>17.71515296</PROFIT_M>
<INCOME_M>2.0924115</INCOME_M>
<PHARMA_REV_M>20.97752029</PHARMA_REV_M>
<PHARMA_PROFIT_M>17.71515296</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.0924115</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.09799673E7</REVENUE>
<PREV_YEAR_REV>9588402.45</PREV_YEAR_REV>
<BUDGET>1.076036796E7</BUDGET>
<GROSS_PROFIT>8595118.407</GROSS_PROFIT>
<EXPENSES>9860010.64</EXPENSES>
<NET_INCOME>1119956.66</NET_INCOME>
<REVENUE_M>10.9799673</REVENUE_M>
<PROFIT_M>8.595118407</PROFIT_M>
<INCOME_M>1.11995666</INCOME_M>
<PHARMA_REV_M>10.9799673</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.595118407</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.11995666</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>2.079193145E7</REVENUE>
<PREV_YEAR_REV>1.833528051E7</PREV_YEAR_REV>
<BUDGET>2.037609281E7</BUDGET>
<GROSS_PROFIT>1.744632726E7</GROSS_PROFIT>
<EXPENSES>1.801585877E7</EXPENSES>
<NET_INCOME>2776072.67</NET_INCOME>
<REVENUE_M>20.79193145</REVENUE_M>
<PROFIT_M>17.44632726</PROFIT_M>
<INCOME_M>2.77607267</INCOME_M>
<PHARMA_REV_M>20.79193145</PHARMA_REV_M>
<PHARMA_PROFIT_M>17.44632726</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.77607267</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7833548.16</REVENUE>
<PREV_YEAR_REV>6699463.06</PREV_YEAR_REV>
<BUDGET>7676877.2</BUDGET>
<GROSS_PROFIT>6370241.369</GROSS_PROFIT>
<EXPENSES>6486177.88</EXPENSES>
<NET_INCOME>1347370.28</NET_INCOME>
<REVENUE_M>7.83354816</REVENUE_M>
<PROFIT_M>6.370241369</PROFIT_M>
<INCOME_M>1.34737028</INCOME_M>
<PHARMA_REV_M>7.83354816</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.370241369</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.34737028</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2459874.24</REVENUE>
<PREV_YEAR_REV>2094847.13</PREV_YEAR_REV>
<BUDGET>2267232.19</BUDGET>
<GROSS_PROFIT>1748572.089</GROSS_PROFIT>
<EXPENSES>2142550.46</EXPENSES>
<NET_INCOME>317323.78</NET_INCOME>
<REVENUE_M>2.45987424</REVENUE_M>
<PROFIT_M>1.748572089</PROFIT_M>
<INCOME_M>0.31732378</INCOME_M>
<PHARMA_REV_M>2.45987424</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.748572089</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31732378</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4958807.02</REVENUE>
<PREV_YEAR_REV>4314394.87</PREV_YEAR_REV>
<BUDGET>4561320.69</BUDGET>
<GROSS_PROFIT>3861446.853</GROSS_PROFIT>
<EXPENSES>4354924.45</EXPENSES>
<NET_INCOME>603882.56</NET_INCOME>
<REVENUE_M>4.95880702</REVENUE_M>
<PROFIT_M>3.861446853</PROFIT_M>
<INCOME_M>0.60388256</INCOME_M>
<PHARMA_REV_M>4.95880702</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.861446853</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60388256</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5547940.57</REVENUE>
<PREV_YEAR_REV>4934319.12</PREV_YEAR_REV>
<BUDGET>5381502.35</BUDGET>
<GROSS_PROFIT>4651223.45</GROSS_PROFIT>
<EXPENSES>5009928.75</EXPENSES>
<NET_INCOME>538011.81</NET_INCOME>
<REVENUE_M>5.54794057</REVENUE_M>
<PROFIT_M>4.65122345</PROFIT_M>
<INCOME_M>0.53801181</INCOME_M>
<PHARMA_REV_M>5.54794057</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.65122345</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53801181</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5551572.41</REVENUE>
<PREV_YEAR_REV>4850658.45</PREV_YEAR_REV>
<BUDGET>5385025.23</BUDGET>
<GROSS_PROFIT>4663657.12</GROSS_PROFIT>
<EXPENSES>5013322.11</EXPENSES>
<NET_INCOME>538250.3</NET_INCOME>
<REVENUE_M>5.55157241</REVENUE_M>
<PROFIT_M>4.66365712</PROFIT_M>
<INCOME_M>0.5382503</INCOME_M>
<PHARMA_REV_M>5.55157241</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.66365712</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5382503</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1844919.27</REVENUE>
<PREV_YEAR_REV>1628751.39</PREV_YEAR_REV>
<BUDGET>1789571.69</BUDGET>
<GROSS_PROFIT>1363609.353</GROSS_PROFIT>
<EXPENSES>1595855.17</EXPENSES>
<NET_INCOME>249064.1</NET_INCOME>
<REVENUE_M>1.8449192700000001</REVENUE_M>
<PROFIT_M>1.363609353</PROFIT_M>
<INCOME_M>0.2490641</INCOME_M>
<PHARMA_REV_M>1.8449192700000001</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.363609353</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2490641</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2979090.57</REVENUE>
<PREV_YEAR_REV>2650250.95</PREV_YEAR_REV>
<BUDGET>2889717.86</BUDGET>
<GROSS_PROFIT>2064476.066</GROSS_PROFIT>
<EXPENSES>2618876.76</EXPENSES>
<NET_INCOME>360213.81</NET_INCOME>
<REVENUE_M>2.97909057</REVENUE_M>
<PROFIT_M>2.064476066</PROFIT_M>
<INCOME_M>0.36021381</INCOME_M>
<PHARMA_REV_M>2.97909057</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.064476066</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36021381</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3090373.84</REVENUE>
<PREV_YEAR_REV>2717791.76</PREV_YEAR_REV>
<BUDGET>2703290.63</BUDGET>
<GROSS_PROFIT>2442631.479</GROSS_PROFIT>
<EXPENSES>2864776.55</EXPENSES>
<NET_INCOME>225597.29</NET_INCOME>
<REVENUE_M>3.09037384</REVENUE_M>
<PROFIT_M>2.442631479</PROFIT_M>
<INCOME_M>0.22559729</INCOME_M>
<PHARMA_REV_M>3.09037384</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.442631479</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22559729</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3123400.79</REVENUE>
<PREV_YEAR_REV>2725028.83</PREV_YEAR_REV>
<BUDGET>2786155.31</BUDGET>
<GROSS_PROFIT>2101689.539</GROSS_PROFIT>
<EXPENSES>2701741.69</EXPENSES>
<NET_INCOME>421659.11</NET_INCOME>
<REVENUE_M>3.12340079</REVENUE_M>
<PROFIT_M>2.101689539</PROFIT_M>
<INCOME_M>0.42165911</INCOME_M>
<PHARMA_REV_M>3.12340079</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.101689539</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42165911</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2854903.25</REVENUE>
<PREV_YEAR_REV>2541441.82</PREV_YEAR_REV>
<BUDGET>2610237.66</BUDGET>
<GROSS_PROFIT>2081275.861</GROSS_PROFIT>
<EXPENSES>2469491.31</EXPENSES>
<NET_INCOME>385411.94</NET_INCOME>
<REVENUE_M>2.85490325</REVENUE_M>
<PROFIT_M>2.081275861</PROFIT_M>
<INCOME_M>0.38541194</INCOME_M>
<PHARMA_REV_M>2.85490325</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.081275861</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38541194</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1725202.61</REVENUE>
<PREV_YEAR_REV>1505819.73</PREV_YEAR_REV>
<BUDGET>1939615.78</BUDGET>
<GROSS_PROFIT>1413423.992</GROSS_PROFIT>
<EXPENSES>1449170.19</EXPENSES>
<NET_INCOME>276032.42</NET_INCOME>
<REVENUE_M>1.72520261</REVENUE_M>
<PROFIT_M>1.413423992</PROFIT_M>
<INCOME_M>0.27603242</INCOME_M>
<PHARMA_REV_M>1.72520261</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.413423992</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27603242</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4091059.28</REVENUE>
<PREV_YEAR_REV>3580398.74</PREV_YEAR_REV>
<BUDGET>4715767.94</BUDGET>
<GROSS_PROFIT>3430997.69</GROSS_PROFIT>
<EXPENSES>3540567.35</EXPENSES>
<NET_INCOME>550491.93</NET_INCOME>
<REVENUE_M>4.09105928</REVENUE_M>
<PROFIT_M>3.43099769</PROFIT_M>
<INCOME_M>0.55049193</INCOME_M>
<PHARMA_REV_M>4.09105928</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.43099769</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55049193</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>6367896.91</REVENUE>
<PREV_YEAR_REV>5555125.95</PREV_YEAR_REV>
<BUDGET>7125140.6</BUDGET>
<GROSS_PROFIT>5216368.63</GROSS_PROFIT>
<EXPENSES>5749673.78</EXPENSES>
<NET_INCOME>618223.13</NET_INCOME>
<REVENUE_M>6.36789691</REVENUE_M>
<PROFIT_M>5.21636863</PROFIT_M>
<INCOME_M>0.61822313</INCOME_M>
<PHARMA_REV_M>6.36789691</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.21636863</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61822313</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>6350668.04</REVENUE>
<PREV_YEAR_REV>5494130.53</PREV_YEAR_REV>
<BUDGET>7130155.72</BUDGET>
<GROSS_PROFIT>5232377.19</GROSS_PROFIT>
<EXPENSES>5734090.25</EXPENSES>
<NET_INCOME>616577.78</NET_INCOME>
<REVENUE_M>6.35066804</REVENUE_M>
<PROFIT_M>5.23237719</PROFIT_M>
<INCOME_M>0.61657778</INCOME_M>
<PHARMA_REV_M>6.35066804</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.23237719</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61657778</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2132650.11</REVENUE>
<PREV_YEAR_REV>1901927.31</PREV_YEAR_REV>
<BUDGET>2369519.97</BUDGET>
<GROSS_PROFIT>1681716.17</GROSS_PROFIT>
<EXPENSES>1765834.29</EXPENSES>
<NET_INCOME>366815.82</NET_INCOME>
<REVENUE_M>2.13265011</REVENUE_M>
<PROFIT_M>1.68171617</PROFIT_M>
<INCOME_M>0.36681582</INCOME_M>
<PHARMA_REV_M>2.13265011</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.68171617</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36681582</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1969580.07</REVENUE>
<PREV_YEAR_REV>1748422.15</PREV_YEAR_REV>
<BUDGET>2291636.22</BUDGET>
<GROSS_PROFIT>1599791.412</GROSS_PROFIT>
<EXPENSES>1768682.9</EXPENSES>
<NET_INCOME>200897.17</NET_INCOME>
<REVENUE_M>1.96958007</REVENUE_M>
<PROFIT_M>1.599791412</PROFIT_M>
<INCOME_M>0.20089717</INCOME_M>
<PHARMA_REV_M>1.96958007</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.599791412</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20089717</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4826700.33</REVENUE>
<PREV_YEAR_REV>4207242.99</PREV_YEAR_REV>
<BUDGET>4761007.71</BUDGET>
<GROSS_PROFIT>4150383.45</GROSS_PROFIT>
<EXPENSES>4359595.39</EXPENSES>
<NET_INCOME>467104.93</NET_INCOME>
<REVENUE_M>4.82670033</REVENUE_M>
<PROFIT_M>4.15038345</PROFIT_M>
<INCOME_M>0.46710493</INCOME_M>
<PHARMA_REV_M>4.82670033</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.15038345</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46710493</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6172462.21</REVENUE>
<PREV_YEAR_REV>5584321.47</PREV_YEAR_REV>
<BUDGET>5678665.23</BUDGET>
<GROSS_PROFIT>4685207.435</GROSS_PROFIT>
<EXPENSES>5110798.71</EXPENSES>
<NET_INCOME>1061663.5</NET_INCOME>
<REVENUE_M>6.17246221</REVENUE_M>
<PROFIT_M>4.685207435</PROFIT_M>
<INCOME_M>1.0616635</INCOME_M>
<PHARMA_REV_M>6.17246221</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.685207435</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.0616635</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.545200103E7</REVENUE>
<PREV_YEAR_REV>1.335503248E7</PREV_YEAR_REV>
<BUDGET>1.421584095E7</BUDGET>
<GROSS_PROFIT>1.265494287E7</GROSS_PROFIT>
<EXPENSES>1.34092733E7</EXPENSES>
<NET_INCOME>2042727.74</NET_INCOME>
<REVENUE_M>15.45200103</REVENUE_M>
<PROFIT_M>12.65494287</PROFIT_M>
<INCOME_M>2.04272774</INCOME_M>
<PHARMA_REV_M>15.45200103</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.65494287</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.04272774</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9490319.93</REVENUE>
<PREV_YEAR_REV>8445599.29</PREV_YEAR_REV>
<BUDGET>8731094.33</BUDGET>
<GROSS_PROFIT>6670745.874</GROSS_PROFIT>
<EXPENSES>8209126.74</EXPENSES>
<NET_INCOME>1281193.19</NET_INCOME>
<REVENUE_M>9.49031993</REVENUE_M>
<PROFIT_M>6.670745874</PROFIT_M>
<INCOME_M>1.28119319</INCOME_M>
<PHARMA_REV_M>9.49031993</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.670745874</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.28119319</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2498131.13</REVENUE>
<PREV_YEAR_REV>2149891.67</PREV_YEAR_REV>
<BUDGET>2423187.19</BUDGET>
<GROSS_PROFIT>2014867.664</GROSS_PROFIT>
<EXPENSES>2168377.82</EXPENSES>
<NET_INCOME>329753.31</NET_INCOME>
<REVENUE_M>2.49813113</REVENUE_M>
<PROFIT_M>2.014867664</PROFIT_M>
<INCOME_M>0.32975331</INCOME_M>
<PHARMA_REV_M>2.49813113</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.014867664</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32975331</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2620717.52</REVENUE>
<PREV_YEAR_REV>2222227.65</PREV_YEAR_REV>
<BUDGET>2542095.99</BUDGET>
<GROSS_PROFIT>1758960.079</GROSS_PROFIT>
<EXPENSES>2282644.96</EXPENSES>
<NET_INCOME>338072.56</NET_INCOME>
<REVENUE_M>2.62071752</REVENUE_M>
<PROFIT_M>1.758960079</PROFIT_M>
<INCOME_M>0.33807256</INCOME_M>
<PHARMA_REV_M>2.62071752</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.758960079</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33807256</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2703782.03</REVENUE>
<PREV_YEAR_REV>2369037.08</PREV_YEAR_REV>
<BUDGET>2622668.56</BUDGET>
<GROSS_PROFIT>2378544.081</GROSS_PROFIT>
<EXPENSES>2506405.94</EXPENSES>
<NET_INCOME>197376.09</NET_INCOME>
<REVENUE_M>2.70378203</REVENUE_M>
<PROFIT_M>2.378544081</PROFIT_M>
<INCOME_M>0.19737609</INCOME_M>
<PHARMA_REV_M>2.70378203</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.378544081</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19737609</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2703782.03</REVENUE>
<PREV_YEAR_REV>2437442.66</PREV_YEAR_REV>
<BUDGET>2622668.56</BUDGET>
<GROSS_PROFIT>2192499.544</GROSS_PROFIT>
<EXPENSES>2238731.52</EXPENSES>
<NET_INCOME>465050.51</NET_INCOME>
<REVENUE_M>2.70378203</REVENUE_M>
<PROFIT_M>2.192499544</PROFIT_M>
<INCOME_M>0.46505051</INCOME_M>
<PHARMA_REV_M>2.70378203</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.192499544</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46505051</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3706653.14</REVENUE>
<PREV_YEAR_REV>3162679.51</PREV_YEAR_REV>
<BUDGET>3595453.54</BUDGET>
<GROSS_PROFIT>2822458.17</GROSS_PROFIT>
<EXPENSES>3297294.96</EXPENSES>
<NET_INCOME>409358.18</NET_INCOME>
<REVENUE_M>3.70665314</REVENUE_M>
<PROFIT_M>2.82245817</PROFIT_M>
<INCOME_M>0.40935818</INCOME_M>
<PHARMA_REV_M>3.70665314</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.82245817</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40935818</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1826799.58</REVENUE>
<PREV_YEAR_REV>1556299.21</PREV_YEAR_REV>
<BUDGET>1771995.59</BUDGET>
<GROSS_PROFIT>1336669.254</GROSS_PROFIT>
<EXPENSES>1591142.44</EXPENSES>
<NET_INCOME>235657.15</NET_INCOME>
<REVENUE_M>1.82679958</REVENUE_M>
<PROFIT_M>1.336669254</PROFIT_M>
<INCOME_M>0.23565715</INCOME_M>
<PHARMA_REV_M>1.82679958</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.336669254</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23565715</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1826799.58</REVENUE>
<PREV_YEAR_REV>1550000.49</PREV_YEAR_REV>
<BUDGET>1771995.59</BUDGET>
<GROSS_PROFIT>1473386.939</GROSS_PROFIT>
<EXPENSES>1499802.46</EXPENSES>
<NET_INCOME>326997.13</NET_INCOME>
<REVENUE_M>1.82679958</REVENUE_M>
<PROFIT_M>1.473386939</PROFIT_M>
<INCOME_M>0.32699713</INCOME_M>
<PHARMA_REV_M>1.82679958</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.473386939</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32699713</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3156784.13</REVENUE>
<PREV_YEAR_REV>2747204.91</PREV_YEAR_REV>
<BUDGET>4147823.08</BUDGET>
<GROSS_PROFIT>2247114.822</GROSS_PROFIT>
<EXPENSES>2688361.44</EXPENSES>
<NET_INCOME>468422.69</NET_INCOME>
<REVENUE_M>3.15678413</REVENUE_M>
<PROFIT_M>2.247114822</PROFIT_M>
<INCOME_M>0.46842269</INCOME_M>
<PHARMA_REV_M>3.15678413</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.247114822</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46842269</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1562838.64</REVENUE>
<PREV_YEAR_REV>1400681.71</PREV_YEAR_REV>
<BUDGET>2059978.9</BUDGET>
<GROSS_PROFIT>1251302.385</GROSS_PROFIT>
<EXPENSES>1403429.1</EXPENSES>
<NET_INCOME>159409.54</NET_INCOME>
<REVENUE_M>1.56283864</REVENUE_M>
<PROFIT_M>1.251302385</PROFIT_M>
<INCOME_M>0.15940954</INCOME_M>
<PHARMA_REV_M>1.56283864</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.251302385</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15940954</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1608863.02</REVENUE>
<PREV_YEAR_REV>1433911.48</PREV_YEAR_REV>
<BUDGET>2067411.62</BUDGET>
<GROSS_PROFIT>1300685.309</GROSS_PROFIT>
<EXPENSES>1444758.99</EXPENSES>
<NET_INCOME>164104.03</NET_INCOME>
<REVENUE_M>1.60886302</REVENUE_M>
<PROFIT_M>1.300685309</PROFIT_M>
<INCOME_M>0.16410403</INCOME_M>
<PHARMA_REV_M>1.60886302</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.300685309</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16410403</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1511922.72</REVENUE>
<PREV_YEAR_REV>1294786.95</PREV_YEAR_REV>
<BUDGET>2055147.63</BUDGET>
<GROSS_PROFIT>1159115.549</GROSS_PROFIT>
<EXPENSES>1251872.01</EXPENSES>
<NET_INCOME>260050.71</NET_INCOME>
<REVENUE_M>1.51192272</REVENUE_M>
<PROFIT_M>1.159115549</PROFIT_M>
<INCOME_M>0.26005071</INCOME_M>
<PHARMA_REV_M>1.51192272</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.159115549</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26005071</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>959272.57</REVENUE>
<PREV_YEAR_REV>829053.18</PREV_YEAR_REV>
<BUDGET>1074914.03</BUDGET>
<GROSS_PROFIT>735570.207</GROSS_PROFIT>
<EXPENSES>835526.41</EXPENSES>
<NET_INCOME>123746.16</NET_INCOME>
<REVENUE_M>0.95927257</REVENUE_M>
<PROFIT_M>0.735570207</PROFIT_M>
<INCOME_M>0.12374616</INCOME_M>
<PHARMA_REV_M>0.95927257</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.735570207</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12374616</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1296535.52</REVENUE>
<PREV_YEAR_REV>1104120.45</PREV_YEAR_REV>
<BUDGET>1492214.01</BUDGET>
<GROSS_PROFIT>1064196.356</GROSS_PROFIT>
<EXPENSES>1064455.67</EXPENSES>
<NET_INCOME>232079.86</NET_INCOME>
<REVENUE_M>1.29653552</REVENUE_M>
<PROFIT_M>1.064196356</PROFIT_M>
<INCOME_M>0.23207986</INCOME_M>
<PHARMA_REV_M>1.29653552</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.064196356</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23207986</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1223711.1</REVENUE>
<PREV_YEAR_REV>1053561</PREV_YEAR_REV>
<BUDGET>1407693.55</BUDGET>
<GROSS_PROFIT>1053615.26</GROSS_PROFIT>
<EXPENSES>1090326.59</EXPENSES>
<NET_INCOME>133384.51</NET_INCOME>
<REVENUE_M>1.2237111</REVENUE_M>
<PROFIT_M>1.05361526</PROFIT_M>
<INCOME_M>0.13338451</INCOME_M>
<PHARMA_REV_M>1.2237111</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.05361526</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13338451</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6528238.93</REVENUE>
<PREV_YEAR_REV>5799476.69</PREV_YEAR_REV>
<BUDGET>6332391.77</BUDGET>
<GROSS_PROFIT>5313986.49</GROSS_PROFIT>
<EXPENSES>5359684.16</EXPENSES>
<NET_INCOME>1168554.77</NET_INCOME>
<REVENUE_M>6.52823893</REVENUE_M>
<PROFIT_M>5.31398649</PROFIT_M>
<INCOME_M>1.16855477</INCOME_M>
<PHARMA_REV_M>6.52823893</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.31398649</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.16855477</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8162820.64</REVENUE>
<PREV_YEAR_REV>7184506.41</PREV_YEAR_REV>
<BUDGET>7917936.02</BUDGET>
<GROSS_PROFIT>6587396.26</GROSS_PROFIT>
<EXPENSES>7273073.19</EXPENSES>
<NET_INCOME>889747.45</NET_INCOME>
<REVENUE_M>8.16282064</REVENUE_M>
<PROFIT_M>6.58739626</PROFIT_M>
<INCOME_M>0.88974745</INCOME_M>
<PHARMA_REV_M>8.16282064</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.58739626</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.88974745</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3177163.17</REVENUE>
<PREV_YEAR_REV>2788257.07</PREV_YEAR_REV>
<BUDGET>2444392.74</BUDGET>
<GROSS_PROFIT>2222076.147</GROSS_PROFIT>
<EXPENSES>2767309.12</EXPENSES>
<NET_INCOME>409854.05</NET_INCOME>
<REVENUE_M>3.17716317</REVENUE_M>
<PROFIT_M>2.222076147</PROFIT_M>
<INCOME_M>0.40985405</INCOME_M>
<PHARMA_REV_M>3.17716317</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.222076147</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40985405</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5392291.44</REVENUE>
<PREV_YEAR_REV>4767376.46</PREV_YEAR_REV>
<BUDGET>4128646.84</BUDGET>
<GROSS_PROFIT>4076160.325</GROSS_PROFIT>
<EXPENSES>4735453.37</EXPENSES>
<NET_INCOME>656838.07</NET_INCOME>
<REVENUE_M>5.39229144</REVENUE_M>
<PROFIT_M>4.076160325</PROFIT_M>
<INCOME_M>0.65683807</INCOME_M>
<PHARMA_REV_M>5.39229144</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.076160325</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65683807</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2924533.56</REVENUE>
<PREV_YEAR_REV>2526267.49</PREV_YEAR_REV>
<BUDGET>2283317.76</BUDGET>
<GROSS_PROFIT>2321494.736</GROSS_PROFIT>
<EXPENSES>2456608.19</EXPENSES>
<NET_INCOME>467925.37</NET_INCOME>
<REVENUE_M>2.92453356</REVENUE_M>
<PROFIT_M>2.321494736</PROFIT_M>
<INCOME_M>0.46792537</INCOME_M>
<PHARMA_REV_M>2.92453356</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.321494736</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46792537</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3087595.41</REVENUE>
<PREV_YEAR_REV>2799169.04</PREV_YEAR_REV>
<BUDGET>2354645.7</BUDGET>
<GROSS_PROFIT>2432778.176</GROSS_PROFIT>
<EXPENSES>2680032.82</EXPENSES>
<NET_INCOME>407562.59</NET_INCOME>
<REVENUE_M>3.08759541</REVENUE_M>
<PROFIT_M>2.432778176</PROFIT_M>
<INCOME_M>0.40756259</INCOME_M>
<PHARMA_REV_M>3.08759541</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.432778176</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40756259</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3258256.84</REVENUE>
<PREV_YEAR_REV>2829133.82</PREV_YEAR_REV>
<BUDGET>2492358.66</BUDGET>
<GROSS_PROFIT>2882775.32</GROSS_PROFIT>
<EXPENSES>2675028.87</EXPENSES>
<NET_INCOME>583227.97</NET_INCOME>
<REVENUE_M>3.25825684</REVENUE_M>
<PROFIT_M>2.88277532</PROFIT_M>
<INCOME_M>0.58322797</INCOME_M>
<PHARMA_REV_M>3.25825684</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.88277532</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58322797</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3348993.97</REVENUE>
<PREV_YEAR_REV>3020921.85</PREV_YEAR_REV>
<BUDGET>2521868.58</BUDGET>
<GROSS_PROFIT>2433881.364</GROSS_PROFIT>
<EXPENSES>2896879.78</EXPENSES>
<NET_INCOME>452114.19</NET_INCOME>
<REVENUE_M>3.34899397</REVENUE_M>
<PROFIT_M>2.433881364</PROFIT_M>
<INCOME_M>0.45211419</INCOME_M>
<PHARMA_REV_M>3.34899397</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.433881364</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45211419</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3182367.28</REVENUE>
<PREV_YEAR_REV>2717092.38</PREV_YEAR_REV>
<BUDGET>2396439.12</BUDGET>
<GROSS_PROFIT>2530459.349</GROSS_PROFIT>
<EXPENSES>2835489.25</EXPENSES>
<NET_INCOME>346878.03</NET_INCOME>
<REVENUE_M>3.18236728</REVENUE_M>
<PROFIT_M>2.530459349</PROFIT_M>
<INCOME_M>0.34687803</INCOME_M>
<PHARMA_REV_M>3.18236728</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.530459349</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34687803</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6296217.05</REVENUE>
<PREV_YEAR_REV>5485949.61</PREV_YEAR_REV>
<BUDGET>4941682.02</BUDGET>
<GROSS_PROFIT>5089969.366</GROSS_PROFIT>
<EXPENSES>5462693.23</EXPENSES>
<NET_INCOME>833523.82</NET_INCOME>
<REVENUE_M>6.29621705</REVENUE_M>
<PROFIT_M>5.089969366</PROFIT_M>
<INCOME_M>0.83352382</INCOME_M>
<PHARMA_REV_M>6.29621705</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.089969366</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83352382</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1517387.26</REVENUE>
<PREV_YEAR_REV>1325993.37</PREV_YEAR_REV>
<BUDGET>1471865.64</BUDGET>
<GROSS_PROFIT>1209433.515</GROSS_PROFIT>
<EXPENSES>1245774.94</EXPENSES>
<NET_INCOME>271612.32</NET_INCOME>
<REVENUE_M>1.51738726</REVENUE_M>
<PROFIT_M>1.209433515</PROFIT_M>
<INCOME_M>0.27161232</INCOME_M>
<PHARMA_REV_M>1.51738726</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.209433515</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27161232</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2297316.72</REVENUE>
<PREV_YEAR_REV>1963262.47</PREV_YEAR_REV>
<BUDGET>2228397.21</BUDGET>
<GROSS_PROFIT>1741161.368</GROSS_PROFIT>
<EXPENSES>1989095.68</EXPENSES>
<NET_INCOME>308221.03</NET_INCOME>
<REVENUE_M>2.29731672</REVENUE_M>
<PROFIT_M>1.741161368</PROFIT_M>
<INCOME_M>0.30822103</INCOME_M>
<PHARMA_REV_M>2.29731672</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.741161368</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30822103</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2702341.41</REVENUE>
<PREV_YEAR_REV>2380973.41</PREV_YEAR_REV>
<BUDGET>2621271.17</BUDGET>
<GROSS_PROFIT>2005059.447</GROSS_PROFIT>
<EXPENSES>2300996.38</EXPENSES>
<NET_INCOME>401345.03</NET_INCOME>
<REVENUE_M>2.70234141</REVENUE_M>
<PROFIT_M>2.005059447</PROFIT_M>
<INCOME_M>0.40134503</INCOME_M>
<PHARMA_REV_M>2.70234141</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.005059447</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40134503</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1218921.36</REVENUE>
<PREV_YEAR_REV>1099613.31</PREV_YEAR_REV>
<BUDGET>1182353.72</BUDGET>
<GROSS_PROFIT>986107.38</GROSS_PROFIT>
<EXPENSES>1129940.1</EXPENSES>
<NET_INCOME>88981.26</NET_INCOME>
<REVENUE_M>1.21892136</REVENUE_M>
<PROFIT_M>0.98610738</PROFIT_M>
<INCOME_M>0.08898126</INCOME_M>
<PHARMA_REV_M>1.21892136</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.98610738</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.08898126</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1364678.28</REVENUE>
<PREV_YEAR_REV>1236121.63</PREV_YEAR_REV>
<BUDGET>1323737.93</BUDGET>
<GROSS_PROFIT>1134388.825</GROSS_PROFIT>
<EXPENSES>1215928.35</EXPENSES>
<NET_INCOME>148749.93</NET_INCOME>
<REVENUE_M>1.36467828</REVENUE_M>
<PROFIT_M>1.134388825</PROFIT_M>
<INCOME_M>0.14874993</INCOME_M>
<PHARMA_REV_M>1.36467828</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.134388825</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14874993</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.585950516E7</REVENUE>
<PREV_YEAR_REV>1.271461494E7</PREV_YEAR_REV>
<BUDGET>1.50665299E7</BUDGET>
<GROSS_PROFIT>1.261810896E7</GROSS_PROFIT>
<EXPENSES>1.372110296E7</EXPENSES>
<NET_INCOME>2138402.2</NET_INCOME>
<REVENUE_M>15.85950516</REVENUE_M>
<PROFIT_M>12.61810896</PROFIT_M>
<INCOME_M>2.1384022</INCOME_M>
<PHARMA_REV_M>15.85950516</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.61810896</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.1384022</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.44626261E7</REVENUE>
<PREV_YEAR_REV>1.162876752E7</PREV_YEAR_REV>
<BUDGET>1.37394948E7</BUDGET>
<GROSS_PROFIT>1.029793341E7</GROSS_PROFIT>
<EXPENSES>1.231139051E7</EXPENSES>
<NET_INCOME>2151235.6</NET_INCOME>
<REVENUE_M>14.4626261</REVENUE_M>
<PROFIT_M>10.29793341</PROFIT_M>
<INCOME_M>2.1512356</INCOME_M>
<PHARMA_REV_M>14.4626261</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.29793341</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.1512356</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.752414451E7</REVENUE>
<PREV_YEAR_REV>1.445981252E7</PREV_YEAR_REV>
<BUDGET>1.664793729E7</BUDGET>
<GROSS_PROFIT>1.378661068E7</GROSS_PROFIT>
<EXPENSES>1.520720869E7</EXPENSES>
<NET_INCOME>2316935.82</NET_INCOME>
<REVENUE_M>17.52414451</REVENUE_M>
<PROFIT_M>13.78661068</PROFIT_M>
<INCOME_M>2.31693582</INCOME_M>
<PHARMA_REV_M>17.52414451</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.78661068</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.31693582</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5392170</REVENUE>
<PREV_YEAR_REV>4329072.95</PREV_YEAR_REV>
<BUDGET>5338248.31</BUDGET>
<GROSS_PROFIT>3828818.733</GROSS_PROFIT>
<EXPENSES>4796832.76</EXPENSES>
<NET_INCOME>595337.24</NET_INCOME>
<REVENUE_M>5.39217</REVENUE_M>
<PROFIT_M>3.828818733</PROFIT_M>
<INCOME_M>0.59533724</INCOME_M>
<PHARMA_REV_M>5.39217</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.828818733</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.59533724</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2757334.42</REVENUE>
<PREV_YEAR_REV>2318217.64</PREV_YEAR_REV>
<BUDGET>2632587.5</BUDGET>
<GROSS_PROFIT>2050519.322</GROSS_PROFIT>
<EXPENSES>2476086.31</EXPENSES>
<NET_INCOME>281248.11</NET_INCOME>
<REVENUE_M>2.75733442</REVENUE_M>
<PROFIT_M>2.050519322</PROFIT_M>
<INCOME_M>0.28124811</INCOME_M>
<PHARMA_REV_M>2.75733442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.050519322</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28124811</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2582834.42</REVENUE>
<PREV_YEAR_REV>2138178.77</PREV_YEAR_REV>
<BUDGET>2468557.5</BUDGET>
<GROSS_PROFIT>1995580.531</GROSS_PROFIT>
<EXPENSES>2249648.78</EXPENSES>
<NET_INCOME>333185.64</NET_INCOME>
<REVENUE_M>2.58283442</REVENUE_M>
<PROFIT_M>1.995580531</PROFIT_M>
<INCOME_M>0.33318564</INCOME_M>
<PHARMA_REV_M>2.58283442</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.995580531</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33318564</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2524521.92</REVENUE>
<PREV_YEAR_REV>2064727.71</PREV_YEAR_REV>
<BUDGET>2413743.75</BUDGET>
<GROSS_PROFIT>1795843.915</GROSS_PROFIT>
<EXPENSES>2198858.6</EXPENSES>
<NET_INCOME>325663.33</NET_INCOME>
<REVENUE_M>2.52452192</REVENUE_M>
<PROFIT_M>1.795843915</PROFIT_M>
<INCOME_M>0.32566333</INCOME_M>
<PHARMA_REV_M>2.52452192</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.795843915</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32566333</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2590137.55</REVENUE>
<PREV_YEAR_REV>2104913</PREV_YEAR_REV>
<BUDGET>2475422.44</BUDGET>
<GROSS_PROFIT>2196436.64</GROSS_PROFIT>
<EXPENSES>2248239.39</EXPENSES>
<NET_INCOME>341898.16</NET_INCOME>
<REVENUE_M>2.59013755</REVENUE_M>
<PROFIT_M>2.19643664</PROFIT_M>
<INCOME_M>0.34189816</INCOME_M>
<PHARMA_REV_M>2.59013755</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.19643664</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34189816</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>8261037.65</REVENUE>
<PREV_YEAR_REV>6068979.92</PREV_YEAR_REV>
<BUDGET>7417454.82</BUDGET>
<GROSS_PROFIT>6728140.711</GROSS_PROFIT>
<EXPENSES>7008413.87</EXPENSES>
<NET_INCOME>752623.78</NET_INCOME>
<REVENUE_M>8.26103765</REVENUE_M>
<PROFIT_M>6.728140711</PROFIT_M>
<INCOME_M>0.75262378</INCOME_M>
<PHARMA_REV_M>8.26103765</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.728140711</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75262378</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2347380</REVENUE>
<PREV_YEAR_REV>1865487.32</PREV_YEAR_REV>
<BUDGET>2323906.2</BUDGET>
<GROSS_PROFIT>1948841.824</GROSS_PROFIT>
<EXPENSES>1971799.2</EXPENSES>
<NET_INCOME>375580.8</NET_INCOME>
<REVENUE_M>2.34738</REVENUE_M>
<PROFIT_M>1.948841824</PROFIT_M>
<INCOME_M>0.3755808</INCOME_M>
<PHARMA_REV_M>2.34738</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.948841824</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3755808</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4758547.5</REVENUE>
<PREV_YEAR_REV>3887811.21</PREV_YEAR_REV>
<BUDGET>4710962.03</BUDGET>
<GROSS_PROFIT>3625247.062</GROSS_PROFIT>
<EXPENSES>4232708.87</EXPENSES>
<NET_INCOME>525838.64</NET_INCOME>
<REVENUE_M>4.7585475</REVENUE_M>
<PROFIT_M>3.625247062</PROFIT_M>
<INCOME_M>0.52583864</INCOME_M>
<PHARMA_REV_M>4.7585475</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.625247062</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52583864</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2873272.5</REVENUE>
<PREV_YEAR_REV>2434935.42</PREV_YEAR_REV>
<BUDGET>2844539.78</BUDGET>
<GROSS_PROFIT>2240348.034</GROSS_PROFIT>
<EXPENSES>2358956.72</EXPENSES>
<NET_INCOME>514315.78</NET_INCOME>
<REVENUE_M>2.8732725</REVENUE_M>
<PROFIT_M>2.240348034</PROFIT_M>
<INCOME_M>0.51431578</INCOME_M>
<PHARMA_REV_M>2.8732725</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.240348034</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51431578</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>8346523.5</REVENUE>
<PREV_YEAR_REV>6920860.65</PREV_YEAR_REV>
<BUDGET>8263058.27</BUDGET>
<GROSS_PROFIT>6375049.401</GROSS_PROFIT>
<EXPENSES>7536278.8</EXPENSES>
<NET_INCOME>810244.71</NET_INCOME>
<REVENUE_M>8.3465235</REVENUE_M>
<PROFIT_M>6.375049401</PROFIT_M>
<INCOME_M>0.81024471</INCOME_M>
<PHARMA_REV_M>8.3465235</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.375049401</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.81024471</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2907292.5</REVENUE>
<PREV_YEAR_REV>2268168.09</PREV_YEAR_REV>
<BUDGET>2878219.58</BUDGET>
<GROSS_PROFIT>2112874.829</GROSS_PROFIT>
<EXPENSES>2514808.01</EXPENSES>
<NET_INCOME>392484.49</NET_INCOME>
<REVENUE_M>2.9072925</REVENUE_M>
<PROFIT_M>2.112874829</PROFIT_M>
<INCOME_M>0.39248449</INCOME_M>
<PHARMA_REV_M>2.9072925</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.112874829</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39248449</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2873272.5</REVENUE>
<PREV_YEAR_REV>2306793.28</PREV_YEAR_REV>
<BUDGET>2844539.78</BUDGET>
<GROSS_PROFIT>2194496.351</GROSS_PROFIT>
<EXPENSES>2379069.63</EXPENSES>
<NET_INCOME>494202.87</NET_INCOME>
<REVENUE_M>2.8732725</REVENUE_M>
<PROFIT_M>2.194496351</PROFIT_M>
<INCOME_M>0.49420287</INCOME_M>
<PHARMA_REV_M>2.8732725</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.194496351</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49420287</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5969432.7</REVENUE>
<PREV_YEAR_REV>4869852.02</PREV_YEAR_REV>
<BUDGET>5909738.37</BUDGET>
<GROSS_PROFIT>4743498.26</GROSS_PROFIT>
<EXPENSES>5390668.93</EXPENSES>
<NET_INCOME>578763.77</NET_INCOME>
<REVENUE_M>5.9694327</REVENUE_M>
<PROFIT_M>4.74349826</PROFIT_M>
<INCOME_M>0.57876377</INCOME_M>
<PHARMA_REV_M>5.9694327</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.74349826</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57876377</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1918579.16</REVENUE>
<PREV_YEAR_REV>1623479.33</PREV_YEAR_REV>
<BUDGET>1899393.37</BUDGET>
<GROSS_PROFIT>1478169.315</GROSS_PROFIT>
<EXPENSES>1722884.09</EXPENSES>
<NET_INCOME>195695.07</NET_INCOME>
<REVENUE_M>1.91857916</REVENUE_M>
<PROFIT_M>1.478169315</PROFIT_M>
<INCOME_M>0.19569507</INCOME_M>
<PHARMA_REV_M>1.91857916</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.478169315</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19569507</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3329779.62</REVENUE>
<PREV_YEAR_REV>2604157.97</PREV_YEAR_REV>
<BUDGET>3296481.83</BUDGET>
<GROSS_PROFIT>2814356.42</GROSS_PROFIT>
<EXPENSES>2886850.67</EXPENSES>
<NET_INCOME>442928.95</NET_INCOME>
<REVENUE_M>3.32977962</REVENUE_M>
<PROFIT_M>2.81435642</PROFIT_M>
<INCOME_M>0.44292895</INCOME_M>
<PHARMA_REV_M>3.32977962</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.81435642</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44292895</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.038892708E7</REVENUE>
<PREV_YEAR_REV>8047318.38</PREV_YEAR_REV>
<BUDGET>1.028503781E7</BUDGET>
<GROSS_PROFIT>8913699.44</GROSS_PROFIT>
<EXPENSES>9017588.71</EXPENSES>
<NET_INCOME>1371338.38</NET_INCOME>
<REVENUE_M>10.38892708</REVENUE_M>
<PROFIT_M>8.91369944</PROFIT_M>
<INCOME_M>1.37133838</INCOME_M>
<PHARMA_REV_M>10.38892708</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.91369944</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.37133838</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.155747747E7</REVENUE>
<PREV_YEAR_REV>9518908.11</PREV_YEAR_REV>
<BUDGET>1.14419027E7</BUDGET>
<GROSS_PROFIT>8980160</GROSS_PROFIT>
<EXPENSES>1.003189045E7</EXPENSES>
<NET_INCOME>1525587.03</NET_INCOME>
<REVENUE_M>11.55747747</REVENUE_M>
<PROFIT_M>8.98016</PROFIT_M>
<INCOME_M>1.52558703</INCOME_M>
<PHARMA_REV_M>11.55747747</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.98016</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.52558703</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.149428642E7</REVENUE>
<PREV_YEAR_REV>9688618.57</PREV_YEAR_REV>
<BUDGET>1.137934355E7</BUDGET>
<GROSS_PROFIT>8048299.347</GROSS_PROFIT>
<EXPENSES>1.001152347E7</EXPENSES>
<NET_INCOME>1482762.95</NET_INCOME>
<REVENUE_M>11.49428642</REVENUE_M>
<PROFIT_M>8.048299347</PROFIT_M>
<INCOME_M>1.48276295</INCOME_M>
<PHARMA_REV_M>11.49428642</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.048299347</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.48276295</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>2.55957083E7</REVENUE>
<PREV_YEAR_REV>2.081036594E7</PREV_YEAR_REV>
<BUDGET>2.533975123E7</BUDGET>
<GROSS_PROFIT>2.116131922E7</GROSS_PROFIT>
<EXPENSES>2.305007393E7</EXPENSES>
<NET_INCOME>2545634.37</NET_INCOME>
<REVENUE_M>25.5957083</REVENUE_M>
<PROFIT_M>21.16131922</PROFIT_M>
<INCOME_M>2.54563437</INCOME_M>
<PHARMA_REV_M>25.5957083</PHARMA_REV_M>
<PHARMA_PROFIT_M>21.16131922</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.54563437</PHARMA_INCOME_M>
<FRANCE_REV_M>25.5957083</FRANCE_REV_M>
<FRANCE_PROFIT_M>21.16131922</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>2.54563437</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.055747711E7</REVENUE>
<PREV_YEAR_REV>8767139.54</PREV_YEAR_REV>
<BUDGET>1.045190234E7</BUDGET>
<GROSS_PROFIT>8009957.88</GROSS_PROFIT>
<EXPENSES>9132217.7</EXPENSES>
<NET_INCOME>1425259.41</NET_INCOME>
<REVENUE_M>10.55747711</REVENUE_M>
<PROFIT_M>8.00995788</PROFIT_M>
<INCOME_M>1.42525941</INCOME_M>
<PHARMA_REV_M>10.55747711</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.00995788</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.42525941</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7058589.02</REVENUE>
<PREV_YEAR_REV>5903952.94</PREV_YEAR_REV>
<BUDGET>6988003.13</BUDGET>
<GROSS_PROFIT>5945731.872</GROSS_PROFIT>
<EXPENSES>6289202.81</EXPENSES>
<NET_INCOME>769386.2</NET_INCOME>
<REVENUE_M>7.05858902</REVENUE_M>
<PROFIT_M>5.945731872</PROFIT_M>
<INCOME_M>0.7693862</INCOME_M>
<PHARMA_REV_M>7.05858902</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.945731872</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.7693862</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4341155.32</REVENUE>
<PREV_YEAR_REV>3820768.85</PREV_YEAR_REV>
<BUDGET>4210920.65</BUDGET>
<GROSS_PROFIT>3440057.189</GROSS_PROFIT>
<EXPENSES>3923027.69</EXPENSES>
<NET_INCOME>418127.63</NET_INCOME>
<REVENUE_M>4.34115532</REVENUE_M>
<PROFIT_M>3.440057189</PROFIT_M>
<INCOME_M>0.41812763</INCOME_M>
<PHARMA_REV_M>4.34115532</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.440057189</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41812763</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1509034.67</REVENUE>
<PREV_YEAR_REV>1288088.79</PREV_YEAR_REV>
<BUDGET>1463763.63</BUDGET>
<GROSS_PROFIT>1067732.57</GROSS_PROFIT>
<EXPENSES>1249480.7</EXPENSES>
<NET_INCOME>259553.96</NET_INCOME>
<REVENUE_M>1.50903467</REVENUE_M>
<PROFIT_M>1.06773257</PROFIT_M>
<INCOME_M>0.25955396</INCOME_M>
<PHARMA_REV_M>1.50903467</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.06773257</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25955396</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1152770.02</REVENUE>
<PREV_YEAR_REV>1012347.33</PREV_YEAR_REV>
<BUDGET>1118186.92</BUDGET>
<GROSS_PROFIT>895817.586</GROSS_PROFIT>
<EXPENSES>1035187.48</EXPENSES>
<NET_INCOME>117582.54</NET_INCOME>
<REVENUE_M>1.15277002</REVENUE_M>
<PROFIT_M>0.895817586</PROFIT_M>
<INCOME_M>0.11758254</INCOME_M>
<PHARMA_REV_M>1.15277002</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.895817586</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11758254</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8500802.95</REVENUE>
<PREV_YEAR_REV>6995451.7</PREV_YEAR_REV>
<BUDGET>8075762.8</BUDGET>
<GROSS_PROFIT>5888149.163</GROSS_PROFIT>
<EXPENSES>7404199.37</EXPENSES>
<NET_INCOME>1096603.58</NET_INCOME>
<REVENUE_M>8.50080295</REVENUE_M>
<PROFIT_M>5.888149163</PROFIT_M>
<INCOME_M>1.09660358</INCOME_M>
<PHARMA_REV_M>8.50080295</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.888149163</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.09660358</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.197460214E7</REVENUE>
<PREV_YEAR_REV>9444809.83</PREV_YEAR_REV>
<BUDGET>1.137587203E7</BUDGET>
<GROSS_PROFIT>9246787.767</GROSS_PROFIT>
<EXPENSES>1.042987846E7</EXPENSES>
<NET_INCOME>1544723.68</NET_INCOME>
<REVENUE_M>11.97460214</REVENUE_M>
<PROFIT_M>9.246787767</PROFIT_M>
<INCOME_M>1.54472368</INCOME_M>
<PHARMA_REV_M>11.97460214</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.246787767</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.54472368</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>2.284403181E7</REVENUE>
<PREV_YEAR_REV>1.805231172E7</PREV_YEAR_REV>
<BUDGET>2.170183022E7</BUDGET>
<GROSS_PROFIT>1.788177356E7</GROSS_PROFIT>
<EXPENSES>2.063348968E7</EXPENSES>
<NET_INCOME>2210542.13</NET_INCOME>
<REVENUE_M>22.84403181</REVENUE_M>
<PROFIT_M>17.88177356</PROFIT_M>
<INCOME_M>2.21054213</INCOME_M>
<PHARMA_REV_M>22.84403181</PHARMA_REV_M>
<PHARMA_PROFIT_M>17.88177356</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.21054213</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8963066.69</REVENUE>
<PREV_YEAR_REV>7101427.47</PREV_YEAR_REV>
<BUDGET>8514913.35</BUDGET>
<GROSS_PROFIT>6785041.48</GROSS_PROFIT>
<EXPENSES>8308762.82</EXPENSES>
<NET_INCOME>654303.87</NET_INCOME>
<REVENUE_M>8.96306669</REVENUE_M>
<PROFIT_M>6.78504148</PROFIT_M>
<INCOME_M>0.65430387</INCOME_M>
<PHARMA_REV_M>8.96306669</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.78504148</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65430387</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8891365.27</REVENUE>
<PREV_YEAR_REV>7379032.55</PREV_YEAR_REV>
<BUDGET>8446797</BUDGET>
<GROSS_PROFIT>7255798.622</GROSS_PROFIT>
<EXPENSES>7362050.44</EXPENSES>
<NET_INCOME>1529314.83</NET_INCOME>
<REVENUE_M>8.89136527</REVENUE_M>
<PROFIT_M>7.255798622</PROFIT_M>
<INCOME_M>1.52931483</INCOME_M>
<PHARMA_REV_M>8.89136527</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.255798622</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.52931483</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6182510.05</REVENUE>
<PREV_YEAR_REV>4941501.39</PREV_YEAR_REV>
<BUDGET>5873384.54</BUDGET>
<GROSS_PROFIT>4561799.036</GROSS_PROFIT>
<EXPENSES>5119118.32</EXPENSES>
<NET_INCOME>1063391.73</NET_INCOME>
<REVENUE_M>6.18251005</REVENUE_M>
<PROFIT_M>4.561799036</PROFIT_M>
<INCOME_M>1.06339173</INCOME_M>
<PHARMA_REV_M>6.18251005</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.561799036</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.06339173</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9403401.25</REVENUE>
<PREV_YEAR_REV>7758389.85</PREV_YEAR_REV>
<BUDGET>8933231.19</BUDGET>
<GROSS_PROFIT>6780322.473</GROSS_PROFIT>
<EXPENSES>7786016.24</EXPENSES>
<NET_INCOME>1617385.02</NET_INCOME>
<REVENUE_M>9.40340125</REVENUE_M>
<PROFIT_M>6.780322473</PROFIT_M>
<INCOME_M>1.61738502</INCOME_M>
<PHARMA_REV_M>9.40340125</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.780322473</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.61738502</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2817975.83</REVENUE>
<PREV_YEAR_REV>2297949.79</PREV_YEAR_REV>
<BUDGET>2789796.07</BUDGET>
<GROSS_PROFIT>1900992.405</GROSS_PROFIT>
<EXPENSES>2454456.94</EXPENSES>
<NET_INCOME>363518.88</NET_INCOME>
<REVENUE_M>2.81797583</REVENUE_M>
<PROFIT_M>1.900992405</PROFIT_M>
<INCOME_M>0.36351888</INCOME_M>
<PHARMA_REV_M>2.81797583</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.900992405</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36351888</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>1.091050326E7</REVENUE>
<PREV_YEAR_REV>8669510.61</PREV_YEAR_REV>
<BUDGET>1.03779525E7</BUDGET>
<GROSS_PROFIT>9206828.119</GROSS_PROFIT>
<EXPENSES>9851348.58</EXPENSES>
<NET_INCOME>1059154.69</NET_INCOME>
<REVENUE_M>10.91050326</REVENUE_M>
<PROFIT_M>9.206828119</PROFIT_M>
<INCOME_M>1.05915469</INCOME_M>
<PHARMA_REV_M>10.91050326</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.206828119</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.05915469</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3578271.92</REVENUE>
<PREV_YEAR_REV>2994795.85</PREV_YEAR_REV>
<BUDGET>3404268.75</BUDGET>
<GROSS_PROFIT>2938620.033</GROSS_PROFIT>
<EXPENSES>2937761.25</EXPENSES>
<NET_INCOME>640510.67</NET_INCOME>
<REVENUE_M>3.57827192</REVENUE_M>
<PROFIT_M>2.938620033</PROFIT_M>
<INCOME_M>0.64051067</INCOME_M>
<PHARMA_REV_M>3.57827192</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.938620033</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.64051067</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7296525.09</REVENUE>
<PREV_YEAR_REV>6012033.15</PREV_YEAR_REV>
<BUDGET>7034119.88</BUDGET>
<GROSS_PROFIT>5930730.927</GROSS_PROFIT>
<EXPENSES>6419291.85</EXPENSES>
<NET_INCOME>977233.26</NET_INCOME>
<REVENUE_M>7.29652509</REVENUE_M>
<PROFIT_M>5.930730927</PROFIT_M>
<INCOME_M>0.97723326</INCOME_M>
<PHARMA_REV_M>7.29652509</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.930730927</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.97723326</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2104678.17</REVENUE>
<PREV_YEAR_REV>1725202.61</PREV_YEAR_REV>
<BUDGET>2019090.63</BUDGET>
<GROSS_PROFIT>1817137.041</GROSS_PROFIT>
<EXPENSES>1767929.67</EXPENSES>
<NET_INCOME>336748.51</NET_INCOME>
<REVENUE_M>2.10467817</REVENUE_M>
<PROFIT_M>1.817137041</PROFIT_M>
<INCOME_M>0.33674851</INCOME_M>
<PHARMA_REV_M>2.10467817</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.817137041</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33674851</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2658584.42</REVENUE>
<PREV_YEAR_REV>2240581.53</PREV_YEAR_REV>
<BUDGET>2539762.5</BUDGET>
<GROSS_PROFIT>1935715.32</GROSS_PROFIT>
<EXPENSES>2315627.03</EXPENSES>
<NET_INCOME>342957.39</NET_INCOME>
<REVENUE_M>2.65858442</REVENUE_M>
<PROFIT_M>1.93571532</PROFIT_M>
<INCOME_M>0.34295739</INCOME_M>
<PHARMA_REV_M>2.65858442</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.93571532</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34295739</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2548896.92</REVENUE>
<PREV_YEAR_REV>1995706.92</PREV_YEAR_REV>
<BUDGET>2436656.25</BUDGET>
<GROSS_PROFIT>2029176.839</GROSS_PROFIT>
<EXPENSES>2212442.53</EXPENSES>
<NET_INCOME>336454.39</NET_INCOME>
<REVENUE_M>2.54889692</REVENUE_M>
<PROFIT_M>2.029176839</PROFIT_M>
<INCOME_M>0.33645439</INCOME_M>
<PHARMA_REV_M>2.54889692</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.029176839</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33645439</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2554990.67</REVENUE>
<PREV_YEAR_REV>2123549.19</PREV_YEAR_REV>
<BUDGET>2442384.38</BUDGET>
<GROSS_PROFIT>2030655.491</GROSS_PROFIT>
<EXPENSES>2097647.34</EXPENSES>
<NET_INCOME>457343.33</NET_INCOME>
<REVENUE_M>2.55499067</REVENUE_M>
<PROFIT_M>2.030655491</PROFIT_M>
<INCOME_M>0.45734333</INCOME_M>
<PHARMA_REV_M>2.55499067</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.030655491</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45734333</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2714512.5</REVENUE>
<PREV_YEAR_REV>2117041.15</PREV_YEAR_REV>
<BUDGET>2687367.38</BUDGET>
<GROSS_PROFIT>2048371.137</GROSS_PROFIT>
<EXPENSES>2356196.85</EXPENSES>
<NET_INCOME>358315.65</NET_INCOME>
<REVENUE_M>2.7145125</REVENUE_M>
<PROFIT_M>2.048371137</PROFIT_M>
<INCOME_M>0.35831565</INCOME_M>
<PHARMA_REV_M>2.7145125</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.048371137</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35831565</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2723726.25</REVENUE>
<PREV_YEAR_REV>2147100.85</PREV_YEAR_REV>
<BUDGET>2696488.99</BUDGET>
<GROSS_PROFIT>1946031.586</GROSS_PROFIT>
<EXPENSES>2356023.21</EXPENSES>
<NET_INCOME>367703.04</NET_INCOME>
<REVENUE_M>2.72372625</REVENUE_M>
<PROFIT_M>1.946031586</PROFIT_M>
<INCOME_M>0.36770304</INCOME_M>
<PHARMA_REV_M>2.72372625</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.946031586</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36770304</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1623864.38</REVENUE>
<PREV_YEAR_REV>1331975.31</PREV_YEAR_REV>
<BUDGET>1607625.73</BUDGET>
<GROSS_PROFIT>1303346.022</GROSS_PROFIT>
<EXPENSES>1364046.08</EXPENSES>
<NET_INCOME>259818.3</NET_INCOME>
<REVENUE_M>1.62386438</REVENUE_M>
<PROFIT_M>1.303346022</PROFIT_M>
<INCOME_M>0.2598183</INCOME_M>
<PHARMA_REV_M>1.62386438</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.303346022</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2598183</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2056083.75</REVENUE>
<PREV_YEAR_REV>1658546.69</PREV_YEAR_REV>
<BUDGET>2035522.91</BUDGET>
<GROSS_PROFIT>1622250.08</GROSS_PROFIT>
<EXPENSES>1784680.7</EXPENSES>
<NET_INCOME>271403.06</NET_INCOME>
<REVENUE_M>2.05608375</REVENUE_M>
<PROFIT_M>1.62225008</PROFIT_M>
<INCOME_M>0.27140306</INCOME_M>
<PHARMA_REV_M>2.05608375</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.62225008</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27140306</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2042617.5</REVENUE>
<PREV_YEAR_REV>1668846.05</PREV_YEAR_REV>
<BUDGET>2022191.33</BUDGET>
<GROSS_PROFIT>1406342.151</GROSS_PROFIT>
<EXPENSES>1779119.84</EXPENSES>
<NET_INCOME>263497.66</NET_INCOME>
<REVENUE_M>2.0426175</REVENUE_M>
<PROFIT_M>1.406342151</PROFIT_M>
<INCOME_M>0.26349766</INCOME_M>
<PHARMA_REV_M>2.0426175</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.406342151</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26349766</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3955172.29</REVENUE>
<PREV_YEAR_REV>3156784.13</PREV_YEAR_REV>
<BUDGET>3915620.57</BUDGET>
<GROSS_PROFIT>2797210.955</GROSS_PROFIT>
<EXPENSES>3367603.35</EXPENSES>
<NET_INCOME>587568.94</NET_INCOME>
<REVENUE_M>3.95517229</REVENUE_M>
<PROFIT_M>2.797210955</PROFIT_M>
<INCOME_M>0.58756894</INCOME_M>
<PHARMA_REV_M>3.95517229</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.797210955</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58756894</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1983784.16</REVENUE>
<PREV_YEAR_REV>1642776.6</PREV_YEAR_REV>
<BUDGET>1963946.32</BUDGET>
<GROSS_PROFIT>1510766.695</GROSS_PROFIT>
<EXPENSES>1642573.29</EXPENSES>
<NET_INCOME>341210.88</NET_INCOME>
<REVENUE_M>1.98378416</REVENUE_M>
<PROFIT_M>1.510766695</PROFIT_M>
<INCOME_M>0.34121088</INCOME_M>
<PHARMA_REV_M>1.98378416</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.510766695</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34121088</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1971388.13</REVENUE>
<PREV_YEAR_REV>1608863.02</PREV_YEAR_REV>
<BUDGET>1951674.24</BUDGET>
<GROSS_PROFIT>1509491.889</GROSS_PROFIT>
<EXPENSES>1770306.54</EXPENSES>
<NET_INCOME>201081.59</NET_INCOME>
<REVENUE_M>1.97138813</REVENUE_M>
<PROFIT_M>1.509491889</PROFIT_M>
<INCOME_M>0.20108159</INCOME_M>
<PHARMA_REV_M>1.97138813</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.509491889</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20108159</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1918579.16</REVENUE>
<PREV_YEAR_REV>1553530.55</PREV_YEAR_REV>
<BUDGET>1899393.37</BUDGET>
<GROSS_PROFIT>1254894.666</GROSS_PROFIT>
<EXPENSES>1659570.98</EXPENSES>
<NET_INCOME>259008.19</NET_INCOME>
<REVENUE_M>1.91857916</REVENUE_M>
<PROFIT_M>1.254894666</PROFIT_M>
<INCOME_M>0.25900819</INCOME_M>
<PHARMA_REV_M>1.91857916</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.254894666</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25900819</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1799516.25</REVENUE>
<PREV_YEAR_REV>1524187.09</PREV_YEAR_REV>
<BUDGET>1781521.09</BUDGET>
<GROSS_PROFIT>1350716.895</GROSS_PROFIT>
<EXPENSES>1556581.56</EXPENSES>
<NET_INCOME>242934.69</NET_INCOME>
<REVENUE_M>1.79951625</REVENUE_M>
<PROFIT_M>1.350716895</PROFIT_M>
<INCOME_M>0.24293469</INCOME_M>
<PHARMA_REV_M>1.79951625</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.350716895</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24293469</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2293274.03</REVENUE>
<PREV_YEAR_REV>1815951.24</PREV_YEAR_REV>
<BUDGET>2270341.28</BUDGET>
<GROSS_PROFIT>1850672.14</GROSS_PROFIT>
<EXPENSES>2043307.16</EXPENSES>
<NET_INCOME>249966.87</NET_INCOME>
<REVENUE_M>2.29327403</REVENUE_M>
<PROFIT_M>1.85067214</PROFIT_M>
<INCOME_M>0.24996687</INCOME_M>
<PHARMA_REV_M>2.29327403</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.85067214</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24996687</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1418970.39</REVENUE>
<PREV_YEAR_REV>1168348.05</PREV_YEAR_REV>
<BUDGET>1404780.69</BUDGET>
<GROSS_PROFIT>1135176.31</GROSS_PROFIT>
<EXPENSES>1231666.3</EXPENSES>
<NET_INCOME>187304.09</NET_INCOME>
<REVENUE_M>1.41897039</REVENUE_M>
<PROFIT_M>1.13517631</PROFIT_M>
<INCOME_M>0.18730409</INCOME_M>
<PHARMA_REV_M>1.41897039</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.13517631</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18730409</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3192225.12</REVENUE>
<PREV_YEAR_REV>2596132.95</PREV_YEAR_REV>
<BUDGET>3160302.87</BUDGET>
<GROSS_PROFIT>2275416.351</GROSS_PROFIT>
<EXPENSES>2806009.7</EXPENSES>
<NET_INCOME>386215.42</NET_INCOME>
<REVENUE_M>3.19222512</REVENUE_M>
<PROFIT_M>2.275416351</PROFIT_M>
<INCOME_M>0.38621542</INCOME_M>
<PHARMA_REV_M>3.19222512</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.275416351</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38621542</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1631599.2</REVENUE>
<PREV_YEAR_REV>1296535.52</PREV_YEAR_REV>
<BUDGET>1615283.21</BUDGET>
<GROSS_PROFIT>1309766.254</GROSS_PROFIT>
<EXPENSES>1339542.94</EXPENSES>
<NET_INCOME>292056.26</NET_INCOME>
<REVENUE_M>1.6315992</REVENUE_M>
<PROFIT_M>1.309766254</PROFIT_M>
<INCOME_M>0.29205626</INCOME_M>
<PHARMA_REV_M>1.6315992</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.309766254</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29205626</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1622617.92</REVENUE>
<PREV_YEAR_REV>1321070.39</PREV_YEAR_REV>
<BUDGET>1606391.74</BUDGET>
<GROSS_PROFIT>1218391.344</GROSS_PROFIT>
<EXPENSES>1343527.64</EXPENSES>
<NET_INCOME>279090.28</NET_INCOME>
<REVENUE_M>1.62261792</REVENUE_M>
<PROFIT_M>1.218391344</PROFIT_M>
<INCOME_M>0.27909028</INCOME_M>
<PHARMA_REV_M>1.62261792</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.218391344</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27909028</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.382969508E7</REVENUE>
<PREV_YEAR_REV>1.098788659E7</PREV_YEAR_REV>
<BUDGET>1.369139813E7</BUDGET>
<GROSS_PROFIT>1.08763244E7</GROSS_PROFIT>
<EXPENSES>1.232012036E7</EXPENSES>
<NET_INCOME>1509574.72</NET_INCOME>
<REVENUE_M>13.82969508</REVENUE_M>
<PROFIT_M>10.8763244</PROFIT_M>
<INCOME_M>1.50957472</INCOME_M>
<PHARMA_REV_M>13.82969508</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.8763244</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.50957472</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.935522781E7</REVENUE>
<PREV_YEAR_REV>1.556103951E7</PREV_YEAR_REV>
<BUDGET>1.916167554E7</BUDGET>
<GROSS_PROFIT>1.440721318E7</GROSS_PROFIT>
<EXPENSES>1.651033729E7</EXPENSES>
<NET_INCOME>2844890.52</NET_INCOME>
<REVENUE_M>19.35522781</REVENUE_M>
<PROFIT_M>14.40721318</PROFIT_M>
<INCOME_M>2.84489052</INCOME_M>
<PHARMA_REV_M>19.35522781</PHARMA_REV_M>
<PHARMA_PROFIT_M>14.40721318</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.84489052</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7810370.27</REVENUE>
<PREV_YEAR_REV>6197673.62</PREV_YEAR_REV>
<BUDGET>7732266.56</BUDGET>
<GROSS_PROFIT>6089901.909</GROSS_PROFIT>
<EXPENSES>7240213.24</EXPENSES>
<NET_INCOME>570157.03</NET_INCOME>
<REVENUE_M>7.81037027</REVENUE_M>
<PROFIT_M>6.089901909</PROFIT_M>
<INCOME_M>0.57015703</INCOME_M>
<PHARMA_REV_M>7.81037027</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.089901909</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57015703</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.574180366E7</REVENUE>
<PREV_YEAR_REV>1.311399057E7</PREV_YEAR_REV>
<BUDGET>1.558438564E7</BUDGET>
<GROSS_PROFIT>1.300272983E7</GROSS_PROFIT>
<EXPENSES>1.362453108E7</EXPENSES>
<NET_INCOME>2117272.6</NET_INCOME>
<REVENUE_M>15.74180366</REVENUE_M>
<PROFIT_M>13.00272983</PROFIT_M>
<INCOME_M>2.1172726</INCOME_M>
<PHARMA_REV_M>15.74180366</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.00272983</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.1172726</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6725541.5</REVENUE>
<PREV_YEAR_REV>5439418.37</PREV_YEAR_REV>
<BUDGET>6389264.43</BUDGET>
<GROSS_PROFIT>5123792.137</GROSS_PROFIT>
<EXPENSES>5982346.38</EXPENSES>
<NET_INCOME>743195.12</NET_INCOME>
<REVENUE_M>6.7255415</REVENUE_M>
<PROFIT_M>5.123792137</PROFIT_M>
<INCOME_M>0.74319512</INCOME_M>
<PHARMA_REV_M>6.7255415</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.123792137</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74319512</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7680666.5</REVENUE>
<PREV_YEAR_REV>6403416.21</PREV_YEAR_REV>
<BUDGET>7296633.18</BUDGET>
<GROSS_PROFIT>5428274.026</GROSS_PROFIT>
<EXPENSES>6539126.49</EXPENSES>
<NET_INCOME>1141540.01</NET_INCOME>
<REVENUE_M>7.6806665</REVENUE_M>
<PROFIT_M>5.428274026</PROFIT_M>
<INCOME_M>1.14154001</INCOME_M>
<PHARMA_REV_M>7.6806665</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.428274026</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.14154001</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>1.15272435E7</REVENUE>
<PREV_YEAR_REV>9144328.14</PREV_YEAR_REV>
<BUDGET>1.095088133E7</BUDGET>
<GROSS_PROFIT>9436997.553</GROSS_PROFIT>
<EXPENSES>1.040834859E7</EXPENSES>
<NET_INCOME>1118894.91</NET_INCOME>
<REVENUE_M>11.5272435</REVENUE_M>
<PROFIT_M>9.436997553</PROFIT_M>
<INCOME_M>1.11889491</INCOME_M>
<PHARMA_REV_M>11.5272435</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.436997553</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.11889491</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3772833.25</REVENUE>
<PREV_YEAR_REV>2942812.88</PREV_YEAR_REV>
<BUDGET>3584191.59</BUDGET>
<GROSS_PROFIT>2908220.603</GROSS_PROFIT>
<EXPENSES>3263500.76</EXPENSES>
<NET_INCOME>509332.49</NET_INCOME>
<REVENUE_M>3.77283325</REVENUE_M>
<PROFIT_M>2.908220603</PROFIT_M>
<INCOME_M>0.50933249</INCOME_M>
<PHARMA_REV_M>3.77283325</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.908220603</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50933249</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5745947.76</REVENUE>
<PREV_YEAR_REV>4776554.76</PREV_YEAR_REV>
<BUDGET>5171352.97</BUDGET>
<GROSS_PROFIT>4362447.718</GROSS_PROFIT>
<EXPENSES>5110906.62</EXPENSES>
<NET_INCOME>635041.14</NET_INCOME>
<REVENUE_M>5.74594776</REVENUE_M>
<PROFIT_M>4.362447718</PROFIT_M>
<INCOME_M>0.63504114</INCOME_M>
<PHARMA_REV_M>5.74594776</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.362447718</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.63504114</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2957770.75</REVENUE>
<PREV_YEAR_REV>2492160.42</PREV_YEAR_REV>
<BUDGET>2661993.68</BUDGET>
<GROSS_PROFIT>2487485.2</GROSS_PROFIT>
<EXPENSES>2484527.43</EXPENSES>
<NET_INCOME>473243.32</NET_INCOME>
<REVENUE_M>2.95777075</REVENUE_M>
<PROFIT_M>2.4874852</PROFIT_M>
<INCOME_M>0.47324332</INCOME_M>
<PHARMA_REV_M>2.95777075</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.4874852</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47324332</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2866637.31</REVENUE>
<PREV_YEAR_REV>2246616.18</PREV_YEAR_REV>
<BUDGET>2579973.58</BUDGET>
<GROSS_PROFIT>2321976.22</GROSS_PROFIT>
<EXPENSES>2407975.34</EXPENSES>
<NET_INCOME>458661.97</NET_INCOME>
<REVENUE_M>2.86663731</REVENUE_M>
<PROFIT_M>2.32197622</PROFIT_M>
<INCOME_M>0.45866197</INCOME_M>
<PHARMA_REV_M>2.86663731</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.32197622</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45866197</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2868755.13</REVENUE>
<PREV_YEAR_REV>2283095.47</PREV_YEAR_REV>
<BUDGET>2581879.61</BUDGET>
<GROSS_PROFIT>2088574.221</GROSS_PROFIT>
<EXPENSES>2576142.1</EXPENSES>
<NET_INCOME>292613.02</NET_INCOME>
<REVENUE_M>2.86875513</REVENUE_M>
<PROFIT_M>2.088574221</PROFIT_M>
<INCOME_M>0.29261302</INCOME_M>
<PHARMA_REV_M>2.86875513</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.088574221</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29261302</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5769142.44</REVENUE>
<PREV_YEAR_REV>4827731.44</PREV_YEAR_REV>
<BUDGET>5192228.19</BUDGET>
<GROSS_PROFIT>4577229.875</GROSS_PROFIT>
<EXPENSES>5005379.52</EXPENSES>
<NET_INCOME>763762.91</NET_INCOME>
<REVENUE_M>5.76914244</REVENUE_M>
<PROFIT_M>4.577229875</PROFIT_M>
<INCOME_M>0.76376291</INCOME_M>
<PHARMA_REV_M>5.76914244</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.577229875</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76376291</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2320222</REVENUE>
<PREV_YEAR_REV>1800659.66</PREV_YEAR_REV>
<BUDGET>2273817.56</BUDGET>
<GROSS_PROFIT>1752347.666</GROSS_PROFIT>
<EXPENSES>1948986.48</EXPENSES>
<NET_INCOME>371235.52</NET_INCOME>
<REVENUE_M>2.320222</REVENUE_M>
<PROFIT_M>1.752347666</PROFIT_M>
<INCOME_M>0.37123552</INCOME_M>
<PHARMA_REV_M>2.320222</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.752347666</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37123552</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>7147940.45</REVENUE>
<PREV_YEAR_REV>5899947.01</PREV_YEAR_REV>
<BUDGET>7004981.64</BUDGET>
<GROSS_PROFIT>5577122.659</GROSS_PROFIT>
<EXPENSES>6458384.95</EXPENSES>
<NET_INCOME>689555.5</NET_INCOME>
<REVENUE_M>7.14794045</REVENUE_M>
<PROFIT_M>5.577122659</PROFIT_M>
<INCOME_M>0.6895555</INCOME_M>
<PHARMA_REV_M>7.14794045</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.577122659</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6895555</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2935096.27</REVENUE>
<PREV_YEAR_REV>2493307.17</PREV_YEAR_REV>
<BUDGET>2374933.77</BUDGET>
<GROSS_PROFIT>2493833.901</GROSS_PROFIT>
<EXPENSES>2409714.04</EXPENSES>
<NET_INCOME>525382.23</NET_INCOME>
<REVENUE_M>2.93509627</REVENUE_M>
<PROFIT_M>2.493833901</PROFIT_M>
<INCOME_M>0.52538223</INCOME_M>
<PHARMA_REV_M>2.93509627</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.493833901</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52538223</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2510111.24</REVENUE>
<PREV_YEAR_REV>2183996.83</PREV_YEAR_REV>
<BUDGET>1836582.66</BUDGET>
<GROSS_PROFIT>1771523.558</GROSS_PROFIT>
<EXPENSES>2254079.89</EXPENSES>
<NET_INCOME>256031.35</NET_INCOME>
<REVENUE_M>2.51011124</REVENUE_M>
<PROFIT_M>1.771523558</PROFIT_M>
<INCOME_M>0.25603135</INCOME_M>
<PHARMA_REV_M>2.51011124</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.771523558</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25603135</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1364924.64</REVENUE>
<PREV_YEAR_REV>1162350.24</PREV_YEAR_REV>
<BUDGET>1323976.9</BUDGET>
<GROSS_PROFIT>1014132.181</GROSS_PROFIT>
<EXPENSES>1180659.81</EXPENSES>
<NET_INCOME>184264.83</NET_INCOME>
<REVENUE_M>1.36492464</REVENUE_M>
<PROFIT_M>1.014132181</PROFIT_M>
<INCOME_M>0.18426483</INCOME_M>
<PHARMA_REV_M>1.36492464</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.014132181</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18426483</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1353954.9</REVENUE>
<PREV_YEAR_REV>1179403.23</PREV_YEAR_REV>
<BUDGET>1313336.26</BUDGET>
<GROSS_PROFIT>1009325.992</GROSS_PROFIT>
<EXPENSES>1215851.5</EXPENSES>
<NET_INCOME>138103.4</NET_INCOME>
<REVENUE_M>1.3539549</REVENUE_M>
<PROFIT_M>1.009325992</PROFIT_M>
<INCOME_M>0.1381034</INCOME_M>
<PHARMA_REV_M>1.3539549</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.009325992</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1381034</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>9605493.97</REVENUE>
<PREV_YEAR_REV>7899449.8</PREV_YEAR_REV>
<BUDGET>9125219.27</BUDGET>
<GROSS_PROFIT>8010981.97</GROSS_PROFIT>
<EXPENSES>8337568.77</EXPENSES>
<NET_INCOME>1267925.2</NET_INCOME>
<REVENUE_M>9.60549397</REVENUE_M>
<PROFIT_M>8.01098197</PROFIT_M>
<INCOME_M>1.2679252</INCOME_M>
<PHARMA_REV_M>9.60549397</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.01098197</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.2679252</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.699533606E7</REVENUE>
<PREV_YEAR_REV>1.34651189E7</PREV_YEAR_REV>
<BUDGET>1.614556926E7</BUDGET>
<GROSS_PROFIT>1.240563393E7</GROSS_PROFIT>
<EXPENSES>1.493875619E7</EXPENSES>
<NET_INCOME>2056579.87</NET_INCOME>
<REVENUE_M>16.99533606</REVENUE_M>
<PROFIT_M>12.40563393</PROFIT_M>
<INCOME_M>2.05657987</INCOME_M>
<PHARMA_REV_M>16.99533606</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.40563393</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.05657987</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.980396896E7</REVENUE>
<PREV_YEAR_REV>1.614926313E7</PREV_YEAR_REV>
<BUDGET>1.881377051E7</BUDGET>
<GROSS_PROFIT>1.38473971E7</GROSS_PROFIT>
<EXPENSES>1.750051156E7</EXPENSES>
<NET_INCOME>2303457.4</NET_INCOME>
<REVENUE_M>19.80396896</REVENUE_M>
<PROFIT_M>13.8473971</PROFIT_M>
<INCOME_M>2.3034574</INCOME_M>
<PHARMA_REV_M>19.80396896</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.8473971</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.3034574</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.474311456E7</REVENUE>
<PREV_YEAR_REV>1.169754673E7</PREV_YEAR_REV>
<BUDGET>1.400595882E7</BUDGET>
<GROSS_PROFIT>1.216306951E7</GROSS_PROFIT>
<EXPENSES>1.276016565E7</EXPENSES>
<NET_INCOME>1982948.91</NET_INCOME>
<REVENUE_M>14.74311456</REVENUE_M>
<PROFIT_M>12.16306951</PROFIT_M>
<INCOME_M>1.98294891</INCOME_M>
<PHARMA_REV_M>14.74311456</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.16306951</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.98294891</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7371557.28</REVENUE>
<PREV_YEAR_REV>6244700.98</PREV_YEAR_REV>
<BUDGET>7002979.41</BUDGET>
<GROSS_PROFIT>5853016.48</GROSS_PROFIT>
<EXPENSES>6052048.52</EXPENSES>
<NET_INCOME>1319508.75</NET_INCOME>
<REVENUE_M>7.37155728</REVENUE_M>
<PROFIT_M>5.85301648</PROFIT_M>
<INCOME_M>1.31950875</INCOME_M>
<PHARMA_REV_M>7.37155728</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.85301648</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.31950875</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.569835494E7</REVENUE>
<PREV_YEAR_REV>1.293506524E7</PREV_YEAR_REV>
<BUDGET>1.491343719E7</BUDGET>
<GROSS_PROFIT>1.089198338E7</GROSS_PROFIT>
<EXPENSES>1.336610551E7</EXPENSES>
<NET_INCOME>2332249.43</NET_INCOME>
<REVENUE_M>15.69835494</REVENUE_M>
<PROFIT_M>10.89198338</PROFIT_M>
<INCOME_M>2.33224943</INCOME_M>
<PHARMA_REV_M>15.69835494</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.89198338</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.33224943</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8832893.39</REVENUE>
<PREV_YEAR_REV>7060383.99</PREV_YEAR_REV>
<BUDGET>8391248.72</BUDGET>
<GROSS_PROFIT>6725365.029</GROSS_PROFIT>
<EXPENSES>7640452.78</EXPENSES>
<NET_INCOME>1192440.61</NET_INCOME>
<REVENUE_M>8.83289339</REVENUE_M>
<PROFIT_M>6.725365029</PROFIT_M>
<INCOME_M>1.19244061</INCOME_M>
<PHARMA_REV_M>8.83289339</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.725365029</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.19244061</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6202149.58</REVENUE>
<PREV_YEAR_REV>4796824.04</PREV_YEAR_REV>
<BUDGET>5892042.1</BUDGET>
<GROSS_PROFIT>4802426.754</GROSS_PROFIT>
<EXPENSES>5569530.32</EXPENSES>
<NET_INCOME>632619.26</NET_INCOME>
<REVENUE_M>6.20214958</REVENUE_M>
<PROFIT_M>4.802426754</PROFIT_M>
<INCOME_M>0.63261926</INCOME_M>
<PHARMA_REV_M>6.20214958</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.802426754</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.63261926</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6189442.47</REVENUE>
<PREV_YEAR_REV>4775951.78</PREV_YEAR_REV>
<BUDGET>5879970.35</BUDGET>
<GROSS_PROFIT>5038577.536</GROSS_PROFIT>
<EXPENSES>5514793.24</EXPENSES>
<NET_INCOME>674649.23</NET_INCOME>
<REVENUE_M>6.18944247</REVENUE_M>
<PROFIT_M>5.038577536</PROFIT_M>
<INCOME_M>0.67464923</INCOME_M>
<PHARMA_REV_M>6.18944247</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.038577536</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67464923</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.020464445E7</REVENUE>
<PREV_YEAR_REV>8170840.53</PREV_YEAR_REV>
<BUDGET>9694412.23</BUDGET>
<GROSS_PROFIT>7512659.244</GROSS_PROFIT>
<EXPENSES>8827017.45</EXPENSES>
<NET_INCOME>1377627</NET_INCOME>
<REVENUE_M>10.20464445</REVENUE_M>
<PROFIT_M>7.512659244</PROFIT_M>
<INCOME_M>1.377627</INCOME_M>
<PHARMA_REV_M>10.20464445</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.512659244</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.377627</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7276150.09</REVENUE>
<PREV_YEAR_REV>5698862.73</PREV_YEAR_REV>
<BUDGET>6920967.38</BUDGET>
<GROSS_PROFIT>6093428.173</GROSS_PROFIT>
<EXPENSES>6297396.64</EXPENSES>
<NET_INCOME>978753.46</NET_INCOME>
<REVENUE_M>7.27615009</REVENUE_M>
<PROFIT_M>6.093428173</PROFIT_M>
<INCOME_M>0.97875346</INCOME_M>
<PHARMA_REV_M>7.27615009</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.093428173</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.97875346</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3658896.92</REVENUE>
<PREV_YEAR_REV>3027434.61</PREV_YEAR_REV>
<BUDGET>3480056.25</BUDGET>
<GROSS_PROFIT>2773809.762</GROSS_PROFIT>
<EXPENSES>3029566.65</EXPENSES>
<NET_INCOME>629330.27</NET_INCOME>
<REVENUE_M>3.65889692</REVENUE_M>
<PROFIT_M>2.773809762</PROFIT_M>
<INCOME_M>0.62933027</INCOME_M>
<PHARMA_REV_M>3.65889692</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.773809762</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62933027</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5085137.59</REVENUE>
<PREV_YEAR_REV>4165401.13</PREV_YEAR_REV>
<BUDGET>4861415.63</BUDGET>
<GROSS_PROFIT>3831445.902</GROSS_PROFIT>
<EXPENSES>4523565.29</EXPENSES>
<NET_INCOME>561572.32</NET_INCOME>
<REVENUE_M>5.08513759</REVENUE_M>
<PROFIT_M>3.831445902</PROFIT_M>
<INCOME_M>0.56157232</INCOME_M>
<PHARMA_REV_M>5.08513759</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.831445902</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56157232</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2554990.67</REVENUE>
<PREV_YEAR_REV>2146834.5</PREV_YEAR_REV>
<BUDGET>2442384.38</BUDGET>
<GROSS_PROFIT>1954567.863</GROSS_PROFIT>
<EXPENSES>2225396.88</EXPENSES>
<NET_INCOME>329593.8</NET_INCOME>
<REVENUE_M>2.55499067</REVENUE_M>
<PROFIT_M>1.954567863</PROFIT_M>
<INCOME_M>0.3295938</INCOME_M>
<PHARMA_REV_M>2.55499067</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.954567863</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3295938</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5465596.5</REVENUE>
<PREV_YEAR_REV>4495407.1</PREV_YEAR_REV>
<BUDGET>5410940.54</BUDGET>
<GROSS_PROFIT>3882154.708</GROSS_PROFIT>
<EXPENSES>4808699.78</EXPENSES>
<NET_INCOME>656896.72</NET_INCOME>
<REVENUE_M>5.4655965</REVENUE_M>
<PROFIT_M>3.882154708</PROFIT_M>
<INCOME_M>0.65689672</INCOME_M>
<PHARMA_REV_M>5.4655965</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.882154708</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65689672</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5560852.5</REVENUE>
<PREV_YEAR_REV>4664936.35</PREV_YEAR_REV>
<BUDGET>5505243.98</BUDGET>
<GROSS_PROFIT>3988093.498</GROSS_PROFIT>
<EXPENSES>4734258.64</EXPENSES>
<NET_INCOME>826593.86</NET_INCOME>
<REVENUE_M>5.5608525</REVENUE_M>
<PROFIT_M>3.988093498</PROFIT_M>
<INCOME_M>0.82659386</INCOME_M>
<PHARMA_REV_M>5.5608525</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.988093498</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.82659386</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2798853.75</REVENUE>
<PREV_YEAR_REV>2350693.95</PREV_YEAR_REV>
<BUDGET>2770865.21</BUDGET>
<GROSS_PROFIT>2230826.385</GROSS_PROFIT>
<EXPENSES>2297858.93</EXPENSES>
<NET_INCOME>500994.82</NET_INCOME>
<REVENUE_M>2.79885375</REVENUE_M>
<PROFIT_M>2.230826385</PROFIT_M>
<INCOME_M>0.50099482</INCOME_M>
<PHARMA_REV_M>2.79885375</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.230826385</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50099482</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4775652</REVENUE>
<PREV_YEAR_REV>3847788.15</PREV_YEAR_REV>
<BUDGET>4727895.48</BUDGET>
<GROSS_PROFIT>3414542.812</GROSS_PROFIT>
<EXPENSES>4072893.68</EXPENSES>
<NET_INCOME>702758.32</NET_INCOME>
<REVENUE_M>4.775652</REVENUE_M>
<PROFIT_M>3.414542812</PROFIT_M>
<INCOME_M>0.70275832</INCOME_M>
<PHARMA_REV_M>4.775652</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.414542812</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.70275832</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2907292.5</REVENUE>
<PREV_YEAR_REV>2333487.84</PREV_YEAR_REV>
<BUDGET>2878219.58</BUDGET>
<GROSS_PROFIT>2030016.993</GROSS_PROFIT>
<EXPENSES>2407238.19</EXPENSES>
<NET_INCOME>500054.31</NET_INCOME>
<REVENUE_M>2.9072925</REVENUE_M>
<PROFIT_M>2.030016993</PROFIT_M>
<INCOME_M>0.50005431</INCOME_M>
<PHARMA_REV_M>2.9072925</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.030016993</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50005431</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1985350.5</REVENUE>
<PREV_YEAR_REV>1615511.46</PREV_YEAR_REV>
<BUDGET>1965497</BUDGET>
<GROSS_PROFIT>1446391.368</GROSS_PROFIT>
<EXPENSES>1729240.29</EXPENSES>
<NET_INCOME>256110.21</NET_INCOME>
<REVENUE_M>1.9853505</REVENUE_M>
<PROFIT_M>1.446391368</PROFIT_M>
<INCOME_M>0.25611021</INCOME_M>
<PHARMA_REV_M>1.9853505</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.446391368</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25611021</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3930491.25</REVENUE>
<PREV_YEAR_REV>3182884.04</PREV_YEAR_REV>
<BUDGET>3891186.34</BUDGET>
<GROSS_PROFIT>2996718.684</GROSS_PROFIT>
<EXPENSES>3494178.61</EXPENSES>
<NET_INCOME>436312.65</NET_INCOME>
<REVENUE_M>3.93049125</REVENUE_M>
<PROFIT_M>2.996718684</PROFIT_M>
<INCOME_M>0.43631265</INCOME_M>
<PHARMA_REV_M>3.93049125</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.996718684</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43631265</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3948084.79</REVENUE>
<PREV_YEAR_REV>3310167.15</PREV_YEAR_REV>
<BUDGET>3908603.94</BUDGET>
<GROSS_PROFIT>3063616.38</GROSS_PROFIT>
<EXPENSES>3416960.22</EXPENSES>
<NET_INCOME>531124.56</NET_INCOME>
<REVENUE_M>3.94808479</REVENUE_M>
<PROFIT_M>3.06361638</PROFIT_M>
<INCOME_M>0.53112456</INCOME_M>
<PHARMA_REV_M>3.94808479</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.06361638</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53112456</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3976222.16</REVENUE>
<PREV_YEAR_REV>3250702.87</PREV_YEAR_REV>
<BUDGET>3936459.95</BUDGET>
<GROSS_PROFIT>3111551.2</GROSS_PROFIT>
<EXPENSES>3441389.92</EXPENSES>
<NET_INCOME>534832.24</NET_INCOME>
<REVENUE_M>3.97622216</REVENUE_M>
<PROFIT_M>3.1115512</PROFIT_M>
<INCOME_M>0.53483224</INCOME_M>
<PHARMA_REV_M>3.97622216</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.1115512</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53483224</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1983784.16</REVENUE>
<PREV_YEAR_REV>1553362.85</PREV_YEAR_REV>
<BUDGET>1963946.32</BUDGET>
<GROSS_PROFIT>1333269.593</GROSS_PROFIT>
<EXPENSES>1715973.3</EXPENSES>
<NET_INCOME>267810.86</NET_INCOME>
<REVENUE_M>1.98378416</REVENUE_M>
<PROFIT_M>1.333269593</PROFIT_M>
<INCOME_M>0.26781086</INCOME_M>
<PHARMA_REV_M>1.98378416</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.333269593</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26781086</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1503532.8</REVENUE>
<PREV_YEAR_REV>1199094.66</PREV_YEAR_REV>
<BUDGET>1488497.47</BUDGET>
<GROSS_PROFIT>1168395.339</GROSS_PROFIT>
<EXPENSES>1262967.55</EXPENSES>
<NET_INCOME>240565.25</NET_INCOME>
<REVENUE_M>1.5035328</REVENUE_M>
<PROFIT_M>1.168395339</PROFIT_M>
<INCOME_M>0.24056525</INCOME_M>
<PHARMA_REV_M>1.5035328</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.168395339</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24056525</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1613636.64</REVENUE>
<PREV_YEAR_REV>1283414.17</PREV_YEAR_REV>
<BUDGET>1597500.27</BUDGET>
<GROSS_PROFIT>1194171.793</GROSS_PROFIT>
<EXPENSES>1336091.14</EXPENSES>
<NET_INCOME>277545.5</NET_INCOME>
<REVENUE_M>1.61363664</REVENUE_M>
<PROFIT_M>1.194171793</PROFIT_M>
<INCOME_M>0.2775455</INCOME_M>
<PHARMA_REV_M>1.61363664</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.194171793</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2775455</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.570590194E7</REVENUE>
<PREV_YEAR_REV>1.279396718E7</PREV_YEAR_REV>
<BUDGET>1.554884292E7</BUDGET>
<GROSS_PROFIT>1.156968689E7</GROSS_PROFIT>
<EXPENSES>1.337339799E7</EXPENSES>
<NET_INCOME>2332503.94</NET_INCOME>
<REVENUE_M>15.70590194</REVENUE_M>
<PROFIT_M>11.56968689</PROFIT_M>
<INCOME_M>2.33250394</INCOME_M>
<PHARMA_REV_M>15.70590194</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.56968689</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.33250394</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7225710.52</REVENUE>
<PREV_YEAR_REV>5740750.57</PREV_YEAR_REV>
<BUDGET>7153453.41</BUDGET>
<GROSS_PROFIT>5407794.005</GROSS_PROFIT>
<EXPENSES>5982888.31</EXPENSES>
<NET_INCOME>1242822.21</NET_INCOME>
<REVENUE_M>7.22571052</REVENUE_M>
<PROFIT_M>5.407794005</PROFIT_M>
<INCOME_M>1.24282221</INCOME_M>
<PHARMA_REV_M>7.22571052</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.407794005</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.24282221</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7561000.9</REVENUE>
<PREV_YEAR_REV>6044207.12</PREV_YEAR_REV>
<BUDGET>7485390.89</BUDGET>
<GROSS_PROFIT>5990581.013</GROSS_PROFIT>
<EXPENSES>6789778.81</EXPENSES>
<NET_INCOME>771222.09</NET_INCOME>
<REVENUE_M>7.5610009</REVENUE_M>
<PROFIT_M>5.990581013</PROFIT_M>
<INCOME_M>0.77122209</INCOME_M>
<PHARMA_REV_M>7.5610009</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.990581013</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.77122209</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7604712.13</REVENUE>
<PREV_YEAR_REV>6173815.65</PREV_YEAR_REV>
<BUDGET>7224476.52</BUDGET>
<GROSS_PROFIT>5276598.471</GROSS_PROFIT>
<EXPENSES>6686094.85</EXPENSES>
<NET_INCOME>918617.28</NET_INCOME>
<REVENUE_M>7.60471213</REVENUE_M>
<PROFIT_M>5.276598471</PROFIT_M>
<INCOME_M>0.91861728</INCOME_M>
<PHARMA_REV_M>7.60471213</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.276598471</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.91861728</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5760704.94</REVENUE>
<PREV_YEAR_REV>4626730.41</PREV_YEAR_REV>
<BUDGET>5184634.44</BUDGET>
<GROSS_PROFIT>4459983.224</GROSS_PROFIT>
<EXPENSES>4985762.55</EXPENSES>
<NET_INCOME>774942.38</NET_INCOME>
<REVENUE_M>5.76070494</REVENUE_M>
<PROFIT_M>4.459983224</PROFIT_M>
<INCOME_M>0.77494238</INCOME_M>
<PHARMA_REV_M>5.76070494</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.459983224</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.77494238</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5769142.44</REVENUE>
<PREV_YEAR_REV>4540504.86</PREV_YEAR_REV>
<BUDGET>5192228.19</BUDGET>
<GROSS_PROFIT>4226697.741</GROSS_PROFIT>
<EXPENSES>4912155.91</EXPENSES>
<NET_INCOME>856986.53</NET_INCOME>
<REVENUE_M>5.76914244</REVENUE_M>
<PROFIT_M>4.226697741</PROFIT_M>
<INCOME_M>0.85698653</INCOME_M>
<PHARMA_REV_M>5.76914244</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.226697741</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.85698653</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>8692724.43</REVENUE>
<PREV_YEAR_REV>7103831.25</PREV_YEAR_REV>
<BUDGET>7823451.99</BUDGET>
<GROSS_PROFIT>6872067.583</GROSS_PROFIT>
<EXPENSES>7849707.35</EXPENSES>
<NET_INCOME>843017.09</NET_INCOME>
<REVENUE_M>8.69272443</REVENUE_M>
<PROFIT_M>6.872067583</PROFIT_M>
<INCOME_M>0.84301709</INCOME_M>
<PHARMA_REV_M>8.69272443</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.872067583</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.84301709</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2891949.81</REVENUE>
<PREV_YEAR_REV>2394731.67</PREV_YEAR_REV>
<BUDGET>2602754.83</BUDGET>
<GROSS_PROFIT>2380074.7</GROSS_PROFIT>
<EXPENSES>2680837.48</EXPENSES>
<NET_INCOME>211112.34</NET_INCOME>
<REVENUE_M>2.89194981</REVENUE_M>
<PROFIT_M>2.3800747</PROFIT_M>
<INCOME_M>0.21111234</INCOME_M>
<PHARMA_REV_M>2.89194981</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.3800747</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21111234</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2877192.63</REVENUE>
<PREV_YEAR_REV>2232753.1</PREV_YEAR_REV>
<BUDGET>2589473.36</BUDGET>
<GROSS_PROFIT>2197599.727</GROSS_PROFIT>
<EXPENSES>2583718.98</EXPENSES>
<NET_INCOME>293473.65</NET_INCOME>
<REVENUE_M>2.87719263</REVENUE_M>
<PROFIT_M>2.197599727</PROFIT_M>
<INCOME_M>0.29347365</INCOME_M>
<PHARMA_REV_M>2.87719263</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.197599727</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29347365</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2672583.25</REVENUE>
<PREV_YEAR_REV>2174033.82</PREV_YEAR_REV>
<BUDGET>2405324.93</BUDGET>
<GROSS_PROFIT>1897801.362</GROSS_PROFIT>
<EXPENSES>2311784.51</EXPENSES>
<NET_INCOME>360798.74</NET_INCOME>
<REVENUE_M>2.67258325</REVENUE_M>
<PROFIT_M>1.897801362</PROFIT_M>
<INCOME_M>0.36079874</INCOME_M>
<PHARMA_REV_M>2.67258325</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.897801362</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36079874</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5733190.25</REVENUE>
<PREV_YEAR_REV>4429838.07</PREV_YEAR_REV>
<BUDGET>5159871.23</BUDGET>
<GROSS_PROFIT>4870800.45</GROSS_PROFIT>
<EXPENSES>4971845.38</EXPENSES>
<NET_INCOME>761344.87</NET_INCOME>
<REVENUE_M>5.73319025</REVENUE_M>
<PROFIT_M>4.87080045</PROFIT_M>
<INCOME_M>0.76134487</INCOME_M>
<PHARMA_REV_M>5.73319025</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.87080045</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76134487</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4970312</REVENUE>
<PREV_YEAR_REV>4037977.26</PREV_YEAR_REV>
<BUDGET>4870905.76</BUDGET>
<GROSS_PROFIT>3609357.258</GROSS_PROFIT>
<EXPENSES>4421718.01</EXPENSES>
<NET_INCOME>548593.99</NET_INCOME>
<REVENUE_M>4.970312</REVENUE_M>
<PROFIT_M>3.609357258</PROFIT_M>
<INCOME_M>0.54859399</INCOME_M>
<PHARMA_REV_M>4.970312</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.609357258</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54859399</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2090621.2</REVENUE>
<PREV_YEAR_REV>1741560.27</PREV_YEAR_REV>
<BUDGET>2048808.78</BUDGET>
<GROSS_PROFIT>1645318.88</GROSS_PROFIT>
<EXPENSES>1756121.81</EXPENSES>
<NET_INCOME>334499.39</NET_INCOME>
<REVENUE_M>2.0906212</REVENUE_M>
<PROFIT_M>1.64531888</PROFIT_M>
<INCOME_M>0.33449939</INCOME_M>
<PHARMA_REV_M>2.0906212</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.64531888</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33449939</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4796954</REVENUE>
<PREV_YEAR_REV>3884304.94</PREV_YEAR_REV>
<BUDGET>4701014.92</BUDGET>
<GROSS_PROFIT>3283413.323</GROSS_PROFIT>
<EXPENSES>4087807.86</EXPENSES>
<NET_INCOME>709146.14</NET_INCOME>
<REVENUE_M>4.796954</REVENUE_M>
<PROFIT_M>3.283413323</PROFIT_M>
<INCOME_M>0.70914614</INCOME_M>
<PHARMA_REV_M>4.796954</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.283413323</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.70914614</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8249638.25</REVENUE>
<PREV_YEAR_REV>7546043.48</PREV_YEAR_REV>
<BUDGET>8509667.19</BUDGET>
<GROSS_PROFIT>6884505.747</GROSS_PROFIT>
<EXPENSES>8056434.92</EXPENSES>
<NET_INCOME>1193203.33</NET_INCOME>
<REVENUE_M>8.24963825</REVENUE_M>
<PROFIT_M>6.884505747</PROFIT_M>
<INCOME_M>1.19320333</INCOME_M>
<PHARMA_REV_M>8.24963825</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.884505747</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.19320333</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>1.182568025E7</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>1.087962583E7</BUDGET>
<GROSS_PROFIT>9611701.713</GROSS_PROFIT>
<EXPENSES>1.04774305E7</EXPENSES>
<NET_INCOME>1348249.75</NET_INCOME>
<REVENUE_M>11.82568025</REVENUE_M>
<PROFIT_M>9.611701713</PROFIT_M>
<INCOME_M>1.34824975</INCOME_M>
<PHARMA_REV_M>11.82568025</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.611701713</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.34824975</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>1.337425291E7</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>1.230431268E7</BUDGET>
<GROSS_PROFIT>1.048997208E7</GROSS_PROFIT>
<EXPENSES>1.175633869E7</EXPENSES>
<NET_INCOME>1617914.22</NET_INCOME>
<REVENUE_M>13.37425291</REVENUE_M>
<PROFIT_M>10.48997208</PROFIT_M>
<INCOME_M>1.61791422</INCOME_M>
<PHARMA_REV_M>13.37425291</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.48997208</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.61791422</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.085144849E7</REVENUE>
<PREV_YEAR_REV>9201649.49</PREV_YEAR_REV>
<BUDGET>1.090333261E7</BUDGET>
<GROSS_PROFIT>9525009.159</GROSS_PROFIT>
<EXPENSES>9812999.35</EXPENSES>
<NET_INCOME>2038449.14</NET_INCOME>
<REVENUE_M>10.85144849</REVENUE_M>
<PROFIT_M>9.525009159</PROFIT_M>
<INCOME_M>2.03844914</INCOME_M>
<PHARMA_REV_M>10.85144849</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.525009159</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.03844914</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.793381138E7</REVENUE>
<PREV_YEAR_REV>1.550650117E7</PREV_YEAR_REV>
<BUDGET>1.741910647E7</BUDGET>
<GROSS_PROFIT>1.586226392E7</GROSS_PROFIT>
<EXPENSES>1.652069151E7</EXPENSES>
<NET_INCOME>2413119.86</NET_INCOME>
<REVENUE_M>17.93381138</REVENUE_M>
<PROFIT_M>15.86226392</PROFIT_M>
<INCOME_M>2.41311986</INCOME_M>
<PHARMA_REV_M>17.93381138</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.86226392</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.41311986</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3684190.67</REVENUE>
<PREV_YEAR_REV>2965286.59</PREV_YEAR_REV>
<BUDGET>3503832.38</BUDGET>
<GROSS_PROFIT>2686935.526</GROSS_PROFIT>
<EXPENSES>3208930.08</EXPENSES>
<NET_INCOME>475260.6</NET_INCOME>
<REVENUE_M>3.68419067</REVENUE_M>
<PROFIT_M>2.686935526</PROFIT_M>
<INCOME_M>0.4752606</INCOME_M>
<PHARMA_REV_M>3.68419067</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.686935526</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4752606</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3061709.42</REVENUE>
<PREV_YEAR_REV>2464469.81</PREV_YEAR_REV>
<BUDGET>2918700</BUDGET>
<GROSS_PROFIT>2681047.091</GROSS_PROFIT>
<EXPENSES>2571835.92</EXPENSES>
<NET_INCOME>489873.51</NET_INCOME>
<REVENUE_M>3.06170942</REVENUE_M>
<PROFIT_M>2.681047091</PROFIT_M>
<INCOME_M>0.48987351</INCOME_M>
<PHARMA_REV_M>3.06170942</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.681047091</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48987351</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7109443.84</REVENUE>
<PREV_YEAR_REV>5734154.71</PREV_YEAR_REV>
<BUDGET>6764263.5</BUDGET>
<GROSS_PROFIT>5679211.329</GROSS_PROFIT>
<EXPENSES>6321366.65</EXPENSES>
<NET_INCOME>788077.21</NET_INCOME>
<REVENUE_M>7.10944384</REVENUE_M>
<PROFIT_M>5.679211329</PROFIT_M>
<INCOME_M>0.78807721</INCOME_M>
<PHARMA_REV_M>7.10944384</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.679211329</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.78807721</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7143043.84</REVENUE>
<PREV_YEAR_REV>5827909.44</PREV_YEAR_REV>
<BUDGET>6795847.5</BUDGET>
<GROSS_PROFIT>5302602.152</GROSS_PROFIT>
<EXPENSES>6284609.17</EXPENSES>
<NET_INCOME>858434.68</NET_INCOME>
<REVENUE_M>7.14304384</REVENUE_M>
<PROFIT_M>5.302602152</PROFIT_M>
<INCOME_M>0.85843468</INCOME_M>
<PHARMA_REV_M>7.14304384</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.302602152</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.85843468</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2530404.77</REVENUE>
<PREV_YEAR_REV>2362734.52</PREV_YEAR_REV>
<BUDGET>2136782.41</BUDGET>
<GROSS_PROFIT>2019369.144</GROSS_PROFIT>
<EXPENSES>2191362.57</EXPENSES>
<NET_INCOME>339042.21</NET_INCOME>
<REVENUE_M>2.53040477</REVENUE_M>
<PROFIT_M>2.019369144</PROFIT_M>
<INCOME_M>0.33904221</INCOME_M>
<PHARMA_REV_M>2.53040477</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.019369144</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33904221</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7385230.55</REVENUE>
<PREV_YEAR_REV>6896026.44</PREV_YEAR_REV>
<BUDGET>7089821.33</BUDGET>
<GROSS_PROFIT>5878643.52</GROSS_PROFIT>
<EXPENSES>6203593.66</EXPENSES>
<NET_INCOME>1181636.89</NET_INCOME>
<REVENUE_M>7.38523055</REVENUE_M>
<PROFIT_M>5.87864352</PROFIT_M>
<INCOME_M>1.18163689</INCOME_M>
<PHARMA_REV_M>7.38523055</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.87864352</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.18163689</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.260253426E7</REVENUE>
<PREV_YEAR_REV>1.193185347E7</PREV_YEAR_REV>
<BUDGET>1.209843289E7</BUDGET>
<GROSS_PROFIT>8696598.005</GROSS_PROFIT>
<EXPENSES>1.119859402E7</EXPENSES>
<NET_INCOME>1403940.24</NET_INCOME>
<REVENUE_M>12.60253426</REVENUE_M>
<PROFIT_M>8.696598005</PROFIT_M>
<INCOME_M>1.40394024</INCOME_M>
<PHARMA_REV_M>12.60253426</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.696598005</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.40394024</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.92658445E7</REVENUE>
<PREV_YEAR_REV>1.814072322E7</PREV_YEAR_REV>
<BUDGET>1.849521072E7</BUDGET>
<GROSS_PROFIT>1.420920436E7</GROSS_PROFIT>
<EXPENSES>1.739185941E7</EXPENSES>
<NET_INCOME>1873985.1</NET_INCOME>
<REVENUE_M>19.2658445</REVENUE_M>
<PROFIT_M>14.20920436</PROFIT_M>
<INCOME_M>1.8739851</INCOME_M>
<PHARMA_REV_M>19.2658445</PHARMA_REV_M>
<PHARMA_PROFIT_M>14.20920436</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.8739851</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.716178648E7</REVENUE>
<PREV_YEAR_REV>1.595766677E7</PREV_YEAR_REV>
<BUDGET>1.647531501E7</BUDGET>
<GROSS_PROFIT>1.213570261E7</GROSS_PROFIT>
<EXPENSES>1.549565009E7</EXPENSES>
<NET_INCOME>1666136.38</NET_INCOME>
<REVENUE_M>17.16178648</REVENUE_M>
<PROFIT_M>12.13570261</PROFIT_M>
<INCOME_M>1.66613638</INCOME_M>
<PHARMA_REV_M>17.16178648</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.13570261</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.66613638</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>9870214.31</REVENUE>
<PREV_YEAR_REV>9218809.62</PREV_YEAR_REV>
<BUDGET>9475405.75</BUDGET>
<GROSS_PROFIT>7279823.11</GROSS_PROFIT>
<EXPENSES>8568022.96</EXPENSES>
<NET_INCOME>1302191.36</NET_INCOME>
<REVENUE_M>9.87021431</REVENUE_M>
<PROFIT_M>7.27982311</PROFIT_M>
<INCOME_M>1.30219136</INCOME_M>
<PHARMA_REV_M>9.87021431</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.27982311</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.30219136</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>4740879.82</REVENUE>
<PREV_YEAR_REV>4455588.49</PREV_YEAR_REV>
<BUDGET>4551244.63</BUDGET>
<GROSS_PROFIT>3200093.88</GROSS_PROFIT>
<EXPENSES>4224123.92</EXPENSES>
<NET_INCOME>516755.9</NET_INCOME>
<REVENUE_M>4.74087982</REVENUE_M>
<PROFIT_M>3.20009388</PROFIT_M>
<INCOME_M>0.5167559</INCOME_M>
<PHARMA_REV_M>4.74087982</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.20009388</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5167559</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6182570.89</REVENUE>
<PREV_YEAR_REV>5812240.28</PREV_YEAR_REV>
<BUDGET>5759023.34</BUDGET>
<GROSS_PROFIT>4200014.532</GROSS_PROFIT>
<EXPENSES>5582974.49</EXPENSES>
<NET_INCOME>599596.4</NET_INCOME>
<REVENUE_M>6.18257089</REVENUE_M>
<PROFIT_M>4.200014532</PROFIT_M>
<INCOME_M>0.5995964</INCOME_M>
<PHARMA_REV_M>6.18257089</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.200014532</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5995964</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4085235.46</REVENUE>
<PREV_YEAR_REV>3814275.8</PREV_YEAR_REV>
<BUDGET>3822010.53</BUDGET>
<GROSS_PROFIT>2715286.507</GROSS_PROFIT>
<EXPENSES>3479138.48</EXPENSES>
<NET_INCOME>606096.98</NET_INCOME>
<REVENUE_M>4.08523546</REVENUE_M>
<PROFIT_M>2.715286507</PROFIT_M>
<INCOME_M>0.60609698</INCOME_M>
<PHARMA_REV_M>4.08523546</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.715286507</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60609698</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2035914.8</REVENUE>
<PREV_YEAR_REV>1933919.87</PREV_YEAR_REV>
<BUDGET>1894210.55</BUDGET>
<GROSS_PROFIT>1374690.394</GROSS_PROFIT>
<EXPENSES>1887293.02</EXPENSES>
<NET_INCOME>148621.78</NET_INCOME>
<REVENUE_M>2.0359148</REVENUE_M>
<PROFIT_M>1.374690394</PROFIT_M>
<INCOME_M>0.14862178</INCOME_M>
<PHARMA_REV_M>2.0359148</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.374690394</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14862178</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2024874.09</REVENUE>
<PREV_YEAR_REV>1927570.34</PREV_YEAR_REV>
<BUDGET>1911286.8</BUDGET>
<GROSS_PROFIT>1280349.153</GROSS_PROFIT>
<EXPENSES>1818336.93</EXPENSES>
<NET_INCOME>206537.16</NET_INCOME>
<REVENUE_M>2.02487409</REVENUE_M>
<PROFIT_M>1.280349153</PROFIT_M>
<INCOME_M>0.20653716</INCOME_M>
<PHARMA_REV_M>2.02487409</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.280349153</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20653716</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2245373.42</REVENUE>
<PREV_YEAR_REV>2120877.89</PREV_YEAR_REV>
<BUDGET>1991095.66</BUDGET>
<GROSS_PROFIT>1607550.401</GROSS_PROFIT>
<EXPENSES>1859169.19</EXPENSES>
<NET_INCOME>386204.23</NET_INCOME>
<REVENUE_M>2.24537342</REVENUE_M>
<PROFIT_M>1.607550401</PROFIT_M>
<INCOME_M>0.38620423</INCOME_M>
<PHARMA_REV_M>2.24537342</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.607550401</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38620423</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1449651.12</REVENUE>
<PREV_YEAR_REV>1354156.04</PREV_YEAR_REV>
<BUDGET>1657058.58</BUDGET>
<GROSS_PROFIT>840348.2583</GROSS_PROFIT>
<EXPENSES>1262646.13</EXPENSES>
<NET_INCOME>187005</NET_INCOME>
<REVENUE_M>1.44965112</REVENUE_M>
<PROFIT_M>0.840348258</PROFIT_M>
<INCOME_M>0.187005</INCOME_M>
<PHARMA_REV_M>1.44965112</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.840348258</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.187005</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2938080.96</REVENUE>
<PREV_YEAR_REV>2768596.75</PREV_YEAR_REV>
<BUDGET>3370072.38</BUDGET>
<GROSS_PROFIT>2087491.601</GROSS_PROFIT>
<EXPENSES>2542769.52</EXPENSES>
<NET_INCOME>395311.43</NET_INCOME>
<REVENUE_M>2.93808096</REVENUE_M>
<PROFIT_M>2.087491601</PROFIT_M>
<INCOME_M>0.39531143</INCOME_M>
<PHARMA_REV_M>2.93808096</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.087491601</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39531143</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.066272331E7</REVENUE>
<PREV_YEAR_REV>9715297.61</PREV_YEAR_REV>
<BUDGET>1.172899564E7</BUDGET>
<GROSS_PROFIT>8103415.077</GROSS_PROFIT>
<EXPENSES>9373566.21</EXPENSES>
<NET_INCOME>1289157.11</NET_INCOME>
<REVENUE_M>10.66272331</REVENUE_M>
<PROFIT_M>8.103415077</PROFIT_M>
<INCOME_M>1.28915711</INCOME_M>
<PHARMA_REV_M>10.66272331</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.103415077</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.28915711</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>4325091.27</REVENUE>
<PREV_YEAR_REV>3995502.28</PREV_YEAR_REV>
<BUDGET>4757600.39</BUDGET>
<GROSS_PROFIT>3429148.617</GROSS_PROFIT>
<EXPENSES>3633076.66</EXPENSES>
<NET_INCOME>692014.6</NET_INCOME>
<REVENUE_M>4.32509127</REVENUE_M>
<PROFIT_M>3.429148617</PROFIT_M>
<INCOME_M>0.6920146</INCOME_M>
<PHARMA_REV_M>4.32509127</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.429148617</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6920146</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.136319405E7</REVENUE>
<PREV_YEAR_REV>1.035593787E7</PREV_YEAR_REV>
<BUDGET>1.249951346E7</BUDGET>
<GROSS_PROFIT>9359100.53</GROSS_PROFIT>
<EXPENSES>9836483.21</EXPENSES>
<NET_INCOME>1526710.84</NET_INCOME>
<REVENUE_M>11.36319405</REVENUE_M>
<PROFIT_M>9.35910053</PROFIT_M>
<INCOME_M>1.52671084</INCOME_M>
<PHARMA_REV_M>11.36319405</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.35910053</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.52671084</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5014306.96</REVENUE>
<PREV_YEAR_REV>4561114.61</PREV_YEAR_REV>
<BUDGET>5515737.65</BUDGET>
<GROSS_PROFIT>3916173.73</GROSS_PROFIT>
<EXPENSES>4648262.55</EXPENSES>
<NET_INCOME>366044.41</NET_INCOME>
<REVENUE_M>5.01430696</REVENUE_M>
<PROFIT_M>3.91617373</PROFIT_M>
<INCOME_M>0.36604441</INCOME_M>
<PHARMA_REV_M>5.01430696</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.91617373</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36604441</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1401161.85</REVENUE>
<PREV_YEAR_REV>1294411.72</PREV_YEAR_REV>
<BUDGET>1693351.73</BUDGET>
<GROSS_PROFIT>989010.097</GROSS_PROFIT>
<EXPENSES>1298877.04</EXPENSES>
<NET_INCOME>102284.82</NET_INCOME>
<REVENUE_M>1.40116185</REVENUE_M>
<PROFIT_M>0.989010097</PROFIT_M>
<INCOME_M>0.10228482</INCOME_M>
<PHARMA_REV_M>1.40116185</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.989010097</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10228482</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1455194.54</REVENUE>
<PREV_YEAR_REV>1354954.97</PREV_YEAR_REV>
<BUDGET>1694688.75</BUDGET>
<GROSS_PROFIT>870933.933</GROSS_PROFIT>
<EXPENSES>1258743.28</EXPENSES>
<NET_INCOME>196451.26</NET_INCOME>
<REVENUE_M>1.45519454</REVENUE_M>
<PROFIT_M>0.870933933</PROFIT_M>
<INCOME_M>0.19645126</INCOME_M>
<PHARMA_REV_M>1.45519454</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.870933933</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19645126</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1315068.53</REVENUE>
<PREV_YEAR_REV>1243187.44</PREV_YEAR_REV>
<BUDGET>1536061.24</BUDGET>
<GROSS_PROFIT>1021808.25</GROSS_PROFIT>
<EXPENSES>1171726.06</EXPENSES>
<NET_INCOME>143342.47</NET_INCOME>
<REVENUE_M>1.31506853</REVENUE_M>
<PROFIT_M>1.02180825</PROFIT_M>
<INCOME_M>0.14334247</INCOME_M>
<PHARMA_REV_M>1.31506853</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.02180825</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14334247</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2070604.25</REVENUE>
<PREV_YEAR_REV>1910543.88</PREV_YEAR_REV>
<BUDGET>2126973.46</BUDGET>
<GROSS_PROFIT>1425367.451</GROSS_PROFIT>
<EXPENSES>1841100.44</EXPENSES>
<NET_INCOME>229503.81</NET_INCOME>
<REVENUE_M>2.07060425</REVENUE_M>
<PROFIT_M>1.425367451</PROFIT_M>
<INCOME_M>0.22950381</INCOME_M>
<PHARMA_REV_M>2.07060425</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.425367451</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22950381</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1195128.55</REVENUE>
<PREV_YEAR_REV>1132029.24</PREV_YEAR_REV>
<BUDGET>1203107.51</BUDGET>
<GROSS_PROFIT>816332.5585</GROSS_PROFIT>
<EXPENSES>1107884.17</EXPENSES>
<NET_INCOME>87244.38</NET_INCOME>
<REVENUE_M>1.19512855</REVENUE_M>
<PROFIT_M>0.816332559</PROFIT_M>
<INCOME_M>0.08724438</INCOME_M>
<PHARMA_REV_M>1.19512855</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.816332559</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.08724438</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3361900.93</REVENUE>
<PREV_YEAR_REV>3158087.3</PREV_YEAR_REV>
<BUDGET>3402402.49</BUDGET>
<GROSS_PROFIT>2474907.92</GROSS_PROFIT>
<EXPENSES>3037435.44</EXPENSES>
<NET_INCOME>324465.49</NET_INCOME>
<REVENUE_M>3.36190093</REVENUE_M>
<PROFIT_M>2.47490792</PROFIT_M>
<INCOME_M>0.32446549</INCOME_M>
<PHARMA_REV_M>3.36190093</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.47490792</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32446549</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7443695.25</REVENUE>
<PREV_YEAR_REV>6789276.85</PREV_YEAR_REV>
<BUDGET>7145947.44</BUDGET>
<GROSS_PROFIT>5031937.99</GROSS_PROFIT>
<EXPENSES>6252704.01</EXPENSES>
<NET_INCOME>1190991.24</NET_INCOME>
<REVENUE_M>7.44369525</REVENUE_M>
<PROFIT_M>5.03193799</PROFIT_M>
<INCOME_M>1.19099124</INCOME_M>
<PHARMA_REV_M>7.44369525</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.03193799</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.19099124</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.126958173E7</REVENUE>
<PREV_YEAR_REV>1.034351271E7</PREV_YEAR_REV>
<BUDGET>1.081879846E7</BUDGET>
<GROSS_PROFIT>8222036.33</GROSS_PROFIT>
<EXPENSES>9748302.28</EXPENSES>
<NET_INCOME>1521279.44</NET_INCOME>
<REVENUE_M>11.26958173</REVENUE_M>
<PROFIT_M>8.22203633</PROFIT_M>
<INCOME_M>1.52127944</INCOME_M>
<PHARMA_REV_M>11.26958173</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.22203633</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.52127944</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>985643.37</REVENUE>
<PREV_YEAR_REV>915123.92</PREV_YEAR_REV>
<BUDGET>975682.03</BUDGET>
<GROSS_PROFIT>729376.09</GROSS_PROFIT>
<EXPENSES>913691.41</EXPENSES>
<NET_INCOME>71951.97</NET_INCOME>
<REVENUE_M>0.98564337</REVENUE_M>
<PROFIT_M>0.72937609</PROFIT_M>
<INCOME_M>0.07195197</INCOME_M>
<PHARMA_REV_M>0.98564337</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.72937609</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.07195197</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3867259.37</REVENUE>
<PREV_YEAR_REV>3580358.93</PREV_YEAR_REV>
<BUDGET>4048090.38</BUDGET>
<GROSS_PROFIT>2337448.59</GROSS_PROFIT>
<EXPENSES>3404201.4</EXPENSES>
<NET_INCOME>463057.97</NET_INCOME>
<REVENUE_M>3.86725937</REVENUE_M>
<PROFIT_M>2.33744859</PROFIT_M>
<INCOME_M>0.46305797</INCOME_M>
<PHARMA_REV_M>3.86725937</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.33744859</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46305797</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1485352.2</REVENUE>
<PREV_YEAR_REV>1330471.96</PREV_YEAR_REV>
<BUDGET>1822245.97</BUDGET>
<GROSS_PROFIT>1004395.16</GROSS_PROFIT>
<EXPENSES>1289285.71</EXPENSES>
<NET_INCOME>196066.49</NET_INCOME>
<REVENUE_M>1.4853522</REVENUE_M>
<PROFIT_M>1.00439516</PROFIT_M>
<INCOME_M>0.19606649</INCOME_M>
<PHARMA_REV_M>1.4853522</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.00439516</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19606649</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2818240.14</REVENUE>
<PREV_YEAR_REV>2563771.27</PREV_YEAR_REV>
<BUDGET>3664716.71</BUDGET>
<GROSS_PROFIT>1922166.909</GROSS_PROFIT>
<EXPENSES>2478811.44</EXPENSES>
<NET_INCOME>339428.7</NET_INCOME>
<REVENUE_M>2.81824014</REVENUE_M>
<PROFIT_M>1.922166909</PROFIT_M>
<INCOME_M>0.3394287</INCOME_M>
<PHARMA_REV_M>2.81824014</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.922166909</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3394287</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2790406.98</REVENUE>
<PREV_YEAR_REV>2561579.06</PREV_YEAR_REV>
<BUDGET>3588611.99</BUDGET>
<GROSS_PROFIT>1870969.357</GROSS_PROFIT>
<EXPENSES>2482185.91</EXPENSES>
<NET_INCOME>308221.07</NET_INCOME>
<REVENUE_M>2.79040698</REVENUE_M>
<PROFIT_M>1.870969357</PROFIT_M>
<INCOME_M>0.30822107</INCOME_M>
<PHARMA_REV_M>2.79040698</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.870969357</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30822107</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2863708.45</REVENUE>
<PREV_YEAR_REV>2624080.92</PREV_YEAR_REV>
<BUDGET>3658211.47</BUDGET>
<GROSS_PROFIT>1936686.274</GROSS_PROFIT>
<EXPENSES>2546466.92</EXPENSES>
<NET_INCOME>317241.53</NET_INCOME>
<REVENUE_M>2.86370845</REVENUE_M>
<PROFIT_M>1.936686274</PROFIT_M>
<INCOME_M>0.31724153</INCOME_M>
<PHARMA_REV_M>2.86370845</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.936686274</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31724153</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2763964.31</REVENUE>
<PREV_YEAR_REV>2522764.45</PREV_YEAR_REV>
<BUDGET>3630238.98</BUDGET>
<GROSS_PROFIT>1665216.714</GROSS_PROFIT>
<EXPENSES>2353594.4</EXPENSES>
<NET_INCOME>410369.92</NET_INCOME>
<REVENUE_M>2.76396431</REVENUE_M>
<PROFIT_M>1.665216714</PROFIT_M>
<INCOME_M>0.41036992</INCOME_M>
<PHARMA_REV_M>2.76396431</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.665216714</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41036992</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1427141.23</REVENUE>
<PREV_YEAR_REV>1293450.21</PREV_YEAR_REV>
<BUDGET>1837403.16</BUDGET>
<GROSS_PROFIT>980417.48</GROSS_PROFIT>
<EXPENSES>1271582.83</EXPENSES>
<NET_INCOME>155558.39</NET_INCOME>
<REVENUE_M>1.42714123</REVENUE_M>
<PROFIT_M>0.98041748</PROFIT_M>
<INCOME_M>0.15555839</INCOME_M>
<PHARMA_REV_M>1.42714123</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.98041748</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15555839</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1421772.47</REVENUE>
<PREV_YEAR_REV>1314447.8</PREV_YEAR_REV>
<BUDGET>1760960.17</BUDGET>
<GROSS_PROFIT>1050832.031</GROSS_PROFIT>
<EXPENSES>1276751.67</EXPENSES>
<NET_INCOME>145020.79</NET_INCOME>
<REVENUE_M>1.42177247</REVENUE_M>
<PROFIT_M>1.050832031</PROFIT_M>
<INCOME_M>0.14502079</INCOME_M>
<PHARMA_REV_M>1.42177247</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.050832031</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14502079</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1581742.61</REVENUE>
<PREV_YEAR_REV>1457827.29</PREV_YEAR_REV>
<BUDGET>1862817.14</BUDGET>
<GROSS_PROFIT>1175234.76</GROSS_PROFIT>
<EXPENSES>1409332.67</EXPENSES>
<NET_INCOME>172409.94</NET_INCOME>
<REVENUE_M>1.58174261</REVENUE_M>
<PROFIT_M>1.17523476</PROFIT_M>
<INCOME_M>0.17240994</INCOME_M>
<PHARMA_REV_M>1.58174261</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.17523476</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17240994</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2167356.46</REVENUE>
<PREV_YEAR_REV>1990517.05</PREV_YEAR_REV>
<BUDGET>2466415.6</BUDGET>
<GROSS_PROFIT>1556544.27</GROSS_PROFIT>
<EXPENSES>1875471.98</EXPENSES>
<NET_INCOME>291884.47</NET_INCOME>
<REVENUE_M>2.16735646</REVENUE_M>
<PROFIT_M>1.55654427</PROFIT_M>
<INCOME_M>0.29188447</INCOME_M>
<PHARMA_REV_M>2.16735646</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.55654427</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29188447</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2146463.13</REVENUE>
<PREV_YEAR_REV>1983773.71</PREV_YEAR_REV>
<BUDGET>2465356.42</BUDGET>
<GROSS_PROFIT>1567995.359</GROSS_PROFIT>
<EXPENSES>1861611.02</EXPENSES>
<NET_INCOME>284852.11</NET_INCOME>
<REVENUE_M>2.14646313</REVENUE_M>
<PROFIT_M>1.567995359</PROFIT_M>
<INCOME_M>0.28485211</INCOME_M>
<PHARMA_REV_M>2.14646313</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.567995359</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28485211</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.251600402E7</REVENUE>
<PREV_YEAR_REV>1.174129125E7</PREV_YEAR_REV>
<BUDGET>1.201536385E7</BUDGET>
<GROSS_PROFIT>1.079631844E7</GROSS_PROFIT>
<EXPENSES>1.084651619E7</EXPENSES>
<NET_INCOME>1669487.82</NET_INCOME>
<REVENUE_M>12.51600402</REVENUE_M>
<PROFIT_M>10.79631844</PROFIT_M>
<INCOME_M>1.66948782</INCOME_M>
<PHARMA_REV_M>12.51600402</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.79631844</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.66948782</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7448421.08</REVENUE>
<PREV_YEAR_REV>7033846.19</PREV_YEAR_REV>
<BUDGET>7150484.24</BUDGET>
<GROSS_PROFIT>6106588.021</GROSS_PROFIT>
<EXPENSES>6167292.65</EXPENSES>
<NET_INCOME>1281128.43</NET_INCOME>
<REVENUE_M>7.44842108</REVENUE_M>
<PROFIT_M>6.106588021</PROFIT_M>
<INCOME_M>1.28112843</INCOME_M>
<PHARMA_REV_M>7.44842108</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.106588021</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.28112843</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5916418.88</REVENUE>
<PREV_YEAR_REV>5594193.35</PREV_YEAR_REV>
<BUDGET>5679762.13</BUDGET>
<GROSS_PROFIT>4745808.079</GROSS_PROFIT>
<EXPENSES>5312944.16</EXPENSES>
<NET_INCOME>603474.73</NET_INCOME>
<REVENUE_M>5.91641888</REVENUE_M>
<PROFIT_M>4.745808079</PROFIT_M>
<INCOME_M>0.60347473</INCOME_M>
<PHARMA_REV_M>5.91641888</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.745808079</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60347473</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7305000.99</REVENUE>
<PREV_YEAR_REV>6714957.66</PREV_YEAR_REV>
<BUDGET>7012800.95</BUDGET>
<GROSS_PROFIT>6131160.378</GROSS_PROFIT>
<EXPENSES>6508755.88</EXPENSES>
<NET_INCOME>796245.11</NET_INCOME>
<REVENUE_M>7.30500099</REVENUE_M>
<PROFIT_M>6.131160378</PROFIT_M>
<INCOME_M>0.79624511</INCOME_M>
<PHARMA_REV_M>7.30500099</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.131160378</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.79624511</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4585926.29</REVENUE>
<PREV_YEAR_REV>4251242.97</PREV_YEAR_REV>
<BUDGET>3508575.19</BUDGET>
<GROSS_PROFIT>3244249.885</GROSS_PROFIT>
<EXPENSES>4034949.74</EXPENSES>
<NET_INCOME>550976.55</NET_INCOME>
<REVENUE_M>4.58592629</REVENUE_M>
<PROFIT_M>3.244249885</PROFIT_M>
<INCOME_M>0.55097655</INCOME_M>
<PHARMA_REV_M>4.58592629</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.244249885</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55097655</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2424880.6</REVENUE>
<PREV_YEAR_REV>2269403.75</PREV_YEAR_REV>
<BUDGET>1797719.67</BUDGET>
<GROSS_PROFIT>1743076.923</GROSS_PROFIT>
<EXPENSES>2112071</EXPENSES>
<NET_INCOME>312809.6</NET_INCOME>
<REVENUE_M>2.4248806</REVENUE_M>
<PROFIT_M>1.743076923</PROFIT_M>
<INCOME_M>0.3128096</INCOME_M>
<PHARMA_REV_M>2.4248806</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.743076923</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3128096</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7133067.56</REVENUE>
<PREV_YEAR_REV>6632542.84</PREV_YEAR_REV>
<BUDGET>5261953.52</BUDGET>
<GROSS_PROFIT>5672084.858</GROSS_PROFIT>
<EXPENSES>6438555.49</EXPENSES>
<NET_INCOME>694512.07</NET_INCOME>
<REVENUE_M>7.13306756</REVENUE_M>
<PROFIT_M>5.672084858</PROFIT_M>
<INCOME_M>0.69451207</INCOME_M>
<PHARMA_REV_M>7.13306756</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.672084858</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69451207</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4616786.87</REVENUE>
<PREV_YEAR_REV>4293570.7</PREV_YEAR_REV>
<BUDGET>3546130.98</BUDGET>
<GROSS_PROFIT>3884860.071</GROSS_PROFIT>
<EXPENSES>3995522.71</EXPENSES>
<NET_INCOME>621264.16</NET_INCOME>
<REVENUE_M>4.61678687</REVENUE_M>
<PROFIT_M>3.884860071</PROFIT_M>
<INCOME_M>0.62126416</INCOME_M>
<PHARMA_REV_M>4.61678687</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.884860071</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62126416</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4803989.95</REVENUE>
<PREV_YEAR_REV>4467234.87</PREV_YEAR_REV>
<BUDGET>3610810.88</BUDGET>
<GROSS_PROFIT>3897028.288</GROSS_PROFIT>
<EXPENSES>4170828.41</EXPENSES>
<NET_INCOME>633161.54</NET_INCOME>
<REVENUE_M>4.80398995</REVENUE_M>
<PROFIT_M>3.897028288</PROFIT_M>
<INCOME_M>0.63316154</INCOME_M>
<PHARMA_REV_M>4.80398995</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.897028288</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.63316154</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4788595.84</REVENUE>
<PREV_YEAR_REV>4550119.98</PREV_YEAR_REV>
<BUDGET>3636152.67</BUDGET>
<GROSS_PROFIT>3966864.062</GROSS_PROFIT>
<EXPENSES>4155310.75</EXPENSES>
<NET_INCOME>633285.1</NET_INCOME>
<REVENUE_M>4.78859584</REVENUE_M>
<PROFIT_M>3.966864062</PROFIT_M>
<INCOME_M>0.6332851</INCOME_M>
<PHARMA_REV_M>4.78859584</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.966864062</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6332851</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3434682.77</REVENUE>
<PREV_YEAR_REV>3213838.49</PREV_YEAR_REV>
<BUDGET>3224954.2</BUDGET>
<GROSS_PROFIT>2567488.682</GROSS_PROFIT>
<EXPENSES>3015668.43</EXPENSES>
<NET_INCOME>419014.34</NET_INCOME>
<REVENUE_M>3.43468277</REVENUE_M>
<PROFIT_M>2.567488682</PROFIT_M>
<INCOME_M>0.41901434</INCOME_M>
<PHARMA_REV_M>3.43468277</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.567488682</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41901434</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1769613.71</REVENUE>
<PREV_YEAR_REV>1646611.81</PREV_YEAR_REV>
<BUDGET>1578137.41</BUDGET>
<GROSS_PROFIT>1427281.938</GROSS_PROFIT>
<EXPENSES>1486475.52</EXPENSES>
<NET_INCOME>283138.19</NET_INCOME>
<REVENUE_M>1.76961371</REVENUE_M>
<PROFIT_M>1.427281938</PROFIT_M>
<INCOME_M>0.28313819</INCOME_M>
<PHARMA_REV_M>1.76961371</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.427281938</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28313819</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1740944.2</REVENUE>
<PREV_YEAR_REV>1652235.66</PREV_YEAR_REV>
<BUDGET>1562637.89</BUDGET>
<GROSS_PROFIT>1422908.511</GROSS_PROFIT>
<EXPENSES>1429315.18</EXPENSES>
<NET_INCOME>311629.01</NET_INCOME>
<REVENUE_M>1.7409442</REVENUE_M>
<PROFIT_M>1.422908511</PROFIT_M>
<INCOME_M>0.31162901</INCOME_M>
<PHARMA_REV_M>1.7409442</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.422908511</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31162901</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1677840.82</REVENUE>
<PREV_YEAR_REV>1551301.18</PREV_YEAR_REV>
<BUDGET>1568276.13</BUDGET>
<GROSS_PROFIT>1354017.54</GROSS_PROFIT>
<EXPENSES>1377507.31</EXPENSES>
<NET_INCOME>300333.51</NET_INCOME>
<REVENUE_M>1.67784082</REVENUE_M>
<PROFIT_M>1.35401754</PROFIT_M>
<INCOME_M>0.30033351</INCOME_M>
<PHARMA_REV_M>1.67784082</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.35401754</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30033351</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1691572.62</REVENUE>
<PREV_YEAR_REV>1600397.95</PREV_YEAR_REV>
<BUDGET>1578137.41</BUDGET>
<GROSS_PROFIT>1256236.251</GROSS_PROFIT>
<EXPENSES>1463210.31</EXPENSES>
<NET_INCOME>228362.3</NET_INCOME>
<REVENUE_M>1.69157262</REVENUE_M>
<PROFIT_M>1.256236251</PROFIT_M>
<INCOME_M>0.2283623</INCOME_M>
<PHARMA_REV_M>1.69157262</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.256236251</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2283623</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1737237.22</REVENUE>
<PREV_YEAR_REV>1608642.35</PREV_YEAR_REV>
<BUDGET>1578137.41</BUDGET>
<GROSS_PROFIT>1376380.038</GROSS_PROFIT>
<EXPENSES>1438432.42</EXPENSES>
<NET_INCOME>298804.8</NET_INCOME>
<REVENUE_M>1.73723722</REVENUE_M>
<PROFIT_M>1.376380038</PROFIT_M>
<INCOME_M>0.2988048</INCOME_M>
<PHARMA_REV_M>1.73723722</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.376380038</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2988048</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.551433453E7</REVENUE>
<PREV_YEAR_REV>2.423861781E7</PREV_YEAR_REV>
<BUDGET>2.47489045E7</BUDGET>
<GROSS_PROFIT>1.921994821E7</GROSS_PROFIT>
<EXPENSES>2.150493911E7</EXPENSES>
<NET_INCOME>3376180.65</NET_INCOME>
<REVENUE_M>25.51433453</REVENUE_M>
<PROFIT_M>19.21994821</PROFIT_M>
<INCOME_M>3.37618065</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.069164756E7</REVENUE>
<PREV_YEAR_REV>2.915706517E7</PREV_YEAR_REV>
<BUDGET>2.977089813E7</BUDGET>
<GROSS_PROFIT>2.080801629E7</GROSS_PROFIT>
<EXPENSES>2.593362143E7</EXPENSES>
<NET_INCOME>3714760.53</NET_INCOME>
<REVENUE_M>30.69164756</REVENUE_M>
<PROFIT_M>20.80801629</PROFIT_M>
<INCOME_M>3.71476053</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.531414454E7</REVENUE>
<PREV_YEAR_REV>1.454843731E7</PREV_YEAR_REV>
<BUDGET>1.48547202E7</BUDGET>
<GROSS_PROFIT>1.038253058E7</GROSS_PROFIT>
<EXPENSES>1.272300517E7</EXPENSES>
<NET_INCOME>2205101.51</NET_INCOME>
<REVENUE_M>15.31414454</REVENUE_M>
<PROFIT_M>10.38253058</PROFIT_M>
<INCOME_M>2.20510151</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.05967413E7</REVENUE>
<PREV_YEAR_REV>1.006690423E7</PREV_YEAR_REV>
<BUDGET>1.027883906E7</BUDGET>
<GROSS_PROFIT>7184272.697</GROSS_PROFIT>
<EXPENSES>8953963.02</EXPENSES>
<NET_INCOME>1430560.07</NET_INCOME>
<REVENUE_M>10.5967413</REVENUE_M>
<PROFIT_M>7.184272697</PROFIT_M>
<INCOME_M>1.43056007</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.111674662E7</REVENUE>
<PREV_YEAR_REV>2.006090929E7</PREV_YEAR_REV>
<BUDGET>2.048324422E7</BUDGET>
<GROSS_PROFIT>1.590724523E7</GROSS_PROFIT>
<EXPENSES>1.784308619E7</EXPENSES>
<NET_INCOME>2798531.11</NET_INCOME>
<REVENUE_M>21.11674662</REVENUE_M>
<PROFIT_M>15.90724523</PROFIT_M>
<INCOME_M>2.79853111</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.336537282E7</REVENUE>
<PREV_YEAR_REV>1.269710418E7</PREV_YEAR_REV>
<BUDGET>1.296441164E7</BUDGET>
<GROSS_PROFIT>1.006813535E7</GROSS_PROFIT>
<EXPENSES>1.129338262E7</EXPENSES>
<NET_INCOME>1456825.64</NET_INCOME>
<REVENUE_M>13.36537282</REVENUE_M>
<PROFIT_M>10.06813535</PROFIT_M>
<INCOME_M>1.45682564</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>32881065</REVENUE>
<PREV_YEAR_REV>3.123701175E7</PREV_YEAR_REV>
<BUDGET>3.189463305E7</BUDGET>
<GROSS_PROFIT>2.353084095E7</GROSS_PROFIT>
<EXPENSES>42275655</EXPENSES>
<NET_INCOME>3189463.31</NET_INCOME>
<REVENUE_M>32.881065</REVENUE_M>
<PROFIT_M>23.53084095</PROFIT_M>
<INCOME_M>3.18946331</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>32421606</REVENUE>
<PREV_YEAR_REV>3.08005257E7</PREV_YEAR_REV>
<BUDGET>3.144895782E7</BUDGET>
<GROSS_PROFIT>2.44231958E7</GROSS_PROFIT>
<EXPENSES>41684922</EXPENSES>
<NET_INCOME>4279651.99</NET_INCOME>
<REVENUE_M>32.421606</REVENUE_M>
<PROFIT_M>24.4231958</PROFIT_M>
<INCOME_M>4.27965199</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.44807066E7</REVENUE>
<PREV_YEAR_REV>1.375667127E7</PREV_YEAR_REV>
<BUDGET>1.40462854E7</BUDGET>
<GROSS_PROFIT>1.090831629E7</GROSS_PROFIT>
<EXPENSES>1.861805134E7</EXPENSES>
<NET_INCOME>1911453.27</NET_INCOME>
<REVENUE_M>14.4807066</REVENUE_M>
<PROFIT_M>10.90831629</PROFIT_M>
<INCOME_M>1.91145327</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.833249842E7</REVENUE>
<PREV_YEAR_REV>1.74158735E7</PREV_YEAR_REV>
<BUDGET>1.778252347E7</BUDGET>
<GROSS_PROFIT>1.242888396E7</GROSS_PROFIT>
<EXPENSES>2.357035512E7</EXPENSES>
<NET_INCOME>2217684.73</NET_INCOME>
<REVENUE_M>18.33249842</REVENUE_M>
<PROFIT_M>12.42888396</PROFIT_M>
<INCOME_M>2.21768473</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.47162015E7</REVENUE>
<PREV_YEAR_REV>1.398039143E7</PREV_YEAR_REV>
<BUDGET>1.427471546E7</BUDGET>
<GROSS_PROFIT>1.108571459E7</GROSS_PROFIT>
<EXPENSES>1.89208305E7</EXPENSES>
<NET_INCOME>2634200.07</NET_INCOME>
<REVENUE_M>14.7162015</REVENUE_M>
<PROFIT_M>11.08571459</PROFIT_M>
<INCOME_M>2.63420007</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.147269123E7</REVENUE>
<PREV_YEAR_REV>1.089905667E7</PREV_YEAR_REV>
<BUDGET>1.112851049E7</BUDGET>
<GROSS_PROFIT>8210259.392</GROSS_PROFIT>
<EXPENSES>1.475060301E7</EXPENSES>
<NET_INCOME>1170214.51</NET_INCOME>
<REVENUE_M>11.47269123</REVENUE_M>
<PROFIT_M>8.210259392</PROFIT_M>
<INCOME_M>1.17021451</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.450393144E7</REVENUE>
<PREV_YEAR_REV>1.377873487E7</PREV_YEAR_REV>
<BUDGET>1.40688135E7</BUDGET>
<GROSS_PROFIT>1.092581156E7</GROSS_PROFIT>
<EXPENSES>1.864791185E7</EXPENSES>
<NET_INCOME>1580928.53</NET_INCOME>
<REVENUE_M>14.50393144</REVENUE_M>
<PROFIT_M>10.92581156</PROFIT_M>
<INCOME_M>1.58092853</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.590152464E7</REVENUE>
<PREV_YEAR_REV>1.510644841E7</PREV_YEAR_REV>
<BUDGET>1.54244789E7</BUDGET>
<GROSS_PROFIT>1.197861851E7</GROSS_PROFIT>
<EXPENSES>1.947125466E7</EXPENSES>
<NET_INCOME>2544243.94</NET_INCOME>
<REVENUE_M>15.90152464</REVENUE_M>
<PROFIT_M>11.97861851</PROFIT_M>
<INCOME_M>2.54424394</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.296033813E7</REVENUE>
<PREV_YEAR_REV>4.081232122E7</PREV_YEAR_REV>
<BUDGET>4.167152798E7</BUDGET>
<GROSS_PROFIT>3.236202271E7</GROSS_PROFIT>
<EXPENSES>5.260449566E7</EXPENSES>
<NET_INCOME>4094730.62</NET_INCOME>
<REVENUE_M>42.96033813</REVENUE_M>
<PROFIT_M>32.36202271</PROFIT_M>
<INCOME_M>4.09473062</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.522912801E7</REVENUE>
<PREV_YEAR_REV>1.446767161E7</PREV_YEAR_REV>
<BUDGET>1.477225417E7</BUDGET>
<GROSS_PROFIT>1.147210213E7</GROSS_PROFIT>
<EXPENSES>1.864791185E7</EXPENSES>
<NET_INCOME>1659974.95</NET_INCOME>
<REVENUE_M>15.22912801</REVENUE_M>
<PROFIT_M>11.47210213</PROFIT_M>
<INCOME_M>1.65997495</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.840418671E7</REVENUE>
<PREV_YEAR_REV>1.56435587E7</PREV_YEAR_REV>
<BUDGET>1.785206111E7</BUDGET>
<GROSS_PROFIT>1.386387385E7</GROSS_PROFIT>
<EXPENSES>1.637972617E7</EXPENSES>
<NET_INCOME>3294349.42</NET_INCOME>
<REVENUE_M>18.40418671</REVENUE_M>
<PROFIT_M>13.86387385</PROFIT_M>
<INCOME_M>3.29434942</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.268072847E7</REVENUE>
<PREV_YEAR_REV>3.62786192E7</PREV_YEAR_REV>
<BUDGET>4.140030662E7</BUDGET>
<GROSS_PROFIT>3.215139276E7</GROSS_PROFIT>
<EXPENSES>3.804907047E7</EXPENSES>
<NET_INCOME>5633856.16</NET_INCOME>
<REVENUE_M>42.68072847</REVENUE_M>
<PROFIT_M>32.15139276</PROFIT_M>
<INCOME_M>5.63385616</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.937282812E7</REVENUE>
<PREV_YEAR_REV>1.64669039E7</PREV_YEAR_REV>
<BUDGET>1.879164327E7</BUDGET>
<GROSS_PROFIT>1.459355143E7</GROSS_PROFIT>
<EXPENSES>1.727051362E7</EXPENSES>
<NET_INCOME>3467736.23</NET_INCOME>
<REVENUE_M>19.37282812</REVENUE_M>
<PROFIT_M>14.59355143</PROFIT_M>
<INCOME_M>3.46773623</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.113519904E7</REVENUE>
<PREV_YEAR_REV>9464919.19</PREV_YEAR_REV>
<BUDGET>1.080114307E7</BUDGET>
<GROSS_PROFIT>8388145.435</GROSS_PROFIT>
<EXPENSES>9926821.5</EXPENSES>
<NET_INCOME>1993200.63</NET_INCOME>
<REVENUE_M>11.13519904</REVENUE_M>
<PROFIT_M>8.388145435</PROFIT_M>
<INCOME_M>1.99320063</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.909338975E7</REVENUE>
<PREV_YEAR_REV>1.622938129E7</PREV_YEAR_REV>
<BUDGET>1.852058806E7</BUDGET>
<GROSS_PROFIT>1.43830505E7</GROSS_PROFIT>
<EXPENSES>1.702139954E7</EXPENSES>
<NET_INCOME>2081179.48</NET_INCOME>
<REVENUE_M>19.09338975</REVENUE_M>
<PROFIT_M>14.3830505</PROFIT_M>
<INCOME_M>2.08117948</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.068672371E7</REVENUE>
<PREV_YEAR_REV>1.758371516E7</PREV_YEAR_REV>
<BUDGET>20066122</BUDGET>
<GROSS_PROFIT>1.500614939E7</GROSS_PROFIT>
<EXPENSES>1.861805134E7</EXPENSES>
<NET_INCOME>2730647.53</NET_INCOME>
<REVENUE_M>20.68672371</REVENUE_M>
<PROFIT_M>15.00614939</PROFIT_M>
<INCOME_M>2.73064753</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.963783393E7</REVENUE>
<PREV_YEAR_REV>2.519215884E7</PREV_YEAR_REV>
<BUDGET>2.874869891E7</BUDGET>
<GROSS_PROFIT>2.232618031E7</GROSS_PROFIT>
<EXPENSES>2.587898055E7</EXPENSES>
<NET_INCOME>3927776.53</NET_INCOME>
<REVENUE_M>29.63783393</REVENUE_M>
<PROFIT_M>22.32618031</PROFIT_M>
<INCOME_M>3.92777653</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.50638415E7</REVENUE>
<PREV_YEAR_REV>1.280426527E7</PREV_YEAR_REV>
<BUDGET>1.461192625E7</BUDGET>
<GROSS_PROFIT>1.13475918E7</GROSS_PROFIT>
<EXPENSES>1.342913271E7</EXPENSES>
<NET_INCOME>1641958.72</NET_INCOME>
<REVENUE_M>15.0638415</REVENUE_M>
<PROFIT_M>11.3475918</PROFIT_M>
<INCOME_M>1.64195872</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.937282812E7</REVENUE>
<PREV_YEAR_REV>1.64669039E7</PREV_YEAR_REV>
<BUDGET>1.879164327E7</BUDGET>
<GROSS_PROFIT>1.386387385E7</GROSS_PROFIT>
<EXPENSES>1.727051362E7</EXPENSES>
<NET_INCOME>1976028.47</NET_INCOME>
<REVENUE_M>19.37282812</REVENUE_M>
<PROFIT_M>13.86387385</PROFIT_M>
<INCOME_M>1.97602847</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.290594224E7</REVENUE>
<PREV_YEAR_REV>3.947346686E7</PREV_YEAR_REV>
<BUDGET>3.356406108E7</BUDGET>
<GROSS_PROFIT>3.232104629E7</GROSS_PROFIT>
<EXPENSES>3.928628859E7</EXPENSES>
<NET_INCOME>5738637.71</NET_INCOME>
<REVENUE_M>42.90594224</REVENUE_M>
<PROFIT_M>32.32104629</PROFIT_M>
<INCOME_M>5.73863771</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.438129176E7</REVENUE>
<PREV_YEAR_REV>1.323078842E7</PREV_YEAR_REV>
<BUDGET>1.466891759E7</BUDGET>
<GROSS_PROFIT>9750084.37</GROSS_PROFIT>
<EXPENSES>1.279934966E7</EXPENSES>
<NET_INCOME>1941474.39</NET_INCOME>
<REVENUE_M>14.38129176</REVENUE_M>
<PROFIT_M>9.75008437</PROFIT_M>
<INCOME_M>1.94147439</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.595895584E7</REVENUE>
<PREV_YEAR_REV>1.468223937E7</PREV_YEAR_REV>
<BUDGET>1.627813496E7</BUDGET>
<GROSS_PROFIT>1.142078736E7</GROSS_PROFIT>
<EXPENSES>1.42034707E7</EXPENSES>
<NET_INCOME>2744940.4</NET_INCOME>
<REVENUE_M>15.95895584</REVENUE_M>
<PROFIT_M>11.42078736</PROFIT_M>
<INCOME_M>2.7449404</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.862139639E7</REVENUE>
<PREV_YEAR_REV>3.553168467E7</PREV_YEAR_REV>
<BUDGET>3.531382431E7</BUDGET>
<GROSS_PROFIT>2.618414811E7</GROSS_PROFIT>
<EXPENSES>3.486432678E7</EXPENSES>
<NET_INCOME>5731746.13</NET_INCOME>
<REVENUE_M>38.62139639</REVENUE_M>
<PROFIT_M>26.18414811</PROFIT_M>
<INCOME_M>5.73174613</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>4.473783656E7</REVENUE>
<PREV_YEAR_REV>4.115880964E7</PREV_YEAR_REV>
<BUDGET>3.543259329E7</BUDGET>
<GROSS_PROFIT>3.370101228E7</GROSS_PROFIT>
<EXPENSES>4.096813102E7</EXPENSES>
<NET_INCOME>4384235.47</NET_INCOME>
<REVENUE_M>44.73783656</REVENUE_M>
<PROFIT_M>33.70101228</PROFIT_M>
<INCOME_M>4.38423547</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.651448497E7</REVENUE>
<PREV_YEAR_REV>4.279332617E7</PREV_YEAR_REV>
<BUDGET>4.33771995E7</BUDGET>
<GROSS_PROFIT>3.503936153E7</GROSS_PROFIT>
<EXPENSES>3.907216738E7</EXPENSES>
<NET_INCOME>7442317.6</NET_INCOME>
<REVENUE_M>46.51448497</REVENUE_M>
<PROFIT_M>35.03936153</PROFIT_M>
<INCOME_M>7.4423176</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>5.011902165E7</REVENUE>
<PREV_YEAR_REV>4.610949992E7</PREV_YEAR_REV>
<BUDGET>3.581220265E7</BUDGET>
<GROSS_PROFIT>3.775465901E7</GROSS_PROFIT>
<EXPENSES>4.538944906E7</EXPENSES>
<NET_INCOME>4729572.59</NET_INCOME>
<REVENUE_M>50.11902165</REVENUE_M>
<PROFIT_M>37.75465901</PROFIT_M>
<INCOME_M>4.72957259</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6866924.14</REVENUE>
<PREV_YEAR_REV>6351147.46</PREV_YEAR_REV>
<BUDGET>7553616.56</BUDGET>
<GROSS_PROFIT>5571135.559</GROSS_PROFIT>
<EXPENSES>5685813.19</EXPENSES>
<NET_INCOME>1181110.95</NET_INCOME>
<REVENUE_M>6.86692414</REVENUE_M>
<PROFIT_M>5.571135559</PROFIT_M>
<INCOME_M>1.18111095</INCOME_M>
<PHARMA_REV_M>6.86692414</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.571135559</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.18111095</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7184506.41</REVENUE>
<PREV_YEAR_REV>6660831.81</PREV_YEAR_REV>
<BUDGET>7902957.05</BUDGET>
<GROSS_PROFIT>6106830.44</GROSS_PROFIT>
<EXPENSES>6401395.21</EXPENSES>
<NET_INCOME>783111.2</NET_INCOME>
<REVENUE_M>7.18450641</REVENUE_M>
<PROFIT_M>6.10683044</PROFIT_M>
<INCOME_M>0.7831112</INCOME_M>
<PHARMA_REV_M>7.18450641</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.10683044</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.7831112</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5231218.19</REVENUE>
<PREV_YEAR_REV>4851491.92</PREV_YEAR_REV>
<BUDGET>5754340.01</BUDGET>
<GROSS_PROFIT>3925134.709</GROSS_PROFIT>
<EXPENSES>4697633.93</EXPENSES>
<NET_INCOME>533584.26</NET_INCOME>
<REVENUE_M>5.23121819</REVENUE_M>
<PROFIT_M>3.925134709</PROFIT_M>
<INCOME_M>0.53358426</INCOME_M>
<PHARMA_REV_M>5.23121819</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.925134709</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53358426</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>7766203.27</REVENUE>
<PREV_YEAR_REV>6350668.04</PREV_YEAR_REV>
<BUDGET>7422310.51</BUDGET>
<GROSS_PROFIT>6619983.85</GROSS_PROFIT>
<EXPENSES>7013240.29</EXPENSES>
<NET_INCOME>752962.98</NET_INCOME>
<REVENUE_M>7.76620327</REVENUE_M>
<PROFIT_M>6.61998385</PROFIT_M>
<INCOME_M>0.75296298</INCOME_M>
<PHARMA_REV_M>7.76620327</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.61998385</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75296298</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4645128.22</REVENUE>
<PREV_YEAR_REV>4166469.63</PREV_YEAR_REV>
<BUDGET>4917806.82</BUDGET>
<GROSS_PROFIT>3908667.931</GROSS_PROFIT>
<EXPENSES>4464119.24</EXPENSES>
<NET_INCOME>681008.98</NET_INCOME>
<REVENUE_M>4.64512822</REVENUE_M>
<PROFIT_M>3.908667931</PROFIT_M>
<INCOME_M>0.68100898</INCOME_M>
<PHARMA_REV_M>4.64512822</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.908667931</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68100898</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2494512.55</REVENUE>
<PREV_YEAR_REV>2007930.7</PREV_YEAR_REV>
<BUDGET>2385534.94</BUDGET>
<GROSS_PROFIT>1780894.873</GROSS_PROFIT>
<EXPENSES>2157753.36</EXPENSES>
<NET_INCOME>336759.19</NET_INCOME>
<REVENUE_M>2.49451255</REVENUE_M>
<PROFIT_M>1.780894873</PROFIT_M>
<INCOME_M>0.33675919</INCOME_M>
<PHARMA_REV_M>2.49451255</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.780894873</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33675919</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1511365.42</REVENUE>
<PREV_YEAR_REV>1227824.02</PREV_YEAR_REV>
<BUDGET>1461376.64</BUDGET>
<GROSS_PROFIT>1168436.61</GROSS_PROFIT>
<EXPENSES>1316399.28</EXPENSES>
<NET_INCOME>194966.14</NET_INCOME>
<REVENUE_M>1.51136542</REVENUE_M>
<PROFIT_M>1.16843661</PROFIT_M>
<INCOME_M>0.19496614</INCOME_M>
<PHARMA_REV_M>1.51136542</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.16843661</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19496614</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.493047466E7</REVENUE>
<PREV_YEAR_REV>2.243742719E7</PREV_YEAR_REV>
<BUDGET>2.368395093E7</BUDGET>
<GROSS_PROFIT>1.878012656E7</GROSS_PROFIT>
<EXPENSES>41094189</EXPENSES>
<NET_INCOME>3988875.95</NET_INCOME>
<REVENUE_M>24.93047466</REVENUE_M>
<PROFIT_M>18.78012656</PROFIT_M>
<INCOME_M>3.98887595</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>8969569.41</REVENUE>
<PREV_YEAR_REV>8072612.47</PREV_YEAR_REV>
<BUDGET>8521090.94</BUDGET>
<GROSS_PROFIT>6418937.803</GROSS_PROFIT>
<EXPENSES>1.478500452E7</EXPENSES>
<NET_INCOME>1542765.94</NET_INCOME>
<REVENUE_M>8.96956941</REVENUE_M>
<PROFIT_M>6.418937803</PROFIT_M>
<INCOME_M>1.54276594</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.131306652E7</REVENUE>
<PREV_YEAR_REV>1.018175987E7</PREV_YEAR_REV>
<BUDGET>1.07474132E7</BUDGET>
<GROSS_PROFIT>8522133.018</GROSS_PROFIT>
<EXPENSES>1.864791185E7</EXPENSES>
<NET_INCOME>1233124.25</NET_INCOME>
<REVENUE_M>11.31306652</REVENUE_M>
<PROFIT_M>8.522133018</PROFIT_M>
<INCOME_M>1.23312425</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.222474859E7</REVENUE>
<PREV_YEAR_REV>1.100227373E7</PREV_YEAR_REV>
<BUDGET>1.090470531E7</BUDGET>
<GROSS_PROFIT>9208903.106</GROSS_PROFIT>
<EXPENSES>1.89208305E7</EXPENSES>
<NET_INCOME>2188230</NET_INCOME>
<REVENUE_M>12.22474859</REVENUE_M>
<PROFIT_M>9.208903106</PROFIT_M>
<INCOME_M>2.18823</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>7026594.56</REVENUE>
<PREV_YEAR_REV>6323935.11</PREV_YEAR_REV>
<BUDGET>6267854.31</BUDGET>
<GROSS_PROFIT>5293133.688</GROSS_PROFIT>
<EXPENSES>1.087539787E7</EXPENSES>
<NET_INCOME>1257760.43</NET_INCOME>
<REVENUE_M>7.02659456</REVENUE_M>
<PROFIT_M>5.293133688</PROFIT_M>
<INCOME_M>1.25776043</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.903600805E7</REVENUE>
<PREV_YEAR_REV>1.713240724E7</PREV_YEAR_REV>
<BUDGET>1.698047666E7</BUDGET>
<GROSS_PROFIT>1.433982486E7</GROSS_PROFIT>
<EXPENSES>2.94629439E7</EXPENSES>
<NET_INCOME>2522777.85</NET_INCOME>
<REVENUE_M>19.03600805</REVENUE_M>
<PROFIT_M>14.33982486</PROFIT_M>
<INCOME_M>2.52277785</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>7404907.36</REVENUE>
<PREV_YEAR_REV>7034662</PREV_YEAR_REV>
<BUDGET>7182760.14</BUDGET>
<GROSS_PROFIT>5578116.713</GROSS_PROFIT>
<EXPENSES>6241279.06</EXPENSES>
<NET_INCOME>1325478.42</NET_INCOME>
<REVENUE_M>7.40490736</REVENUE_M>
<PROFIT_M>5.578116713</PROFIT_M>
<INCOME_M>1.32547842</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2557351.99</REVENUE>
<PREV_YEAR_REV>2290466.8</PREV_YEAR_REV>
<BUDGET>1853051.07</BUDGET>
<GROSS_PROFIT>1902286.28</GROSS_PROFIT>
<EXPENSES>2219781.53</EXPENSES>
<NET_INCOME>337570.46</NET_INCOME>
<REVENUE_M>2.55735199</REVENUE_M>
<PROFIT_M>1.90228628</PROFIT_M>
<INCOME_M>0.33757046</INCOME_M>
<PHARMA_REV_M>2.55735199</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.90228628</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33757046</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5027076.18</REVENUE>
<PREV_YEAR_REV>4585926.29</PREV_YEAR_REV>
<BUDGET>3792144.35</BUDGET>
<GROSS_PROFIT>3570116.206</GROSS_PROFIT>
<EXPENSES>4423229.3</EXPENSES>
<NET_INCOME>603846.88</NET_INCOME>
<REVENUE_M>5.02707618</REVENUE_M>
<PROFIT_M>3.570116206</PROFIT_M>
<INCOME_M>0.60384688</INCOME_M>
<PHARMA_REV_M>5.02707618</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.570116206</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60384688</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2687107.19</REVENUE>
<PREV_YEAR_REV>2424880.6</PREV_YEAR_REV>
<BUDGET>1943014.5</BUDGET>
<GROSS_PROFIT>2047704.658</GROSS_PROFIT>
<EXPENSES>2340470.36</EXPENSES>
<NET_INCOME>346636.83</NET_INCOME>
<REVENUE_M>2.68710719</REVENUE_M>
<PROFIT_M>2.047704658</PROFIT_M>
<INCOME_M>0.34663683</INCOME_M>
<PHARMA_REV_M>2.68710719</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.047704658</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34663683</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2717791.76</REVENUE>
<PREV_YEAR_REV>2480461.23</PREV_YEAR_REV>
<BUDGET>1945948.09</BUDGET>
<GROSS_PROFIT>2235927.287</GROSS_PROFIT>
<EXPENSES>2519392.96</EXPENSES>
<NET_INCOME>198398.8</NET_INCOME>
<REVENUE_M>2.71779176</REVENUE_M>
<PROFIT_M>2.235927287</PROFIT_M>
<INCOME_M>0.1983988</INCOME_M>
<PHARMA_REV_M>2.71779176</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.235927287</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1983988</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5023004.64</REVENUE>
<PREV_YEAR_REV>4616786.87</PREV_YEAR_REV>
<BUDGET>3832735.45</BUDGET>
<GROSS_PROFIT>4225930.072</GROSS_PROFIT>
<EXPENSES>4347062.26</EXPENSES>
<NET_INCOME>675942.39</NET_INCOME>
<REVENUE_M>5.02300464</REVENUE_M>
<PROFIT_M>4.225930072</PROFIT_M>
<INCOME_M>0.67594239</INCOME_M>
<PHARMA_REV_M>5.02300464</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.225930072</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67594239</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5061304.29</REVENUE>
<PREV_YEAR_REV>4573789.18</PREV_YEAR_REV>
<BUDGET>3839864.08</BUDGET>
<GROSS_PROFIT>4071090.334</GROSS_PROFIT>
<EXPENSES>4380037.83</EXPENSES>
<NET_INCOME>681266.46</NET_INCOME>
<REVENUE_M>5.06130429</REVENUE_M>
<PROFIT_M>4.071090334</PROFIT_M>
<INCOME_M>0.68126646</INCOME_M>
<PHARMA_REV_M>5.06130429</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.071090334</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68126646</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2839387.64</REVENUE>
<PREV_YEAR_REV>2600409.96</PREV_YEAR_REV>
<BUDGET>1987018.35</BUDGET>
<GROSS_PROFIT>2276166.708</GROSS_PROFIT>
<EXPENSES>2529894.38</EXPENSES>
<NET_INCOME>309493.25</NET_INCOME>
<REVENUE_M>2.83938764</REVENUE_M>
<PROFIT_M>2.276166708</PROFIT_M>
<INCOME_M>0.30949325</INCOME_M>
<PHARMA_REV_M>2.83938764</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.276166708</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30949325</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1917305.67</REVENUE>
<PREV_YEAR_REV>1769613.71</PREV_YEAR_REV>
<BUDGET>1705685.22</BUDGET>
<GROSS_PROFIT>1433473.582</GROSS_PROFIT>
<EXPENSES>1610536.76</EXPENSES>
<NET_INCOME>306768.91</NET_INCOME>
<REVENUE_M>1.91730567</REVENUE_M>
<PROFIT_M>1.433473582</PROFIT_M>
<INCOME_M>0.30676891</INCOME_M>
<PHARMA_REV_M>1.91730567</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.433473582</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30676891</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3547559.28</REVENUE>
<PREV_YEAR_REV>3253147.67</PREV_YEAR_REV>
<BUDGET>3400712.16</BUDGET>
<GROSS_PROFIT>2619160.334</GROSS_PROFIT>
<EXPENSES>3020111.72</EXPENSES>
<NET_INCOME>527447.55</NET_INCOME>
<REVENUE_M>3.54755928</REVENUE_M>
<PROFIT_M>2.619160334</PROFIT_M>
<INCOME_M>0.52744755</INCOME_M>
<PHARMA_REV_M>3.54755928</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.619160334</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52744755</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1880452.7</REVENUE>
<PREV_YEAR_REV>1692957.64</PREV_YEAR_REV>
<BUDGET>1705685.22</BUDGET>
<GROSS_PROFIT>1605116.814</GROSS_PROFIT>
<EXPENSES>1743179.65</EXPENSES>
<NET_INCOME>137273.05</NET_INCOME>
<REVENUE_M>1.8804527</REVENUE_M>
<PROFIT_M>1.605116814</PROFIT_M>
<INCOME_M>0.13727305</INCOME_M>
<PHARMA_REV_M>1.8804527</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.605116814</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13727305</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3580398.74</REVENUE>
<PREV_YEAR_REV>3279816.21</PREV_YEAR_REV>
<BUDGET>3394618.23</BUDGET>
<GROSS_PROFIT>2920752.96</GROSS_PROFIT>
<EXPENSES>3098209.94</EXPENSES>
<NET_INCOME>482188.8</NET_INCOME>
<REVENUE_M>3.58039874</REVENUE_M>
<PROFIT_M>2.92075296</PROFIT_M>
<INCOME_M>0.4821888</INCOME_M>
<PHARMA_REV_M>3.58039874</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.92075296</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4821888</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1860373.08</REVENUE>
<PREV_YEAR_REV>1703076.9</PREV_YEAR_REV>
<BUDGET>1705685.22</BUDGET>
<GROSS_PROFIT>1650150.92</GROSS_PROFIT>
<EXPENSES>1724565.85</EXPENSES>
<NET_INCOME>135807.24</NET_INCOME>
<REVENUE_M>1.86037308</REVENUE_M>
<PROFIT_M>1.65015092</PROFIT_M>
<INCOME_M>0.13580724</INCOME_M>
<PHARMA_REV_M>1.86037308</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.65015092</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13580724</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5409118.58</REVENUE>
<PREV_YEAR_REV>4854711.41</PREV_YEAR_REV>
<BUDGET>5138695.21</BUDGET>
<GROSS_PROFIT>4259919.358</GROSS_PROFIT>
<EXPENSES>4883954.06</EXPENSES>
<NET_INCOME>525164.53</NET_INCOME>
<REVENUE_M>5.40911858</REVENUE_M>
<PROFIT_M>4.259919358</PROFIT_M>
<INCOME_M>0.52516453</INCOME_M>
<PHARMA_REV_M>5.40911858</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.259919358</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52516453</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1788984.83</REVENUE>
<PREV_YEAR_REV>1605493.03</PREV_YEAR_REV>
<BUDGET>1695026.94</BUDGET>
<GROSS_PROFIT>1502389.461</GROSS_PROFIT>
<EXPENSES>1606508.38</EXPENSES>
<NET_INCOME>182476.45</NET_INCOME>
<REVENUE_M>1.78898483</REVENUE_M>
<PROFIT_M>1.502389461</PROFIT_M>
<INCOME_M>0.18247645</INCOME_M>
<PHARMA_REV_M>1.78898483</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.502389461</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18247645</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2235870.35</REVENUE>
<PREV_YEAR_REV>2048961.48</PREV_YEAR_REV>
<BUDGET>1852273.88</BUDGET>
<GROSS_PROFIT>1748799.948</GROSS_PROFIT>
<EXPENSES>1936534.64</EXPENSES>
<NET_INCOME>299335.7</NET_INCOME>
<REVENUE_M>2.23587035</REVENUE_M>
<PROFIT_M>1.748799948</PROFIT_M>
<INCOME_M>0.2993357</INCOME_M>
<PHARMA_REV_M>2.23587035</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.748799948</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2993357</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4314386.23</REVENUE>
<PREV_YEAR_REV>3912373.03</PREV_YEAR_REV>
<BUDGET>3500174.17</BUDGET>
<GROSS_PROFIT>3509524.466</GROSS_PROFIT>
<EXPENSES>3900535.07</EXPENSES>
<NET_INCOME>413851.16</NET_INCOME>
<REVENUE_M>4.31438623</REVENUE_M>
<PROFIT_M>3.509524466</PROFIT_M>
<INCOME_M>0.41385116</INCOME_M>
<PHARMA_REV_M>4.31438623</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.509524466</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41385116</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8239334.99</REVENUE>
<PREV_YEAR_REV>7394910.19</PREV_YEAR_REV>
<BUDGET>7415401.49</BUDGET>
<GROSS_PROFIT>7308290.14</GROSS_PROFIT>
<EXPENSES>7151742.77</EXPENSES>
<NET_INCOME>1087592.22</NET_INCOME>
<REVENUE_M>8.23933499</REVENUE_M>
<PROFIT_M>7.30829014</PROFIT_M>
<INCOME_M>1.08759222</INCOME_M>
<PHARMA_REV_M>8.23933499</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.30829014</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.08759222</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7243656.74</REVENUE>
<PREV_YEAR_REV>6454986.49</PREV_YEAR_REV>
<BUDGET>6519291.07</BUDGET>
<GROSS_PROFIT>6374417.93</GROSS_PROFIT>
<EXPENSES>6084671.66</EXPENSES>
<NET_INCOME>1158985.08</NET_INCOME>
<REVENUE_M>7.24365674</REVENUE_M>
<PROFIT_M>6.37441793</PROFIT_M>
<INCOME_M>1.15898508</INCOME_M>
<PHARMA_REV_M>7.24365674</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.37441793</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.15898508</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.719388036E7</REVENUE>
<PREV_YEAR_REV>1.547283482E7</PREV_YEAR_REV>
<BUDGET>1.547449232E7</BUDGET>
<GROSS_PROFIT>1.395198628E7</GROSS_PROFIT>
<EXPENSES>1.552570399E7</EXPENSES>
<NET_INCOME>1668176.36</NET_INCOME>
<REVENUE_M>17.19388036</REVENUE_M>
<PROFIT_M>13.95198628</PROFIT_M>
<INCOME_M>1.66817636</INCOME_M>
<PHARMA_REV_M>17.19388036</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.95198628</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.66817636</PHARMA_INCOME_M>
<FRANCE_REV_M>17.19388036</FRANCE_REV_M>
<FRANCE_PROFIT_M>13.95198628</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>1.66817636</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2330501.48</REVENUE>
<PREV_YEAR_REV>2030354.22</PREV_YEAR_REV>
<BUDGET>2423551.36</BUDGET>
<GROSS_PROFIT>1939023.845</GROSS_PROFIT>
<EXPENSES>2076476.82</EXPENSES>
<NET_INCOME>254024.66</NET_INCOME>
<REVENUE_M>2.33050148</REVENUE_M>
<PROFIT_M>1.939023845</PROFIT_M>
<INCOME_M>0.25402466</INCOME_M>
<PHARMA_REV_M>2.33050148</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.939023845</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25402466</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1668846.05</REVENUE>
<PREV_YEAR_REV>1469067.55</PREV_YEAR_REV>
<BUDGET>2142110.48</BUDGET>
<GROSS_PROFIT>1224098.577</GROSS_PROFIT>
<EXPENSES>1453564.91</EXPENSES>
<NET_INCOME>215281.14</NET_INCOME>
<REVENUE_M>1.66884605</REVENUE_M>
<PROFIT_M>1.224098577</PROFIT_M>
<INCOME_M>0.21528114</INCOME_M>
<PHARMA_REV_M>1.66884605</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.224098577</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21528114</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1544919.02</REVENUE>
<PREV_YEAR_REV>1345338.11</PREV_YEAR_REV>
<BUDGET>2080411.46</BUDGET>
<GROSS_PROFIT>1174138.45</GROSS_PROFIT>
<EXPENSES>1297731.97</EXPENSES>
<NET_INCOME>247187.04</NET_INCOME>
<REVENUE_M>1.54491902</REVENUE_M>
<PROFIT_M>1.17413845</PROFIT_M>
<INCOME_M>0.24718704</INCOME_M>
<PHARMA_REV_M>1.54491902</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.17413845</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24718704</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1623444.52</REVENUE>
<PREV_YEAR_REV>1440910.03</PREV_YEAR_REV>
<BUDGET>2035822.56</BUDGET>
<GROSS_PROFIT>1227031.832</GROSS_PROFIT>
<EXPENSES>1414020.17</EXPENSES>
<NET_INCOME>209424.34</NET_INCOME>
<REVENUE_M>1.62344452</REVENUE_M>
<PROFIT_M>1.227031832</PROFIT_M>
<INCOME_M>0.20942434</INCOME_M>
<PHARMA_REV_M>1.62344452</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.227031832</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20942434</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.335503248E7</REVENUE>
<PREV_YEAR_REV>1.207438482E7</PREV_YEAR_REV>
<BUDGET>1.201952923E7</BUDGET>
<GROSS_PROFIT>1.118953391E7</GROSS_PROFIT>
<EXPENSES>1.158999346E7</EXPENSES>
<NET_INCOME>1765039.01</NET_INCOME>
<REVENUE_M>13.35503248</REVENUE_M>
<PROFIT_M>11.18953391</PROFIT_M>
<INCOME_M>1.76503901</INCOME_M>
<PHARMA_REV_M>13.35503248</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.18953391</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.76503901</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8445599.29</REVENUE>
<PREV_YEAR_REV>7503530.98</PREV_YEAR_REV>
<BUDGET>7601039.36</BUDGET>
<GROSS_PROFIT>6742121.913</GROSS_PROFIT>
<EXPENSES>7305443.39</EXPENSES>
<NET_INCOME>1140155.9</NET_INCOME>
<REVENUE_M>8.44559929</REVENUE_M>
<PROFIT_M>6.742121913</PROFIT_M>
<INCOME_M>1.1401559</INCOME_M>
<PHARMA_REV_M>8.44559929</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.742121913</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.1401559</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2115635.93</REVENUE>
<PREV_YEAR_REV>1904211.35</PREV_YEAR_REV>
<BUDGET>2061570.71</BUDGET>
<GROSS_PROFIT>1675245.153</GROSS_PROFIT>
<EXPENSES>1777134.18</EXPENSES>
<NET_INCOME>338501.75</NET_INCOME>
<REVENUE_M>2.11563593</REVENUE_M>
<PROFIT_M>1.675245153</PROFIT_M>
<INCOME_M>0.33850175</INCOME_M>
<PHARMA_REV_M>2.11563593</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.675245153</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33850175</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2339117.67</REVENUE>
<PREV_YEAR_REV>2097806.94</PREV_YEAR_REV>
<BUDGET>2209234.14</BUDGET>
<GROSS_PROFIT>1913281.295</GROSS_PROFIT>
<EXPENSES>2168362.08</EXPENSES>
<NET_INCOME>170755.59</NET_INCOME>
<REVENUE_M>2.33911767</REVENUE_M>
<PROFIT_M>1.913281295</PROFIT_M>
<INCOME_M>0.17075559</INCOME_M>
<PHARMA_REV_M>2.33911767</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.913281295</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17075559</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>6745852.06</REVENUE>
<PREV_YEAR_REV>6094000.47</PREV_YEAR_REV>
<BUDGET>6536890.7</BUDGET>
<GROSS_PROFIT>5594782.123</GROSS_PROFIT>
<EXPENSES>6091037.83</EXPENSES>
<NET_INCOME>654814.22</NET_INCOME>
<REVENUE_M>6.74585206</REVENUE_M>
<PROFIT_M>5.594782123</PROFIT_M>
<INCOME_M>0.65481422</INCOME_M>
<PHARMA_REV_M>6.74585206</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.594782123</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65481422</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2192857.03</REVENUE>
<PREV_YEAR_REV>1963817.04</PREV_YEAR_REV>
<BUDGET>2163706.15</BUDGET>
<GROSS_PROFIT>1704069.198</GROSS_PROFIT>
<EXPENSES>1953835.61</EXPENSES>
<NET_INCOME>239021.42</NET_INCOME>
<REVENUE_M>2.19285703</REVENUE_M>
<PROFIT_M>1.704069198</PROFIT_M>
<INCOME_M>0.23902142</INCOME_M>
<PHARMA_REV_M>2.19285703</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.704069198</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23902142</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2437442.66</REVENUE>
<PREV_YEAR_REV>2245373.42</PREV_YEAR_REV>
<BUDGET>2276954.38</BUDGET>
<GROSS_PROFIT>1801791.746</GROSS_PROFIT>
<EXPENSES>2018202.53</EXPENSES>
<NET_INCOME>419240.14</NET_INCOME>
<REVENUE_M>2.43744266</REVENUE_M>
<PROFIT_M>1.801791746</PROFIT_M>
<INCOME_M>0.41924014</INCOME_M>
<PHARMA_REV_M>2.43744266</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.801791746</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41924014</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3313453.35</REVENUE>
<PREV_YEAR_REV>2973144.17</PREV_YEAR_REV>
<BUDGET>3957201.08</BUDGET>
<GROSS_PROFIT>2482471.987</GROSS_PROFIT>
<EXPENSES>2911529.58</EXPENSES>
<NET_INCOME>401923.76</NET_INCOME>
<REVENUE_M>3.31345335</REVENUE_M>
<PROFIT_M>2.482471987</PROFIT_M>
<INCOME_M>0.40192376</INCOME_M>
<PHARMA_REV_M>3.31345335</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.482471987</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40192376</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3311841.88</REVENUE>
<PREV_YEAR_REV>2959772.9</PREV_YEAR_REV>
<BUDGET>3881375</BUDGET>
<GROSS_PROFIT>2800177.95</GROSS_PROFIT>
<EXPENSES>2866227.04</EXPENSES>
<NET_INCOME>445614.83</NET_INCOME>
<REVENUE_M>3.31184188</REVENUE_M>
<PROFIT_M>2.80017795</PROFIT_M>
<INCOME_M>0.44561483</INCOME_M>
<PHARMA_REV_M>3.31184188</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.80017795</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44561483</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3201430.81</REVENUE>
<PREV_YEAR_REV>2891828.71</PREV_YEAR_REV>
<BUDGET>3860827.24</BUDGET>
<GROSS_PROFIT>2584750.441</GROSS_PROFIT>
<EXPENSES>2778638.75</EXPENSES>
<NET_INCOME>422792.05</NET_INCOME>
<REVENUE_M>3.20143081</REVENUE_M>
<PROFIT_M>2.584750441</PROFIT_M>
<INCOME_M>0.42279205</INCOME_M>
<PHARMA_REV_M>3.20143081</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.584750441</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42279205</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1963262.47</REVENUE>
<PREV_YEAR_REV>1765512.72</PREV_YEAR_REV>
<BUDGET>2102885.84</BUDGET>
<GROSS_PROFIT>1580330.7</GROSS_PROFIT>
<EXPENSES>1699887.26</EXPENSES>
<NET_INCOME>263375.22</NET_INCOME>
<REVENUE_M>1.96326247</REVENUE_M>
<PROFIT_M>1.5803307</PROFIT_M>
<INCOME_M>0.26337522</INCOME_M>
<PHARMA_REV_M>1.96326247</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.5803307</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26337522</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2380973.41</REVENUE>
<PREV_YEAR_REV>2135570.05</PREV_YEAR_REV>
<BUDGET>2473631.73</BUDGET>
<GROSS_PROFIT>1800864.63</GROSS_PROFIT>
<EXPENSES>2027478.22</EXPENSES>
<NET_INCOME>353495.18</NET_INCOME>
<REVENUE_M>2.38097341</REVENUE_M>
<PROFIT_M>1.80086463</PROFIT_M>
<INCOME_M>0.35349518</INCOME_M>
<PHARMA_REV_M>2.38097341</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.80086463</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35349518</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1137199.6</REVENUE>
<PREV_YEAR_REV>1019772.77</PREV_YEAR_REV>
<BUDGET>1201385.79</BUDGET>
<GROSS_PROFIT>1000735.65</GROSS_PROFIT>
<EXPENSES>933640.87</EXPENSES>
<NET_INCOME>203558.73</NET_INCOME>
<REVENUE_M>1.1371996</REVENUE_M>
<PROFIT_M>1.00073565</PROFIT_M>
<INCOME_M>0.20355873</INCOME_M>
<PHARMA_REV_M>1.1371996</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.00073565</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20355873</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1012347.33</REVENUE>
<PREV_YEAR_REV>904390.26</PREV_YEAR_REV>
<BUDGET>1055206.61</BUDGET>
<GROSS_PROFIT>771307.432</GROSS_PROFIT>
<EXPENSES>909087.9</EXPENSES>
<NET_INCOME>103259.43</NET_INCOME>
<REVENUE_M>1.01234733</REVENUE_M>
<PROFIT_M>0.771307432</PROFIT_M>
<INCOME_M>0.10325943</INCOME_M>
<PHARMA_REV_M>1.01234733</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.771307432</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10325943</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6244700.98</REVENUE>
<PREV_YEAR_REV>5458273.01</PREV_YEAR_REV>
<BUDGET>6369595</BUDGET>
<GROSS_PROFIT>4939558.48</GROSS_PROFIT>
<EXPENSES>5126899.51</EXPENSES>
<NET_INCOME>1117801.48</NET_INCOME>
<REVENUE_M>6.24470098</REVENUE_M>
<PROFIT_M>4.93955848</PROFIT_M>
<INCOME_M>1.11780148</INCOME_M>
<PHARMA_REV_M>6.24470098</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.93955848</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.11780148</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7308077.32</REVENUE>
<PREV_YEAR_REV>6366586.51</PREV_YEAR_REV>
<BUDGET>7454238.87</BUDGET>
<GROSS_PROFIT>6431108.04</GROSS_PROFIT>
<EXPENSES>5999931.48</EXPENSES>
<NET_INCOME>1308145.84</NET_INCOME>
<REVENUE_M>7.30807732</REVENUE_M>
<PROFIT_M>6.43110804</PROFIT_M>
<INCOME_M>1.30814584</INCOME_M>
<PHARMA_REV_M>7.30807732</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.43110804</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.30814584</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>4775951.78</REVENUE>
<PREV_YEAR_REV>4259678.72</PREV_YEAR_REV>
<BUDGET>4871470.82</BUDGET>
<GROSS_PROFIT>4138744.296</GROSS_PROFIT>
<EXPENSES>4255373.04</EXPENSES>
<NET_INCOME>520578.74</NET_INCOME>
<REVENUE_M>4.77595178</REVENUE_M>
<PROFIT_M>4.138744296</PROFIT_M>
<INCOME_M>0.52057874</INCOME_M>
<PHARMA_REV_M>4.77595178</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.138744296</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52057874</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4480222.71</REVENUE>
<PREV_YEAR_REV>3867259.37</PREV_YEAR_REV>
<BUDGET>4625249.97</BUDGET>
<GROSS_PROFIT>3081130.873</GROSS_PROFIT>
<EXPENSES>3942566.79</EXPENSES>
<NET_INCOME>537655.93</NET_INCOME>
<REVENUE_M>4.48022271</REVENUE_M>
<PROFIT_M>3.081130873</PROFIT_M>
<INCOME_M>0.53765593</INCOME_M>
<PHARMA_REV_M>4.48022271</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.081130873</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53765593</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3020921.85</REVENUE>
<PREV_YEAR_REV>2701665.98</PREV_YEAR_REV>
<BUDGET>2088328.67</BUDGET>
<GROSS_PROFIT>2146380.081</GROSS_PROFIT>
<EXPENSES>2613097.4</EXPENSES>
<NET_INCOME>407824.45</NET_INCOME>
<REVENUE_M>3.02092185</REVENUE_M>
<PROFIT_M>2.146380081</PROFIT_M>
<INCOME_M>0.40782445</INCOME_M>
<PHARMA_REV_M>3.02092185</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.146380081</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40782445</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2527842.29</REVENUE>
<PREV_YEAR_REV>2349557.84</PREV_YEAR_REV>
<BUDGET>1956471.74</BUDGET>
<GROSS_PROFIT>1939350.491</GROSS_PROFIT>
<EXPENSES>2186583.58</EXPENSES>
<NET_INCOME>341258.71</NET_INCOME>
<REVENUE_M>2.52784229</REVENUE_M>
<PROFIT_M>1.939350491</PROFIT_M>
<INCOME_M>0.34125871</INCOME_M>
<PHARMA_REV_M>2.52784229</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.939350491</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34125871</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3936636.59</REVENUE>
<PREV_YEAR_REV>3520721.62</PREV_YEAR_REV>
<BUDGET>3629381.64</BUDGET>
<GROSS_PROFIT>2901555.602</GROSS_PROFIT>
<EXPENSES>3459708.41</EXPENSES>
<NET_INCOME>476928.17</NET_INCOME>
<REVENUE_M>3.93663659</REVENUE_M>
<PROFIT_M>2.901555602</PROFIT_M>
<INCOME_M>0.47692817</INCOME_M>
<PHARMA_REV_M>3.93663659</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.901555602</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47692817</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2051275.93</REVENUE>
<PREV_YEAR_REV>1869384.79</PREV_YEAR_REV>
<BUDGET>1776044.74</BUDGET>
<GROSS_PROFIT>1595995.241</GROSS_PROFIT>
<EXPENSES>1723071.78</EXPENSES>
<NET_INCOME>328204.15</NET_INCOME>
<REVENUE_M>2.05127593</REVENUE_M>
<PROFIT_M>1.595995241</PROFIT_M>
<INCOME_M>0.32820415</INCOME_M>
<PHARMA_REV_M>2.05127593</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.595995241</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32820415</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1967708.97</REVENUE>
<PREV_YEAR_REV>1820840.01</PREV_YEAR_REV>
<BUDGET>1754477.04</BUDGET>
<GROSS_PROFIT>1517890.696</GROSS_PROFIT>
<EXPENSES>1707971.38</EXPENSES>
<NET_INCOME>259737.58</NET_INCOME>
<REVENUE_M>1.96770897</REVENUE_M>
<PROFIT_M>1.517890696</PROFIT_M>
<INCOME_M>0.25973758</INCOME_M>
<PHARMA_REV_M>1.96770897</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.517890696</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25973758</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4153557.07</REVENUE>
<PREV_YEAR_REV>3774676.9</PREV_YEAR_REV>
<BUDGET>3583187.82</BUDGET>
<GROSS_PROFIT>2962698.898</GROSS_PROFIT>
<EXPENSES>3652744.94</EXPENSES>
<NET_INCOME>500812.14</NET_INCOME>
<REVENUE_M>4.15355707</REVENUE_M>
<PROFIT_M>2.962698898</PROFIT_M>
<INCOME_M>0.50081214</INCOME_M>
<PHARMA_REV_M>4.15355707</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.962698898</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50081214</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4193920.28</REVENUE>
<PREV_YEAR_REV>3812658.58</PREV_YEAR_REV>
<BUDGET>3540991.53</BUDGET>
<GROSS_PROFIT>3125361.408</GROSS_PROFIT>
<EXPENSES>3569612.01</EXPENSES>
<NET_INCOME>624308.27</NET_INCOME>
<REVENUE_M>4.19392028</REVENUE_M>
<PROFIT_M>3.125361408</PROFIT_M>
<INCOME_M>0.62430827</INCOME_M>
<PHARMA_REV_M>4.19392028</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.125361408</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62430827</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2192646.04</REVENUE>
<PREV_YEAR_REV>1991576.48</PREV_YEAR_REV>
<BUDGET>1776044.74</BUDGET>
<GROSS_PROFIT>1620619.769</GROSS_PROFIT>
<EXPENSES>1896638.82</EXPENSES>
<NET_INCOME>296007.22</NET_INCOME>
<REVENUE_M>2.19264604</REVENUE_M>
<PROFIT_M>1.620619769</PROFIT_M>
<INCOME_M>0.29600722</INCOME_M>
<PHARMA_REV_M>2.19264604</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.620619769</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29600722</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1912786.84</REVENUE>
<PREV_YEAR_REV>1748737.75</PREV_YEAR_REV>
<BUDGET>1758601.49</BUDGET>
<GROSS_PROFIT>1595455.508</GROSS_PROFIT>
<EXPENSES>1583787.5</EXPENSES>
<NET_INCOME>328999.34</NET_INCOME>
<REVENUE_M>1.91278684</REVENUE_M>
<PROFIT_M>1.595455508</PROFIT_M>
<INCOME_M>0.32899934</INCOME_M>
<PHARMA_REV_M>1.91278684</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.595455508</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32899934</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2036578.44</REVENUE>
<PREV_YEAR_REV>1878138.66</PREV_YEAR_REV>
<BUDGET>1725847.02</BUDGET>
<GROSS_PROFIT>1453867.52</GROSS_PROFIT>
<EXPENSES>1828847.44</EXPENSES>
<NET_INCOME>207731</NET_INCOME>
<REVENUE_M>2.03657844</REVENUE_M>
<PROFIT_M>1.45386752</PROFIT_M>
<INCOME_M>0.207731</INCOME_M>
<PHARMA_REV_M>2.03657844</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.45386752</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.207731</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2202264.45</REVENUE>
<PREV_YEAR_REV>1994226.72</PREV_YEAR_REV>
<BUDGET>1788107.16</BUDGET>
<GROSS_PROFIT>1653636.337</GROSS_PROFIT>
<EXPENSES>1823474.97</EXPENSES>
<NET_INCOME>378789.49</NET_INCOME>
<REVENUE_M>2.20226445</REVENUE_M>
<PROFIT_M>1.653636337</PROFIT_M>
<INCOME_M>0.37878949</INCOME_M>
<PHARMA_REV_M>2.20226445</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.653636337</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37878949</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3569046.08</REVENUE>
<PREV_YEAR_REV>3217770.69</PREV_YEAR_REV>
<BUDGET>2501053.91</BUDGET>
<GROSS_PROFIT>2619765.811</GROSS_PROFIT>
<EXPENSES>3137306.59</EXPENSES>
<NET_INCOME>431739.51</NET_INCOME>
<REVENUE_M>3.56904608</REVENUE_M>
<PROFIT_M>2.619765811</PROFIT_M>
<INCOME_M>0.43173951</INCOME_M>
<PHARMA_REV_M>3.56904608</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.619765811</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43173951</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>5225433.33</REVENUE>
<PREV_YEAR_REV>4802993.73</PREV_YEAR_REV>
<BUDGET>3644556.35</BUDGET>
<GROSS_PROFIT>4145280.882</GROSS_PROFIT>
<EXPENSES>4722538.25</EXPENSES>
<NET_INCOME>502895.08</NET_INCOME>
<REVENUE_M>5.22543333</REVENUE_M>
<PROFIT_M>4.145280882</PROFIT_M>
<INCOME_M>0.50289508</INCOME_M>
<PHARMA_REV_M>5.22543333</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.145280882</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50289508</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1674982.79</REVENUE>
<PREV_YEAR_REV>1553816.2</PREV_YEAR_REV>
<BUDGET>1261859.97</BUDGET>
<GROSS_PROFIT>1298446.653</GROSS_PROFIT>
<EXPENSES>1552709.04</EXPENSES>
<NET_INCOME>122273.74</NET_INCOME>
<REVENUE_M>1.67498279</REVENUE_M>
<PROFIT_M>1.298446653</PROFIT_M>
<INCOME_M>0.12227374</INCOME_M>
<PHARMA_REV_M>1.67498279</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.298446653</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12227374</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.006152791E7</REVENUE>
<PREV_YEAR_REV>9018130.24</PREV_YEAR_REV>
<BUDGET>9055375.12</BUDGET>
<GROSS_PROFIT>8300760.53</GROSS_PROFIT>
<EXPENSES>8451683.44</EXPENSES>
<NET_INCOME>1609844.47</NET_INCOME>
<REVENUE_M>10.06152791</REVENUE_M>
<PROFIT_M>8.30076053</PROFIT_M>
<INCOME_M>1.60984447</INCOME_M>
<PHARMA_REV_M>10.06152791</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.30076053</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.60984447</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.090498835E7</REVENUE>
<PREV_YEAR_REV>9789916.83</PREV_YEAR_REV>
<BUDGET>9814489.52</BUDGET>
<GROSS_PROFIT>8715266.694</GROSS_PROFIT>
<EXPENSES>9498244.85</EXPENSES>
<NET_INCOME>1406743.5</NET_INCOME>
<REVENUE_M>10.90498835</REVENUE_M>
<PROFIT_M>8.715266694</PROFIT_M>
<INCOME_M>1.4067435</INCOME_M>
<PHARMA_REV_M>10.90498835</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.715266694</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.4067435</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6648753.21</REVENUE>
<PREV_YEAR_REV>5916418.88</PREV_YEAR_REV>
<BUDGET>5983877.89</BUDGET>
<GROSS_PROFIT>5078065.054</GROSS_PROFIT>
<EXPENSES>5970580.39</EXPENSES>
<NET_INCOME>678172.83</NET_INCOME>
<REVENUE_M>6.64875321</REVENUE_M>
<PROFIT_M>5.078065054</PROFIT_M>
<INCOME_M>0.67817283</INCOME_M>
<PHARMA_REV_M>6.64875321</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.078065054</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67817283</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9407176.37</REVENUE>
<PREV_YEAR_REV>8594874.76</PREV_YEAR_REV>
<BUDGET>8466458.74</BUDGET>
<GROSS_PROFIT>7801841.731</GROSS_PROFIT>
<EXPENSES>8447644.38</EXPENSES>
<NET_INCOME>959531.99</NET_INCOME>
<REVENUE_M>9.40717637</REVENUE_M>
<PROFIT_M>7.801841731</PROFIT_M>
<INCOME_M>0.95953199</INCOME_M>
<PHARMA_REV_M>9.40717637</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.801841731</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.95953199</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2435690.01</REVENUE>
<PREV_YEAR_REV>2172240.66</PREV_YEAR_REV>
<BUDGET>2222920.26</BUDGET>
<GROSS_PROFIT>2140971.52</GROSS_PROFIT>
<EXPENSES>2114178.93</EXPENSES>
<NET_INCOME>321511.08</NET_INCOME>
<REVENUE_M>2.43569001</REVENUE_M>
<PROFIT_M>2.14097152</PROFIT_M>
<INCOME_M>0.32151108</INCOME_M>
<PHARMA_REV_M>2.43569001</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.14097152</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32151108</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2250044.15</REVENUE>
<PREV_YEAR_REV>1954232.04</PREV_YEAR_REV>
<BUDGET>2098786.14</BUDGET>
<GROSS_PROFIT>1504402.015</GROSS_PROFIT>
<EXPENSES>1959788.45</EXPENSES>
<NET_INCOME>290255.7</NET_INCOME>
<REVENUE_M>2.25004415</REVENUE_M>
<PROFIT_M>1.504402015</PROFIT_M>
<INCOME_M>0.2902557</INCOME_M>
<PHARMA_REV_M>2.25004415</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.504402015</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2902557</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4473609.78</REVENUE>
<PREV_YEAR_REV>3976382.42</PREV_YEAR_REV>
<BUDGET>4268443.67</BUDGET>
<GROSS_PROFIT>3607953.7</GROSS_PROFIT>
<EXPENSES>3871770.83</EXPENSES>
<NET_INCOME>601838.95</NET_INCOME>
<REVENUE_M>4.47360978</REVENUE_M>
<PROFIT_M>3.6079537</PROFIT_M>
<INCOME_M>0.60183895</INCOME_M>
<PHARMA_REV_M>4.47360978</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.6079537</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60183895</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2283095.47</REVENUE>
<PREV_YEAR_REV>1980426.84</PREV_YEAR_REV>
<BUDGET>2123689.59</BUDGET>
<GROSS_PROFIT>1749337.437</GROSS_PROFIT>
<EXPENSES>2050219.74</EXPENSES>
<NET_INCOME>232875.74</NET_INCOME>
<REVENUE_M>2.28309547</REVENUE_M>
<PROFIT_M>1.749337437</PROFIT_M>
<INCOME_M>0.23287574</INCOME_M>
<PHARMA_REV_M>2.28309547</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.749337437</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23287574</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2382205.48</REVENUE>
<PREV_YEAR_REV>2116330.84</PREV_YEAR_REV>
<BUDGET>2144754.08</BUDGET>
<GROSS_PROFIT>1869633.474</GROSS_PROFIT>
<EXPENSES>1972466.14</EXPENSES>
<NET_INCOME>409739.34</NET_INCOME>
<REVENUE_M>2.38220548</REVENUE_M>
<PROFIT_M>1.869633474</PROFIT_M>
<INCOME_M>0.40973934</INCOME_M>
<PHARMA_REV_M>2.38220548</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.869633474</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40973934</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2257974.88</REVENUE>
<PREV_YEAR_REV>2036578.44</PREV_YEAR_REV>
<BUDGET>2084135.25</BUDGET>
<GROSS_PROFIT>1721959.865</GROSS_PROFIT>
<EXPENSES>2027661.44</EXPENSES>
<NET_INCOME>230313.44</NET_INCOME>
<REVENUE_M>2.25797488</REVENUE_M>
<PROFIT_M>1.721959865</PROFIT_M>
<INCOME_M>0.23031344</INCOME_M>
<PHARMA_REV_M>2.25797488</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.721959865</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23031344</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3884304.94</REVENUE>
<PREV_YEAR_REV>3414051.55</PREV_YEAR_REV>
<BUDGET>2959189.2</BUDGET>
<GROSS_PROFIT>2865157.309</GROSS_PROFIT>
<EXPENSES>3310502.27</EXPENSES>
<NET_INCOME>573802.68</NET_INCOME>
<REVENUE_M>3.88430494</REVENUE_M>
<PROFIT_M>2.865157309</PROFIT_M>
<INCOME_M>0.57380268</INCOME_M>
<PHARMA_REV_M>3.88430494</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.865157309</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57380268</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1909691.65</REVENUE>
<PREV_YEAR_REV>1626958.76</PREV_YEAR_REV>
<BUDGET>1383794.57</BUDGET>
<GROSS_PROFIT>1413992.989</GROSS_PROFIT>
<EXPENSES>1651883.28</EXPENSES>
<NET_INCOME>257808.37</NET_INCOME>
<REVENUE_M>1.90969165</REVENUE_M>
<PROFIT_M>1.413992989</PROFIT_M>
<INCOME_M>0.25780837</INCOME_M>
<PHARMA_REV_M>1.90969165</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.413992989</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25780837</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.874998204E7</REVENUE>
<PREV_YEAR_REV>1.637467255E7</PREV_YEAR_REV>
<BUDGET>1.83749824E7</BUDGET>
<GROSS_PROFIT>1.501649241E7</GROSS_PROFIT>
<EXPENSES>1.667835418E7</EXPENSES>
<NET_INCOME>2071627.87</NET_INCOME>
<REVENUE_M>18.74998204</REVENUE_M>
<PROFIT_M>15.01649241</PROFIT_M>
<INCOME_M>2.07162787</INCOME_M>
<PHARMA_REV_M>18.74998204</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.01649241</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.07162787</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.877828061E7</REVENUE>
<PREV_YEAR_REV>1.653797678E7</PREV_YEAR_REV>
<BUDGET>1.840271501E7</BUDGET>
<GROSS_PROFIT>1.432230232E7</GROSS_PROFIT>
<EXPENSES>1.666307316E7</EXPENSES>
<NET_INCOME>2115207.46</NET_INCOME>
<REVENUE_M>18.77828061</REVENUE_M>
<PROFIT_M>14.32230232</PROFIT_M>
<INCOME_M>2.11520746</INCOME_M>
<PHARMA_REV_M>18.77828061</PHARMA_REV_M>
<PHARMA_PROFIT_M>14.32230232</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.11520746</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7479305.06</REVENUE>
<PREV_YEAR_REV>6684157.66</PREV_YEAR_REV>
<BUDGET>7329718.95</BUDGET>
<GROSS_PROFIT>6559350.53</GROSS_PROFIT>
<EXPENSES>6933315.79</EXPENSES>
<NET_INCOME>545989.27</NET_INCOME>
<REVENUE_M>7.47930506</REVENUE_M>
<PROFIT_M>6.55935053</PROFIT_M>
<INCOME_M>0.54598927</INCOME_M>
<PHARMA_REV_M>7.47930506</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.55935053</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54598927</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6386763.66</REVENUE>
<PREV_YEAR_REV>5677627.93</PREV_YEAR_REV>
<BUDGET>6259028.38</BUDGET>
<GROSS_PROFIT>5377655</GROSS_PROFIT>
<EXPENSES>5243532.96</EXPENSES>
<NET_INCOME>1143230.69</NET_INCOME>
<REVENUE_M>6.38676366</REVENUE_M>
<PROFIT_M>5.377655</PROFIT_M>
<INCOME_M>1.14323069</INCOME_M>
<PHARMA_REV_M>6.38676366</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.377655</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.14323069</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.503362404E7</REVENUE>
<PREV_YEAR_REV>1.329433232E7</PREV_YEAR_REV>
<BUDGET>1.473295156E7</BUDGET>
<GROSS_PROFIT>1.240547577E7</GROSS_PROFIT>
<EXPENSES>1.307669223E7</EXPENSES>
<NET_INCOME>1956931.8</NET_INCOME>
<REVENUE_M>15.03362404</REVENUE_M>
<PROFIT_M>12.40547577</PROFIT_M>
<INCOME_M>1.9569318</INCOME_M>
<PHARMA_REV_M>15.03362404</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.40547577</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.9569318</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1826799.58</REVENUE>
<PREV_YEAR_REV>1613295.99</PREV_YEAR_REV>
<BUDGET>1771995.59</BUDGET>
<GROSS_PROFIT>1485553.418</GROSS_PROFIT>
<EXPENSES>1499802.46</EXPENSES>
<NET_INCOME>326997.13</NET_INCOME>
<REVENUE_M>1.82679958</REVENUE_M>
<PROFIT_M>1.485553418</PROFIT_M>
<INCOME_M>0.32699713</INCOME_M>
<PHARMA_REV_M>1.82679958</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.485553418</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32699713</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3660190.54</REVENUE>
<PREV_YEAR_REV>3191325.87</PREV_YEAR_REV>
<BUDGET>3550384.82</BUDGET>
<GROSS_PROFIT>2752502.733</GROSS_PROFIT>
<EXPENSES>3116596.22</EXPENSES>
<NET_INCOME>543594.32</NET_INCOME>
<REVENUE_M>3.66019054</REVENUE_M>
<PROFIT_M>2.752502733</PROFIT_M>
<INCOME_M>0.54359432</INCOME_M>
<PHARMA_REV_M>3.66019054</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.752502733</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54359432</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3678310.23</REVENUE>
<PREV_YEAR_REV>3201430.81</PREV_YEAR_REV>
<BUDGET>3567960.92</BUDGET>
<GROSS_PROFIT>2908979.991</GROSS_PROFIT>
<EXPENSES>3191440.7</EXPENSES>
<NET_INCOME>486869.53</NET_INCOME>
<REVENUE_M>3.67831023</REVENUE_M>
<PROFIT_M>2.908979991</PROFIT_M>
<INCOME_M>0.48686953</INCOME_M>
<PHARMA_REV_M>3.67831023</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.908979991</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48686953</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1826799.58</REVENUE>
<PREV_YEAR_REV>1565931.12</PREV_YEAR_REV>
<BUDGET>1771995.59</BUDGET>
<GROSS_PROFIT>1360600.327</GROSS_PROFIT>
<EXPENSES>1512590.05</EXPENSES>
<NET_INCOME>314209.53</NET_INCOME>
<REVENUE_M>1.82679958</REVENUE_M>
<PROFIT_M>1.360600327</PROFIT_M>
<INCOME_M>0.31420953</INCOME_M>
<PHARMA_REV_M>1.82679958</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.360600327</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31420953</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1319642.46</REVENUE>
<PREV_YEAR_REV>1131458.32</PREV_YEAR_REV>
<BUDGET>1280053.19</BUDGET>
<GROSS_PROFIT>1097942.53</GROSS_PROFIT>
<EXPENSES>1145449.66</EXPENSES>
<NET_INCOME>174192.81</NET_INCOME>
<REVENUE_M>1.31964246</REVENUE_M>
<PROFIT_M>1.09794253</PROFIT_M>
<INCOME_M>0.17419281</INCOME_M>
<PHARMA_REV_M>1.31964246</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.09794253</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17419281</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3028807.32</REVENUE>
<PREV_YEAR_REV>2630451.71</PREV_YEAR_REV>
<BUDGET>2786155.31</BUDGET>
<GROSS_PROFIT>2554344.651</GROSS_PROFIT>
<EXPENSES>2807704.39</EXPENSES>
<NET_INCOME>221102.93</NET_INCOME>
<REVENUE_M>3.02880732</REVENUE_M>
<PROFIT_M>2.554344651</PROFIT_M>
<INCOME_M>0.22110293</INCOME_M>
<PHARMA_REV_M>3.02880732</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.554344651</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22110293</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2318217.64</REVENUE>
<PREV_YEAR_REV>2011486.12</PREV_YEAR_REV>
<BUDGET>2029052.81</BUDGET>
<GROSS_PROFIT>1684214.093</GROSS_PROFIT>
<EXPENSES>2081759.44</EXPENSES>
<NET_INCOME>236458.2</NET_INCOME>
<REVENUE_M>2.31821764</REVENUE_M>
<PROFIT_M>1.684214093</PROFIT_M>
<INCOME_M>0.2364582</INCOME_M>
<PHARMA_REV_M>2.31821764</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.684214093</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2364582</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3031121.25</REVENUE>
<PREV_YEAR_REV>2576936.23</PREV_YEAR_REV>
<BUDGET>2647581.1</BUDGET>
<GROSS_PROFIT>2320929.534</GROSS_PROFIT>
<EXPENSES>2700729.03</EXPENSES>
<NET_INCOME>330392.22</NET_INCOME>
<REVENUE_M>3.03112125</REVENUE_M>
<PROFIT_M>2.320929534</PROFIT_M>
<INCOME_M>0.33039222</INCOME_M>
<PHARMA_REV_M>3.03112125</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.320929534</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33039222</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2138178.77</REVENUE>
<PREV_YEAR_REV>1883891.14</PREV_YEAR_REV>
<BUDGET>2371390.88</BUDGET>
<GROSS_PROFIT>1493611.946</GROSS_PROFIT>
<EXPENSES>1862353.71</EXPENSES>
<NET_INCOME>275825.06</NET_INCOME>
<REVENUE_M>2.13817877</REVENUE_M>
<PROFIT_M>1.493611946</PROFIT_M>
<INCOME_M>0.27582506</INCOME_M>
<PHARMA_REV_M>2.13817877</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.493611946</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27582506</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4084805.06</REVENUE>
<PREV_YEAR_REV>3583027.24</PREV_YEAR_REV>
<BUDGET>4747505.57</BUDGET>
<GROSS_PROFIT>3131007.381</GROSS_PROFIT>
<EXPENSES>3591395.99</EXPENSES>
<NET_INCOME>493409.08</NET_INCOME>
<REVENUE_M>4.08480506</REVENUE_M>
<PROFIT_M>3.131007381</PROFIT_M>
<INCOME_M>0.49340908</INCOME_M>
<PHARMA_REV_M>4.08480506</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.131007381</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49340908</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4144492.61</REVENUE>
<PREV_YEAR_REV>3746474.65</PREV_YEAR_REV>
<BUDGET>4715767.94</BUDGET>
<GROSS_PROFIT>3370199.41</GROSS_PROFIT>
<EXPENSES>3586326.25</EXPENSES>
<NET_INCOME>558166.36</NET_INCOME>
<REVENUE_M>4.14449261</REVENUE_M>
<PROFIT_M>3.37019941</PROFIT_M>
<INCOME_M>0.55816636</INCOME_M>
<PHARMA_REV_M>4.14449261</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.37019941</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55816636</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4166469.63</REVENUE>
<PREV_YEAR_REV>3665085.3</PREV_YEAR_REV>
<BUDGET>4724233.57</BUDGET>
<GROSS_PROFIT>3557434.408</GROSS_PROFIT>
<EXPENSES>3612161.33</EXPENSES>
<NET_INCOME>554308.3</NET_INCOME>
<REVENUE_M>4.16646963</REVENUE_M>
<PROFIT_M>3.557434408</PROFIT_M>
<INCOME_M>0.5543083</INCOME_M>
<PHARMA_REV_M>4.16646963</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.557434408</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5543083</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4069260.59</REVENUE>
<PREV_YEAR_REV>3634519.02</PREV_YEAR_REV>
<BUDGET>4686993.28</BUDGET>
<GROSS_PROFIT>3369853.357</GROSS_PROFIT>
<EXPENSES>3528417.3</EXPENSES>
<NET_INCOME>540843.3</NET_INCOME>
<REVENUE_M>4.06926059</REVENUE_M>
<PROFIT_M>3.369853357</PROFIT_M>
<INCOME_M>0.5408433</INCOME_M>
<PHARMA_REV_M>4.06926059</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.369853357</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5408433</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2596395.41</REVENUE>
<PREV_YEAR_REV>2235870.35</PREV_YEAR_REV>
<BUDGET>2573159.4</BUDGET>
<GROSS_PROFIT>2047639.728</GROSS_PROFIT>
<EXPENSES>2248633.52</EXPENSES>
<NET_INCOME>347761.9</NET_INCOME>
<REVENUE_M>2.59639541</REVENUE_M>
<PROFIT_M>2.047639728</PROFIT_M>
<INCOME_M>0.3477619</INCOME_M>
<PHARMA_REV_M>2.59639541</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.047639728</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3477619</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9482176.15</REVENUE>
<PREV_YEAR_REV>8490107.13</PREV_YEAR_REV>
<BUDGET>8723602.06</BUDGET>
<GROSS_PROFIT>7373340.171</GROSS_PROFIT>
<EXPENSES>8258975.43</EXPENSES>
<NET_INCOME>1223200.72</NET_INCOME>
<REVENUE_M>9.48217615</REVENUE_M>
<PROFIT_M>7.373340171</PROFIT_M>
<INCOME_M>1.22320072</INCOME_M>
<PHARMA_REV_M>9.48217615</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.373340171</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.22320072</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>2.222186256E7</REVENUE>
<PREV_YEAR_REV>1.892742616E7</PREV_YEAR_REV>
<BUDGET>2.044411355E7</BUDGET>
<GROSS_PROFIT>1.64504896E7</GROSS_PROFIT>
<EXPENSES>1.953418785E7</EXPENSES>
<NET_INCOME>2687674.71</NET_INCOME>
<REVENUE_M>22.22186256</REVENUE_M>
<PROFIT_M>16.4504896</PROFIT_M>
<INCOME_M>2.68767471</INCOME_M>
<PHARMA_REV_M>22.22186256</PHARMA_REV_M>
<PHARMA_PROFIT_M>16.4504896</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.68767471</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.286564316E7</REVENUE>
<PREV_YEAR_REV>1.133726674E7</PREV_YEAR_REV>
<BUDGET>1.183639172E7</BUDGET>
<GROSS_PROFIT>1.061415561E7</GROSS_PROFIT>
<EXPENSES>1.113521416E7</EXPENSES>
<NET_INCOME>1730429</NET_INCOME>
<REVENUE_M>12.86564316</REVENUE_M>
<PROFIT_M>10.61415561</PROFIT_M>
<INCOME_M>1.730429</INCOME_M>
<PHARMA_REV_M>12.86564316</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.61415561</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.730429</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6171803.13</REVENUE>
<PREV_YEAR_REV>5489707.03</PREV_YEAR_REV>
<BUDGET>5678058.88</BUDGET>
<GROSS_PROFIT>4726984.023</GROSS_PROFIT>
<EXPENSES>5338609.71</EXPENSES>
<NET_INCOME>833193.42</NET_INCOME>
<REVENUE_M>6.17180313</REVENUE_M>
<PROFIT_M>4.726984023</PROFIT_M>
<INCOME_M>0.83319342</INCOME_M>
<PHARMA_REV_M>6.17180313</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.726984023</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83319342</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7791864.17</REVENUE>
<PREV_YEAR_REV>6818639.72</PREV_YEAR_REV>
<BUDGET>7168515.04</BUDGET>
<GROSS_PROFIT>5914141.781</GROSS_PROFIT>
<EXPENSES>6739962.51</EXPENSES>
<NET_INCOME>1051901.66</NET_INCOME>
<REVENUE_M>7.79186417</REVENUE_M>
<PROFIT_M>5.914141781</PROFIT_M>
<INCOME_M>1.05190166</INCOME_M>
<PHARMA_REV_M>7.79186417</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.914141781</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.05190166</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7828841.79</REVENUE>
<PREV_YEAR_REV>6726502.55</PREV_YEAR_REV>
<BUDGET>7202534.44</BUDGET>
<GROSS_PROFIT>6550266.663</GROSS_PROFIT>
<EXPENSES>7030299.92</EXPENSES>
<NET_INCOME>798541.86</NET_INCOME>
<REVENUE_M>7.82884179</REVENUE_M>
<PROFIT_M>6.550266663</PROFIT_M>
<INCOME_M>0.79854186</INCOME_M>
<PHARMA_REV_M>7.82884179</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.550266663</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.79854186</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2490221.48</REVENUE>
<PREV_YEAR_REV>2162983.67</PREV_YEAR_REV>
<BUDGET>2415514.83</BUDGET>
<GROSS_PROFIT>2008488.129</GROSS_PROFIT>
<EXPENSES>2091786.04</EXPENSES>
<NET_INCOME>398435.44</NET_INCOME>
<REVENUE_M>2.49022148</REVENUE_M>
<PROFIT_M>2.008488129</PROFIT_M>
<INCOME_M>0.39843544</INCOME_M>
<PHARMA_REV_M>2.49022148</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.008488129</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39843544</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2201361.06</REVENUE>
<PREV_YEAR_REV>1933987.31</PREV_YEAR_REV>
<BUDGET>2135320.23</BUDGET>
<GROSS_PROFIT>1816497.1</GROSS_PROFIT>
<EXPENSES>1910781.4</EXPENSES>
<NET_INCOME>290579.66</NET_INCOME>
<REVENUE_M>2.20136106</REVENUE_M>
<PROFIT_M>1.8164971</PROFIT_M>
<INCOME_M>0.29057966</INCOME_M>
<PHARMA_REV_M>2.20136106</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.8164971</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29057966</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2619412.43</REVENUE>
<PREV_YEAR_REV>2326236.8</PREV_YEAR_REV>
<BUDGET>2540830.05</BUDGET>
<GROSS_PROFIT>1859809.014</GROSS_PROFIT>
<EXPENSES>2281508.22</EXPENSES>
<NET_INCOME>337904.2</NET_INCOME>
<REVENUE_M>2.61941243</REVENUE_M>
<PROFIT_M>1.859809014</PROFIT_M>
<INCOME_M>0.3379042</INCOME_M>
<PHARMA_REV_M>2.61941243</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.859809014</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3379042</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7667061.03</REVENUE>
<PREV_YEAR_REV>6703564.07</PREV_YEAR_REV>
<BUDGET>7437049.21</BUDGET>
<GROSS_PROFIT>6026849.866</GROSS_PROFIT>
<EXPENSES>6924048.41</EXPENSES>
<NET_INCOME>743012.63</NET_INCOME>
<REVENUE_M>7.66706103</REVENUE_M>
<PROFIT_M>6.026849866</PROFIT_M>
<INCOME_M>0.74301263</INCOME_M>
<PHARMA_REV_M>7.66706103</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.026849866</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74301263</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2623367.25</REVENUE>
<PREV_YEAR_REV>2339117.67</PREV_YEAR_REV>
<BUDGET>2544666.23</BUDGET>
<GROSS_PROFIT>1981298.112</GROSS_PROFIT>
<EXPENSES>2431861.44</EXPENSES>
<NET_INCOME>191505.81</NET_INCOME>
<REVENUE_M>2.62336725</REVENUE_M>
<PROFIT_M>1.981298112</PROFIT_M>
<INCOME_M>0.19150581</INCOME_M>
<PHARMA_REV_M>2.62336725</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.981298112</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19150581</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5190048.68</REVENUE>
<PREV_YEAR_REV>4534959.78</PREV_YEAR_REV>
<BUDGET>5034347.21</BUDGET>
<GROSS_PROFIT>3765096.603</GROSS_PROFIT>
<EXPENSES>4419315.24</EXPENSES>
<NET_INCOME>770733.44</NET_INCOME>
<REVENUE_M>5.19004868</REVENUE_M>
<PROFIT_M>3.765096603</PROFIT_M>
<INCOME_M>0.77073344</INCOME_M>
<PHARMA_REV_M>5.19004868</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.765096603</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.77073344</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1969063.43</REVENUE>
<PREV_YEAR_REV>1669405.19</PREV_YEAR_REV>
<BUDGET>1909991.52</BUDGET>
<GROSS_PROFIT>1425217.955</GROSS_PROFIT>
<EXPENSES>1768218.96</EXPENSES>
<NET_INCOME>200844.47</NET_INCOME>
<REVENUE_M>1.96906343</REVENUE_M>
<PROFIT_M>1.425217955</PROFIT_M>
<INCOME_M>0.20084447</INCOME_M>
<PHARMA_REV_M>1.96906343</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.425217955</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20084447</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2569304.79</REVENUE>
<PREV_YEAR_REV>2192857.03</PREV_YEAR_REV>
<BUDGET>2492225.65</BUDGET>
<GROSS_PROFIT>2018574.307</GROSS_PROFIT>
<EXPENSES>2289250.57</EXPENSES>
<NET_INCOME>280054.22</NET_INCOME>
<REVENUE_M>2.56930479</REVENUE_M>
<PROFIT_M>2.018574307</PROFIT_M>
<INCOME_M>0.28005422</INCOME_M>
<PHARMA_REV_M>2.56930479</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.018574307</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28005422</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5298147.23</REVENUE>
<PREV_YEAR_REV>4691727.1</PREV_YEAR_REV>
<BUDGET>5139202.8</BUDGET>
<GROSS_PROFIT>4517489.691</GROSS_PROFIT>
<EXPENSES>4598385.76</EXPENSES>
<NET_INCOME>699761.47</NET_INCOME>
<REVENUE_M>5.29814723</REVENUE_M>
<PROFIT_M>4.517489691</PROFIT_M>
<INCOME_M>0.69976147</INCOME_M>
<PHARMA_REV_M>5.29814723</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.517489691</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69976147</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2678734.8</REVENUE>
<PREV_YEAR_REV>2334877.4</PREV_YEAR_REV>
<BUDGET>2598372.76</BUDGET>
<GROSS_PROFIT>2236636.409</GROSS_PROFIT>
<EXPENSES>2386752.71</EXPENSES>
<NET_INCOME>291982.09</NET_INCOME>
<REVENUE_M>2.6787348</REVENUE_M>
<PROFIT_M>2.236636409</PROFIT_M>
<INCOME_M>0.29198209</INCOME_M>
<PHARMA_REV_M>2.6787348</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.236636409</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29198209</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1510193.87</REVENUE>
<PREV_YEAR_REV>1339655.7</PREV_YEAR_REV>
<BUDGET>1464888.05</BUDGET>
<GROSS_PROFIT>1228391.692</GROSS_PROFIT>
<EXPENSES>1268562.85</EXPENSES>
<NET_INCOME>241631.02</NET_INCOME>
<REVENUE_M>1.51019387</REVENUE_M>
<PROFIT_M>1.228391692</PROFIT_M>
<INCOME_M>0.24163102</INCOME_M>
<PHARMA_REV_M>1.51019387</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.228391692</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24163102</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1846375.97</REVENUE>
<PREV_YEAR_REV>1625588.53</PREV_YEAR_REV>
<BUDGET>1790984.69</BUDGET>
<GROSS_PROFIT>1583267.391</GROSS_PROFIT>
<EXPENSES>1602654.34</EXPENSES>
<NET_INCOME>243721.63</NET_INCOME>
<REVENUE_M>1.84637597</REVENUE_M>
<PROFIT_M>1.583267391</PROFIT_M>
<INCOME_M>0.24372163</INCOME_M>
<PHARMA_REV_M>1.84637597</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.583267391</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24372163</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3722142.87</REVENUE>
<PREV_YEAR_REV>3220040.19</PREV_YEAR_REV>
<BUDGET>3610478.58</BUDGET>
<GROSS_PROFIT>2587153.965</GROSS_PROFIT>
<EXPENSES>3272203.08</EXPENSES>
<NET_INCOME>449939.79</NET_INCOME>
<REVENUE_M>3.72214287</REVENUE_M>
<PROFIT_M>2.587153965</PROFIT_M>
<INCOME_M>0.44993979</INCOME_M>
<PHARMA_REV_M>3.72214287</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.587153965</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44993979</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3671718.85</REVENUE>
<PREV_YEAR_REV>3197058.53</PREV_YEAR_REV>
<BUDGET>3561567.28</BUDGET>
<GROSS_PROFIT>3004904.93</GROSS_PROFIT>
<EXPENSES>3177773.01</EXPENSES>
<NET_INCOME>493945.85</NET_INCOME>
<REVENUE_M>3.67171885</REVENUE_M>
<PROFIT_M>3.00490493</PROFIT_M>
<INCOME_M>0.49394585</INCOME_M>
<PHARMA_REV_M>3.67171885</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.00490493</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49394585</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4789910.09</REVENUE>
<PREV_YEAR_REV>4250620.77</PREV_YEAR_REV>
<BUDGET>6267627.97</BUDGET>
<GROSS_PROFIT>3781467.096</GROSS_PROFIT>
<EXPENSES>4325555.19</EXPENSES>
<NET_INCOME>464354.9</NET_INCOME>
<REVENUE_M>4.78991009</REVENUE_M>
<PROFIT_M>3.781467096</PROFIT_M>
<INCOME_M>0.4643549</INCOME_M>
<PHARMA_REV_M>4.78991009</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.781467096</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4643549</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1581889.57</REVENUE>
<PREV_YEAR_REV>1354775.07</PREV_YEAR_REV>
<BUDGET>2082054.09</BUDGET>
<GROSS_PROFIT>1390480.93</GROSS_PROFIT>
<EXPENSES>1466411.63</EXPENSES>
<NET_INCOME>115477.94</NET_INCOME>
<REVENUE_M>1.58188957</REVENUE_M>
<PROFIT_M>1.39048093</PROFIT_M>
<INCOME_M>0.11547794</INCOME_M>
<PHARMA_REV_M>1.58188957</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.39048093</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11547794</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1657729.19</REVENUE>
<PREV_YEAR_REV>1426359.42</PREV_YEAR_REV>
<BUDGET>2067411.62</BUDGET>
<GROSS_PROFIT>1296344.22</GROSS_PROFIT>
<EXPENSES>1360995.66</EXPENSES>
<NET_INCOME>296733.52</NET_INCOME>
<REVENUE_M>1.65772919</REVENUE_M>
<PROFIT_M>1.29634422</PROFIT_M>
<INCOME_M>0.29673352</INCOME_M>
<PHARMA_REV_M>1.65772919</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.29634422</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29673352</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1553362.85</REVENUE>
<PREV_YEAR_REV>1338206.08</PREV_YEAR_REV>
<BUDGET>2080411.46</BUDGET>
<GROSS_PROFIT>1163186.063</GROSS_PROFIT>
<EXPENSES>1343658.87</EXPENSES>
<NET_INCOME>209703.98</NET_INCOME>
<REVENUE_M>1.55336285</REVENUE_M>
<PROFIT_M>1.163186063</PROFIT_M>
<INCOME_M>0.20970398</INCOME_M>
<PHARMA_REV_M>1.55336285</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.163186063</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20970398</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3122062.72</REVENUE>
<PREV_YEAR_REV>2726307.45</PREV_YEAR_REV>
<BUDGET>4115126.53</BUDGET>
<GROSS_PROFIT>2443829.248</GROSS_PROFIT>
<EXPENSES>2708490.2</EXPENSES>
<NET_INCOME>413572.52</NET_INCOME>
<REVENUE_M>3.12206272</REVENUE_M>
<PROFIT_M>2.443829248</PROFIT_M>
<INCOME_M>0.41357252</INCOME_M>
<PHARMA_REV_M>3.12206272</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.443829248</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41357252</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>958912.05</REVENUE>
<PREV_YEAR_REV>823107.54</PREV_YEAR_REV>
<BUDGET>1133645.73</BUDGET>
<GROSS_PROFIT>800739.5055</GROSS_PROFIT>
<EXPENSES>861103.02</EXPENSES>
<NET_INCOME>97809.03</NET_INCOME>
<REVENUE_M>0.95891205</REVENUE_M>
<PROFIT_M>0.800739506</PROFIT_M>
<INCOME_M>0.09780903</INCOME_M>
<PHARMA_REV_M>0.95891205</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.800739506</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.09780903</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1283414.17</REVENUE>
<PREV_YEAR_REV>1108647.05</PREV_YEAR_REV>
<BUDGET>1475785.97</BUDGET>
<GROSS_PROFIT>1070495.758</GROSS_PROFIT>
<EXPENSES>1062666.94</EXPENSES>
<NET_INCOME>220747.24</NET_INCOME>
<REVENUE_M>1.28341417</REVENUE_M>
<PROFIT_M>1.070495758</PROFIT_M>
<INCOME_M>0.22074724</INCOME_M>
<PHARMA_REV_M>1.28341417</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.070495758</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22074724</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.213183934E7</REVENUE>
<PREV_YEAR_REV>1.066272331E7</PREV_YEAR_REV>
<BUDGET>1.176788415E7</BUDGET>
<GROSS_PROFIT>8746652.412</GROSS_PROFIT>
<EXPENSES>1.066684187E7</EXPENSES>
<NET_INCOME>1464997.46</NET_INCOME>
<REVENUE_M>12.13183934</REVENUE_M>
<PROFIT_M>8.746652412</PROFIT_M>
<INCOME_M>1.46499746</INCOME_M>
<PHARMA_REV_M>12.13183934</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.746652412</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.46499746</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6147285.29</REVENUE>
<PREV_YEAR_REV>5383618.94</PREV_YEAR_REV>
<BUDGET>5962866.73</BUDGET>
<GROSS_PROFIT>4899386.38</GROSS_PROFIT>
<EXPENSES>5046921.22</EXPENSES>
<NET_INCOME>1100364.07</NET_INCOME>
<REVENUE_M>6.14728529</REVENUE_M>
<PROFIT_M>4.89938638</PROFIT_M>
<INCOME_M>1.10036407</INCOME_M>
<PHARMA_REV_M>6.14728529</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.89938638</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.10036407</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.279097895E7</REVENUE>
<PREV_YEAR_REV>1.12572572E7</PREV_YEAR_REV>
<BUDGET>1.240724958E7</BUDGET>
<GROSS_PROFIT>1.024398274E7</GROSS_PROFIT>
<EXPENSES>1.107438255E7</EXPENSES>
<NET_INCOME>1716596.39</NET_INCOME>
<REVENUE_M>12.79097895</REVENUE_M>
<PROFIT_M>10.24398274</PROFIT_M>
<INCOME_M>1.71659639</INCOME_M>
<PHARMA_REV_M>12.79097895</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.24398274</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.71659639</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6139709.25</REVENUE>
<PREV_YEAR_REV>5214810.46</PREV_YEAR_REV>
<BUDGET>5955517.97</BUDGET>
<GROSS_PROFIT>5041499.456</GROSS_PROFIT>
<EXPENSES>5040701.29</EXPENSES>
<NET_INCOME>1099007.96</NET_INCOME>
<REVENUE_M>6.13970925</REVENUE_M>
<PROFIT_M>5.041499456</PROFIT_M>
<INCOME_M>1.09900796</INCOME_M>
<PHARMA_REV_M>6.13970925</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.041499456</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.09900796</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.209626148E7</REVENUE>
<PREV_YEAR_REV>1.088562521E7</PREV_YEAR_REV>
<BUDGET>1.173337364E7</BUDGET>
<GROSS_PROFIT>1.000098712E7</GROSS_PROFIT>
<EXPENSES>1.049961584E7</EXPENSES>
<NET_INCOME>1596645.65</NET_INCOME>
<REVENUE_M>12.09626148</REVENUE_M>
<PROFIT_M>10.00098712</PROFIT_M>
<INCOME_M>1.59664565</INCOME_M>
<PHARMA_REV_M>12.09626148</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.00098712</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.59664565</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5439418.37</REVENUE>
<PREV_YEAR_REV>4795117.3</PREV_YEAR_REV>
<BUDGET>4127700.06</BUDGET>
<GROSS_PROFIT>4309758.603</GROSS_PROFIT>
<EXPENSES>4839091.85</EXPENSES>
<NET_INCOME>600326.51</NET_INCOME>
<REVENUE_M>5.43941837</REVENUE_M>
<PROFIT_M>4.309758603</PROFIT_M>
<INCOME_M>0.60032651</INCOME_M>
<PHARMA_REV_M>5.43941837</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.309758603</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60032651</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3238601.59</REVENUE>
<PREV_YEAR_REV>2849802.97</PREV_YEAR_REV>
<BUDGET>2446864.2</BUDGET>
<GROSS_PROFIT>2461337.207</GROSS_PROFIT>
<EXPENSES>3002183.67</EXPENSES>
<NET_INCOME>236417.92</NET_INCOME>
<REVENUE_M>3.23860159</REVENUE_M>
<PROFIT_M>2.461337207</PROFIT_M>
<INCOME_M>0.23641792</INCOME_M>
<PHARMA_REV_M>3.23860159</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.461337207</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23641792</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>9552352.05</REVENUE>
<PREV_YEAR_REV>8583764.9</PREV_YEAR_REV>
<BUDGET>7294225.14</BUDGET>
<GROSS_PROFIT>7903961.414</GROSS_PROFIT>
<EXPENSES>8626390.45</EXPENSES>
<NET_INCOME>925961.6</NET_INCOME>
<REVENUE_M>9.55235205</REVENUE_M>
<PROFIT_M>7.903961414</PROFIT_M>
<INCOME_M>0.9259616</INCOME_M>
<PHARMA_REV_M>9.55235205</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.903961414</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.9259616</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>6226376</REVENUE>
<PREV_YEAR_REV>5613548.33</PREV_YEAR_REV>
<BUDGET>4828302.45</BUDGET>
<GROSS_PROFIT>5146022.777</GROSS_PROFIT>
<EXPENSES>5387822.91</EXPENSES>
<NET_INCOME>838553.09</NET_INCOME>
<REVENUE_M>6.226376</REVENUE_M>
<PROFIT_M>5.146022777</PROFIT_M>
<INCOME_M>0.83855309</INCOME_M>
<PHARMA_REV_M>6.226376</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.146022777</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83855309</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2864376.1</REVENUE>
<PREV_YEAR_REV>2434209.56</PREV_YEAR_REV>
<BUDGET>2778444.81</BUDGET>
<GROSS_PROFIT>2253390.272</GROSS_PROFIT>
<EXPENSES>2482038.01</EXPENSES>
<NET_INCOME>382338.09</NET_INCOME>
<REVENUE_M>2.8643761</REVENUE_M>
<PROFIT_M>2.253390272</PROFIT_M>
<INCOME_M>0.38233809</INCOME_M>
<PHARMA_REV_M>2.8643761</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.253390272</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38233809</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1431440.96</REVENUE>
<PREV_YEAR_REV>1248019.53</PREV_YEAR_REV>
<BUDGET>1388497.73</BUDGET>
<GROSS_PROFIT>1130838.36</GROSS_PROFIT>
<EXPENSES>1275413.89</EXPENSES>
<NET_INCOME>156027.06</NET_INCOME>
<REVENUE_M>1.43144096</REVENUE_M>
<PROFIT_M>1.13083836</PROFIT_M>
<INCOME_M>0.15602706</INCOME_M>
<PHARMA_REV_M>1.43144096</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.13083836</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15602706</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8945525.13</REVENUE>
<PREV_YEAR_REV>7308077.32</PREV_YEAR_REV>
<BUDGET>8498248.87</BUDGET>
<GROSS_PROFIT>7648423.98</GROSS_PROFIT>
<EXPENSES>7344276.13</EXPENSES>
<NET_INCOME>1601249</NET_INCOME>
<REVENUE_M>8.94552513</REVENUE_M>
<PROFIT_M>7.64842398</PROFIT_M>
<INCOME_M>1.601249</INCOME_M>
<PHARMA_REV_M>8.94552513</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.64842398</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.601249</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>2.032701925E7</REVENUE>
<PREV_YEAR_REV>1.675696076E7</PREV_YEAR_REV>
<BUDGET>1.931066828E7</BUDGET>
<GROSS_PROFIT>1.727810971E7</GROSS_PROFIT>
<EXPENSES>1.763319943E7</EXPENSES>
<NET_INCOME>2693819.82</NET_INCOME>
<REVENUE_M>20.32701925</REVENUE_M>
<PROFIT_M>17.27810971</PROFIT_M>
<INCOME_M>2.69381982</INCOME_M>
<PHARMA_REV_M>20.32701925</PHARMA_REV_M>
<PHARMA_PROFIT_M>17.27810971</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.69381982</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>7249043.84</REVENUE>
<PREV_YEAR_REV>6023076.99</PREV_YEAR_REV>
<BUDGET>7083487.5</BUDGET>
<GROSS_PROFIT>6369536.276</GROSS_PROFIT>
<EXPENSES>6465235.85</EXPENSES>
<NET_INCOME>983808</NET_INCOME>
<REVENUE_M>7.24904384</REVENUE_M>
<PROFIT_M>6.369536276</PROFIT_M>
<INCOME_M>0.983808</INCOME_M>
<PHARMA_REV_M>7.24904384</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.369536276</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.983808</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3757334.42</REVENUE>
<PREV_YEAR_REV>3094876.18</PREV_YEAR_REV>
<BUDGET>3572587.5</BUDGET>
<GROSS_PROFIT>3039151.887</GROSS_PROFIT>
<EXPENSES>3111072.9</EXPENSES>
<NET_INCOME>646261.52</NET_INCOME>
<REVENUE_M>3.75733442</REVENUE_M>
<PROFIT_M>3.039151887</PROFIT_M>
<INCOME_M>0.64626152</INCOME_M>
<PHARMA_REV_M>3.75733442</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.039151887</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.64626152</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5119356.34</REVENUE>
<PREV_YEAR_REV>4305098.62</PREV_YEAR_REV>
<BUDGET>4893581.26</BUDGET>
<GROSS_PROFIT>4086926.731</GROSS_PROFIT>
<EXPENSES>4553540.91</EXPENSES>
<NET_INCOME>565815.44</NET_INCOME>
<REVENUE_M>5.11935634</REVENUE_M>
<PROFIT_M>4.086926731</PROFIT_M>
<INCOME_M>0.56581544</INCOME_M>
<PHARMA_REV_M>5.11935634</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.086926731</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56581544</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2653896.92</REVENUE>
<PREV_YEAR_REV>2246856.42</PREV_YEAR_REV>
<BUDGET>2535356.25</BUDGET>
<GROSS_PROFIT>2189464.96</GROSS_PROFIT>
<EXPENSES>2229273.42</EXPENSES>
<NET_INCOME>424623.51</NET_INCOME>
<REVENUE_M>2.65389692</REVENUE_M>
<PROFIT_M>2.18946496</PROFIT_M>
<INCOME_M>0.42462351</INCOME_M>
<PHARMA_REV_M>2.65389692</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.18946496</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42462351</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2552637.55</REVENUE>
<PREV_YEAR_REV>1987679.43</PREV_YEAR_REV>
<BUDGET>2440172.44</BUDGET>
<GROSS_PROFIT>2210584.12</GROSS_PROFIT>
<EXPENSES>2144215.54</EXPENSES>
<NET_INCOME>408422.01</NET_INCOME>
<REVENUE_M>2.55263755</REVENUE_M>
<PROFIT_M>2.21058412</PROFIT_M>
<INCOME_M>0.40842201</INCOME_M>
<PHARMA_REV_M>2.55263755</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.21058412</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40842201</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>8409021.08</REVENUE>
<PREV_YEAR_REV>6763834.55</PREV_YEAR_REV>
<BUDGET>8324930.87</BUDGET>
<GROSS_PROFIT>6737154.338</GROSS_PROFIT>
<EXPENSES>7594993.66</EXPENSES>
<NET_INCOME>814027.42</NET_INCOME>
<REVENUE_M>8.40902108</REVENUE_M>
<PROFIT_M>6.737154338</PROFIT_M>
<INCOME_M>0.81402742</INCOME_M>
<PHARMA_REV_M>8.40902108</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.737154338</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.81402742</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1985350.5</REVENUE>
<PREV_YEAR_REV>1635298.5</PREV_YEAR_REV>
<BUDGET>1965497</BUDGET>
<GROSS_PROFIT>1503982.421</GROSS_PROFIT>
<EXPENSES>1723284.23</EXPENSES>
<NET_INCOME>262066.27</NET_INCOME>
<REVENUE_M>1.9853505</REVENUE_M>
<PROFIT_M>1.503982421</PROFIT_M>
<INCOME_M>0.26206627</INCOME_M>
<PHARMA_REV_M>1.9853505</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.503982421</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26206627</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3985648.54</REVENUE>
<PREV_YEAR_REV>3208678.62</PREV_YEAR_REV>
<BUDGET>3945792.05</BUDGET>
<GROSS_PROFIT>3034901.265</GROSS_PROFIT>
<EXPENSES>3545478.46</EXPENSES>
<NET_INCOME>440170.08</NET_INCOME>
<REVENUE_M>3.98564854</REVENUE_M>
<PROFIT_M>3.034901265</PROFIT_M>
<INCOME_M>0.44017008</INCOME_M>
<PHARMA_REV_M>3.98564854</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.034901265</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44017008</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1964300.63</REVENUE>
<PREV_YEAR_REV>1653535.22</PREV_YEAR_REV>
<BUDGET>1944657.62</BUDGET>
<GROSS_PROFIT>1534236.648</GROSS_PROFIT>
<EXPENSES>1612690.81</EXPENSES>
<NET_INCOME>351609.81</NET_INCOME>
<REVENUE_M>1.96430063</REVENUE_M>
<PROFIT_M>1.534236648</PROFIT_M>
<INCOME_M>0.35160981</INCOME_M>
<PHARMA_REV_M>1.96430063</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.534236648</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35160981</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1964300.63</REVENUE>
<PREV_YEAR_REV>1605201.09</PREV_YEAR_REV>
<BUDGET>1944657.62</BUDGET>
<GROSS_PROFIT>1653941.13</GROSS_PROFIT>
<EXPENSES>1612690.81</EXPENSES>
<NET_INCOME>351609.81</NET_INCOME>
<REVENUE_M>1.96430063</REVENUE_M>
<PROFIT_M>1.65394113</PROFIT_M>
<INCOME_M>0.35160981</INCOME_M>
<PHARMA_REV_M>1.96430063</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.65394113</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35160981</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1964300.63</REVENUE>
<PREV_YEAR_REV>1663590.08</PREV_YEAR_REV>
<BUDGET>1944657.62</BUDGET>
<GROSS_PROFIT>1593637.094</GROSS_PROFIT>
<EXPENSES>1612690.81</EXPENSES>
<NET_INCOME>351609.81</NET_INCOME>
<REVENUE_M>1.96430063</REVENUE_M>
<PROFIT_M>1.593637094</PROFIT_M>
<INCOME_M>0.35160981</INCOME_M>
<PHARMA_REV_M>1.96430063</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.593637094</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35160981</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1964300.63</REVENUE>
<PREV_YEAR_REV>1562838.64</PREV_YEAR_REV>
<BUDGET>1944657.62</BUDGET>
<GROSS_PROFIT>1554449.298</GROSS_PROFIT>
<EXPENSES>1763941.96</EXPENSES>
<NET_INCOME>200358.66</NET_INCOME>
<REVENUE_M>1.96430063</REVENUE_M>
<PROFIT_M>1.554449298</PROFIT_M>
<INCOME_M>0.20035866</INCOME_M>
<PHARMA_REV_M>1.96430063</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.554449298</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20035866</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3955172.29</REVENUE>
<PREV_YEAR_REV>3178980.27</PREV_YEAR_REV>
<BUDGET>3915620.57</BUDGET>
<GROSS_PROFIT>3084179.021</GROSS_PROFIT>
<EXPENSES>3431656.67</EXPENSES>
<NET_INCOME>523515.63</NET_INCOME>
<REVENUE_M>3.95517229</REVENUE_M>
<PROFIT_M>3.084179021</PROFIT_M>
<INCOME_M>0.52351563</INCOME_M>
<PHARMA_REV_M>3.95517229</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.084179021</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52351563</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3923994.38</REVENUE>
<PREV_YEAR_REV>3122062.72</PREV_YEAR_REV>
<BUDGET>3884754.43</BUDGET>
<GROSS_PROFIT>3011839.255</GROSS_PROFIT>
<EXPENSES>3403970.68</EXPENSES>
<NET_INCOME>520023.7</NET_INCOME>
<REVENUE_M>3.92399438</REVENUE_M>
<PROFIT_M>3.011839255</PROFIT_M>
<INCOME_M>0.5200237</INCOME_M>
<PHARMA_REV_M>3.92399438</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.011839255</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5200237</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1997257.5</REVENUE>
<PREV_YEAR_REV>1567017.25</PREV_YEAR_REV>
<BUDGET>1977284.93</BUDGET>
<GROSS_PROFIT>1355498.72</GROSS_PROFIT>
<EXPENSES>1653729.21</EXPENSES>
<NET_INCOME>343528.29</NET_INCOME>
<REVENUE_M>1.9972575</REVENUE_M>
<PROFIT_M>1.35549872</PROFIT_M>
<INCOME_M>0.34352829</INCOME_M>
<PHARMA_REV_M>1.9972575</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.35549872</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34352829</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2857238.56</REVENUE>
<PREV_YEAR_REV>2299542.79</PREV_YEAR_REV>
<BUDGET>2828666.17</BUDGET>
<GROSS_PROFIT>2150050.26</GROSS_PROFIT>
<EXPENSES>2541044.8</EXPENSES>
<NET_INCOME>316193.76</NET_INCOME>
<REVENUE_M>2.85723856</REVENUE_M>
<PROFIT_M>2.15005026</PROFIT_M>
<INCOME_M>0.31619376</INCOME_M>
<PHARMA_REV_M>2.85723856</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.15005026</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31619376</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1616176.8</REVENUE>
<PREV_YEAR_REV>1307861.52</PREV_YEAR_REV>
<BUDGET>1600015.03</BUDGET>
<GROSS_PROFIT>1165344.281</GROSS_PROFIT>
<EXPENSES>1498195.89</EXPENSES>
<NET_INCOME>117980.91</NET_INCOME>
<REVENUE_M>1.6161768</REVENUE_M>
<PROFIT_M>1.165344281</PROFIT_M>
<INCOME_M>0.11798091</INCOME_M>
<PHARMA_REV_M>1.6161768</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.165344281</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11798091</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1455300</REVENUE>
<PREV_YEAR_REV>1164612.68</PREV_YEAR_REV>
<BUDGET>1440747</BUDGET>
<GROSS_PROFIT>1075321.17</GROSS_PROFIT>
<EXPENSES>1258834.5</EXPENSES>
<NET_INCOME>196465.5</NET_INCOME>
<REVENUE_M>1.4553</REVENUE_M>
<PROFIT_M>1.07532117</PROFIT_M>
<INCOME_M>0.1964655</INCOME_M>
<PHARMA_REV_M>1.4553</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.07532117</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1964655</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1239537.66</REVENUE>
<PREV_YEAR_REV>958912.05</PREV_YEAR_REV>
<BUDGET>1227142.28</BUDGET>
<GROSS_PROFIT>984440.806</GROSS_PROFIT>
<EXPENSES>1113104.82</EXPENSES>
<NET_INCOME>126432.84</NET_INCOME>
<REVENUE_M>1.23953766</REVENUE_M>
<PROFIT_M>0.984440806</PROFIT_M>
<INCOME_M>0.12643284</INCOME_M>
<PHARMA_REV_M>1.23953766</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.984440806</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12643284</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.560143464E7</REVENUE>
<PREV_YEAR_REV>1.213183934E7</PREV_YEAR_REV>
<BUDGET>1.544542029E7</BUDGET>
<GROSS_PROFIT>1.135276479E7</GROSS_PROFIT>
<EXPENSES>1.371392772E7</EXPENSES>
<NET_INCOME>1887506.91</NET_INCOME>
<REVENUE_M>15.60143464</REVENUE_M>
<PROFIT_M>11.35276479</PROFIT_M>
<INCOME_M>1.88750691</INCOME_M>
<PHARMA_REV_M>15.60143464</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.35276479</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.88750691</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>2.046231429E7</REVENUE>
<PREV_YEAR_REV>1.658615585E7</PREV_YEAR_REV>
<BUDGET>2.025769116E7</BUDGET>
<GROSS_PROFIT>1.628375969E7</GROSS_PROFIT>
<EXPENSES>1.816687216E7</EXPENSES>
<NET_INCOME>2295442.13</NET_INCOME>
<REVENUE_M>20.46231429</REVENUE_M>
<PROFIT_M>16.28375969</PROFIT_M>
<INCOME_M>2.29544213</INCOME_M>
<PHARMA_REV_M>20.46231429</PHARMA_REV_M>
<PHARMA_PROFIT_M>16.28375969</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.29544213</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.673878544E7</REVENUE>
<PREV_YEAR_REV>1.348365271E7</PREV_YEAR_REV>
<BUDGET>1.657139759E7</BUDGET>
<GROSS_PROFIT>1.240798262E7</GROSS_PROFIT>
<EXPENSES>1.424136055E7</EXPENSES>
<NET_INCOME>2497424.9</NET_INCOME>
<REVENUE_M>16.73878544</REVENUE_M>
<PROFIT_M>12.40798262</PROFIT_M>
<INCOME_M>2.4974249</INCOME_M>
<PHARMA_REV_M>16.73878544</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.40798262</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.4974249</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7311330.22</REVENUE>
<PREV_YEAR_REV>5702620.87</PREV_YEAR_REV>
<BUDGET>7238216.92</BUDGET>
<GROSS_PROFIT>5966045.46</GROSS_PROFIT>
<EXPENSES>6777603.12</EXPENSES>
<NET_INCOME>533727.11</NET_INCOME>
<REVENUE_M>7.31133022</REVENUE_M>
<PROFIT_M>5.96604546</PROFIT_M>
<INCOME_M>0.53372711</INCOME_M>
<PHARMA_REV_M>7.31133022</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.96604546</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53372711</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.050361616E7</REVENUE>
<PREV_YEAR_REV>8582297.27</PREV_YEAR_REV>
<BUDGET>10398580</BUDGET>
<GROSS_PROFIT>8451734.746</GROSS_PROFIT>
<EXPENSES>9432247.31</EXPENSES>
<NET_INCOME>1071368.85</NET_INCOME>
<REVENUE_M>10.50361616</REVENUE_M>
<PROFIT_M>8.451734746</PROFIT_M>
<INCOME_M>1.07136885</INCOME_M>
<PHARMA_REV_M>10.50361616</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.451734746</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.07136885</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.414346253E7</REVENUE>
<PREV_YEAR_REV>1.130518945E7</PREV_YEAR_REV>
<BUDGET>1.400202791E7</BUDGET>
<GROSS_PROFIT>1.175441205E7</GROSS_PROFIT>
<EXPENSES>12275422</EXPENSES>
<NET_INCOME>1868040.53</NET_INCOME>
<REVENUE_M>14.14346253</REVENUE_M>
<PROFIT_M>11.75441205</PROFIT_M>
<INCOME_M>1.86804053</INCOME_M>
<PHARMA_REV_M>14.14346253</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.75441205</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.86804053</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7536776.83</REVENUE>
<PREV_YEAR_REV>5837846.69</PREV_YEAR_REV>
<BUDGET>7461409.07</BUDGET>
<GROSS_PROFIT>5521442.706</GROSS_PROFIT>
<EXPENSES>6519311.96</EXPENSES>
<NET_INCOME>1017464.87</NET_INCOME>
<REVENUE_M>7.53677683</REVENUE_M>
<PROFIT_M>5.521442706</PROFIT_M>
<INCOME_M>1.01746487</INCOME_M>
<PHARMA_REV_M>7.53677683</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.521442706</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.01746487</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.510363327E7</REVENUE>
<PREV_YEAR_REV>1.209626148E7</PREV_YEAR_REV>
<BUDGET>1.495259694E7</BUDGET>
<GROSS_PROFIT>1.242276669E7</GROSS_PROFIT>
<EXPENSES>1.310233354E7</EXPENSES>
<NET_INCOME>2001299.73</NET_INCOME>
<REVENUE_M>15.10363327</REVENUE_M>
<PROFIT_M>12.42276669</PROFIT_M>
<INCOME_M>2.00129973</INCOME_M>
<PHARMA_REV_M>15.10363327</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.42276669</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.00129973</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7537620.5</REVENUE>
<PREV_YEAR_REV>6132534.25</PREV_YEAR_REV>
<BUDGET>7462244.3</BUDGET>
<GROSS_PROFIT>5699948.624</GROSS_PROFIT>
<EXPENSES>6241149.77</EXPENSES>
<NET_INCOME>1296470.73</NET_INCOME>
<REVENUE_M>7.5376205</REVENUE_M>
<PROFIT_M>5.699948624</PROFIT_M>
<INCOME_M>1.29647073</INCOME_M>
<PHARMA_REV_M>7.5376205</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.699948624</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.29647073</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7545873.39</REVENUE>
<PREV_YEAR_REV>5997594.39</PREV_YEAR_REV>
<BUDGET>7470414.65</BUDGET>
<GROSS_PROFIT>5938602.36</GROSS_PROFIT>
<EXPENSES>6723373.19</EXPENSES>
<NET_INCOME>822500.2</NET_INCOME>
<REVENUE_M>7.54587339</REVENUE_M>
<PROFIT_M>5.93860236</PROFIT_M>
<INCOME_M>0.8225002</INCOME_M>
<PHARMA_REV_M>7.54587339</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.93860236</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.8225002</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3885035.13</REVENUE>
<PREV_YEAR_REV>3177163.17</PREV_YEAR_REV>
<BUDGET>3690783.37</BUDGET>
<GROSS_PROFIT>2757015.173</GROSS_PROFIT>
<EXPENSES>3383865.59</EXPENSES>
<NET_INCOME>501169.53</NET_INCOME>
<REVENUE_M>3.88503513</REVENUE_M>
<PROFIT_M>2.757015173</PROFIT_M>
<INCOME_M>0.50116953</INCOME_M>
<PHARMA_REV_M>3.88503513</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.757015173</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50116953</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3324802</REVENUE>
<PREV_YEAR_REV>2678375.96</PREV_YEAR_REV>
<BUDGET>3158561.9</BUDGET>
<GROSS_PROFIT>2673007.814</GROSS_PROFIT>
<EXPENSES>2792833.68</EXPENSES>
<NET_INCOME>531968.32</NET_INCOME>
<REVENUE_M>3.324802</REVENUE_M>
<PROFIT_M>2.673007814</PROFIT_M>
<INCOME_M>0.53196832</INCOME_M>
<PHARMA_REV_M>3.324802</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.673007814</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53196832</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3991364.5</REVENUE>
<PREV_YEAR_REV>3305943.28</PREV_YEAR_REV>
<BUDGET>3791796.28</BUDGET>
<GROSS_PROFIT>3269366.576</GROSS_PROFIT>
<EXPENSES>3699994.89</EXPENSES>
<NET_INCOME>291369.61</NET_INCOME>
<REVENUE_M>3.9913645</REVENUE_M>
<PROFIT_M>3.269366576</PROFIT_M>
<INCOME_M>0.29136961</INCOME_M>
<PHARMA_REV_M>3.9913645</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.269366576</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29136961</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>7842666.5</REVENUE>
<PREV_YEAR_REV>6296217.05</PREV_YEAR_REV>
<BUDGET>7450533.18</BUDGET>
<GROSS_PROFIT>6474857.076</GROSS_PROFIT>
<EXPENSES>6806384.47</EXPENSES>
<NET_INCOME>1036282.03</NET_INCOME>
<REVENUE_M>7.8426665</REVENUE_M>
<PROFIT_M>6.474857076</PROFIT_M>
<INCOME_M>1.03628203</INCOME_M>
<PHARMA_REV_M>7.8426665</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.474857076</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03628203</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3836114.5</REVENUE>
<PREV_YEAR_REV>3194658.93</PREV_YEAR_REV>
<BUDGET>3644308.78</BUDGET>
<GROSS_PROFIT>3188693.452</GROSS_PROFIT>
<EXPENSES>3417978.02</EXPENSES>
<NET_INCOME>418136.48</NET_INCOME>
<REVENUE_M>3.8361145</REVENUE_M>
<PROFIT_M>3.188693452</PROFIT_M>
<INCOME_M>0.41813648</INCOME_M>
<PHARMA_REV_M>3.8361145</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.188693452</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41813648</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5825251.81</REVENUE>
<PREV_YEAR_REV>4713833</PREV_YEAR_REV>
<BUDGET>5242726.64</BUDGET>
<GROSS_PROFIT>4067457.146</GROSS_PROFIT>
<EXPENSES>5120958.93</EXPENSES>
<NET_INCOME>704292.88</NET_INCOME>
<REVENUE_M>5.82525181</REVENUE_M>
<PROFIT_M>4.067457146</PROFIT_M>
<INCOME_M>0.70429288</INCOME_M>
<PHARMA_REV_M>5.82525181</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.067457146</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.70429288</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5737510.26</REVENUE>
<PREV_YEAR_REV>4564964.22</PREV_YEAR_REV>
<BUDGET>5163759.22</BUDGET>
<GROSS_PROFIT>4338705.252</GROSS_PROFIT>
<EXPENSES>4965815.12</EXPENSES>
<NET_INCOME>771695.13</NET_INCOME>
<REVENUE_M>5.73751026</REVENUE_M>
<PROFIT_M>4.338705252</PROFIT_M>
<INCOME_M>0.77169513</INCOME_M>
<PHARMA_REV_M>5.73751026</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.338705252</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.77169513</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2891949.81</REVENUE>
<PREV_YEAR_REV>2374187.09</PREV_YEAR_REV>
<BUDGET>2602754.83</BUDGET>
<GROSS_PROFIT>2329754.768</GROSS_PROFIT>
<EXPENSES>2680837.48</EXPENSES>
<NET_INCOME>211112.34</NET_INCOME>
<REVENUE_M>2.89194981</REVENUE_M>
<PROFIT_M>2.329754768</PROFIT_M>
<INCOME_M>0.21111234</INCOME_M>
<PHARMA_REV_M>2.89194981</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.329754768</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21111234</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2891949.81</REVENUE>
<PREV_YEAR_REV>2382205.48</PREV_YEAR_REV>
<BUDGET>2602754.83</BUDGET>
<GROSS_PROFIT>2188925.491</GROSS_PROFIT>
<EXPENSES>2394534.44</EXPENSES>
<NET_INCOME>497415.37</NET_INCOME>
<REVENUE_M>2.89194981</REVENUE_M>
<PROFIT_M>2.188925491</PROFIT_M>
<INCOME_M>0.49741537</INCOME_M>
<PHARMA_REV_M>2.89194981</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.188925491</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49741537</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5732025.88</REVENUE>
<PREV_YEAR_REV>4524080.87</PREV_YEAR_REV>
<BUDGET>5158823.29</BUDGET>
<GROSS_PROFIT>4293683.422</GROSS_PROFIT>
<EXPENSES>4972420.02</EXPENSES>
<NET_INCOME>759605.85</NET_INCOME>
<REVENUE_M>5.73202588</REVENUE_M>
<PROFIT_M>4.293683422</PROFIT_M>
<INCOME_M>0.75960585</INCOME_M>
<PHARMA_REV_M>5.73202588</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.293683422</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75960585</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2907989.5</REVENUE>
<PREV_YEAR_REV>2424759.23</PREV_YEAR_REV>
<BUDGET>2617190.55</BUDGET>
<GROSS_PROFIT>2020834.608</GROSS_PROFIT>
<EXPENSES>2407815.31</EXPENSES>
<NET_INCOME>500174.19</NET_INCOME>
<REVENUE_M>2.9079895</REVENUE_M>
<PROFIT_M>2.020834608</PROFIT_M>
<INCOME_M>0.50017419</INCOME_M>
<PHARMA_REV_M>2.9079895</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.020834608</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50017419</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>5010583</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>4609736.36</BUDGET>
<GROSS_PROFIT>3806038.845</GROSS_PROFIT>
<EXPENSES>4364217.79</EXPENSES>
<NET_INCOME>646365.21</NET_INCOME>
<REVENUE_M>5.010583</REVENUE_M>
<PROFIT_M>3.806038845</PROFIT_M>
<INCOME_M>0.64636521</INCOME_M>
<PHARMA_REV_M>5.010583</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.806038845</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.64636521</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8451551</REVENUE>
<PREV_YEAR_REV>7372217.15</PREV_YEAR_REV>
<BUDGET>8695426.92</BUDGET>
<GROSS_PROFIT>7446399.274</GROSS_PROFIT>
<EXPENSES>7939302.84</EXPENSES>
<NET_INCOME>1512248.16</NET_INCOME>
<REVENUE_M>8.451551</REVENUE_M>
<PROFIT_M>7.446399274</PROFIT_M>
<INCOME_M>1.51224816</INCOME_M>
<PHARMA_REV_M>8.451551</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.446399274</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.51224816</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>4709657</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>4332884.44</BUDGET>
<GROSS_PROFIT>3581694.153</GROSS_PROFIT>
<EXPENSES>4102111.25</EXPENSES>
<NET_INCOME>607545.75</NET_INCOME>
<REVENUE_M>4.709657</REVENUE_M>
<PROFIT_M>3.581694153</PROFIT_M>
<INCOME_M>0.60754575</INCOME_M>
<PHARMA_REV_M>4.709657</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.581694153</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60754575</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>1048795.13</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>1332891.52</BUDGET>
<GROSS_PROFIT>831475.86</GROSS_PROFIT>
<EXPENSES>1343033.08</EXPENSES>
<NET_INCOME>105762.04</NET_INCOME>
<REVENUE_M>1.04879513</REVENUE_M>
<PROFIT_M>0.83147586</PROFIT_M>
<INCOME_M>0.10576204</INCOME_M>
<PHARMA_REV_M>1.04879513</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.83147586</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10576204</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>20408545</REVENUE>
<PREV_YEAR_REV>1.664738475E7</PREV_YEAR_REV>
<BUDGET>1.87758614E7</BUDGET>
<GROSS_PROFIT>1.534891557E7</GROSS_PROFIT>
<EXPENSES>1.738053435E7</EXPENSES>
<NET_INCOME>3028010.65</NET_INCOME>
<REVENUE_M>20.408545</REVENUE_M>
<PROFIT_M>15.34891557</PROFIT_M>
<INCOME_M>3.02801065</INCOME_M>
<PHARMA_REV_M>20.408545</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.34891557</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>3.02801065</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>5789883.38</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>5326692.71</BUDGET>
<GROSS_PROFIT>4384949.355</GROSS_PROFIT>
<EXPENSES>4929231.05</EXPENSES>
<NET_INCOME>860652.33</NET_INCOME>
<REVENUE_M>5.78988338</REVENUE_M>
<PROFIT_M>4.384949355</PROFIT_M>
<INCOME_M>0.86065233</INCOME_M>
<PHARMA_REV_M>5.78988338</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.384949355</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.86065233</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>8465162.91</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>7787949.88</BUDGET>
<GROSS_PROFIT>7386504.07</GROSS_PROFIT>
<EXPENSES>7261198.7</EXPENSES>
<NET_INCOME>1203964.21</NET_INCOME>
<REVENUE_M>8.46516291</REVENUE_M>
<PROFIT_M>7.38650407</PROFIT_M>
<INCOME_M>1.20396421</INCOME_M>
<PHARMA_REV_M>8.46516291</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.38650407</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.20396421</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>2.500242772E7</REVENUE>
<PREV_YEAR_REV>2.079193145E7</PREV_YEAR_REV>
<BUDGET>2.30022335E7</BUDGET>
<GROSS_PROFIT>2.052389835E7</GROSS_PROFIT>
<EXPENSES>2.16684582E7</EXPENSES>
<NET_INCOME>3333969.52</NET_INCOME>
<REVENUE_M>25.00242772</REVENUE_M>
<PROFIT_M>20.52389835</PROFIT_M>
<INCOME_M>3.33396952</INCOME_M>
<PHARMA_REV_M>25.00242772</PHARMA_REV_M>
<PHARMA_PROFIT_M>20.52389835</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>3.33396952</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6207793.84</REVENUE>
<PREV_YEAR_REV>5067775.39</PREV_YEAR_REV>
<BUDGET>5916712.5</BUDGET>
<GROSS_PROFIT>4902084.867</GROSS_PROFIT>
<EXPENSES>5521807.32</EXPENSES>
<NET_INCOME>685986.53</NET_INCOME>
<REVENUE_M>6.20779384</REVENUE_M>
<PROFIT_M>4.902084867</PROFIT_M>
<INCOME_M>0.68598653</INCOME_M>
<PHARMA_REV_M>6.20779384</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.902084867</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68598653</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3547334.42</REVENUE>
<PREV_YEAR_REV>2991587.26</PREV_YEAR_REV>
<BUDGET>3375187.5</BUDGET>
<GROSS_PROFIT>2868019.882</GROSS_PROFIT>
<EXPENSES>3079086.28</EXPENSES>
<NET_INCOME>468248.14</NET_INCOME>
<REVENUE_M>3.54733442</REVENUE_M>
<PROFIT_M>2.868019882</PROFIT_M>
<INCOME_M>0.46824814</INCOME_M>
<PHARMA_REV_M>3.54733442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.868019882</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46824814</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1.139317201E7</REVENUE>
<PREV_YEAR_REV>8924258.19</PREV_YEAR_REV>
<BUDGET>1.045566113E7</BUDGET>
<GROSS_PROFIT>9231345.937</GROSS_PROFIT>
<EXPENSES>9929013.75</EXPENSES>
<NET_INCOME>1064158.29</NET_INCOME>
<REVENUE_M>11.39317201</REVENUE_M>
<PROFIT_M>9.231345937</PROFIT_M>
<INCOME_M>1.06415829</INCOME_M>
<PHARMA_REV_M>11.39317201</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.231345937</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.06415829</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1453706.12</REVENUE>
<PREV_YEAR_REV>1367023.18</PREV_YEAR_REV>
<BUDGET>1119486.74</BUDGET>
<GROSS_PROFIT>1068910.116</GROSS_PROFIT>
<EXPENSES>1266178.03</EXPENSES>
<NET_INCOME>187528.09</NET_INCOME>
<REVENUE_M>1.45370612</REVENUE_M>
<PROFIT_M>1.068910116</PROFIT_M>
<INCOME_M>0.18752809</INCOME_M>
<PHARMA_REV_M>1.45370612</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.068910116</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18752809</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1059923.67</REVENUE>
<PREV_YEAR_REV>988660.99</PREV_YEAR_REV>
<BUDGET>909297.39</BUDGET>
<GROSS_PROFIT>874437.03</GROSS_PROFIT>
<EXPENSES>890335.88</EXPENSES>
<NET_INCOME>169587.79</NET_INCOME>
<REVENUE_M>1.05992367</REVENUE_M>
<PROFIT_M>0.87443703</PROFIT_M>
<INCOME_M>0.16958779</INCOME_M>
<PHARMA_REV_M>1.05992367</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.87443703</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16958779</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2599607.07</REVENUE>
<PREV_YEAR_REV>2451275.22</PREV_YEAR_REV>
<BUDGET>2177409.16</BUDGET>
<GROSS_PROFIT>1900390.836</GROSS_PROFIT>
<EXPENSES>2215451.98</EXPENSES>
<NET_INCOME>384155.08</NET_INCOME>
<REVENUE_M>2.59960707</REVENUE_M>
<PROFIT_M>1.900390836</PROFIT_M>
<INCOME_M>0.38415508</INCOME_M>
<PHARMA_REV_M>2.59960707</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.900390836</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38415508</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1341839.04</REVENUE>
<PREV_YEAR_REV>1237687.62</PREV_YEAR_REV>
<BUDGET>1131948.56</BUDGET>
<GROSS_PROFIT>1023621.913</GROSS_PROFIT>
<EXPENSES>1101649.85</EXPENSES>
<NET_INCOME>240189.19</NET_INCOME>
<REVENUE_M>1.34183904</REVENUE_M>
<PROFIT_M>1.023621913</PROFIT_M>
<INCOME_M>0.24018919</INCOME_M>
<PHARMA_REV_M>1.34183904</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.023621913</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24018919</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1225750.91</REVENUE>
<PREV_YEAR_REV>1149968.02</PREV_YEAR_REV>
<BUDGET>979079.43</BUDGET>
<GROSS_PROFIT>1066403.29</GROSS_PROFIT>
<EXPENSES>1006341.5</EXPENSES>
<NET_INCOME>219409.41</NET_INCOME>
<REVENUE_M>1.22575091</REVENUE_M>
<PROFIT_M>1.06640329</PROFIT_M>
<INCOME_M>0.21940941</INCOME_M>
<PHARMA_REV_M>1.22575091</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.06640329</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21940941</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1326278.17</REVENUE>
<PREV_YEAR_REV>1239523.89</PREV_YEAR_REV>
<BUDGET>1119486.74</BUDGET>
<GROSS_PROFIT>1030650.763</GROSS_PROFIT>
<EXPENSES>1098158.33</EXPENSES>
<NET_INCOME>228119.85</NET_INCOME>
<REVENUE_M>1.32627817</REVENUE_M>
<PROFIT_M>1.030650763</PROFIT_M>
<INCOME_M>0.22811985</INCOME_M>
<PHARMA_REV_M>1.32627817</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.030650763</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22811985</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.359791551E7</REVENUE>
<PREV_YEAR_REV>1.269008487E7</PREV_YEAR_REV>
<BUDGET>1.305399889E7</BUDGET>
<GROSS_PROFIT>9398411.923</GROSS_PROFIT>
<EXPENSES>1.17700584E7</EXPENSES>
<NET_INCOME>1827857.11</NET_INCOME>
<REVENUE_M>13.59791551</REVENUE_M>
<PROFIT_M>9.398411923</PROFIT_M>
<INCOME_M>1.82785711</INCOME_M>
<PHARMA_REV_M>13.59791551</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.398411923</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.82785711</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6310013.05</REVENUE>
<PREV_YEAR_REV>5904658.26</PREV_YEAR_REV>
<BUDGET>6057612.52</BUDGET>
<GROSS_PROFIT>4577169.881</GROSS_PROFIT>
<EXPENSES>5224690.8</EXPENSES>
<NET_INCOME>1085322.24</NET_INCOME>
<REVENUE_M>6.31001305</REVENUE_M>
<PROFIT_M>4.577169881</PROFIT_M>
<INCOME_M>1.08532224</INCOME_M>
<PHARMA_REV_M>6.31001305</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.577169881</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.08532224</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>1904211.35</REVENUE>
<PREV_YEAR_REV>1751063.35</PREV_YEAR_REV>
<BUDGET>1802752.18</BUDGET>
<GROSS_PROFIT>1328682.51</GROSS_PROFIT>
<EXPENSES>1599537.53</EXPENSES>
<NET_INCOME>304673.82</NET_INCOME>
<REVENUE_M>1.90421135</REVENUE_M>
<PROFIT_M>1.32868251</PROFIT_M>
<INCOME_M>0.30467382</INCOME_M>
<PHARMA_REV_M>1.90421135</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.32868251</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30467382</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4164574.86</REVENUE>
<PREV_YEAR_REV>3903470.03</PREV_YEAR_REV>
<BUDGET>3819088.44</BUDGET>
<GROSS_PROFIT>2905636.152</GROSS_PROFIT>
<EXPENSES>3605087.23</EXPENSES>
<NET_INCOME>559487.63</NET_INCOME>
<REVENUE_M>4.16457486</REVENUE_M>
<PROFIT_M>2.905636152</PROFIT_M>
<INCOME_M>0.55948763</INCOME_M>
<PHARMA_REV_M>4.16457486</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.905636152</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55948763</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2878664.68</REVENUE>
<PREV_YEAR_REV>2694670.4</PREV_YEAR_REV>
<BUDGET>3416353.86</BUDGET>
<GROSS_PROFIT>1736631.891</GROSS_PROFIT>
<EXPENSES>2529459.94</EXPENSES>
<NET_INCOME>349204.75</NET_INCOME>
<REVENUE_M>2.87866468</REVENUE_M>
<PROFIT_M>1.736631891</PROFIT_M>
<INCOME_M>0.34920475</INCOME_M>
<PHARMA_REV_M>2.87866468</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.736631891</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34920475</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1508640.56</REVENUE>
<PREV_YEAR_REV>1386248.67</PREV_YEAR_REV>
<BUDGET>1699401.6</BUDGET>
<GROSS_PROFIT>1089238.48</GROSS_PROFIT>
<EXPENSES>1309500.01</EXPENSES>
<NET_INCOME>199140.55</NET_INCOME>
<REVENUE_M>1.50864056</REVENUE_M>
<PROFIT_M>1.08923848</PROFIT_M>
<INCOME_M>0.19914055</INCOME_M>
<PHARMA_REV_M>1.50864056</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.08923848</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19914055</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6066218.74</REVENUE>
<PREV_YEAR_REV>5574748.88</PREV_YEAR_REV>
<BUDGET>6672840.62</BUDGET>
<GROSS_PROFIT>5083491.31</GROSS_PROFIT>
<EXPENSES>5095623.74</EXPENSES>
<NET_INCOME>970595</NET_INCOME>
<REVENUE_M>6.06621874</REVENUE_M>
<PROFIT_M>5.08349131</PROFIT_M>
<INCOME_M>0.970595</INCOME_M>
<PHARMA_REV_M>6.06621874</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.08349131</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.970595</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5383618.94</REVENUE>
<PREV_YEAR_REV>4864613.34</PREV_YEAR_REV>
<BUDGET>5921980.84</BUDGET>
<GROSS_PROFIT>4780653.62</GROSS_PROFIT>
<EXPENSES>4419951.15</EXPENSES>
<NET_INCOME>963667.79</NET_INCOME>
<REVENUE_M>5.38361894</REVENUE_M>
<PROFIT_M>4.78065362</PROFIT_M>
<INCOME_M>0.96366779</INCOME_M>
<PHARMA_REV_M>5.38361894</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.78065362</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.96366779</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5214810.46</REVENUE>
<PREV_YEAR_REV>4752098.62</PREV_YEAR_REV>
<BUDGET>5736291.51</BUDGET>
<GROSS_PROFIT>4476914.779</GROSS_PROFIT>
<EXPENSES>4281359.39</EXPENSES>
<NET_INCOME>933451.07</NET_INCOME>
<REVENUE_M>5.21481046</REVENUE_M>
<PROFIT_M>4.476914779</PROFIT_M>
<INCOME_M>0.93345107</INCOME_M>
<PHARMA_REV_M>5.21481046</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.476914779</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.93345107</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5367674.22</REVENUE>
<PREV_YEAR_REV>4833043.01</PREV_YEAR_REV>
<BUDGET>5904441.64</BUDGET>
<GROSS_PROFIT>4320977.75</GROSS_PROFIT>
<EXPENSES>4975834</EXPENSES>
<NET_INCOME>391840.22</NET_INCOME>
<REVENUE_M>5.36767422</REVENUE_M>
<PROFIT_M>4.32097775</PROFIT_M>
<INCOME_M>0.39184022</INCOME_M>
<PHARMA_REV_M>5.36767422</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.32097775</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39184022</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1458645.93</REVENUE>
<PREV_YEAR_REV>1388512.18</PREV_YEAR_REV>
<BUDGET>1708784.94</BUDGET>
<GROSS_PROFIT>964894.2898</GROSS_PROFIT>
<EXPENSES>1299653.53</EXPENSES>
<NET_INCOME>158992.41</NET_INCOME>
<REVENUE_M>1.45864593</REVENUE_M>
<PROFIT_M>0.96489429</PROFIT_M>
<INCOME_M>0.15899241</INCOME_M>
<PHARMA_REV_M>1.45864593</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.96489429</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15899241</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1419058.56</REVENUE>
<PREV_YEAR_REV>1327401.48</PREV_YEAR_REV>
<BUDGET>1676720.65</BUDGET>
<GROSS_PROFIT>1001642.485</GROSS_PROFIT>
<EXPENSES>1174980.48</EXPENSES>
<NET_INCOME>244078.07</NET_INCOME>
<REVENUE_M>1.41905856</REVENUE_M>
<PROFIT_M>1.001642485</PROFIT_M>
<INCOME_M>0.24407807</INCOME_M>
<PHARMA_REV_M>1.41905856</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.001642485</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24407807</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1479469.62</REVENUE>
<PREV_YEAR_REV>1358682.73</PREV_YEAR_REV>
<BUDGET>1708784.94</BUDGET>
<GROSS_PROFIT>944493.4105</GROSS_PROFIT>
<EXPENSES>1318207.44</EXPENSES>
<NET_INCOME>161262.19</NET_INCOME>
<REVENUE_M>1.47946962</REVENUE_M>
<PROFIT_M>0.944493411</PROFIT_M>
<INCOME_M>0.16126219</INCOME_M>
<PHARMA_REV_M>1.47946962</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.944493411</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16126219</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1014615.23</REVENUE>
<PREV_YEAR_REV>937427.45</PREV_YEAR_REV>
<BUDGET>1056303.95</BUDGET>
<GROSS_PROFIT>776180.65</GROSS_PROFIT>
<EXPENSES>880686.02</EXPENSES>
<NET_INCOME>133929.21</NET_INCOME>
<REVENUE_M>1.01461523</REVENUE_M>
<PROFIT_M>0.77618065</PROFIT_M>
<INCOME_M>0.13392921</INCOME_M>
<PHARMA_REV_M>1.01461523</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.77618065</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13392921</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.000752968E7</REVENUE>
<PREV_YEAR_REV>9174197.91</PREV_YEAR_REV>
<BUDGET>9607228.48</BUDGET>
<GROSS_PROFIT>7443124.77</GROSS_PROFIT>
<EXPENSES>8661029.37</EXPENSES>
<NET_INCOME>1346500.31</NET_INCOME>
<REVENUE_M>10.00752968</REVENUE_M>
<PROFIT_M>7.44312477</PROFIT_M>
<INCOME_M>1.34650031</INCOME_M>
<PHARMA_REV_M>10.00752968</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.44312477</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.34650031</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1045737.11</REVENUE>
<PREV_YEAR_REV>962570.98</PREV_YEAR_REV>
<BUDGET>1083769.24</BUDGET>
<GROSS_PROFIT>632331.0837</GROSS_PROFIT>
<EXPENSES>939071.92</EXPENSES>
<NET_INCOME>106665.19</NET_INCOME>
<REVENUE_M>1.04573711</REVENUE_M>
<PROFIT_M>0.632331084</PROFIT_M>
<INCOME_M>0.10666519</INCOME_M>
<PHARMA_REV_M>1.04573711</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.632331084</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10666519</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1123491.6</REVENUE>
<PREV_YEAR_REV>1037925.06</PREV_YEAR_REV>
<BUDGET>1092352.74</BUDGET>
<GROSS_PROFIT>735381.4245</GROSS_PROFIT>
<EXPENSES>1001031.01</EXPENSES>
<NET_INCOME>122460.58</NET_INCOME>
<REVENUE_M>1.1234916</REVENUE_M>
<PROFIT_M>0.735381425</PROFIT_M>
<INCOME_M>0.12246058</INCOME_M>
<PHARMA_REV_M>1.1234916</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.735381425</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12246058</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>9075018.94</REVENUE>
<PREV_YEAR_REV>8350757.72</PREV_YEAR_REV>
<BUDGET>8712018.18</BUDGET>
<GROSS_PROFIT>7241865.11</GROSS_PROFIT>
<EXPENSES>7623015.91</EXPENSES>
<NET_INCOME>1452003.03</NET_INCOME>
<REVENUE_M>9.07501894</REVENUE_M>
<PROFIT_M>7.24186511</PROFIT_M>
<INCOME_M>1.45200303</INCOME_M>
<PHARMA_REV_M>9.07501894</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.24186511</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.45200303</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.54655968E7</REVENUE>
<PREV_YEAR_REV>1.395550725E7</PREV_YEAR_REV>
<BUDGET>1.484697292E7</BUDGET>
<GROSS_PROFIT>1.107501449E7</GROSS_PROFIT>
<EXPENSES>1.37779108E7</EXPENSES>
<NET_INCOME>1687686</NET_INCOME>
<REVENUE_M>15.4655968</REVENUE_M>
<PROFIT_M>11.07501449</PROFIT_M>
<INCOME_M>1.687686</INCOME_M>
<PHARMA_REV_M>15.4655968</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.07501449</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.687686</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.696103122E7</REVENUE>
<PREV_YEAR_REV>1.562556658E7</PREV_YEAR_REV>
<BUDGET>1.628258998E7</BUDGET>
<GROSS_PROFIT>1.183230548E7</GROSS_PROFIT>
<EXPENSES>1.532198318E7</EXPENSES>
<NET_INCOME>1639048.05</NET_INCOME>
<REVENUE_M>16.96103122</REVENUE_M>
<PROFIT_M>11.83230548</PROFIT_M>
<INCOME_M>1.63904805</INCOME_M>
<PHARMA_REV_M>16.96103122</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.83230548</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.63904805</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>4413506.39</REVENUE>
<PREV_YEAR_REV>4067560.38</PREV_YEAR_REV>
<BUDGET>4236966.13</BUDGET>
<GROSS_PROFIT>2671910.282</GROSS_PROFIT>
<EXPENSES>3817683.03</EXPENSES>
<NET_INCOME>595823.36</NET_INCOME>
<REVENUE_M>4.41350639</REVENUE_M>
<PROFIT_M>2.671910282</PROFIT_M>
<INCOME_M>0.59582336</INCOME_M>
<PHARMA_REV_M>4.41350639</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.671910282</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.59582336</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1904044.8</REVENUE>
<PREV_YEAR_REV>1760868.58</PREV_YEAR_REV>
<BUDGET>2061107.55</BUDGET>
<GROSS_PROFIT>1369565.148</GROSS_PROFIT>
<EXPENSES>1576549.1</EXPENSES>
<NET_INCOME>327495.71</NET_INCOME>
<REVENUE_M>1.9040448</REVENUE_M>
<PROFIT_M>1.369565148</PROFIT_M>
<INCOME_M>0.32749571</INCOME_M>
<PHARMA_REV_M>1.9040448</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.369565148</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32749571</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2076994.59</REVENUE>
<PREV_YEAR_REV>1871419.19</PREV_YEAR_REV>
<BUDGET>2115910.36</BUDGET>
<GROSS_PROFIT>1337220.004</GROSS_PROFIT>
<EXPENSES>1719751.52</EXPENSES>
<NET_INCOME>357243.07</NET_INCOME>
<REVENUE_M>2.07699459</REVENUE_M>
<PROFIT_M>1.337220004</PROFIT_M>
<INCOME_M>0.35724307</INCOME_M>
<PHARMA_REV_M>2.07699459</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.337220004</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35724307</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>1997113.94</REVENUE>
<PREV_YEAR_REV>1791535.27</PREV_YEAR_REV>
<BUDGET>2140963.07</BUDGET>
<GROSS_PROFIT>1463279.392</GROSS_PROFIT>
<EXPENSES>1653610.34</EXPENSES>
<NET_INCOME>343503.6</NET_INCOME>
<REVENUE_M>1.99711394</REVENUE_M>
<PROFIT_M>1.463279392</PROFIT_M>
<INCOME_M>0.3435036</INCOME_M>
<PHARMA_REV_M>1.99711394</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.463279392</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3435036</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1195561.71</REVENUE>
<PREV_YEAR_REV>1104149.2</PREV_YEAR_REV>
<BUDGET>1490457.38</BUDGET>
<GROSS_PROFIT>886939.4156</GROSS_PROFIT>
<EXPENSES>1004271.84</EXPENSES>
<NET_INCOME>191289.87</NET_INCOME>
<REVENUE_M>1.19556171</REVENUE_M>
<PROFIT_M>0.886939416</PROFIT_M>
<INCOME_M>0.19128987</INCOME_M>
<PHARMA_REV_M>1.19556171</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.886939416</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19128987</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1334127.26</REVENUE>
<PREV_YEAR_REV>1242886.93</PREV_YEAR_REV>
<BUDGET>1798697.03</BUDGET>
<GROSS_PROFIT>1005064.765</GROSS_PROFIT>
<EXPENSES>1158022.46</EXPENSES>
<NET_INCOME>176104.8</NET_INCOME>
<REVENUE_M>1.33412726</REVENUE_M>
<PROFIT_M>1.005064765</PROFIT_M>
<INCOME_M>0.1761048</INCOME_M>
<PHARMA_REV_M>1.33412726</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.005064765</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1761048</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2828857.64</REVENUE>
<PREV_YEAR_REV>2551690.55</PREV_YEAR_REV>
<BUDGET>3629635.3</BUDGET>
<GROSS_PROFIT>1845803.142</GROSS_PROFIT>
<EXPENSES>2407974.94</EXPENSES>
<NET_INCOME>420882.7</NET_INCOME>
<REVENUE_M>2.82885764</REVENUE_M>
<PROFIT_M>1.845803142</PROFIT_M>
<INCOME_M>0.4208827</INCOME_M>
<PHARMA_REV_M>2.82885764</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.845803142</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4208827</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4250620.77</REVENUE>
<PREV_YEAR_REV>3889447.66</PREV_YEAR_REV>
<BUDGET>5485525.02</BUDGET>
<GROSS_PROFIT>3072971.907</GROSS_PROFIT>
<EXPENSES>3839703.8</EXPENSES>
<NET_INCOME>410916.97</NET_INCOME>
<REVENUE_M>4.25062077</REVENUE_M>
<PROFIT_M>3.072971907</PROFIT_M>
<INCOME_M>0.41091697</INCOME_M>
<PHARMA_REV_M>4.25062077</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.072971907</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41091697</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1354775.07</REVENUE>
<PREV_YEAR_REV>1256317.47</PREV_YEAR_REV>
<BUDGET>1822245.97</BUDGET>
<GROSS_PROFIT>956471.2</GROSS_PROFIT>
<EXPENSES>1255876.49</EXPENSES>
<NET_INCOME>98898.58</NET_INCOME>
<REVENUE_M>1.35477507</REVENUE_M>
<PROFIT_M>0.9564712</PROFIT_M>
<INCOME_M>0.09889858</INCOME_M>
<PHARMA_REV_M>1.35477507</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.9564712</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.09889858</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2009196.1</REVENUE>
<PREV_YEAR_REV>1861576.79</PREV_YEAR_REV>
<BUDGET>2287068.24</BUDGET>
<GROSS_PROFIT>1354247.62</GROSS_PROFIT>
<EXPENSES>1786314.5</EXPENSES>
<NET_INCOME>222881.6</NET_INCOME>
<REVENUE_M>2.0091961</REVENUE_M>
<PROFIT_M>1.35424762</PROFIT_M>
<INCOME_M>0.2228816</INCOME_M>
<PHARMA_REV_M>2.0091961</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.35424762</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2228816</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>829053.18</REVENUE>
<PREV_YEAR_REV>769830.15</PREV_YEAR_REV>
<BUDGET>940781.4</BUDGET>
<GROSS_PROFIT>590949.108</GROSS_PROFIT>
<EXPENSES>722105.32</EXPENSES>
<NET_INCOME>106947.86</NET_INCOME>
<REVENUE_M>0.82905318</REVENUE_M>
<PROFIT_M>0.590949108</PROFIT_M>
<INCOME_M>0.10694786</INCOME_M>
<PHARMA_REV_M>0.82905318</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.590949108</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10694786</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1814379.12</REVENUE>
<PREV_YEAR_REV>1661873.04</PREV_YEAR_REV>
<BUDGET>1977290.79</BUDGET>
<GROSS_PROFIT>1275638.027</GROSS_PROFIT>
<EXPENSES>1571116</EXPENSES>
<NET_INCOME>243263.13</NET_INCOME>
<REVENUE_M>1.81437912</REVENUE_M>
<PROFIT_M>1.275638027</PROFIT_M>
<INCOME_M>0.24326313</INCOME_M>
<PHARMA_REV_M>1.81437912</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.275638027</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24326313</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5796662.73</REVENUE>
<PREV_YEAR_REV>5344861.58</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>4452445.629</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>747769.49</NET_INCOME>
<REVENUE_M>5.79666273</REVENUE_M>
<PROFIT_M>4.452445629</PROFIT_M>
<INCOME_M>0.74776949</INCOME_M>
<PHARMA_REV_M>5.79666273</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.452445629</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74776949</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7481284.54</REVENUE>
<PREV_YEAR_REV>6938808.49</PREV_YEAR_REV>
<BUDGET>7182033.16</BUDGET>
<GROSS_PROFIT>6553605.26</GROSS_PROFIT>
<EXPENSES>6493754.98</EXPENSES>
<NET_INCOME>987529.56</NET_INCOME>
<REVENUE_M>7.48128454</REVENUE_M>
<PROFIT_M>6.55360526</PROFIT_M>
<INCOME_M>0.98752956</INCOME_M>
<PHARMA_REV_M>7.48128454</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.55360526</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.98752956</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9789916.83</REVENUE>
<PREV_YEAR_REV>9246762.02</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>7277824.17</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>1262899.27</NET_INCOME>
<REVENUE_M>9.78991683</REVENUE_M>
<PROFIT_M>7.27782417</PROFIT_M>
<INCOME_M>1.26289927</INCOME_M>
<PHARMA_REV_M>9.78991683</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.27782417</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.26289927</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.599326802E7</REVENUE>
<PREV_YEAR_REV>1.48340422E7</PREV_YEAR_REV>
<BUDGET>1.53535373E7</BUDGET>
<GROSS_PROFIT>1.351529781E7</GROSS_PROFIT>
<EXPENSES>1.386602704E7</EXPENSES>
<NET_INCOME>2127240.98</NET_INCOME>
<REVENUE_M>15.99326802</REVENUE_M>
<PROFIT_M>13.51529781</PROFIT_M>
<INCOME_M>2.12724098</INCOME_M>
<PHARMA_REV_M>15.99326802</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.51529781</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.12724098</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.612985177E7</REVENUE>
<PREV_YEAR_REV>1.508144954E7</PREV_YEAR_REV>
<BUDGET>1.548465769E7</BUDGET>
<GROSS_PROFIT>1.258299296E7</GROSS_PROFIT>
<EXPENSES>13709017</EXPENSES>
<NET_INCOME>2420834.77</NET_INCOME>
<REVENUE_M>16.12985177</REVENUE_M>
<PROFIT_M>12.58299296</PROFIT_M>
<INCOME_M>2.42083477</INCOME_M>
<PHARMA_REV_M>16.12985177</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.58299296</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.42083477</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>2.085287609E7</REVENUE>
<PREV_YEAR_REV>1.953479322E7</PREV_YEAR_REV>
<BUDGET>2.001876106E7</BUDGET>
<GROSS_PROFIT>1.745384357E7</GROSS_PROFIT>
<EXPENSES>1.884681153E7</EXPENSES>
<NET_INCOME>2006064.58</NET_INCOME>
<REVENUE_M>20.85287609</REVENUE_M>
<PROFIT_M>17.45384357</PROFIT_M>
<INCOME_M>2.00606458</INCOME_M>
<PHARMA_REV_M>20.85287609</PHARMA_REV_M>
<PHARMA_PROFIT_M>17.45384357</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.00606458</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4642359.07</REVENUE>
<PREV_YEAR_REV>4351588.79</PREV_YEAR_REV>
<BUDGET>3488498.99</BUDGET>
<GROSS_PROFIT>3353595.534</GROSS_PROFIT>
<EXPENSES>4085344.79</EXPENSES>
<NET_INCOME>557014.28</NET_INCOME>
<REVENUE_M>4.64235907</REVENUE_M>
<PROFIT_M>3.353595534</PROFIT_M>
<INCOME_M>0.55701428</INCOME_M>
<PHARMA_REV_M>4.64235907</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.353595534</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55701428</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2390189.83</REVENUE>
<PREV_YEAR_REV>2200870.92</PREV_YEAR_REV>
<BUDGET>1855623.07</BUDGET>
<GROSS_PROFIT>2117158.445</GROSS_PROFIT>
<EXPENSES>2215705.97</EXPENSES>
<NET_INCOME>174483.86</NET_INCOME>
<REVENUE_M>2.39018983</REVENUE_M>
<PROFIT_M>2.117158445</PROFIT_M>
<INCOME_M>0.17448386</INCOME_M>
<PHARMA_REV_M>2.39018983</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.117158445</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17448386</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4573789.18</REVENUE>
<PREV_YEAR_REV>4202232.69</PREV_YEAR_REV>
<BUDGET>3552726.53</BUDGET>
<GROSS_PROFIT>3675746.123</GROSS_PROFIT>
<EXPENSES>3957893.26</EXPENSES>
<NET_INCOME>615895.91</NET_INCOME>
<REVENUE_M>4.57378918</REVENUE_M>
<PROFIT_M>3.675746123</PROFIT_M>
<INCOME_M>0.61589591</INCOME_M>
<PHARMA_REV_M>4.57378918</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.675746123</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61589591</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2305097.99</REVENUE>
<PREV_YEAR_REV>2135397.91</PREV_YEAR_REV>
<BUDGET>1765329.95</BUDGET>
<GROSS_PROFIT>1711867.185</GROSS_PROFIT>
<EXPENSES>1993909.76</EXPENSES>
<NET_INCOME>311188.23</NET_INCOME>
<REVENUE_M>2.30509799</REVENUE_M>
<PROFIT_M>1.711867185</PROFIT_M>
<INCOME_M>0.31118823</INCOME_M>
<PHARMA_REV_M>2.30509799</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.711867185</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31118823</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4758605.71</REVENUE>
<PREV_YEAR_REV>4430102.56</PREV_YEAR_REV>
<BUDGET>3615153.63</BUDGET>
<GROSS_PROFIT>4042608.231</GROSS_PROFIT>
<EXPENSES>4129209.97</EXPENSES>
<NET_INCOME>629395.74</NET_INCOME>
<REVENUE_M>4.75860571</REVENUE_M>
<PROFIT_M>4.042608231</PROFIT_M>
<INCOME_M>0.62939574</INCOME_M>
<PHARMA_REV_M>4.75860571</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.042608231</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62939574</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1556464.97</REVENUE>
<PREV_YEAR_REV>1450532.57</PREV_YEAR_REV>
<BUDGET>1558973.03</BUDGET>
<GROSS_PROFIT>1255366.822</GROSS_PROFIT>
<EXPENSES>1351011.59</EXPENSES>
<NET_INCOME>205453.38</NET_INCOME>
<REVENUE_M>1.55646497</REVENUE_M>
<PROFIT_M>1.255366822</PROFIT_M>
<INCOME_M>0.20545338</INCOME_M>
<PHARMA_REV_M>1.55646497</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.255366822</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20545338</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1703076.9</REVENUE>
<PREV_YEAR_REV>1598022.88</PREV_YEAR_REV>
<BUDGET>1578137.41</BUDGET>
<GROSS_PROFIT>1384601.52</GROSS_PROFIT>
<EXPENSES>1578752.29</EXPENSES>
<NET_INCOME>124324.61</NET_INCOME>
<REVENUE_M>1.7030769</REVENUE_M>
<PROFIT_M>1.38460152</PROFIT_M>
<INCOME_M>0.12432461</INCOME_M>
<PHARMA_REV_M>1.7030769</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.38460152</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12432461</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1618700.17</REVENUE>
<PREV_YEAR_REV>1539083.39</PREV_YEAR_REV>
<BUDGET>1562637.89</BUDGET>
<GROSS_PROFIT>1380751.25</GROSS_PROFIT>
<EXPENSES>1328952.84</EXPENSES>
<NET_INCOME>289747.33</NET_INCOME>
<REVENUE_M>1.61870017</REVENUE_M>
<PROFIT_M>1.38075125</PROFIT_M>
<INCOME_M>0.28974733</INCOME_M>
<PHARMA_REV_M>1.61870017</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.38075125</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28974733</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.535548091E7</REVENUE>
<PREV_YEAR_REV>1.458770686E7</PREV_YEAR_REV>
<BUDGET>1.489481648E7</BUDGET>
<GROSS_PROFIT>1.156728377E7</GROSS_PROFIT>
<EXPENSES>1.319200817E7</EXPENSES>
<NET_INCOME>2456876.95</NET_INCOME>
<REVENUE_M>15.35548091</REVENUE_M>
<PROFIT_M>11.56728377</PROFIT_M>
<INCOME_M>2.45687695</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.53193183E7</REVENUE>
<PREV_YEAR_REV>1.455335238E7</PREV_YEAR_REV>
<BUDGET>1.485973875E7</BUDGET>
<GROSS_PROFIT>1.096304035E7</GROSS_PROFIT>
<EXPENSES>1.316145173E7</EXPENSES>
<NET_INCOME>1485973.87</NET_INCOME>
<REVENUE_M>15.3193183</REVENUE_M>
<PROFIT_M>10.96304035</PROFIT_M>
<INCOME_M>1.48597387</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>18866925</REVENUE>
<PREV_YEAR_REV>1.792357875E7</PREV_YEAR_REV>
<BUDGET>1.830091725E7</BUDGET>
<GROSS_PROFIT>1.42124546E7</GROSS_PROFIT>
<EXPENSES>24257475</EXPENSES>
<NET_INCOME>2538230.31</NET_INCOME>
<REVENUE_M>18.866925</REVENUE_M>
<PROFIT_M>14.2124546</PROFIT_M>
<INCOME_M>2.53823031</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.981027125E7</REVENUE>
<PREV_YEAR_REV>1.881975769E7</PREV_YEAR_REV>
<BUDGET>1.921596312E7</BUDGET>
<GROSS_PROFIT>1.492307734E7</GROSS_PROFIT>
<EXPENSES>24257475</EXPENSES>
<NET_INCOME>2665141.83</NET_INCOME>
<REVENUE_M>19.81027125</REVENUE_M>
<PROFIT_M>14.92307734</PROFIT_M>
<INCOME_M>2.66514183</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.406140418E7</REVENUE>
<PREV_YEAR_REV>2.285833397E7</PREV_YEAR_REV>
<BUDGET>2.333956206E7</BUDGET>
<GROSS_PROFIT>1.812545577E7</GROSS_PROFIT>
<EXPENSES>2.94629439E7</EXPENSES>
<NET_INCOME>3188776.63</NET_INCOME>
<REVENUE_M>24.06140418</REVENUE_M>
<PROFIT_M>18.12545577</PROFIT_M>
<INCOME_M>3.18877663</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.165295025E7</REVENUE>
<PREV_YEAR_REV>3.540500771E7</PREV_YEAR_REV>
<BUDGET>4.040336174E7</BUDGET>
<GROSS_PROFIT>2.823945068E7</GROSS_PROFIT>
<EXPENSES>3.707112572E7</EXPENSES>
<NET_INCOME>5041460.72</NET_INCOME>
<REVENUE_M>41.65295025</REVENUE_M>
<PROFIT_M>28.23945068</PROFIT_M>
<INCOME_M>5.04146072</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.010967511E7</REVENUE>
<PREV_YEAR_REV>1.709322384E7</PREV_YEAR_REV>
<BUDGET>1.950638485E7</BUDGET>
<GROSS_PROFIT>1.514861826E7</GROSS_PROFIT>
<EXPENSES>1.811761085E7</EXPENSES>
<NET_INCOME>2654477.11</NET_INCOME>
<REVENUE_M>20.10967511</REVENUE_M>
<PROFIT_M>15.14861826</PROFIT_M>
<INCOME_M>2.65447711</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.438129176E7</REVENUE>
<PREV_YEAR_REV>1.222409799E7</PREV_YEAR_REV>
<BUDGET>13949853</BUDGET>
<GROSS_PROFIT>1.029175572E7</GROSS_PROFIT>
<EXPENSES>1.279934966E7</EXPENSES>
<NET_INCOME>2473582.18</NET_INCOME>
<REVENUE_M>14.38129176</REVENUE_M>
<PROFIT_M>10.29175572</PROFIT_M>
<INCOME_M>2.47358218</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.644904934E7</REVENUE>
<PREV_YEAR_REV>3.098169194E7</PREV_YEAR_REV>
<BUDGET>3.535557786E7</BUDGET>
<GROSS_PROFIT>2.745706886E7</GROSS_PROFIT>
<EXPENSES>3.243965391E7</EXPENSES>
<NET_INCOME>4823115.2</NET_INCOME>
<REVENUE_M>36.44904934</REVENUE_M>
<PROFIT_M>27.45706886</PROFIT_M>
<INCOME_M>4.8231152</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>5.886115861E7</REVENUE>
<PREV_YEAR_REV>5.003198481E7</PREV_YEAR_REV>
<BUDGET>5.709532384E7</BUDGET>
<GROSS_PROFIT>4.434011078E7</GROSS_PROFIT>
<EXPENSES>5.301621465E7</EXPENSES>
<NET_INCOME>5723733.71</NET_INCOME>
<REVENUE_M>58.86115861</REVENUE_M>
<PROFIT_M>44.34011078</PROFIT_M>
<INCOME_M>5.72373371</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>4.473783656E7</REVENUE>
<PREV_YEAR_REV>3.802716108E7</PREV_YEAR_REV>
<BUDGET>4.339570147E7</BUDGET>
<GROSS_PROFIT>3.370101228E7</GROSS_PROFIT>
<EXPENSES>4.096813102E7</EXPENSES>
<NET_INCOME>4384235.47</NET_INCOME>
<REVENUE_M>44.73783656</REVENUE_M>
<PROFIT_M>33.70101228</PROFIT_M>
<INCOME_M>4.38423547</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.016678089E7</REVENUE>
<PREV_YEAR_REV>2.564176376E7</PREV_YEAR_REV>
<BUDGET>2.926177746E7</BUDGET>
<GROSS_PROFIT>2.272463604E7</GROSS_PROFIT>
<EXPENSES>2.689312046E7</EXPENSES>
<NET_INCOME>3997901.57</NET_INCOME>
<REVENUE_M>30.16678089</REVENUE_M>
<PROFIT_M>22.72463604</PROFIT_M>
<INCOME_M>3.99790157</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.63470879E7</REVENUE>
<PREV_YEAR_REV>1.389502472E7</PREV_YEAR_REV>
<BUDGET>1.585667526E7</BUDGET>
<GROSS_PROFIT>1.185817756E7</GROSS_PROFIT>
<EXPENSES>1.471237911E7</EXPENSES>
<NET_INCOME>1781832.58</NET_INCOME>
<REVENUE_M>16.3470879</REVENUE_M>
<PROFIT_M>11.85817756</PROFIT_M>
<INCOME_M>1.78183258</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>21023145</REVENUE>
<PREV_YEAR_REV>1.786967325E7</PREV_YEAR_REV>
<BUDGET>2.039245065E7</BUDGET>
<GROSS_PROFIT>1.448767991E7</GROSS_PROFIT>
<EXPENSES>1.89208305E7</EXPENSES>
<NET_INCOME>2144360.79</NET_INCOME>
<REVENUE_M>21.023145</REVENUE_M>
<PROFIT_M>14.48767991</PROFIT_M>
<INCOME_M>2.14436079</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.507588352E7</REVENUE>
<PREV_YEAR_REV>3.831450099E7</PREV_YEAR_REV>
<BUDGET>4.372360701E7</BUDGET>
<GROSS_PROFIT>3.395566305E7</GROSS_PROFIT>
<EXPENSES>4.050986252E7</EXPENSES>
<NET_INCOME>7212141.36</NET_INCOME>
<REVENUE_M>45.07588352</REVENUE_M>
<PROFIT_M>33.95566305</PROFIT_M>
<INCOME_M>7.21214136</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>5.886115861E7</REVENUE>
<PREV_YEAR_REV>5.003198481E7</PREV_YEAR_REV>
<BUDGET>5.709532384E7</BUDGET>
<GROSS_PROFIT>4.434011078E7</GROSS_PROFIT>
<EXPENSES>5.301621465E7</EXPENSES>
<NET_INCOME>5723733.71</NET_INCOME>
<REVENUE_M>58.86115861</REVENUE_M>
<PROFIT_M>44.34011078</PROFIT_M>
<INCOME_M>5.72373371</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.951841786E7</REVENUE>
<PREV_YEAR_REV>1.659065518E7</PREV_YEAR_REV>
<BUDGET>1.893286532E7</BUDGET>
<GROSS_PROFIT>1.323290175E7</GROSS_PROFIT>
<EXPENSES>1.740030414E7</EXPENSES>
<NET_INCOME>2634986.41</NET_INCOME>
<REVENUE_M>19.51841786</REVENUE_M>
<PROFIT_M>13.23290175</PROFIT_M>
<INCOME_M>2.63498641</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.08905034E7</REVENUE>
<PREV_YEAR_REV>1.921926313E7</PREV_YEAR_REV>
<BUDGET>1.926831347E7</BUDGET>
<GROSS_PROFIT>1.494997541E7</GROSS_PROFIT>
<EXPENSES>1.881254803E7</EXPENSES>
<NET_INCOME>2026378.83</NET_INCOME>
<REVENUE_M>20.8905034</REVENUE_M>
<PROFIT_M>14.94997541</PROFIT_M>
<INCOME_M>2.02637883</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.968348187E7</REVENUE>
<PREV_YEAR_REV>3.650880333E7</PREV_YEAR_REV>
<BUDGET>2.313715151E7</BUDGET>
<GROSS_PROFIT>2.690421021E7</GROSS_PROFIT>
<EXPENSES>3.718829887E7</EXPENSES>
<NET_INCOME>5921687.76</NET_INCOME>
<REVENUE_M>39.68348187</REVENUE_M>
<PROFIT_M>26.90421021</PROFIT_M>
<INCOME_M>5.92168776</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>5.100094473E7</REVENUE>
<PREV_YEAR_REV>4.692086916E7</PREV_YEAR_REV>
<BUDGET>3.366096364E7</BUDGET>
<GROSS_PROFIT>3.841901166E7</GROSS_PROFIT>
<EXPENSES>4.737084082E7</EXPENSES>
<NET_INCOME>4979023.69</NET_INCOME>
<REVENUE_M>51.00094473</REVENUE_M>
<PROFIT_M>38.41901166</PROFIT_M>
<INCOME_M>4.97902369</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.384521079E7</REVENUE>
<PREV_YEAR_REV>4.033759393E7</PREV_YEAR_REV>
<BUDGET>44722115</BUDGET>
<GROSS_PROFIT>2.972573756E7</GROSS_PROFIT>
<EXPENSES>3.908718466E7</EXPENSES>
<NET_INCOME>5306800.76</NET_INCOME>
<REVENUE_M>43.84521079</REVENUE_M>
<PROFIT_M>29.72573756</PROFIT_M>
<INCOME_M>5.30680076</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.188474042E7</REVENUE>
<PREV_YEAR_REV>2.013396119E7</PREV_YEAR_REV>
<BUDGET>2.028243523E7</BUDGET>
<GROSS_PROFIT>1.566148621E7</GROSS_PROFIT>
<EXPENSES>1.972687386E7</EXPENSES>
<NET_INCOME>2122819.82</NET_INCOME>
<REVENUE_M>21.88474042</REVENUE_M>
<PROFIT_M>15.66148621</PROFIT_M>
<INCOME_M>2.12281982</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.90628159E7</REVENUE>
<PREV_YEAR_REV>1.753779063E7</PREV_YEAR_REV>
<BUDGET>1.944407222E7</BUDGET>
<GROSS_PROFIT>1.436001922E7</GROSS_PROFIT>
<EXPENSES>1.699414353E7</EXPENSES>
<NET_INCOME>2516291.7</NET_INCOME>
<REVENUE_M>19.0628159</REVENUE_M>
<PROFIT_M>14.36001922</PROFIT_M>
<INCOME_M>2.5162917</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.937282812E7</REVENUE>
<PREV_YEAR_REV>1.782300187E7</PREV_YEAR_REV>
<BUDGET>1.976028468E7</BUDGET>
<GROSS_PROFIT>1.459355143E7</GROSS_PROFIT>
<EXPENSES>1.727051362E7</EXPENSES>
<NET_INCOME>3467736.23</NET_INCOME>
<REVENUE_M>19.37282812</REVENUE_M>
<PROFIT_M>14.59355143</PROFIT_M>
<INCOME_M>3.46773623</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.016678089E7</REVENUE>
<PREV_YEAR_REV>2.775343841E7</PREV_YEAR_REV>
<BUDGET>3.077011651E7</BUDGET>
<GROSS_PROFIT>2.272463604E7</GROSS_PROFIT>
<EXPENSES>2.689312046E7</EXPENSES>
<NET_INCOME>3997901.57</NET_INCOME>
<REVENUE_M>30.16678089</REVENUE_M>
<PROFIT_M>22.72463604</PROFIT_M>
<INCOME_M>3.99790157</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.679890088E7</REVENUE>
<PREV_YEAR_REV>1.545498881E7</PREV_YEAR_REV>
<BUDGET>1.71348789E7</BUDGET>
<GROSS_PROFIT>1.202188144E7</GROSS_PROFIT>
<EXPENSES>1.497590567E7</EXPENSES>
<NET_INCOME>2889410.95</NET_INCOME>
<REVENUE_M>16.79890088</REVENUE_M>
<PROFIT_M>12.02188144</PROFIT_M>
<INCOME_M>2.88941095</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>9743246.15</REVENUE>
<PREV_YEAR_REV>8938223.26</PREV_YEAR_REV>
<BUDGET>1.071757076E7</BUDGET>
<GROSS_PROFIT>8078549.236</GROSS_PROFIT>
<EXPENSES>8456953.48</EXPENSES>
<NET_INCOME>1286292.66</NET_INCOME>
<REVENUE_M>9.74324615</REVENUE_M>
<PROFIT_M>8.078549236</PROFIT_M>
<INCOME_M>1.28629266</INCOME_M>
<PHARMA_REV_M>9.74324615</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.078549236</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.28629266</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2396015.95</REVENUE>
<PREV_YEAR_REV>2185707.2</PREV_YEAR_REV>
<BUDGET>1699376.18</BUDGET>
<GROSS_PROFIT>1923155.011</GROSS_PROFIT>
<EXPENSES>2086929.89</EXPENSES>
<NET_INCOME>309086.06</NET_INCOME>
<REVENUE_M>2.39601595</REVENUE_M>
<PROFIT_M>1.923155011</PROFIT_M>
<INCOME_M>0.30908606</INCOME_M>
<PHARMA_REV_M>2.39601595</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.923155011</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30908606</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5145128.22</REVENUE>
<PREV_YEAR_REV>4209007.24</PREV_YEAR_REV>
<BUDGET>4917806.82</BUDGET>
<GROSS_PROFIT>4004976.204</GROSS_PROFIT>
<EXPENSES>4380777.93</EXPENSES>
<NET_INCOME>764350.29</NET_INCOME>
<REVENUE_M>5.14512822</REVENUE_M>
<PROFIT_M>4.004976204</PROFIT_M>
<INCOME_M>0.76435029</INCOME_M>
<PHARMA_REV_M>5.14512822</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.004976204</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76435029</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2580762.55</REVENUE>
<PREV_YEAR_REV>2154423.65</PREV_YEAR_REV>
<BUDGET>2466609.94</BUDGET>
<GROSS_PROFIT>2085256.14</GROSS_PROFIT>
<EXPENSES>2392366.88</EXPENSES>
<NET_INCOME>188395.67</NET_INCOME>
<REVENUE_M>2.58076255</REVENUE_M>
<PROFIT_M>2.08525614</PROFIT_M>
<INCOME_M>0.18839567</INCOME_M>
<PHARMA_REV_M>2.58076255</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.08525614</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18839567</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5172971.97</REVENUE>
<PREV_YEAR_REV>4138203.92</PREV_YEAR_REV>
<BUDGET>4943979.94</BUDGET>
<GROSS_PROFIT>4332374.98</GROSS_PROFIT>
<EXPENSES>4477167.07</EXPENSES>
<NET_INCOME>695804.9</NET_INCOME>
<REVENUE_M>5.17297197</REVENUE_M>
<PROFIT_M>4.33237498</PROFIT_M>
<INCOME_M>0.6958049</INCOME_M>
<PHARMA_REV_M>5.17297197</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.33237498</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6958049</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2604678.17</REVENUE>
<PREV_YEAR_REV>2160518.73</PREV_YEAR_REV>
<BUDGET>2489090.63</BUDGET>
<GROSS_PROFIT>2162039.162</GROSS_PROFIT>
<EXPENSES>2320768.25</EXPENSES>
<NET_INCOME>283909.92</NET_INCOME>
<REVENUE_M>2.60467817</REVENUE_M>
<PROFIT_M>2.162039162</PROFIT_M>
<INCOME_M>0.28390992</INCOME_M>
<PHARMA_REV_M>2.60467817</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.162039162</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28390992</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2554990.67</REVENUE>
<PREV_YEAR_REV>2059513.03</PREV_YEAR_REV>
<BUDGET>2442384.38</BUDGET>
<GROSS_PROFIT>2038882.562</GROSS_PROFIT>
<EXPENSES>2115532.28</EXPENSES>
<NET_INCOME>439458.4</NET_INCOME>
<REVENUE_M>2.55499067</REVENUE_M>
<PROFIT_M>2.038882562</PROFIT_M>
<INCOME_M>0.4394584</INCOME_M>
<PHARMA_REV_M>2.55499067</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.038882562</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4394584</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4150618.84</REVENUE>
<PREV_YEAR_REV>3465826.25</PREV_YEAR_REV>
<BUDGET>3982968</BUDGET>
<GROSS_PROFIT>3007272.04</GROSS_PROFIT>
<EXPENSES>3648758.29</EXPENSES>
<NET_INCOME>501860.56</NET_INCOME>
<REVENUE_M>4.15061884</REVENUE_M>
<PROFIT_M>3.00727204</PROFIT_M>
<INCOME_M>0.50186056</INCOME_M>
<PHARMA_REV_M>4.15061884</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.00727204</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50186056</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4064918.84</REVENUE>
<PREV_YEAR_REV>3221067.63</PREV_YEAR_REV>
<BUDGET>3902410</BUDGET>
<GROSS_PROFIT>2876287.383</GROSS_PROFIT>
<EXPENSES>3464835.64</EXPENSES>
<NET_INCOME>600083.2</NET_INCOME>
<REVENUE_M>4.06491884</REVENUE_M>
<PROFIT_M>2.876287383</PROFIT_M>
<INCOME_M>0.6000832</INCOME_M>
<PHARMA_REV_M>4.06491884</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.876287383</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6000832</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1823000</REVENUE>
<PREV_YEAR_REV>1510456.37</PREV_YEAR_REV>
<BUDGET>1754731.92</BUDGET>
<GROSS_PROFIT>1540435</GROSS_PROFIT>
<EXPENSES>1496683</EXPENSES>
<NET_INCOME>326317</NET_INCOME>
<REVENUE_M>1.823</REVENUE_M>
<PROFIT_M>1.540435</PROFIT_M>
<INCOME_M>0.326317</INCOME_M>
<PHARMA_REV_M>1.823</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.540435</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.326317</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2103029.42</REVENUE>
<PREV_YEAR_REV>1745846.66</PREV_YEAR_REV>
<BUDGET>2017540.8</BUDGET>
<GROSS_PROFIT>1556346.927</GROSS_PROFIT>
<EXPENSES>1741308.36</EXPENSES>
<NET_INCOME>361721.06</NET_INCOME>
<REVENUE_M>2.10302942</REVENUE_M>
<PROFIT_M>1.556346927</PROFIT_M>
<INCOME_M>0.36172106</INCOME_M>
<PHARMA_REV_M>2.10302942</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.556346927</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36172106</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1082600</REVENUE>
<PREV_YEAR_REV>883027.06</PREV_YEAR_REV>
<BUDGET>1113799.99</BUDGET>
<GROSS_PROFIT>921292.6</GROSS_PROFIT>
<EXPENSES>964596.6</EXPENSES>
<NET_INCOME>118003.4</NET_INCOME>
<REVENUE_M>1.0826</REVENUE_M>
<PROFIT_M>0.9212926</PROFIT_M>
<INCOME_M>0.1180034</INCOME_M>
<PHARMA_REV_M>1.0826</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.9212926</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1180034</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.147863717E7</REVENUE>
<PREV_YEAR_REV>1.033077345E7</PREV_YEAR_REV>
<BUDGET>1.090470531E7</BUDGET>
<GROSS_PROFIT>8646857.382</GROSS_PROFIT>
<EXPENSES>1.89208305E7</EXPENSES>
<NET_INCOME>2054676.05</NET_INCOME>
<REVENUE_M>11.47863717</REVENUE_M>
<PROFIT_M>8.646857382</PROFIT_M>
<INCOME_M>2.05467605</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.47162015E7</REVENUE>
<PREV_YEAR_REV>1.324458135E7</PREV_YEAR_REV>
<BUDGET>1.398039143E7</BUDGET>
<GROSS_PROFIT>1.108571459E7</GROSS_PROFIT>
<EXPENSES>24257475</EXPENSES>
<NET_INCOME>1979819.64</NET_INCOME>
<REVENUE_M>14.7162015</REVENUE_M>
<PROFIT_M>11.08571459</PROFIT_M>
<INCOME_M>1.97981964</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>8969569.41</REVENUE>
<PREV_YEAR_REV>8072612.47</PREV_YEAR_REV>
<BUDGET>8521090.94</BUDGET>
<GROSS_PROFIT>6081098.971</GROSS_PROFIT>
<EXPENSES>1.478500452E7</EXPENSES>
<NET_INCOME>1210891.87</NET_INCOME>
<REVENUE_M>8.96956941</REVENUE_M>
<PROFIT_M>6.081098971</PROFIT_M>
<INCOME_M>1.21089187</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>8948699.16</REVENUE>
<PREV_YEAR_REV>8053829.24</PREV_YEAR_REV>
<BUDGET>8501264.2</BUDGET>
<GROSS_PROFIT>6404002.324</GROSS_PROFIT>
<EXPENSES>1.475060301E7</EXPENSES>
<NET_INCOME>912767.31</NET_INCOME>
<REVENUE_M>8.94869916</REVENUE_M>
<PROFIT_M>6.404002324</PROFIT_M>
<INCOME_M>0.91276731</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.69326281E7</REVENUE>
<PREV_YEAR_REV>2.423936529E7</PREV_YEAR_REV>
<BUDGET>2.402441005E7</BUDGET>
<GROSS_PROFIT>2.028834875E7</GROSS_PROFIT>
<EXPENSES>41684922</EXPENSES>
<NET_INCOME>3555106.91</NET_INCOME>
<REVENUE_M>26.9326281</REVENUE_M>
<PROFIT_M>20.28834875</PROFIT_M>
<INCOME_M>3.55510691</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.398776465E7</REVENUE>
<PREV_YEAR_REV>3.058898818E7</PREV_YEAR_REV>
<BUDGET>3.031772433E7</BUDGET>
<GROSS_PROFIT>2.56029831E7</GROSS_PROFIT>
<EXPENSES>5.260449566E7</EXPENSES>
<NET_INCOME>3239516.88</NET_INCOME>
<REVENUE_M>33.98776465</REVENUE_M>
<PROFIT_M>25.6029831</PROFIT_M>
<INCOME_M>3.23951688</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>6779653.69</REVENUE>
<PREV_YEAR_REV>6101688.32</PREV_YEAR_REV>
<BUDGET>6047578.41</BUDGET>
<GROSS_PROFIT>5107113.126</GROSS_PROFIT>
<EXPENSES>1.049319563E7</EXPENSES>
<NET_INCOME>494914.72</NET_INCOME>
<REVENUE_M>6.77965369</REVENUE_M>
<PROFIT_M>5.107113126</PROFIT_M>
<INCOME_M>0.49491472</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.838268443E7</REVENUE>
<PREV_YEAR_REV>2.696355021E7</PREV_YEAR_REV>
<BUDGET>2.75312039E7</BUDGET>
<GROSS_PROFIT>2.138067618E7</GROSS_PROFIT>
<EXPENSES>2.392254831E7</EXPENSES>
<NET_INCOME>3746514.35</NET_INCOME>
<REVENUE_M>28.38268443</REVENUE_M>
<PROFIT_M>21.38067618</PROFIT_M>
<INCOME_M>3.74651435</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.915706517E7</REVENUE>
<PREV_YEAR_REV>2.769921191E7</PREV_YEAR_REV>
<BUDGET>2.828235322E7</BUDGET>
<GROSS_PROFIT>1.976761548E7</GROSS_PROFIT>
<EXPENSES>2.457524065E7</EXPENSES>
<NET_INCOME>3529022.51</NET_INCOME>
<REVENUE_M>29.15706517</REVENUE_M>
<PROFIT_M>19.76761548</PROFIT_M>
<INCOME_M>3.52902251</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.286615946E7</REVENUE>
<PREV_YEAR_REV>1.222285149E7</PREV_YEAR_REV>
<BUDGET>1.248017468E7</BUDGET>
<GROSS_PROFIT>9692077.928</GROSS_PROFIT>
<EXPENSES>1.084433441E7</EXPENSES>
<NET_INCOME>939229.64</NET_INCOME>
<REVENUE_M>12.86615946</REVENUE_M>
<PROFIT_M>9.692077928</PROFIT_M>
<INCOME_M>0.93922964</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2175959.36</REVENUE>
<PREV_YEAR_REV>1996677.67</PREV_YEAR_REV>
<BUDGET>1619341.73</BUDGET>
<GROSS_PROFIT>1879049.703</GROSS_PROFIT>
<EXPENSES>1827805.86</EXPENSES>
<NET_INCOME>348153.5</NET_INCOME>
<REVENUE_M>2.17595936</REVENUE_M>
<PROFIT_M>1.879049703</PROFIT_M>
<INCOME_M>0.3481535</INCOME_M>
<PHARMA_REV_M>2.17595936</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.879049703</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3481535</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2163893.09</REVENUE>
<PREV_YEAR_REV>1932409.73</PREV_YEAR_REV>
<BUDGET>1632914.47</BUDGET>
<GROSS_PROFIT>1757167.74</GROSS_PROFIT>
<EXPENSES>1878259.2</EXPENSES>
<NET_INCOME>285633.89</NET_INCOME>
<REVENUE_M>2.16389309</REVENUE_M>
<PROFIT_M>1.75716774</PROFIT_M>
<INCOME_M>0.28563389</INCOME_M>
<PHARMA_REV_M>2.16389309</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.75716774</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28563389</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2694813.75</REVENUE>
<PREV_YEAR_REV>2448028.04</PREV_YEAR_REV>
<BUDGET>1930791.21</BUDGET>
<GROSS_PROFIT>2079419.348</GROSS_PROFIT>
<EXPENSES>2231305.79</EXPENSES>
<NET_INCOME>463507.97</NET_INCOME>
<REVENUE_M>2.69481375</REVENUE_M>
<PROFIT_M>2.079419348</PROFIT_M>
<INCOME_M>0.46350797</INCOME_M>
<PHARMA_REV_M>2.69481375</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.079419348</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46350797</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1887780.49</REVENUE>
<PREV_YEAR_REV>1683263.92</PREV_YEAR_REV>
<BUDGET>1711779.15</BUDGET>
<GROSS_PROFIT>1583847.83</GROSS_PROFIT>
<EXPENSES>1638593.47</EXPENSES>
<NET_INCOME>249187.02</NET_INCOME>
<REVENUE_M>1.88778049</REVENUE_M>
<PROFIT_M>1.58384783</PROFIT_M>
<INCOME_M>0.24918702</INCOME_M>
<PHARMA_REV_M>1.88778049</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.58384783</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24918702</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3665085.3</REVENUE>
<PREV_YEAR_REV>3333883.72</PREV_YEAR_REV>
<BUDGET>3400712.16</BUDGET>
<GROSS_PROFIT>2924762.401</GROSS_PROFIT>
<EXPENSES>3175066.32</EXPENSES>
<NET_INCOME>490018.98</NET_INCOME>
<REVENUE_M>3.6650853</REVENUE_M>
<PROFIT_M>2.924762401</PROFIT_M>
<INCOME_M>0.49001898</INCOME_M>
<PHARMA_REV_M>3.6650853</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.924762401</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49001898</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1748422.15</REVENUE>
<PREV_YEAR_REV>1597097.19</PREV_YEAR_REV>
<BUDGET>1649621.06</BUDGET>
<GROSS_PROFIT>1360359.853</GROSS_PROFIT>
<EXPENSES>1570083.09</EXPENSES>
<NET_INCOME>178339.06</NET_INCOME>
<REVENUE_M>1.74842215</REVENUE_M>
<PROFIT_M>1.360359853</PROFIT_M>
<INCOME_M>0.17833906</INCOME_M>
<PHARMA_REV_M>1.74842215</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.360359853</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17833906</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1070428.25</REVENUE>
<PREV_YEAR_REV>979492.2</PREV_YEAR_REV>
<BUDGET>881299.21</BUDGET>
<GROSS_PROFIT>801536.679</GROSS_PROFIT>
<EXPENSES>932343.01</EXPENSES>
<NET_INCOME>138085.24</NET_INCOME>
<REVENUE_M>1.07042825</REVENUE_M>
<PROFIT_M>0.801536679</PROFIT_M>
<INCOME_M>0.13808524</INCOME_M>
<PHARMA_REV_M>1.07042825</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.801536679</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13808524</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1127112.65</REVENUE>
<PREV_YEAR_REV>1033782.75</PREV_YEAR_REV>
<BUDGET>929452.09</BUDGET>
<GROSS_PROFIT>904789.6805</GROSS_PROFIT>
<EXPENSES>1012147.16</EXPENSES>
<NET_INCOME>114965.49</NET_INCOME>
<REVENUE_M>1.12711265</REVENUE_M>
<PROFIT_M>0.904789681</PROFIT_M>
<INCOME_M>0.11496549</INCOME_M>
<PHARMA_REV_M>1.12711265</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.904789681</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11496549</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.677022804E7</REVENUE>
<PREV_YEAR_REV>1.503510438E7</PREV_YEAR_REV>
<BUDGET>1.509320523E7</BUDGET>
<GROSS_PROFIT>1.303195337E7</GROSS_PROFIT>
<EXPENSES>1.48861221E7</EXPENSES>
<NET_INCOME>1884105.94</NET_INCOME>
<REVENUE_M>16.77022804</REVENUE_M>
<PROFIT_M>13.03195337</PROFIT_M>
<INCOME_M>1.88410594</INCOME_M>
<PHARMA_REV_M>16.77022804</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.03195337</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.88410594</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5540672.18</REVENUE>
<PREV_YEAR_REV>5083185.49</PREV_YEAR_REV>
<BUDGET>4986604.96</BUDGET>
<GROSS_PROFIT>4499025.81</GROSS_PROFIT>
<EXPENSES>5136203.11</EXPENSES>
<NET_INCOME>404469.07</NET_INCOME>
<REVENUE_M>5.54067218</REVENUE_M>
<PROFIT_M>4.49902581</PROFIT_M>
<INCOME_M>0.40446907</INCOME_M>
<PHARMA_REV_M>5.54067218</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.49902581</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40446907</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5489317.66</REVENUE>
<PREV_YEAR_REV>4867797.3</PREV_YEAR_REV>
<BUDGET>4940385.9</BUDGET>
<GROSS_PROFIT>4781195.68</GROSS_PROFIT>
<EXPENSES>4506729.8</EXPENSES>
<NET_INCOME>982587.86</NET_INCOME>
<REVENUE_M>5.48931766</REVENUE_M>
<PROFIT_M>4.78119568</PROFIT_M>
<INCOME_M>0.98258786</INCOME_M>
<PHARMA_REV_M>5.48931766</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.78119568</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.98258786</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>2.135892713E7</REVENUE>
<PREV_YEAR_REV>1.92658445E7</PREV_YEAR_REV>
<BUDGET>1.922303442E7</BUDGET>
<GROSS_PROFIT>1.829085023E7</GROSS_PROFIT>
<EXPENSES>1.928418004E7</EXPENSES>
<NET_INCOME>2074747.1</NET_INCOME>
<REVENUE_M>21.35892713</REVENUE_M>
<PROFIT_M>18.29085023</PROFIT_M>
<INCOME_M>2.0747471</INCOME_M>
<PHARMA_REV_M>21.35892713</PHARMA_REV_M>
<PHARMA_PROFIT_M>18.29085023</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.0747471</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3182884.04</REVENUE>
<PREV_YEAR_REV>2806607.1</PREV_YEAR_REV>
<BUDGET>4121939.86</BUDGET>
<GROSS_PROFIT>2533062.159</GROSS_PROFIT>
<EXPENSES>2830062.91</EXPENSES>
<NET_INCOME>352821.12</NET_INCOME>
<REVENUE_M>3.18288404</REVENUE_M>
<PROFIT_M>2.533062159</PROFIT_M>
<INCOME_M>0.35282112</INCOME_M>
<PHARMA_REV_M>3.18288404</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.533062159</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35282112</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3141084.41</REVENUE>
<PREV_YEAR_REV>2818240.14</PREV_YEAR_REV>
<BUDGET>4187216.51</BUDGET>
<GROSS_PROFIT>2410677.162</GROSS_PROFIT>
<EXPENSES>2762134.6</EXPENSES>
<NET_INCOME>378949.81</NET_INCOME>
<REVENUE_M>3.14108441</REVENUE_M>
<PROFIT_M>2.410677162</PROFIT_M>
<INCOME_M>0.37894981</INCOME_M>
<PHARMA_REV_M>3.14108441</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.410677162</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37894981</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3208678.62</REVENUE>
<PREV_YEAR_REV>2863708.45</PREV_YEAR_REV>
<BUDGET>4179783.79</BUDGET>
<GROSS_PROFIT>2553746.832</GROSS_PROFIT>
<EXPENSES>2853234.83</EXPENSES>
<NET_INCOME>355443.79</NET_INCOME>
<REVENUE_M>3.20867862</REVENUE_M>
<PROFIT_M>2.553746832</PROFIT_M>
<INCOME_M>0.35544379</INCOME_M>
<PHARMA_REV_M>3.20867862</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.553746832</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35544379</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8620276.96</REVENUE>
<PREV_YEAR_REV>7653488.32</PREV_YEAR_REV>
<BUDGET>7758249.27</BUDGET>
<GROSS_PROFIT>7008285.17</GROSS_PROFIT>
<EXPENSES>7680666.77</EXPENSES>
<NET_INCOME>939610.19</NET_INCOME>
<REVENUE_M>8.62027696</REVENUE_M>
<PROFIT_M>7.00828517</PROFIT_M>
<INCOME_M>0.93961019</INCOME_M>
<PHARMA_REV_M>8.62027696</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.00828517</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.93961019</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2222227.65</REVENUE>
<PREV_YEAR_REV>2039751.49</PREV_YEAR_REV>
<BUDGET>2207002.7</BUDGET>
<GROSS_PROFIT>1622603.969</GROSS_PROFIT>
<EXPENSES>1935560.29</EXPENSES>
<NET_INCOME>286667.37</NET_INCOME>
<REVENUE_M>2.22222765</REVENUE_M>
<PROFIT_M>1.622603969</PROFIT_M>
<INCOME_M>0.28666737</INCOME_M>
<PHARMA_REV_M>2.22222765</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.622603969</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28666737</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4453990.48</REVENUE>
<PREV_YEAR_REV>3959405.72</PREV_YEAR_REV>
<BUDGET>4260691.22</BUDGET>
<GROSS_PROFIT>3601101.381</GROSS_PROFIT>
<EXPENSES>3961526.69</EXPENSES>
<NET_INCOME>492463.8</NET_INCOME>
<REVENUE_M>4.45399048</REVENUE_M>
<PROFIT_M>3.601101381</PROFIT_M>
<INCOME_M>0.4924638</INCOME_M>
<PHARMA_REV_M>4.45399048</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.601101381</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4924638</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4613134.63</REVENUE>
<PREV_YEAR_REV>4216939.26</PREV_YEAR_REV>
<BUDGET>4430669.02</BUDGET>
<GROSS_PROFIT>3529891.516</GROSS_PROFIT>
<EXPENSES>4004754.31</EXPENSES>
<NET_INCOME>608380.32</NET_INCOME>
<REVENUE_M>4.61313463</REVENUE_M>
<PROFIT_M>3.529891516</PROFIT_M>
<INCOME_M>0.60838032</INCOME_M>
<PHARMA_REV_M>4.61313463</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.529891516</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60838032</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2250548.58</REVENUE>
<PREV_YEAR_REV>2048038.53</PREV_YEAR_REV>
<BUDGET>2144289.32</BUDGET>
<GROSS_PROFIT>1793543.188</GROSS_PROFIT>
<EXPENSES>2020992.63</EXPENSES>
<NET_INCOME>229555.96</NET_INCOME>
<REVENUE_M>2.25054858</REVENUE_M>
<PROFIT_M>1.793543188</PROFIT_M>
<INCOME_M>0.22955596</INCOME_M>
<PHARMA_REV_M>2.25054858</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.793543188</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22955596</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1599937.58</REVENUE>
<PREV_YEAR_REV>1469922.9</PREV_YEAR_REV>
<BUDGET>1937992.77</BUDGET>
<GROSS_PROFIT>1114804.509</GROSS_PROFIT>
<EXPENSES>1393545.63</EXPENSES>
<NET_INCOME>206391.95</NET_INCOME>
<REVENUE_M>1.59993758</REVENUE_M>
<PROFIT_M>1.114804509</PROFIT_M>
<INCOME_M>0.20639195</INCOME_M>
<PHARMA_REV_M>1.59993758</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.114804509</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20639195</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1593673.96</REVENUE>
<PREV_YEAR_REV>1449651.12</PREV_YEAR_REV>
<BUDGET>1894960.09</BUDGET>
<GROSS_PROFIT>1174553.651</GROSS_PROFIT>
<EXPENSES>1388090.02</EXPENSES>
<NET_INCOME>205583.94</NET_INCOME>
<REVENUE_M>1.59367396</REVENUE_M>
<PROFIT_M>1.174553651</PROFIT_M>
<INCOME_M>0.20558394</INCOME_M>
<PHARMA_REV_M>1.59367396</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.174553651</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20558394</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3212886.62</REVENUE>
<PREV_YEAR_REV>2885652.15</PREV_YEAR_REV>
<BUDGET>3853908.8</BUDGET>
<GROSS_PROFIT>2675651.07</GROSS_PROFIT>
<EXPENSES>2781043.2</EXPENSES>
<NET_INCOME>431843.42</NET_INCOME>
<REVENUE_M>3.21288662</REVENUE_M>
<PROFIT_M>2.67565107</PROFIT_M>
<INCOME_M>0.43184342</INCOME_M>
<PHARMA_REV_M>3.21288662</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.67565107</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43184342</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1628751.39</REVENUE>
<PREV_YEAR_REV>1500213.13</PREV_YEAR_REV>
<BUDGET>1936463.79</BUDGET>
<GROSS_PROFIT>1246932.968</GROSS_PROFIT>
<EXPENSES>1408869.95</EXPENSES>
<NET_INCOME>219881.44</NET_INCOME>
<REVENUE_M>1.62875139</REVENUE_M>
<PROFIT_M>1.246932968</PROFIT_M>
<INCOME_M>0.21988144</INCOME_M>
<PHARMA_REV_M>1.62875139</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.246932968</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21988144</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1466932.65</REVENUE>
<PREV_YEAR_REV>1315068.53</PREV_YEAR_REV>
<BUDGET>1756591.33</BUDGET>
<GROSS_PROFIT>1154475.99</GROSS_PROFIT>
<EXPENSES>1307036.99</EXPENSES>
<NET_INCOME>159895.66</NET_INCOME>
<REVENUE_M>1.46693265</REVENUE_M>
<PROFIT_M>1.15447599</PROFIT_M>
<INCOME_M>0.15989566</INCOME_M>
<PHARMA_REV_M>1.46693265</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.15447599</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15989566</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1360360.81</REVENUE>
<PREV_YEAR_REV>1234648.86</PREV_YEAR_REV>
<BUDGET>1388964.86</BUDGET>
<GROSS_PROFIT>1041628.27</GROSS_PROFIT>
<EXPENSES>1180793.18</EXPENSES>
<NET_INCOME>179567.63</NET_INCOME>
<REVENUE_M>1.36036081</REVENUE_M>
<PROFIT_M>1.04162827</PROFIT_M>
<INCOME_M>0.17956763</INCOME_M>
<PHARMA_REV_M>1.36036081</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.04162827</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17956763</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2650250.95</REVENUE>
<PREV_YEAR_REV>2385272.41</PREV_YEAR_REV>
<BUDGET>2726958.53</BUDGET>
<GROSS_PROFIT>1850070.033</GROSS_PROFIT>
<EXPENSES>2329655.57</EXPENSES>
<NET_INCOME>320595.38</NET_INCOME>
<REVENUE_M>2.65025095</REVENUE_M>
<PROFIT_M>1.850070033</PROFIT_M>
<INCOME_M>0.32059538</INCOME_M>
<PHARMA_REV_M>2.65025095</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.850070033</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32059538</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1046140.75</REVENUE>
<PREV_YEAR_REV>936504.21</PREV_YEAR_REV>
<BUDGET>1115759.29</BUDGET>
<GROSS_PROFIT>930019.13</GROSS_PROFIT>
<EXPENSES>878758.23</EXPENSES>
<NET_INCOME>167382.52</NET_INCOME>
<REVENUE_M>1.04614075</REVENUE_M>
<PROFIT_M>0.93001913</PROFIT_M>
<INCOME_M>0.16738252</INCOME_M>
<PHARMA_REV_M>1.04614075</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.93001913</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16738252</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2319569.2</REVENUE>
<PREV_YEAR_REV>2070604.25</PREV_YEAR_REV>
<BUDGET>2432339.97</BUDGET>
<GROSS_PROFIT>1927059.857</GROSS_PROFIT>
<EXPENSES>2062695.24</EXPENSES>
<NET_INCOME>256873.96</NET_INCOME>
<REVENUE_M>2.3195692</REVENUE_M>
<PROFIT_M>1.927059857</PROFIT_M>
<INCOME_M>0.25687396</INCOME_M>
<PHARMA_REV_M>2.3195692</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.927059857</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25687396</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2504103.54</REVENUE>
<PREV_YEAR_REV>2265595.4</PREV_YEAR_REV>
<BUDGET>2623079.25</BUDGET>
<GROSS_PROFIT>2140669.38</GROSS_PROFIT>
<EXPENSES>2166388.7</EXPENSES>
<NET_INCOME>337714.84</NET_INCOME>
<REVENUE_M>2.50410354</REVENUE_M>
<PROFIT_M>2.14066938</PROFIT_M>
<INCOME_M>0.33771484</INCOME_M>
<PHARMA_REV_M>2.50410354</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.14066938</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33771484</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.032165429E7</REVENUE>
<PREV_YEAR_REV>9075018.94</PREV_YEAR_REV>
<BUDGET>1.052808738E7</BUDGET>
<GROSS_PROFIT>9093377.43</GROSS_PROFIT>
<EXPENSES>8670189.61</EXPENSES>
<NET_INCOME>1651464.69</NET_INCOME>
<REVENUE_M>10.32165429</REVENUE_M>
<PROFIT_M>9.09337743</PROFIT_M>
<INCOME_M>1.65146469</INCOME_M>
<PHARMA_REV_M>10.32165429</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.09337743</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.65146469</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6995451.7</REVENUE>
<PREV_YEAR_REV>6303401.27</PREV_YEAR_REV>
<BUDGET>7135360.73</BUDGET>
<GROSS_PROFIT>5443188.945</GROSS_PROFIT>
<EXPENSES>6093038.43</EXPENSES>
<NET_INCOME>902413.27</NET_INCOME>
<REVENUE_M>6.9954517</REVENUE_M>
<PROFIT_M>5.443188945</PROFIT_M>
<INCOME_M>0.90241327</INCOME_M>
<PHARMA_REV_M>6.9954517</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.443188945</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.90241327</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9444809.83</REVENUE>
<PREV_YEAR_REV>8561207.59</PREV_YEAR_REV>
<BUDGET>9633706.02</BUDGET>
<GROSS_PROFIT>6791762.745</GROSS_PROFIT>
<EXPENSES>8226429.36</EXPENSES>
<NET_INCOME>1218380.47</NET_INCOME>
<REVENUE_M>9.44480983</REVENUE_M>
<PROFIT_M>6.791762745</PROFIT_M>
<INCOME_M>1.21838047</INCOME_M>
<PHARMA_REV_M>9.44480983</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.791762745</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.21838047</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.169754673E7</REVENUE>
<PREV_YEAR_REV>1.000752968E7</PREV_YEAR_REV>
<BUDGET>1.193149767E7</BUDGET>
<GROSS_PROFIT>1.027639724E7</GROSS_PROFIT>
<EXPENSES>1.012400133E7</EXPENSES>
<NET_INCOME>1573545.41</NET_INCOME>
<REVENUE_M>11.69754673</REVENUE_M>
<PROFIT_M>10.27639724</PROFIT_M>
<INCOME_M>1.57354541</INCOME_M>
<PHARMA_REV_M>11.69754673</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.27639724</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.57354541</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7119519.15</REVENUE>
<PREV_YEAR_REV>6330993.87</PREV_YEAR_REV>
<BUDGET>7261909.53</BUDGET>
<GROSS_PROFIT>6169632.904</GROSS_PROFIT>
<EXPENSES>6599794.25</EXPENSES>
<NET_INCOME>519724.9</NET_INCOME>
<REVENUE_M>7.11951915</REVENUE_M>
<PROFIT_M>6.169632904</PROFIT_M>
<INCOME_M>0.5197249</INCOME_M>
<PHARMA_REV_M>7.11951915</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.169632904</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5197249</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2297949.79</REVENUE>
<PREV_YEAR_REV>1955202.75</PREV_YEAR_REV>
<BUDGET>2371060.96</BUDGET>
<GROSS_PROFIT>1654317.031</GROSS_PROFIT>
<EXPENSES>2001514.27</EXPENSES>
<NET_INCOME>296435.52</NET_INCOME>
<REVENUE_M>2.29794979</REVENUE_M>
<PROFIT_M>1.654317031</PROFIT_M>
<INCOME_M>0.29643552</INCOME_M>
<PHARMA_REV_M>2.29794979</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.654317031</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29643552</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1836807.07</REVENUE>
<PREV_YEAR_REV>1608173.1</PREV_YEAR_REV>
<BUDGET>1990603.95</BUDGET>
<GROSS_PROFIT>1405851.719</GROSS_PROFIT>
<EXPENSES>1599858.95</EXPENSES>
<NET_INCOME>236948.11</NET_INCOME>
<REVENUE_M>1.83680707</REVENUE_M>
<PROFIT_M>1.405851719</PROFIT_M>
<INCOME_M>0.23694811</INCOME_M>
<PHARMA_REV_M>1.83680707</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.405851719</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23694811</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4495407.1</REVENUE>
<PREV_YEAR_REV>3908618.39</PREV_YEAR_REV>
<BUDGET>4598784.13</BUDGET>
<GROSS_PROFIT>3465161.936</GROSS_PROFIT>
<EXPENSES>3956770.71</EXPENSES>
<NET_INCOME>538636.39</NET_INCOME>
<REVENUE_M>4.4954071</REVENUE_M>
<PROFIT_M>3.465161936</PROFIT_M>
<INCOME_M>0.53863639</INCOME_M>
<PHARMA_REV_M>4.4954071</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.465161936</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53863639</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2692819.16</REVENUE>
<PREV_YEAR_REV>2448329.02</PREV_YEAR_REV>
<BUDGET>1986712.28</BUDGET>
<GROSS_PROFIT>2311731.388</GROSS_PROFIT>
<EXPENSES>2496243.36</EXPENSES>
<NET_INCOME>196575.8</NET_INCOME>
<REVENUE_M>2.69281916</REVENUE_M>
<PROFIT_M>2.311731388</PROFIT_M>
<INCOME_M>0.1965758</INCOME_M>
<PHARMA_REV_M>2.69281916</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.311731388</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1965758</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2227776.98</REVENUE>
<PREV_YEAR_REV>2053837.49</PREV_YEAR_REV>
<BUDGET>1828717.12</BUDGET>
<GROSS_PROFIT>1748359.377</GROSS_PROFIT>
<EXPENSES>1940393.75</EXPENSES>
<NET_INCOME>287383.23</NET_INCOME>
<REVENUE_M>2.22777698</REVENUE_M>
<PROFIT_M>1.748359377</PROFIT_M>
<INCOME_M>0.28738323</INCOME_M>
<PHARMA_REV_M>2.22777698</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.748359377</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28738323</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4029769.36</REVENUE>
<PREV_YEAR_REV>3751677.71</PREV_YEAR_REV>
<BUDGET>3540991.53</BUDGET>
<GROSS_PROFIT>3012303.605</GROSS_PROFIT>
<EXPENSES>3430878.88</EXPENSES>
<NET_INCOME>598890.48</NET_INCOME>
<REVENUE_M>4.02976936</REVENUE_M>
<PROFIT_M>3.012303605</PROFIT_M>
<INCOME_M>0.59889048</INCOME_M>
<PHARMA_REV_M>4.02976936</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.012303605</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.59889048</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>6039302.88</REVENUE>
<PREV_YEAR_REV>5542449.71</PREV_YEAR_REV>
<BUDGET>5350666.39</BUDGET>
<GROSS_PROFIT>4849365.801</GROSS_PROFIT>
<EXPENSES>5454119.18</EXPENSES>
<NET_INCOME>585183.7</NET_INCOME>
<REVENUE_M>6.03930288</REVENUE_M>
<PROFIT_M>4.849365801</PROFIT_M>
<INCOME_M>0.5851837</INCOME_M>
<PHARMA_REV_M>6.03930288</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.849365801</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5851837</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4254577.57</REVENUE>
<PREV_YEAR_REV>3901553.57</PREV_YEAR_REV>
<BUDGET>3540991.53</BUDGET>
<GROSS_PROFIT>3390033.013</GROSS_PROFIT>
<EXPENSES>3690606.09</EXPENSES>
<NET_INCOME>563971.47</NET_INCOME>
<REVENUE_M>4.25457757</REVENUE_M>
<PROFIT_M>3.390033013</PROFIT_M>
<INCOME_M>0.56397147</INCOME_M>
<PHARMA_REV_M>4.25457757</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.390033013</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56397147</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1583470.81</REVENUE>
<PREV_YEAR_REV>1456065.11</PREV_YEAR_REV>
<BUDGET>1173911.08</BUDGET>
<GROSS_PROFIT>1242549.546</GROSS_PROFIT>
<EXPENSES>1330115.48</EXPENSES>
<NET_INCOME>253355.33</NET_INCOME>
<REVENUE_M>1.58347081</REVENUE_M>
<PROFIT_M>1.242549546</PROFIT_M>
<INCOME_M>0.25335533</INCOME_M>
<PHARMA_REV_M>1.58347081</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.242549546</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25335533</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>2.172346677E7</REVENUE>
<PREV_YEAR_REV>1.971481859E7</PREV_YEAR_REV>
<BUDGET>1.955112009E7</BUDGET>
<GROSS_PROFIT>1.791070866E7</GROSS_PROFIT>
<EXPENSES>1.958420735E7</EXPENSES>
<NET_INCOME>2139259.41</NET_INCOME>
<REVENUE_M>21.72346677</REVENUE_M>
<PROFIT_M>17.91070866</PROFIT_M>
<INCOME_M>2.13925941</INCOME_M>
<PHARMA_REV_M>21.72346677</PHARMA_REV_M>
<PHARMA_PROFIT_M>17.91070866</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.13925941</PHARMA_INCOME_M>
<FRANCE_REV_M>21.72346677</FRANCE_REV_M>
<FRANCE_PROFIT_M>17.91070866</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>2.13925941</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6712560.79</REVENUE>
<PREV_YEAR_REV>6104214.75</PREV_YEAR_REV>
<BUDGET>6041304.71</BUDGET>
<GROSS_PROFIT>5276072.78</GROSS_PROFIT>
<EXPENSES>6222543.85</EXPENSES>
<NET_INCOME>490016.94</NET_INCOME>
<REVENUE_M>6.71256079</REVENUE_M>
<PROFIT_M>5.27607278</PROFIT_M>
<INCOME_M>0.49001694</INCOME_M>
<PHARMA_REV_M>6.71256079</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.27607278</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49001694</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7821260.16</REVENUE>
<PREV_YEAR_REV>7143877.68</PREV_YEAR_REV>
<BUDGET>7039134.14</BUDGET>
<GROSS_PROFIT>5736894.327</GROSS_PROFIT>
<EXPENSES>6765390.04</EXPENSES>
<NET_INCOME>1055870.12</NET_INCOME>
<REVENUE_M>7.82126016</REVENUE_M>
<PROFIT_M>5.736894327</PROFIT_M>
<INCOME_M>1.05587012</INCOME_M>
<PHARMA_REV_M>7.82126016</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.736894327</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.05587012</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8213523.96</REVENUE>
<PREV_YEAR_REV>7305000.99</PREV_YEAR_REV>
<BUDGET>7392171.57</BUDGET>
<GROSS_PROFIT>7291884.446</GROSS_PROFIT>
<EXPENSES>7318249.85</EXPENSES>
<NET_INCOME>895274.11</NET_INCOME>
<REVENUE_M>8.21352396</REVENUE_M>
<PROFIT_M>7.291884446</PROFIT_M>
<INCOME_M>0.89527411</INCOME_M>
<PHARMA_REV_M>8.21352396</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.291884446</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.89527411</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6699463.06</REVENUE>
<PREV_YEAR_REV>5995689.07</PREV_YEAR_REV>
<BUDGET>6029516.75</BUDGET>
<GROSS_PROFIT>5524377.234</GROSS_PROFIT>
<EXPENSES>5547155.41</EXPENSES>
<NET_INCOME>1152307.65</NET_INCOME>
<REVENUE_M>6.69946306</REVENUE_M>
<PROFIT_M>5.524377234</PROFIT_M>
<INCOME_M>1.15230765</INCOME_M>
<PHARMA_REV_M>6.69946306</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.524377234</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.15230765</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4540504.86</REVENUE>
<PREV_YEAR_REV>4029769.36</PREV_YEAR_REV>
<BUDGET>4276106.27</BUDGET>
<GROSS_PROFIT>3366798.518</GROSS_PROFIT>
<EXPENSES>3866458.23</EXPENSES>
<NET_INCOME>674046.64</NET_INCOME>
<REVENUE_M>4.54050486</REVENUE_M>
<PROFIT_M>3.366798518</PROFIT_M>
<INCOME_M>0.67404664</INCOME_M>
<PHARMA_REV_M>4.54050486</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.366798518</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67404664</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2394731.67</REVENUE>
<PREV_YEAR_REV>2155726.3</PREV_YEAR_REV>
<BUDGET>2144754.08</BUDGET>
<GROSS_PROFIT>2033127.19</GROSS_PROFIT>
<EXPENSES>2219916.26</EXPENSES>
<NET_INCOME>174815.41</NET_INCOME>
<REVENUE_M>2.39473167</REVENUE_M>
<PROFIT_M>2.03312719</PROFIT_M>
<INCOME_M>0.17481541</INCOME_M>
<PHARMA_REV_M>2.39473167</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.03312719</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17481541</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2374187.09</REVENUE>
<PREV_YEAR_REV>2079045.76</PREV_YEAR_REV>
<BUDGET>2144754.08</BUDGET>
<GROSS_PROFIT>1919411.55</GROSS_PROFIT>
<EXPENSES>2200871.43</EXPENSES>
<NET_INCOME>173315.66</NET_INCOME>
<REVENUE_M>2.37418709</REVENUE_M>
<PROFIT_M>1.91941155</PROFIT_M>
<INCOME_M>0.17331566</INCOME_M>
<PHARMA_REV_M>2.37418709</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.91941155</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17331566</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4698574.74</REVENUE>
<PREV_YEAR_REV>4131531.36</PREV_YEAR_REV>
<BUDGET>4298864.19</BUDGET>
<GROSS_PROFIT>3954536</GROSS_PROFIT>
<EXPENSES>4067032.42</EXPENSES>
<NET_INCOME>631542.32</NET_INCOME>
<REVENUE_M>4.69857474</REVENUE_M>
<PROFIT_M>3.954536</PROFIT_M>
<INCOME_M>0.63154232</INCOME_M>
<PHARMA_REV_M>4.69857474</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.954536</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.63154232</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2256731.57</REVENUE>
<PREV_YEAR_REV>1986174.84</PREV_YEAR_REV>
<BUDGET>2074258.16</BUDGET>
<GROSS_PROFIT>1895203.175</GROSS_PROFIT>
<EXPENSES>2026544.95</EXPENSES>
<NET_INCOME>230186.62</NET_INCOME>
<REVENUE_M>2.25673157</REVENUE_M>
<PROFIT_M>1.895203175</PROFIT_M>
<INCOME_M>0.23018662</INCOME_M>
<PHARMA_REV_M>2.25673157</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.895203175</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23018662</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4059567.58</REVENUE>
<PREV_YEAR_REV>3569046.08</PREV_YEAR_REV>
<BUDGET>3020276.16</BUDGET>
<GROSS_PROFIT>2898769.633</GROSS_PROFIT>
<EXPENSES>3569820.21</EXPENSES>
<NET_INCOME>489747.37</NET_INCOME>
<REVENUE_M>4.05956758</REVENUE_M>
<PROFIT_M>2.898769633</PROFIT_M>
<INCOME_M>0.48974737</INCOME_M>
<PHARMA_REV_M>4.05956758</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.898769633</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48974737</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1601331.53</REVENUE>
<PREV_YEAR_REV>1375619.83</PREV_YEAR_REV>
<BUDGET>1108158.8</BUDGET>
<GROSS_PROFIT>1269695.772</GROSS_PROFIT>
<EXPENSES>1394759.76</EXPENSES>
<NET_INCOME>206571.77</NET_INCOME>
<REVENUE_M>1.60133153</REVENUE_M>
<PROFIT_M>1.269695772</PROFIT_M>
<INCOME_M>0.20657177</INCOME_M>
<PHARMA_REV_M>1.60133153</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.269695772</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20657177</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1895603.32</REVENUE>
<PREV_YEAR_REV>1631117.6</PREV_YEAR_REV>
<BUDGET>1383544.8</BUDGET>
<GROSS_PROFIT>1509089.801</GROSS_PROFIT>
<EXPENSES>1688982.55</EXPENSES>
<NET_INCOME>206620.76</NET_INCOME>
<REVENUE_M>1.89560332</REVENUE_M>
<PROFIT_M>1.509089801</PROFIT_M>
<INCOME_M>0.20662076</INCOME_M>
<PHARMA_REV_M>1.89560332</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.509089801</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20662076</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1581150.25</REVENUE>
<PREV_YEAR_REV>1404530.53</PREV_YEAR_REV>
<BUDGET>1168706.94</BUDGET>
<GROSS_PROFIT>1180644.886</GROSS_PROFIT>
<EXPENSES>1419872.92</EXPENSES>
<NET_INCOME>161277.33</NET_INCOME>
<REVENUE_M>1.58115025</REVENUE_M>
<PROFIT_M>1.180644886</PROFIT_M>
<INCOME_M>0.16127733</INCOME_M>
<PHARMA_REV_M>1.58115025</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.180644886</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16127733</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3348224.5</REVENUE>
<PREV_YEAR_REV>2649037.53</PREV_YEAR_REV>
<BUDGET>3180813.28</BUDGET>
<GROSS_PROFIT>2695220.279</GROSS_PROFIT>
<EXPENSES>2906258.87</EXPENSES>
<NET_INCOME>441965.63</NET_INCOME>
<REVENUE_M>3.3482245</REVENUE_M>
<PROFIT_M>2.695220279</PROFIT_M>
<INCOME_M>0.44196563</INCOME_M>
<PHARMA_REV_M>3.3482245</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.695220279</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44196563</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3663972.63</REVENUE>
<PREV_YEAR_REV>2924533.56</PREV_YEAR_REV>
<BUDGET>3480773.99</BUDGET>
<GROSS_PROFIT>3041317.114</GROSS_PROFIT>
<EXPENSES>3077737.01</EXPENSES>
<NET_INCOME>586235.62</NET_INCOME>
<REVENUE_M>3.66397263</REVENUE_M>
<PROFIT_M>3.041317114</PROFIT_M>
<INCOME_M>0.58623562</INCOME_M>
<PHARMA_REV_M>3.66397263</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.041317114</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58623562</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7537026.5</REVENUE>
<PREV_YEAR_REV>6111398.8</PREV_YEAR_REV>
<BUDGET>7160175.18</BUDGET>
<GROSS_PROFIT>5499610.117</GROSS_PROFIT>
<EXPENSES>6701949.77</EXPENSES>
<NET_INCOME>835076.73</NET_INCOME>
<REVENUE_M>7.5370265</REVENUE_M>
<PROFIT_M>5.499610117</PROFIT_M>
<INCOME_M>0.83507673</INCOME_M>
<PHARMA_REV_M>7.5370265</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.499610117</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83507673</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3888427</REVENUE>
<PREV_YEAR_REV>3238601.59</PREV_YEAR_REV>
<BUDGET>3694005.65</BUDGET>
<GROSS_PROFIT>3125128.778</GROSS_PROFIT>
<EXPENSES>3604571.83</EXPENSES>
<NET_INCOME>283855.17</NET_INCOME>
<REVENUE_M>3.888427</REVENUE_M>
<PROFIT_M>3.125128778</PROFIT_M>
<INCOME_M>0.28385517</INCOME_M>
<PHARMA_REV_M>3.888427</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.125128778</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28385517</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7687062.13</REVENUE>
<PREV_YEAR_REV>6226376</PREV_YEAR_REV>
<BUDGET>7302709.02</BUDGET>
<GROSS_PROFIT>6180599.075</GROSS_PROFIT>
<EXPENSES>6653052.13</EXPENSES>
<NET_INCOME>1034010</NET_INCOME>
<REVENUE_M>7.68706213</REVENUE_M>
<PROFIT_M>6.180599075</PROFIT_M>
<INCOME_M>1.03401</INCOME_M>
<PHARMA_REV_M>7.68706213</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.180599075</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03401</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3822952</REVENUE>
<PREV_YEAR_REV>2981812.51</PREV_YEAR_REV>
<BUDGET>3631804.4</BUDGET>
<GROSS_PROFIT>3199504.99</GROSS_PROFIT>
<EXPENSES>3543876.5</EXPENSES>
<NET_INCOME>279075.5</NET_INCOME>
<REVENUE_M>3.822952</REVENUE_M>
<PROFIT_M>3.19950499</PROFIT_M>
<INCOME_M>0.2790755</INCOME_M>
<PHARMA_REV_M>3.822952</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.19950499</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2790755</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3991364.5</REVENUE>
<PREV_YEAR_REV>3348993.97</PREV_YEAR_REV>
<BUDGET>3791796.28</BUDGET>
<GROSS_PROFIT>2695967.156</GROSS_PROFIT>
<EXPENSES>3452530.29</EXPENSES>
<NET_INCOME>538834.21</NET_INCOME>
<REVENUE_M>3.9913645</REVENUE_M>
<PROFIT_M>2.695967156</PROFIT_M>
<INCOME_M>0.53883421</INCOME_M>
<PHARMA_REV_M>3.9913645</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.695967156</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53883421</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3862270.75</REVENUE>
<PREV_YEAR_REV>3035207.15</PREV_YEAR_REV>
<BUDGET>3669157.21</BUDGET>
<GROSS_PROFIT>2987244.342</GROSS_PROFIT>
<EXPENSES>3197960.18</EXPENSES>
<NET_INCOME>664310.57</NET_INCOME>
<REVENUE_M>3.86227075</REVENUE_M>
<PROFIT_M>2.987244342</PROFIT_M>
<INCOME_M>0.66431057</INCOME_M>
<PHARMA_REV_M>3.86227075</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.987244342</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.66431057</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3950864.5</REVENUE>
<PREV_YEAR_REV>3099811.31</PREV_YEAR_REV>
<BUDGET>3753321.28</BUDGET>
<GROSS_PROFIT>3252553.15</GROSS_PROFIT>
<EXPENSES>3271315.81</EXPENSES>
<NET_INCOME>679548.69</NET_INCOME>
<REVENUE_M>3.9508645</REVENUE_M>
<PROFIT_M>3.25255315</PROFIT_M>
<INCOME_M>0.67954869</INCOME_M>
<PHARMA_REV_M>3.9508645</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.25255315</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67954869</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3789708.25</REVENUE>
<PREV_YEAR_REV>2970014.07</PREV_YEAR_REV>
<BUDGET>3600222.84</BUDGET>
<GROSS_PROFIT>2871969.766</GROSS_PROFIT>
<EXPENSES>3403158.01</EXPENSES>
<NET_INCOME>386550.24</NET_INCOME>
<REVENUE_M>3.78970825</REVENUE_M>
<PROFIT_M>2.871969766</PROFIT_M>
<INCOME_M>0.38655024</INCOME_M>
<PHARMA_REV_M>3.78970825</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.871969766</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38655024</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7803499.63</REVENUE>
<PREV_YEAR_REV>6294381.69</PREV_YEAR_REV>
<BUDGET>7413324.65</BUDGET>
<GROSS_PROFIT>6354147.647</GROSS_PROFIT>
<EXPENSES>6767522.22</EXPENSES>
<NET_INCOME>1035977.4</NET_INCOME>
<REVENUE_M>7.80349963</REVENUE_M>
<PROFIT_M>6.354147647</PROFIT_M>
<INCOME_M>1.0359774</INCOME_M>
<PHARMA_REV_M>7.80349963</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.354147647</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.0359774</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2891949.81</REVENUE>
<PREV_YEAR_REV>2400177.45</PREV_YEAR_REV>
<BUDGET>2602754.83</BUDGET>
<GROSS_PROFIT>2148429.513</GROSS_PROFIT>
<EXPENSES>2429237.84</EXPENSES>
<NET_INCOME>462711.97</NET_INCOME>
<REVENUE_M>2.89194981</REVENUE_M>
<PROFIT_M>2.148429513</PROFIT_M>
<INCOME_M>0.46271197</INCOME_M>
<PHARMA_REV_M>2.89194981</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.148429513</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46271197</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5715150.88</REVENUE>
<PREV_YEAR_REV>4659446.43</PREV_YEAR_REV>
<BUDGET>5143635.79</BUDGET>
<GROSS_PROFIT>4180628.296</GROSS_PROFIT>
<EXPENSES>5083928.56</EXPENSES>
<NET_INCOME>631222.32</NET_INCOME>
<REVENUE_M>5.71515088</REVENUE_M>
<PROFIT_M>4.180628296</PROFIT_M>
<INCOME_M>0.63122232</INCOME_M>
<PHARMA_REV_M>5.71515088</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.180628296</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.63122232</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5805423.69</REVENUE>
<PREV_YEAR_REV>4680291.41</PREV_YEAR_REV>
<BUDGET>5224881.32</BUDGET>
<GROSS_PROFIT>4318568.891</GROSS_PROFIT>
<EXPENSES>5164214.95</EXPENSES>
<NET_INCOME>641208.75</NET_INCOME>
<REVENUE_M>5.80542369</REVENUE_M>
<PROFIT_M>4.318568891</PROFIT_M>
<INCOME_M>0.64120875</INCOME_M>
<PHARMA_REV_M>5.80542369</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.318568891</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.64120875</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5792337.12</REVENUE>
<PREV_YEAR_REV>4794609.12</PREV_YEAR_REV>
<BUDGET>5213103.41</BUDGET>
<GROSS_PROFIT>4246167.654</GROSS_PROFIT>
<EXPENSES>5091658.4</EXPENSES>
<NET_INCOME>700678.73</NET_INCOME>
<REVENUE_M>5.79233712</REVENUE_M>
<PROFIT_M>4.246167654</PROFIT_M>
<INCOME_M>0.70067873</INCOME_M>
<PHARMA_REV_M>5.79233712</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.246167654</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.70067873</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2893814.5</REVENUE>
<PREV_YEAR_REV>2322819.11</PREV_YEAR_REV>
<BUDGET>2604433.05</BUDGET>
<GROSS_PROFIT>2482892.84</GROSS_PROFIT>
<EXPENSES>2682566.04</EXPENSES>
<NET_INCOME>211248.46</NET_INCOME>
<REVENUE_M>2.8938145</REVENUE_M>
<PROFIT_M>2.48289284</PROFIT_M>
<INCOME_M>0.21124846</INCOME_M>
<PHARMA_REV_M>2.8938145</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.48289284</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21124846</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2877192.63</REVENUE>
<PREV_YEAR_REV>2229224.07</PREV_YEAR_REV>
<BUDGET>2589473.36</BUDGET>
<GROSS_PROFIT>2226947.09</GROSS_PROFIT>
<EXPENSES>2362175.15</EXPENSES>
<NET_INCOME>515017.48</NET_INCOME>
<REVENUE_M>2.87719263</REVENUE_M>
<PROFIT_M>2.22694709</PROFIT_M>
<INCOME_M>0.51501748</INCOME_M>
<PHARMA_REV_M>2.87719263</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.22694709</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51501748</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2090621.2</REVENUE>
<PREV_YEAR_REV>1711841.94</PREV_YEAR_REV>
<BUDGET>2048808.78</BUDGET>
<GROSS_PROFIT>1666225.1</GROSS_PROFIT>
<EXPENSES>1938005.85</EXPENSES>
<NET_INCOME>152615.35</NET_INCOME>
<REVENUE_M>2.0906212</REVENUE_M>
<PROFIT_M>1.6662251</PROFIT_M>
<INCOME_M>0.15261535</INCOME_M>
<PHARMA_REV_M>2.0906212</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.6662251</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15261535</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2263475.2</REVENUE>
<PREV_YEAR_REV>1795967.02</PREV_YEAR_REV>
<BUDGET>2218205.7</BUDGET>
<GROSS_PROFIT>1697555.471</GROSS_PROFIT>
<EXPENSES>2032600.73</EXPENSES>
<NET_INCOME>230874.47</NET_INCOME>
<REVENUE_M>2.2634752</REVENUE_M>
<PROFIT_M>1.697555471</PROFIT_M>
<INCOME_M>0.23087447</INCOME_M>
<PHARMA_REV_M>2.2634752</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.697555471</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23087447</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.097975857E7</REVENUE>
<PREV_YEAR_REV>9293740.2</PREV_YEAR_REV>
<BUDGET>1.010137789E7</BUDGET>
<GROSS_PROFIT>8613333.653</GROSS_PROFIT>
<EXPENSES>9651017.04</EXPENSES>
<NET_INCOME>1328741.53</NET_INCOME>
<REVENUE_M>10.97975857</REVENUE_M>
<PROFIT_M>8.613333653</PROFIT_M>
<INCOME_M>1.32874153</INCOME_M>
<PHARMA_REV_M>10.97975857</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.613333653</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.32874153</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.225784513E7</REVENUE>
<PREV_YEAR_REV>1.877828061E7</PREV_YEAR_REV>
<BUDGET>1.127721752E7</BUDGET>
<GROSS_PROFIT>9898405.756</GROSS_PROFIT>
<EXPENSES>1.090317932E7</EXPENSES>
<NET_INCOME>1354665.81</NET_INCOME>
<REVENUE_M>12.25784513</REVENUE_M>
<PROFIT_M>9.898405756</PROFIT_M>
<INCOME_M>1.35466581</INCOME_M>
<PHARMA_REV_M>12.25784513</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.898405756</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.35466581</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.378148656E7</REVENUE>
<PREV_YEAR_REV>3.149285318E7</PREV_YEAR_REV>
<BUDGET>1.267896764E7</BUDGET>
<GROSS_PROFIT>1.054568751E7</GROSS_PROFIT>
<EXPENSES>1.207858722E7</EXPENSES>
<NET_INCOME>1702899.34</NET_INCOME>
<REVENUE_M>13.78148656</REVENUE_M>
<PROFIT_M>10.54568751</PROFIT_M>
<INCOME_M>1.70289934</INCOME_M>
<PHARMA_REV_M>13.78148656</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.54568751</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.70289934</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>1.362881726E7</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>1.143451188E7</BUDGET>
<GROSS_PROFIT>10731117</GROSS_PROFIT>
<EXPENSES>1.120975553E7</EXPENSES>
<NET_INCOME>1219061.71</NET_INCOME>
<REVENUE_M>13.62881726</REVENUE_M>
<PROFIT_M>10.731117</PROFIT_M>
<INCOME_M>1.21906171</INCOME_M>
<PHARMA_REV_M>13.62881726</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.731117</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.21906171</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>3255112</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>2994703.04</BUDGET>
<GROSS_PROFIT>2476977.475</GROSS_PROFIT>
<EXPENSES>2695232.74</EXPENSES>
<NET_INCOME>559879.26</NET_INCOME>
<REVENUE_M>3.255112</REVENUE_M>
<PROFIT_M>2.476977475</PROFIT_M>
<INCOME_M>0.55987926</INCOME_M>
<PHARMA_REV_M>3.255112</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.476977475</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55987926</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3687959.42</REVENUE>
<PREV_YEAR_REV>3090373.84</PREV_YEAR_REV>
<BUDGET>3507375</BUDGET>
<GROSS_PROFIT>3044594.903</GROSS_PROFIT>
<EXPENSES>3418738.39</EXPENSES>
<NET_INCOME>269221.04</NET_INCOME>
<REVENUE_M>3.68795942</REVENUE_M>
<PROFIT_M>3.044594903</PROFIT_M>
<INCOME_M>0.26922104</INCOME_M>
<PHARMA_REV_M>3.68795942</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.044594903</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26922104</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6454986.49</REVENUE>
<PREV_YEAR_REV>6077683.88</PREV_YEAR_REV>
<BUDGET>6196787.03</BUDGET>
<GROSS_PROFIT>4873514.8</GROSS_PROFIT>
<EXPENSES>5422188.65</EXPENSES>
<NET_INCOME>1032797.84</NET_INCOME>
<REVENUE_M>6.45498649</REVENUE_M>
<PROFIT_M>4.8735148</PROFIT_M>
<INCOME_M>1.03279784</INCOME_M>
<PHARMA_REV_M>6.45498649</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.8735148</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03279784</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5011620.18</REVENUE>
<PREV_YEAR_REV>4642409.36</PREV_YEAR_REV>
<BUDGET>4811155.37</BUDGET>
<GROSS_PROFIT>3218462.478</GROSS_PROFIT>
<EXPENSES>4500434.92</EXPENSES>
<NET_INCOME>511185.26</NET_INCOME>
<REVENUE_M>5.01162018</REVENUE_M>
<PROFIT_M>3.218462478</PROFIT_M>
<INCOME_M>0.51118526</INCOME_M>
<PHARMA_REV_M>5.01162018</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.218462478</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51118526</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5060966.88</REVENUE>
<PREV_YEAR_REV>4688250.93</PREV_YEAR_REV>
<BUDGET>4858528.21</BUDGET>
<GROSS_PROFIT>3562667.637</GROSS_PROFIT>
<EXPENSES>4190480.58</EXPENSES>
<NET_INCOME>870486.3</NET_INCOME>
<REVENUE_M>5.06096688</REVENUE_M>
<PROFIT_M>3.562667637</PROFIT_M>
<INCOME_M>0.8704863</INCOME_M>
<PHARMA_REV_M>5.06096688</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.562667637</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.8704863</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.207438482E7</REVENUE>
<PREV_YEAR_REV>1.12209112E7</PREV_YEAR_REV>
<BUDGET>1.159140943E7</BUDGET>
<GROSS_PROFIT>8845116.137</GROSS_PROFIT>
<EXPENSES>1.047926425E7</EXPENSES>
<NET_INCOME>1595120.58</NET_INCOME>
<REVENUE_M>12.07438482</REVENUE_M>
<PROFIT_M>8.845116137</PROFIT_M>
<INCOME_M>1.59512058</INCOME_M>
<PHARMA_REV_M>12.07438482</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.845116137</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.59512058</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7503530.98</REVENUE>
<PREV_YEAR_REV>6943342.14</PREV_YEAR_REV>
<BUDGET>7203389.74</BUDGET>
<GROSS_PROFIT>4882547.61</GROSS_PROFIT>
<EXPENSES>6490554.3</EXPENSES>
<NET_INCOME>1012976.68</NET_INCOME>
<REVENUE_M>7.50353098</REVENUE_M>
<PROFIT_M>4.88254761</PROFIT_M>
<INCOME_M>1.01297668</INCOME_M>
<PHARMA_REV_M>7.50353098</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.88254761</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.01297668</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7767689.55</REVENUE>
<PREV_YEAR_REV>7373152.18</PREV_YEAR_REV>
<BUDGET>7456981.97</BUDGET>
<GROSS_PROFIT>5578754.635</GROSS_PROFIT>
<EXPENSES>6975385.22</EXPENSES>
<NET_INCOME>792304.33</NET_INCOME>
<REVENUE_M>7.76768955</REVENUE_M>
<PROFIT_M>5.578754635</PROFIT_M>
<INCOME_M>0.79230433</INCOME_M>
<PHARMA_REV_M>7.76768955</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.578754635</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.79230433</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1933112.44</REVENUE>
<PREV_YEAR_REV>1820890.93</PREV_YEAR_REV>
<BUDGET>1839652.01</BUDGET>
<GROSS_PROFIT>1371833.241</GROSS_PROFIT>
<EXPENSES>1677941.6</EXPENSES>
<NET_INCOME>255170.84</NET_INCOME>
<REVENUE_M>1.93311244</REVENUE_M>
<PROFIT_M>1.371833241</PROFIT_M>
<INCOME_M>0.25517084</INCOME_M>
<PHARMA_REV_M>1.93311244</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.371833241</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25517084</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>1930396.68</REVENUE>
<PREV_YEAR_REV>1787354.69</PREV_YEAR_REV>
<BUDGET>1859067.86</BUDGET>
<GROSS_PROFIT>1456677.341</GROSS_PROFIT>
<EXPENSES>1675584.32</EXPENSES>
<NET_INCOME>254812.36</NET_INCOME>
<REVENUE_M>1.93039668</REVENUE_M>
<PROFIT_M>1.456677341</PROFIT_M>
<INCOME_M>0.25481236</INCOME_M>
<PHARMA_REV_M>1.93039668</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.456677341</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25481236</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2097806.94</REVENUE>
<PREV_YEAR_REV>1934782.19</PREV_YEAR_REV>
<BUDGET>1931877.31</BUDGET>
<GROSS_PROFIT>1436892.86</GROSS_PROFIT>
<EXPENSES>1944667.03</EXPENSES>
<NET_INCOME>153139.91</NET_INCOME>
<REVENUE_M>2.09780694</REVENUE_M>
<PROFIT_M>1.43689286</PROFIT_M>
<INCOME_M>0.15313991</INCOME_M>
<PHARMA_REV_M>2.09780694</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.43689286</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15313991</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2987467.11</REVENUE>
<PREV_YEAR_REV>2766407.72</PREV_YEAR_REV>
<BUDGET>3359491.16</BUDGET>
<GROSS_PROFIT>1984811.087</GROSS_PROFIT>
<EXPENSES>2656934.9</EXPENSES>
<NET_INCOME>330532.21</NET_INCOME>
<REVENUE_M>2.98746711</REVENUE_M>
<PROFIT_M>1.984811087</PROFIT_M>
<INCOME_M>0.33053221</INCOME_M>
<PHARMA_REV_M>2.98746711</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.984811087</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33053221</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1451547.93</REVENUE>
<PREV_YEAR_REV>1381768.62</PREV_YEAR_REV>
<BUDGET>1694688.75</BUDGET>
<GROSS_PROFIT>1092493.034</GROSS_PROFIT>
<EXPENSES>1259943.61</EXPENSES>
<NET_INCOME>191604.33</NET_INCOME>
<REVENUE_M>1.45154793</REVENUE_M>
<PROFIT_M>1.092493034</PROFIT_M>
<INCOME_M>0.19160433</INCOME_M>
<PHARMA_REV_M>1.45154793</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.092493034</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19160433</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2896067.14</REVENUE>
<PREV_YEAR_REV>2689770.07</PREV_YEAR_REV>
<BUDGET>3337409.15</BUDGET>
<GROSS_PROFIT>1899830.738</GROSS_PROFIT>
<EXPENSES>2575161.58</EXPENSES>
<NET_INCOME>320905.55</NET_INCOME>
<REVENUE_M>2.89606714</REVENUE_M>
<PROFIT_M>1.899830738</PROFIT_M>
<INCOME_M>0.32090555</INCOME_M>
<PHARMA_REV_M>2.89606714</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.899830738</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32090555</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4471634.12</REVENUE>
<PREV_YEAR_REV>4150049.75</PREV_YEAR_REV>
<BUDGET>5101538.27</BUDGET>
<GROSS_PROFIT>3168277.199</GROSS_PROFIT>
<EXPENSES>4039137.85</EXPENSES>
<NET_INCOME>432496.27</NET_INCOME>
<REVENUE_M>4.47163412</REVENUE_M>
<PROFIT_M>3.168277199</PROFIT_M>
<INCOME_M>0.43249627</INCOME_M>
<PHARMA_REV_M>4.47163412</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.168277199</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43249627</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5346840.53</REVENUE>
<PREV_YEAR_REV>4899155.69</PREV_YEAR_REV>
<BUDGET>5881524.58</BUDGET>
<GROSS_PROFIT>3835288.71</GROSS_PROFIT>
<EXPENSES>4657098.1</EXPENSES>
<NET_INCOME>689742.43</NET_INCOME>
<REVENUE_M>5.34684053</REVENUE_M>
<PROFIT_M>3.83528871</PROFIT_M>
<INCOME_M>0.68974243</INCOME_M>
<PHARMA_REV_M>5.34684053</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.83528871</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68974243</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.345903601E7</REVENUE>
<PREV_YEAR_REV>1.228471823E7</PREV_YEAR_REV>
<BUDGET>1.480493961E7</BUDGET>
<GROSS_PROFIT>1.032171162E7</GROSS_PROFIT>
<EXPENSES>1.147505651E7</EXPENSES>
<NET_INCOME>1983979.48</NET_INCOME>
<REVENUE_M>13.45903601</REVENUE_M>
<PROFIT_M>10.32171162</PROFIT_M>
<INCOME_M>1.98397948</INCOME_M>
<PHARMA_REV_M>13.45903601</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.32171162</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.98397948</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.113834012E7</REVENUE>
<PREV_YEAR_REV>1.013322835E7</PREV_YEAR_REV>
<BUDGET>1.225217414E7</BUDGET>
<GROSS_PROFIT>8161587.513</GROSS_PROFIT>
<EXPENSES>9479964.02</EXPENSES>
<NET_INCOME>1658376.1</NET_INCOME>
<REVENUE_M>11.13834012</REVENUE_M>
<PROFIT_M>8.161587513</PROFIT_M>
<INCOME_M>1.6583761</INCOME_M>
<PHARMA_REV_M>11.13834012</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.161587513</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.6583761</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1473316.22</REVENUE>
<PREV_YEAR_REV>1365294.14</PREV_YEAR_REV>
<BUDGET>1676720.65</BUDGET>
<GROSS_PROFIT>1000750.036</GROSS_PROFIT>
<EXPENSES>1209592.61</EXPENSES>
<NET_INCOME>263723.6</NET_INCOME>
<REVENUE_M>1.47331622</REVENUE_M>
<PROFIT_M>1.000750036</PROFIT_M>
<INCOME_M>0.2637236</INCOME_M>
<PHARMA_REV_M>1.47331622</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.000750036</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2637236</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2899249.8</REVENUE>
<PREV_YEAR_REV>2695183.09</PREV_YEAR_REV>
<BUDGET>3359491.16</BUDGET>
<GROSS_PROFIT>2007893.673</GROSS_PROFIT>
<EXPENSES>2468366.9</EXPENSES>
<NET_INCOME>430882.91</NET_INCOME>
<REVENUE_M>2.8992498</REVENUE_M>
<PROFIT_M>2.007893673</PROFIT_M>
<INCOME_M>0.43088291</INCOME_M>
<PHARMA_REV_M>2.8992498</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.007893673</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43088291</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2907529.24</REVENUE>
<PREV_YEAR_REV>2706653.31</PREV_YEAR_REV>
<BUDGET>3402136.67</BUDGET>
<GROSS_PROFIT>2056447.84</GROSS_PROFIT>
<EXPENSES>2520534.61</EXPENSES>
<NET_INCOME>386994.63</NET_INCOME>
<REVENUE_M>2.90752924</REVENUE_M>
<PROFIT_M>2.05644784</PROFIT_M>
<INCOME_M>0.38699463</INCOME_M>
<PHARMA_REV_M>2.90752924</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.05644784</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38699463</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1446428.48</REVENUE>
<PREV_YEAR_REV>1373730.65</PREV_YEAR_REV>
<BUDGET>1704852.53</BUDGET>
<GROSS_PROFIT>1006464.715</GROSS_PROFIT>
<EXPENSES>1197642.78</EXPENSES>
<NET_INCOME>248785.7</NET_INCOME>
<REVENUE_M>1.44642848</REVENUE_M>
<PROFIT_M>1.006464715</PROFIT_M>
<INCOME_M>0.2487857</INCOME_M>
<PHARMA_REV_M>1.44642848</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.006464715</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2487857</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.446508513E7</REVENUE>
<PREV_YEAR_REV>1.327451881E7</PREV_YEAR_REV>
<BUDGET>1.388648173E7</BUDGET>
<GROSS_PROFIT>9141332.949</GROSS_PROFIT>
<EXPENSES>1.278883316E7</EXPENSES>
<NET_INCOME>1676251.97</NET_INCOME>
<REVENUE_M>14.46508513</REVENUE_M>
<PROFIT_M>9.141332949</PROFIT_M>
<INCOME_M>1.67625197</INCOME_M>
<PHARMA_REV_M>14.46508513</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.141332949</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.67625197</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6056189.7</REVENUE>
<PREV_YEAR_REV>5578605.3</PREV_YEAR_REV>
<BUDGET>5813942.11</BUDGET>
<GROSS_PROFIT>4469468</GROSS_PROFIT>
<EXPENSES>5614087.85</EXPENSES>
<NET_INCOME>442101.85</NET_INCOME>
<REVENUE_M>6.0561897</REVENUE_M>
<PROFIT_M>4.469468</PROFIT_M>
<INCOME_M>0.44210185</INCOME_M>
<PHARMA_REV_M>6.0561897</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.469468</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44210185</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>4280547.24</REVENUE>
<PREV_YEAR_REV>3924479.24</PREV_YEAR_REV>
<BUDGET>4109325.35</BUDGET>
<GROSS_PROFIT>3269319.318</GROSS_PROFIT>
<EXPENSES>3843931.42</EXPENSES>
<NET_INCOME>436615.82</NET_INCOME>
<REVENUE_M>4.28054724</REVENUE_M>
<PROFIT_M>3.269319318</PROFIT_M>
<INCOME_M>0.43661582</INCOME_M>
<PHARMA_REV_M>4.28054724</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.269319318</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43661582</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3889984.77</REVENUE>
<PREV_YEAR_REV>3504587.02</PREV_YEAR_REV>
<BUDGET>4006221.04</BUDGET>
<GROSS_PROFIT>2628748.372</GROSS_PROFIT>
<EXPENSES>3456715.17</EXPENSES>
<NET_INCOME>433269.6</NET_INCOME>
<REVENUE_M>3.88998477</REVENUE_M>
<PROFIT_M>2.628748372</PROFIT_M>
<INCOME_M>0.4332696</INCOME_M>
<PHARMA_REV_M>3.88998477</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.628748372</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4332696</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4032926.35</REVENUE>
<PREV_YEAR_REV>3660245.58</PREV_YEAR_REV>
<BUDGET>4095074.66</BUDGET>
<GROSS_PROFIT>2443043.527</GROSS_PROFIT>
<EXPENSES>3434054.63</EXPENSES>
<NET_INCOME>598871.72</NET_INCOME>
<REVENUE_M>4.03292635</REVENUE_M>
<PROFIT_M>2.443043527</PROFIT_M>
<INCOME_M>0.59887172</INCOME_M>
<PHARMA_REV_M>4.03292635</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.443043527</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.59887172</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3433358.27</REVENUE>
<PREV_YEAR_REV>3089323.12</PREV_YEAR_REV>
<BUDGET>3516844.13</BUDGET>
<GROSS_PROFIT>2331948.046</GROSS_PROFIT>
<EXPENSES>2929374.78</EXPENSES>
<NET_INCOME>503983.49</NET_INCOME>
<REVENUE_M>3.43335827</REVENUE_M>
<PROFIT_M>2.331948046</PROFIT_M>
<INCOME_M>0.50398349</INCOME_M>
<PHARMA_REV_M>3.43335827</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.331948046</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50398349</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2066454.4</REVENUE>
<PREV_YEAR_REV>1900275.32</PREV_YEAR_REV>
<BUDGET>2036785.54</BUDGET>
<GROSS_PROFIT>1541120.364</GROSS_PROFIT>
<EXPENSES>1915603.23</EXPENSES>
<NET_INCOME>150851.17</NET_INCOME>
<REVENUE_M>2.0664544</REVENUE_M>
<PROFIT_M>1.541120364</PROFIT_M>
<INCOME_M>0.15085117</INCOME_M>
<PHARMA_REV_M>2.0664544</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.541120364</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15085117</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1951414.49</REVENUE>
<PREV_YEAR_REV>1818635.89</PREV_YEAR_REV>
<BUDGET>2140963.07</BUDGET>
<GROSS_PROFIT>1333099.054</GROSS_PROFIT>
<EXPENSES>1687973.54</EXPENSES>
<NET_INCOME>263440.96</NET_INCOME>
<REVENUE_M>1.95141449</REVENUE_M>
<PROFIT_M>1.333099054</PROFIT_M>
<INCOME_M>0.26344096</INCOME_M>
<PHARMA_REV_M>1.95141449</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.333099054</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26344096</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4024847.04</REVENUE>
<PREV_YEAR_REV>3752484.62</PREV_YEAR_REV>
<BUDGET>4166046.9</BUDGET>
<GROSS_PROFIT>2561862.445</GROSS_PROFIT>
<EXPENSES>3491044.44</EXPENSES>
<NET_INCOME>533802.6</NET_INCOME>
<REVENUE_M>4.02484704</REVENUE_M>
<PROFIT_M>2.561862445</PROFIT_M>
<INCOME_M>0.5338026</INCOME_M>
<PHARMA_REV_M>4.02484704</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.561862445</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5338026</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2071817.07</REVENUE>
<PREV_YEAR_REV>1864989.71</PREV_YEAR_REV>
<BUDGET>2036785.54</BUDGET>
<GROSS_PROFIT>1324823.42</GROSS_PROFIT>
<EXPENSES>1792121.76</EXPENSES>
<NET_INCOME>279695.3</NET_INCOME>
<REVENUE_M>2.07181707</REVENUE_M>
<PROFIT_M>1.32482342</PROFIT_M>
<INCOME_M>0.2796953</INCOME_M>
<PHARMA_REV_M>2.07181707</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.32482342</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2796953</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>1891729.37</REVENUE>
<PREV_YEAR_REV>1739057.51</PREV_YEAR_REV>
<BUDGET>2016221.44</BUDGET>
<GROSS_PROFIT>1320900.035</GROSS_PROFIT>
<EXPENSES>1698772.98</EXPENSES>
<NET_INCOME>192956.4</NET_INCOME>
<REVENUE_M>1.89172937</REVENUE_M>
<PROFIT_M>1.320900035</PROFIT_M>
<INCOME_M>0.1929564</INCOME_M>
<PHARMA_REV_M>1.89172937</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.320900035</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1929564</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2806607.1</REVENUE>
<PREV_YEAR_REV>2522550.76</PREV_YEAR_REV>
<BUDGET>3607585.58</BUDGET>
<GROSS_PROFIT>1984286.489</GROSS_PROFIT>
<EXPENSES>2495185.9</EXPENSES>
<NET_INCOME>311421.2</NET_INCOME>
<REVENUE_M>2.8066071</REVENUE_M>
<PROFIT_M>1.984286489</PROFIT_M>
<INCOME_M>0.3114212</INCOME_M>
<PHARMA_REV_M>2.8066071</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.984286489</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3114212</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4316988.19</REVENUE>
<PREV_YEAR_REV>3917327.05</PREV_YEAR_REV>
<BUDGET>5475166.03</BUDGET>
<GROSS_PROFIT>3169440.28</GROSS_PROFIT>
<EXPENSES>3895229.24</EXPENSES>
<NET_INCOME>421758.95</NET_INCOME>
<REVENUE_M>4.31698819</REVENUE_M>
<PROFIT_M>3.16944028</PROFIT_M>
<INCOME_M>0.42175895</INCOME_M>
<PHARMA_REV_M>4.31698819</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.16944028</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42175895</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4206386.38</REVENUE>
<PREV_YEAR_REV>3845040.24</PREV_YEAR_REV>
<BUDGET>5479019.78</BUDGET>
<GROSS_PROFIT>2989619.83</GROSS_PROFIT>
<EXPENSES>3798210.82</EXPENSES>
<NET_INCOME>408175.56</NET_INCOME>
<REVENUE_M>4.20638638</REVENUE_M>
<PROFIT_M>2.98961983</PROFIT_M>
<INCOME_M>0.40817556</INCOME_M>
<PHARMA_REV_M>4.20638638</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.98961983</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40817556</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1400681.71</REVENUE>
<PREV_YEAR_REV>1285843.07</PREV_YEAR_REV>
<BUDGET>1802925.43</BUDGET>
<GROSS_PROFIT>936296.8966</GROSS_PROFIT>
<EXPENSES>1257812.18</EXPENSES>
<NET_INCOME>142869.53</NET_INCOME>
<REVENUE_M>1.40068171</REVENUE_M>
<PROFIT_M>0.936296897</PROFIT_M>
<INCOME_M>0.14286953</INCOME_M>
<PHARMA_REV_M>1.40068171</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.936296897</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14286953</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2789224.92</REVENUE>
<PREV_YEAR_REV>2560020.36</PREV_YEAR_REV>
<BUDGET>3630238.98</BUDGET>
<GROSS_PROFIT>2104876.624</GROSS_PROFIT>
<EXPENSES>2416985.37</EXPENSES>
<NET_INCOME>372239.54</NET_INCOME>
<REVENUE_M>2.78922492</REVENUE_M>
<PROFIT_M>2.104876624</PROFIT_M>
<INCOME_M>0.37223954</INCOME_M>
<PHARMA_REV_M>2.78922492</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.104876624</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37223954</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1331818.16</REVENUE>
<PREV_YEAR_REV>1220988.99</PREV_YEAR_REV>
<BUDGET>1833174.76</BUDGET>
<GROSS_PROFIT>936331.4309</GROSS_PROFIT>
<EXPENSES>1102745.44</EXPENSES>
<NET_INCOME>229072.72</NET_INCOME>
<REVENUE_M>1.33181816</REVENUE_M>
<PROFIT_M>0.936331431</PROFIT_M>
<INCOME_M>0.22907272</INCOME_M>
<PHARMA_REV_M>1.33181816</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.936331431</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22907272</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2258912</REVENUE>
<PREV_YEAR_REV>2069179.92</PREV_YEAR_REV>
<BUDGET>2564090.68</BUDGET>
<GROSS_PROFIT>1372054.478</GROSS_PROFIT>
<EXPENSES>1983606.64</EXPENSES>
<NET_INCOME>275305.36</NET_INCOME>
<REVENUE_M>2.258912</REVENUE_M>
<PROFIT_M>1.372054478</PROFIT_M>
<INCOME_M>0.27530536</INCOME_M>
<PHARMA_REV_M>2.258912</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.372054478</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27530536</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>945356.15</REVENUE>
<PREV_YEAR_REV>875297.35</PREV_YEAR_REV>
<BUDGET>1049120.47</BUDGET>
<GROSS_PROFIT>640951.47</GROSS_PROFIT>
<EXPENSES>794099.17</EXPENSES>
<NET_INCOME>151256.98</NET_INCOME>
<REVENUE_M>0.94535615</REVENUE_M>
<PROFIT_M>0.64095147</PROFIT_M>
<INCOME_M>0.15125698</INCOME_M>
<PHARMA_REV_M>0.94535615</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.64095147</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15125698</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2257888.98</REVENUE>
<PREV_YEAR_REV>2039412.09</PREV_YEAR_REV>
<BUDGET>2512230.35</BUDGET>
<GROSS_PROFIT>1317188.196</GROSS_PROFIT>
<EXPENSES>1924060.22</EXPENSES>
<NET_INCOME>333828.76</NET_INCOME>
<REVENUE_M>2.25788898</REVENUE_M>
<PROFIT_M>1.317188196</PROFIT_M>
<INCOME_M>0.33382876</INCOME_M>
<PHARMA_REV_M>2.25788898</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.317188196</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33382876</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1182942.77</REVENUE>
<PREV_YEAR_REV>1062116.41</PREV_YEAR_REV>
<BUDGET>1293663.99</BUDGET>
<GROSS_PROFIT>894541.318</GROSS_PROFIT>
<EXPENSES>1096587.95</EXPENSES>
<NET_INCOME>86354.82</NET_INCOME>
<REVENUE_M>1.18294277</REVENUE_M>
<PROFIT_M>0.894541318</PROFIT_M>
<INCOME_M>0.08635482</INCOME_M>
<PHARMA_REV_M>1.18294277</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.894541318</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.08635482</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1104120.45</REVENUE>
<PREV_YEAR_REV>994514.96</PREV_YEAR_REV>
<BUDGET>1306008.8</BUDGET>
<GROSS_PROFIT>819202.1665</GROSS_PROFIT>
<EXPENSES>906482.89</EXPENSES>
<NET_INCOME>197637.56</NET_INCOME>
<REVENUE_M>1.10412045</REVENUE_M>
<PROFIT_M>0.819202167</PROFIT_M>
<INCOME_M>0.19763756</INCOME_M>
<PHARMA_REV_M>1.10412045</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.819202167</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19763756</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>961565.19</REVENUE>
<PREV_YEAR_REV>866673.15</PREV_YEAR_REV>
<BUDGET>1049120.47</BUDGET>
<GROSS_PROFIT>700019.46</GROSS_PROFIT>
<EXPENSES>891370.93</EXPENSES>
<NET_INCOME>70194.26</NET_INCOME>
<REVENUE_M>0.96156519</REVENUE_M>
<PROFIT_M>0.70001946</PROFIT_M>
<INCOME_M>0.07019426</INCOME_M>
<PHARMA_REV_M>0.96156519</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.70001946</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.07019426</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1186988.2</REVENUE>
<PREV_YEAR_REV>1085901.62</PREV_YEAR_REV>
<BUDGET>1298819.77</BUDGET>
<GROSS_PROFIT>837722.864</GROSS_PROFIT>
<EXPENSES>982826.23</EXPENSES>
<NET_INCOME>204161.97</NET_INCOME>
<REVENUE_M>1.1869882</REVENUE_M>
<PROFIT_M>0.837722864</PROFIT_M>
<INCOME_M>0.20416197</INCOME_M>
<PHARMA_REV_M>1.1869882</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.837722864</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20416197</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>9988115.83</REVENUE>
<PREV_YEAR_REV>9411565.33</PREV_YEAR_REV>
<BUDGET>6005990.88</BUDGET>
<GROSS_PROFIT>8046431.018</GROSS_PROFIT>
<EXPENSES>5649385.17</EXPENSES>
<NET_INCOME>1069607.87</NET_INCOME>
<REVENUE_M>9.98811583</REVENUE_M>
<PROFIT_M>8.046431018</PROFIT_M>
<INCOME_M>1.06960787</INCOME_M>
<PHARMA_REV_M>9.98811583</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.046431018</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.06960787</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7183256.69</REVENUE>
<PREV_YEAR_REV>6793878.03</PREV_YEAR_REV>
<BUDGET>6895926.42</BUDGET>
<GROSS_PROFIT>5332124.362</GROSS_PROFIT>
<EXPENSES>6311272.03</EXPENSES>
<NET_INCOME>871984.66</NET_INCOME>
<REVENUE_M>7.18325669</REVENUE_M>
<PROFIT_M>5.332124362</PROFIT_M>
<INCOME_M>0.87198466</INCOME_M>
<PHARMA_REV_M>7.18325669</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.332124362</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.87198466</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>4629223.5</REVENUE>
<PREV_YEAR_REV>4317620.81</PREV_YEAR_REV>
<BUDGET>4444054.56</BUDGET>
<GROSS_PROFIT>3911693.86</GROSS_PROFIT>
<EXPENSES>4124638.14</EXPENSES>
<NET_INCOME>504585.36</NET_INCOME>
<REVENUE_M>4.6292235</REVENUE_M>
<PROFIT_M>3.91169386</PROFIT_M>
<INCOME_M>0.50458536</INCOME_M>
<PHARMA_REV_M>4.6292235</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.91169386</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50458536</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3955684.96</REVENUE>
<PREV_YEAR_REV>3692898.18</PREV_YEAR_REV>
<BUDGET>3037214.36</BUDGET>
<GROSS_PROFIT>3084057.283</GROSS_PROFIT>
<EXPENSES>3518150.29</EXPENSES>
<NET_INCOME>437534.68</NET_INCOME>
<REVENUE_M>3.95568496</REVENUE_M>
<PROFIT_M>3.084057283</PROFIT_M>
<INCOME_M>0.43753468</INCOME_M>
<PHARMA_REV_M>3.95568496</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.084057283</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43753468</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2504184.77</REVENUE>
<PREV_YEAR_REV>2342198.34</PREV_YEAR_REV>
<BUDGET>1855623.07</BUDGET>
<GROSS_PROFIT>1768530.41</GROSS_PROFIT>
<EXPENSES>2166119.83</EXPENSES>
<NET_INCOME>338064.94</NET_INCOME>
<REVENUE_M>2.50418477</REVENUE_M>
<PROFIT_M>1.76853041</PROFIT_M>
<INCOME_M>0.33806494</INCOME_M>
<PHARMA_REV_M>2.50418477</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.76853041</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33806494</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3211258.84</REVENUE>
<PREV_YEAR_REV>3041734.62</PREV_YEAR_REV>
<BUDGET>3161913.06</BUDGET>
<GROSS_PROFIT>2435866.92</GROSS_PROFIT>
<EXPENSES>2822124.12</EXPENSES>
<NET_INCOME>389134.72</NET_INCOME>
<REVENUE_M>3.21125884</REVENUE_M>
<PROFIT_M>2.43586692</PROFIT_M>
<INCOME_M>0.38913472</INCOME_M>
<PHARMA_REV_M>3.21125884</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.43586692</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38913472</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3397642.87</REVENUE>
<PREV_YEAR_REV>3153528.98</PREV_YEAR_REV>
<BUDGET>3140775.3</BUDGET>
<GROSS_PROFIT>2908704.592</GROSS_PROFIT>
<EXPENSES>2940306.54</EXPENSES>
<NET_INCOME>457336.33</NET_INCOME>
<REVENUE_M>3.39764287</REVENUE_M>
<PROFIT_M>2.908704592</PROFIT_M>
<INCOME_M>0.45733633</INCOME_M>
<PHARMA_REV_M>3.39764287</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.908704592</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45733633</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3315091.09</REVENUE>
<PREV_YEAR_REV>3103491.6</PREV_YEAR_REV>
<BUDGET>3146413.54</BUDGET>
<GROSS_PROFIT>2401953.62</GROSS_PROFIT>
<EXPENSES>2823110.27</EXPENSES>
<NET_INCOME>491980.82</NET_INCOME>
<REVENUE_M>3.31509109</REVENUE_M>
<PROFIT_M>2.40195362</PROFIT_M>
<INCOME_M>0.49198082</INCOME_M>
<PHARMA_REV_M>3.31509109</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.40195362</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49198082</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1546841.98</REVENUE>
<PREV_YEAR_REV>1470535.88</PREV_YEAR_REV>
<BUDGET>1562637.89</BUDGET>
<GROSS_PROFIT>1261536.263</GROSS_PROFIT>
<EXPENSES>1389064.1</EXPENSES>
<NET_INCOME>157777.88</NET_INCOME>
<REVENUE_M>1.54684198</REVENUE_M>
<PROFIT_M>1.261536263</PROFIT_M>
<INCOME_M>0.15777788</INCOME_M>
<PHARMA_REV_M>1.54684198</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.261536263</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15777788</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3333883.72</REVENUE>
<PREV_YEAR_REV>3117258.99</PREV_YEAR_REV>
<BUDGET>3146413.54</BUDGET>
<GROSS_PROFIT>2805792.479</GROSS_PROFIT>
<EXPENSES>2886852.43</EXPENSES>
<NET_INCOME>447031.29</NET_INCOME>
<REVENUE_M>3.33388372</REVENUE_M>
<PROFIT_M>2.805792479</PROFIT_M>
<INCOME_M>0.44703129</INCOME_M>
<PHARMA_REV_M>3.33388372</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.805792479</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44703129</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.297974787E7</REVENUE>
<PREV_YEAR_REV>1.233076048E7</PREV_YEAR_REV>
<BUDGET>1.259035544E7</BUDGET>
<GROSS_PROFIT>8799879.668</GROSS_PROFIT>
<EXPENSES>1.094007321E7</EXPENSES>
<NET_INCOME>1752265.96</NET_INCOME>
<REVENUE_M>12.97974787</REVENUE_M>
<PROFIT_M>8.799879668</PROFIT_M>
<INCOME_M>1.75226596</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.155311846E7</REVENUE>
<PREV_YEAR_REV>2.997546254E7</PREV_YEAR_REV>
<BUDGET>3.060652491E7</BUDGET>
<GROSS_PROFIT>2.376896413E7</GROSS_PROFIT>
<EXPENSES>2.698709746E7</EXPENSES>
<NET_INCOME>5048498.95</NET_INCOME>
<REVENUE_M>31.55311846</REVENUE_M>
<PROFIT_M>23.76896413</PROFIT_M>
<INCOME_M>5.04849895</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.179339729E7</REVENUE>
<PREV_YEAR_REV>2.070372744E7</PREV_YEAR_REV>
<BUDGET>2.113959538E7</BUDGET>
<GROSS_PROFIT>1.477526956E7</GROSS_PROFIT>
<EXPENSES>1.917446895E7</EXPENSES>
<NET_INCOME>2652596.48</NET_INCOME>
<REVENUE_M>21.79339729</REVENUE_M>
<PROFIT_M>14.77526956</PROFIT_M>
<INCOME_M>2.65259648</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>31962147</REVENUE>
<PREV_YEAR_REV>3.036403965E7</PREV_YEAR_REV>
<BUDGET>3.100328259E7</BUDGET>
<GROSS_PROFIT>2.407708534E7</GROSS_PROFIT>
<EXPENSES>41094189</EXPENSES>
<NET_INCOME>5113943.52</NET_INCOME>
<REVENUE_M>31.962147</REVENUE_M>
<PROFIT_M>24.07708534</PROFIT_M>
<INCOME_M>5.11394352</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.514430918E7</REVENUE>
<PREV_YEAR_REV>1.438709372E7</PREV_YEAR_REV>
<BUDGET>1.46899799E7</BUDGET>
<GROSS_PROFIT>1.140820811E7</GROSS_PROFIT>
<EXPENSES>1.947125466E7</EXPENSES>
<NET_INCOME>2423089.47</NET_INCOME>
<REVENUE_M>15.14430918</REVENUE_M>
<PROFIT_M>11.40820811</PROFIT_M>
<INCOME_M>2.42308947</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.144296153E7</REVENUE>
<PREV_YEAR_REV>1.087081345E7</PREV_YEAR_REV>
<BUDGET>1.109967268E7</BUDGET>
<GROSS_PROFIT>8619982.921</GROSS_PROFIT>
<EXPENSES>1.471237911E7</EXPENSES>
<NET_INCOME>1247282.81</NET_INCOME>
<REVENUE_M>11.44296153</REVENUE_M>
<PROFIT_M>8.619982921</PROFIT_M>
<INCOME_M>1.24728281</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.47162015E7</REVENUE>
<PREV_YEAR_REV>1.398039143E7</PREV_YEAR_REV>
<BUDGET>1.427471546E7</BUDGET>
<GROSS_PROFIT>1.053142886E7</GROSS_PROFIT>
<EXPENSES>1.89208305E7</EXPENSES>
<NET_INCOME>1501052.55</NET_INCOME>
<REVENUE_M>14.7162015</REVENUE_M>
<PROFIT_M>10.53142886</PROFIT_M>
<INCOME_M>1.50105255</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.520474193E7</REVENUE>
<PREV_YEAR_REV>1.444450483E7</PREV_YEAR_REV>
<BUDGET>1.474859967E7</BUDGET>
<GROSS_PROFIT>1.145373209E7</GROSS_PROFIT>
<EXPENSES>1.861805134E7</EXPENSES>
<NET_INCOME>2007025.93</NET_INCOME>
<REVENUE_M>15.20474193</REVENUE_M>
<PROFIT_M>11.45373209</PROFIT_M>
<INCOME_M>2.00702593</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.543189587E7</REVENUE>
<PREV_YEAR_REV>1.466030107E7</PREV_YEAR_REV>
<BUDGET>1.496893899E7</BUDGET>
<GROSS_PROFIT>1.162484715E7</GROSS_PROFIT>
<EXPENSES>1.889619902E7</EXPENSES>
<NET_INCOME>1126528.4</NET_INCOME>
<REVENUE_M>15.43189587</REVENUE_M>
<PROFIT_M>11.62484715</PROFIT_M>
<INCOME_M>1.1265284</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.215429132E7</REVENUE>
<PREV_YEAR_REV>1.883114762E7</PREV_YEAR_REV>
<BUDGET>2.148966258E7</BUDGET>
<GROSS_PROFIT>1.585438627E7</GROSS_PROFIT>
<EXPENSES>1.76309489E7</EXPENSES>
<NET_INCOME>2148966.26</NET_INCOME>
<REVENUE_M>22.15429132</REVENUE_M>
<PROFIT_M>15.85438627</PROFIT_M>
<INCOME_M>2.14896626</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.08905034E7</REVENUE>
<PREV_YEAR_REV>1.775692789E7</PREV_YEAR_REV>
<BUDGET>2.02637883E7</BUDGET>
<GROSS_PROFIT>1.494997541E7</GROSS_PROFIT>
<EXPENSES>1.881254803E7</EXPENSES>
<NET_INCOME>2026378.83</NET_INCOME>
<REVENUE_M>20.8905034</REVENUE_M>
<PROFIT_M>14.94997541</PROFIT_M>
<INCOME_M>2.02637883</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.290594224E7</REVENUE>
<PREV_YEAR_REV>3.64700509E7</PREV_YEAR_REV>
<BUDGET>4.161876396E7</BUDGET>
<GROSS_PROFIT>3.232104629E7</GROSS_PROFIT>
<EXPENSES>3.928628859E7</EXPENSES>
<NET_INCOME>5738637.71</NET_INCOME>
<REVENUE_M>42.90594224</REVENUE_M>
<PROFIT_M>32.32104629</PROFIT_M>
<INCOME_M>5.73863771</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.840418671E7</REVENUE>
<PREV_YEAR_REV>1.56435587E7</PREV_YEAR_REV>
<BUDGET>1.785206111E7</BUDGET>
<GROSS_PROFIT>1.317068016E7</GROSS_PROFIT>
<EXPENSES>1.637972617E7</EXPENSES>
<NET_INCOME>1877227.04</NET_INCOME>
<REVENUE_M>18.40418671</REVENUE_M>
<PROFIT_M>13.17068016</PROFIT_M>
<INCOME_M>1.87722704</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.19364013E7</REVENUE>
<PREV_YEAR_REV>1.86459411E7</PREV_YEAR_REV>
<BUDGET>2.127830926E7</BUDGET>
<GROSS_PROFIT>1.65246911E7</GROSS_PROFIT>
<EXPENSES>1.977292856E7</EXPENSES>
<NET_INCOME>3509824.21</NET_INCOME>
<REVENUE_M>21.9364013</REVENUE_M>
<PROFIT_M>16.5246911</PROFIT_M>
<INCOME_M>3.50982421</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.951841786E7</REVENUE>
<PREV_YEAR_REV>1.659065518E7</PREV_YEAR_REV>
<BUDGET>1.893286532E7</BUDGET>
<GROSS_PROFIT>1.323290175E7</GROSS_PROFIT>
<EXPENSES>1.740030414E7</EXPENSES>
<NET_INCOME>2634986.41</NET_INCOME>
<REVENUE_M>19.51841786</REVENUE_M>
<PROFIT_M>13.23290175</PROFIT_M>
<INCOME_M>2.63498641</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.937282812E7</REVENUE>
<PREV_YEAR_REV>1.64669039E7</PREV_YEAR_REV>
<BUDGET>1.879164327E7</BUDGET>
<GROSS_PROFIT>1.386387385E7</GROSS_PROFIT>
<EXPENSES>1.727051362E7</EXPENSES>
<NET_INCOME>1976028.47</NET_INCOME>
<REVENUE_M>19.37282812</REVENUE_M>
<PROFIT_M>13.86387385</PROFIT_M>
<INCOME_M>1.97602847</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.836742036E7</REVENUE>
<PREV_YEAR_REV>3.26123073E7</PREV_YEAR_REV>
<BUDGET>3.721639774E7</BUDGET>
<GROSS_PROFIT>2.890217776E7</GROSS_PROFIT>
<EXPENSES>3.420383703E7</EXPENSES>
<NET_INCOME>5076963.38</NET_INCOME>
<REVENUE_M>38.36742036</REVENUE_M>
<PROFIT_M>28.90217776</PROFIT_M>
<INCOME_M>5.07696338</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>45660210</REVENUE>
<PREV_YEAR_REV>3.88111785E7</PREV_YEAR_REV>
<BUDGET>4.42904037E7</BUDGET>
<GROSS_PROFIT>3.312191633E7</GROSS_PROFIT>
<EXPENSES>41094189</EXPENSES>
<NET_INCOME>7305633.6</NET_INCOME>
<REVENUE_M>45.66021</REVENUE_M>
<PROFIT_M>33.12191633</PROFIT_M>
<INCOME_M>7.3056336</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>46972950</REVENUE>
<PREV_YEAR_REV>3.99270075E7</PREV_YEAR_REV>
<BUDGET>4.55637615E7</BUDGET>
<GROSS_PROFIT>3.237046903E7</GROSS_PROFIT>
<EXPENSES>42275655</EXPENSES>
<NET_INCOME>4556376.15</NET_INCOME>
<REVENUE_M>46.97295</REVENUE_M>
<PROFIT_M>32.37046903</PROFIT_M>
<INCOME_M>4.55637615</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>46316580</REVENUE>
<PREV_YEAR_REV>39369093</PREV_YEAR_REV>
<BUDGET>4.49270826E7</BUDGET>
<GROSS_PROFIT>3.359804713E7</GROSS_PROFIT>
<EXPENSES>41684922</EXPENSES>
<NET_INCOME>6113788.56</NET_INCOME>
<REVENUE_M>46.31658</REVENUE_M>
<PROFIT_M>33.59804713</PROFIT_M>
<INCOME_M>6.11378856</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.328557343E7</REVENUE>
<PREV_YEAR_REV>3.679273741E7</PREV_YEAR_REV>
<BUDGET>4.198700622E7</BUDGET>
<GROSS_PROFIT>3.097667133E7</GROSS_PROFIT>
<EXPENSES>3.858827843E7</EXPENSES>
<NET_INCOME>4198700.62</NET_INCOME>
<REVENUE_M>43.28557343</REVENUE_M>
<PROFIT_M>30.97667133</PROFIT_M>
<INCOME_M>4.19870062</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.187734934E7</REVENUE>
<PREV_YEAR_REV>1.859574694E7</PREV_YEAR_REV>
<BUDGET>2.122102886E7</BUDGET>
<GROSS_PROFIT>1.483218654E7</GROSS_PROFIT>
<EXPENSES>1.928620997E7</EXPENSES>
<NET_INCOME>3150145.01</NET_INCOME>
<REVENUE_M>21.87734934</REVENUE_M>
<PROFIT_M>14.83218654</PROFIT_M>
<INCOME_M>3.15014501</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.113519904E7</REVENUE>
<PREV_YEAR_REV>9464919.19</PREV_YEAR_REV>
<BUDGET>1.080114307E7</BUDGET>
<GROSS_PROFIT>8388145.435</GROSS_PROFIT>
<EXPENSES>9926821.5</EXPENSES>
<NET_INCOME>1993200.63</NET_INCOME>
<REVENUE_M>11.13519904</REVENUE_M>
<PROFIT_M>8.388145435</PROFIT_M>
<INCOME_M>1.99320063</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.909338975E7</REVENUE>
<PREV_YEAR_REV>1.622938129E7</PREV_YEAR_REV>
<BUDGET>1.852058806E7</BUDGET>
<GROSS_PROFIT>1.43830505E7</GROSS_PROFIT>
<EXPENSES>1.702139954E7</EXPENSES>
<NET_INCOME>2081179.48</NET_INCOME>
<REVENUE_M>19.09338975</REVENUE_M>
<PROFIT_M>14.3830505</PROFIT_M>
<INCOME_M>2.08117948</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.997208934E7</REVENUE>
<PREV_YEAR_REV>3.677432219E7</PREV_YEAR_REV>
<BUDGET>4.077153113E7</BUDGET>
<GROSS_PROFIT>3.011097489E7</GROSS_PROFIT>
<EXPENSES>3.557515951E7</EXPENSES>
<NET_INCOME>6395534.29</NET_INCOME>
<REVENUE_M>39.97208934</REVENUE_M>
<PROFIT_M>30.11097489</PROFIT_M>
<INCOME_M>6.39553429</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.054669205E7</REVENUE>
<PREV_YEAR_REV>3.730295668E7</PREV_YEAR_REV>
<BUDGET>4.135762589E7</BUDGET>
<GROSS_PROFIT>3.054382312E7</GROSS_PROFIT>
<EXPENSES>3.608655592E7</EXPENSES>
<NET_INCOME>5352163.35</NET_INCOME>
<REVENUE_M>40.54669205</REVENUE_M>
<PROFIT_M>30.54382312</PROFIT_M>
<INCOME_M>5.35216335</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.644904934E7</REVENUE>
<PREV_YEAR_REV>3.353312539E7</PREV_YEAR_REV>
<BUDGET>3.717803032E7</BUDGET>
<GROSS_PROFIT>2.745706886E7</GROSS_PROFIT>
<EXPENSES>3.243965391E7</EXPENSES>
<NET_INCOME>4823115.2</NET_INCOME>
<REVENUE_M>36.44904934</REVENUE_M>
<PROFIT_M>27.45706886</PROFIT_M>
<INCOME_M>4.8231152</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.813872026E7</REVENUE>
<PREV_YEAR_REV>1.668762264E7</PREV_YEAR_REV>
<BUDGET>1.850149467E7</BUDGET>
<GROSS_PROFIT>1.366389797E7</GROSS_PROFIT>
<EXPENSES>1.614346103E7</EXPENSES>
<NET_INCOME>1977120.51</NET_INCOME>
<REVENUE_M>18.13872026</REVENUE_M>
<PROFIT_M>13.66389797</PROFIT_M>
<INCOME_M>1.97712051</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.19364013E7</REVENUE>
<PREV_YEAR_REV>2.01814892E7</PREV_YEAR_REV>
<BUDGET>2.033512933E7</BUDGET>
<GROSS_PROFIT>1.65246911E7</GROSS_PROFIT>
<EXPENSES>1.977292856E7</EXPENSES>
<NET_INCOME>3509824.21</NET_INCOME>
<REVENUE_M>21.9364013</REVENUE_M>
<PROFIT_M>16.5246911</PROFIT_M>
<INCOME_M>3.50982421</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.187734934E7</REVENUE>
<PREV_YEAR_REV>2.932716139E7</PREV_YEAR_REV>
<BUDGET>2.435489633E7</BUDGET>
<GROSS_PROFIT>2.161188654E7</GROSS_PROFIT>
<EXPENSES>2.928620997E7</EXPENSES>
<NET_INCOME>4720145.01</NET_INCOME>
<REVENUE_M>31.87734934</REVENUE_M>
<PROFIT_M>21.61188654</PROFIT_M>
<INCOME_M>4.72014501</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.248900237E7</REVENUE>
<PREV_YEAR_REV>2.068988218E7</PREV_YEAR_REV>
<BUDGET>2.055299103E7</BUDGET>
<GROSS_PROFIT>1.694096549E7</GROSS_PROFIT>
<EXPENSES>1.889076199E7</EXPENSES>
<NET_INCOME>3598240.38</NET_INCOME>
<REVENUE_M>22.48900237</REVENUE_M>
<PROFIT_M>16.94096549</PROFIT_M>
<INCOME_M>3.59824038</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.866129994E7</REVENUE>
<PREV_YEAR_REV>3.556839594E7</PREV_YEAR_REV>
<BUDGET>2.56051125E7</BUDGET>
<GROSS_PROFIT>2.912355725E7</GROSS_PROFIT>
<EXPENSES>3.351545667E7</EXPENSES>
<NET_INCOME>5145843.27</NET_INCOME>
<REVENUE_M>38.66129994</REVENUE_M>
<PROFIT_M>29.12355725</PROFIT_M>
<INCOME_M>5.14584327</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.293805038E7</REVENUE>
<PREV_YEAR_REV>1.190300635E7</PREV_YEAR_REV>
<BUDGET>1.147958664E7</BUDGET>
<GROSS_PROFIT>9746233.353</GROSS_PROFIT>
<EXPENSES>1.062213936E7</EXPENSES>
<NET_INCOME>2315911.02</NET_INCOME>
<REVENUE_M>12.93805038</REVENUE_M>
<PROFIT_M>9.746233353</PROFIT_M>
<INCOME_M>2.31591102</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5343182.05</REVENUE>
<PREV_YEAR_REV>4908215.95</PREV_YEAR_REV>
<BUDGET>5877500.25</BUDGET>
<GROSS_PROFIT>3953559.323</GROSS_PROFIT>
<EXPENSES>4621852.47</EXPENSES>
<NET_INCOME>721329.58</NET_INCOME>
<REVENUE_M>5.34318205</REVENUE_M>
<PROFIT_M>3.953559323</PROFIT_M>
<INCOME_M>0.72132958</INCOME_M>
<PHARMA_REV_M>5.34318205</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.953559323</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.72132958</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2353767.84</REVENUE>
<PREV_YEAR_REV>2171112.17</PREV_YEAR_REV>
<BUDGET>1686139.58</BUDGET>
<GROSS_PROFIT>1908976.326</GROSS_PROFIT>
<EXPENSES>1977164.98</EXPENSES>
<NET_INCOME>376602.85</NET_INCOME>
<REVENUE_M>2.35376784</REVENUE_M>
<PROFIT_M>1.908976326</PROFIT_M>
<INCOME_M>0.37660285</INCOME_M>
<PHARMA_REV_M>2.35376784</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.908976326</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37660285</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2324104.49</REVENUE>
<PREV_YEAR_REV>2101037.35</PREV_YEAR_REV>
<BUDGET>1700272.19</BUDGET>
<GROSS_PROFIT>2049232.652</GROSS_PROFIT>
<EXPENSES>2017322.69</EXPENSES>
<NET_INCOME>306781.79</NET_INCOME>
<REVENUE_M>2.32410449</REVENUE_M>
<PROFIT_M>2.049232652</PROFIT_M>
<INCOME_M>0.30678179</INCOME_M>
<PHARMA_REV_M>2.32410449</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.049232652</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30678179</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5238845.47</REVENUE>
<PREV_YEAR_REV>4742500.57</PREV_YEAR_REV>
<BUDGET>3925976.43</BUDGET>
<GROSS_PROFIT>3785791.066</GROSS_PROFIT>
<EXPENSES>4603320.27</EXPENSES>
<NET_INCOME>635525.2</NET_INCOME>
<REVENUE_M>5.23884547</REVENUE_M>
<PROFIT_M>3.785791066</PROFIT_M>
<INCOME_M>0.6355252</INCOME_M>
<PHARMA_REV_M>5.23884547</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.785791066</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6355252</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>8775578.27</REVENUE>
<PREV_YEAR_REV>6260969.44</PREV_YEAR_REV>
<BUDGET>7431123.01</BUDGET>
<GROSS_PROFIT>6906105.639</GROSS_PROFIT>
<EXPENSES>7021631.3</EXPENSES>
<NET_INCOME>753946.97</NET_INCOME>
<REVENUE_M>8.77557827</REVENUE_M>
<PROFIT_M>6.906105639</PROFIT_M>
<INCOME_M>0.75394697</INCOME_M>
<PHARMA_REV_M>8.77557827</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.906105639</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75394697</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2580762.55</REVENUE>
<PREV_YEAR_REV>2060851.05</PREV_YEAR_REV>
<BUDGET>2466609.94</BUDGET>
<GROSS_PROFIT>2027576.099</GROSS_PROFIT>
<EXPENSES>2392366.88</EXPENSES>
<NET_INCOME>188395.67</NET_INCOME>
<REVENUE_M>2.58076255</REVENUE_M>
<PROFIT_M>2.027576099</PROFIT_M>
<INCOME_M>0.18839567</INCOME_M>
<PHARMA_REV_M>2.58076255</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.027576099</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18839567</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2582834.42</REVENUE>
<PREV_YEAR_REV>2007753.57</PREV_YEAR_REV>
<BUDGET>2468557.5</BUDGET>
<GROSS_PROFIT>2249648.78</GROSS_PROFIT>
<EXPENSES>2394287.51</EXPENSES>
<NET_INCOME>188546.91</NET_INCOME>
<REVENUE_M>2.58283442</REVENUE_M>
<PROFIT_M>2.24964878</PROFIT_M>
<INCOME_M>0.18854691</INCOME_M>
<PHARMA_REV_M>2.58283442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.24964878</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18854691</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2554990.67</REVENUE>
<PREV_YEAR_REV>1985877.81</PREV_YEAR_REV>
<BUDGET>2442384.38</BUDGET>
<GROSS_PROFIT>2005240.997</GROSS_PROFIT>
<EXPENSES>2294381.63</EXPENSES>
<NET_INCOME>260609.05</NET_INCOME>
<REVENUE_M>2.55499067</REVENUE_M>
<PROFIT_M>2.005240997</PROFIT_M>
<INCOME_M>0.26060905</INCOME_M>
<PHARMA_REV_M>2.55499067</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.005240997</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26060905</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2580762.55</REVENUE>
<PREV_YEAR_REV>2132650.11</PREV_YEAR_REV>
<BUDGET>2466609.94</BUDGET>
<GROSS_PROFIT>2095145.619</GROSS_PROFIT>
<EXPENSES>2136871.39</EXPENSES>
<NET_INCOME>443891.16</NET_INCOME>
<REVENUE_M>2.58076255</REVENUE_M>
<PROFIT_M>2.095145619</PROFIT_M>
<INCOME_M>0.44389116</INCOME_M>
<PHARMA_REV_M>2.58076255</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.095145619</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44389116</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>5915852.34</REVENUE>
<PREV_YEAR_REV>4826700.33</PREV_YEAR_REV>
<BUDGET>5682980.64</BUDGET>
<GROSS_PROFIT>4847064.98</GROSS_PROFIT>
<EXPENSES>5343558.05</EXPENSES>
<NET_INCOME>572294.3</NET_INCOME>
<REVENUE_M>5.91585234</REVENUE_M>
<PROFIT_M>4.84706498</PROFIT_M>
<INCOME_M>0.5722943</INCOME_M>
<PHARMA_REV_M>5.91585234</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.84706498</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5722943</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.597882267E7</REVENUE>
<PREV_YEAR_REV>2.33809404E7</PREV_YEAR_REV>
<BUDGET>2.467988154E7</BUDGET>
<GROSS_PROFIT>1.76128624E7</GROSS_PROFIT>
<EXPENSES>4.282223517E7</EXPENSES>
<NET_INCOME>3144344.24</NET_INCOME>
<REVENUE_M>25.97882267</REVENUE_M>
<PROFIT_M>17.6128624</PROFIT_M>
<INCOME_M>3.14434424</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.146369407E7</REVENUE>
<PREV_YEAR_REV>1.031732466E7</PREV_YEAR_REV>
<BUDGET>1.089050937E7</BUDGET>
<GROSS_PROFIT>8635600.746</GROSS_PROFIT>
<EXPENSES>1.889619902E7</EXPENSES>
<NET_INCOME>836849.67</NET_INCOME>
<REVENUE_M>11.46369407</REVENUE_M>
<PROFIT_M>8.635600746</PROFIT_M>
<INCOME_M>0.83684967</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.258037764E7</REVENUE>
<PREV_YEAR_REV>1.132233987E7</PREV_YEAR_REV>
<BUDGET>1.12219331E7</BUDGET>
<GROSS_PROFIT>9476798.478</GROSS_PROFIT>
<EXPENSES>1.947125466E7</EXPENSES>
<NET_INCOME>2012860.42</NET_INCOME>
<REVENUE_M>12.58037764</REVENUE_M>
<PROFIT_M>9.476798478</PROFIT_M>
<INCOME_M>2.01286042</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.220883419E7</REVENUE>
<PREV_YEAR_REV>1.098795077E7</PREV_YEAR_REV>
<BUDGET>1.089050937E7</BUDGET>
<GROSS_PROFIT>9196914.792</GROSS_PROFIT>
<EXPENSES>1.889619902E7</EXPENSES>
<NET_INCOME>891244.9</NET_INCOME>
<REVENUE_M>12.20883419</REVENUE_M>
<PROFIT_M>9.196914792</PROFIT_M>
<INCOME_M>0.8912449</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.567275459E7</REVENUE>
<PREV_YEAR_REV>1.410547914E7</PREV_YEAR_REV>
<BUDGET>1.398039143E7</BUDGET>
<GROSS_PROFIT>1.180628603E7</GROSS_PROFIT>
<EXPENSES>24257475</EXPENSES>
<NET_INCOME>2108507.92</NET_INCOME>
<REVENUE_M>15.67275459</REVENUE_M>
<PROFIT_M>11.80628603</PROFIT_M>
<INCOME_M>2.10850792</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>9505668.14</REVENUE>
<PREV_YEAR_REV>8555101.33</PREV_YEAR_REV>
<BUDGET>8479234.49</BUDGET>
<GROSS_PROFIT>7160619.816</GROSS_PROFIT>
<EXPENSES>1.471237911E7</EXPENSES>
<NET_INCOME>1036117.83</NET_INCOME>
<REVENUE_M>9.50566814</REVENUE_M>
<PROFIT_M>7.160619816</PROFIT_M>
<INCOME_M>1.03611783</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.407677258E7</REVENUE>
<PREV_YEAR_REV>1.337293395E7</PREV_YEAR_REV>
<BUDGET>1.36544694E7</BUDGET>
<GROSS_PROFIT>1.060403278E7</GROSS_PROFIT>
<EXPENSES>1.208470831E7</EXPENSES>
<NET_INCOME>1858133.98</NET_INCOME>
<REVENUE_M>14.07677258</REVENUE_M>
<PROFIT_M>10.60403278</PROFIT_M>
<INCOME_M>1.85813398</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.28829307E7</REVENUE>
<PREV_YEAR_REV>1.223878416E7</PREV_YEAR_REV>
<BUDGET>1.249644278E7</BUDGET>
<GROSS_PROFIT>9704711.699</GROSS_PROFIT>
<EXPENSES>1.085847016E7</EXPENSES>
<NET_INCOME>2306044.59</NET_INCOME>
<REVENUE_M>12.8829307</REVENUE_M>
<PROFIT_M>9.704711699</PROFIT_M>
<INCOME_M>2.30604459</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2434313.51</REVENUE>
<PREV_YEAR_REV>2247833.27</PREV_YEAR_REV>
<BUDGET>1815882.49</BUDGET>
<GROSS_PROFIT>1872717.388</GROSS_PROFIT>
<EXPENSES>2044823.35</EXPENSES>
<NET_INCOME>389490.16</NET_INCOME>
<REVENUE_M>2.43431351</REVENUE_M>
<PROFIT_M>1.872717388</PROFIT_M>
<INCOME_M>0.38949016</INCOME_M>
<PHARMA_REV_M>2.43431351</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.872717388</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38949016</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2630451.71</REVENUE>
<PREV_YEAR_REV>2390189.83</PREV_YEAR_REV>
<BUDGET>2005597.76</BUDGET>
<GROSS_PROFIT>2322004.948</GROSS_PROFIT>
<EXPENSES>2438428.74</EXPENSES>
<NET_INCOME>192022.98</NET_INCOME>
<REVENUE_M>2.63045171</REVENUE_M>
<PROFIT_M>2.322004948</PROFIT_M>
<INCOME_M>0.19202298</INCOME_M>
<PHARMA_REV_M>2.63045171</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.322004948</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19202298</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5297809.94</REVENUE>
<PREV_YEAR_REV>4803989.95</PREV_YEAR_REV>
<BUDGET>3902642.9</BUDGET>
<GROSS_PROFIT>4200770.116</GROSS_PROFIT>
<EXPENSES>4597732.77</EXPENSES>
<NET_INCOME>700077.17</NET_INCOME>
<REVENUE_M>5.29780994</REVENUE_M>
<PROFIT_M>4.200770116</PROFIT_M>
<INCOME_M>0.70007717</INCOME_M>
<PHARMA_REV_M>5.29780994</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.200770116</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.70007717</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2541441.82</REVENUE>
<PREV_YEAR_REV>2339884.19</PREV_YEAR_REV>
<BUDGET>1878964.45</BUDGET>
<GROSS_PROFIT>1949783.993</GROSS_PROFIT>
<EXPENSES>2198347.17</EXPENSES>
<NET_INCOME>343094.65</NET_INCOME>
<REVENUE_M>2.54144182</REVENUE_M>
<PROFIT_M>1.949783993</PROFIT_M>
<INCOME_M>0.34309465</INCOME_M>
<PHARMA_REV_M>2.54144182</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.949783993</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34309465</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1910682.68</REVENUE>
<PREV_YEAR_REV>1713509.18</PREV_YEAR_REV>
<BUDGET>1707031.98</BUDGET>
<GROSS_PROFIT>1546659.412</GROSS_PROFIT>
<EXPENSES>1658472.57</EXPENSES>
<NET_INCOME>252210.11</NET_INCOME>
<REVENUE_M>1.91068268</REVENUE_M>
<PROFIT_M>1.546659412</PROFIT_M>
<INCOME_M>0.25221011</INCOME_M>
<PHARMA_REV_M>1.91068268</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.546659412</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25221011</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1928526.64</REVENUE>
<PREV_YEAR_REV>1739621.17</PREV_YEAR_REV>
<BUDGET>1756270.94</BUDGET>
<GROSS_PROFIT>1437138.054</GROSS_PROFIT>
<EXPENSES>1679746.7</EXPENSES>
<NET_INCOME>248779.94</NET_INCOME>
<REVENUE_M>1.92852664</REVENUE_M>
<PROFIT_M>1.437138054</PROFIT_M>
<INCOME_M>0.24877994</INCOME_M>
<PHARMA_REV_M>1.92852664</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.437138054</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24877994</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3746474.65</REVENUE>
<PREV_YEAR_REV>3397642.87</PREV_YEAR_REV>
<BUDGET>3394618.23</BUDGET>
<GROSS_PROFIT>3051417.425</GROSS_PROFIT>
<EXPENSES>3241893.97</EXPENSES>
<NET_INCOME>504580.68</NET_INCOME>
<REVENUE_M>3.74647465</REVENUE_M>
<PROFIT_M>3.051417425</PROFIT_M>
<INCOME_M>0.50458068</INCOME_M>
<PHARMA_REV_M>3.74647465</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.051417425</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50458068</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1184454.1</REVENUE>
<PREV_YEAR_REV>1059923.67</PREV_YEAR_REV>
<BUDGET>982788.39</BUDGET>
<GROSS_PROFIT>1028106.16</GROSS_PROFIT>
<EXPENSES>994941.45</EXPENSES>
<NET_INCOME>189512.66</NET_INCOME>
<REVENUE_M>1.1844541</REVENUE_M>
<PROFIT_M>1.02810616</PROFIT_M>
<INCOME_M>0.18951266</INCOME_M>
<PHARMA_REV_M>1.1844541</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.02810616</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18951266</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2981468.16</REVENUE>
<PREV_YEAR_REV>2682367.07</PREV_YEAR_REV>
<BUDGET>2393650.79</BUDGET>
<GROSS_PROFIT>2279744.865</GROSS_PROFIT>
<EXPENSES>2617954.9</EXPENSES>
<NET_INCOME>363513.24</NET_INCOME>
<REVENUE_M>2.98146816</REVENUE_M>
<PROFIT_M>2.279744865</PROFIT_M>
<INCOME_M>0.36351324</INCOME_M>
<PHARMA_REV_M>2.98146816</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.279744865</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36351324</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1488515.46</REVENUE>
<PREV_YEAR_REV>1341839.04</PREV_YEAR_REV>
<BUDGET>1223434.61</BUDGET>
<GROSS_PROFIT>1108646.314</GROSS_PROFIT>
<EXPENSES>1222071.2</EXPENSES>
<NET_INCOME>266444.27</NET_INCOME>
<REVENUE_M>1.48851546</REVENUE_M>
<PROFIT_M>1.108646314</PROFIT_M>
<INCOME_M>0.26644427</INCOME_M>
<PHARMA_REV_M>1.48851546</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.108646314</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26644427</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1347406.69</REVENUE>
<PREV_YEAR_REV>1225750.91</PREV_YEAR_REV>
<BUDGET>1058210.33</BUDGET>
<GROSS_PROFIT>1180328.26</GROSS_PROFIT>
<EXPENSES>1106220.89</EXPENSES>
<NET_INCOME>241185.8</NET_INCOME>
<REVENUE_M>1.34740669</REVENUE_M>
<PROFIT_M>1.18032826</PROFIT_M>
<INCOME_M>0.2411858</INCOME_M>
<PHARMA_REV_M>1.34740669</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.18032826</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2411858</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1282317.71</REVENUE>
<PREV_YEAR_REV>1158591.7</PREV_YEAR_REV>
<BUDGET>1091238.83</BUDGET>
<GROSS_PROFIT>993667.995</GROSS_PROFIT>
<EXPENSES>1109204.82</EXPENSES>
<NET_INCOME>173112.89</NET_INCOME>
<REVENUE_M>1.28231771</REVENUE_M>
<PROFIT_M>0.993667995</PROFIT_M>
<INCOME_M>0.17311289</INCOME_M>
<PHARMA_REV_M>1.28231771</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.993667995</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17311289</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.657294174E7</REVENUE>
<PREV_YEAR_REV>1.488451489E7</PREV_YEAR_REV>
<BUDGET>1.491564756E7</BUDGET>
<GROSS_PROFIT>1.274035058E7</GROSS_PROFIT>
<EXPENSES>1.474417079E7</EXPENSES>
<NET_INCOME>1828770.95</NET_INCOME>
<REVENUE_M>16.57294174</REVENUE_M>
<PROFIT_M>12.74035058</PROFIT_M>
<INCOME_M>1.82877095</INCOME_M>
<PHARMA_REV_M>16.57294174</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.74035058</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.82877095</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7480986.2</REVENUE>
<PREV_YEAR_REV>6672719.67</PREV_YEAR_REV>
<BUDGET>6732887.58</BUDGET>
<GROSS_PROFIT>6067304.239</GROSS_PROFIT>
<EXPENSES>6141889.67</EXPENSES>
<NET_INCOME>1339096.53</NET_INCOME>
<REVENUE_M>7.4809862</REVENUE_M>
<PROFIT_M>6.067304239</PROFIT_M>
<INCOME_M>1.33909653</INCOME_M>
<PHARMA_REV_M>7.4809862</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.067304239</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.33909653</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4525367.01</REVENUE>
<PREV_YEAR_REV>4026851.67</PREV_YEAR_REV>
<BUDGET>4683453.37</BUDGET>
<GROSS_PROFIT>3722470.612</GROSS_PROFIT>
<EXPENSES>3916534.17</EXPENSES>
<NET_INCOME>608832.84</NET_INCOME>
<REVENUE_M>4.52536701</REVENUE_M>
<PROFIT_M>3.722470612</PROFIT_M>
<INCOME_M>0.60883284</INCOME_M>
<PHARMA_REV_M>4.52536701</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.722470612</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60883284</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2306793.28</REVENUE>
<PREV_YEAR_REV>2076994.59</PREV_YEAR_REV>
<BUDGET>2417587.9</BUDGET>
<GROSS_PROFIT>1814961.885</GROSS_PROFIT>
<EXPENSES>1910024.83</EXPENSES>
<NET_INCOME>396768.44</NET_INCOME>
<REVENUE_M>2.30679328</REVENUE_M>
<PROFIT_M>1.814961885</PROFIT_M>
<INCOME_M>0.39676844</INCOME_M>
<PHARMA_REV_M>2.30679328</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.814961885</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39676844</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2281526.39</REVENUE>
<PREV_YEAR_REV>2071817.07</PREV_YEAR_REV>
<BUDGET>2327181.8</BUDGET>
<GROSS_PROFIT>1611857.328</GROSS_PROFIT>
<EXPENSES>1973520.33</EXPENSES>
<NET_INCOME>308006.06</NET_INCOME>
<REVENUE_M>2.28152639</REVENUE_M>
<PROFIT_M>1.611857328</PROFIT_M>
<INCOME_M>0.30800606</INCOME_M>
<PHARMA_REV_M>2.28152639</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.611857328</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30800606</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1331975.31</REVENUE>
<PREV_YEAR_REV>1195561.71</PREV_YEAR_REV>
<BUDGET>1702960.49</BUDGET>
<GROSS_PROFIT>1083428.71</GROSS_PROFIT>
<EXPENSES>1118859.26</EXPENSES>
<NET_INCOME>213116.05</NET_INCOME>
<REVENUE_M>1.33197531</REVENUE_M>
<PROFIT_M>1.08342871</PROFIT_M>
<INCOME_M>0.21311605</INCOME_M>
<PHARMA_REV_M>1.33197531</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.08342871</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21311605</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3234372.18</REVENUE>
<PREV_YEAR_REV>2828857.64</PREV_YEAR_REV>
<BUDGET>4147133.33</BUDGET>
<GROSS_PROFIT>2327515.569</GROSS_PROFIT>
<EXPENSES>2753787</EXPENSES>
<NET_INCOME>480585.18</NET_INCOME>
<REVENUE_M>3.23437218</REVENUE_M>
<PROFIT_M>2.327515569</PROFIT_M>
<INCOME_M>0.48058518</INCOME_M>
<PHARMA_REV_M>3.23437218</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.327515569</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48058518</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6009086.59</REVENUE>
<PREV_YEAR_REV>5444098.09</PREV_YEAR_REV>
<BUDGET>5408177.93</BUDGET>
<GROSS_PROFIT>4873369.22</GROSS_PROFIT>
<EXPENSES>4933460.09</EXPENSES>
<NET_INCOME>1075626.5</NET_INCOME>
<REVENUE_M>6.00908659</REVENUE_M>
<PROFIT_M>4.87336922</PROFIT_M>
<INCOME_M>1.0756265</INCOME_M>
<PHARMA_REV_M>6.00908659</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.87336922</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.0756265</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5577281.75</REVENUE>
<PREV_YEAR_REV>5011620.18</PREV_YEAR_REV>
<BUDGET>5019553.58</BUDGET>
<GROSS_PROFIT>4392388.242</GROSS_PROFIT>
<EXPENSES>5008399.01</EXPENSES>
<NET_INCOME>568882.74</NET_INCOME>
<REVENUE_M>5.57728175</REVENUE_M>
<PROFIT_M>4.392388242</PROFIT_M>
<INCOME_M>0.56888274</INCOME_M>
<PHARMA_REV_M>5.57728175</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.392388242</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56888274</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3906485.63</REVENUE>
<PREV_YEAR_REV>3526894.61</PREV_YEAR_REV>
<BUDGET>3726833.67</BUDGET>
<GROSS_PROFIT>3230420.929</GROSS_PROFIT>
<EXPENSES>3473277.86</EXPENSES>
<NET_INCOME>433207.78</NET_INCOME>
<REVENUE_M>3.90648563</REVENUE_M>
<PROFIT_M>3.230420929</PROFIT_M>
<INCOME_M>0.43320778</INCOME_M>
<PHARMA_REV_M>3.90648563</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.230420929</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43320778</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2170209.86</REVENUE>
<PREV_YEAR_REV>1930396.68</PREV_YEAR_REV>
<BUDGET>2125971.55</BUDGET>
<GROSS_PROFIT>1854574.54</GROSS_PROFIT>
<EXPENSES>1883742.16</EXPENSES>
<NET_INCOME>286467.7</NET_INCOME>
<REVENUE_M>2.17020986</REVENUE_M>
<PROFIT_M>1.85457454</PROFIT_M>
<INCOME_M>0.2864677</INCOME_M>
<PHARMA_REV_M>2.17020986</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.85457454</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2864677</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2278631.31</REVENUE>
<PREV_YEAR_REV>2024874.09</PREV_YEAR_REV>
<BUDGET>2185687.48</BUDGET>
<GROSS_PROFIT>1742518.359</GROSS_PROFIT>
<EXPENSES>2046210.92</EXPENSES>
<NET_INCOME>232420.39</NET_INCOME>
<REVENUE_M>2.27863131</REVENUE_M>
<PROFIT_M>1.742518359</PROFIT_M>
<INCOME_M>0.23242039</INCOME_M>
<PHARMA_REV_M>2.27863131</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.742518359</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23242039</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2421516.47</REVENUE>
<PREV_YEAR_REV>2207056.76</PREV_YEAR_REV>
<BUDGET>2250310.35</BUDGET>
<GROSS_PROFIT>2014426.861</GROSS_PROFIT>
<EXPENSES>2005015.64</EXPENSES>
<NET_INCOME>416500.83</NET_INCOME>
<REVENUE_M>2.42151647</REVENUE_M>
<PROFIT_M>2.014426861</PROFIT_M>
<INCOME_M>0.41650083</INCOME_M>
<PHARMA_REV_M>2.42151647</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.014426861</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41650083</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3197058.53</REVENUE>
<PREV_YEAR_REV>2938080.96</PREV_YEAR_REV>
<BUDGET>3853908.8</BUDGET>
<GROSS_PROFIT>2570910.685</GROSS_PROFIT>
<EXPENSES>2766930.11</EXPENSES>
<NET_INCOME>430128.42</NET_INCOME>
<REVENUE_M>3.19705853</REVENUE_M>
<PROFIT_M>2.570910685</PROFIT_M>
<INCOME_M>0.43012842</INCOME_M>
<PHARMA_REV_M>3.19705853</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.570910685</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43012842</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1613295.99</REVENUE>
<PREV_YEAR_REV>1473316.22</PREV_YEAR_REV>
<BUDGET>1917445.01</BUDGET>
<GROSS_PROFIT>1301203.885</GROSS_PROFIT>
<EXPENSES>1324516.01</EXPENSES>
<NET_INCOME>288779.98</NET_INCOME>
<REVENUE_M>1.61329599</REVENUE_M>
<PROFIT_M>1.301203885</PROFIT_M>
<INCOME_M>0.28877998</INCOME_M>
<PHARMA_REV_M>1.61329599</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.301203885</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28877998</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3191325.87</REVENUE>
<PREV_YEAR_REV>2899249.8</PREV_YEAR_REV>
<BUDGET>3841808.46</BUDGET>
<GROSS_PROFIT>2422495.773</GROSS_PROFIT>
<EXPENSES>2716661.22</EXPENSES>
<NET_INCOME>474664.66</NET_INCOME>
<REVENUE_M>3.19132587</REVENUE_M>
<PROFIT_M>2.422495773</PROFIT_M>
<INCOME_M>0.47466466</INCOME_M>
<PHARMA_REV_M>3.19132587</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.422495773</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47466466</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4850658.45</REVENUE>
<PREV_YEAR_REV>4388981.94</PREV_YEAR_REV>
<BUDGET>5827040.31</BUDGET>
<GROSS_PROFIT>4062895.5</GROSS_PROFIT>
<EXPENSES>4381354.79</EXPENSES>
<NET_INCOME>469303.65</NET_INCOME>
<REVENUE_M>4.85065845</REVENUE_M>
<PROFIT_M>4.0628955</PROFIT_M>
<INCOME_M>0.46930365</INCOME_M>
<PHARMA_REV_M>4.85065845</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.0628955</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46930365</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1620745.26</REVENUE>
<PREV_YEAR_REV>1458645.93</PREV_YEAR_REV>
<BUDGET>1954112.73</BUDGET>
<GROSS_PROFIT>1238897.674</GROSS_PROFIT>
<EXPENSES>1444084.02</EXPENSES>
<NET_INCOME>176661.23</NET_INCOME>
<REVENUE_M>1.62074526</REVENUE_M>
<PROFIT_M>1.238897674</PROFIT_M>
<INCOME_M>0.17666123</INCOME_M>
<PHARMA_REV_M>1.62074526</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.238897674</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17666123</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1608242.66</REVENUE>
<PREV_YEAR_REV>1479469.62</PREV_YEAR_REV>
<BUDGET>1954112.73</BUDGET>
<GROSS_PROFIT>1254348.859</GROSS_PROFIT>
<EXPENSES>1432944.21</EXPENSES>
<NET_INCOME>175298.45</NET_INCOME>
<REVENUE_M>1.60824266</REVENUE_M>
<PROFIT_M>1.254348859</PROFIT_M>
<INCOME_M>0.17529845</INCOME_M>
<PHARMA_REV_M>1.60824266</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.254348859</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17529845</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1357518.21</REVENUE>
<PREV_YEAR_REV>1236107.71</PREV_YEAR_REV>
<BUDGET>1373673.5</BUDGET>
<GROSS_PROFIT>958720.0842</GROSS_PROFIT>
<EXPENSES>1182398.36</EXPENSES>
<NET_INCOME>175119.85</NET_INCOME>
<REVENUE_M>1.35751821</REVENUE_M>
<PROFIT_M>0.958720084</PROFIT_M>
<INCOME_M>0.17511985</INCOME_M>
<PHARMA_REV_M>1.35751821</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.958720084</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17511985</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1131458.32</REVENUE>
<PREV_YEAR_REV>1014615.23</PREV_YEAR_REV>
<BUDGET>1207955.98</BUDGET>
<GROSS_PROFIT>975317.07</GROSS_PROFIT>
<EXPENSES>982105.82</EXPENSES>
<NET_INCOME>149352.5</NET_INCOME>
<REVENUE_M>1.13145832</REVENUE_M>
<PROFIT_M>0.97531707</PROFIT_M>
<INCOME_M>0.1493525</INCOME_M>
<PHARMA_REV_M>1.13145832</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.97531707</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1493525</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1314987.99</REVENUE>
<PREV_YEAR_REV>1195128.55</PREV_YEAR_REV>
<BUDGET>1375835.92</BUDGET>
<GROSS_PROFIT>996892.399</GROSS_PROFIT>
<EXPENSES>1218993.87</EXPENSES>
<NET_INCOME>95994.12</NET_INCOME>
<REVENUE_M>1.31498799</REVENUE_M>
<PROFIT_M>0.996892399</PROFIT_M>
<INCOME_M>0.09599412</INCOME_M>
<PHARMA_REV_M>1.31498799</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.996892399</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.09599412</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1278471.03</REVENUE>
<PREV_YEAR_REV>1137622.04</PREV_YEAR_REV>
<BUDGET>1373673.5</BUDGET>
<GROSS_PROFIT>1014147.145</GROSS_PROFIT>
<EXPENSES>1058574.01</EXPENSES>
<NET_INCOME>219897.02</NET_INCOME>
<REVENUE_M>1.27847103</REVENUE_M>
<PROFIT_M>1.014147145</PROFIT_M>
<INCOME_M>0.21989702</INCOME_M>
<PHARMA_REV_M>1.27847103</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.014147145</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21989702</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8143151.58</REVENUE>
<PREV_YEAR_REV>7189468.57</PREV_YEAR_REV>
<BUDGET>8306014.61</BUDGET>
<GROSS_PROFIT>6449376.05</GROSS_PROFIT>
<EXPENSES>7068255.57</EXPENSES>
<NET_INCOME>1074896.01</NET_INCOME>
<REVENUE_M>8.14315158</REVENUE_M>
<PROFIT_M>6.44937605</PROFIT_M>
<INCOME_M>1.07489601</INCOME_M>
<PHARMA_REV_M>8.14315158</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.44937605</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.07489601</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.305417591E7</REVENUE>
<PREV_YEAR_REV>1.108312107E7</PREV_YEAR_REV>
<BUDGET>1.331525942E7</BUDGET>
<GROSS_PROFIT>1.106044842E7</GROSS_PROFIT>
<EXPENSES>1.130047765E7</EXPENSES>
<NET_INCOME>1753698.26</NET_INCOME>
<REVENUE_M>13.05417591</REVENUE_M>
<PROFIT_M>11.06044842</PROFIT_M>
<INCOME_M>1.75369826</INCOME_M>
<PHARMA_REV_M>13.05417591</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.06044842</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.75369826</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2117041.15</REVENUE>
<PREV_YEAR_REV>1816360.78</PREV_YEAR_REV>
<BUDGET>2284006.33</BUDGET>
<GROSS_PROFIT>1639013.26</GROSS_PROFIT>
<EXPENSES>1837591.72</EXPENSES>
<NET_INCOME>279449.43</NET_INCOME>
<REVENUE_M>2.11704115</REVENUE_M>
<PROFIT_M>1.63901326</PROFIT_M>
<INCOME_M>0.27944943</INCOME_M>
<PHARMA_REV_M>2.11704115</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.63901326</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27944943</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5557593.41</REVENUE>
<PREV_YEAR_REV>5075286.92</PREV_YEAR_REV>
<BUDGET>4063626.92</BUDGET>
<GROSS_PROFIT>4529285.522</GROSS_PROFIT>
<EXPENSES>4827376.92</EXPENSES>
<NET_INCOME>730216.49</NET_INCOME>
<REVENUE_M>5.55759341</REVENUE_M>
<PROFIT_M>4.529285522</PROFIT_M>
<INCOME_M>0.73021649</INCOME_M>
<PHARMA_REV_M>5.55759341</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.529285522</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.73021649</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5485949.61</REVENUE>
<PREV_YEAR_REV>5027948.85</PREV_YEAR_REV>
<BUDGET>4092146.72</BUDGET>
<GROSS_PROFIT>4814838.438</GROSS_PROFIT>
<EXPENSES>4758903.14</EXPENSES>
<NET_INCOME>727046.47</NET_INCOME>
<REVENUE_M>5.48594961</REVENUE_M>
<PROFIT_M>4.814838438</PROFIT_M>
<INCOME_M>0.72704647</INCOME_M>
<PHARMA_REV_M>5.48594961</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.814838438</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.72704647</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2152663.81</REVENUE>
<PREV_YEAR_REV>1958498.29</PREV_YEAR_REV>
<BUDGET>1825544.47</BUDGET>
<GROSS_PROFIT>1773794.98</GROSS_PROFIT>
<EXPENSES>1808237.6</EXPENSES>
<NET_INCOME>344426.21</NET_INCOME>
<REVENUE_M>2.15266381</REVENUE_M>
<PROFIT_M>1.77379498</PROFIT_M>
<INCOME_M>0.34442621</INCOME_M>
<PHARMA_REV_M>2.15266381</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.77379498</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34442621</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2172240.66</REVENUE>
<PREV_YEAR_REV>2019111.27</PREV_YEAR_REV>
<BUDGET>1840773.2</BUDGET>
<GROSS_PROFIT>1720414.61</GROSS_PROFIT>
<EXPENSES>1885504.9</EXPENSES>
<NET_INCOME>286735.77</NET_INCOME>
<REVENUE_M>2.17224066</REVENUE_M>
<PROFIT_M>1.72041461</PROFIT_M>
<INCOME_M>0.28673577</INCOME_M>
<PHARMA_REV_M>2.17224066</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.72041461</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28673577</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1954232.04</REVENUE>
<PREV_YEAR_REV>1809792.5</PREV_YEAR_REV>
<BUDGET>1737979.25</BUDGET>
<GROSS_PROFIT>1321656.905</GROSS_PROFIT>
<EXPENSES>1702136.11</EXPENSES>
<NET_INCOME>252095.93</NET_INCOME>
<REVENUE_M>1.95423204</REVENUE_M>
<PROFIT_M>1.321656905</PROFIT_M>
<INCOME_M>0.25209593</INCOME_M>
<PHARMA_REV_M>1.95423204</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.321656905</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25209593</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4160721.98</REVENUE>
<PREV_YEAR_REV>3745177.08</PREV_YEAR_REV>
<BUDGET>3558434.78</BUDGET>
<GROSS_PROFIT>3056624.154</GROSS_PROFIT>
<EXPENSES>3655313.74</EXPENSES>
<NET_INCOME>505408.24</NET_INCOME>
<REVENUE_M>4.16072198</REVENUE_M>
<PROFIT_M>3.056624154</PROFIT_M>
<INCOME_M>0.50540824</INCOME_M>
<PHARMA_REV_M>4.16072198</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.056624154</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50540824</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>6275233.72</REVENUE>
<PREV_YEAR_REV>5739977.72</PREV_YEAR_REV>
<BUDGET>5340824.82</BUDGET>
<GROSS_PROFIT>5166171.675</GROSS_PROFIT>
<EXPENSES>5662860.31</EXPENSES>
<NET_INCOME>612373.42</NET_INCOME>
<REVENUE_M>6.27523372</REVENUE_M>
<PROFIT_M>5.166171675</PROFIT_M>
<INCOME_M>0.61237342</INCOME_M>
<PHARMA_REV_M>6.27523372</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.166171675</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61237342</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2135577.11</REVENUE>
<PREV_YEAR_REV>1959586.63</PREV_YEAR_REV>
<BUDGET>1758601.49</BUDGET>
<GROSS_PROFIT>1751173.23</GROSS_PROFIT>
<EXPENSES>1753308.8</EXPENSES>
<NET_INCOME>382268.3</NET_INCOME>
<REVENUE_M>2.13557711</REVENUE_M>
<PROFIT_M>1.75117323</PROFIT_M>
<INCOME_M>0.3822683</INCOME_M>
<PHARMA_REV_M>2.13557711</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.75117323</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3822683</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4000205.01</REVENUE>
<PREV_YEAR_REV>3695007.37</PREV_YEAR_REV>
<BUDGET>3517202.98</BUDGET>
<GROSS_PROFIT>3130931.701</GROSS_PROFIT>
<EXPENSES>3461888.68</EXPENSES>
<NET_INCOME>538316.33</NET_INCOME>
<REVENUE_M>4.00020501</REVENUE_M>
<PROFIT_M>3.130931701</PROFIT_M>
<INCOME_M>0.53831633</INCOME_M>
<PHARMA_REV_M>4.00020501</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.130931701</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53831633</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2102384.13</REVENUE>
<PREV_YEAR_REV>1963102.04</PREV_YEAR_REV>
<BUDGET>1777447.05</BUDGET>
<GROSS_PROFIT>1772309.82</GROSS_PROFIT>
<EXPENSES>1948910.09</EXPENSES>
<NET_INCOME>153474.04</NET_INCOME>
<REVENUE_M>2.10238413</REVENUE_M>
<PROFIT_M>1.77230982</PROFIT_M>
<INCOME_M>0.15347404</INCOME_M>
<PHARMA_REV_M>2.10238413</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.77230982</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15347404</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1975351.83</REVENUE>
<PREV_YEAR_REV>1813813.59</PREV_YEAR_REV>
<BUDGET>1754477.04</BUDGET>
<GROSS_PROFIT>1491884.465</GROSS_PROFIT>
<EXPENSES>1635591.31</EXPENSES>
<NET_INCOME>339760.51</NET_INCOME>
<REVENUE_M>1.97535183</REVENUE_M>
<PROFIT_M>1.491884465</PROFIT_M>
<INCOME_M>0.33976051</INCOME_M>
<PHARMA_REV_M>1.97535183</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.491884465</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33976051</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1714603.95</REVENUE>
<PREV_YEAR_REV>1569532.1</PREV_YEAR_REV>
<BUDGET>1273901.29</BUDGET>
<GROSS_PROFIT>1322645.49</GROSS_PROFIT>
<EXPENSES>1488276.23</EXPENSES>
<NET_INCOME>226327.72</NET_INCOME>
<REVENUE_M>1.71460395</REVENUE_M>
<PROFIT_M>1.32264549</PROFIT_M>
<INCOME_M>0.22632772</INCOME_M>
<PHARMA_REV_M>1.71460395</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.32264549</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22632772</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4884159.92</REVENUE>
<PREV_YEAR_REV>4511544.54</PREV_YEAR_REV>
<BUDGET>3568555.14</BUDGET>
<GROSS_PROFIT>4211444.41</GROSS_PROFIT>
<EXPENSES>4412096.68</EXPENSES>
<NET_INCOME>472063.23</NET_INCOME>
<REVENUE_M>4.88415992</REVENUE_M>
<PROFIT_M>4.21144441</PROFIT_M>
<INCOME_M>0.47206323</INCOME_M>
<PHARMA_REV_M>4.88415992</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.21144441</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47206323</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3262273.88</REVENUE>
<PREV_YEAR_REV>2946119.49</PREV_YEAR_REV>
<BUDGET>2404746.97</BUDGET>
<GROSS_PROFIT>2629063.963</GROSS_PROFIT>
<EXPENSES>2828372.65</EXPENSES>
<NET_INCOME>433901.23</NET_INCOME>
<REVENUE_M>3.26227388</REVENUE_M>
<PROFIT_M>2.629063963</PROFIT_M>
<INCOME_M>0.43390123</INCOME_M>
<PHARMA_REV_M>3.26227388</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.629063963</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43390123</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1631117.6</REVENUE>
<PREV_YEAR_REV>1498252.56</PREV_YEAR_REV>
<BUDGET>1145696.6</BUDGET>
<GROSS_PROFIT>1341920.448</GROSS_PROFIT>
<EXPENSES>1453325.78</EXPENSES>
<NET_INCOME>177791.82</NET_INCOME>
<REVENUE_M>1.6311176</REVENUE_M>
<PROFIT_M>1.341920448</PROFIT_M>
<INCOME_M>0.17779182</INCOME_M>
<PHARMA_REV_M>1.6311176</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.341920448</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17779182</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5113903.2</REVENUE>
<PREV_YEAR_REV>4629223.5</PREV_YEAR_REV>
<BUDGET>4602512.88</BUDGET>
<GROSS_PROFIT>4351931.63</GROSS_PROFIT>
<EXPENSES>4556487.76</EXPENSES>
<NET_INCOME>557415.45</NET_INCOME>
<REVENUE_M>5.1139032</REVENUE_M>
<PROFIT_M>4.35193163</PROFIT_M>
<INCOME_M>0.55741545</INCOME_M>
<PHARMA_REV_M>5.1139032</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.35193163</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55741545</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4776554.76</REVENUE>
<PREV_YEAR_REV>4103917.14</PREV_YEAR_REV>
<BUDGET>4255041.78</BUDGET>
<GROSS_PROFIT>3548738.859</GROSS_PROFIT>
<EXPENSES>4248859.02</EXPENSES>
<NET_INCOME>527695.73</NET_INCOME>
<REVENUE_M>4.77655476</REVENUE_M>
<PROFIT_M>3.548738859</PROFIT_M>
<INCOME_M>0.52769573</INCOME_M>
<PHARMA_REV_M>4.77655476</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.548738859</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52769573</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2492160.42</REVENUE>
<PREV_YEAR_REV>2152663.81</PREV_YEAR_REV>
<BUDGET>2204530.02</BUDGET>
<GROSS_PROFIT>2031110.74</GROSS_PROFIT>
<EXPENSES>2093414.75</EXPENSES>
<NET_INCOME>398745.67</NET_INCOME>
<REVENUE_M>2.49216042</REVENUE_M>
<PROFIT_M>2.03111074</PROFIT_M>
<INCOME_M>0.39874567</INCOME_M>
<PHARMA_REV_M>2.49216042</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.03111074</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39874567</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4680291.41</REVENUE>
<PREV_YEAR_REV>4067333.36</PREV_YEAR_REV>
<BUDGET>4309055.45</BUDGET>
<GROSS_PROFIT>3626896.643</GROSS_PROFIT>
<EXPENSES>4162724.66</EXPENSES>
<NET_INCOME>517566.75</NET_INCOME>
<REVENUE_M>4.68029141</REVENUE_M>
<PROFIT_M>3.626896643</PROFIT_M>
<INCOME_M>0.51756675</INCOME_M>
<PHARMA_REV_M>4.68029141</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.626896643</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51756675</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2321219.77</REVENUE>
<PREV_YEAR_REV>1994860.58</PREV_YEAR_REV>
<BUDGET>2152416.68</BUDGET>
<GROSS_PROFIT>1942860.95</GROSS_PROFIT>
<EXPENSES>2014818.76</EXPENSES>
<NET_INCOME>306401.01</NET_INCOME>
<REVENUE_M>2.32121977</REVENUE_M>
<PROFIT_M>1.94286095</PROFIT_M>
<INCOME_M>0.30640101</INCOME_M>
<PHARMA_REV_M>2.32121977</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.94286095</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30640101</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4773301.43</REVENUE>
<PREV_YEAR_REV>4198266.09</PREV_YEAR_REV>
<BUDGET>4275395.19</BUDGET>
<GROSS_PROFIT>3507623.613</GROSS_PROFIT>
<EXPENSES>4064698.72</EXPENSES>
<NET_INCOME>708602.7</NET_INCOME>
<REVENUE_M>4.77330143</REVENUE_M>
<PROFIT_M>3.507623613</PROFIT_M>
<INCOME_M>0.7086027</INCOME_M>
<PHARMA_REV_M>4.77330143</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.507623613</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.7086027</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4712717.32</REVENUE>
<PREV_YEAR_REV>4193920.28</PREV_YEAR_REV>
<BUDGET>4276106.27</BUDGET>
<GROSS_PROFIT>3283513.016</GROSS_PROFIT>
<EXPENSES>4011976.42</EXPENSES>
<NET_INCOME>700740.91</NET_INCOME>
<REVENUE_M>4.71271732</REVENUE_M>
<PROFIT_M>3.283513016</PROFIT_M>
<INCOME_M>0.70074091</INCOME_M>
<PHARMA_REV_M>4.71271732</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.283513016</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.70074091</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2360823.87</REVENUE>
<PREV_YEAR_REV>2141453.38</PREV_YEAR_REV>
<BUDGET>2123689.59</BUDGET>
<GROSS_PROFIT>1832353.445</GROSS_PROFIT>
<EXPENSES>1938236.4</EXPENSES>
<NET_INCOME>422587.47</NET_INCOME>
<REVENUE_M>2.36082387</REVENUE_M>
<PROFIT_M>1.832353445</PROFIT_M>
<INCOME_M>0.42258747</INCOME_M>
<PHARMA_REV_M>2.36082387</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.832353445</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42258747</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2232753.1</REVENUE>
<PREV_YEAR_REV>2012196.27</PREV_YEAR_REV>
<BUDGET>2131352.19</BUDGET>
<GROSS_PROFIT>1760525.817</GROSS_PROFIT>
<EXPENSES>2005012.28</EXPENSES>
<NET_INCOME>227740.82</NET_INCOME>
<REVENUE_M>2.2327531</REVENUE_M>
<PROFIT_M>1.760525817</PROFIT_M>
<INCOME_M>0.22774082</INCOME_M>
<PHARMA_REV_M>2.2327531</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.760525817</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22774082</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1914418.48</REVENUE>
<PREV_YEAR_REV>1714875.56</PREV_YEAR_REV>
<BUDGET>1521428.83</BUDGET>
<GROSS_PROFIT>1432224.325</GROSS_PROFIT>
<EXPENSES>1667458.5</EXPENSES>
<NET_INCOME>246959.98</NET_INCOME>
<REVENUE_M>1.91441848</REVENUE_M>
<PROFIT_M>1.432224325</PROFIT_M>
<INCOME_M>0.24695998</INCOME_M>
<PHARMA_REV_M>1.91441848</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.432224325</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24695998</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1741560.27</REVENUE>
<PREV_YEAR_REV>1501707.55</PREV_YEAR_REV>
<BUDGET>1235772.81</BUDGET>
<GROSS_PROFIT>1361900.13</GROSS_PROFIT>
<EXPENSES>1462910.63</EXPENSES>
<NET_INCOME>278649.64</NET_INCOME>
<REVENUE_M>1.74156027</REVENUE_M>
<PROFIT_M>1.36190013</PROFIT_M>
<INCOME_M>0.27864964</INCOME_M>
<PHARMA_REV_M>1.74156027</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.36190013</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27864964</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3727992.34</REVENUE>
<PREV_YEAR_REV>3202316.11</PREV_YEAR_REV>
<BUDGET>2739700.97</BUDGET>
<GROSS_PROFIT>2789648.919</GROSS_PROFIT>
<EXPENSES>3175076.65</EXPENSES>
<NET_INCOME>552915.69</NET_INCOME>
<REVENUE_M>3.72799234</REVENUE_M>
<PROFIT_M>2.789648919</PROFIT_M>
<INCOME_M>0.55291569</INCOME_M>
<PHARMA_REV_M>3.72799234</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.789648919</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55291569</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.083986572E7</REVENUE>
<PREV_YEAR_REV>9297502.96</PREV_YEAR_REV>
<BUDGET>1.062306841E7</BUDGET>
<GROSS_PROFIT>8563493.92</GROSS_PROFIT>
<EXPENSES>9105487.21</EXPENSES>
<NET_INCOME>1734378.52</NET_INCOME>
<REVENUE_M>10.83986572</REVENUE_M>
<PROFIT_M>8.56349392</PROFIT_M>
<INCOME_M>1.73437852</INCOME_M>
<PHARMA_REV_M>10.83986572</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.56349392</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.73437852</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7372795</REVENUE>
<PREV_YEAR_REV>6525232.54</PREV_YEAR_REV>
<BUDGET>7225339.1</BUDGET>
<GROSS_PROFIT>6284865.37</GROSS_PROFIT>
<EXPENSES>6834580.96</EXPENSES>
<NET_INCOME>538214.03</NET_INCOME>
<REVENUE_M>7.372795</REVENUE_M>
<PROFIT_M>6.28486537</PROFIT_M>
<INCOME_M>0.53821403</INCOME_M>
<PHARMA_REV_M>7.372795</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.28486537</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53821403</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>9201649.49</REVENUE>
<PREV_YEAR_REV>8122279.74</PREV_YEAR_REV>
<BUDGET>9017616.5</BUDGET>
<GROSS_PROFIT>6975770.476</GROSS_PROFIT>
<EXPENSES>7618965.78</EXPENSES>
<NET_INCOME>1582683.71</NET_INCOME>
<REVENUE_M>9.20164949</REVENUE_M>
<PROFIT_M>6.975770476</PROFIT_M>
<INCOME_M>1.58268371</INCOME_M>
<PHARMA_REV_M>9.20164949</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.975770476</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.58268371</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7468145.56</REVENUE>
<PREV_YEAR_REV>6648753.21</PREV_YEAR_REV>
<BUDGET>7318782.65</BUDGET>
<GROSS_PROFIT>5754045.584</GROSS_PROFIT>
<EXPENSES>6706394.71</EXPENSES>
<NET_INCOME>761750.85</NET_INCOME>
<REVENUE_M>7.46814556</REVENUE_M>
<PROFIT_M>5.754045584</PROFIT_M>
<INCOME_M>0.76175085</INCOME_M>
<PHARMA_REV_M>7.46814556</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.754045584</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76175085</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2991587.26</REVENUE>
<PREV_YEAR_REV>2650307.2</PREV_YEAR_REV>
<BUDGET>2601407.81</BUDGET>
<GROSS_PROFIT>2389380.748</GROSS_PROFIT>
<EXPENSES>2596697.74</EXPENSES>
<NET_INCOME>394889.52</NET_INCOME>
<REVENUE_M>2.99158726</REVENUE_M>
<PROFIT_M>2.389380748</PROFIT_M>
<INCOME_M>0.39488952</INCOME_M>
<PHARMA_REV_M>2.99158726</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.389380748</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39488952</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>8893392.05</REVENUE>
<PREV_YEAR_REV>7792915.29</PREV_YEAR_REV>
<BUDGET>7900645.34</BUDGET>
<GROSS_PROFIT>7253082.145</GROSS_PROFIT>
<EXPENSES>8031057.77</EXPENSES>
<NET_INCOME>862334.28</NET_INCOME>
<REVENUE_M>8.89339205</REVENUE_M>
<PROFIT_M>7.253082145</PROFIT_M>
<INCOME_M>0.86233428</INCOME_M>
<PHARMA_REV_M>8.89339205</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.253082145</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.86233428</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1500682.08</REVENUE>
<PREV_YEAR_REV>1357518.21</PREV_YEAR_REV>
<BUDGET>1455661.61</BUDGET>
<GROSS_PROFIT>1103451.526</GROSS_PROFIT>
<EXPENSES>1307094.09</EXPENSES>
<NET_INCOME>193587.99</NET_INCOME>
<REVENUE_M>1.50068208</REVENUE_M>
<PROFIT_M>1.103451526</PROFIT_M>
<INCOME_M>0.19358799</INCOME_M>
<PHARMA_REV_M>1.50068208</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.103451526</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19358799</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3152760.98</REVENUE>
<PREV_YEAR_REV>2754850.39</PREV_YEAR_REV>
<BUDGET>2753552.81</BUDGET>
<GROSS_PROFIT>2786252.519</GROSS_PROFIT>
<EXPENSES>2588416.76</EXPENSES>
<NET_INCOME>564344.22</NET_INCOME>
<REVENUE_M>3.15276098</REVENUE_M>
<PROFIT_M>2.786252519</PROFIT_M>
<INCOME_M>0.56434422</INCOME_M>
<PHARMA_REV_M>3.15276098</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.786252519</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56434422</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>8669510.61</REVENUE>
<PREV_YEAR_REV>7570208.62</PREV_YEAR_REV>
<BUDGET>7998751.69</BUDGET>
<GROSS_PROFIT>7045899.326</GROSS_PROFIT>
<EXPENSES>7827583.54</EXPENSES>
<NET_INCOME>841927.08</NET_INCOME>
<REVENUE_M>8.66951061</REVENUE_M>
<PROFIT_M>7.045899326</PROFIT_M>
<INCOME_M>0.84192708</INCOME_M>
<PHARMA_REV_M>8.66951061</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.045899326</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.84192708</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2841734.77</REVENUE>
<PREV_YEAR_REV>2515366.02</PREV_YEAR_REV>
<BUDGET>2674478.17</BUDGET>
<GROSS_PROFIT>2350367.568</GROSS_PROFIT>
<EXPENSES>2551877.82</EXPENSES>
<NET_INCOME>289856.95</NET_INCOME>
<REVENUE_M>2.84173477</REVENUE_M>
<PROFIT_M>2.350367568</PROFIT_M>
<INCOME_M>0.28985695</INCOME_M>
<PHARMA_REV_M>2.84173477</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.350367568</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28985695</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4176475.95</REVENUE>
<PREV_YEAR_REV>3623938.72</PREV_YEAR_REV>
<BUDGET>4694753.44</BUDGET>
<GROSS_PROFIT>3255259.227</GROSS_PROFIT>
<EXPENSES>3714642.06</EXPENSES>
<NET_INCOME>461833.9</NET_INCOME>
<REVENUE_M>4.17647595</REVENUE_M>
<PROFIT_M>3.255259227</PROFIT_M>
<INCOME_M>0.4618339</INCOME_M>
<PHARMA_REV_M>4.17647595</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.255259227</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4618339</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1995706.92</REVENUE>
<PREV_YEAR_REV>1712920.82</PREV_YEAR_REV>
<BUDGET>2340745.31</BUDGET>
<GROSS_PROFIT>1662723.222</GROSS_PROFIT>
<EXPENSES>1732273.61</EXPENSES>
<NET_INCOME>263433.31</NET_INCOME>
<REVENUE_M>1.99570692</REVENUE_M>
<PROFIT_M>1.662723222</PROFIT_M>
<INCOME_M>0.26343331</INCOME_M>
<PHARMA_REV_M>1.99570692</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.662723222</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26343331</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2064727.71</REVENUE>
<PREV_YEAR_REV>1853369.46</PREV_YEAR_REV>
<BUDGET>2318734.69</BUDGET>
<GROSS_PROFIT>1408743.067</GROSS_PROFIT>
<EXPENSES>1798377.84</EXPENSES>
<NET_INCOME>266349.87</NET_INCOME>
<REVENUE_M>2.06472771</REVENUE_M>
<PROFIT_M>1.408743067</PROFIT_M>
<INCOME_M>0.26634987</INCOME_M>
<PHARMA_REV_M>2.06472771</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.408743067</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26634987</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4244962.3</REVENUE>
<PREV_YEAR_REV>3690717.65</PREV_YEAR_REV>
<BUDGET>4780529.97</BUDGET>
<GROSS_PROFIT>3113771.02</GROSS_PROFIT>
<EXPENSES>3732625.96</EXPENSES>
<NET_INCOME>512336.33</NET_INCOME>
<REVENUE_M>4.2449623</REVENUE_M>
<PROFIT_M>3.11377102</PROFIT_M>
<INCOME_M>0.51233633</INCOME_M>
<PHARMA_REV_M>4.2449623</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.11377102</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51233633</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4062033.06</REVENUE>
<PREV_YEAR_REV>3547559.28</PREV_YEAR_REV>
<BUDGET>4724233.57</BUDGET>
<GROSS_PROFIT>3063712.58</GROSS_PROFIT>
<EXPENSES>3458062.72</EXPENSES>
<NET_INCOME>603970.35</NET_INCOME>
<REVENUE_M>4.06203306</REVENUE_M>
<PROFIT_M>3.06371258</PROFIT_M>
<INCOME_M>0.60397035</INCOME_M>
<PHARMA_REV_M>4.06203306</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.06371258</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60397035</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>6068979.92</REVENUE>
<PREV_YEAR_REV>5305976.8</PREV_YEAR_REV>
<BUDGET>7125491.17</BUDGET>
<GROSS_PROFIT>4868838.107</GROSS_PROFIT>
<EXPENSES>5480472.38</EXPENSES>
<NET_INCOME>588507.55</NET_INCOME>
<REVENUE_M>6.06897992</REVENUE_M>
<PROFIT_M>4.868838107</PROFIT_M>
<INCOME_M>0.58850755</INCOME_M>
<PHARMA_REV_M>6.06897992</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.868838107</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58850755</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2154423.65</REVENUE>
<PREV_YEAR_REV>1860373.08</PREV_YEAR_REV>
<BUDGET>2369519.97</BUDGET>
<GROSS_PROFIT>1893738.39</GROSS_PROFIT>
<EXPENSES>1997150.73</EXPENSES>
<NET_INCOME>157272.93</NET_INCOME>
<REVENUE_M>2.15442365</REVENUE_M>
<PROFIT_M>1.89373839</PROFIT_M>
<INCOME_M>0.15727293</INCOME_M>
<PHARMA_REV_M>2.15442365</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.89373839</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15727293</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2160518.73</REVENUE>
<PREV_YEAR_REV>1936070.12</PREV_YEAR_REV>
<BUDGET>2391115.78</BUDGET>
<GROSS_PROFIT>1751014.01</GROSS_PROFIT>
<EXPENSES>1925022.19</EXPENSES>
<NET_INCOME>235496.54</NET_INCOME>
<REVENUE_M>2.16051873</REVENUE_M>
<PROFIT_M>1.75101401</PROFIT_M>
<INCOME_M>0.23549654</INCOME_M>
<PHARMA_REV_M>2.16051873</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.75101401</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23549654</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2073200.32</REVENUE>
<PREV_YEAR_REV>1778258.39</PREV_YEAR_REV>
<BUDGET>2371390.88</BUDGET>
<GROSS_PROFIT>1563607.683</GROSS_PROFIT>
<EXPENSES>1793318.28</EXPENSES>
<NET_INCOME>279882.04</NET_INCOME>
<REVENUE_M>2.07320032</REVENUE_M>
<PROFIT_M>1.563607683</PROFIT_M>
<INCOME_M>0.27988204</INCOME_M>
<PHARMA_REV_M>2.07320032</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.563607683</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27988204</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2059513.03</REVENUE>
<PREV_YEAR_REV>1757098.76</PREV_YEAR_REV>
<BUDGET>2346247.97</BUDGET>
<GROSS_PROFIT>1549577.604</GROSS_PROFIT>
<EXPENSES>1705276.79</EXPENSES>
<NET_INCOME>354236.24</NET_INCOME>
<REVENUE_M>2.05951303</REVENUE_M>
<PROFIT_M>1.549577604</PROFIT_M>
<INCOME_M>0.35423624</INCOME_M>
<PHARMA_REV_M>2.05951303</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.549577604</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35423624</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1601097.37</REVENUE>
<PREV_YEAR_REV>1418997.43</PREV_YEAR_REV>
<BUDGET>1566180</BUDGET>
<GROSS_PROFIT>1324828.02</GROSS_PROFIT>
<EXPENSES>1344921.79</EXPENSES>
<NET_INCOME>256175.58</NET_INCOME>
<REVENUE_M>1.60109737</REVENUE_M>
<PROFIT_M>1.32482802</PROFIT_M>
<INCOME_M>0.25617558</INCOME_M>
<PHARMA_REV_M>1.60109737</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.32482802</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25617558</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1227824.02</REVENUE>
<PREV_YEAR_REV>1070428.25</PREV_YEAR_REV>
<BUDGET>1224291.6</BUDGET>
<GROSS_PROFIT>969121.503</GROSS_PROFIT>
<EXPENSES>1069434.72</EXPENSES>
<NET_INCOME>158389.3</NET_INCOME>
<REVENUE_M>1.22782402</REVENUE_M>
<PROFIT_M>0.969121503</PROFIT_M>
<INCOME_M>0.1583893</INCOME_M>
<PHARMA_REV_M>1.22782402</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.969121503</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1583893</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3336465.29</REVENUE>
<PREV_YEAR_REV>2981468.16</PREV_YEAR_REV>
<BUDGET>3325234.5</BUDGET>
<GROSS_PROFIT>2415051.558</GROSS_PROFIT>
<EXPENSES>2930746.22</EXPENSES>
<NET_INCOME>405719.08</NET_INCOME>
<REVENUE_M>3.33646529</REVENUE_M>
<PROFIT_M>2.415051558</PROFIT_M>
<INCOME_M>0.40571908</INCOME_M>
<PHARMA_REV_M>3.33646529</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.415051558</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40571908</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2953622.71</REVENUE>
<PREV_YEAR_REV>2556865.42</PREV_YEAR_REV>
<BUDGET>3026816.1</BUDGET>
<GROSS_PROFIT>2209840.263</GROSS_PROFIT>
<EXPENSES>2514832.48</EXPENSES>
<NET_INCOME>438790.23</NET_INCOME>
<REVENUE_M>2.95362271</REVENUE_M>
<PROFIT_M>2.209840263</PROFIT_M>
<INCOME_M>0.43879023</INCOME_M>
<PHARMA_REV_M>2.95362271</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.209840263</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43879023</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3260865.65</REVENUE>
<PREV_YEAR_REV>2790665.51</PREV_YEAR_REV>
<BUDGET>3208306.56</BUDGET>
<GROSS_PROFIT>2592090.343</GROSS_PROFIT>
<EXPENSES>2825000.01</EXPENSES>
<NET_INCOME>435865.64</NET_INCOME>
<REVENUE_M>3.26086565</REVENUE_M>
<PROFIT_M>2.592090343</PROFIT_M>
<INCOME_M>0.43586564</INCOME_M>
<PHARMA_REV_M>3.26086565</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.592090343</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43586564</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1636766.64</REVENUE>
<PREV_YEAR_REV>1484622.52</PREV_YEAR_REV>
<BUDGET>1680871.5</BUDGET>
<GROSS_PROFIT>1315469.351</GROSS_PROFIT>
<EXPENSES>1355242.78</EXPENSES>
<NET_INCOME>281523.86</NET_INCOME>
<REVENUE_M>1.63676664</REVENUE_M>
<PROFIT_M>1.315469351</PROFIT_M>
<INCOME_M>0.28152386</INCOME_M>
<PHARMA_REV_M>1.63676664</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.315469351</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28152386</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7349411.8</REVENUE>
<PREV_YEAR_REV>6499302.97</PREV_YEAR_REV>
<BUDGET>6761458.85</BUDGET>
<GROSS_PROFIT>6042245.412</GROSS_PROFIT>
<EXPENSES>6173505.91</EXPENSES>
<NET_INCOME>1175905.89</NET_INCOME>
<REVENUE_M>7.3494118</REVENUE_M>
<PROFIT_M>6.042245412</PROFIT_M>
<INCOME_M>1.17590589</INCOME_M>
<PHARMA_REV_M>7.3494118</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.042245412</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.17590589</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.487680338E7</REVENUE>
<PREV_YEAR_REV>1.31727461E7</PREV_YEAR_REV>
<BUDGET>1.368665911E7</BUDGET>
<GROSS_PROFIT>1.269602483E7</GROSS_PROFIT>
<EXPENSES>1.287563405E7</EXPENSES>
<NET_INCOME>2001169.32</NET_INCOME>
<REVENUE_M>14.87680338</REVENUE_M>
<PROFIT_M>12.69602483</PROFIT_M>
<INCOME_M>2.00116932</INCOME_M>
<PHARMA_REV_M>14.87680338</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.69602483</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.00116932</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.459947127E7</REVENUE>
<PREV_YEAR_REV>1.252101588E7</PREV_YEAR_REV>
<BUDGET>1.343151357E7</BUDGET>
<GROSS_PROFIT>1.079042706E7</GROSS_PROFIT>
<EXPENSES>1.243047912E7</EXPENSES>
<NET_INCOME>2168992.15</NET_INCOME>
<REVENUE_M>14.59947127</REVENUE_M>
<PROFIT_M>10.79042706</PROFIT_M>
<INCOME_M>2.16899215</INCOME_M>
<PHARMA_REV_M>14.59947127</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.79042706</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.16899215</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7846243.02</REVENUE>
<PREV_YEAR_REV>7038125.45</PREV_YEAR_REV>
<BUDGET>7218543.57</BUDGET>
<GROSS_PROFIT>5924906.023</GROSS_PROFIT>
<EXPENSES>6496689.22</EXPENSES>
<NET_INCOME>1349553.8</NET_INCOME>
<REVENUE_M>7.84624302</REVENUE_M>
<PROFIT_M>5.924906023</PROFIT_M>
<INCOME_M>1.3495538</INCOME_M>
<PHARMA_REV_M>7.84624302</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.924906023</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.3495538</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9448243.75</REVENUE>
<PREV_YEAR_REV>8492803.37</PREV_YEAR_REV>
<BUDGET>8692384.25</BUDGET>
<GROSS_PROFIT>7826925.123</GROSS_PROFIT>
<EXPENSES>8484522.89</EXPENSES>
<NET_INCOME>963720.86</NET_INCOME>
<REVENUE_M>9.44824375</REVENUE_M>
<PROFIT_M>7.826925123</PROFIT_M>
<INCOME_M>0.96372086</INCOME_M>
<PHARMA_REV_M>9.44824375</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.826925123</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.96372086</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5014718.11</REVENUE>
<PREV_YEAR_REV>4451448.47</PREV_YEAR_REV>
<BUDGET>4864276.56</BUDGET>
<GROSS_PROFIT>3729956.726</GROSS_PROFIT>
<EXPENSES>4461054.46</EXPENSES>
<NET_INCOME>553663.63</NET_INCOME>
<REVENUE_M>5.01471811</REVENUE_M>
<PROFIT_M>3.729956726</PROFIT_M>
<INCOME_M>0.55366363</INCOME_M>
<PHARMA_REV_M>5.01471811</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.729956726</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55366363</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5112257.27</REVENUE>
<PREV_YEAR_REV>4453275.92</PREV_YEAR_REV>
<BUDGET>4958889.55</BUDGET>
<GROSS_PROFIT>3653193.914</GROSS_PROFIT>
<EXPENSES>4494887.25</EXPENSES>
<NET_INCOME>617370.01</NET_INCOME>
<REVENUE_M>5.11225727</REVENUE_M>
<PROFIT_M>3.653193914</PROFIT_M>
<INCOME_M>0.61737001</INCOME_M>
<PHARMA_REV_M>5.11225727</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.653193914</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61737001</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2703782.03</REVENUE>
<PREV_YEAR_REV>2331791.35</PREV_YEAR_REV>
<BUDGET>2622668.56</BUDGET>
<GROSS_PROFIT>1805463.965</GROSS_PROFIT>
<EXPENSES>2338771.45</EXPENSES>
<NET_INCOME>365010.57</NET_INCOME>
<REVENUE_M>2.70378203</REVENUE_M>
<PROFIT_M>1.805463965</PROFIT_M>
<INCOME_M>0.36501057</INCOME_M>
<PHARMA_REV_M>2.70378203</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.805463965</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36501057</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5261222.34</REVENUE>
<PREV_YEAR_REV>4613134.63</PREV_YEAR_REV>
<BUDGET>5103385.68</BUDGET>
<GROSS_PROFIT>3976905.884</GROSS_PROFIT>
<EXPENSES>4566083.45</EXPENSES>
<NET_INCOME>695138.89</NET_INCOME>
<REVENUE_M>5.26122234</REVENUE_M>
<PROFIT_M>3.976905884</PROFIT_M>
<INCOME_M>0.69513889</INCOME_M>
<PHARMA_REV_M>5.26122234</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.976905884</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69513889</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3770128.08</REVENUE>
<PREV_YEAR_REV>3313453.35</PREV_YEAR_REV>
<BUDGET>3657024.24</BUDGET>
<GROSS_PROFIT>2776620.266</GROSS_PROFIT>
<EXPENSES>3312696.26</EXPENSES>
<NET_INCOME>457431.82</NET_INCOME>
<REVENUE_M>3.77012808</REVENUE_M>
<PROFIT_M>2.776620266</PROFIT_M>
<INCOME_M>0.45743182</INCOME_M>
<PHARMA_REV_M>3.77012808</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.776620266</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45743182</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3678310.23</REVENUE>
<PREV_YEAR_REV>3148074.24</PREV_YEAR_REV>
<BUDGET>3567960.92</BUDGET>
<GROSS_PROFIT>2721244.769</GROSS_PROFIT>
<EXPENSES>3131871.11</EXPENSES>
<NET_INCOME>546439.11</NET_INCOME>
<REVENUE_M>3.67831023</REVENUE_M>
<PROFIT_M>2.721244769</PROFIT_M>
<INCOME_M>0.54643911</INCOME_M>
<PHARMA_REV_M>3.67831023</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.721244769</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54643911</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1605201.09</REVENUE>
<PREV_YEAR_REV>1363459.69</PREV_YEAR_REV>
<BUDGET>2059978.9</BUDGET>
<GROSS_PROFIT>1280950.47</GROSS_PROFIT>
<EXPENSES>1317870.09</EXPENSES>
<NET_INCOME>287330.99</NET_INCOME>
<REVENUE_M>1.60520109</REVENUE_M>
<PROFIT_M>1.28095047</PROFIT_M>
<INCOME_M>0.28733099</INCOME_M>
<PHARMA_REV_M>1.60520109</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.28095047</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28733099</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4869852.02</REVENUE>
<PREV_YEAR_REV>4206386.38</PREV_YEAR_REV>
<BUDGET>6260195.25</BUDGET>
<GROSS_PROFIT>4065531.43</GROSS_PROFIT>
<EXPENSES>4397313.89</EXPENSES>
<NET_INCOME>472538.13</NET_INCOME>
<REVENUE_M>4.86985202</REVENUE_M>
<PROFIT_M>4.06553143</PROFIT_M>
<INCOME_M>0.47253813</INCOME_M>
<PHARMA_REV_M>4.86985202</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.06553143</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47253813</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3289041.4</REVENUE>
<PREV_YEAR_REV>2846817.64</PREV_YEAR_REV>
<BUDGET>4179783.79</BUDGET>
<GROSS_PROFIT>2763362.52</GROSS_PROFIT>
<EXPENSES>2851464.93</EXPENSES>
<NET_INCOME>437576.47</NET_INCOME>
<REVENUE_M>3.2890414</REVENUE_M>
<PROFIT_M>2.76336252</PROFIT_M>
<INCOME_M>0.43757647</INCOME_M>
<PHARMA_REV_M>3.2890414</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.76336252</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43757647</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1444663.54</REVENUE>
<PREV_YEAR_REV>1234080.11</PREV_YEAR_REV>
<BUDGET>1887168.12</BUDGET>
<GROSS_PROFIT>1212072.71</GROSS_PROFIT>
<EXPENSES>1287195.22</EXPENSES>
<NET_INCOME>157468.33</NET_INCOME>
<REVENUE_M>1.44466354</REVENUE_M>
<PROFIT_M>1.21207271</PROFIT_M>
<INCOME_M>0.15746833</INCOME_M>
<PHARMA_REV_M>1.44466354</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.21207271</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15746833</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1328172.52</REVENUE>
<PREV_YEAR_REV>1139807.87</PREV_YEAR_REV>
<BUDGET>1475785.97</BUDGET>
<GROSS_PROFIT>984554.3709</GROSS_PROFIT>
<EXPENSES>1156838.27</EXPENSES>
<NET_INCOME>171334.26</NET_INCOME>
<REVENUE_M>1.32817252</REVENUE_M>
<PROFIT_M>0.984554371</PROFIT_M>
<INCOME_M>0.17133426</INCOME_M>
<PHARMA_REV_M>1.32817252</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.984554371</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17133426</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1105703.81</REVENUE>
<PREV_YEAR_REV>961565.19</PREV_YEAR_REV>
<BUDGET>1198699.62</BUDGET>
<GROSS_PROFIT>894514.38</GROSS_PROFIT>
<EXPENSES>1024987.43</EXPENSES>
<NET_INCOME>80716.38</NET_INCOME>
<REVENUE_M>1.10570381</REVENUE_M>
<PROFIT_M>0.89451438</PROFIT_M>
<INCOME_M>0.08071638</INCOME_M>
<PHARMA_REV_M>1.10570381</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.89451438</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.08071638</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7329061.69</REVENUE>
<PREV_YEAR_REV>6293254.87</PREV_YEAR_REV>
<BUDGET>7109189.84</BUDGET>
<GROSS_PROFIT>6262390.052</GROSS_PROFIT>
<EXPENSES>6361625.55</EXPENSES>
<NET_INCOME>967436.14</NET_INCOME>
<REVENUE_M>7.32906169</REVENUE_M>
<PROFIT_M>6.262390052</PROFIT_M>
<INCOME_M>0.96743614</INCOME_M>
<PHARMA_REV_M>7.32906169</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.262390052</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.96743614</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6197673.62</REVENUE>
<PREV_YEAR_REV>5546066.29</PREV_YEAR_REV>
<BUDGET>6011743.41</BUDGET>
<GROSS_PROFIT>5370780</GROSS_PROFIT>
<EXPENSES>5745243.44</EXPENSES>
<NET_INCOME>452430.17</NET_INCOME>
<REVENUE_M>6.19767362</REVENUE_M>
<PROFIT_M>5.37078</PROFIT_M>
<INCOME_M>0.45243017</INCOME_M>
<PHARMA_REV_M>6.19767362</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.37078</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45243017</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7562200.21</REVENUE>
<PREV_YEAR_REV>6866924.14</PREV_YEAR_REV>
<BUDGET>7335334.21</BUDGET>
<GROSS_PROFIT>6063372.131</GROSS_PROFIT>
<EXPENSES>6261501.78</EXPENSES>
<NET_INCOME>1300698.44</NET_INCOME>
<REVENUE_M>7.56220021</REVENUE_M>
<PROFIT_M>6.063372131</PROFIT_M>
<INCOME_M>1.30069844</INCOME_M>
<PHARMA_REV_M>7.56220021</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.063372131</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.30069844</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6132534.25</REVENUE>
<PREV_YEAR_REV>5392661.14</PREV_YEAR_REV>
<BUDGET>5948558.22</BUDGET>
<GROSS_PROFIT>4602466.957</GROSS_PROFIT>
<EXPENSES>5077738.36</EXPENSES>
<NET_INCOME>1054795.89</NET_INCOME>
<REVENUE_M>6.13253425</REVENUE_M>
<PROFIT_M>4.602466957</PROFIT_M>
<INCOME_M>1.05479589</INCOME_M>
<PHARMA_REV_M>6.13253425</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.602466957</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.05479589</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5997594.39</REVENUE>
<PREV_YEAR_REV>5311977.46</PREV_YEAR_REV>
<BUDGET>5817666.56</BUDGET>
<GROSS_PROFIT>5145935.99</GROSS_PROFIT>
<EXPENSES>5343856.61</EXPENSES>
<NET_INCOME>653737.79</NET_INCOME>
<REVENUE_M>5.99759439</REVENUE_M>
<PROFIT_M>5.14593599</PROFIT_M>
<INCOME_M>0.65373779</INCOME_M>
<PHARMA_REV_M>5.99759439</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.14593599</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65373779</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2923683.24</REVENUE>
<PREV_YEAR_REV>2644383.46</PREV_YEAR_REV>
<BUDGET>2322676.62</BUDGET>
<GROSS_PROFIT>2271994.246</GROSS_PROFIT>
<EXPENSES>2455893.92</EXPENSES>
<NET_INCOME>467789.32</NET_INCOME>
<REVENUE_M>2.92368324</REVENUE_M>
<PROFIT_M>2.271994246</PROFIT_M>
<INCOME_M>0.46778932</INCOME_M>
<PHARMA_REV_M>2.92368324</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.271994246</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46778932</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5246279.04</REVENUE>
<PREV_YEAR_REV>4526049.99</PREV_YEAR_REV>
<BUDGET>4142537</BUDGET>
<GROSS_PROFIT>4070244.18</GROSS_PROFIT>
<EXPENSES>4473455.53</EXPENSES>
<NET_INCOME>772823.52</NET_INCOME>
<REVENUE_M>5.24627904</REVENUE_M>
<PROFIT_M>4.07024418</PROFIT_M>
<INCOME_M>0.77282352</INCOME_M>
<PHARMA_REV_M>5.24627904</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.07024418</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.77282352</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>6178294.99</REVENUE>
<PREV_YEAR_REV>5276788.84</PREV_YEAR_REV>
<BUDGET>4840856.46</BUDGET>
<GROSS_PROFIT>4400878.788</GROSS_PROFIT>
<EXPENSES>5259759.1</EXPENSES>
<NET_INCOME>918535.89</NET_INCOME>
<REVENUE_M>6.17829499</REVENUE_M>
<PROFIT_M>4.400878788</PROFIT_M>
<INCOME_M>0.91853589</INCOME_M>
<PHARMA_REV_M>6.17829499</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.400878788</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.91853589</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1627257.33</REVENUE>
<PREV_YEAR_REV>1494061.73</PREV_YEAR_REV>
<BUDGET>1936463.79</BUDGET>
<GROSS_PROFIT>1381541.47</GROSS_PROFIT>
<EXPENSES>1508467.55</EXPENSES>
<NET_INCOME>118789.79</NET_INCOME>
<REVENUE_M>1.62725733</REVENUE_M>
<PROFIT_M>1.38154147</PROFIT_M>
<INCOME_M>0.11878979</INCOME_M>
<PHARMA_REV_M>1.62725733</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.38154147</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11878979</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3251676.08</REVENUE>
<PREV_YEAR_REV>2935888.03</PREV_YEAR_REV>
<BUDGET>3860827.24</BUDGET>
<GROSS_PROFIT>2350879.99</GROSS_PROFIT>
<EXPENSES>2768032.74</EXPENSES>
<NET_INCOME>483643.33</NET_INCOME>
<REVENUE_M>3.25167608</REVENUE_M>
<PROFIT_M>2.35087999</PROFIT_M>
<INCOME_M>0.48364333</INCOME_M>
<PHARMA_REV_M>3.25167608</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.35087999</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48364333</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4927682.58</REVENUE>
<PREV_YEAR_REV>4471634.12</PREV_YEAR_REV>
<BUDGET>5833958.75</BUDGET>
<GROSS_PROFIT>3985330.541</GROSS_PROFIT>
<EXPENSES>4450678.05</EXPENSES>
<NET_INCOME>477004.53</NET_INCOME>
<REVENUE_M>4.92768258</REVENUE_M>
<PROFIT_M>3.985330541</PROFIT_M>
<INCOME_M>0.47700453</INCOME_M>
<PHARMA_REV_M>4.92768258</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.985330541</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47700453</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1588184.77</REVENUE>
<PREV_YEAR_REV>1455194.54</PREV_YEAR_REV>
<BUDGET>1937992.77</BUDGET>
<GROSS_PROFIT>1239260.571</GROSS_PROFIT>
<EXPENSES>1373779.82</EXPENSES>
<NET_INCOME>214404.94</NET_INCOME>
<REVENUE_M>1.58818477</REVENUE_M>
<PROFIT_M>1.239260571</PROFIT_M>
<INCOME_M>0.21440494</INCOME_M>
<PHARMA_REV_M>1.58818477</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.239260571</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21440494</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3222390.9</REVENUE>
<PREV_YEAR_REV>2907529.24</PREV_YEAR_REV>
<BUDGET>3890576.52</BUDGET>
<GROSS_PROFIT>2688417.2</GROSS_PROFIT>
<EXPENSES>2794215.65</EXPENSES>
<NET_INCOME>428175.25</NET_INCOME>
<REVENUE_M>3.2223909</REVENUE_M>
<PROFIT_M>2.6884172</PROFIT_M>
<INCOME_M>0.42817525</INCOME_M>
<PHARMA_REV_M>3.2223909</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.6884172</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42817525</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3194531.13</REVENUE>
<PREV_YEAR_REV>2914583.29</PREV_YEAR_REV>
<BUDGET>3830393.03</BUDGET>
<GROSS_PROFIT>2435640.429</GROSS_PROFIT>
<EXPENSES>2771591.04</EXPENSES>
<NET_INCOME>422940.09</NET_INCOME>
<REVENUE_M>3.19453113</REVENUE_M>
<PROFIT_M>2.435640429</PROFIT_M>
<INCOME_M>0.42294009</INCOME_M>
<PHARMA_REV_M>3.19453113</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.435640429</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42294009</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>932355.99</REVENUE>
<PREV_YEAR_REV>847889.26</PREV_YEAR_REV>
<BUDGET>1000538.67</BUDGET>
<GROSS_PROFIT>710734.968</GROSS_PROFIT>
<EXPENSES>812082.06</EXPENSES>
<NET_INCOME>120273.92</NET_INCOME>
<REVENUE_M>0.93235599</REVENUE_M>
<PROFIT_M>0.710734968</PROFIT_M>
<INCOME_M>0.12027392</INCOME_M>
<PHARMA_REV_M>0.93235599</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.710734968</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12027392</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2614331.45</REVENUE>
<PREV_YEAR_REV>2372084.99</PREV_YEAR_REV>
<BUDGET>2717510.85</BUDGET>
<GROSS_PROFIT>1892908.593</GROSS_PROFIT>
<EXPENSES>2297994.85</EXPENSES>
<NET_INCOME>316336.61</NET_INCOME>
<REVENUE_M>2.61433145</REVENUE_M>
<PROFIT_M>1.892908593</PROFIT_M>
<INCOME_M>0.31633661</INCOME_M>
<PHARMA_REV_M>2.61433145</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.892908593</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31633661</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1288088.79</REVENUE>
<PREV_YEAR_REV>1154015.3</PREV_YEAR_REV>
<BUDGET>1381319.18</BUDGET>
<GROSS_PROFIT>919537.6116</GROSS_PROFIT>
<EXPENSES>1066537.52</EXPENSES>
<NET_INCOME>221551.27</NET_INCOME>
<REVENUE_M>1.28808879</REVENUE_M>
<PROFIT_M>0.919537612</PROFIT_M>
<INCOME_M>0.22155127</INCOME_M>
<PHARMA_REV_M>1.28808879</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.919537612</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22155127</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.34651189E7</REVENUE>
<PREV_YEAR_REV>1.171088231E7</PREV_YEAR_REV>
<BUDGET>1.373442128E7</BUDGET>
<GROSS_PROFIT>1.020189545E7</GROSS_PROFIT>
<EXPENSES>1.183585654E7</EXPENSES>
<NET_INCOME>1629262.37</NET_INCOME>
<REVENUE_M>13.4651189</REVENUE_M>
<PROFIT_M>10.20189545</PROFIT_M>
<INCOME_M>1.62926237</INCOME_M>
<PHARMA_REV_M>13.4651189</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.20189545</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.62926237</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6128438.23</REVENUE>
<PREV_YEAR_REV>5492071.86</PREV_YEAR_REV>
<BUDGET>6251007</BUDGET>
<GROSS_PROFIT>5368511.89</GROSS_PROFIT>
<EXPENSES>5681062.24</EXPENSES>
<NET_INCOME>447375.99</NET_INCOME>
<REVENUE_M>6.12843823</REVENUE_M>
<PROFIT_M>5.36851189</PROFIT_M>
<INCOME_M>0.44737599</INCOME_M>
<PHARMA_REV_M>6.12843823</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.36851189</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44737599</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.271461494E7</REVENUE>
<PREV_YEAR_REV>1.126958173E7</PREV_YEAR_REV>
<BUDGET>1.296890725E7</BUDGET>
<GROSS_PROFIT>1.085337278E7</GROSS_PROFIT>
<EXPENSES>1.09981987E7</EXPENSES>
<NET_INCOME>1716416.24</NET_INCOME>
<REVENUE_M>12.71461494</REVENUE_M>
<PROFIT_M>10.85337278</PROFIT_M>
<INCOME_M>1.71641624</INCOME_M>
<PHARMA_REV_M>12.71461494</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.85337278</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.71641624</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.162876752E7</REVENUE>
<PREV_YEAR_REV>1.014060944E7</PREV_YEAR_REV>
<BUDGET>1.186134288E7</BUDGET>
<GROSS_PROFIT>8906431.559</GROSS_PROFIT>
<EXPENSES>9901233.44</EXPENSES>
<NET_INCOME>1727534.07</NET_INCOME>
<REVENUE_M>11.62876752</REVENUE_M>
<PROFIT_M>8.906431559</PROFIT_M>
<INCOME_M>1.72753407</INCOME_M>
<PHARMA_REV_M>11.62876752</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.906431559</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.72753407</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6845497.19</REVENUE>
<PREV_YEAR_REV>6104747.16</PREV_YEAR_REV>
<BUDGET>6982407.13</BUDGET>
<GROSS_PROFIT>5748848.535</GROSS_PROFIT>
<EXPENSES>6147256.47</EXPENSES>
<NET_INCOME>698240.71</NET_INCOME>
<REVENUE_M>6.84549719</REVENUE_M>
<PROFIT_M>5.748848535</PROFIT_M>
<INCOME_M>0.69824071</INCOME_M>
<PHARMA_REV_M>6.84549719</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.748848535</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69824071</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.445981252E7</REVENUE>
<PREV_YEAR_REV>1.242452835E7</PREV_YEAR_REV>
<BUDGET>1.474900877E7</BUDGET>
<GROSS_PROFIT>1.160505432E7</GROSS_PROFIT>
<EXPENSES>1.254134351E7</EXPENSES>
<NET_INCOME>1918469.02</NET_INCOME>
<REVENUE_M>14.45981252</REVENUE_M>
<PROFIT_M>11.60505432</PROFIT_M>
<INCOME_M>1.91846902</INCOME_M>
<PHARMA_REV_M>14.45981252</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.60505432</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.91846902</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4329072.95</REVENUE>
<PREV_YEAR_REV>3765566.26</PREV_YEAR_REV>
<BUDGET>4537002.65</BUDGET>
<GROSS_PROFIT>3346884.076</GROSS_PROFIT>
<EXPENSES>3852211.51</EXPENSES>
<NET_INCOME>476861.45</NET_INCOME>
<REVENUE_M>4.32907295</REVENUE_M>
<PROFIT_M>3.346884076</PROFIT_M>
<INCOME_M>0.47686145</INCOME_M>
<PHARMA_REV_M>4.32907295</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.346884076</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47686145</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1857825.05</REVENUE>
<PREV_YEAR_REV>1597895.41</PREV_YEAR_REV>
<BUDGET>1991653.52</BUDGET>
<GROSS_PROFIT>1615583.244</GROSS_PROFIT>
<EXPENSES>1612592.15</EXPENSES>
<NET_INCOME>245232.91</NET_INCOME>
<REVENUE_M>1.85782505</REVENUE_M>
<PROFIT_M>1.615583244</PROFIT_M>
<INCOME_M>0.24523291</INCOME_M>
<PHARMA_REV_M>1.85782505</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.615583244</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24523291</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4604251.33</REVENUE>
<PREV_YEAR_REV>4027709.17</PREV_YEAR_REV>
<BUDGET>4692040.76</BUDGET>
<GROSS_PROFIT>3525844.393</GROSS_PROFIT>
<EXPENSES>3985061.73</EXPENSES>
<NET_INCOME>619189.6</NET_INCOME>
<REVENUE_M>4.60425133</REVENUE_M>
<PROFIT_M>3.525844393</PROFIT_M>
<INCOME_M>0.6191896</INCOME_M>
<PHARMA_REV_M>4.60425133</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.525844393</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6191896</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4664936.35</REVENUE>
<PREV_YEAR_REV>4032926.35</PREV_YEAR_REV>
<BUDGET>4678933.07</BUDGET>
<GROSS_PROFIT>3310424.508</GROSS_PROFIT>
<EXPENSES>3971720.31</EXPENSES>
<NET_INCOME>693216.04</NET_INCOME>
<REVENUE_M>4.66493635</REVENUE_M>
<PROFIT_M>3.310424508</PROFIT_M>
<INCOME_M>0.69321604</INCOME_M>
<PHARMA_REV_M>4.66493635</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.310424508</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69321604</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2350693.95</REVENUE>
<PREV_YEAR_REV>2009449.27</PREV_YEAR_REV>
<BUDGET>2354971.54</BUDGET>
<GROSS_PROFIT>1833423.744</GROSS_PROFIT>
<EXPENSES>1929919.73</EXPENSES>
<NET_INCOME>420774.22</NET_INCOME>
<REVENUE_M>2.35069395</REVENUE_M>
<PROFIT_M>1.833423744</PROFIT_M>
<INCOME_M>0.42077422</INCOME_M>
<PHARMA_REV_M>2.35069395</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.833423744</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42077422</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3847788.15</REVENUE>
<PREV_YEAR_REV>3433358.27</PREV_YEAR_REV>
<BUDGET>4018260.88</BUDGET>
<GROSS_PROFIT>2970955.757</GROSS_PROFIT>
<EXPENSES>3282601.05</EXPENSES>
<NET_INCOME>565187.1</NET_INCOME>
<REVENUE_M>3.84778815</REVENUE_M>
<PROFIT_M>2.970955757</PROFIT_M>
<INCOME_M>0.5651871</INCOME_M>
<PHARMA_REV_M>3.84778815</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.970955757</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5651871</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2696308.18</REVENUE>
<PREV_YEAR_REV>2467316.53</PREV_YEAR_REV>
<BUDGET>2010436.35</BUDGET>
<GROSS_PROFIT>2039204.391</GROSS_PROFIT>
<EXPENSES>2232543.17</EXPENSES>
<NET_INCOME>463765.01</NET_INCOME>
<REVENUE_M>2.69630818</REVENUE_M>
<PROFIT_M>2.039204391</PROFIT_M>
<INCOME_M>0.46376501</INCOME_M>
<PHARMA_REV_M>2.69630818</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.039204391</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46376501</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2576325.73</REVENUE>
<PREV_YEAR_REV>2341348.04</PREV_YEAR_REV>
<BUDGET>1966653.74</BUDGET>
<GROSS_PROFIT>2091543.673</GROSS_PROFIT>
<EXPENSES>2313540.51</EXPENSES>
<NET_INCOME>262785.22</NET_INCOME>
<REVENUE_M>2.57632573</REVENUE_M>
<PROFIT_M>2.091543673</PROFIT_M>
<INCOME_M>0.26278522</INCOME_M>
<PHARMA_REV_M>2.57632573</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.091543673</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26278522</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4103917.14</REVENUE>
<PREV_YEAR_REV>3749275.01</PREV_YEAR_REV>
<BUDGET>3523548.29</BUDGET>
<GROSS_PROFIT>3309306.746</GROSS_PROFIT>
<EXPENSES>3650825.79</EXPENSES>
<NET_INCOME>453091.35</NET_INCOME>
<REVENUE_M>4.10391714</REVENUE_M>
<PROFIT_M>3.309306746</PROFIT_M>
<INCOME_M>0.45309135</INCOME_M>
<PHARMA_REV_M>4.10391714</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.309306746</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45309135</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4132210.2</REVENUE>
<PREV_YEAR_REV>3778871.91</PREV_YEAR_REV>
<BUDGET>3534646.23</BUDGET>
<GROSS_PROFIT>3225373.129</GROSS_PROFIT>
<EXPENSES>3576666.29</EXPENSES>
<NET_INCOME>555543.91</NET_INCOME>
<REVENUE_M>4.1322102</REVENUE_M>
<PROFIT_M>3.225373129</PROFIT_M>
<INCOME_M>0.55554391</INCOME_M>
<PHARMA_REV_M>4.1322102</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.225373129</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55554391</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4131531.36</REVENUE>
<PREV_YEAR_REV>3837047.16</PREV_YEAR_REV>
<BUDGET>3559837.09</BUDGET>
<GROSS_PROFIT>3353514.88</GROSS_PROFIT>
<EXPENSES>3576627.87</EXPENSES>
<NET_INCOME>554903.49</NET_INCOME>
<REVENUE_M>4.13153136</REVENUE_M>
<PROFIT_M>3.35351488</PROFIT_M>
<INCOME_M>0.55490349</INCOME_M>
<PHARMA_REV_M>4.13153136</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.35351488</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55490349</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2116330.84</REVENUE>
<PREV_YEAR_REV>1891523.3</PREV_YEAR_REV>
<BUDGET>1776044.74</BUDGET>
<GROSS_PROFIT>1743719.047</GROSS_PROFIT>
<EXPENSES>1752321.94</EXPENSES>
<NET_INCOME>364008.9</NET_INCOME>
<REVENUE_M>2.11633084</REVENUE_M>
<PROFIT_M>1.743719047</PROFIT_M>
<INCOME_M>0.3640089</INCOME_M>
<PHARMA_REV_M>2.11633084</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.743719047</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3640089</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1966597.15</REVENUE>
<PREV_YEAR_REV>1803754.22</PREV_YEAR_REV>
<BUDGET>1611073.13</BUDGET>
<GROSS_PROFIT>1398250.575</GROSS_PROFIT>
<EXPENSES>1701106.53</EXPENSES>
<NET_INCOME>265490.62</NET_INCOME>
<REVENUE_M>1.96659715</REVENUE_M>
<PROFIT_M>1.398250575</PROFIT_M>
<INCOME_M>0.26549062</INCOME_M>
<PHARMA_REV_M>1.96659715</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.398250575</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26549062</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1714875.56</REVENUE>
<PREV_YEAR_REV>1586305.5</PREV_YEAR_REV>
<BUDGET>1259876.69</BUDGET>
<GROSS_PROFIT>1212562.787</GROSS_PROFIT>
<EXPENSES>1493656.61</EXPENSES>
<NET_INCOME>221218.95</NET_INCOME>
<REVENUE_M>1.71487556</REVENUE_M>
<PROFIT_M>1.212562787</PROFIT_M>
<INCOME_M>0.22121895</INCOME_M>
<PHARMA_REV_M>1.71487556</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.212562787</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22121895</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1501707.55</REVENUE>
<PREV_YEAR_REV>1390972.24</PREV_YEAR_REV>
<BUDGET>1023328.41</BUDGET>
<GROSS_PROFIT>1198362.62</GROSS_PROFIT>
<EXPENSES>1261434.34</EXPENSES>
<NET_INCOME>240273.21</NET_INCOME>
<REVENUE_M>1.50170755</REVENUE_M>
<PROFIT_M>1.19836262</PROFIT_M>
<INCOME_M>0.24027321</INCOME_M>
<PHARMA_REV_M>1.50170755</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.19836262</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24027321</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1571832.03</REVENUE>
<PREV_YEAR_REV>1440699.56</PREV_YEAR_REV>
<BUDGET>1107887.41</BUDGET>
<GROSS_PROFIT>1381640.35</GROSS_PROFIT>
<EXPENSES>1364350.2</EXPENSES>
<NET_INCOME>207481.83</NET_INCOME>
<REVENUE_M>1.57183203</REVENUE_M>
<PROFIT_M>1.38164035</PROFIT_M>
<INCOME_M>0.20748183</INCOME_M>
<PHARMA_REV_M>1.57183203</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.38164035</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20748183</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2964724.79</REVENUE>
<PREV_YEAR_REV>2677138.53</PREV_YEAR_REV>
<BUDGET>1928680.18</BUDGET>
<GROSS_PROFIT>2442542.996</GROSS_PROFIT>
<EXPENSES>2567004.2</EXPENSES>
<NET_INCOME>397720.6</NET_INCOME>
<REVENUE_M>2.96472479</REVENUE_M>
<PROFIT_M>2.442542996</PROFIT_M>
<INCOME_M>0.3977206</INCOME_M>
<PHARMA_REV_M>2.96472479</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.442542996</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3977206</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3190927.68</REVENUE>
<PREV_YEAR_REV>2912633.02</PREV_YEAR_REV>
<BUDGET>2405780.12</BUDGET>
<GROSS_PROFIT>2669536.42</GROSS_PROFIT>
<EXPENSES>2761174.13</EXPENSES>
<NET_INCOME>429753.54</NET_INCOME>
<REVENUE_M>3.19092768</REVENUE_M>
<PROFIT_M>2.66953642</PROFIT_M>
<INCOME_M>0.42975354</INCOME_M>
<PHARMA_REV_M>3.19092768</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.66953642</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42975354</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3675227.62</REVENUE>
<PREV_YEAR_REV>3316398.25</PREV_YEAR_REV>
<BUDGET>2442384.18</BUDGET>
<GROSS_PROFIT>3038963.95</GROSS_PROFIT>
<EXPENSES>3186091.95</EXPENSES>
<NET_INCOME>489135.68</NET_INCOME>
<REVENUE_M>3.67522762</REVENUE_M>
<PROFIT_M>3.03896395</PROFIT_M>
<INCOME_M>0.48913568</INCOME_M>
<PHARMA_REV_M>3.67522762</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.03896395</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48913568</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1781259.88</REVENUE>
<PREV_YEAR_REV>1598775.63</PREV_YEAR_REV>
<BUDGET>1201746.28</BUDGET>
<GROSS_PROFIT>1522977.2</GROSS_PROFIT>
<EXPENSES>1587102.56</EXPENSES>
<NET_INCOME>194157.33</NET_INCOME>
<REVENUE_M>1.78125988</REVENUE_M>
<PROFIT_M>1.5229772</PROFIT_M>
<INCOME_M>0.19415733</INCOME_M>
<PHARMA_REV_M>1.78125988</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.5229772</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19415733</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.119408417E7</REVENUE>
<PREV_YEAR_REV>9988115.83</PREV_YEAR_REV>
<BUDGET>1.007467575E7</BUDGET>
<GROSS_PROFIT>9226558.141</GROSS_PROFIT>
<EXPENSES>9995404.08</EXPENSES>
<NET_INCOME>1198680.09</NET_INCOME>
<REVENUE_M>11.19408417</REVENUE_M>
<PROFIT_M>9.226558141</PROFIT_M>
<INCOME_M>1.19868009</INCOME_M>
<PHARMA_REV_M>11.19408417</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.226558141</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.19868009</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8159238.54</REVENUE>
<PREV_YEAR_REV>7481284.54</PREV_YEAR_REV>
<BUDGET>7343314.69</BUDGET>
<GROSS_PROFIT>6951671.24</GROSS_PROFIT>
<EXPENSES>7082219.06</EXPENSES>
<NET_INCOME>1077019.49</NET_INCOME>
<REVENUE_M>8.15923854</REVENUE_M>
<PROFIT_M>6.95167124</PROFIT_M>
<INCOME_M>1.07701949</INCOME_M>
<PHARMA_REV_M>8.15923854</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.95167124</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.07701949</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.44096337E7</REVENUE>
<PREV_YEAR_REV>1.297758518E7</PREV_YEAR_REV>
<BUDGET>1.296867033E7</BUDGET>
<GROSS_PROFIT>1.125680585E7</GROSS_PROFIT>
<EXPENSES>1.227338339E7</EXPENSES>
<NET_INCOME>2136250.3</NET_INCOME>
<REVENUE_M>14.4096337</REVENUE_M>
<PROFIT_M>11.25680585</PROFIT_M>
<INCOME_M>2.1362503</INCOME_M>
<PHARMA_REV_M>14.4096337</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.25680585</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.1362503</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5644814.33</REVENUE>
<PREV_YEAR_REV>5037898.68</PREV_YEAR_REV>
<BUDGET>5080332.9</BUDGET>
<GROSS_PROFIT>4578113.769</GROSS_PROFIT>
<EXPENSES>4634392.57</EXPENSES>
<NET_INCOME>1010421.77</NET_INCOME>
<REVENUE_M>5.64481433</REVENUE_M>
<PROFIT_M>4.578113769</PROFIT_M>
<INCOME_M>1.01042177</INCOME_M>
<PHARMA_REV_M>5.64481433</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.578113769</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.01042177</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.189012424E7</REVENUE>
<PREV_YEAR_REV>1.075929299E7</PREV_YEAR_REV>
<BUDGET>1.070111182E7</BUDGET>
<GROSS_PROFIT>9310601.124</GROSS_PROFIT>
<EXPENSES>1.01205429E7</EXPENSES>
<NET_INCOME>1769581.33</NET_INCOME>
<REVENUE_M>11.89012424</REVENUE_M>
<PROFIT_M>9.310601124</PROFIT_M>
<INCOME_M>1.76958133</INCOME_M>
<PHARMA_REV_M>11.89012424</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.310601124</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.76958133</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>9588402.45</REVENUE>
<PREV_YEAR_REV>8754852.91</PREV_YEAR_REV>
<BUDGET>8629562.21</BUDGET>
<GROSS_PROFIT>7114115.204</GROSS_PROFIT>
<EXPENSES>8610385.4</EXPENSES>
<NET_INCOME>978017.05</NET_INCOME>
<REVENUE_M>9.58840245</REVENUE_M>
<PROFIT_M>7.114115204</PROFIT_M>
<INCOME_M>0.97801705</INCOME_M>
<PHARMA_REV_M>9.58840245</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.114115204</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.97801705</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2358766.27</REVENUE>
<PREV_YEAR_REV>2135577.11</PREV_YEAR_REV>
<BUDGET>2123689.59</BUDGET>
<GROSS_PROFIT>1846913.99</GROSS_PROFIT>
<EXPENSES>1936547.11</EXPENSES>
<NET_INCOME>422219.16</NET_INCOME>
<REVENUE_M>2.35876627</REVENUE_M>
<PROFIT_M>1.84691399</PROFIT_M>
<INCOME_M>0.42221916</INCOME_M>
<PHARMA_REV_M>2.35876627</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.84691399</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42221916</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>7041448.59</REVENUE>
<PREV_YEAR_REV>6201400.52</PREV_YEAR_REV>
<BUDGET>6453809.53</BUDGET>
<GROSS_PROFIT>5808119.75</GROSS_PROFIT>
<EXPENSES>6357114.5</EXPENSES>
<NET_INCOME>684334.09</NET_INCOME>
<REVENUE_M>7.04144859</REVENUE_M>
<PROFIT_M>5.80811975</PROFIT_M>
<INCOME_M>0.68433409</INCOME_M>
<PHARMA_REV_M>7.04144859</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.80811975</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68433409</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2229224.07</REVENUE>
<PREV_YEAR_REV>2005401.23</PREV_YEAR_REV>
<BUDGET>2131352.19</BUDGET>
<GROSS_PROFIT>1890382.01</GROSS_PROFIT>
<EXPENSES>1830192.96</EXPENSES>
<NET_INCOME>399031.11</NET_INCOME>
<REVENUE_M>2.22922407</REVENUE_M>
<PROFIT_M>1.89038201</PROFIT_M>
<INCOME_M>0.39903111</INCOME_M>
<PHARMA_REV_M>2.22922407</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.89038201</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39903111</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2396973.93</REVENUE>
<PREV_YEAR_REV>2154873.85</PREV_YEAR_REV>
<BUDGET>2164301.37</BUDGET>
<GROSS_PROFIT>1776157.687</GROSS_PROFIT>
<EXPENSES>2135703.77</EXPENSES>
<NET_INCOME>261270.16</NET_INCOME>
<REVENUE_M>2.39697393</REVENUE_M>
<PROFIT_M>1.776157687</PROFIT_M>
<INCOME_M>0.26127016</INCOME_M>
<PHARMA_REV_M>2.39697393</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.776157687</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26127016</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3518005.39</REVENUE>
<PREV_YEAR_REV>3146936.85</PREV_YEAR_REV>
<BUDGET>2693967.78</BUDGET>
<GROSS_PROFIT>2842100.494</GROSS_PROFIT>
<EXPENSES>3128129.23</EXPENSES>
<NET_INCOME>389876.15</NET_INCOME>
<REVENUE_M>3.51800539</REVENUE_M>
<PROFIT_M>2.842100494</PROFIT_M>
<INCOME_M>0.38987615</INCOME_M>
<PHARMA_REV_M>3.51800539</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.842100494</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38987615</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1765283.53</REVENUE>
<PREV_YEAR_REV>1587057.03</PREV_YEAR_REV>
<BUDGET>1330609.48</BUDGET>
<GROSS_PROFIT>1482838.17</GROSS_PROFIT>
<EXPENSES>1449297.78</EXPENSES>
<NET_INCOME>315985.75</NET_INCOME>
<REVENUE_M>1.76528353</REVENUE_M>
<PROFIT_M>1.48283817</PROFIT_M>
<INCOME_M>0.31598575</INCOME_M>
<PHARMA_REV_M>1.76528353</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.48283817</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31598575</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1903017.51</REVENUE>
<PREV_YEAR_REV>1627442.65</PREV_YEAR_REV>
<BUDGET>1372140</BUDGET>
<GROSS_PROFIT>1424979.513</GROSS_PROFIT>
<EXPENSES>1646110.15</EXPENSES>
<NET_INCOME>256907.36</NET_INCOME>
<REVENUE_M>1.90301751</REVENUE_M>
<PROFIT_M>1.424979513</PROFIT_M>
<INCOME_M>0.25690736</INCOME_M>
<PHARMA_REV_M>1.90301751</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.424979513</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25690736</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1978035.66</REVENUE>
<PREV_YEAR_REV>1781259.88</PREV_YEAR_REV>
<BUDGET>1451230.46</BUDGET>
<GROSS_PROFIT>1627923.35</GROSS_PROFIT>
<EXPENSES>1762429.77</EXPENSES>
<NET_INCOME>215605.89</NET_INCOME>
<REVENUE_M>1.97803566</REVENUE_M>
<PROFIT_M>1.62792335</PROFIT_M>
<INCOME_M>0.21560589</INCOME_M>
<PHARMA_REV_M>1.97803566</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.62792335</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21560589</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>9293740.2</REVENUE>
<PREV_YEAR_REV>7889058.29</PREV_YEAR_REV>
<BUDGET>9107865.4</BUDGET>
<GROSS_PROFIT>7163869.223</GROSS_PROFIT>
<EXPENSES>8169288.59</EXPENSES>
<NET_INCOME>1124451.63</NET_INCOME>
<REVENUE_M>9.2937402</REVENUE_M>
<PROFIT_M>7.163869223</PROFIT_M>
<INCOME_M>1.12445163</INCOME_M>
<PHARMA_REV_M>9.2937402</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.163869223</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.12445163</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>3.149285318E7</REVENUE>
<PREV_YEAR_REV>2.739407828E7</PREV_YEAR_REV>
<BUDGET>3.086299612E7</BUDGET>
<GROSS_PROFIT>2.330416831E7</GROSS_PROFIT>
<EXPENSES>2.740849788E7</EXPENSES>
<NET_INCOME>4084355.3</NET_INCOME>
<REVENUE_M>31.49285318</REVENUE_M>
<PROFIT_M>23.30416831</PROFIT_M>
<INCOME_M>4.0843553</INCOME_M>
<PHARMA_REV_M>31.49285318</PHARMA_REV_M>
<PHARMA_PROFIT_M>23.30416831</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>4.0843553</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>2.06315345E7</REVENUE>
<PREV_YEAR_REV>1.762950424E7</PREV_YEAR_REV>
<BUDGET>2.02189038E7</BUDGET>
<GROSS_PROFIT>1.544821437E7</GROSS_PROFIT>
<EXPENSES>1.753759568E7</EXPENSES>
<NET_INCOME>3093938.8</NET_INCOME>
<REVENUE_M>20.6315345</REVENUE_M>
<PROFIT_M>15.44821437</PROFIT_M>
<INCOME_M>3.0939388</INCOME_M>
<PHARMA_REV_M>20.6315345</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.44821437</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>3.0939388</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>2.606805003E7</REVENUE>
<PREV_YEAR_REV>2.297331493E7</PREV_YEAR_REV>
<BUDGET>2.554668903E7</BUDGET>
<GROSS_PROFIT>2.226190838E7</GROSS_PROFIT>
<EXPENSES>2.356031349E7</EXPENSES>
<NET_INCOME>2507736.54</NET_INCOME>
<REVENUE_M>26.06805003</REVENUE_M>
<PROFIT_M>22.26190838</PROFIT_M>
<INCOME_M>2.50773654</INCOME_M>
<PHARMA_REV_M>26.06805003</PHARMA_REV_M>
<PHARMA_PROFIT_M>22.26190838</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.50773654</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.550650117E7</REVENUE>
<PREV_YEAR_REV>1.324874512E7</PREV_YEAR_REV>
<BUDGET>1.519637115E7</BUDGET>
<GROSS_PROFIT>1.306390744E7</GROSS_PROFIT>
<EXPENSES>1.35311245E7</EXPENSES>
<NET_INCOME>1975376.66</NET_INCOME>
<REVENUE_M>15.50650117</REVENUE_M>
<PROFIT_M>13.06390744</PROFIT_M>
<INCOME_M>1.97537666</INCOME_M>
<PHARMA_REV_M>15.50650117</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.06390744</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.97537666</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8717385.17</REVENUE>
<PREV_YEAR_REV>7853712.42</PREV_YEAR_REV>
<BUDGET>8543037.47</BUDGET>
<GROSS_PROFIT>6684490.953</GROSS_PROFIT>
<EXPENSES>7540538.17</EXPENSES>
<NET_INCOME>1176847</NET_INCOME>
<REVENUE_M>8.71738517</REVENUE_M>
<PROFIT_M>6.684490953</PROFIT_M>
<INCOME_M>1.176847</INCOME_M>
<PHARMA_REV_M>8.71738517</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.684490953</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.176847</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.048702615E7</REVENUE>
<PREV_YEAR_REV>9407176.37</PREV_YEAR_REV>
<BUDGET>1.027728563E7</BUDGET>
<GROSS_PROFIT>8209244.073</GROSS_PROFIT>
<EXPENSES>9417349.48</EXPENSES>
<NET_INCOME>1069676.67</NET_INCOME>
<REVENUE_M>10.48702615</REVENUE_M>
<PROFIT_M>8.209244073</PROFIT_M>
<INCOME_M>1.06967667</INCOME_M>
<PHARMA_REV_M>10.48702615</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.209244073</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.06967667</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5724298.69</REVENUE>
<PREV_YEAR_REV>5113903.2</PREV_YEAR_REV>
<BUDGET>5609812.72</BUDGET>
<GROSS_PROFIT>4739719.32</GROSS_PROFIT>
<EXPENSES>5100350.13</EXPENSES>
<NET_INCOME>623948.56</NET_INCOME>
<REVENUE_M>5.72429869</REVENUE_M>
<PROFIT_M>4.73971932</PROFIT_M>
<INCOME_M>0.62394856</INCOME_M>
<PHARMA_REV_M>5.72429869</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.73971932</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62394856</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2735448.89</REVENUE>
<PREV_YEAR_REV>2356256.53</PREV_YEAR_REV>
<BUDGET>2566088.44</BUDGET>
<GROSS_PROFIT>2159500.129</GROSS_PROFIT>
<EXPENSES>2297777.07</EXPENSES>
<NET_INCOME>437671.82</NET_INCOME>
<REVENUE_M>2.73544889</REVENUE_M>
<PROFIT_M>2.159500129</PROFIT_M>
<INCOME_M>0.43767182</INCOME_M>
<PHARMA_REV_M>2.73544889</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.159500129</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43767182</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2923181.19</REVENUE>
<PREV_YEAR_REV>2557351.99</PREV_YEAR_REV>
<BUDGET>2574239.06</BUDGET>
<GROSS_PROFIT>2452110.541</GROSS_PROFIT>
<EXPENSES>2537321.27</EXPENSES>
<NET_INCOME>385859.92</NET_INCOME>
<REVENUE_M>2.92318119</REVENUE_M>
<PROFIT_M>2.452110541</PROFIT_M>
<INCOME_M>0.38585992</INCOME_M>
<PHARMA_REV_M>2.92318119</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.452110541</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38585992</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5670287.46</REVENUE>
<PREV_YEAR_REV>5027076.18</PREV_YEAR_REV>
<BUDGET>5268007.04</BUDGET>
<GROSS_PROFIT>3800817.222</GROSS_PROFIT>
<EXPENSES>4986600.1</EXPENSES>
<NET_INCOME>683687.36</NET_INCOME>
<REVENUE_M>5.67028746</REVENUE_M>
<PROFIT_M>3.800817222</PROFIT_M>
<INCOME_M>0.68368736</INCOME_M>
<PHARMA_REV_M>5.67028746</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.800817222</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68368736</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>6010536.21</REVENUE>
<PREV_YEAR_REV>5340255.05</PREV_YEAR_REV>
<BUDGET>5329150.31</BUDGET>
<GROSS_PROFIT>4231774.338</GROSS_PROFIT>
<EXPENSES>5118129.96</EXPENSES>
<NET_INCOME>892406.26</NET_INCOME>
<REVENUE_M>6.01053621</REVENUE_M>
<PROFIT_M>4.231774338</PROFIT_M>
<INCOME_M>0.89240626</INCOME_M>
<PHARMA_REV_M>6.01053621</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.231774338</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.89240626</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1844919.27</REVENUE>
<PREV_YEAR_REV>1673836.45</PREV_YEAR_REV>
<BUDGET>1789571.69</BUDGET>
<GROSS_PROFIT>1353484.439</GROSS_PROFIT>
<EXPENSES>1527593.16</EXPENSES>
<NET_INCOME>317326.11</NET_INCOME>
<REVENUE_M>1.8449192700000001</REVENUE_M>
<PROFIT_M>1.353484439</PROFIT_M>
<INCOME_M>0.31732611</INCOME_M>
<PHARMA_REV_M>1.8449192700000001</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.353484439</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31732611</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1846375.97</REVENUE>
<PREV_YEAR_REV>1588184.77</PREV_YEAR_REV>
<BUDGET>1790984.69</BUDGET>
<GROSS_PROFIT>1409154.138</GROSS_PROFIT>
<EXPENSES>1597115.21</EXPENSES>
<NET_INCOME>249260.76</NET_INCOME>
<REVENUE_M>1.84637597</REVENUE_M>
<PROFIT_M>1.409154138</PROFIT_M>
<INCOME_M>0.24926076</INCOME_M>
<PHARMA_REV_M>1.84637597</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.409154138</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24926076</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1673550.11</REVENUE>
<PREV_YEAR_REV>1434479.72</PREV_YEAR_REV>
<BUDGET>1623343.61</BUDGET>
<GROSS_PROFIT>1323945.495</GROSS_PROFIT>
<EXPENSES>1447620.85</EXPENSES>
<NET_INCOME>225929.27</NET_INCOME>
<REVENUE_M>1.67355011</REVENUE_M>
<PROFIT_M>1.323945495</PROFIT_M>
<INCOME_M>0.22592927</INCOME_M>
<PHARMA_REV_M>1.67355011</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.323945495</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22592927</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2132744.84</REVENUE>
<PREV_YEAR_REV>1872323.38</PREV_YEAR_REV>
<BUDGET>2068762.5</BUDGET>
<GROSS_PROFIT>1853355.27</GROSS_PROFIT>
<EXPENSES>1900275.66</EXPENSES>
<NET_INCOME>232469.19</NET_INCOME>
<REVENUE_M>2.13274484</REVENUE_M>
<PROFIT_M>1.85335527</PROFIT_M>
<INCOME_M>0.23246919</INCOME_M>
<PHARMA_REV_M>2.13274484</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.85335527</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23246919</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1517387.26</REVENUE>
<PREV_YEAR_REV>1360360.81</PREV_YEAR_REV>
<BUDGET>1471865.64</BUDGET>
<GROSS_PROFIT>1154655.831</GROSS_PROFIT>
<EXPENSES>1317092.14</EXPENSES>
<NET_INCOME>200295.12</NET_INCOME>
<REVENUE_M>1.51738726</REVENUE_M>
<PROFIT_M>1.154655831</PROFIT_M>
<INCOME_M>0.20029512</INCOME_M>
<PHARMA_REV_M>1.51738726</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.154655831</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20029512</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2968769.36</REVENUE>
<PREV_YEAR_REV>2614331.45</PREV_YEAR_REV>
<BUDGET>2879706.28</BUDGET>
<GROSS_PROFIT>2311183.755</GROSS_PROFIT>
<EXPENSES>2609589.02</EXPENSES>
<NET_INCOME>359180.35</NET_INCOME>
<REVENUE_M>2.96876936</REVENUE_M>
<PROFIT_M>2.311183755</PROFIT_M>
<INCOME_M>0.35918035</INCOME_M>
<PHARMA_REV_M>2.96876936</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.311183755</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35918035</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>8924258.19</REVENUE>
<PREV_YEAR_REV>7825097.11</PREV_YEAR_REV>
<BUDGET>8058645.2</BUDGET>
<GROSS_PROFIT>7475150.895</GROSS_PROFIT>
<EXPENSES>8059327.27</EXPENSES>
<NET_INCOME>864930.92</NET_INCOME>
<REVENUE_M>8.92425819</REVENUE_M>
<PROFIT_M>7.475150895</PROFIT_M>
<INCOME_M>0.86493092</INCOME_M>
<PHARMA_REV_M>8.92425819</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.475150895</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.86493092</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>6143982.99</REVENUE>
<PREV_YEAR_REV>5303267.22</PREV_YEAR_REV>
<BUDGET>5428030.98</BUDGET>
<GROSS_PROFIT>4953405.884</GROSS_PROFIT>
<EXPENSES>5329077.66</EXPENSES>
<NET_INCOME>814905.32</NET_INCOME>
<REVENUE_M>6.14398299</REVENUE_M>
<PROFIT_M>4.953405884</PROFIT_M>
<INCOME_M>0.81490532</INCOME_M>
<PHARMA_REV_M>6.14398299</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.953405884</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.81490532</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2951160.67</REVENUE>
<PREV_YEAR_REV>2584679.03</PREV_YEAR_REV>
<BUDGET>2786155.31</BUDGET>
<GROSS_PROFIT>2305178.158</GROSS_PROFIT>
<EXPENSES>2443561.03</EXPENSES>
<NET_INCOME>507599.63</NET_INCOME>
<REVENUE_M>2.95116067</REVENUE_M>
<PROFIT_M>2.305178158</PROFIT_M>
<INCOME_M>0.50759963</INCOME_M>
<PHARMA_REV_M>2.95116067</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.305178158</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50759963</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2103833.59</REVENUE>
<PREV_YEAR_REV>1910682.68</PREV_YEAR_REV>
<BUDGET>2371390.88</BUDGET>
<GROSS_PROFIT>1818469.605</GROSS_PROFIT>
<EXPENSES>1826127.56</EXPENSES>
<NET_INCOME>277706.03</NET_INCOME>
<REVENUE_M>2.10383359</REVENUE_M>
<PROFIT_M>1.818469605</PROFIT_M>
<INCOME_M>0.27770603</INCOME_M>
<PHARMA_REV_M>2.10383359</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.818469605</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27770603</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2179724.83</REVENUE>
<PREV_YEAR_REV>1905220.64</PREV_YEAR_REV>
<BUDGET>2455877.81</BUDGET>
<GROSS_PROFIT>1772116.28</GROSS_PROFIT>
<EXPENSES>1892001.15</EXPENSES>
<NET_INCOME>287723.68</NET_INCOME>
<REVENUE_M>2.17972483</REVENUE_M>
<PROFIT_M>1.77211628</PROFIT_M>
<INCOME_M>0.28772368</INCOME_M>
<PHARMA_REV_M>2.17972483</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.77211628</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28772368</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2149489.06</REVENUE>
<PREV_YEAR_REV>1880452.7</PREV_YEAR_REV>
<BUDGET>2369519.97</BUDGET>
<GROSS_PROFIT>1651495.441</GROSS_PROFIT>
<EXPENSES>1992576.36</EXPENSES>
<NET_INCOME>156912.7</NET_INCOME>
<REVENUE_M>2.14948906</REVENUE_M>
<PROFIT_M>1.651495441</PROFIT_M>
<INCOME_M>0.1569127</INCOME_M>
<PHARMA_REV_M>2.14948906</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.651495441</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1569127</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4080169.71</REVENUE>
<PREV_YEAR_REV>3649443.89</PREV_YEAR_REV>
<BUDGET>4692495.94</BUDGET>
<GROSS_PROFIT>3318008.314</GROSS_PROFIT>
<EXPENSES>3531403.46</EXPENSES>
<NET_INCOME>548766.25</NET_INCOME>
<REVENUE_M>4.08016971</REVENUE_M>
<PROFIT_M>3.318008314</PROFIT_M>
<INCOME_M>0.54876625</INCOME_M>
<PHARMA_REV_M>4.08016971</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.318008314</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54876625</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4202081.43</REVENUE>
<PREV_YEAR_REV>3630603</PREV_YEAR_REV>
<BUDGET>4724233.57</BUDGET>
<GROSS_PROFIT>3000602.373</GROSS_PROFIT>
<EXPENSES>3577926.36</EXPENSES>
<NET_INCOME>624155.07</NET_INCOME>
<REVENUE_M>4.20208143</REVENUE_M>
<PROFIT_M>3.000602373</PROFIT_M>
<INCOME_M>0.62415507</INCOME_M>
<PHARMA_REV_M>4.20208143</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.000602373</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62415507</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2502817.15</REVENUE>
<PREV_YEAR_REV>2139562.27</PREV_YEAR_REV>
<BUDGET>2424188.42</BUDGET>
<GROSS_PROFIT>2169942.47</GROSS_PROFIT>
<EXPENSES>2230010.08</EXPENSES>
<NET_INCOME>272807.07</NET_INCOME>
<REVENUE_M>2.50281715</REVENUE_M>
<PROFIT_M>2.16994247</PROFIT_M>
<INCOME_M>0.27280707</INCOME_M>
<PHARMA_REV_M>2.50281715</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.16994247</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27280707</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3548488.15</REVENUE>
<PREV_YEAR_REV>3052615.78</PREV_YEAR_REV>
<BUDGET>3420994.5</BUDGET>
<GROSS_PROFIT>2708360.895</GROSS_PROFIT>
<EXPENSES>3157087.39</EXPENSES>
<NET_INCOME>391400.77</NET_INCOME>
<REVENUE_M>3.54848815</REVENUE_M>
<PROFIT_M>2.708360895</PROFIT_M>
<INCOME_M>0.39140077</INCOME_M>
<PHARMA_REV_M>3.54848815</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.708360895</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39140077</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1649386.56</REVENUE>
<PREV_YEAR_REV>1426780.3</PREV_YEAR_REV>
<BUDGET>1699582.5</BUDGET>
<GROSS_PROFIT>1325611.979</GROSS_PROFIT>
<EXPENSES>1431667.54</EXPENSES>
<NET_INCOME>217719.03</NET_INCOME>
<REVENUE_M>1.64938656</REVENUE_M>
<PROFIT_M>1.325611979</PROFIT_M>
<INCOME_M>0.21771903</INCOME_M>
<PHARMA_REV_M>1.64938656</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.325611979</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21771903</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1547557.44</REVENUE>
<PREV_YEAR_REV>1341409.61</PREV_YEAR_REV>
<BUDGET>1478094.16</BUDGET>
<GROSS_PROFIT>1354112.76</GROSS_PROFIT>
<EXPENSES>1343279.86</EXPENSES>
<NET_INCOME>204277.58</NET_INCOME>
<REVENUE_M>1.54755744</REVENUE_M>
<PROFIT_M>1.35411276</PROFIT_M>
<INCOME_M>0.20427758</INCOME_M>
<PHARMA_REV_M>1.54755744</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.35411276</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20427758</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.665111826E7</REVENUE>
<PREV_YEAR_REV>1.492366282E7</PREV_YEAR_REV>
<BUDGET>1.53190288E7</BUDGET>
<GROSS_PROFIT>1.269139491E7</GROSS_PROFIT>
<EXPENSES>1.463619884E7</EXPENSES>
<NET_INCOME>2014919.42</NET_INCOME>
<REVENUE_M>16.65111826</REVENUE_M>
<PROFIT_M>12.69139491</PROFIT_M>
<INCOME_M>2.01491942</INCOME_M>
<PHARMA_REV_M>16.65111826</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.69139491</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.01491942</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8303025.3</REVENUE>
<PREV_YEAR_REV>7197241.17</PREV_YEAR_REV>
<BUDGET>7638783.28</BUDGET>
<GROSS_PROFIT>6926881.889</GROSS_PROFIT>
<EXPENSES>7696904.46</EXPENSES>
<NET_INCOME>606120.85</NET_INCOME>
<REVENUE_M>8.3030253</REVENUE_M>
<PROFIT_M>6.926881889</PROFIT_M>
<INCOME_M>0.60612085</INCOME_M>
<PHARMA_REV_M>8.3030253</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.926881889</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60612085</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2183063.4</REVENUE>
<PREV_YEAR_REV>1905440.69</PREV_YEAR_REV>
<BUDGET>2117571.5</BUDGET>
<GROSS_PROFIT>1874159.929</GROSS_PROFIT>
<EXPENSES>1833773.26</EXPENSES>
<NET_INCOME>349290.14</NET_INCOME>
<REVENUE_M>2.1830634</REVENUE_M>
<PROFIT_M>1.874159929</PROFIT_M>
<INCOME_M>0.34929014</INCOME_M>
<PHARMA_REV_M>2.1830634</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.874159929</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34929014</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2672143.43</REVENUE>
<PREV_YEAR_REV>2421516.47</PREV_YEAR_REV>
<BUDGET>2591979.12</BUDGET>
<GROSS_PROFIT>2215228.277</GROSS_PROFIT>
<EXPENSES>2212534.76</EXPENSES>
<NET_INCOME>459608.67</NET_INCOME>
<REVENUE_M>2.67214343</REVENUE_M>
<PROFIT_M>2.215228277</PROFIT_M>
<INCOME_M>0.45960867</INCOME_M>
<PHARMA_REV_M>2.67214343</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.215228277</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45960867</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2582500.73</REVENUE>
<PREV_YEAR_REV>2271248.79</PREV_YEAR_REV>
<BUDGET>2505025.7</BUDGET>
<GROSS_PROFIT>2107527.196</GROSS_PROFIT>
<EXPENSES>2301008.15</EXPENSES>
<NET_INCOME>281492.58</NET_INCOME>
<REVENUE_M>2.58250073</REVENUE_M>
<PROFIT_M>2.107527196</PROFIT_M>
<INCOME_M>0.28149258</INCOME_M>
<PHARMA_REV_M>2.58250073</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.107527196</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28149258</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1846375.97</REVENUE>
<PREV_YEAR_REV>1599937.58</PREV_YEAR_REV>
<BUDGET>1790984.69</BUDGET>
<GROSS_PROFIT>1341886.972</GROSS_PROFIT>
<EXPENSES>1608193.47</EXPENSES>
<NET_INCOME>238182.5</NET_INCOME>
<REVENUE_M>1.84637597</REVENUE_M>
<PROFIT_M>1.341886972</PROFIT_M>
<INCOME_M>0.2381825</INCOME_M>
<PHARMA_REV_M>1.84637597</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.341886972</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2381825</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3636132.02</REVENUE>
<PREV_YEAR_REV>3216925.55</PREV_YEAR_REV>
<BUDGET>3527048.05</BUDGET>
<GROSS_PROFIT>2671324.434</GROSS_PROFIT>
<EXPENSES>3234575.24</EXPENSES>
<NET_INCOME>401556.78</NET_INCOME>
<REVENUE_M>3.63613202</REVENUE_M>
<PROFIT_M>2.671324434</PROFIT_M>
<INCOME_M>0.40155678</INCOME_M>
<PHARMA_REV_M>3.63613202</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.671324434</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40155678</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3696429.92</REVENUE>
<PREV_YEAR_REV>3216623.79</PREV_YEAR_REV>
<BUDGET>3585537.02</BUDGET>
<GROSS_PROFIT>2787853.374</GROSS_PROFIT>
<EXPENSES>3249313.5</EXPENSES>
<NET_INCOME>447116.42</NET_INCOME>
<REVENUE_M>3.69642992</REVENUE_M>
<PROFIT_M>2.787853374</PROFIT_M>
<INCOME_M>0.44711642</INCOME_M>
<PHARMA_REV_M>3.69642992</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.787853374</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44711642</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1844919.27</REVENUE>
<PREV_YEAR_REV>1666307.74</PREV_YEAR_REV>
<BUDGET>1789571.69</BUDGET>
<GROSS_PROFIT>1578402.23</GROSS_PROFIT>
<EXPENSES>1710240.16</EXPENSES>
<NET_INCOME>134679.11</NET_INCOME>
<REVENUE_M>1.8449192700000001</REVENUE_M>
<PROFIT_M>1.57840223</PROFIT_M>
<INCOME_M>0.13467911</INCOME_M>
<PHARMA_REV_M>1.8449192700000001</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.57840223</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13467911</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3274965.26</REVENUE>
<PREV_YEAR_REV>2890442.11</PREV_YEAR_REV>
<BUDGET>4119957.8</BUDGET>
<GROSS_PROFIT>2572770.259</GROSS_PROFIT>
<EXPENSES>2834650.44</EXPENSES>
<NET_INCOME>440314.82</NET_INCOME>
<REVENUE_M>3.27496526</REVENUE_M>
<PROFIT_M>2.572770259</PROFIT_M>
<INCOME_M>0.44031482</INCOME_M>
<PHARMA_REV_M>3.27496526</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.572770259</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44031482</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1815951.24</REVENUE>
<PREV_YEAR_REV>1581742.61</PREV_YEAR_REV>
<BUDGET>2128409.73</BUDGET>
<GROSS_PROFIT>1607116.85</GROSS_PROFIT>
<EXPENSES>1618012.56</EXPENSES>
<NET_INCOME>197938.69</NET_INCOME>
<REVENUE_M>1.81595124</REVENUE_M>
<PROFIT_M>1.60711685</PROFIT_M>
<INCOME_M>0.19793869</INCOME_M>
<PHARMA_REV_M>1.81595124</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.60711685</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19793869</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1088350.73</REVENUE>
<PREV_YEAR_REV>945356.15</PREV_YEAR_REV>
<BUDGET>1198699.62</BUDGET>
<GROSS_PROFIT>937069.97</GROSS_PROFIT>
<EXPENSES>914214.61</EXPENSES>
<NET_INCOME>174136.12</NET_INCOME>
<REVENUE_M>1.08835073</REVENUE_M>
<PROFIT_M>0.93706997</PROFIT_M>
<INCOME_M>0.17413612</INCOME_M>
<PHARMA_REV_M>1.08835073</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.93706997</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17413612</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5983500.78</REVENUE>
<PREV_YEAR_REV>5300977.25</PREV_YEAR_REV>
<BUDGET>4677322.32</BUDGET>
<GROSS_PROFIT>4627007.061</GROSS_PROFIT>
<EXPENSES>5321439.66</EXPENSES>
<NET_INCOME>662061.12</NET_INCOME>
<REVENUE_M>5.98350078</REVENUE_M>
<PROFIT_M>4.627007061</PROFIT_M>
<INCOME_M>0.66206112</INCOME_M>
<PHARMA_REV_M>5.98350078</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.627007061</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.66206112</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3197632.26</REVENUE>
<PREV_YEAR_REV>2726517.33</PREV_YEAR_REV>
<BUDGET>2443175.46</BUDGET>
<GROSS_PROFIT>2236507.139</GROSS_PROFIT>
<EXPENSES>2785137.7</EXPENSES>
<NET_INCOME>412494.56</NET_INCOME>
<REVENUE_M>3.19763226</REVENUE_M>
<PROFIT_M>2.236507139</PROFIT_M>
<INCOME_M>0.41249456</INCOME_M>
<PHARMA_REV_M>3.19763226</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.236507139</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41249456</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3305943.28</REVENUE>
<PREV_YEAR_REV>2868298.32</PREV_YEAR_REV>
<BUDGET>2521868.58</BUDGET>
<GROSS_PROFIT>2631134.133</GROSS_PROFIT>
<EXPENSES>3064609.42</EXPENSES>
<NET_INCOME>241333.86</NET_INCOME>
<REVENUE_M>3.30594328</REVENUE_M>
<PROFIT_M>2.631134133</PROFIT_M>
<INCOME_M>0.24133386</INCOME_M>
<PHARMA_REV_M>3.30594328</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.631134133</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24133386</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>6294381.69</REVENUE>
<PREV_YEAR_REV>5622021.35</PREV_YEAR_REV>
<BUDGET>4913143.47</BUDGET>
<GROSS_PROFIT>5287639.353</GROSS_PROFIT>
<EXPENSES>5459010.98</EXPENSES>
<NET_INCOME>835370.71</NET_INCOME>
<REVENUE_M>6.29438169</REVENUE_M>
<PROFIT_M>5.287639353</PROFIT_M>
<INCOME_M>0.83537071</INCOME_M>
<PHARMA_REV_M>6.29438169</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.287639353</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83537071</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1918384.19</REVENUE>
<PREV_YEAR_REV>1648153.02</PREV_YEAR_REV>
<BUDGET>1755629.37</BUDGET>
<GROSS_PROFIT>1607414.11</GROSS_PROFIT>
<EXPENSES>1611442.72</EXPENSES>
<NET_INCOME>306941.47</NET_INCOME>
<REVENUE_M>1.91838419</REVENUE_M>
<PROFIT_M>1.60741411</PROFIT_M>
<INCOME_M>0.30694147</INCOME_M>
<PHARMA_REV_M>1.91838419</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.60741411</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30694147</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1503044.42</REVENUE>
<PREV_YEAR_REV>1314987.99</PREV_YEAR_REV>
<BUDGET>1457953.09</BUDGET>
<GROSS_PROFIT>1119467.489</GROSS_PROFIT>
<EXPENSES>1393322.18</EXPENSES>
<NET_INCOME>109722.24</NET_INCOME>
<REVENUE_M>1.50304442</REVENUE_M>
<PROFIT_M>1.119467489</PROFIT_M>
<INCOME_M>0.10972224</INCOME_M>
<PHARMA_REV_M>1.50304442</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.119467489</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10972224</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1353429</REVENUE>
<PREV_YEAR_REV>1182467.8</PREV_YEAR_REV>
<BUDGET>1312826.13</BUDGET>
<GROSS_PROFIT>1068261.507</GROSS_PROFIT>
<EXPENSES>1170716.09</EXPENSES>
<NET_INCOME>182712.92</NET_INCOME>
<REVENUE_M>1.353429</REVENUE_M>
<PROFIT_M>1.068261507</PROFIT_M>
<INCOME_M>0.18271292</INCOME_M>
<PHARMA_REV_M>1.353429</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.068261507</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18271292</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.670551955E7</REVENUE>
<PREV_YEAR_REV>1.383408669E7</PREV_YEAR_REV>
<BUDGET>1.587024357E7</BUDGET>
<GROSS_PROFIT>1.187791601E7</GROSS_PROFIT>
<EXPENSES>1.468435309E7</EXPENSES>
<NET_INCOME>2021166.46</NET_INCOME>
<REVENUE_M>16.70551955</REVENUE_M>
<PROFIT_M>11.87791601</PROFIT_M>
<INCOME_M>2.02116646</INCOME_M>
<PHARMA_REV_M>16.70551955</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.87791601</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.02116646</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>2.216029392E7</REVENUE>
<PREV_YEAR_REV>1.869592435E7</PREV_YEAR_REV>
<BUDGET>2.105227922E7</BUDGET>
<GROSS_PROFIT>1.705740033E7</GROSS_PROFIT>
<EXPENSES>2.001209888E7</EXPENSES>
<NET_INCOME>2148195.04</NET_INCOME>
<REVENUE_M>22.16029392</REVENUE_M>
<PROFIT_M>17.05740033</PROFIT_M>
<INCOME_M>2.14819504</INCOME_M>
<PHARMA_REV_M>22.16029392</PHARMA_REV_M>
<PHARMA_PROFIT_M>17.05740033</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.14819504</PHARMA_INCOME_M>
<FRANCE_REV_M>22.16029392</FRANCE_REV_M>
<FRANCE_PROFIT_M>17.05740033</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>2.14819504</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.59965615E7</REVENUE>
<PREV_YEAR_REV>1.305417591E7</PREV_YEAR_REV>
<BUDGET>1.519673343E7</BUDGET>
<GROSS_PROFIT>1.269930517E7</GROSS_PROFIT>
<EXPENSES>1.38447667E7</EXPENSES>
<NET_INCOME>2151794.8</NET_INCOME>
<REVENUE_M>15.9965615</REVENUE_M>
<PROFIT_M>12.69930517</PROFIT_M>
<INCOME_M>2.1517948</INCOME_M>
<PHARMA_REV_M>15.9965615</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.69930517</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.1517948</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>2.451873855E7</REVENUE>
<PREV_YEAR_REV>1.979775181E7</PREV_YEAR_REV>
<BUDGET>2.329280162E7</BUDGET>
<GROSS_PROFIT>1.958053307E7</GROSS_PROFIT>
<EXPENSES>2.215545747E7</EXPENSES>
<NET_INCOME>2363281.08</NET_INCOME>
<REVENUE_M>24.51873855</REVENUE_M>
<PROFIT_M>19.58053307</PROFIT_M>
<INCOME_M>2.36328108</INCOME_M>
<PHARMA_REV_M>24.51873855</PHARMA_REV_M>
<PHARMA_PROFIT_M>19.58053307</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.36328108</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2677657.5</REVENUE>
<PREV_YEAR_REV>2197629.33</PREV_YEAR_REV>
<BUDGET>2650880.93</BUDGET>
<GROSS_PROFIT>2118964.265</GROSS_PROFIT>
<EXPENSES>2249232.3</EXPENSES>
<NET_INCOME>428425.2</NET_INCOME>
<REVENUE_M>2.6776575</REVENUE_M>
<PROFIT_M>2.118964265</PROFIT_M>
<INCOME_M>0.4284252</INCOME_M>
<PHARMA_REV_M>2.6776575</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.118964265</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4284252</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3802334.42</REVENUE>
<PREV_YEAR_REV>3123400.79</PREV_YEAR_REV>
<BUDGET>3614887.5</BUDGET>
<GROSS_PROFIT>2730836.587</GROSS_PROFIT>
<EXPENSES>3289019.28</EXPENSES>
<NET_INCOME>513315.15</NET_INCOME>
<REVENUE_M>3.80233442</REVENUE_M>
<PROFIT_M>2.730836587</PROFIT_M>
<INCOME_M>0.51331515</INCOME_M>
<PHARMA_REV_M>3.80233442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.730836587</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51331515</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3615209.42</REVENUE>
<PREV_YEAR_REV>2806055.31</PREV_YEAR_REV>
<BUDGET>3438990</BUDGET>
<GROSS_PROFIT>2758151.724</GROSS_PROFIT>
<EXPENSES>3127156.15</EXPENSES>
<NET_INCOME>488053.27</NET_INCOME>
<REVENUE_M>3.61520942</REVENUE_M>
<PROFIT_M>2.758151724</PROFIT_M>
<INCOME_M>0.48805327</INCOME_M>
<PHARMA_REV_M>3.61520942</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.758151724</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48805327</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3578271.92</REVENUE>
<PREV_YEAR_REV>2868124.34</PREV_YEAR_REV>
<BUDGET>3404268.75</BUDGET>
<GROSS_PROFIT>2731724.354</GROSS_PROFIT>
<EXPENSES>3213288.19</EXPENSES>
<NET_INCOME>364983.74</NET_INCOME>
<REVENUE_M>3.57827192</REVENUE_M>
<PROFIT_M>2.731724354</PROFIT_M>
<INCOME_M>0.36498374</INCOME_M>
<PHARMA_REV_M>3.57827192</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.731724354</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36498374</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3802334.42</REVENUE>
<PREV_YEAR_REV>2951160.67</PREV_YEAR_REV>
<BUDGET>3614887.5</BUDGET>
<GROSS_PROFIT>2987737.503</GROSS_PROFIT>
<EXPENSES>3148332.9</EXPENSES>
<NET_INCOME>654001.52</NET_INCOME>
<REVENUE_M>3.80233442</REVENUE_M>
<PROFIT_M>2.987737503</PROFIT_M>
<INCOME_M>0.65400152</INCOME_M>
<PHARMA_REV_M>3.80233442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.987737503</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65400152</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3766709.42</REVENUE>
<PREV_YEAR_REV>3131617.41</PREV_YEAR_REV>
<BUDGET>3581400</BUDGET>
<GROSS_PROFIT>3038001.823</GROSS_PROFIT>
<EXPENSES>3356138.1</EXPENSES>
<NET_INCOME>410571.33</NET_INCOME>
<REVENUE_M>3.76670942</REVENUE_M>
<PROFIT_M>3.038001823</PROFIT_M>
<INCOME_M>0.41057133</INCOME_M>
<PHARMA_REV_M>3.76670942</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.038001823</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41057133</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5194815.72</REVENUE>
<PREV_YEAR_REV>4320140.36</PREV_YEAR_REV>
<BUDGET>4964513.07</BUDGET>
<GROSS_PROFIT>3824423.343</GROSS_PROFIT>
<EXPENSES>4566577.45</EXPENSES>
<NET_INCOME>628238.27</NET_INCOME>
<REVENUE_M>5.19481572</REVENUE_M>
<PROFIT_M>3.824423343</PROFIT_M>
<INCOME_M>0.62823827</INCOME_M>
<PHARMA_REV_M>5.19481572</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.824423343</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62823827</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5207471.97</REVENUE>
<PREV_YEAR_REV>4244962.3</PREV_YEAR_REV>
<BUDGET>4976409.94</BUDGET>
<GROSS_PROFIT>3741849.146</GROSS_PROFIT>
<EXPENSES>4577992.96</EXPENSES>
<NET_INCOME>629479.01</NET_INCOME>
<REVENUE_M>5.20747197</REVENUE_M>
<PROFIT_M>3.741849146</PROFIT_M>
<INCOME_M>0.62947901</INCOME_M>
<PHARMA_REV_M>5.20747197</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.741849146</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62947901</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5135753.22</REVENUE>
<PREV_YEAR_REV>4144492.61</PREV_YEAR_REV>
<BUDGET>4908994.32</BUDGET>
<GROSS_PROFIT>4162979.22</GROSS_PROFIT>
<EXPENSES>4444852.67</EXPENSES>
<NET_INCOME>690900.56</NET_INCOME>
<REVENUE_M>5.13575322</REVENUE_M>
<PROFIT_M>4.16297922</PROFIT_M>
<INCOME_M>0.69090056</INCOME_M>
<PHARMA_REV_M>5.13575322</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.16297922</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69090056</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5497050.83</REVENUE>
<PREV_YEAR_REV>4480222.71</PREV_YEAR_REV>
<BUDGET>5442080.32</BUDGET>
<GROSS_PROFIT>3923706.159</GROSS_PROFIT>
<EXPENSES>4833212.11</EXPENSES>
<NET_INCOME>663838.73</NET_INCOME>
<REVENUE_M>5.49705083</REVENUE_M>
<PROFIT_M>3.923706159</PROFIT_M>
<INCOME_M>0.66383873</INCOME_M>
<PHARMA_REV_M>5.49705083</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.923706159</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.66383873</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2365807.5</REVENUE>
<PREV_YEAR_REV>1836807.07</PREV_YEAR_REV>
<BUDGET>2342149.43</BUDGET>
<GROSS_PROFIT>1791382.344</GROSS_PROFIT>
<EXPENSES>2060618.33</EXPENSES>
<NET_INCOME>305189.17</NET_INCOME>
<REVENUE_M>2.3658075</REVENUE_M>
<PROFIT_M>1.791382344</PROFIT_M>
<INCOME_M>0.30518917</INCOME_M>
<PHARMA_REV_M>2.3658075</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.791382344</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30518917</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2765826</REVENUE>
<PREV_YEAR_REV>2337304.58</PREV_YEAR_REV>
<BUDGET>2738167.74</BUDGET>
<GROSS_PROFIT>2195512.679</GROSS_PROFIT>
<EXPENSES>2563920.7</EXPENSES>
<NET_INCOME>201905.3</NET_INCOME>
<REVENUE_M>2.765826</REVENUE_M>
<PROFIT_M>2.195512679</PROFIT_M>
<INCOME_M>0.2019053</INCOME_M>
<PHARMA_REV_M>2.765826</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.195512679</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2019053</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2117272.5</REVENUE>
<PREV_YEAR_REV>1778159.67</PREV_YEAR_REV>
<BUDGET>2096099.78</BUDGET>
<GROSS_PROFIT>1496186.494</GROSS_PROFIT>
<EXPENSES>1901310.71</EXPENSES>
<NET_INCOME>215961.8</NET_INCOME>
<REVENUE_M>2.1172725</REVENUE_M>
<PROFIT_M>1.496186494</PROFIT_M>
<INCOME_M>0.2159618</INCOME_M>
<PHARMA_REV_M>2.1172725</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.496186494</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2159618</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2762693.33</REVENUE>
<PREV_YEAR_REV>2138655.14</PREV_YEAR_REV>
<BUDGET>2735066.39</BUDGET>
<GROSS_PROFIT>2057653.992</GROSS_PROFIT>
<EXPENSES>2461559.75</EXPENSES>
<NET_INCOME>301133.57</NET_INCOME>
<REVENUE_M>2.76269333</REVENUE_M>
<PROFIT_M>2.057653992</PROFIT_M>
<INCOME_M>0.30113357</INCOME_M>
<PHARMA_REV_M>2.76269333</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.057653992</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30113357</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2765826</REVENUE>
<PREV_YEAR_REV>2281526.39</PREV_YEAR_REV>
<BUDGET>2738167.74</BUDGET>
<GROSS_PROFIT>1936930.071</GROSS_PROFIT>
<EXPENSES>2392439.49</EXPENSES>
<NET_INCOME>373386.51</NET_INCOME>
<REVENUE_M>2.765826</REVENUE_M>
<PROFIT_M>1.936930071</PROFIT_M>
<INCOME_M>0.37338651</INCOME_M>
<PHARMA_REV_M>2.765826</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.936930071</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37338651</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2039073.75</REVENUE>
<PREV_YEAR_REV>1688086.75</PREV_YEAR_REV>
<BUDGET>2018683.01</BUDGET>
<GROSS_PROFIT>1566008.64</GROSS_PROFIT>
<EXPENSES>1712821.95</EXPENSES>
<NET_INCOME>326251.8</NET_INCOME>
<REVENUE_M>2.03907375</REVENUE_M>
<PROFIT_M>1.56600864</PROFIT_M>
<INCOME_M>0.3262518</INCOME_M>
<PHARMA_REV_M>2.03907375</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.56600864</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3262518</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4002304.16</REVENUE>
<PREV_YEAR_REV>3233731.53</PREV_YEAR_REV>
<BUDGET>3962281.12</BUDGET>
<GROSS_PROFIT>2755599.404</GROSS_PROFIT>
<EXPENSES>3518497.93</EXPENSES>
<NET_INCOME>483806.23</NET_INCOME>
<REVENUE_M>4.00230416</REVENUE_M>
<PROFIT_M>2.755599404</PROFIT_M>
<INCOME_M>0.48380623</INCOME_M>
<PHARMA_REV_M>4.00230416</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.755599404</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48380623</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3948084.79</REVENUE>
<PREV_YEAR_REV>3247173.42</PREV_YEAR_REV>
<BUDGET>3908603.94</BUDGET>
<GROSS_PROFIT>3050278.479</GROSS_PROFIT>
<EXPENSES>3416960.22</EXPENSES>
<NET_INCOME>531124.56</NET_INCOME>
<REVENUE_M>3.94808479</REVENUE_M>
<PROFIT_M>3.050278479</PROFIT_M>
<INCOME_M>0.53112456</INCOME_M>
<PHARMA_REV_M>3.94808479</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.050278479</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53112456</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5965527.48</REVENUE>
<PREV_YEAR_REV>4874420.94</PREV_YEAR_REV>
<BUDGET>5905872.22</BUDGET>
<GROSS_PROFIT>4913610.87</GROSS_PROFIT>
<EXPENSES>5387020.16</EXPENSES>
<NET_INCOME>578507.33</NET_INCOME>
<REVENUE_M>5.96552748</REVENUE_M>
<PROFIT_M>4.91361087</PROFIT_M>
<INCOME_M>0.57850733</INCOME_M>
<PHARMA_REV_M>5.96552748</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.91361087</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57850733</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3928601.26</REVENUE>
<PREV_YEAR_REV>3274965.26</PREV_YEAR_REV>
<BUDGET>3889315.24</BUDGET>
<GROSS_PROFIT>3011862.14</GROSS_PROFIT>
<EXPENSES>3400204.38</EXPENSES>
<NET_INCOME>528396.87</NET_INCOME>
<REVENUE_M>3.92860126</REVENUE_M>
<PROFIT_M>3.01186214</PROFIT_M>
<INCOME_M>0.52839687</INCOME_M>
<PHARMA_REV_M>3.92860126</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.01186214</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52839687</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3985648.54</REVENUE>
<PREV_YEAR_REV>3289041.4</PREV_YEAR_REV>
<BUDGET>3945792.05</BUDGET>
<GROSS_PROFIT>3272542.89</GROSS_PROFIT>
<EXPENSES>3457179.47</EXPENSES>
<NET_INCOME>528469.08</NET_INCOME>
<REVENUE_M>3.98564854</REVENUE_M>
<PROFIT_M>3.27254289</PROFIT_M>
<INCOME_M>0.52846908</INCOME_M>
<PHARMA_REV_M>3.98564854</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.27254289</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52846908</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1959693.75</REVENUE>
<PREV_YEAR_REV>1511922.72</PREV_YEAR_REV>
<BUDGET>1940096.81</BUDGET>
<GROSS_PROFIT>1440962.812</GROSS_PROFIT>
<EXPENSES>1622626.43</EXPENSES>
<NET_INCOME>337067.33</NET_INCOME>
<REVENUE_M>1.95969375</REVENUE_M>
<PROFIT_M>1.440962812</PROFIT_M>
<INCOME_M>0.33706733</INCOME_M>
<PHARMA_REV_M>1.95969375</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.440962812</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33706733</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1631599.2</REVENUE>
<PREV_YEAR_REV>1377214</PREV_YEAR_REV>
<BUDGET>1615283.21</BUDGET>
<GROSS_PROFIT>1191964.791</GROSS_PROFIT>
<EXPENSES>1416228.11</EXPENSES>
<NET_INCOME>215371.09</NET_INCOME>
<REVENUE_M>1.6315992</REVENUE_M>
<PROFIT_M>1.191964791</PROFIT_M>
<INCOME_M>0.21537109</INCOME_M>
<PHARMA_REV_M>1.6315992</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.191964791</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21537109</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1613636.64</REVENUE>
<PREV_YEAR_REV>1328172.52</PREV_YEAR_REV>
<BUDGET>1597500.27</BUDGET>
<GROSS_PROFIT>1174090.087</GROSS_PROFIT>
<EXPENSES>1405477.51</EXPENSES>
<NET_INCOME>208159.13</NET_INCOME>
<REVENUE_M>1.61363664</REVENUE_M>
<PROFIT_M>1.174090087</PROFIT_M>
<INCOME_M>0.20815913</INCOME_M>
<PHARMA_REV_M>1.61363664</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.174090087</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20815913</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3081297.54</REVENUE>
<PREV_YEAR_REV>2488290.25</PREV_YEAR_REV>
<BUDGET>3050484.56</BUDGET>
<GROSS_PROFIT>2520785.44</GROSS_PROFIT>
<EXPENSES>2666060.16</EXPENSES>
<NET_INCOME>415237.39</NET_INCOME>
<REVENUE_M>3.08129754</REVENUE_M>
<PROFIT_M>2.52078544</PROFIT_M>
<INCOME_M>0.41523739</INCOME_M>
<PHARMA_REV_M>3.08129754</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.52078544</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41523739</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1411252.48</REVENUE>
<PREV_YEAR_REV>1171144.44</PREV_YEAR_REV>
<BUDGET>1397139.95</BUDGET>
<GROSS_PROFIT>1210854.62</GROSS_PROFIT>
<EXPENSES>1158638.28</EXPENSES>
<NET_INCOME>252614.19</NET_INCOME>
<REVENUE_M>1.41125248</REVENUE_M>
<PROFIT_M>1.21085462</PROFIT_M>
<INCOME_M>0.25261419</INCOME_M>
<PHARMA_REV_M>1.41125248</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.21085462</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25261419</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3079974.3</REVENUE>
<PREV_YEAR_REV>2435866.83</PREV_YEAR_REV>
<BUDGET>3049174.55</BUDGET>
<GROSS_PROFIT>2340519.56</GROSS_PROFIT>
<EXPENSES>2668858.07</EXPENSES>
<NET_INCOME>411116.23</NET_INCOME>
<REVENUE_M>3.0799743</REVENUE_M>
<PROFIT_M>2.34051956</PROFIT_M>
<INCOME_M>0.41111623</INCOME_M>
<PHARMA_REV_M>3.0799743</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.34051956</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41111623</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7796448.39</REVENUE>
<PREV_YEAR_REV>6139709.25</PREV_YEAR_REV>
<BUDGET>7718483.91</BUDGET>
<GROSS_PROFIT>6181414.11</GROSS_PROFIT>
<EXPENSES>6400884.13</EXPENSES>
<NET_INCOME>1395564.26</NET_INCOME>
<REVENUE_M>7.79644839</REVENUE_M>
<PROFIT_M>6.18141411</PROFIT_M>
<INCOME_M>1.39556426</INCOME_M>
<PHARMA_REV_M>7.79644839</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.18141411</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.39556426</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>9603616.16</REVENUE>
<PREV_YEAR_REV>7562200.21</PREV_YEAR_REV>
<BUDGET>9507580</BUDGET>
<GROSS_PROFIT>7508587.295</GROSS_PROFIT>
<EXPENSES>7951794.18</EXPENSES>
<NET_INCOME>1651821.98</NET_INCOME>
<REVENUE_M>9.60361616</REVENUE_M>
<PROFIT_M>7.508587295</PROFIT_M>
<INCOME_M>1.65182198</INCOME_M>
<PHARMA_REV_M>9.60361616</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.508587295</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.65182198</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.055052731E7</REVENUE>
<PREV_YEAR_REV>8162820.64</PREV_YEAR_REV>
<BUDGET>1.044502204E7</BUDGET>
<GROSS_PROFIT>8872993.47</GROSS_PROFIT>
<EXPENSES>9400519.83</EXPENSES>
<NET_INCOME>1150007.48</NET_INCOME>
<REVENUE_M>10.55052731</REVENUE_M>
<PROFIT_M>8.87299347</PROFIT_M>
<INCOME_M>1.15000748</INCOME_M>
<PHARMA_REV_M>10.55052731</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.87299347</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.15000748</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3728114.5</REVENUE>
<PREV_YEAR_REV>2973215.17</PREV_YEAR_REV>
<BUDGET>3541708.78</BUDGET>
<GROSS_PROFIT>2766074.549</GROSS_PROFIT>
<EXPENSES>3236003.39</EXPENSES>
<NET_INCOME>492111.11</NET_INCOME>
<REVENUE_M>3.7281145</REVENUE_M>
<PROFIT_M>2.766074549</PROFIT_M>
<INCOME_M>0.49211111</INCOME_M>
<PHARMA_REV_M>3.7281145</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.766074549</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49211111</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6726840.88</REVENUE>
<PREV_YEAR_REV>5392291.44</PREV_YEAR_REV>
<BUDGET>6390498.84</BUDGET>
<GROSS_PROFIT>4848862.702</GROSS_PROFIT>
<EXPENSES>5912107.95</EXPENSES>
<NET_INCOME>814732.92</NET_INCOME>
<REVENUE_M>6.72684088</REVENUE_M>
<PROFIT_M>4.848862702</PROFIT_M>
<INCOME_M>0.81473292</INCOME_M>
<PHARMA_REV_M>6.72684088</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.848862702</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.81473292</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3883364.5</REVENUE>
<PREV_YEAR_REV>3197632.26</PREV_YEAR_REV>
<BUDGET>3689196.28</BUDGET>
<GROSS_PROFIT>2938759.385</GROSS_PROFIT>
<EXPENSES>3382410.48</EXPENSES>
<NET_INCOME>500954.02</NET_INCOME>
<REVENUE_M>3.8833645</REVENUE_M>
<PROFIT_M>2.938759385</PROFIT_M>
<INCOME_M>0.50095402</INCOME_M>
<PHARMA_REV_M>3.8833645</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.938759385</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50095402</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3862270.75</REVENUE>
<PREV_YEAR_REV>3270367.02</PREV_YEAR_REV>
<BUDGET>3669157.21</BUDGET>
<GROSS_PROFIT>3151806.042</GROSS_PROFIT>
<EXPENSES>3170924.29</EXPENSES>
<NET_INCOME>691346.46</NET_INCOME>
<REVENUE_M>3.86227075</REVENUE_M>
<PROFIT_M>3.151806042</PROFIT_M>
<INCOME_M>0.69134646</INCOME_M>
<PHARMA_REV_M>3.86227075</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.151806042</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69134646</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6745904</REVENUE>
<PREV_YEAR_REV>5246279.04</PREV_YEAR_REV>
<BUDGET>6408608.8</BUDGET>
<GROSS_PROFIT>4922786.599</GROSS_PROFIT>
<EXPENSES>5751787.26</EXPENSES>
<NET_INCOME>994116.74</NET_INCOME>
<REVENUE_M>6.745904</REVENUE_M>
<PROFIT_M>4.922786599</PROFIT_M>
<INCOME_M>0.99411674</INCOME_M>
<PHARMA_REV_M>6.745904</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.922786599</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.99411674</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3822952</REVENUE>
<PREV_YEAR_REV>2980324.78</PREV_YEAR_REV>
<BUDGET>3631804.4</BUDGET>
<GROSS_PROFIT>2663756.495</GROSS_PROFIT>
<EXPENSES>3306853.48</EXPENSES>
<NET_INCOME>516098.52</NET_INCOME>
<REVENUE_M>3.822952</REVENUE_M>
<PROFIT_M>2.663756495</PROFIT_M>
<INCOME_M>0.51609852</INCOME_M>
<PHARMA_REV_M>3.822952</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.663756495</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51609852</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2868755.13</REVENUE>
<PREV_YEAR_REV>2360823.87</PREV_YEAR_REV>
<BUDGET>2581879.61</BUDGET>
<GROSS_PROFIT>2286541.273</GROSS_PROFIT>
<EXPENSES>2355247.96</EXPENSES>
<NET_INCOME>513507.17</NET_INCOME>
<REVENUE_M>2.86875513</REVENUE_M>
<PROFIT_M>2.286541273</PROFIT_M>
<INCOME_M>0.51350717</INCOME_M>
<PHARMA_REV_M>2.86875513</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.286541273</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51350717</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4462078.47</REVENUE>
<PREV_YEAR_REV>3518005.39</PREV_YEAR_REV>
<BUDGET>4372836.9</BUDGET>
<GROSS_PROFIT>3557970.98</GROSS_PROFIT>
<EXPENSES>3968460.58</EXPENSES>
<NET_INCOME>493617.89</NET_INCOME>
<REVENUE_M>4.46207847</REVENUE_M>
<PROFIT_M>3.55797098</PROFIT_M>
<INCOME_M>0.49361789</INCOME_M>
<PHARMA_REV_M>4.46207847</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.55797098</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49361789</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4860872</REVENUE>
<PREV_YEAR_REV>3864949.51</PREV_YEAR_REV>
<BUDGET>4763654.56</BUDGET>
<GROSS_PROFIT>3508567.2</GROSS_PROFIT>
<EXPENSES>4272758.65</EXPENSES>
<NET_INCOME>588113.35</NET_INCOME>
<REVENUE_M>4.860872</REVENUE_M>
<PROFIT_M>3.5085672</PROFIT_M>
<INCOME_M>0.58811335</INCOME_M>
<PHARMA_REV_M>4.860872</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.5085672</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58811335</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>13331042</REVENUE>
<PREV_YEAR_REV>9310787.36</PREV_YEAR_REV>
<BUDGET>1.042455864E7</BUDGET>
<GROSS_PROFIT>9552068.41</GROSS_PROFIT>
<EXPENSES>9835344.46</EXPENSES>
<NET_INCOME>1495697.54</NET_INCOME>
<REVENUE_M>13.331042</REVENUE_M>
<PROFIT_M>9.55206841</PROFIT_M>
<INCOME_M>1.49569754</INCOME_M>
<PHARMA_REV_M>13.331042</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.55206841</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.49569754</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.459015247E7</REVENUE>
<PREV_YEAR_REV>2.097752029E7</PREV_YEAR_REV>
<BUDGET>1.342294028E7</BUDGET>
<GROSS_PROFIT>1.223678119E7</GROSS_PROFIT>
<EXPENSES>1.317669798E7</EXPENSES>
<NET_INCOME>1413454.49</NET_INCOME>
<REVENUE_M>14.59015247</REVENUE_M>
<PROFIT_M>12.23678119</PROFIT_M>
<INCOME_M>1.41345449</INCOME_M>
<PHARMA_REV_M>14.59015247</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.23678119</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.41345449</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>4843268.59</REVENUE>
<PREV_YEAR_REV>6773802.23</PREV_YEAR_REV>
<BUDGET>4455807.11</BUDGET>
<GROSS_PROFIT>4058659.08</GROSS_PROFIT>
<EXPENSES>3976323.52</EXPENSES>
<NET_INCOME>866945.08</NET_INCOME>
<REVENUE_M>4.84326859</REVENUE_M>
<PROFIT_M>4.05865908</PROFIT_M>
<INCOME_M>0.86694508</INCOME_M>
<PHARMA_REV_M>4.84326859</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.05865908</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.86694508</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.180814163E7</REVENUE>
<PREV_YEAR_REV>9589122.73</PREV_YEAR_REV>
<BUDGET>1.08634903E7</BUDGET>
<GROSS_PROFIT>9913672.901</GROSS_PROFIT>
<EXPENSES>9777141.27</EXPENSES>
<NET_INCOME>2031000.36</NET_INCOME>
<REVENUE_M>11.80814163</REVENUE_M>
<PROFIT_M>9.913672901</PROFIT_M>
<INCOME_M>2.03100036</INCOME_M>
<PHARMA_REV_M>11.80814163</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.913672901</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.03100036</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>3679090.75</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>3384763.49</BUDGET>
<GROSS_PROFIT>2758214.331</GROSS_PROFIT>
<EXPENSES>3182413.5</EXPENSES>
<NET_INCOME>496677.25</NET_INCOME>
<REVENUE_M>3.67909075</REVENUE_M>
<PROFIT_M>2.758214331</PROFIT_M>
<INCOME_M>0.49667725</INCOME_M>
<PHARMA_REV_M>3.67909075</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.758214331</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49667725</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>3450324.5</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>3174298.54</BUDGET>
<GROSS_PROFIT>2805803.882</GROSS_PROFIT>
<EXPENSES>3098391.4</EXPENSES>
<NET_INCOME>351933.1</NET_INCOME>
<REVENUE_M>3.4503245</REVENUE_M>
<PROFIT_M>2.805803882</PROFIT_M>
<INCOME_M>0.3519331</INCOME_M>
<PHARMA_REV_M>3.4503245</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.805803882</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3519331</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>4695178.25</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>4319563.99</BUDGET>
<GROSS_PROFIT>4084805.08</GROSS_PROFIT>
<EXPENSES>4183403.82</EXPENSES>
<NET_INCOME>511774.43</NET_INCOME>
<REVENUE_M>4.69517825</REVENUE_M>
<PROFIT_M>4.08480508</PROFIT_M>
<INCOME_M>0.51177443</INCOME_M>
<PHARMA_REV_M>4.69517825</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.08480508</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51177443</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3087734.42</REVENUE>
<PREV_YEAR_REV>2428667.05</PREV_YEAR_REV>
<BUDGET>2943163.5</BUDGET>
<GROSS_PROFIT>2644582.778</GROSS_PROFIT>
<EXPENSES>2680153.48</EXPENSES>
<NET_INCOME>407580.94</NET_INCOME>
<REVENUE_M>3.08773442</REVENUE_M>
<PROFIT_M>2.644582778</PROFIT_M>
<INCOME_M>0.40758094</INCOME_M>
<PHARMA_REV_M>3.08773442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.644582778</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40758094</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3086084.42</REVENUE>
<PREV_YEAR_REV>2459874.24</PREV_YEAR_REV>
<BUDGET>2941612.5</BUDGET>
<GROSS_PROFIT>2275058.353</GROSS_PROFIT>
<EXPENSES>2687979.53</EXPENSES>
<NET_INCOME>398104.89</NET_INCOME>
<REVENUE_M>3.08608442</REVENUE_M>
<PROFIT_M>2.275058353</PROFIT_M>
<INCOME_M>0.39810489</INCOME_M>
<PHARMA_REV_M>3.08608442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.275058353</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39810489</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6209237.59</REVENUE>
<PREV_YEAR_REV>4958807.02</PREV_YEAR_REV>
<BUDGET>5918069.63</BUDGET>
<GROSS_PROFIT>4847848.003</GROSS_PROFIT>
<EXPENSES>5457047.43</EXPENSES>
<NET_INCOME>752190.17</NET_INCOME>
<REVENUE_M>6.20923759</REVENUE_M>
<PROFIT_M>4.847848003</PROFIT_M>
<INCOME_M>0.75219017</INCOME_M>
<PHARMA_REV_M>6.20923759</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.847848003</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75219017</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7289650.09</REVENUE>
<PREV_YEAR_REV>5927192.09</PREV_YEAR_REV>
<BUDGET>6933657.38</BUDGET>
<GROSS_PROFIT>5918934.787</GROSS_PROFIT>
<EXPENSES>6309563.51</EXPENSES>
<NET_INCOME>980086.58</NET_INCOME>
<REVENUE_M>7.28965009</REVENUE_M>
<PROFIT_M>5.918934787</PROFIT_M>
<INCOME_M>0.98008658</INCOME_M>
<PHARMA_REV_M>7.28965009</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.918934787</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.98008658</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3658896.92</REVENUE>
<PREV_YEAR_REV>2930376.12</PREV_YEAR_REV>
<BUDGET>3480056.25</BUDGET>
<GROSS_PROFIT>3058837.826</GROSS_PROFIT>
<EXPENSES>3003954.37</EXPENSES>
<NET_INCOME>654942.55</NET_INCOME>
<REVENUE_M>3.65889692</REVENUE_M>
<PROFIT_M>3.058837826</PROFIT_M>
<INCOME_M>0.65494255</INCOME_M>
<PHARMA_REV_M>3.65889692</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.058837826</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65494255</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1288777.96</REVENUE>
<PREV_YEAR_REV>1188492.92</PREV_YEAR_REV>
<BUDGET>1131948.56</BUDGET>
<GROSS_PROFIT>983144.265</GROSS_PROFIT>
<EXPENSES>1118659.27</EXPENSES>
<NET_INCOME>170118.69</NET_INCOME>
<REVENUE_M>1.28877796</REVENUE_M>
<PROFIT_M>0.983144265</PROFIT_M>
<INCOME_M>0.17011869</INCOME_M>
<PHARMA_REV_M>1.28877796</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.983144265</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17011869</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2291163.58</REVENUE>
<PREV_YEAR_REV>2132279.67</PREV_YEAR_REV>
<BUDGET>2015906.92</BUDGET>
<GROSS_PROFIT>1779941.583</GROSS_PROFIT>
<EXPENSES>1950692.72</EXPENSES>
<NET_INCOME>340470.86</NET_INCOME>
<REVENUE_M>2.29116358</REVENUE_M>
<PROFIT_M>1.779941583</PROFIT_M>
<INCOME_M>0.34047086</INCOME_M>
<PHARMA_REV_M>2.29116358</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.779941583</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34047086</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3768205.75</REVENUE>
<PREV_YEAR_REV>3549742.58</PREV_YEAR_REV>
<BUDGET>3170905.69</BUDGET>
<GROSS_PROFIT>3235443.86</GROSS_PROFIT>
<EXPENSES>3403998.41</EXPENSES>
<NET_INCOME>364207.36</NET_INCOME>
<REVENUE_M>3.76820575</REVENUE_M>
<PROFIT_M>3.23544386</PROFIT_M>
<INCOME_M>0.36420736</INCOME_M>
<PHARMA_REV_M>3.76820575</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.23544386</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36420736</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1036863.97</REVENUE>
<PREV_YEAR_REV>972275.7</PREV_YEAR_REV>
<BUDGET>909297.39</BUDGET>
<GROSS_PROFIT>835712.36</GROSS_PROFIT>
<EXPENSES>961172.9</EXPENSES>
<NET_INCOME>75691.07</NET_INCOME>
<REVENUE_M>1.03686397</REVENUE_M>
<PROFIT_M>0.83571236</PROFIT_M>
<INCOME_M>0.07569107</INCOME_M>
<PHARMA_REV_M>1.03686397</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.83571236</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.07569107</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.013982646E7</REVENUE>
<PREV_YEAR_REV>9368423.85</PREV_YEAR_REV>
<BUDGET>9734233.41</BUDGET>
<GROSS_PROFIT>7495926.58</GROSS_PROFIT>
<EXPENSES>8776866.69</EXPENSES>
<NET_INCOME>1362959.77</NET_INCOME>
<REVENUE_M>10.13982646</REVENUE_M>
<PROFIT_M>7.49592658</PROFIT_M>
<INCOME_M>1.36295977</INCOME_M>
<PHARMA_REV_M>10.13982646</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.49592658</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.36295977</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5083185.49</REVENUE>
<PREV_YEAR_REV>4736961.01</PREV_YEAR_REV>
<BUDGET>4879858.07</BUDGET>
<GROSS_PROFIT>3776806.82</GROSS_PROFIT>
<EXPENSES>4712112.95</EXPENSES>
<NET_INCOME>371072.54</NET_INCOME>
<REVENUE_M>5.08318549</REVENUE_M>
<PROFIT_M>3.77680682</PROFIT_M>
<INCOME_M>0.37107254</INCOME_M>
<PHARMA_REV_M>5.08318549</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.77680682</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37107254</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>12833605</REVENUE>
<PREV_YEAR_REV>1.206418577E7</PREV_YEAR_REV>
<BUDGET>1.232026081E7</BUDGET>
<GROSS_PROFIT>8670717.405</GROSS_PROFIT>
<EXPENSES>1.092542439E7</EXPENSES>
<NET_INCOME>1908180.62</NET_INCOME>
<REVENUE_M>12.833605</REVENUE_M>
<PROFIT_M>8.670717405</PROFIT_M>
<INCOME_M>1.90818062</INCOME_M>
<PHARMA_REV_M>12.833605</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.670717405</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.90818062</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.131422763E7</REVENUE>
<PREV_YEAR_REV>1.049371548E7</PREV_YEAR_REV>
<BUDGET>1.086165852E7</BUDGET>
<GROSS_PROFIT>7623746.145</GROSS_PROFIT>
<EXPENSES>9630878.34</EXPENSES>
<NET_INCOME>1683349.28</NET_INCOME>
<REVENUE_M>11.31422763</REVENUE_M>
<PROFIT_M>7.623746145</PROFIT_M>
<INCOME_M>1.68334928</INCOME_M>
<PHARMA_REV_M>11.31422763</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.623746145</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.68334928</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6162460.58</REVENUE>
<PREV_YEAR_REV>5839755.68</PREV_YEAR_REV>
<BUDGET>5915962.16</BUDGET>
<GROSS_PROFIT>4568478.521</GROSS_PROFIT>
<EXPENSES>5490752.38</EXPENSES>
<NET_INCOME>671708.2</NET_INCOME>
<REVENUE_M>6.16246058</REVENUE_M>
<PROFIT_M>4.568478521</PROFIT_M>
<INCOME_M>0.6717082</INCOME_M>
<PHARMA_REV_M>6.16246058</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.568478521</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6717082</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7653488.32</REVENUE>
<PREV_YEAR_REV>7074445</PREV_YEAR_REV>
<BUDGET>7347348.79</BUDGET>
<GROSS_PROFIT>5939106.94</GROSS_PROFIT>
<EXPENSES>6819258.09</EXPENSES>
<NET_INCOME>834230.23</NET_INCOME>
<REVENUE_M>7.65348832</REVENUE_M>
<PROFIT_M>5.93910694</PROFIT_M>
<INCOME_M>0.83423023</INCOME_M>
<PHARMA_REV_M>7.65348832</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.93910694</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83423023</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1946722.3</REVENUE>
<PREV_YEAR_REV>1844797.25</PREV_YEAR_REV>
<BUDGET>1833827.25</BUDGET>
<GROSS_PROFIT>1203950.4</GROSS_PROFIT>
<EXPENSES>1635246.73</EXPENSES>
<NET_INCOME>311475.57</NET_INCOME>
<REVENUE_M>1.9467223</REVENUE_M>
<PROFIT_M>1.2039504</PROFIT_M>
<INCOME_M>0.31147557</INCOME_M>
<PHARMA_REV_M>1.9467223</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.2039504</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31147557</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2039751.49</REVENUE>
<PREV_YEAR_REV>1901103.97</PREV_YEAR_REV>
<BUDGET>1929926.01</BUDGET>
<GROSS_PROFIT>1194631.453</GROSS_PROFIT>
<EXPENSES>1776623.54</EXPENSES>
<NET_INCOME>263127.94</NET_INCOME>
<REVENUE_M>2.03975149</REVENUE_M>
<PROFIT_M>1.194631453</PROFIT_M>
<INCOME_M>0.26312794</INCOME_M>
<PHARMA_REV_M>2.03975149</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.194631453</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26312794</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4108945.26</REVENUE>
<PREV_YEAR_REV>3850516.52</PREV_YEAR_REV>
<BUDGET>3808419.43</BUDGET>
<GROSS_PROFIT>2397200.085</GROSS_PROFIT>
<EXPENSES>3497502.16</EXPENSES>
<NET_INCOME>611443.1</NET_INCOME>
<REVENUE_M>4.10894526</REVENUE_M>
<PROFIT_M>2.397200085</PROFIT_M>
<INCOME_M>0.6114431</INCOME_M>
<PHARMA_REV_M>4.10894526</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.397200085</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6114431</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>6097266.35</REVENUE>
<PREV_YEAR_REV>5701739.84</PREV_YEAR_REV>
<BUDGET>5646110.44</BUDGET>
<GROSS_PROFIT>4194000.844</GROSS_PROFIT>
<EXPENSES>5506077.35</EXPENSES>
<NET_INCOME>591189</NET_INCOME>
<REVENUE_M>6.09726635</REVENUE_M>
<PROFIT_M>4.194000844</PROFIT_M>
<INCOME_M>0.591189</INCOME_M>
<PHARMA_REV_M>6.09726635</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.194000844</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.591189</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>6094000.47</REVENUE>
<PREV_YEAR_REV>5735443.82</PREV_YEAR_REV>
<BUDGET>5716221.09</BUDGET>
<GROSS_PROFIT>4061279.23</GROSS_PROFIT>
<EXPENSES>5503262.97</EXPENSES>
<NET_INCOME>590737.5</NET_INCOME>
<REVENUE_M>6.09400047</REVENUE_M>
<PROFIT_M>4.06127923</PROFIT_M>
<INCOME_M>0.5907375</INCOME_M>
<PHARMA_REV_M>6.09400047</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.06127923</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5907375</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1487750.82</REVENUE>
<PREV_YEAR_REV>1366877.81</PREV_YEAR_REV>
<BUDGET>1450040.57</BUDGET>
<GROSS_PROFIT>929145.0219</GROSS_PROFIT>
<EXPENSES>1336000.23</EXPENSES>
<NET_INCOME>151750.58</NET_INCOME>
<REVENUE_M>1.48775082</REVENUE_M>
<PROFIT_M>0.929145022</PROFIT_M>
<INCOME_M>0.15175058</INCOME_M>
<PHARMA_REV_M>1.48775082</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.929145022</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15175058</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1508644.78</REVENUE>
<PREV_YEAR_REV>1420195.03</PREV_YEAR_REV>
<BUDGET>1743571.68</BUDGET>
<GROSS_PROFIT>1026481.905</GROSS_PROFIT>
<EXPENSES>1314029.6</EXPENSES>
<NET_INCOME>194615.18</NET_INCOME>
<REVENUE_M>1.50864478</REVENUE_M>
<PROFIT_M>1.026481905</PROFIT_M>
<INCOME_M>0.19461518</INCOME_M>
<PHARMA_REV_M>1.50864478</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.026481905</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19461518</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2862209.89</REVENUE>
<PREV_YEAR_REV>2663179.74</PREV_YEAR_REV>
<BUDGET>3392753.33</BUDGET>
<GROSS_PROFIT>1832178.789</GROSS_PROFIT>
<EXPENSES>2516860.64</EXPENSES>
<NET_INCOME>345349.25</NET_INCOME>
<REVENUE_M>2.86220989</REVENUE_M>
<PROFIT_M>1.832178789</PROFIT_M>
<INCOME_M>0.34534925</INCOME_M>
<PHARMA_REV_M>2.86220989</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.832178789</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34534925</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4409797.88</REVENUE>
<PREV_YEAR_REV>4124399</PREV_YEAR_REV>
<BUDGET>5092154.93</BUDGET>
<GROSS_PROFIT>3189100.977</GROSS_PROFIT>
<EXPENSES>3981471.59</EXPENSES>
<NET_INCOME>428326.29</NET_INCOME>
<REVENUE_M>4.40979788</REVENUE_M>
<PROFIT_M>3.189100977</PROFIT_M>
<INCOME_M>0.42832629</INCOME_M>
<PHARMA_REV_M>4.40979788</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.189100977</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42832629</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2880552.63</REVENUE>
<PREV_YEAR_REV>2695913.24</PREV_YEAR_REV>
<BUDGET>3375560.83</BUDGET>
<GROSS_PROFIT>1748449.773</GROSS_PROFIT>
<EXPENSES>2452870.19</EXPENSES>
<NET_INCOME>427682.44</NET_INCOME>
<REVENUE_M>2.88055263</REVENUE_M>
<PROFIT_M>1.748449773</PROFIT_M>
<INCOME_M>0.42768244</INCOME_M>
<PHARMA_REV_M>2.88055263</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.748449773</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42768244</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1450149.58</REVENUE>
<PREV_YEAR_REV>1378495.39</PREV_YEAR_REV>
<BUDGET>1676720.65</BUDGET>
<GROSS_PROFIT>1112264.73</GROSS_PROFIT>
<EXPENSES>1190572.8</EXPENSES>
<NET_INCOME>259576.77</NET_INCOME>
<REVENUE_M>1.45014958</REVENUE_M>
<PROFIT_M>1.11226473</PROFIT_M>
<INCOME_M>0.25957677</INCOME_M>
<PHARMA_REV_M>1.45014958</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.11226473</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25957677</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2935888.03</REVENUE>
<PREV_YEAR_REV>2707119.31</PREV_YEAR_REV>
<BUDGET>3376122.25</BUDGET>
<GROSS_PROFIT>1764520.358</GROSS_PROFIT>
<EXPENSES>2498753.28</EXPENSES>
<NET_INCOME>437134.76</NET_INCOME>
<REVENUE_M>2.93588803</REVENUE_M>
<PROFIT_M>1.764520358</PROFIT_M>
<INCOME_M>0.43713476</INCOME_M>
<PHARMA_REV_M>2.93588803</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.764520358</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43713476</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8089515.4</REVENUE>
<PREV_YEAR_REV>7404378.15</PREV_YEAR_REV>
<BUDGET>8898466.94</BUDGET>
<GROSS_PROFIT>5961087.313</GROSS_PROFIT>
<EXPENSES>7104790.89</EXPENSES>
<NET_INCOME>984724.49</NET_INCOME>
<REVENUE_M>8.0895154</REVENUE_M>
<PROFIT_M>5.961087313</PROFIT_M>
<INCOME_M>0.98472449</INCOME_M>
<PHARMA_REV_M>8.0895154</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.961087313</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.98472449</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1466565.6</REVENUE>
<PREV_YEAR_REV>1379569.92</PREV_YEAR_REV>
<BUDGET>1694688.75</BUDGET>
<GROSS_PROFIT>1124855.81</GROSS_PROFIT>
<EXPENSES>1359506.31</EXPENSES>
<NET_INCOME>107059.29</NET_INCOME>
<REVENUE_M>1.4665656</REVENUE_M>
<PROFIT_M>1.12485581</PROFIT_M>
<INCOME_M>0.10705929</INCOME_M>
<PHARMA_REV_M>1.4665656</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.12485581</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10705929</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1500213.13</REVENUE>
<PREV_YEAR_REV>1396833.48</PREV_YEAR_REV>
<BUDGET>1693351.73</BUDGET>
<GROSS_PROFIT>995037.3581</GROSS_PROFIT>
<EXPENSES>1297684.35</EXPENSES>
<NET_INCOME>202528.77</NET_INCOME>
<REVENUE_M>1.50021313</REVENUE_M>
<PROFIT_M>0.995037358</PROFIT_M>
<INCOME_M>0.20252877</INCOME_M>
<PHARMA_REV_M>1.50021313</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.995037358</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20252877</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1536602.48</REVENUE>
<PREV_YEAR_REV>1413188.71</PREV_YEAR_REV>
<BUDGET>1693351.73</BUDGET>
<GROSS_PROFIT>1090099.605</GROSS_PROFIT>
<EXPENSES>1272306.85</EXPENSES>
<NET_INCOME>264295.63</NET_INCOME>
<REVENUE_M>1.53660248</REVENUE_M>
<PROFIT_M>1.090099605</PROFIT_M>
<INCOME_M>0.26429563</INCOME_M>
<PHARMA_REV_M>1.53660248</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.090099605</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26429563</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1421664.84</REVENUE>
<PREV_YEAR_REV>1319581.98</PREV_YEAR_REV>
<BUDGET>1645491.23</BUDGET>
<GROSS_PROFIT>891721.5057</GROSS_PROFIT>
<EXPENSES>1276655.03</EXPENSES>
<NET_INCOME>145009.81</NET_INCOME>
<REVENUE_M>1.42166484</REVENUE_M>
<PROFIT_M>0.891721506</PROFIT_M>
<INCOME_M>0.14500981</INCOME_M>
<PHARMA_REV_M>1.42166484</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.891721506</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14500981</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2914583.29</REVENUE>
<PREV_YEAR_REV>2731759.12</PREV_YEAR_REV>
<BUDGET>3349508.88</BUDGET>
<GROSS_PROFIT>1926343.947</GROSS_PROFIT>
<EXPENSES>2528942.92</EXPENSES>
<NET_INCOME>385640.36</NET_INCOME>
<REVENUE_M>2.91458329</REVENUE_M>
<PROFIT_M>1.926343947</PROFIT_M>
<INCOME_M>0.38564036</INCOME_M>
<PHARMA_REV_M>2.91458329</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.926343947</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38564036</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2352194.67</REVENUE>
<PREV_YEAR_REV>2174748.34</PREV_YEAR_REV>
<BUDGET>2444776.59</BUDGET>
<GROSS_PROFIT>1645877.319</GROSS_PROFIT>
<EXPENSES>2092976.27</EXPENSES>
<NET_INCOME>259218.4</NET_INCOME>
<REVENUE_M>2.35219467</REVENUE_M>
<PROFIT_M>1.645877319</PROFIT_M>
<INCOME_M>0.2592184</INCOME_M>
<PHARMA_REV_M>2.35219467</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.645877319</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2592184</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1234648.86</REVENUE>
<PREV_YEAR_REV>1172962.75</PREV_YEAR_REV>
<BUDGET>1214588.19</BUDGET>
<GROSS_PROFIT>903145.639</GROSS_PROFIT>
<EXPENSES>1071675.21</EXPENSES>
<NET_INCOME>162973.65</NET_INCOME>
<REVENUE_M>1.23464886</REVENUE_M>
<PROFIT_M>0.903145639</PROFIT_M>
<INCOME_M>0.16297365</INCOME_M>
<PHARMA_REV_M>1.23464886</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.903145639</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16297365</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3450974.5</REVENUE>
<PREV_YEAR_REV>3255687.16</PREV_YEAR_REV>
<BUDGET>3474865.06</BUDGET>
<GROSS_PROFIT>2337180.937</GROSS_PROFIT>
<EXPENSES>3118635.86</EXPENSES>
<NET_INCOME>332338.63</NET_INCOME>
<REVENUE_M>3.4509745</REVENUE_M>
<PROFIT_M>2.337180937</PROFIT_M>
<INCOME_M>0.33233863</INCOME_M>
<PHARMA_REV_M>3.4509745</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.337180937</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33233863</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6303401.27</REVENUE>
<PREV_YEAR_REV>5669852.01</PREV_YEAR_REV>
<BUDGET>6051265.22</BUDGET>
<GROSS_PROFIT>4343182.147</GROSS_PROFIT>
<EXPENSES>5490262.51</EXPENSES>
<NET_INCOME>813138.76</NET_INCOME>
<REVENUE_M>6.30340127</REVENUE_M>
<PROFIT_M>4.343182147</PROFIT_M>
<INCOME_M>0.81313876</INCOME_M>
<PHARMA_REV_M>6.30340127</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.343182147</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.81313876</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.171088231E7</REVENUE>
<PREV_YEAR_REV>1.060244171E7</PREV_YEAR_REV>
<BUDGET>1.124244702E7</BUDGET>
<GROSS_PROFIT>7950341.441</GROSS_PROFIT>
<EXPENSES>1.02914302E7</EXPENSES>
<NET_INCOME>1419452.11</NET_INCOME>
<REVENUE_M>11.71088231</REVENUE_M>
<PROFIT_M>7.950341441</PROFIT_M>
<INCOME_M>1.41945211</INCOME_M>
<PHARMA_REV_M>11.71088231</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.950341441</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.41945211</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7189468.57</REVENUE>
<PREV_YEAR_REV>6530062.83</PREV_YEAR_REV>
<BUDGET>6901889.83</BUDGET>
<GROSS_PROFIT>4716291.38</GROSS_PROFIT>
<EXPENSES>6240458.72</EXPENSES>
<NET_INCOME>949009.85</NET_INCOME>
<REVENUE_M>7.18946857</REVENUE_M>
<PROFIT_M>4.71629138</PROFIT_M>
<INCOME_M>0.94900985</INCOME_M>
<PHARMA_REV_M>7.18946857</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.71629138</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.94900985</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7575526.32</REVENUE>
<PREV_YEAR_REV>6978193</PREV_YEAR_REV>
<BUDGET>7272505.27</BUDGET>
<GROSS_PROFIT>5249839.743</GROSS_PROFIT>
<EXPENSES>6598283.43</EXPENSES>
<NET_INCOME>977242.9</NET_INCOME>
<REVENUE_M>7.57552632</REVENUE_M>
<PROFIT_M>5.249839743</PROFIT_M>
<INCOME_M>0.9772429</INCOME_M>
<PHARMA_REV_M>7.57552632</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.249839743</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.9772429</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.242452835E7</REVENUE>
<PREV_YEAR_REV>1.126580527E7</PREV_YEAR_REV>
<BUDGET>1.192754722E7</BUDGET>
<GROSS_PROFIT>9413734.96</GROSS_PROFIT>
<EXPENSES>1.077449747E7</EXPENSES>
<NET_INCOME>1650030.88</NET_INCOME>
<REVENUE_M>12.42452835</REVENUE_M>
<PROFIT_M>9.41373496</PROFIT_M>
<INCOME_M>1.65003088</INCOME_M>
<PHARMA_REV_M>12.42452835</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.41373496</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.65003088</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6428400.66</REVENUE>
<PREV_YEAR_REV>5983636.92</PREV_YEAR_REV>
<BUDGET>6171264.63</BUDGET>
<GROSS_PROFIT>4671840.175</GROSS_PROFIT>
<EXPENSES>5322715.74</EXPENSES>
<NET_INCOME>1105684.91</NET_INCOME>
<REVENUE_M>6.42840066</REVENUE_M>
<PROFIT_M>4.671840175</PROFIT_M>
<INCOME_M>1.10568491</INCOME_M>
<PHARMA_REV_M>6.42840066</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.671840175</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.10568491</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7048141.99</REVENUE>
<PREV_YEAR_REV>6528414.88</PREV_YEAR_REV>
<BUDGET>6766216.31</BUDGET>
<GROSS_PROFIT>5074662.231</GROSS_PROFIT>
<EXPENSES>6096642.82</EXPENSES>
<NET_INCOME>951499.17</NET_INCOME>
<REVENUE_M>7.04814199</REVENUE_M>
<PROFIT_M>5.074662231</PROFIT_M>
<INCOME_M>0.95149917</INCOME_M>
<PHARMA_REV_M>7.04814199</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.074662231</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.95149917</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1608173.1</REVENUE>
<PREV_YEAR_REV>1439725.24</PREV_YEAR_REV>
<BUDGET>1742207.39</BUDGET>
<GROSS_PROFIT>1103681.157</GROSS_PROFIT>
<EXPENSES>1400718.77</EXPENSES>
<NET_INCOME>207454.33</NET_INCOME>
<REVENUE_M>1.6081731</REVENUE_M>
<PROFIT_M>1.103681157</PROFIT_M>
<INCOME_M>0.20745433</INCOME_M>
<PHARMA_REV_M>1.6081731</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.103681157</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20745433</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>1974502.46</REVENUE>
<PREV_YEAR_REV>1805556.54</PREV_YEAR_REV>
<BUDGET>1938443.21</BUDGET>
<GROSS_PROFIT>1445454.273</GROSS_PROFIT>
<EXPENSES>1658582.07</EXPENSES>
<NET_INCOME>315920.39</NET_INCOME>
<REVENUE_M>1.97450246</REVENUE_M>
<PROFIT_M>1.445454273</PROFIT_M>
<INCOME_M>0.31592039</INCOME_M>
<PHARMA_REV_M>1.97450246</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.445454273</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31592039</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4027709.17</REVENUE>
<PREV_YEAR_REV>3721945.08</PREV_YEAR_REV>
<BUDGET>4106546.71</BUDGET>
<GROSS_PROFIT>2746777.019</GROSS_PROFIT>
<EXPENSES>3485906.52</EXPENSES>
<NET_INCOME>541802.63</NET_INCOME>
<REVENUE_M>4.02770917</REVENUE_M>
<PROFIT_M>2.746777019</PROFIT_M>
<INCOME_M>0.54180263</INCOME_M>
<PHARMA_REV_M>4.02770917</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.746777019</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54180263</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1885593.01</REVENUE>
<PREV_YEAR_REV>1738691.01</PREV_YEAR_REV>
<BUDGET>2077287.43</BUDGET>
<GROSS_PROFIT>1262875.917</GROSS_PROFIT>
<EXPENSES>1747944.72</EXPENSES>
<NET_INCOME>137648.29</NET_INCOME>
<REVENUE_M>1.88559301</REVENUE_M>
<PROFIT_M>1.262875917</PROFIT_M>
<INCOME_M>0.13764829</INCOME_M>
<PHARMA_REV_M>1.88559301</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.262875917</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13764829</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>6045150.3</REVENUE>
<PREV_YEAR_REV>5582910.51</PREV_YEAR_REV>
<BUDGET>6146474.28</BUDGET>
<GROSS_PROFIT>4460389.493</GROSS_PROFIT>
<EXPENSES>5460300.86</EXPENSES>
<NET_INCOME>584849.45</NET_INCOME>
<REVENUE_M>6.0451503</REVENUE_M>
<PROFIT_M>4.460389493</PROFIT_M>
<INCOME_M>0.58484945</INCOME_M>
<PHARMA_REV_M>6.0451503</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.460389493</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58484945</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1831450.37</REVENUE>
<PREV_YEAR_REV>1672313.06</PREV_YEAR_REV>
<BUDGET>2005782.81</BUDGET>
<GROSS_PROFIT>1098760.34</GROSS_PROFIT>
<EXPENSES>1584204.57</EXPENSES>
<NET_INCOME>247245.8</NET_INCOME>
<REVENUE_M>1.83145037</REVENUE_M>
<PROFIT_M>1.09876034</PROFIT_M>
<INCOME_M>0.2472458</INCOME_M>
<PHARMA_REV_M>1.83145037</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.09876034</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2472458</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4025826.87</REVENUE>
<PREV_YEAR_REV>3658654.37</PREV_YEAR_REV>
<BUDGET>4195285.51</BUDGET>
<GROSS_PROFIT>2825827.854</GROSS_PROFIT>
<EXPENSES>3496582.69</EXPENSES>
<NET_INCOME>529244.18</NET_INCOME>
<REVENUE_M>4.02582687</REVENUE_M>
<PROFIT_M>2.825827854</PROFIT_M>
<INCOME_M>0.52924418</INCOME_M>
<PHARMA_REV_M>4.02582687</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.825827854</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52924418</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1402231.98</REVENUE>
<PREV_YEAR_REV>1306553.09</PREV_YEAR_REV>
<BUDGET>1822245.97</BUDGET>
<GROSS_PROFIT>902841.0779</GROSS_PROFIT>
<EXPENSES>1221344.05</EXPENSES>
<NET_INCOME>180887.93</NET_INCOME>
<REVENUE_M>1.40223198</REVENUE_M>
<PROFIT_M>0.902841078</PROFIT_M>
<INCOME_M>0.18088793</INCOME_M>
<PHARMA_REV_M>1.40223198</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.902841078</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18088793</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1467888.76</REVENUE>
<PREV_YEAR_REV>1324391</PREV_YEAR_REV>
<BUDGET>1871555.64</BUDGET>
<GROSS_PROFIT>989357.02</GROSS_PROFIT>
<EXPENSES>1233026.56</EXPENSES>
<NET_INCOME>234862.2</NET_INCOME>
<REVENUE_M>1.46788876</REVENUE_M>
<PROFIT_M>0.98935702</PROFIT_M>
<INCOME_M>0.2348622</INCOME_M>
<PHARMA_REV_M>1.46788876</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.98935702</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2348622</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2846817.64</REVENUE>
<PREV_YEAR_REV>2597784.72</PREV_YEAR_REV>
<BUDGET>3658211.47</BUDGET>
<GROSS_PROFIT>1992024.1</GROSS_PROFIT>
<EXPENSES>2467422.98</EXPENSES>
<NET_INCOME>379394.66</NET_INCOME>
<REVENUE_M>2.84681764</REVENUE_M>
<PROFIT_M>1.9920241</PROFIT_M>
<INCOME_M>0.37939466</INCOME_M>
<PHARMA_REV_M>2.84681764</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.9920241</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37939466</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1342189.41</REVENUE>
<PREV_YEAR_REV>1212752.35</PREV_YEAR_REV>
<BUDGET>1760960.17</BUDGET>
<GROSS_PROFIT>881335.2569</GROSS_PROFIT>
<EXPENSES>1160993.84</EXPENSES>
<NET_INCOME>181195.57</NET_INCOME>
<REVENUE_M>1.34218941</REVENUE_M>
<PROFIT_M>0.881335257</PROFIT_M>
<INCOME_M>0.18119557</INCOME_M>
<PHARMA_REV_M>1.34218941</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.881335257</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18119557</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1353677.83</REVENUE>
<PREV_YEAR_REV>1220222.14</PREV_YEAR_REV>
<BUDGET>1651678.75</BUDGET>
<GROSS_PROFIT>862563.519</GROSS_PROFIT>
<EXPENSES>1170931.33</EXPENSES>
<NET_INCOME>182746.51</NET_INCOME>
<REVENUE_M>1.35367783</REVENUE_M>
<PROFIT_M>0.862563519</PROFIT_M>
<INCOME_M>0.18274651</INCOME_M>
<PHARMA_REV_M>1.35367783</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.862563519</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18274651</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2826596.53</REVENUE>
<PREV_YEAR_REV>2618651.65</PREV_YEAR_REV>
<BUDGET>3602520.17</BUDGET>
<GROSS_PROFIT>1983068.6</GROSS_PROFIT>
<EXPENSES>2453220.79</EXPENSES>
<NET_INCOME>373375.74</NET_INCOME>
<REVENUE_M>2.82659653</REVENUE_M>
<PROFIT_M>1.9830686</PROFIT_M>
<INCOME_M>0.37337574</INCOME_M>
<PHARMA_REV_M>2.82659653</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.9830686</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37337574</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>993202.32</REVENUE>
<PREV_YEAR_REV>889998.13</PREV_YEAR_REV>
<BUDGET>1129632.91</BUDGET>
<GROSS_PROFIT>746888.14</GROSS_PROFIT>
<EXPENSES>815419.1</EXPENSES>
<NET_INCOME>177783.21</NET_INCOME>
<REVENUE_M>0.99320232</REVENUE_M>
<PROFIT_M>0.74688814</PROFIT_M>
<INCOME_M>0.17778321</INCOME_M>
<PHARMA_REV_M>0.99320232</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.74688814</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17778321</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1064397.3</REVENUE>
<PREV_YEAR_REV>988803.29</PREV_YEAR_REV>
<BUDGET>1165343.27</BUDGET>
<GROSS_PROFIT>697409.0771</GROSS_PROFIT>
<EXPENSES>955828.78</EXPENSES>
<NET_INCOME>108568.52</NET_INCOME>
<REVENUE_M>1.0643973</REVENUE_M>
<PROFIT_M>0.697409077</PROFIT_M>
<INCOME_M>0.10856852</INCOME_M>
<PHARMA_REV_M>1.0643973</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.697409077</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10856852</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2263051.53</REVENUE>
<PREV_YEAR_REV>2064129.19</PREV_YEAR_REV>
<BUDGET>2503942.22</BUDGET>
<GROSS_PROFIT>1694474.16</GROSS_PROFIT>
<EXPENSES>1962345.33</EXPENSES>
<NET_INCOME>300706.2</NET_INCOME>
<REVENUE_M>2.26305153</REVENUE_M>
<PROFIT_M>1.69447416</PROFIT_M>
<INCOME_M>0.3007062</INCOME_M>
<PHARMA_REV_M>2.26305153</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.69447416</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3007062</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1053561</REVENUE>
<PREV_YEAR_REV>945287.74</PREV_YEAR_REV>
<BUDGET>1232035.19</BUDGET>
<GROSS_PROFIT>784902.95</GROSS_PROFIT>
<EXPENSES>938722.85</EXPENSES>
<NET_INCOME>114838.15</NET_INCOME>
<REVENUE_M>1.053561</REVENUE_M>
<PROFIT_M>0.78490295</PROFIT_M>
<INCOME_M>0.11483815</INCOME_M>
<PHARMA_REV_M>1.053561</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.78490295</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11483815</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>2.49341957E7</REVENUE>
<PREV_YEAR_REV>2.342224504E7</PREV_YEAR_REV>
<BUDGET>2.393682787E7</BUDGET>
<GROSS_PROFIT>1.868820935E7</GROSS_PROFIT>
<EXPENSES>2.171650794E7</EXPENSES>
<NET_INCOME>3217687.76</NET_INCOME>
<REVENUE_M>24.9341957</REVENUE_M>
<PROFIT_M>18.68820935</PROFIT_M>
<INCOME_M>3.21768776</INCOME_M>
<PHARMA_REV_M>24.9341957</PHARMA_REV_M>
<PHARMA_PROFIT_M>18.68820935</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>3.21768776</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6153198.19</REVENUE>
<PREV_YEAR_REV>5651720.99</PREV_YEAR_REV>
<BUDGET>5907070.26</BUDGET>
<GROSS_PROFIT>5168686.48</GROSS_PROFIT>
<EXPENSES>5704014.72</EXPENSES>
<NET_INCOME>449183.47</NET_INCOME>
<REVENUE_M>6.15319819</REVENUE_M>
<PROFIT_M>5.16868648</PROFIT_M>
<INCOME_M>0.44918347</INCOME_M>
<PHARMA_REV_M>6.15319819</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.16868648</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44918347</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5037898.68</REVENUE>
<PREV_YEAR_REV>4643780.99</PREV_YEAR_REV>
<BUDGET>4836382.73</BUDGET>
<GROSS_PROFIT>4208005.632</GROSS_PROFIT>
<EXPENSES>4136114.81</EXPENSES>
<NET_INCOME>901783.86</NET_INCOME>
<REVENUE_M>5.03789868</REVENUE_M>
<PROFIT_M>4.208005632</PROFIT_M>
<INCOME_M>0.90178386</INCOME_M>
<PHARMA_REV_M>5.03789868</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.208005632</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.90178386</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5416578.07</REVENUE>
<PREV_YEAR_REV>5128072.7</PREV_YEAR_REV>
<BUDGET>5199914.95</BUDGET>
<GROSS_PROFIT>4663673.72</GROSS_PROFIT>
<EXPENSES>4447010.6</EXPENSES>
<NET_INCOME>969567.48</NET_INCOME>
<REVENUE_M>5.41657807</REVENUE_M>
<PROFIT_M>4.66367372</PROFIT_M>
<INCOME_M>0.96956748</INCOME_M>
<PHARMA_REV_M>5.41657807</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.66367372</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.96956748</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6990460.46</REVENUE>
<PREV_YEAR_REV>6516028.43</PREV_YEAR_REV>
<BUDGET>6710842.04</BUDGET>
<GROSS_PROFIT>5184125.478</GROSS_PROFIT>
<EXPENSES>6046748.29</EXPENSES>
<NET_INCOME>943712.16</NET_INCOME>
<REVENUE_M>6.99046046</REVENUE_M>
<PROFIT_M>5.184125478</PROFIT_M>
<INCOME_M>0.94371216</INCOME_M>
<PHARMA_REV_M>6.99046046</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.184125478</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.94371216</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2282139.67</REVENUE>
<PREV_YEAR_REV>2095551.74</PREV_YEAR_REV>
<BUDGET>1786410.41</BUDGET>
<GROSS_PROFIT>1888356.468</GROSS_PROFIT>
<EXPENSES>1873636.67</EXPENSES>
<NET_INCOME>408503</NET_INCOME>
<REVENUE_M>2.28213967</REVENUE_M>
<PROFIT_M>1.888356468</PROFIT_M>
<INCOME_M>0.408503</INCOME_M>
<PHARMA_REV_M>2.28213967</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.888356468</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.408503</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3984538.19</REVENUE>
<PREV_YEAR_REV>3723506.55</PREV_YEAR_REV>
<BUDGET>3048131.56</BUDGET>
<GROSS_PROFIT>3046251.572</GROSS_PROFIT>
<EXPENSES>3397411.28</EXPENSES>
<NET_INCOME>587126.91</NET_INCOME>
<REVENUE_M>3.98453819</REVENUE_M>
<PROFIT_M>3.046251572</PROFIT_M>
<INCOME_M>0.58712691</INCOME_M>
<PHARMA_REV_M>3.98453819</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.046251572</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58712691</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2528058.28</REVENUE>
<PREV_YEAR_REV>2402320.81</PREV_YEAR_REV>
<BUDGET>1833909.29</BUDGET>
<GROSS_PROFIT>2116717.913</GROSS_PROFIT>
<EXPENSES>2075535.85</EXPENSES>
<NET_INCOME>452522.43</NET_INCOME>
<REVENUE_M>2.52805828</REVENUE_M>
<PROFIT_M>2.116717913</PROFIT_M>
<INCOME_M>0.45252243</INCOME_M>
<PHARMA_REV_M>2.52805828</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.116717913</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45252243</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2339884.19</REVENUE>
<PREV_YEAR_REV>2211631.67</PREV_YEAR_REV>
<BUDGET>1738459.16</BUDGET>
<GROSS_PROFIT>1869593.213</GROSS_PROFIT>
<EXPENSES>2023999.83</EXPENSES>
<NET_INCOME>315884.37</NET_INCOME>
<REVENUE_M>2.33988419</REVENUE_M>
<PROFIT_M>1.869593213</PROFIT_M>
<INCOME_M>0.31588437</INCOME_M>
<PHARMA_REV_M>2.33988419</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.869593213</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31588437</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2587509.09</REVENUE>
<PREV_YEAR_REV>2414734.82</PREV_YEAR_REV>
<BUDGET>1833909.29</BUDGET>
<GROSS_PROFIT>2107825.014</GROSS_PROFIT>
<EXPENSES>2142457.53</EXPENSES>
<NET_INCOME>445051.56</NET_INCOME>
<REVENUE_M>2.58750909</REVENUE_M>
<PROFIT_M>2.107825014</PROFIT_M>
<INCOME_M>0.44505156</INCOME_M>
<PHARMA_REV_M>2.58750909</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.107825014</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44505156</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1713509.18</REVENUE>
<PREV_YEAR_REV>1573166.95</PREV_YEAR_REV>
<BUDGET>1579383.46</BUDGET>
<GROSS_PROFIT>1447504.012</GROSS_PROFIT>
<EXPENSES>1487325.97</EXPENSES>
<NET_INCOME>226183.21</NET_INCOME>
<REVENUE_M>1.71350918</REVENUE_M>
<PROFIT_M>1.447504012</PROFIT_M>
<INCOME_M>0.22618321</INCOME_M>
<PHARMA_REV_M>1.71350918</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.447504012</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22618321</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3285129.59</REVENUE>
<PREV_YEAR_REV>3040727.02</PREV_YEAR_REV>
<BUDGET>3170657.97</BUDGET>
<GROSS_PROFIT>2546676.153</GROSS_PROFIT>
<EXPENSES>2922071.03</EXPENSES>
<NET_INCOME>363058.56</NET_INCOME>
<REVENUE_M>3.28512959</REVENUE_M>
<PROFIT_M>2.546676153</PROFIT_M>
<INCOME_M>0.36305856</INCOME_M>
<PHARMA_REV_M>3.28512959</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.546676153</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36305856</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4794276.85</REVENUE>
<PREV_YEAR_REV>4493530.29</PREV_YEAR_REV>
<BUDGET>4745688.71</BUDGET>
<GROSS_PROFIT>3961442.015</GROSS_PROFIT>
<EXPENSES>4330879.59</EXPENSES>
<NET_INCOME>463397.26</NET_INCOME>
<REVENUE_M>4.79427685</REVENUE_M>
<PROFIT_M>3.961442015</PROFIT_M>
<INCOME_M>0.46339726</INCOME_M>
<PHARMA_REV_M>4.79427685</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.961442015</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46339726</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3279816.21</REVENUE>
<PREV_YEAR_REV>3050848.34</PREV_YEAR_REV>
<BUDGET>3140775.3</BUDGET>
<GROSS_PROFIT>2714612.85</GROSS_PROFIT>
<EXPENSES>2838045.53</EXPENSES>
<NET_INCOME>441770.68</NET_INCOME>
<REVENUE_M>3.27981621</REVENUE_M>
<PROFIT_M>2.71461285</PROFIT_M>
<INCOME_M>0.44177068</INCOME_M>
<PHARMA_REV_M>3.27981621</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.71461285</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44177068</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1635899.41</REVENUE>
<PREV_YEAR_REV>1536416.44</PREV_YEAR_REV>
<BUDGET>1562637.89</BUDGET>
<GROSS_PROFIT>1272811.539</GROSS_PROFIT>
<EXPENSES>1343073.42</EXPENSES>
<NET_INCOME>292825.99</NET_INCOME>
<REVENUE_M>1.63589941</REVENUE_M>
<PROFIT_M>1.272811539</PROFIT_M>
<INCOME_M>0.29282599</INCOME_M>
<PHARMA_REV_M>1.63589941</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.272811539</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29282599</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1756184.18</REVENUE>
<PREV_YEAR_REV>1625524.52</PREV_YEAR_REV>
<BUDGET>1592520.56</BUDGET>
<GROSS_PROFIT>1385453.695</GROSS_PROFIT>
<EXPENSES>1564760.1</EXPENSES>
<NET_INCOME>191424.08</NET_INCOME>
<REVENUE_M>1.75618418</REVENUE_M>
<PROFIT_M>1.385453695</PROFIT_M>
<INCOME_M>0.19142408</INCOME_M>
<PHARMA_REV_M>1.75618418</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.385453695</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19142408</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1639234.88</REVENUE>
<PREV_YEAR_REV>1540503.98</PREV_YEAR_REV>
<BUDGET>1579383.46</BUDGET>
<GROSS_PROFIT>1243687.5</GROSS_PROFIT>
<EXPENSES>1417938.17</EXPENSES>
<NET_INCOME>221296.71</NET_INCOME>
<REVENUE_M>1.63923488</REVENUE_M>
<PROFIT_M>1.2436875</PROFIT_M>
<INCOME_M>0.22129671</INCOME_M>
<PHARMA_REV_M>1.63923488</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.2436875</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22129671</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3233181.19</REVENUE>
<PREV_YEAR_REV>3011986.01</PREV_YEAR_REV>
<BUDGET>3170657.97</BUDGET>
<GROSS_PROFIT>2832299.85</GROSS_PROFIT>
<EXPENSES>2805124.21</EXPENSES>
<NET_INCOME>428056.98</NET_INCOME>
<REVENUE_M>3.23318119</REVENUE_M>
<PROFIT_M>2.83229985</PROFIT_M>
<INCOME_M>0.42805698</INCOME_M>
<PHARMA_REV_M>3.23318119</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.83229985</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42805698</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.02999014E7</REVENUE>
<PREV_YEAR_REV>2.878490633E7</PREV_YEAR_REV>
<BUDGET>2.939090436E7</BUDGET>
<GROSS_PROFIT>2.168366993E7</GROSS_PROFIT>
<EXPENSES>2.56026064E7</EXPENSES>
<NET_INCOME>2939090.44</NET_INCOME>
<REVENUE_M>30.2999014</REVENUE_M>
<PROFIT_M>21.68366993</PROFIT_M>
<INCOME_M>2.93909044</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.120281102E7</REVENUE>
<PREV_YEAR_REV>3.914267048E7</PREV_YEAR_REV>
<BUDGET>3.99667267E7</BUDGET>
<GROSS_PROFIT>3.103807754E7</GROSS_PROFIT>
<EXPENSES>3.535786706E7</EXPENSES>
<NET_INCOME>4006613.59</NET_INCOME>
<REVENUE_M>41.20281102</REVENUE_M>
<PROFIT_M>31.03807754</PROFIT_M>
<INCOME_M>4.00661359</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.354332575E7</REVENUE>
<PREV_YEAR_REV>1.286615946E7</PREV_YEAR_REV>
<BUDGET>1.313702598E7</BUDGET>
<GROSS_PROFIT>1.020218729E7</GROSS_PROFIT>
<EXPENSES>1.144374808E7</EXPENSES>
<NET_INCOME>988662.78</NET_INCOME>
<REVENUE_M>13.54332575</REVENUE_M>
<PROFIT_M>10.20218729</PROFIT_M>
<INCOME_M>0.98866278</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.05967413E7</REVENUE>
<PREV_YEAR_REV>1.006690423E7</PREV_YEAR_REV>
<BUDGET>1.027883906E7</BUDGET>
<GROSS_PROFIT>7583398.958</GROSS_PROFIT>
<EXPENSES>8953963.02</EXPENSES>
<NET_INCOME>1822639.5</NET_INCOME>
<REVENUE_M>10.5967413</REVENUE_M>
<PROFIT_M>7.583398958</PROFIT_M>
<INCOME_M>1.8226395</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.054468905E7</REVENUE>
<PREV_YEAR_REV>1.00174546E7</PREV_YEAR_REV>
<BUDGET>1.022834838E7</BUDGET>
<GROSS_PROFIT>7943314.261</GROSS_PROFIT>
<EXPENSES>8909980.26</EXPENSES>
<NET_INCOME>1149371.11</NET_INCOME>
<REVENUE_M>10.54468905</REVENUE_M>
<PROFIT_M>7.943314261</PROFIT_M>
<INCOME_M>1.14937111</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.36628925E7</REVENUE>
<PREV_YEAR_REV>1.297974787E7</PREV_YEAR_REV>
<BUDGET>1.325300572E7</BUDGET>
<GROSS_PROFIT>9263031.224</GROSS_PROFIT>
<EXPENSES>1.154477879E7</EXPENSES>
<NET_INCOME>1844490.49</NET_INCOME>
<REVENUE_M>13.6628925</REVENUE_M>
<PROFIT_M>9.263031224</PROFIT_M>
<INCOME_M>1.84449049</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.149944796E7</REVENUE>
<PREV_YEAR_REV>1.092447556E7</PREV_YEAR_REV>
<BUDGET>1.115446452E7</BUDGET>
<GROSS_PROFIT>7796280.735</GROSS_PROFIT>
<EXPENSES>1.478500452E7</EXPENSES>
<NET_INCOME>1552425.47</NET_INCOME>
<REVENUE_M>11.49944796</REVENUE_M>
<PROFIT_M>7.796280735</PROFIT_M>
<INCOME_M>1.55242547</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.761446157E7</REVENUE>
<PREV_YEAR_REV>2.623373849E7</PREV_YEAR_REV>
<BUDGET>2.678602773E7</BUDGET>
<GROSS_PROFIT>1.872177651E7</GROSS_PROFIT>
<EXPENSES>3.381362642E7</EXPENSES>
<NET_INCOME>4070812.16</NET_INCOME>
<REVENUE_M>27.61446157</REVENUE_M>
<PROFIT_M>18.72177651</PROFIT_M>
<INCOME_M>4.07081216</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.438129176E7</REVENUE>
<PREV_YEAR_REV>1.222409799E7</PREV_YEAR_REV>
<BUDGET>13949853</BUDGET>
<GROSS_PROFIT>9750084.37</GROSS_PROFIT>
<EXPENSES>1.279934966E7</EXPENSES>
<NET_INCOME>1941474.39</NET_INCOME>
<REVENUE_M>14.38129176</REVENUE_M>
<PROFIT_M>9.75008437</PROFIT_M>
<INCOME_M>1.94147439</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.783695913E7</REVENUE>
<PREV_YEAR_REV>1.516141525E7</PREV_YEAR_REV>
<BUDGET>1.730185035E7</BUDGET>
<GROSS_PROFIT>1.343658131E7</GROSS_PROFIT>
<EXPENSES>1.514168413E7</EXPENSES>
<NET_INCOME>2438398.9</NET_INCOME>
<REVENUE_M>17.83695913</REVENUE_M>
<PROFIT_M>13.43658131</PROFIT_M>
<INCOME_M>2.4383989</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.074386641E7</REVENUE>
<PREV_YEAR_REV>9132286.45</PREV_YEAR_REV>
<BUDGET>1.042155042E7</BUDGET>
<GROSS_PROFIT>8093354.565</GROSS_PROFIT>
<EXPENSES>9577955.78</EXPENSES>
<NET_INCOME>784302.25</NET_INCOME>
<REVENUE_M>10.74386641</REVENUE_M>
<PROFIT_M>8.093354565</PROFIT_M>
<INCOME_M>0.78430225</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.758853384E7</REVENUE>
<PREV_YEAR_REV>3.195025376E7</PREV_YEAR_REV>
<BUDGET>3.646087783E7</BUDGET>
<GROSS_PROFIT>2.726672244E7</GROSS_PROFIT>
<EXPENSES>3.382968046E7</EXPENSES>
<NET_INCOME>5081689.13</NET_INCOME>
<REVENUE_M>37.58853384</REVENUE_M>
<PROFIT_M>27.26672244</PROFIT_M>
<INCOME_M>5.08168913</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.591139375E7</REVENUE>
<PREV_YEAR_REV>2.202468469E7</PREV_YEAR_REV>
<BUDGET>2.513405194E7</BUDGET>
<GROSS_PROFIT>1.691651253E7</GROSS_PROFIT>
<EXPENSES>2.332025438E7</EXPENSES>
<NET_INCOME>3851486.72</NET_INCOME>
<REVENUE_M>25.91139375</REVENUE_M>
<PROFIT_M>16.91651253</PROFIT_M>
<INCOME_M>3.85148672</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>4.163583327E7</REVENUE>
<PREV_YEAR_REV>3.539045827E7</PREV_YEAR_REV>
<BUDGET>4.038675827E7</BUDGET>
<GROSS_PROFIT>3.020263345E7</GROSS_PROFIT>
<EXPENSES>3.747224994E7</EXPENSES>
<NET_INCOME>5509455.65</NET_INCOME>
<REVENUE_M>41.63583327</REVENUE_M>
<PROFIT_M>30.20263345</PROFIT_M>
<INCOME_M>5.50945565</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.113342471E7</REVENUE>
<PREV_YEAR_REV>2.646341101E7</PREV_YEAR_REV>
<BUDGET>3.019942197E7</BUDGET>
<GROSS_PROFIT>2.110752795E7</GROSS_PROFIT>
<EXPENSES>2.851449637E7</EXPENSES>
<NET_INCOME>3789423.55</NET_INCOME>
<REVENUE_M>31.13342471</REVENUE_M>
<PROFIT_M>21.10752795</PROFIT_M>
<INCOME_M>3.78942355</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.510297853E7</REVENUE>
<PREV_YEAR_REV>1.283753175E7</PREV_YEAR_REV>
<BUDGET>1.464988917E7</BUDGET>
<GROSS_PROFIT>1.080822004E7</GROSS_PROFIT>
<EXPENSES>1.346402264E7</EXPENSES>
<NET_INCOME>1540503.81</NET_INCOME>
<REVENUE_M>15.10297853</REVENUE_M>
<PROFIT_M>10.80822004</PROFIT_M>
<INCOME_M>1.54050381</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.513820185E7</REVENUE>
<PREV_YEAR_REV>1.286747157E7</PREV_YEAR_REV>
<BUDGET>1.468405579E7</BUDGET>
<GROSS_PROFIT>1.083342708E7</GROSS_PROFIT>
<EXPENSES>1.349542357E7</EXPENSES>
<NET_INCOME>2603770.72</NET_INCOME>
<REVENUE_M>15.13820185</REVENUE_M>
<PROFIT_M>10.83342708</PROFIT_M>
<INCOME_M>2.60377072</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.165295025E7</REVENUE>
<PREV_YEAR_REV>3.832071423E7</PREV_YEAR_REV>
<BUDGET>4.248600925E7</BUDGET>
<GROSS_PROFIT>2.823945068E7</GROSS_PROFIT>
<EXPENSES>3.707112572E7</EXPENSES>
<NET_INCOME>5041460.72</NET_INCOME>
<REVENUE_M>41.65295025</REVENUE_M>
<PROFIT_M>28.23945068</PROFIT_M>
<INCOME_M>5.04146072</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.359511117E7</REVENUE>
<PREV_YEAR_REV>3.090750228E7</PREV_YEAR_REV>
<BUDGET>2.406701339E7</BUDGET>
<GROSS_PROFIT>2.530719725E7</GROSS_PROFIT>
<EXPENSES>3.099964894E7</EXPENSES>
<NET_INCOME>4464328.96</NET_INCOME>
<REVENUE_M>33.59511117</REVENUE_M>
<PROFIT_M>25.30719725</PROFIT_M>
<INCOME_M>4.46432896</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.057843909E7</REVENUE>
<PREV_YEAR_REV>9732163.96</PREV_YEAR_REV>
<BUDGET>1.079000787E7</BUDGET>
<GROSS_PROFIT>7968738.164</GROSS_PROFIT>
<EXPENSES>9414810.79</EXPENSES>
<NET_INCOME>1893540.6</NET_INCOME>
<REVENUE_M>10.57843909</REVENUE_M>
<PROFIT_M>7.968738164</PROFIT_M>
<INCOME_M>1.8935406</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.854249696E7</REVENUE>
<PREV_YEAR_REV>1.705909721E7</PREV_YEAR_REV>
<BUDGET>1.89133469E7</BUDGET>
<GROSS_PROFIT>1.257125667E7</GROSS_PROFIT>
<EXPENSES>1.65028223E7</EXPENSES>
<NET_INCOME>2503237.09</NET_INCOME>
<REVENUE_M>18.54249696</REVENUE_M>
<PROFIT_M>12.57125667</PROFIT_M>
<INCOME_M>2.50323709</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.268072847E7</REVENUE>
<PREV_YEAR_REV>3.926627019E7</PREV_YEAR_REV>
<BUDGET>4.353434304E7</BUDGET>
<GROSS_PROFIT>3.215139276E7</GROSS_PROFIT>
<EXPENSES>3.804907047E7</EXPENSES>
<NET_INCOME>5633856.16</NET_INCOME>
<REVENUE_M>42.68072847</REVENUE_M>
<PROFIT_M>32.15139276</PROFIT_M>
<INCOME_M>5.63385616</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.963783393E7</REVENUE>
<PREV_YEAR_REV>3.646680722E7</PREV_YEAR_REV>
<BUDGET>3.533059062E7</BUDGET>
<GROSS_PROFIT>2.985918031E7</GROSS_PROFIT>
<EXPENSES>3.587898055E7</EXPENSES>
<NET_INCOME>5327776.53</NET_INCOME>
<REVENUE_M>39.63783393</REVENUE_M>
<PROFIT_M>29.85918031</PROFIT_M>
<INCOME_M>5.32777653</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.934760822E7</REVENUE>
<PREV_YEAR_REV>1.779979956E7</PREV_YEAR_REV>
<BUDGET>1.973456038E7</BUDGET>
<GROSS_PROFIT>1.457455327E7</GROSS_PROFIT>
<EXPENSES>1.724803055E7</EXPENSES>
<NET_INCOME>1412375.4</NET_INCOME>
<REVENUE_M>19.34760822</REVENUE_M>
<PROFIT_M>14.57455327</PROFIT_M>
<INCOME_M>1.4123754</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.783695913E7</REVENUE>
<PREV_YEAR_REV>2.56100024E7</PREV_YEAR_REV>
<BUDGET>2.533369831E7</BUDGET>
<GROSS_PROFIT>2.096958131E7</GROSS_PROFIT>
<EXPENSES>2.514168413E7</EXPENSES>
<NET_INCOME>3728398.9</NET_INCOME>
<REVENUE_M>27.83695913</REVENUE_M>
<PROFIT_M>20.96958131</PROFIT_M>
<INCOME_M>3.7283989</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.717085497E7</REVENUE>
<PREV_YEAR_REV>4.339718657E7</PREV_YEAR_REV>
<BUDGET>44000751</BUDGET>
<GROSS_PROFIT>3.553380505E7</GROSS_PROFIT>
<EXPENSES>4.094430211E7</EXPENSES>
<NET_INCOME>6226552.86</NET_INCOME>
<REVENUE_M>47.17085497</REVENUE_M>
<PROFIT_M>35.53380505</PROFIT_M>
<INCOME_M>6.22655286</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.78978334E7</REVENUE>
<PREV_YEAR_REV>2.566600673E7</PREV_YEAR_REV>
<BUDGET>2.487981929E7</BUDGET>
<GROSS_PROFIT>1.891389411E7</GROSS_PROFIT>
<EXPENSES>2.452297781E7</EXPENSES>
<NET_INCOME>3374855.59</NET_INCOME>
<REVENUE_M>27.8978334</REVENUE_M>
<PROFIT_M>18.91389411</PROFIT_M>
<INCOME_M>3.37485559</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.591994369E7</REVENUE>
<PREV_YEAR_REV>3.304634819E7</PREV_YEAR_REV>
<BUDGET>2.461582406E7</BUDGET>
<GROSS_PROFIT>2.435264422E7</GROSS_PROFIT>
<EXPENSES>3.06527373E7</EXPENSES>
<NET_INCOME>5267206.39</NET_INCOME>
<REVENUE_M>35.91994369</REVENUE_M>
<PROFIT_M>24.35264422</PROFIT_M>
<INCOME_M>5.26720639</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.251338122E7</REVENUE>
<PREV_YEAR_REV>1.151231072E7</PREV_YEAR_REV>
<BUDGET>1.107615094E7</BUDGET>
<GROSS_PROFIT>9426330.075</GROSS_PROFIT>
<EXPENSES>1.159990439E7</EXPENSES>
<NET_INCOME>913476.83</NET_INCOME>
<REVENUE_M>12.51338122</REVENUE_M>
<PROFIT_M>9.426330075</PROFIT_M>
<INCOME_M>0.91347683</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.203541209E7</REVENUE>
<PREV_YEAR_REV>2.027257912E7</PREV_YEAR_REV>
<BUDGET>2.012208026E7</BUDGET>
<GROSS_PROFIT>1.493934833E7</GROSS_PROFIT>
<EXPENSES>1.906063146E7</EXPENSES>
<NET_INCOME>2974780.63</NET_INCOME>
<REVENUE_M>22.03541209</REVENUE_M>
<PROFIT_M>14.93934833</PROFIT_M>
<INCOME_M>2.97478063</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5392661.14</REVENUE>
<PREV_YEAR_REV>4925119.54</PREV_YEAR_REV>
<BUDGET>5931927.26</BUDGET>
<GROSS_PROFIT>4088176.411</GROSS_PROFIT>
<EXPENSES>4465123.43</EXPENSES>
<NET_INCOME>927537.72</NET_INCOME>
<REVENUE_M>5.39266114</REVENUE_M>
<PROFIT_M>4.088176411</PROFIT_M>
<INCOME_M>0.92753772</INCOME_M>
<PHARMA_REV_M>5.39266114</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.088176411</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.92753772</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5311977.46</REVENUE>
<PREV_YEAR_REV>4875476.09</PREV_YEAR_REV>
<BUDGET>5843175.21</BUDGET>
<GROSS_PROFIT>4589548.53</GROSS_PROFIT>
<EXPENSES>4732971.92</EXPENSES>
<NET_INCOME>579005.54</NET_INCOME>
<REVENUE_M>5.31197746</REVENUE_M>
<PROFIT_M>4.58954853</PROFIT_M>
<INCOME_M>0.57900554</INCOME_M>
<PHARMA_REV_M>5.31197746</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.58954853</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57900554</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4795117.3</REVENUE>
<PREV_YEAR_REV>4390664.1</PREV_YEAR_REV>
<BUDGET>3418098.16</BUDGET>
<GROSS_PROFIT>3832227.149</GROSS_PROFIT>
<EXPENSES>4267037.59</EXPENSES>
<NET_INCOME>528079.73</NET_INCOME>
<REVENUE_M>4.7951173</REVENUE_M>
<PROFIT_M>3.832227149</PROFIT_M>
<INCOME_M>0.52807973</INCOME_M>
<PHARMA_REV_M>4.7951173</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.832227149</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52807973</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4767376.46</REVENUE>
<PREV_YEAR_REV>4300168.34</PREV_YEAR_REV>
<BUDGET>3418882.17</BUDGET>
<GROSS_PROFIT>3815948.722</GROSS_PROFIT>
<EXPENSES>4189049.81</EXPENSES>
<NET_INCOME>578326.66</NET_INCOME>
<REVENUE_M>4.76737646</REVENUE_M>
<PROFIT_M>3.815948722</PROFIT_M>
<INCOME_M>0.57832666</INCOME_M>
<PHARMA_REV_M>4.76737646</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.815948722</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57832666</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2526267.49</REVENUE>
<PREV_YEAR_REV>2296126.71</PREV_YEAR_REV>
<BUDGET>1890787.64</BUDGET>
<GROSS_PROFIT>2032584.298</GROSS_PROFIT>
<EXPENSES>2122064.69</EXPENSES>
<NET_INCOME>404202.8</NET_INCOME>
<REVENUE_M>2.52626749</REVENUE_M>
<PROFIT_M>2.032584298</PROFIT_M>
<INCOME_M>0.4042028</INCOME_M>
<PHARMA_REV_M>2.52626749</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.032584298</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4042028</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>8089714.31</REVENUE>
<PREV_YEAR_REV>7386490.3</PREV_YEAR_REV>
<BUDGET>5921832.15</BUDGET>
<GROSS_PROFIT>6531570.293</GROSS_PROFIT>
<EXPENSES>7302113.2</EXPENSES>
<NET_INCOME>787601.11</NET_INCOME>
<REVENUE_M>8.08971431</REVENUE_M>
<PROFIT_M>6.531570293</PROFIT_M>
<INCOME_M>0.78760111</INCOME_M>
<PHARMA_REV_M>8.08971431</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.531570293</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.78760111</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2927970.19</REVENUE>
<PREV_YEAR_REV>2642930.17</PREV_YEAR_REV>
<BUDGET>2010436.35</BUDGET>
<GROSS_PROFIT>2403277.928</GROSS_PROFIT>
<EXPENSES>2403863.52</EXPENSES>
<NET_INCOME>524106.66</NET_INCOME>
<REVENUE_M>2.92797019</REVENUE_M>
<PROFIT_M>2.403277928</PROFIT_M>
<INCOME_M>0.52410666</INCOME_M>
<PHARMA_REV_M>2.92797019</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.403277928</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52410666</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5448765.06</REVENUE>
<PREV_YEAR_REV>4966235.52</PREV_YEAR_REV>
<BUDGET>3990835.79</BUDGET>
<GROSS_PROFIT>4526537.331</GROSS_PROFIT>
<EXPENSES>4715107.59</EXPENSES>
<NET_INCOME>733657.48</NET_INCOME>
<REVENUE_M>5.44876506</REVENUE_M>
<PROFIT_M>4.526537331</PROFIT_M>
<INCOME_M>0.73365748</INCOME_M>
<PHARMA_REV_M>5.44876506</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.526537331</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.73365748</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2868298.32</REVENUE>
<PREV_YEAR_REV>2630645.78</PREV_YEAR_REV>
<BUDGET>2088328.67</BUDGET>
<GROSS_PROFIT>2291512.21</GROSS_PROFIT>
<EXPENSES>2658912.54</EXPENSES>
<NET_INCOME>209385.78</NET_INCOME>
<REVENUE_M>2.86829832</REVENUE_M>
<PROFIT_M>2.29151221</PROFIT_M>
<INCOME_M>0.20938578</INCOME_M>
<PHARMA_REV_M>2.86829832</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.29151221</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20938578</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5145128.22</REVENUE>
<PREV_YEAR_REV>4202081.43</PREV_YEAR_REV>
<BUDGET>4917806.82</BUDGET>
<GROSS_PROFIT>3726986.305</GROSS_PROFIT>
<EXPENSES>4380777.93</EXPENSES>
<NET_INCOME>764350.29</NET_INCOME>
<REVENUE_M>5.14512822</REVENUE_M>
<PROFIT_M>3.726986305</PROFIT_M>
<INCOME_M>0.76435029</INCOME_M>
<PHARMA_REV_M>5.14512822</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.726986305</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76435029</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2598584.42</REVENUE>
<PREV_YEAR_REV>2086395.25</PREV_YEAR_REV>
<BUDGET>2483362.5</BUDGET>
<GROSS_PROFIT>2030962.634</GROSS_PROFIT>
<EXPENSES>2151627.9</EXPENSES>
<NET_INCOME>446956.52</NET_INCOME>
<REVENUE_M>2.59858442</REVENUE_M>
<PROFIT_M>2.030962634</PROFIT_M>
<INCOME_M>0.44695652</INCOME_M>
<PHARMA_REV_M>2.59858442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.030962634</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44695652</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2494512.55</REVENUE>
<PREV_YEAR_REV>1969580.07</PREV_YEAR_REV>
<BUDGET>2385534.94</BUDGET>
<GROSS_PROFIT>1964553.355</GROSS_PROFIT>
<EXPENSES>2240072.27</EXPENSES>
<NET_INCOME>254440.28</NET_INCOME>
<REVENUE_M>2.49451255</REVENUE_M>
<PROFIT_M>1.964553355</PROFIT_M>
<INCOME_M>0.25444028</INCOME_M>
<PHARMA_REV_M>2.49451255</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.964553355</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25444028</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4135938.84</REVENUE>
<PREV_YEAR_REV>3336465.29</PREV_YEAR_REV>
<BUDGET>3969168.8</BUDGET>
<GROSS_PROFIT>3016975.338</GROSS_PROFIT>
<EXPENSES>3635548.21</EXPENSES>
<NET_INCOME>500390.64</NET_INCOME>
<REVENUE_M>4.13593884</REVENUE_M>
<PROFIT_M>3.016975338</PROFIT_M>
<INCOME_M>0.50039064</INCOME_M>
<PHARMA_REV_M>4.13593884</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.016975338</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50039064</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.56472307E7</REVENUE>
<PREV_YEAR_REV>2.308250763E7</PREV_YEAR_REV>
<BUDGET>2.436486917E7</BUDGET>
<GROSS_PROFIT>1.835405594E7</GROSS_PROFIT>
<EXPENSES>42275655</EXPENSES>
<NET_INCOME>2487781.38</NET_INCOME>
<REVENUE_M>25.6472307</REVENUE_M>
<PROFIT_M>18.35405594</PROFIT_M>
<INCOME_M>2.48778138</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.429934877E7</REVENUE>
<PREV_YEAR_REV>1.286941389E7</PREV_YEAR_REV>
<BUDGET>1.358438133E7</BUDGET>
<GROSS_PROFIT>9694529.491</GROSS_PROFIT>
<EXPENSES>2.357035512E7</EXPENSES>
<NET_INCOME>1729794.09</NET_INCOME>
<REVENUE_M>14.29934877</REVENUE_M>
<PROFIT_M>9.694529491</PROFIT_M>
<INCOME_M>1.72979409</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.051360003E7</REVENUE>
<PREV_YEAR_REV>1.846224002E7</PREV_YEAR_REV>
<BUDGET>1.948792002E7</BUDGET>
<GROSS_PROFIT>1.390760541E7</GROSS_PROFIT>
<EXPENSES>3.381362642E7</EXPENSES>
<NET_INCOME>3024031.89</NET_INCOME>
<REVENUE_M>20.51360003</REVENUE_M>
<PROFIT_M>13.90760541</PROFIT_M>
<INCOME_M>3.02403189</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.73143007E7</REVENUE>
<PREV_YEAR_REV>2.458287063E7</PREV_YEAR_REV>
<BUDGET>2.436486917E7</BUDGET>
<GROSS_PROFIT>1.954706958E7</GROSS_PROFIT>
<EXPENSES>42275655</EXPENSES>
<NET_INCOME>2649487.17</NET_INCOME>
<REVENUE_M>27.3143007</REVENUE_M>
<PROFIT_M>19.54706958</PROFIT_M>
<INCOME_M>2.64948717</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.185735654E7</REVENUE>
<PREV_YEAR_REV>1.967162089E7</PREV_YEAR_REV>
<BUDGET>1.94971725E7</BUDGET>
<GROSS_PROFIT>1.646514668E7</GROSS_PROFIT>
<EXPENSES>3.382968046E7</EXPENSES>
<NET_INCOME>2954951.41</NET_INCOME>
<REVENUE_M>21.85735654</REVENUE_M>
<PROFIT_M>16.46514668</PROFIT_M>
<INCOME_M>2.95495141</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2650307.2</REVENUE>
<PREV_YEAR_REV>2443467.66</PREV_YEAR_REV>
<BUDGET>1872608.34</BUDGET>
<GROSS_PROFIT>2070048.943</GROSS_PROFIT>
<EXPENSES>2300466.65</EXPENSES>
<NET_INCOME>349840.55</NET_INCOME>
<REVENUE_M>2.6503072</REVENUE_M>
<PROFIT_M>2.070048943</PROFIT_M>
<INCOME_M>0.34984055</INCOME_M>
<PHARMA_REV_M>2.6503072</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.070048943</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34984055</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7792915.29</REVENUE>
<PREV_YEAR_REV>7133067.56</PREV_YEAR_REV>
<BUDGET>5687233.77</BUDGET>
<GROSS_PROFIT>6264365.797</GROSS_PROFIT>
<EXPENSES>7034967.69</EXPENSES>
<NET_INCOME>757947.59</NET_INCOME>
<REVENUE_M>7.79291529</REVENUE_M>
<PROFIT_M>6.264365797</PROFIT_M>
<INCOME_M>0.75794759</INCOME_M>
<PHARMA_REV_M>7.79291529</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.264365797</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75794759</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5100955.12</REVENUE>
<PREV_YEAR_REV>4647809.66</PREV_YEAR_REV>
<BUDGET>3849848.06</BUDGET>
<GROSS_PROFIT>3850766.33</GROSS_PROFIT>
<EXPENSES>4342322.03</EXPENSES>
<NET_INCOME>758633.1</NET_INCOME>
<REVENUE_M>5.10095512</REVENUE_M>
<PROFIT_M>3.85076633</PROFIT_M>
<INCOME_M>0.7586331</INCOME_M>
<PHARMA_REV_M>5.10095512</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.85076633</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.7586331</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2506601.91</REVENUE>
<PREV_YEAR_REV>2236659.48</PREV_YEAR_REV>
<BUDGET>1908006.99</BUDGET>
<GROSS_PROFIT>2029044.116</GROSS_PROFIT>
<EXPENSES>2323619.97</EXPENSES>
<NET_INCOME>182981.94</NET_INCOME>
<REVENUE_M>2.50660191</REVENUE_M>
<PROFIT_M>2.029044116</PROFIT_M>
<INCOME_M>0.18298194</INCOME_M>
<PHARMA_REV_M>2.50660191</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.029044116</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18298194</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2011486.12</REVENUE>
<PREV_YEAR_REV>1831620.94</PREV_YEAR_REV>
<BUDGET>1460601.91</BUDGET>
<GROSS_PROFIT>1581183.98</GROSS_PROFIT>
<EXPENSES>1806314.54</EXPENSES>
<NET_INCOME>205171.58</NET_INCOME>
<REVENUE_M>2.01148612</REVENUE_M>
<PROFIT_M>1.58118398</PROFIT_M>
<INCOME_M>0.20517158</INCOME_M>
<PHARMA_REV_M>2.01148612</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.58118398</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20517158</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2584679.03</REVENUE>
<PREV_YEAR_REV>2362811.07</PREV_YEAR_REV>
<BUDGET>2005597.76</BUDGET>
<GROSS_PROFIT>1929881.612</GROSS_PROFIT>
<EXPENSES>2140114.23</EXPENSES>
<NET_INCOME>444564.79</NET_INCOME>
<REVENUE_M>2.58467903</REVENUE_M>
<PROFIT_M>1.929881612</PROFIT_M>
<INCOME_M>0.44456479</INCOME_M>
<PHARMA_REV_M>2.58467903</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.929881612</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44456479</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1853369.46</REVENUE>
<PREV_YEAR_REV>1693889.74</PREV_YEAR_REV>
<BUDGET>1669127.73</BUDGET>
<GROSS_PROFIT>1383382.767</GROSS_PROFIT>
<EXPENSES>1614284.8</EXPENSES>
<NET_INCOME>239084.66</NET_INCOME>
<REVENUE_M>1.85336946</REVENUE_M>
<PROFIT_M>1.383382767</PROFIT_M>
<INCOME_M>0.23908466</INCOME_M>
<PHARMA_REV_M>1.85336946</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.383382767</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23908466</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3583027.24</REVENUE>
<PREV_YEAR_REV>3211258.84</PREV_YEAR_REV>
<BUDGET>3417464.37</BUDGET>
<GROSS_PROFIT>2718595.377</GROSS_PROFIT>
<EXPENSES>3148505.87</EXPENSES>
<NET_INCOME>434521.37</NET_INCOME>
<REVENUE_M>3.58302724</REVENUE_M>
<PROFIT_M>2.718595377</PROFIT_M>
<INCOME_M>0.43452137</INCOME_M>
<PHARMA_REV_M>3.58302724</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.718595377</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43452137</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3601895.13</REVENUE>
<PREV_YEAR_REV>3285053.99</PREV_YEAR_REV>
<BUDGET>3400146.66</BUDGET>
<GROSS_PROFIT>2696292.045</GROSS_PROFIT>
<EXPENSES>3066007.44</EXPENSES>
<NET_INCOME>535887.69</NET_INCOME>
<REVENUE_M>3.60189513</REVENUE_M>
<PROFIT_M>2.696292045</PROFIT_M>
<INCOME_M>0.53588769</INCOME_M>
<PHARMA_REV_M>3.60189513</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.696292045</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53588769</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3630603</REVENUE>
<PREV_YEAR_REV>3315091.09</PREV_YEAR_REV>
<BUDGET>3400712.16</BUDGET>
<GROSS_PROFIT>2581407.484</GROSS_PROFIT>
<EXPENSES>3091847.91</EXPENSES>
<NET_INCOME>538755.09</NET_INCOME>
<REVENUE_M>3.630603</REVENUE_M>
<PROFIT_M>2.581407484</PROFIT_M>
<INCOME_M>0.53875509</INCOME_M>
<PHARMA_REV_M>3.630603</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.581407484</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53875509</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1748751.39</REVENUE>
<PREV_YEAR_REV>1565592.7</PREV_YEAR_REV>
<BUDGET>1705685.22</BUDGET>
<GROSS_PROFIT>1435375.14</GROSS_PROFIT>
<EXPENSES>1621092.54</EXPENSES>
<NET_INCOME>127658.85</NET_INCOME>
<REVENUE_M>1.74875139</REVENUE_M>
<PROFIT_M>1.43537514</PROFIT_M>
<INCOME_M>0.12765885</INCOME_M>
<PHARMA_REV_M>1.74875139</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.43537514</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12765885</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1778258.39</REVENUE>
<PREV_YEAR_REV>1639234.88</PREV_YEAR_REV>
<BUDGET>1707031.98</BUDGET>
<GROSS_PROFIT>1269143.01</GROSS_PROFIT>
<EXPENSES>1538193.5</EXPENSES>
<NET_INCOME>240064.88</NET_INCOME>
<REVENUE_M>1.77825839</REVENUE_M>
<PROFIT_M>1.26914301</PROFIT_M>
<INCOME_M>0.24006488</INCOME_M>
<PHARMA_REV_M>1.77825839</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.26914301</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24006488</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1693880.85</REVENUE>
<PREV_YEAR_REV>1522890.69</PREV_YEAR_REV>
<BUDGET>1547249.11</BUDGET>
<GROSS_PROFIT>1253133.054</GROSS_PROFIT>
<EXPENSES>1465206.94</EXPENSES>
<NET_INCOME>228673.92</NET_INCOME>
<REVENUE_M>1.69388085</REVENUE_M>
<PROFIT_M>1.253133054</PROFIT_M>
<INCOME_M>0.22867392</INCOME_M>
<PHARMA_REV_M>1.69388085</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.253133054</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22867392</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1341409.61</REVENUE>
<PREV_YEAR_REV>1231487.07</PREV_YEAR_REV>
<BUDGET>1063997.51</BUDGET>
<GROSS_PROFIT>1079834.74</GROSS_PROFIT>
<EXPENSES>1164343.54</EXPENSES>
<NET_INCOME>177066.07</NET_INCOME>
<REVENUE_M>1.34140961</REVENUE_M>
<PROFIT_M>1.07983474</PROFIT_M>
<INCOME_M>0.17706607</INCOME_M>
<PHARMA_REV_M>1.34140961</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.07983474</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17706607</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1519413.96</REVENUE>
<PREV_YEAR_REV>1394060.07</PREV_YEAR_REV>
<BUDGET>1211870.32</BUDGET>
<GROSS_PROFIT>1153311.163</GROSS_PROFIT>
<EXPENSES>1408496.74</EXPENSES>
<NET_INCOME>110917.22</NET_INCOME>
<REVENUE_M>1.51941396</REVENUE_M>
<PROFIT_M>1.153311163</PROFIT_M>
<INCOME_M>0.11091722</INCOME_M>
<PHARMA_REV_M>1.51941396</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.153311163</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11091722</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2700853.69</REVENUE>
<PREV_YEAR_REV>2444710.77</PREV_YEAR_REV>
<BUDGET>2310473.11</BUDGET>
<GROSS_PROFIT>2353179.1</GROSS_PROFIT>
<EXPENSES>2337191</EXPENSES>
<NET_INCOME>363662.69</NET_INCOME>
<REVENUE_M>2.70085369</REVENUE_M>
<PROFIT_M>2.3531791</PROFIT_M>
<INCOME_M>0.36366269</INCOME_M>
<PHARMA_REV_M>2.70085369</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.3531791</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36366269</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9903585.21</REVENUE>
<PREV_YEAR_REV>8811018.87</PREV_YEAR_REV>
<BUDGET>8913226.69</BUDGET>
<GROSS_PROFIT>8180361.38</GROSS_PROFIT>
<EXPENSES>8596311.96</EXPENSES>
<NET_INCOME>1307273.25</NET_INCOME>
<REVENUE_M>9.90358521</REVENUE_M>
<PROFIT_M>8.18036138</PROFIT_M>
<INCOME_M>1.30727325</INCOME_M>
<PHARMA_REV_M>9.90358521</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.18036138</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.30727325</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8490107.13</REVENUE>
<PREV_YEAR_REV>7618135.36</PREV_YEAR_REV>
<BUDGET>7641096.42</BUDGET>
<GROSS_PROFIT>6028825.077</GROSS_PROFIT>
<EXPENSES>7394883.31</EXPENSES>
<NET_INCOME>1095223.82</NET_INCOME>
<REVENUE_M>8.49010713</REVENUE_M>
<PROFIT_M>6.028825077</PROFIT_M>
<INCOME_M>1.09522382</INCOME_M>
<PHARMA_REV_M>8.49010713</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.028825077</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.09522382</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.436143116E7</REVENUE>
<PREV_YEAR_REV>12833605</PREV_YEAR_REV>
<BUDGET>1.292528805E7</BUDGET>
<GROSS_PROFIT>1.072479282E7</GROSS_PROFIT>
<EXPENSES>1.222693535E7</EXPENSES>
<NET_INCOME>2134495.8</NET_INCOME>
<REVENUE_M>14.36143116</REVENUE_M>
<PROFIT_M>10.72479282</PROFIT_M>
<INCOME_M>2.1344958</INCOME_M>
<PHARMA_REV_M>14.36143116</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.72479282</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.1344958</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2168016.45</REVENUE>
<PREV_YEAR_REV>1891729.37</PREV_YEAR_REV>
<BUDGET>2303685.76</BUDGET>
<GROSS_PROFIT>1697494.004</GROSS_PROFIT>
<EXPENSES>1946878.77</EXPENSES>
<NET_INCOME>221137.68</NET_INCOME>
<REVENUE_M>2.16801645</REVENUE_M>
<PROFIT_M>1.697494004</PROFIT_M>
<INCOME_M>0.22113768</INCOME_M>
<PHARMA_REV_M>2.16801645</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.697494004</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22113768</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1635298.5</REVENUE>
<PREV_YEAR_REV>1485352.2</PREV_YEAR_REV>
<BUDGET>2082054.09</BUDGET>
<GROSS_PROFIT>1363806.249</GROSS_PROFIT>
<EXPENSES>1419439.1</EXPENSES>
<NET_INCOME>215859.4</NET_INCOME>
<REVENUE_M>1.6352985</REVENUE_M>
<PROFIT_M>1.363806249</PROFIT_M>
<INCOME_M>0.2158594</INCOME_M>
<PHARMA_REV_M>1.6352985</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.363806249</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2158594</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4874420.94</REVENUE>
<PREV_YEAR_REV>4316988.19</PREV_YEAR_REV>
<BUDGET>6255792.02</BUDGET>
<GROSS_PROFIT>4008271.17</GROSS_PROFIT>
<EXPENSES>4399728</EXPENSES>
<NET_INCOME>474692.95</NET_INCOME>
<REVENUE_M>4.87442094</REVENUE_M>
<PROFIT_M>4.00827117</PROFIT_M>
<INCOME_M>0.47469295</INCOME_M>
<PHARMA_REV_M>4.87442094</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.00827117</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47469295</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.886196191E7</REVENUE>
<PREV_YEAR_REV>1.716178648E7</PREV_YEAR_REV>
<BUDGET>1.697576572E7</BUDGET>
<GROSS_PROFIT>1.621335406E7</GROSS_PROFIT>
<EXPENSES>1.702868203E7</EXPENSES>
<NET_INCOME>1833279.88</NET_INCOME>
<REVENUE_M>18.86196191</REVENUE_M>
<PROFIT_M>16.21335406</PROFIT_M>
<INCOME_M>1.83327988</INCOME_M>
<PHARMA_REV_M>18.86196191</PHARMA_REV_M>
<PHARMA_PROFIT_M>16.21335406</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.83327988</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6709625.45</REVENUE>
<PREV_YEAR_REV>6162460.58</PREV_YEAR_REV>
<BUDGET>6038662.91</BUDGET>
<GROSS_PROFIT>5943184.935</GROSS_PROFIT>
<EXPENSES>5978276.28</EXPENSES>
<NET_INCOME>731349.17</NET_INCOME>
<REVENUE_M>6.70962545</REVENUE_M>
<PROFIT_M>5.943184935</PROFIT_M>
<INCOME_M>0.73134917</INCOME_M>
<PHARMA_REV_M>6.70962545</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.943184935</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.73134917</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1905440.69</REVENUE>
<PREV_YEAR_REV>1744126.44</PREV_YEAR_REV>
<BUDGET>1838438.06</BUDGET>
<GROSS_PROFIT>1553067.546</GROSS_PROFIT>
<EXPENSES>1600570.18</EXPENSES>
<NET_INCOME>304870.51</NET_INCOME>
<REVENUE_M>1.90544069</REVENUE_M>
<PROFIT_M>1.553067546</PROFIT_M>
<INCOME_M>0.30487051</INCOME_M>
<PHARMA_REV_M>1.90544069</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.553067546</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30487051</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4374092.17</REVENUE>
<PREV_YEAR_REV>3928617.9</PREV_YEAR_REV>
<BUDGET>4280585.43</BUDGET>
<GROSS_PROFIT>3158543.351</GROSS_PROFIT>
<EXPENSES>3847715.5</EXPENSES>
<NET_INCOME>526376.67</NET_INCOME>
<REVENUE_M>4.37409217</REVENUE_M>
<PROFIT_M>3.158543351</PROFIT_M>
<INCOME_M>0.52637667</INCOME_M>
<PHARMA_REV_M>4.37409217</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.158543351</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52637667</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>6703564.07</REVENUE>
<PREV_YEAR_REV>6097266.35</PREV_YEAR_REV>
<BUDGET>6456714.36</BUDGET>
<GROSS_PROFIT>5298752.937</GROSS_PROFIT>
<EXPENSES>6052594.18</EXPENSES>
<NET_INCOME>650969.89</NET_INCOME>
<REVENUE_M>6.70356407</REVENUE_M>
<PROFIT_M>5.298752937</PROFIT_M>
<INCOME_M>0.65096989</INCOME_M>
<PHARMA_REV_M>6.70356407</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.298752937</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65096989</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4483589.87</REVENUE>
<PREV_YEAR_REV>4047659.34</PREV_YEAR_REV>
<BUDGET>4351303.12</BUDGET>
<GROSS_PROFIT>3782325.942</GROSS_PROFIT>
<EXPENSES>3879557.38</EXPENSES>
<NET_INCOME>604032.49</NET_INCOME>
<REVENUE_M>4.48358987</REVENUE_M>
<PROFIT_M>3.782325942</PROFIT_M>
<INCOME_M>0.60403249</INCOME_M>
<PHARMA_REV_M>4.48358987</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.782325942</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60403249</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3803129.34</REVENUE>
<PREV_YEAR_REV>3445707</PREV_YEAR_REV>
<BUDGET>3740229.7</BUDGET>
<GROSS_PROFIT>2888234.02</GROSS_PROFIT>
<EXPENSES>3243661.03</EXPENSES>
<NET_INCOME>559468.31</NET_INCOME>
<REVENUE_M>3.80312934</REVENUE_M>
<PROFIT_M>2.88823402</PROFIT_M>
<INCOME_M>0.55946831</INCOME_M>
<PHARMA_REV_M>3.80312934</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.88823402</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55946831</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2369037.08</REVENUE>
<PREV_YEAR_REV>2177043.61</PREV_YEAR_REV>
<BUDGET>2276954.38</BUDGET>
<GROSS_PROFIT>2048174.697</GROSS_PROFIT>
<EXPENSES>2196097.38</EXPENSES>
<NET_INCOME>172939.71</NET_INCOME>
<REVENUE_M>2.36903708</REVENUE_M>
<PROFIT_M>2.048174697</PROFIT_M>
<INCOME_M>0.17293971</INCOME_M>
<PHARMA_REV_M>2.36903708</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.048174697</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17293971</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2321866.63</REVENUE>
<PREV_YEAR_REV>2079109.77</PREV_YEAR_REV>
<BUDGET>2250310.35</BUDGET>
<GROSS_PROFIT>1836201.786</GROSS_PROFIT>
<EXPENSES>1906252.5</EXPENSES>
<NET_INCOME>415614.13</NET_INCOME>
<REVENUE_M>2.32186663</REVENUE_M>
<PROFIT_M>1.836201786</PROFIT_M>
<INCOME_M>0.41561413</INCOME_M>
<PHARMA_REV_M>2.32186663</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.836201786</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41561413</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2234050.03</REVENUE>
<PREV_YEAR_REV>2035914.8</PREV_YEAR_REV>
<BUDGET>2166159.63</BUDGET>
<GROSS_PROFIT>1871910.515</GROSS_PROFIT>
<EXPENSES>2070964.38</EXPENSES>
<NET_INCOME>163085.65</NET_INCOME>
<REVENUE_M>2.23405003</REVENUE_M>
<PROFIT_M>1.871910515</PROFIT_M>
<INCOME_M>0.16308565</INCOME_M>
<PHARMA_REV_M>2.23405003</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.871910515</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16308565</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2172789.16</REVENUE>
<PREV_YEAR_REV>1931350.98</PREV_YEAR_REV>
<BUDGET>2144289.32</BUDGET>
<GROSS_PROFIT>1818450.701</GROSS_PROFIT>
<EXPENSES>1783859.9</EXPENSES>
<NET_INCOME>388929.26</NET_INCOME>
<REVENUE_M>2.17278916</REVENUE_M>
<PROFIT_M>1.818450701</PROFIT_M>
<INCOME_M>0.38892926</INCOME_M>
<PHARMA_REV_M>2.17278916</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.818450701</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38892926</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4658914.02</REVENUE>
<PREV_YEAR_REV>4272543.79</PREV_YEAR_REV>
<BUDGET>4435997.83</BUDGET>
<GROSS_PROFIT>3619328.297</GROSS_PROFIT>
<EXPENSES>4039341.51</EXPENSES>
<NET_INCOME>619572.51</NET_INCOME>
<REVENUE_M>4.65891402</REVENUE_M>
<PROFIT_M>3.619328297</PROFIT_M>
<INCOME_M>0.61957251</INCOME_M>
<PHARMA_REV_M>4.65891402</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.619328297</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61957251</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1580623.26</REVENUE>
<PREV_YEAR_REV>1455829.55</PREV_YEAR_REV>
<BUDGET>1936463.79</BUDGET>
<GROSS_PROFIT>1286864.424</GROSS_PROFIT>
<EXPENSES>1327723.54</EXPENSES>
<NET_INCOME>252899.72</NET_INCOME>
<REVENUE_M>1.58062326</REVENUE_M>
<PROFIT_M>1.286864424</PROFIT_M>
<INCOME_M>0.25289972</INCOME_M>
<PHARMA_REV_M>1.58062326</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.286864424</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25289972</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1634076.72</REVENUE>
<PREV_YEAR_REV>1466565.6</PREV_YEAR_REV>
<BUDGET>1937992.77</BUDGET>
<GROSS_PROFIT>1421646.74</GROSS_PROFIT>
<EXPENSES>1514789.12</EXPENSES>
<NET_INCOME>119287.6</NET_INCOME>
<REVENUE_M>1.63407672</REVENUE_M>
<PROFIT_M>1.42164674</PROFIT_M>
<INCOME_M>0.1192876</INCOME_M>
<PHARMA_REV_M>1.63407672</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.42164674</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1192876</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1550539.89</REVENUE>
<PREV_YEAR_REV>1401922.12</PREV_YEAR_REV>
<BUDGET>1917445.01</BUDGET>
<GROSS_PROFIT>1278987.635</GROSS_PROFIT>
<EXPENSES>1392384.82</EXPENSES>
<NET_INCOME>158155.07</NET_INCOME>
<REVENUE_M>1.55053989</REVENUE_M>
<PROFIT_M>1.278987635</PROFIT_M>
<INCOME_M>0.15815507</INCOME_M>
<PHARMA_REV_M>1.55053989</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.278987635</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15815507</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1565931.12</REVENUE>
<PREV_YEAR_REV>1419058.56</PREV_YEAR_REV>
<BUDGET>1917445.01</BUDGET>
<GROSS_PROFIT>1221347.978</GROSS_PROFIT>
<EXPENSES>1296590.96</EXPENSES>
<NET_INCOME>269340.15</NET_INCOME>
<REVENUE_M>1.56593112</REVENUE_M>
<PROFIT_M>1.221347978</PROFIT_M>
<INCOME_M>0.26934015</INCOME_M>
<PHARMA_REV_M>1.56593112</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.221347978</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26934015</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1618466.68</REVENUE>
<PREV_YEAR_REV>1446428.48</PREV_YEAR_REV>
<BUDGET>1949615.74</BUDGET>
<GROSS_PROFIT>1234262.926</GROSS_PROFIT>
<EXPENSES>1340090.41</EXPENSES>
<NET_INCOME>278376.27</NET_INCOME>
<REVENUE_M>1.61846668</REVENUE_M>
<PROFIT_M>1.234262926</PROFIT_M>
<INCOME_M>0.27837627</INCOME_M>
<PHARMA_REV_M>1.61846668</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.234262926</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27837627</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1617278.45</REVENUE>
<PREV_YEAR_REV>1470413.54</PREV_YEAR_REV>
<BUDGET>1872814.17</BUDGET>
<GROSS_PROFIT>1353581.195</GROSS_PROFIT>
<EXPENSES>1452316.05</EXPENSES>
<NET_INCOME>164962.4</NET_INCOME>
<REVENUE_M>1.61727845</REVENUE_M>
<PROFIT_M>1.353581195</PROFIT_M>
<INCOME_M>0.1649624</INCOME_M>
<PHARMA_REV_M>1.61727845</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.353581195</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1649624</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3194508.25</REVENUE>
<PREV_YEAR_REV>2894136.32</PREV_YEAR_REV>
<BUDGET>3831347.77</BUDGET>
<GROSS_PROFIT>2594490.04</GROSS_PROFIT>
<EXPENSES>2768046.15</EXPENSES>
<NET_INCOME>426462.09</NET_INCOME>
<REVENUE_M>3.19450825</REVENUE_M>
<PROFIT_M>2.59449004</PROFIT_M>
<INCOME_M>0.42646209</INCOME_M>
<PHARMA_REV_M>3.19450825</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.59449004</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42646209</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1624533.31</REVENUE>
<PREV_YEAR_REV>1451707.53</PREV_YEAR_REV>
<BUDGET>1912948.02</BUDGET>
<GROSS_PROFIT>1276314.598</GROSS_PROFIT>
<EXPENSES>1345113.58</EXPENSES>
<NET_INCOME>279419.73</NET_INCOME>
<REVENUE_M>1.62453331</REVENUE_M>
<PROFIT_M>1.276314598</PROFIT_M>
<INCOME_M>0.27941973</INCOME_M>
<PHARMA_REV_M>1.62453331</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.276314598</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27941973</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1872323.38</REVENUE>
<PREV_YEAR_REV>1689746.3</PREV_YEAR_REV>
<BUDGET>1981140.97</BUDGET>
<GROSS_PROFIT>1509092.65</GROSS_PROFIT>
<EXPENSES>1668240.13</EXPENSES>
<NET_INCOME>204083.25</NET_INCOME>
<REVENUE_M>1.87232338</REVENUE_M>
<PROFIT_M>1.50909265</PROFIT_M>
<INCOME_M>0.20408325</INCOME_M>
<PHARMA_REV_M>1.87232338</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.50909265</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20408325</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1193728.23</REVENUE>
<PREV_YEAR_REV>1063995.29</PREV_YEAR_REV>
<BUDGET>1279943.15</BUDGET>
<GROSS_PROFIT>1000224.885</GROSS_PROFIT>
<EXPENSES>1002731.72</EXPENSES>
<NET_INCOME>190996.52</NET_INCOME>
<REVENUE_M>1.19372823</REVENUE_M>
<PROFIT_M>1.000224885</PROFIT_M>
<INCOME_M>0.19099652</INCOME_M>
<PHARMA_REV_M>1.19372823</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.000224885</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19099652</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1325993.37</REVENUE>
<PREV_YEAR_REV>1216630.46</PREV_YEAR_REV>
<BUDGET>1388964.86</BUDGET>
<GROSS_PROFIT>1053103.937</GROSS_PROFIT>
<EXPENSES>1088640.56</EXPENSES>
<NET_INCOME>237352.81</NET_INCOME>
<REVENUE_M>1.32599337</REVENUE_M>
<PROFIT_M>1.053103937</PROFIT_M>
<INCOME_M>0.23735281</INCOME_M>
<PHARMA_REV_M>1.32599337</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.053103937</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23735281</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2709922.28</REVENUE>
<PREV_YEAR_REV>2493472.52</PREV_YEAR_REV>
<BUDGET>2662989.52</BUDGET>
<GROSS_PROFIT>2234431.91</GROSS_PROFIT>
<EXPENSES>2348968.28</EXPENSES>
<NET_INCOME>360954</NET_INCOME>
<REVENUE_M>2.70992228</REVENUE_M>
<PROFIT_M>2.23443191</PROFIT_M>
<INCOME_M>0.360954</INCOME_M>
<PHARMA_REV_M>2.70992228</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.23443191</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.360954</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8453529.82</REVENUE>
<PREV_YEAR_REV>7575526.32</PREV_YEAR_REV>
<BUDGET>8622600.42</BUDGET>
<GROSS_PROFIT>6504991.2</GROSS_PROFIT>
<EXPENSES>7363024.48</EXPENSES>
<NET_INCOME>1090505.35</NET_INCOME>
<REVENUE_M>8.45352982</REVENUE_M>
<PROFIT_M>6.5049912</PROFIT_M>
<INCOME_M>1.09050535</INCOME_M>
<PHARMA_REV_M>8.45352982</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.5049912</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.09050535</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.805231172E7</REVENUE>
<PREV_YEAR_REV>1.602079256E7</PREV_YEAR_REV>
<BUDGET>1.841335794E7</BUDGET>
<GROSS_PROFIT>1.567032278E7</GROSS_PROFIT>
<EXPENSES>1.63105499E7</EXPENSES>
<NET_INCOME>1741761.82</NET_INCOME>
<REVENUE_M>18.05231172</REVENUE_M>
<PROFIT_M>15.67032278</PROFIT_M>
<INCOME_M>1.74176182</INCOME_M>
<PHARMA_REV_M>18.05231172</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.67032278</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.74176182</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7379032.55</REVENUE>
<PREV_YEAR_REV>6428400.66</PREV_YEAR_REV>
<BUDGET>7526613.2</BUDGET>
<GROSS_PROFIT>5629094.974</GROSS_PROFIT>
<EXPENSES>6109838.95</EXPENSES>
<NET_INCOME>1269193.6</NET_INCOME>
<REVENUE_M>7.37903255</REVENUE_M>
<PROFIT_M>5.629094974</PROFIT_M>
<INCOME_M>1.2691936</INCOME_M>
<PHARMA_REV_M>7.37903255</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.629094974</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.2691936</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>4796824.04</REVENUE>
<PREV_YEAR_REV>4280547.24</PREV_YEAR_REV>
<BUDGET>4892760.52</BUDGET>
<GROSS_PROFIT>3902964.665</GROSS_PROFIT>
<EXPENSES>4307547.99</EXPENSES>
<NET_INCOME>489276.05</NET_INCOME>
<REVENUE_M>4.79682404</REVENUE_M>
<PROFIT_M>3.902964665</PROFIT_M>
<INCOME_M>0.48927605</INCOME_M>
<PHARMA_REV_M>4.79682404</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.902964665</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48927605</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8545570.3</REVENUE>
<PREV_YEAR_REV>7475981.61</PREV_YEAR_REV>
<BUDGET>8716481.71</BUDGET>
<GROSS_PROFIT>7071032.144</GROSS_PROFIT>
<EXPENSES>7673922.13</EXPENSES>
<NET_INCOME>871648.17</NET_INCOME>
<REVENUE_M>8.5455703</REVENUE_M>
<PROFIT_M>7.071032144</PROFIT_M>
<INCOME_M>0.87164817</INCOME_M>
<PHARMA_REV_M>8.5455703</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.071032144</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.87164817</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3736013.75</REVENUE>
<PREV_YEAR_REV>3241134.94</PREV_YEAR_REV>
<BUDGET>4004787.43</BUDGET>
<GROSS_PROFIT>2730615.393</GROSS_PROFIT>
<EXPENSES>3284808.12</EXPENSES>
<NET_INCOME>451205.63</NET_INCOME>
<REVENUE_M>3.73601375</REVENUE_M>
<PROFIT_M>2.730615393</PROFIT_M>
<INCOME_M>0.45120563</INCOME_M>
<PHARMA_REV_M>3.73601375</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.730615393</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45120563</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4383835.68</REVENUE>
<PREV_YEAR_REV>3889984.77</PREV_YEAR_REV>
<BUDGET>4577411.08</BUDGET>
<GROSS_PROFIT>3325046.297</GROSS_PROFIT>
<EXPENSES>3895552.99</EXPENSES>
<NET_INCOME>488282.69</NET_INCOME>
<REVENUE_M>4.38383568</REVENUE_M>
<PROFIT_M>3.325046297</PROFIT_M>
<INCOME_M>0.48828269</INCOME_M>
<PHARMA_REV_M>4.38383568</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.325046297</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48828269</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2766354.89</REVENUE>
<PREV_YEAR_REV>2578149.94</PREV_YEAR_REV>
<BUDGET>2063891.86</BUDGET>
<GROSS_PROFIT>2155305.823</GROSS_PROFIT>
<EXPENSES>2290541.85</EXPENSES>
<NET_INCOME>475813.04</NET_INCOME>
<REVENUE_M>2.76635489</REVENUE_M>
<PROFIT_M>2.155305823</PROFIT_M>
<INCOME_M>0.47581304</INCOME_M>
<PHARMA_REV_M>2.76635489</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.155305823</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47581304</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1934020.45</REVENUE>
<PREV_YEAR_REV>1740870.83</PREV_YEAR_REV>
<BUDGET>1757008.82</BUDGET>
<GROSS_PROFIT>1568490.59</GROSS_PROFIT>
<EXPENSES>1624577.18</EXPENSES>
<NET_INCOME>309443.27</NET_INCOME>
<REVENUE_M>1.93402045</REVENUE_M>
<PROFIT_M>1.56849059</PROFIT_M>
<INCOME_M>0.30944327</INCOME_M>
<PHARMA_REV_M>1.93402045</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.56849059</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30944327</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2051365.79</REVENUE>
<PREV_YEAR_REV>1869091.95</PREV_YEAR_REV>
<BUDGET>1758601.49</BUDGET>
<GROSS_PROFIT>1614301.795</GROSS_PROFIT>
<EXPENSES>1684171.32</EXPENSES>
<NET_INCOME>367194.48</NET_INCOME>
<REVENUE_M>2.05136579</REVENUE_M>
<PROFIT_M>1.614301795</PROFIT_M>
<INCOME_M>0.36719448</INCOME_M>
<PHARMA_REV_M>2.05136579</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.614301795</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36719448</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2141453.38</REVENUE>
<PREV_YEAR_REV>1936529.8</PREV_YEAR_REV>
<BUDGET>1758601.49</BUDGET>
<GROSS_PROFIT>1751601.792</GROSS_PROFIT>
<EXPENSES>1758133.23</EXPENSES>
<NET_INCOME>383320.16</NET_INCOME>
<REVENUE_M>2.14145338</REVENUE_M>
<PROFIT_M>1.751601792</PROFIT_M>
<INCOME_M>0.38332016</INCOME_M>
<PHARMA_REV_M>2.14145338</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.751601792</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38332016</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1375619.83</REVENUE>
<PREV_YEAR_REV>1231663.05</PREV_YEAR_REV>
<BUDGET>917652.81</BUDGET>
<GROSS_PROFIT>1082062.557</GROSS_PROFIT>
<EXPENSES>1198164.87</EXPENSES>
<NET_INCOME>177454.96</NET_INCOME>
<REVENUE_M>1.37561983</REVENUE_M>
<PROFIT_M>1.082062557</PROFIT_M>
<INCOME_M>0.17745496</INCOME_M>
<PHARMA_REV_M>1.37561983</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.082062557</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17745496</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1764568.49</REVENUE>
<PREV_YEAR_REV>1609934.3</PREV_YEAR_REV>
<BUDGET>1273901.29</BUDGET>
<GROSS_PROFIT>1419860.035</GROSS_PROFIT>
<EXPENSES>1448710.73</EXPENSES>
<NET_INCOME>315857.76</NET_INCOME>
<REVENUE_M>1.76456849</REVENUE_M>
<PROFIT_M>1.419860035</PROFIT_M>
<INCOME_M>0.31585776</INCOME_M>
<PHARMA_REV_M>1.76456849</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.419860035</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31585776</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6453927.32</REVENUE>
<PREV_YEAR_REV>5771040.14</PREV_YEAR_REV>
<BUDGET>5808534.59</BUDGET>
<GROSS_PROFIT>5260402.544</GROSS_PROFIT>
<EXPENSES>5602008.92</EXPENSES>
<NET_INCOME>851918.41</NET_INCOME>
<REVENUE_M>6.45392732</REVENUE_M>
<PROFIT_M>5.260402544</PROFIT_M>
<INCOME_M>0.85191841</INCOME_M>
<PHARMA_REV_M>6.45392732</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.260402544</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.85191841</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7889058.29</REVENUE>
<PREV_YEAR_REV>7183256.69</PREV_YEAR_REV>
<BUDGET>7100152.46</BUDGET>
<GROSS_PROFIT>5994997.977</GROSS_PROFIT>
<EXPENSES>6934390.78</EXPENSES>
<NET_INCOME>954667.51</NET_INCOME>
<REVENUE_M>7.88905829</REVENUE_M>
<PROFIT_M>5.994997977</PROFIT_M>
<INCOME_M>0.95466751</INCOME_M>
<PHARMA_REV_M>7.88905829</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.994997977</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.95466751</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8508840.36</REVENUE>
<PREV_YEAR_REV>7717209.06</PREV_YEAR_REV>
<BUDGET>7657956.32</BUDGET>
<GROSS_PROFIT>6915104.785</GROSS_PROFIT>
<EXPENSES>7045319.82</EXPENSES>
<NET_INCOME>1463520.54</NET_INCOME>
<REVENUE_M>8.50884036</REVENUE_M>
<PROFIT_M>6.915104785</PROFIT_M>
<INCOME_M>1.46352054</INCOME_M>
<PHARMA_REV_M>8.50884036</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.915104785</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.46352054</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4767474.48</REVENUE>
<PREV_YEAR_REV>4254520</PREV_YEAR_REV>
<BUDGET>4316718.05</BUDGET>
<GROSS_PROFIT>3459372.183</GROSS_PROFIT>
<EXPENSES>4189550.07</EXPENSES>
<NET_INCOME>577924.41</NET_INCOME>
<REVENUE_M>4.76747448</REVENUE_M>
<PROFIT_M>3.459372183</PROFIT_M>
<INCOME_M>0.57792441</INCOME_M>
<PHARMA_REV_M>4.76747448</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.459372183</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57792441</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2400177.45</REVENUE>
<PREV_YEAR_REV>2051275.93</PREV_YEAR_REV>
<BUDGET>2144754.08</BUDGET>
<GROSS_PROFIT>1826415.033</GROSS_PROFIT>
<EXPENSES>2016149.06</EXPENSES>
<NET_INCOME>384028.39</NET_INCOME>
<REVENUE_M>2.40017745</REVENUE_M>
<PROFIT_M>1.826415033</PROFIT_M>
<INCOME_M>0.38402839</INCOME_M>
<PHARMA_REV_M>2.40017745</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.826415033</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38402839</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2439866.88</REVENUE>
<PREV_YEAR_REV>2192646.04</PREV_YEAR_REV>
<BUDGET>2144754.08</BUDGET>
<GROSS_PROFIT>1835624.089</GROSS_PROFIT>
<EXPENSES>2110484.85</EXPENSES>
<NET_INCOME>329382.03</NET_INCOME>
<REVENUE_M>2.43986688</REVENUE_M>
<PROFIT_M>1.835624089</PROFIT_M>
<INCOME_M>0.32938203</INCOME_M>
<PHARMA_REV_M>2.43986688</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.835624089</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32938203</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2251627.75</REVENUE>
<PREV_YEAR_REV>1973484.8</PREV_YEAR_REV>
<BUDGET>2146447.51</BUDGET>
<GROSS_PROFIT>1606986.729</GROSS_PROFIT>
<EXPENSES>1947658</EXPENSES>
<NET_INCOME>303969.75</NET_INCOME>
<REVENUE_M>2.25162775</REVENUE_M>
<PROFIT_M>1.606986729</PROFIT_M>
<INCOME_M>0.30396975</INCOME_M>
<PHARMA_REV_M>2.25162775</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.606986729</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30396975</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4625156.56</REVENUE>
<PREV_YEAR_REV>4051604.71</PREV_YEAR_REV>
<BUDGET>4309055.45</BUDGET>
<GROSS_PROFIT>3764655.59</GROSS_PROFIT>
<EXPENSES>4010049.28</EXPENSES>
<NET_INCOME>615107.28</NET_INCOME>
<REVENUE_M>4.62515656</REVENUE_M>
<PROFIT_M>3.76465559</PROFIT_M>
<INCOME_M>0.61510728</INCOME_M>
<PHARMA_REV_M>4.62515656</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.76465559</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61510728</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4429838.07</REVENUE>
<PREV_YEAR_REV>3905839.1</PREV_YEAR_REV>
<BUDGET>4243455.93</BUDGET>
<GROSS_PROFIT>3562253.33</GROSS_PROFIT>
<EXPENSES>3841184.24</EXPENSES>
<NET_INCOME>588653.82</NET_INCOME>
<REVENUE_M>4.42983807</REVENUE_M>
<PROFIT_M>3.56225333</PROFIT_M>
<INCOME_M>0.58865382</INCOME_M>
<PHARMA_REV_M>4.42983807</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.56225333</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58865382</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1711841.94</REVENUE>
<PREV_YEAR_REV>1542908.85</PREV_YEAR_REV>
<BUDGET>1235772.81</BUDGET>
<GROSS_PROFIT>1444794.59</GROSS_PROFIT>
<EXPENSES>1586877.47</EXPENSES>
<NET_INCOME>124964.46</NET_INCOME>
<REVENUE_M>1.71184194</REVENUE_M>
<PROFIT_M>1.44479459</PROFIT_M>
<INCOME_M>0.12496446</INCOME_M>
<PHARMA_REV_M>1.71184194</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.44479459</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12496446</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1795967.02</REVENUE>
<PREV_YEAR_REV>1600498.18</PREV_YEAR_REV>
<BUDGET>1372673.17</BUDGET>
<GROSS_PROFIT>1385835.509</GROSS_PROFIT>
<EXPENSES>1612778.39</EXPENSES>
<NET_INCOME>183188.64</NET_INCOME>
<REVENUE_M>1.79596702</REVENUE_M>
<PROFIT_M>1.385835509</PROFIT_M>
<INCOME_M>0.18318864</INCOME_M>
<PHARMA_REV_M>1.79596702</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.385835509</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18318864</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7546043.48</REVENUE>
<PREV_YEAR_REV>6766477.59</PREV_YEAR_REV>
<BUDGET>7395122.61</BUDGET>
<GROSS_PROFIT>5772723.255</GROSS_PROFIT>
<EXPENSES>6572603.87</EXPENSES>
<NET_INCOME>973439.61</NET_INCOME>
<REVENUE_M>7.54604348</REVENUE_M>
<PROFIT_M>5.772723255</PROFIT_M>
<INCOME_M>0.97343961</INCOME_M>
<PHARMA_REV_M>7.54604348</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.772723255</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.97343961</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>9836950.1</REVENUE>
<PREV_YEAR_REV>8644296.51</PREV_YEAR_REV>
<BUDGET>9640211.09</BUDGET>
<GROSS_PROFIT>8577820.48</GROSS_PROFIT>
<EXPENSES>8764722.54</EXPENSES>
<NET_INCOME>1072227.56</NET_INCOME>
<REVENUE_M>9.8369501</REVENUE_M>
<PROFIT_M>8.57782048</PROFIT_M>
<INCOME_M>1.07222756</INCOME_M>
<PHARMA_REV_M>9.8369501</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.57782048</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.07222756</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2965286.59</REVENUE>
<PREV_YEAR_REV>2521266.37</PREV_YEAR_REV>
<BUDGET>2700560.17</BUDGET>
<GROSS_PROFIT>2180375.232</GROSS_PROFIT>
<EXPENSES>2582764.62</EXPENSES>
<NET_INCOME>382521.97</NET_INCOME>
<REVENUE_M>2.96528659</REVENUE_M>
<PROFIT_M>2.180375232</PROFIT_M>
<INCOME_M>0.38252197</INCOME_M>
<PHARMA_REV_M>2.96528659</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.180375232</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38252197</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5067775.39</REVENUE>
<PREV_YEAR_REV>4336517.4</PREV_YEAR_REV>
<BUDGET>4560274.69</BUDGET>
<GROSS_PROFIT>3869874.667</GROSS_PROFIT>
<EXPENSES>4507083.12</EXPENSES>
<NET_INCOME>560692.27</NET_INCOME>
<REVENUE_M>5.06777539</REVENUE_M>
<PROFIT_M>3.869874667</PROFIT_M>
<INCOME_M>0.56069227</INCOME_M>
<PHARMA_REV_M>5.06777539</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.869874667</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56069227</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3653599.16</REVENUE>
<PREV_YEAR_REV>3140722.86</PREV_YEAR_REV>
<BUDGET>3543991.18</BUDGET>
<GROSS_PROFIT>2801031.804</GROSS_PROFIT>
<EXPENSES>3162190.08</EXPENSES>
<NET_INCOME>491409.09</NET_INCOME>
<REVENUE_M>3.65359916</REVENUE_M>
<PROFIT_M>2.801031804</PROFIT_M>
<INCOME_M>0.49140909</INCOME_M>
<PHARMA_REV_M>3.65359916</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.801031804</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49140909</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1861733.87</REVENUE>
<PREV_YEAR_REV>1620745.26</PREV_YEAR_REV>
<BUDGET>1805881.85</BUDGET>
<GROSS_PROFIT>1488791.343</GROSS_PROFIT>
<EXPENSES>1658804.88</EXPENSES>
<NET_INCOME>202928.99</NET_INCOME>
<REVENUE_M>1.86173387</REVENUE_M>
<PROFIT_M>1.488791343</PROFIT_M>
<INCOME_M>0.20292899</INCOME_M>
<PHARMA_REV_M>1.86173387</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.488791343</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20292899</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1792774.9</REVENUE>
<PREV_YEAR_REV>1575304.16</PREV_YEAR_REV>
<BUDGET>1738991.66</BUDGET>
<GROSS_PROFIT>1339686.902</GROSS_PROFIT>
<EXPENSES>1609911.86</EXPENSES>
<NET_INCOME>182863.04</NET_INCOME>
<REVENUE_M>1.7927749</REVENUE_M>
<PROFIT_M>1.339686902</PROFIT_M>
<INCOME_M>0.18286304</INCOME_M>
<PHARMA_REV_M>1.7927749</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.339686902</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18286304</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1784278.62</REVENUE>
<PREV_YEAR_REV>1617278.45</PREV_YEAR_REV>
<BUDGET>1730750.26</BUDGET>
<GROSS_PROFIT>1334015.907</GROSS_PROFIT>
<EXPENSES>1602282.2</EXPENSES>
<NET_INCOME>181996.42</NET_INCOME>
<REVENUE_M>1.78427862</REVENUE_M>
<PROFIT_M>1.334015907</PROFIT_M>
<INCOME_M>0.18199642</INCOME_M>
<PHARMA_REV_M>1.78427862</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.334015907</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18199642</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3650224.38</REVENUE>
<PREV_YEAR_REV>3194508.25</PREV_YEAR_REV>
<BUDGET>3540717.65</BUDGET>
<GROSS_PROFIT>3008172.93</GROSS_PROFIT>
<EXPENSES>3165243.82</EXPENSES>
<NET_INCOME>484980.56</NET_INCOME>
<REVENUE_M>3.65022438</REVENUE_M>
<PROFIT_M>3.00817293</PROFIT_M>
<INCOME_M>0.48498056</INCOME_M>
<PHARMA_REV_M>3.65022438</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.00817293</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48498056</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1218921.36</REVENUE>
<PREV_YEAR_REV>1046140.75</PREV_YEAR_REV>
<BUDGET>1182353.72</BUDGET>
<GROSS_PROFIT>976356.01</GROSS_PROFIT>
<EXPENSES>1023893.94</EXPENSES>
<NET_INCOME>195027.42</NET_INCOME>
<REVENUE_M>1.21892136</REVENUE_M>
<PROFIT_M>0.97635601</PROFIT_M>
<INCOME_M>0.19502742</INCOME_M>
<PHARMA_REV_M>1.21892136</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.97635601</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19502742</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5698862.73</REVENUE>
<PREV_YEAR_REV>5061304.29</PREV_YEAR_REV>
<BUDGET>5334298.8</BUDGET>
<GROSS_PROFIT>4691196.486</GROSS_PROFIT>
<EXPENSES>4932310.94</EXPENSES>
<NET_INCOME>766551.78</NET_INCOME>
<REVENUE_M>5.69886273</REVENUE_M>
<PROFIT_M>4.691196486</PROFIT_M>
<INCOME_M>0.76655178</INCOME_M>
<PHARMA_REV_M>5.69886273</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.691196486</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76655178</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3005003.95</REVENUE>
<PREV_YEAR_REV>2592979.51</PREV_YEAR_REV>
<BUDGET>2661179.06</BUDGET>
<GROSS_PROFIT>2601041.274</GROSS_PROFIT>
<EXPENSES>2677458.52</EXPENSES>
<NET_INCOME>327545.43</NET_INCOME>
<REVENUE_M>3.00500395</REVENUE_M>
<PROFIT_M>2.601041274</PROFIT_M>
<INCOME_M>0.32754543</INCOME_M>
<PHARMA_REV_M>3.00500395</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.601041274</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32754543</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2806055.31</REVENUE>
<PREV_YEAR_REV>2495890.95</PREV_YEAR_REV>
<BUDGET>2650583.25</BUDGET>
<GROSS_PROFIT>2177947.896</GROSS_PROFIT>
<EXPENSES>2427237.85</EXPENSES>
<NET_INCOME>378817.47</NET_INCOME>
<REVENUE_M>2.80605531</REVENUE_M>
<PROFIT_M>2.177947896</PROFIT_M>
<INCOME_M>0.37881747</INCOME_M>
<PHARMA_REV_M>2.80605531</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.177947896</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37881747</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1987679.43</REVENUE>
<PREV_YEAR_REV>1717276.99</PREV_YEAR_REV>
<BUDGET>2344123.1</BUDGET>
<GROSS_PROFIT>1743194.86</GROSS_PROFIT>
<EXPENSES>1669650.72</EXPENSES>
<NET_INCOME>318028.71</NET_INCOME>
<REVENUE_M>1.98767943</REVENUE_M>
<PROFIT_M>1.74319486</PROFIT_M>
<INCOME_M>0.31802871</INCOME_M>
<PHARMA_REV_M>1.98767943</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.74319486</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31802871</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4209007.24</REVENUE>
<PREV_YEAR_REV>3601895.13</PREV_YEAR_REV>
<BUDGET>4723447.97</BUDGET>
<GROSS_PROFIT>3209119.146</GROSS_PROFIT>
<EXPENSES>3582762.61</EXPENSES>
<NET_INCOME>626244.65</NET_INCOME>
<REVENUE_M>4.20900724</REVENUE_M>
<PROFIT_M>3.209119146</PROFIT_M>
<INCOME_M>0.62624465</INCOME_M>
<PHARMA_REV_M>4.20900724</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.209119146</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62624465</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1991978.01</REVENUE>
<PREV_YEAR_REV>1779727.69</PREV_YEAR_REV>
<BUDGET>2346247.97</BUDGET>
<GROSS_PROFIT>1570674.663</GROSS_PROFIT>
<EXPENSES>1635413.95</EXPENSES>
<NET_INCOME>356564.06</NET_INCOME>
<REVENUE_M>1.99197801</REVENUE_M>
<PROFIT_M>1.570674663</PROFIT_M>
<INCOME_M>0.35656406</INCOME_M>
<PHARMA_REV_M>1.99197801</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.570674663</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35656406</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4138203.92</REVENUE>
<PREV_YEAR_REV>3589083.68</PREV_YEAR_REV>
<BUDGET>4749376.48</BUDGET>
<GROSS_PROFIT>3555194.79</GROSS_PROFIT>
<EXPENSES>3582272.21</EXPENSES>
<NET_INCOME>555931.71</NET_INCOME>
<REVENUE_M>4.13820392</REVENUE_M>
<PROFIT_M>3.55519479</PROFIT_M>
<INCOME_M>0.55593171</INCOME_M>
<PHARMA_REV_M>4.13820392</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.55519479</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55593171</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2067073.99</REVENUE>
<PREV_YEAR_REV>1867022.53</PREV_YEAR_REV>
<BUDGET>2369519.97</BUDGET>
<GROSS_PROFIT>1489521.115</GROSS_PROFIT>
<EXPENSES>1788019</EXPENSES>
<NET_INCOME>279054.99</NET_INCOME>
<REVENUE_M>2.06707399</REVENUE_M>
<PROFIT_M>1.489521115</PROFIT_M>
<INCOME_M>0.27905499</INCOME_M>
<PHARMA_REV_M>2.06707399</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.489521115</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27905499</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4136558.83</REVENUE>
<PREV_YEAR_REV>3664088.32</PREV_YEAR_REV>
<BUDGET>4688161.54</BUDGET>
<GROSS_PROFIT>3382871.22</GROSS_PROFIT>
<EXPENSES>3585178.09</EXPENSES>
<NET_INCOME>551380.74</NET_INCOME>
<REVENUE_M>4.13655883</REVENUE_M>
<PROFIT_M>3.38287122</PROFIT_M>
<INCOME_M>0.55138074</INCOME_M>
<PHARMA_REV_M>4.13655883</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.38287122</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55138074</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3465826.25</REVENUE>
<PREV_YEAR_REV>2978296.24</PREV_YEAR_REV>
<BUDGET>3336795</BUDGET>
<GROSS_PROFIT>2532616.353</GROSS_PROFIT>
<EXPENSES>3047411.71</EXPENSES>
<NET_INCOME>418414.54</NET_INCOME>
<REVENUE_M>3.46582625</REVENUE_M>
<PROFIT_M>2.532616353</PROFIT_M>
<INCOME_M>0.41841454</INCOME_M>
<PHARMA_REV_M>3.46582625</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.532616353</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41841454</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1702578.87</REVENUE>
<PREV_YEAR_REV>1488515.46</PREV_YEAR_REV>
<BUDGET>1699582.5</BUDGET>
<GROSS_PROFIT>1268080.748</GROSS_PROFIT>
<EXPENSES>1397817.25</EXPENSES>
<NET_INCOME>304761.62</NET_INCOME>
<REVENUE_M>1.70257887</REVENUE_M>
<PROFIT_M>1.268080748</PROFIT_M>
<INCOME_M>0.30476162</INCOME_M>
<PHARMA_REV_M>1.70257887</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.268080748</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30476162</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3091420.8</REVENUE>
<PREV_YEAR_REV>2700853.69</PREV_YEAR_REV>
<BUDGET>3209684.94</BUDGET>
<GROSS_PROFIT>2535504.76</GROSS_PROFIT>
<EXPENSES>2675308.53</EXPENSES>
<NET_INCOME>416112.27</NET_INCOME>
<REVENUE_M>3.0914208</REVENUE_M>
<PROFIT_M>2.53550476</PROFIT_M>
<INCOME_M>0.41611227</INCOME_M>
<PHARMA_REV_M>3.0914208</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.53550476</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41611227</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1482800.46</REVENUE>
<PREV_YEAR_REV>1287566.72</PREV_YEAR_REV>
<BUDGET>1516526.55</BUDGET>
<GROSS_PROFIT>1128125.713</GROSS_PROFIT>
<EXPENSES>1331554.81</EXPENSES>
<NET_INCOME>151245.65</NET_INCOME>
<REVENUE_M>1.48280046</REVENUE_M>
<PROFIT_M>1.128125713</PROFIT_M>
<INCOME_M>0.15124565</INCOME_M>
<PHARMA_REV_M>1.48280046</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.128125713</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15124565</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.570340356E7</REVENUE>
<PREV_YEAR_REV>1.393339045E7</PREV_YEAR_REV>
<BUDGET>1.444713128E7</BUDGET>
<GROSS_PROFIT>1.258833608E7</GROSS_PROFIT>
<EXPENSES>1.395439575E7</EXPENSES>
<NET_INCOME>1749007.81</NET_INCOME>
<REVENUE_M>15.70340356</REVENUE_M>
<PROFIT_M>12.58833608</PROFIT_M>
<INCOME_M>1.74900781</INCOME_M>
<PHARMA_REV_M>15.70340356</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.58833608</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.74900781</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.111093128E7</REVENUE>
<PREV_YEAR_REV>9903585.21</PREV_YEAR_REV>
<BUDGET>1.022205678E7</BUDGET>
<GROSS_PROFIT>8699859.19</GROSS_PROFIT>
<EXPENSES>9644288.35</EXPENSES>
<NET_INCOME>1466642.93</NET_INCOME>
<REVENUE_M>11.11093128</REVENUE_M>
<PROFIT_M>8.69985919</PROFIT_M>
<INCOME_M>1.46664293</INCOME_M>
<PHARMA_REV_M>11.11093128</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.69985919</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.46664293</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>2.497976841E7</REVENUE>
<PREV_YEAR_REV>2.135892713E7</PREV_YEAR_REV>
<BUDGET>2.298138694E7</BUDGET>
<GROSS_PROFIT>2.054121667E7</GROSS_PROFIT>
<EXPENSES>2.255495268E7</EXPENSES>
<NET_INCOME>2424815.72</NET_INCOME>
<REVENUE_M>24.97976841</REVENUE_M>
<PROFIT_M>20.54121667</PROFIT_M>
<INCOME_M>2.42481572</INCOME_M>
<PHARMA_REV_M>24.97976841</PHARMA_REV_M>
<PHARMA_PROFIT_M>20.54121667</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.42481572</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7067527.1</REVENUE>
<PREV_YEAR_REV>6009086.59</PREV_YEAR_REV>
<BUDGET>6502124.93</BUDGET>
<GROSS_PROFIT>5943790.29</GROSS_PROFIT>
<EXPENSES>5802439.75</EXPENSES>
<NET_INCOME>1265087.35</NET_INCOME>
<REVENUE_M>7.0675271</REVENUE_M>
<PROFIT_M>5.94379029</PROFIT_M>
<INCOME_M>1.26508735</INCOME_M>
<PHARMA_REV_M>7.0675271</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.94379029</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.26508735</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.236710446E7</REVENUE>
<PREV_YEAR_REV>1.103465034E7</PREV_YEAR_REV>
<BUDGET>1.13777361E7</BUDGET>
<GROSS_PROFIT>1.07160947E7</GROSS_PROFIT>
<EXPENSES>1.072840974E7</EXPENSES>
<NET_INCOME>1638694.71</NET_INCOME>
<REVENUE_M>12.36710446</REVENUE_M>
<PROFIT_M>10.7160947</PROFIT_M>
<INCOME_M>1.63869471</INCOME_M>
<PHARMA_REV_M>12.36710446</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.7160947</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.63869471</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8745166</REVENUE>
<PREV_YEAR_REV>7920915.53</PREV_YEAR_REV>
<BUDGET>8045552.72</BUDGET>
<GROSS_PROFIT>6538323.358</GROSS_PROFIT>
<EXPENSES>7240997.45</EXPENSES>
<NET_INCOME>1504168.55</NET_INCOME>
<REVENUE_M>8.745166</REVENUE_M>
<PROFIT_M>6.538323358</PROFIT_M>
<INCOME_M>1.50416855</INCOME_M>
<PHARMA_REV_M>8.745166</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.538323358</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.50416855</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5171592.83</REVENUE>
<PREV_YEAR_REV>4512971.66</PREV_YEAR_REV>
<BUDGET>5016445.04</BUDGET>
<GROSS_PROFIT>3729013.45</GROSS_PROFIT>
<EXPENSES>4402860.53</EXPENSES>
<NET_INCOME>768732.29</NET_INCOME>
<REVENUE_M>5.17159283</REVENUE_M>
<PROFIT_M>3.72901345</PROFIT_M>
<INCOME_M>0.76873229</INCOME_M>
<PHARMA_REV_M>5.17159283</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.72901345</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76873229</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4441356.36</REVENUE>
<PREV_YEAR_REV>3803129.34</PREV_YEAR_REV>
<BUDGET>4308115.66</BUDGET>
<GROSS_PROFIT>3325384.437</GROSS_PROFIT>
<EXPENSES>3787791.12</EXPENSES>
<NET_INCOME>653565.24</NET_INCOME>
<REVENUE_M>4.44135636</REVENUE_M>
<PROFIT_M>3.325384437</PROFIT_M>
<INCOME_M>0.65356524</INCOME_M>
<PHARMA_REV_M>4.44135636</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.325384437</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65356524</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2602933.99</REVENUE>
<PREV_YEAR_REV>2351510.49</PREV_YEAR_REV>
<BUDGET>2524845.97</BUDGET>
<GROSS_PROFIT>2076646.76</GROSS_PROFIT>
<EXPENSES>2155229.34</EXPENSES>
<NET_INCOME>447704.65</NET_INCOME>
<REVENUE_M>2.60293399</REVENUE_M>
<PROFIT_M>2.07664676</PROFIT_M>
<INCOME_M>0.44770465</INCOME_M>
<PHARMA_REV_M>2.60293399</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.07664676</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44770465</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5267550.07</REVENUE>
<PREV_YEAR_REV>4658914.02</PREV_YEAR_REV>
<BUDGET>5109523.56</BUDGET>
<GROSS_PROFIT>4524028.253</GROSS_PROFIT>
<EXPENSES>4568026.57</EXPENSES>
<NET_INCOME>699523.48</NET_INCOME>
<REVENUE_M>5.26755007</REVENUE_M>
<PROFIT_M>4.524028253</PROFIT_M>
<INCOME_M>0.69952348</INCOME_M>
<PHARMA_REV_M>5.26755007</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.524028253</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69952348</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3655356.87</REVENUE>
<PREV_YEAR_REV>3115531.07</PREV_YEAR_REV>
<BUDGET>3545696.16</BUDGET>
<GROSS_PROFIT>2875769.586</GROSS_PROFIT>
<EXPENSES>3249586.1</EXPENSES>
<NET_INCOME>405770.75</NET_INCOME>
<REVENUE_M>3.65535687</REVENUE_M>
<PROFIT_M>2.875769586</PROFIT_M>
<INCOME_M>0.40577075</INCOME_M>
<PHARMA_REV_M>3.65535687</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.875769586</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40577075</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1844919.27</REVENUE>
<PREV_YEAR_REV>1580623.26</PREV_YEAR_REV>
<BUDGET>1789571.69</BUDGET>
<GROSS_PROFIT>1459976.863</GROSS_PROFIT>
<EXPENSES>1549732.19</EXPENSES>
<NET_INCOME>295187.08</NET_INCOME>
<REVENUE_M>1.8449192700000001</REVENUE_M>
<PROFIT_M>1.459976863</PROFIT_M>
<INCOME_M>0.29518708</INCOME_M>
<PHARMA_REV_M>1.8449192700000001</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.459976863</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29518708</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1630727.18</REVENUE>
<PREV_YEAR_REV>1393033.82</PREV_YEAR_REV>
<BUDGET>2099372.33</BUDGET>
<GROSS_PROFIT>1257942.947</GROSS_PROFIT>
<EXPENSES>1452977.91</EXPENSES>
<NET_INCOME>177749.26</NET_INCOME>
<REVENUE_M>1.63072718</REVENUE_M>
<PROFIT_M>1.257942947</PROFIT_M>
<INCOME_M>0.17774926</INCOME_M>
<PHARMA_REV_M>1.63072718</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.257942947</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17774926</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3169183.93</REVENUE>
<PREV_YEAR_REV>2826596.53</PREV_YEAR_REV>
<BUDGET>4116152.25</BUDGET>
<GROSS_PROFIT>2666600.79</GROSS_PROFIT>
<EXPENSES>2749959.39</EXPENSES>
<NET_INCOME>419224.54</NET_INCOME>
<REVENUE_M>3.16918393</REVENUE_M>
<PROFIT_M>2.66660079</PROFIT_M>
<INCOME_M>0.41922454</INCOME_M>
<PHARMA_REV_M>3.16918393</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.66660079</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41922454</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2596132.95</REVENUE>
<PREV_YEAR_REV>2286604.6</PREV_YEAR_REV>
<BUDGET>2919517.89</BUDGET>
<GROSS_PROFIT>1927575.252</GROSS_PROFIT>
<EXPENSES>2283367.11</EXPENSES>
<NET_INCOME>312765.85</NET_INCOME>
<REVENUE_M>2.59613295</REVENUE_M>
<PROFIT_M>1.927575252</PROFIT_M>
<INCOME_M>0.31276585</INCOME_M>
<PHARMA_REV_M>2.59613295</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.927575252</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31276585</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3699529.87</REVENUE>
<PREV_YEAR_REV>3229036.87</PREV_YEAR_REV>
<BUDGET>4269136.14</BUDGET>
<GROSS_PROFIT>2931514.294</GROSS_PROFIT>
<EXPENSES>3343978</EXPENSES>
<NET_INCOME>355551.89</NET_INCOME>
<REVENUE_M>3.69952987</REVENUE_M>
<PROFIT_M>2.931514294</PROFIT_M>
<INCOME_M>0.35555189</INCOME_M>
<PHARMA_REV_M>3.69952987</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.931514294</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35555189</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.259089048E7</REVENUE>
<PREV_YEAR_REV>1.136319405E7</PREV_YEAR_REV>
<BUDGET>1.221316376E7</BUDGET>
<GROSS_PROFIT>1.020542236E7</GROSS_PROFIT>
<EXPENSES>1.089911598E7</EXPENSES>
<NET_INCOME>1691774.5</NET_INCOME>
<REVENUE_M>12.59089048</REVENUE_M>
<PROFIT_M>10.20542236</PROFIT_M>
<INCOME_M>1.6917745</INCOME_M>
<PHARMA_REV_M>12.59089048</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.20542236</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.6917745</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>2.171819494E7</REVENUE>
<PREV_YEAR_REV>1.896319531E7</PREV_YEAR_REV>
<BUDGET>2.106664908E7</BUDGET>
<GROSS_PROFIT>1.887839991E7</GROSS_PROFIT>
<EXPENSES>1.964791429E7</EXPENSES>
<NET_INCOME>2070280.65</NET_INCOME>
<REVENUE_M>21.71819494</REVENUE_M>
<PROFIT_M>18.87839991</PROFIT_M>
<INCOME_M>2.07028065</INCOME_M>
<PHARMA_REV_M>21.71819494</PHARMA_REV_M>
<PHARMA_PROFIT_M>18.87839991</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.07028065</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2973215.17</REVENUE>
<PREV_YEAR_REV>2554067.2</PREV_YEAR_REV>
<BUDGET>2330054.1</BUDGET>
<GROSS_PROFIT>2474309.666</GROSS_PROFIT>
<EXPENSES>2580750.77</EXPENSES>
<NET_INCOME>392464.4</NET_INCOME>
<REVENUE_M>2.97321517</REVENUE_M>
<PROFIT_M>2.474309666</PROFIT_M>
<INCOME_M>0.3924644</INCOME_M>
<PHARMA_REV_M>2.97321517</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.474309666</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3924644</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2662884.21</REVENUE>
<PREV_YEAR_REV>2396015.95</PREV_YEAR_REV>
<BUDGET>2052169.02</BUDGET>
<GROSS_PROFIT>2050215.794</GROSS_PROFIT>
<EXPENSES>2319372.14</EXPENSES>
<NET_INCOME>343512.06</NET_INCOME>
<REVENUE_M>2.66288421</REVENUE_M>
<PROFIT_M>2.050215794</PROFIT_M>
<INCOME_M>0.34351206</INCOME_M>
<PHARMA_REV_M>2.66288421</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.050215794</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34351206</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>6361193.68</REVENUE>
<PREV_YEAR_REV>5557593.41</PREV_YEAR_REV>
<BUDGET>4907241.48</BUDGET>
<GROSS_PROFIT>5064868.124</GROSS_PROFIT>
<EXPENSES>5525129.11</EXPENSES>
<NET_INCOME>836064.57</NET_INCOME>
<REVENUE_M>6.36119368</REVENUE_M>
<PROFIT_M>5.064868124</PROFIT_M>
<INCOME_M>0.83606457</INCOME_M>
<PHARMA_REV_M>6.36119368</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.064868124</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83606457</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2942812.88</REVENUE>
<PREV_YEAR_REV>2527842.29</PREV_YEAR_REV>
<BUDGET>2362637.97</BUDGET>
<GROSS_PROFIT>2233639.114</GROSS_PROFIT>
<EXPENSES>2545533.14</EXPENSES>
<NET_INCOME>397279.74</NET_INCOME>
<REVENUE_M>2.94281288</REVENUE_M>
<PROFIT_M>2.233639114</PROFIT_M>
<INCOME_M>0.39727974</INCOME_M>
<PHARMA_REV_M>2.94281288</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.233639114</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39727974</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3121517.83</REVENUE>
<PREV_YEAR_REV>2648002.1</PREV_YEAR_REV>
<BUDGET>2498506.56</BUDGET>
<GROSS_PROFIT>2505392.638</GROSS_PROFIT>
<EXPENSES>2781272.39</EXPENSES>
<NET_INCOME>340245.44</NET_INCOME>
<REVENUE_M>3.12151783</REVENUE_M>
<PROFIT_M>2.505392638</PROFIT_M>
<INCOME_M>0.34024544</INCOME_M>
<PHARMA_REV_M>3.12151783</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.505392638</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34024544</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2865606.72</REVENUE>
<PREV_YEAR_REV>2504103.54</PREV_YEAR_REV>
<BUDGET>2779638.51</BUDGET>
<GROSS_PROFIT>2395482.06</GROSS_PROFIT>
<EXPENSES>2479435.94</EXPENSES>
<NET_INCOME>386170.77</NET_INCOME>
<REVENUE_M>2.86560672</REVENUE_M>
<PROFIT_M>2.39548206</PROFIT_M>
<INCOME_M>0.38617077</INCOME_M>
<PHARMA_REV_M>2.86560672</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.39548206</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38617077</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.27575647E7</REVENUE>
<PREV_YEAR_REV>1.032165429E7</PREV_YEAR_REV>
<BUDGET>1.211968647E7</BUDGET>
<GROSS_PROFIT>1.086944513E7</GROSS_PROFIT>
<EXPENSES>1.071635435E7</EXPENSES>
<NET_INCOME>2041210.35</NET_INCOME>
<REVENUE_M>12.7575647</REVENUE_M>
<PROFIT_M>10.86944513</PROFIT_M>
<INCOME_M>2.04121035</INCOME_M>
<PHARMA_REV_M>12.7575647</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.86944513</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.04121035</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.065043315E7</REVENUE>
<PREV_YEAR_REV>8453529.82</PREV_YEAR_REV>
<BUDGET>1.01179115E7</BUDGET>
<GROSS_PROFIT>7582043.367</GROSS_PROFIT>
<EXPENSES>9276527.28</EXPENSES>
<NET_INCOME>1373905.88</NET_INCOME>
<REVENUE_M>10.65043315</REVENUE_M>
<PROFIT_M>7.582043367</PROFIT_M>
<INCOME_M>1.37390588</INCOME_M>
<PHARMA_REV_M>10.65043315</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.582043367</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.37390588</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8513646.18</REVENUE>
<PREV_YEAR_REV>6936777.84</PREV_YEAR_REV>
<BUDGET>8087963.87</BUDGET>
<GROSS_PROFIT>7343360.368</GROSS_PROFIT>
<EXPENSES>7151462.79</EXPENSES>
<NET_INCOME>1362183.39</NET_INCOME>
<REVENUE_M>8.51364618</REVENUE_M>
<PROFIT_M>7.343360368</PROFIT_M>
<INCOME_M>1.36218339</INCOME_M>
<PHARMA_REV_M>8.51364618</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.343360368</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.36218339</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.006306243E7</REVENUE>
<PREV_YEAR_REV>8143151.58</PREV_YEAR_REV>
<BUDGET>9559909.31</BUDGET>
<GROSS_PROFIT>8050449.94</GROSS_PROFIT>
<EXPENSES>8734738.19</EXPENSES>
<NET_INCOME>1328324.24</NET_INCOME>
<REVENUE_M>10.06306243</REVENUE_M>
<PROFIT_M>8.05044994</PROFIT_M>
<INCOME_M>1.32832424</INCOME_M>
<PHARMA_REV_M>10.06306243</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.05044994</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.32832424</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8473438.11</REVENUE>
<PREV_YEAR_REV>7119519.15</PREV_YEAR_REV>
<BUDGET>8049766.2</BUDGET>
<GROSS_PROFIT>7051934.13</GROSS_PROFIT>
<EXPENSES>7854877.13</EXPENSES>
<NET_INCOME>618560.98</NET_INCOME>
<REVENUE_M>8.47343811</REVENUE_M>
<PROFIT_M>7.05193413</PROFIT_M>
<INCOME_M>0.61856098</INCOME_M>
<PHARMA_REV_M>8.47343811</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.05193413</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61856098</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8461743.73</REVENUE>
<PREV_YEAR_REV>6602741.78</PREV_YEAR_REV>
<BUDGET>8038656.55</BUDGET>
<GROSS_PROFIT>7025108.884</GROSS_PROFIT>
<EXPENSES>6947091.6</EXPENSES>
<NET_INCOME>1514652.13</NET_INCOME>
<REVENUE_M>8.46174373</REVENUE_M>
<PROFIT_M>7.025108884</PROFIT_M>
<INCOME_M>1.51465213</INCOME_M>
<PHARMA_REV_M>8.46174373</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.025108884</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.51465213</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3629834.42</REVENUE>
<PREV_YEAR_REV>3005003.95</PREV_YEAR_REV>
<BUDGET>3452737.5</BUDGET>
<GROSS_PROFIT>3108880.586</GROSS_PROFIT>
<EXPENSES>3234182.47</EXPENSES>
<NET_INCOME>395651.95</NET_INCOME>
<REVENUE_M>3.62983442</REVENUE_M>
<PROFIT_M>3.108880586</PROFIT_M>
<INCOME_M>0.39565195</INCOME_M>
<PHARMA_REV_M>3.62983442</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.108880586</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39565195</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2582834.42</REVENUE>
<PREV_YEAR_REV>2103833.59</PREV_YEAR_REV>
<BUDGET>2468557.5</BUDGET>
<GROSS_PROFIT>2186937.561</GROSS_PROFIT>
<EXPENSES>2241900.28</EXPENSES>
<NET_INCOME>340934.14</NET_INCOME>
<REVENUE_M>2.58283442</REVENUE_M>
<PROFIT_M>2.186937561</PROFIT_M>
<INCOME_M>0.34093414</INCOME_M>
<PHARMA_REV_M>2.58283442</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.186937561</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34093414</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2580762.55</REVENUE>
<PREV_YEAR_REV>2159633.93</PREV_YEAR_REV>
<BUDGET>2466609.94</BUDGET>
<GROSS_PROFIT>2159969.22</GROSS_PROFIT>
<EXPENSES>2167840.54</EXPENSES>
<NET_INCOME>412922.01</NET_INCOME>
<REVENUE_M>2.58076255</REVENUE_M>
<PROFIT_M>2.15996922</PROFIT_M>
<INCOME_M>0.41292201</INCOME_M>
<PHARMA_REV_M>2.58076255</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.15996922</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41292201</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5145128.22</REVENUE>
<PREV_YEAR_REV>4062033.06</PREV_YEAR_REV>
<BUDGET>4917806.82</BUDGET>
<GROSS_PROFIT>3718475.035</GROSS_PROFIT>
<EXPENSES>4380777.93</EXPENSES>
<NET_INCOME>764350.29</NET_INCOME>
<REVENUE_M>5.14512822</REVENUE_M>
<PROFIT_M>3.718475035</PROFIT_M>
<INCOME_M>0.76435029</INCOME_M>
<PHARMA_REV_M>5.14512822</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.718475035</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76435029</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>8244151.66</REVENUE>
<PREV_YEAR_REV>6654828.69</PREV_YEAR_REV>
<BUDGET>8161710.13</BUDGET>
<GROSS_PROFIT>6147495.847</GROSS_PROFIT>
<EXPENSES>7445213.34</EXPENSES>
<NET_INCOME>798938.31</NET_INCOME>
<REVENUE_M>8.24415166</REVENUE_M>
<PROFIT_M>6.147495847</PROFIT_M>
<INCOME_M>0.79893831</INCOME_M>
<PHARMA_REV_M>8.24415166</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.147495847</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.79893831</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2737901.25</REVENUE>
<PREV_YEAR_REV>2168016.45</PREV_YEAR_REV>
<BUDGET>2710522.24</BUDGET>
<GROSS_PROFIT>2072325.673</GROSS_PROFIT>
<EXPENSES>2458635.32</EXPENSES>
<NET_INCOME>279265.93</NET_INCOME>
<REVENUE_M>2.73790125</REVENUE_M>
<PROFIT_M>2.072325673</PROFIT_M>
<INCOME_M>0.27926593</INCOME_M>
<PHARMA_REV_M>2.73790125</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.072325673</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27926593</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2880360</REVENUE>
<PREV_YEAR_REV>2330501.48</PREV_YEAR_REV>
<BUDGET>2851556.4</BUDGET>
<GROSS_PROFIT>2393694.374</GROSS_PROFIT>
<EXPENSES>2566400.76</EXPENSES>
<NET_INCOME>313959.24</NET_INCOME>
<REVENUE_M>2.88036</REVENUE_M>
<PROFIT_M>2.393694374</PROFIT_M>
<INCOME_M>0.31395924</INCOME_M>
<PHARMA_REV_M>2.88036</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.393694374</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31395924</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3935688.76</REVENUE>
<PREV_YEAR_REV>3109992.1</PREV_YEAR_REV>
<BUDGET>3896331.86</BUDGET>
<GROSS_PROFIT>2989762.046</GROSS_PROFIT>
<EXPENSES>3500699.46</EXPENSES>
<NET_INCOME>434989.29</NET_INCOME>
<REVENUE_M>3.93568876</REVENUE_M>
<PROFIT_M>2.989762046</PROFIT_M>
<INCOME_M>0.43498929</INCOME_M>
<PHARMA_REV_M>3.93568876</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.989762046</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43498929</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4053901.16</REVENUE>
<PREV_YEAR_REV>3334451.34</PREV_YEAR_REV>
<BUDGET>4013362.15</BUDGET>
<GROSS_PROFIT>2942787.673</GROSS_PROFIT>
<EXPENSES>3562039</EXPENSES>
<NET_INCOME>491862.17</NET_INCOME>
<REVENUE_M>4.05390116</REVENUE_M>
<PROFIT_M>2.942787673</PROFIT_M>
<INCOME_M>0.49186217</INCOME_M>
<PHARMA_REV_M>4.05390116</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.942787673</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49186217</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1983784.16</REVENUE>
<PREV_YEAR_REV>1544919.02</PREV_YEAR_REV>
<BUDGET>1963946.32</BUDGET>
<GROSS_PROFIT>1562329.217</GROSS_PROFIT>
<EXPENSES>1666378.7</EXPENSES>
<NET_INCOME>317405.47</NET_INCOME>
<REVENUE_M>1.98378416</REVENUE_M>
<PROFIT_M>1.562329217</PROFIT_M>
<INCOME_M>0.31740547</INCOME_M>
<PHARMA_REV_M>1.98378416</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.562329217</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31740547</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1959693.75</REVENUE>
<PREV_YEAR_REV>1509605.01</PREV_YEAR_REV>
<BUDGET>1940096.81</BUDGET>
<GROSS_PROFIT>1494952.376</GROSS_PROFIT>
<EXPENSES>1701014.18</EXPENSES>
<NET_INCOME>258679.58</NET_INCOME>
<REVENUE_M>1.95969375</REVENUE_M>
<PROFIT_M>1.494952376</PROFIT_M>
<INCOME_M>0.25867958</INCOME_M>
<PHARMA_REV_M>1.95969375</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.494952376</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25867958</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1983784.16</REVENUE>
<PREV_YEAR_REV>1629525.35</PREV_YEAR_REV>
<BUDGET>1963946.32</BUDGET>
<GROSS_PROFIT>1619442.366</GROSS_PROFIT>
<EXPENSES>1838967.92</EXPENSES>
<NET_INCOME>144816.24</NET_INCOME>
<REVENUE_M>1.98378416</REVENUE_M>
<PROFIT_M>1.619442366</PROFIT_M>
<INCOME_M>0.14481624</INCOME_M>
<PHARMA_REV_M>1.98378416</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.619442366</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14481624</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3955172.29</REVENUE>
<PREV_YEAR_REV>3234372.18</PREV_YEAR_REV>
<BUDGET>3915620.57</BUDGET>
<GROSS_PROFIT>2766425.913</GROSS_PROFIT>
<EXPENSES>3367603.35</EXPENSES>
<NET_INCOME>587568.94</NET_INCOME>
<REVENUE_M>3.95517229</REVENUE_M>
<PROFIT_M>2.766425913</PROFIT_M>
<INCOME_M>0.58756894</INCOME_M>
<PHARMA_REV_M>3.95517229</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.766425913</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58756894</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5976520.2</REVENUE>
<PREV_YEAR_REV>4789910.09</PREV_YEAR_REV>
<BUDGET>5916755</BUDGET>
<GROSS_PROFIT>4553152.372</GROSS_PROFIT>
<EXPENSES>5397012.54</EXPENSES>
<NET_INCOME>579507.67</NET_INCOME>
<REVENUE_M>5.9765202</REVENUE_M>
<PROFIT_M>4.553152372</PROFIT_M>
<INCOME_M>0.57950767</INCOME_M>
<PHARMA_REV_M>5.9765202</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.553152372</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57950767</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2001864.38</REVENUE>
<PREV_YEAR_REV>1664489.08</PREV_YEAR_REV>
<BUDGET>1981845.73</BUDGET>
<GROSS_PROFIT>1510606.859</GROSS_PROFIT>
<EXPENSES>1783661.16</EXPENSES>
<NET_INCOME>218203.22</NET_INCOME>
<REVENUE_M>2.00186438</REVENUE_M>
<PROFIT_M>1.510606859</PROFIT_M>
<INCOME_M>0.21820322</INCOME_M>
<PHARMA_REV_M>2.00186438</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.510606859</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21820322</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1175319.94</REVENUE>
<PREV_YEAR_REV>959272.57</PREV_YEAR_REV>
<BUDGET>1163566.74</BUDGET>
<GROSS_PROFIT>884310.723</GROSS_PROFIT>
<EXPENSES>1023703.66</EXPENSES>
<NET_INCOME>151616.27</NET_INCOME>
<REVENUE_M>1.17531994</REVENUE_M>
<PROFIT_M>0.884310723</PROFIT_M>
<INCOME_M>0.15161627</INCOME_M>
<PHARMA_REV_M>1.17531994</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.884310723</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15161627</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4667908.94</REVENUE>
<PREV_YEAR_REV>3699529.87</PREV_YEAR_REV>
<BUDGET>4621229.85</BUDGET>
<GROSS_PROFIT>3679745.371</GROSS_PROFIT>
<EXPENSES>4218309.34</EXPENSES>
<NET_INCOME>449599.6</NET_INCOME>
<REVENUE_M>4.66790894</REVENUE_M>
<PROFIT_M>3.679745371</PROFIT_M>
<INCOME_M>0.4495996</INCOME_M>
<PHARMA_REV_M>4.66790894</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.679745371</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4495996</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2905743.46</REVENUE>
<PREV_YEAR_REV>2328864.17</PREV_YEAR_REV>
<BUDGET>2876686.02</BUDGET>
<GROSS_PROFIT>2093208.453</GROSS_PROFIT>
<EXPENSES>2474189.66</EXPENSES>
<NET_INCOME>431553.8</NET_INCOME>
<REVENUE_M>2.90574346</REVENUE_M>
<PROFIT_M>2.093208453</PROFIT_M>
<INCOME_M>0.4315538</INCOME_M>
<PHARMA_REV_M>2.90574346</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.093208453</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4315538</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1467396</REVENUE>
<PREV_YEAR_REV>1153504.39</PREV_YEAR_REV>
<BUDGET>1452722.04</BUDGET>
<GROSS_PROFIT>1126373.172</GROSS_PROFIT>
<EXPENSES>1307449.84</EXPENSES>
<NET_INCOME>159946.16</NET_INCOME>
<REVENUE_M>1.467396</REVENUE_M>
<PROFIT_M>1.126373172</PROFIT_M>
<INCOME_M>0.15994616</INCOME_M>
<PHARMA_REV_M>1.467396</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.126373172</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15994616</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7870901.83</REVENUE>
<PREV_YEAR_REV>6528238.93</PREV_YEAR_REV>
<BUDGET>7792192.82</BUDGET>
<GROSS_PROFIT>6422655.9</GROSS_PROFIT>
<EXPENSES>6462010.41</EXPENSES>
<NET_INCOME>1408891.43</NET_INCOME>
<REVENUE_M>7.87090183</REVENUE_M>
<PROFIT_M>6.4226559</PROFIT_M>
<INCOME_M>1.40889143</INCOME_M>
<PHARMA_REV_M>7.87090183</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.4226559</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.40889143</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1.140537226E7</REVENUE>
<PREV_YEAR_REV>9050041.46</PREV_YEAR_REV>
<BUDGET>1.083510363E7</BUDGET>
<GROSS_PROFIT>9083322.723</GROSS_PROFIT>
<EXPENSES>1.029993734E7</EXPENSES>
<NET_INCOME>1105434.91</NET_INCOME>
<REVENUE_M>11.40537226</REVENUE_M>
<PROFIT_M>9.083322723</PROFIT_M>
<INCOME_M>1.10543491</INCOME_M>
<PHARMA_REV_M>11.40537226</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.083322723</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.10543491</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7704291.5</REVENUE>
<PREV_YEAR_REV>6178294.99</PREV_YEAR_REV>
<BUDGET>7319076.93</BUDGET>
<GROSS_PROFIT>5606000.926</GROSS_PROFIT>
<EXPENSES>6560189.87</EXPENSES>
<NET_INCOME>1144101.63</NET_INCOME>
<REVENUE_M>7.7042915</REVENUE_M>
<PROFIT_M>5.606000926</PROFIT_M>
<INCOME_M>1.14410163</INCOME_M>
<PHARMA_REV_M>7.7042915</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.606000926</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.14410163</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2978020.75</REVENUE>
<PREV_YEAR_REV>2435690.01</PREV_YEAR_REV>
<BUDGET>2680218.68</BUDGET>
<GROSS_PROFIT>2418152.85</GROSS_PROFIT>
<EXPENSES>2584922.01</EXPENSES>
<NET_INCOME>393098.74</NET_INCOME>
<REVENUE_M>2.97802075</REVENUE_M>
<PROFIT_M>2.41815285</PROFIT_M>
<INCOME_M>0.39309874</INCOME_M>
<PHARMA_REV_M>2.97802075</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.41815285</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39309874</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2863270.75</REVENUE>
<PREV_YEAR_REV>2248382.97</PREV_YEAR_REV>
<BUDGET>2576943.68</BUDGET>
<GROSS_PROFIT>2328411.772</GROSS_PROFIT>
<EXPENSES>2485319.01</EXPENSES>
<NET_INCOME>377951.74</NET_INCOME>
<REVENUE_M>2.86327075</REVENUE_M>
<PROFIT_M>2.328411772</PROFIT_M>
<INCOME_M>0.37795174</INCOME_M>
<PHARMA_REV_M>2.86327075</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.328411772</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37795174</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2868755.13</REVENUE>
<PREV_YEAR_REV>2400049.46</PREV_YEAR_REV>
<BUDGET>2581879.61</BUDGET>
<GROSS_PROFIT>2106813.762</GROSS_PROFIT>
<EXPENSES>2498685.71</EXPENSES>
<NET_INCOME>370069.41</NET_INCOME>
<REVENUE_M>2.86875513</REVENUE_M>
<PROFIT_M>2.106813762</PROFIT_M>
<INCOME_M>0.37006941</INCOME_M>
<PHARMA_REV_M>2.86875513</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.106813762</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37006941</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5794201.81</REVENUE>
<PREV_YEAR_REV>4698574.74</PREV_YEAR_REV>
<BUDGET>5214781.63</BUDGET>
<GROSS_PROFIT>4635210.27</GROSS_PROFIT>
<EXPENSES>5014845.52</EXPENSES>
<NET_INCOME>779356.29</NET_INCOME>
<REVENUE_M>5.79420181</REVENUE_M>
<PROFIT_M>4.63521027</PROFIT_M>
<INCOME_M>0.77935629</INCOME_M>
<PHARMA_REV_M>5.79420181</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.63521027</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.77935629</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2891949.81</REVENUE>
<PREV_YEAR_REV>2439866.88</PREV_YEAR_REV>
<BUDGET>2602754.83</BUDGET>
<GROSS_PROFIT>2137486.375</GROSS_PROFIT>
<EXPENSES>2501536.59</EXPENSES>
<NET_INCOME>390413.22</NET_INCOME>
<REVENUE_M>2.89194981</REVENUE_M>
<PROFIT_M>2.137486375</PROFIT_M>
<INCOME_M>0.39041322</INCOME_M>
<PHARMA_REV_M>2.89194981</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.137486375</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39041322</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2868755.13</REVENUE>
<PREV_YEAR_REV>2223117.38</PREV_YEAR_REV>
<BUDGET>2581879.61</BUDGET>
<GROSS_PROFIT>2343772.94</GROSS_PROFIT>
<EXPENSES>2375329.24</EXPENSES>
<NET_INCOME>493425.88</NET_INCOME>
<REVENUE_M>2.86875513</REVENUE_M>
<PROFIT_M>2.34377294</PROFIT_M>
<INCOME_M>0.49342588</INCOME_M>
<PHARMA_REV_M>2.86875513</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.34377294</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49342588</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2472682</REVENUE>
<PREV_YEAR_REV>1952759.72</PREV_YEAR_REV>
<BUDGET>2423228.36</BUDGET>
<GROSS_PROFIT>1930917.37</GROSS_PROFIT>
<EXPENSES>2030071.92</EXPENSES>
<NET_INCOME>442610.08</NET_INCOME>
<REVENUE_M>2.472682</REVENUE_M>
<PROFIT_M>1.93091737</PROFIT_M>
<INCOME_M>0.44261008</INCOME_M>
<PHARMA_REV_M>2.472682</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.93091737</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44261008</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4519822.4</REVENUE>
<PREV_YEAR_REV>3727992.34</PREV_YEAR_REV>
<BUDGET>4429425.96</BUDGET>
<GROSS_PROFIT>3197245.383</GROSS_PROFIT>
<EXPENSES>3848568.18</EXPENSES>
<NET_INCOME>671254.22</NET_INCOME>
<REVENUE_M>4.5198224</REVENUE_M>
<PROFIT_M>3.197245383</PROFIT_M>
<INCOME_M>0.67125422</INCOME_M>
<PHARMA_REV_M>4.5198224</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.197245383</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67125422</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4727273.07</REVENUE>
<PREV_YEAR_REV>3763592.4</PREV_YEAR_REV>
<BUDGET>4632727.61</BUDGET>
<GROSS_PROFIT>3673393.728</GROSS_PROFIT>
<EXPENSES>4097314.45</EXPENSES>
<NET_INCOME>629958.62</NET_INCOME>
<REVENUE_M>4.72727307</REVENUE_M>
<PROFIT_M>3.673393728</PROFIT_M>
<INCOME_M>0.62995862</INCOME_M>
<PHARMA_REV_M>4.72727307</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.673393728</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62995862</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>3227439.5</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>2969244.34</BUDGET>
<GROSS_PROFIT>2623908.31</GROSS_PROFIT>
<EXPENSES>2711049.18</EXPENSES>
<NET_INCOME>516390.32</NET_INCOME>
<REVENUE_M>3.2274395</REVENUE_M>
<PROFIT_M>2.62390831</PROFIT_M>
<INCOME_M>0.51639032</INCOME_M>
<PHARMA_REV_M>3.2274395</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.62390831</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51639032</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.30575545E7</REVENUE>
<PREV_YEAR_REV>1.116618306E7</PREV_YEAR_REV>
<BUDGET>1.293295014E7</BUDGET>
<GROSS_PROFIT>1.17099429E7</GROSS_PROFIT>
<EXPENSES>1.180834578E7</EXPENSES>
<NET_INCOME>2249208.72</NET_INCOME>
<REVENUE_M>13.0575545</REVENUE_M>
<PROFIT_M>11.7099429</PROFIT_M>
<INCOME_M>2.24920872</INCOME_M>
<PHARMA_REV_M>13.0575545</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.7099429</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.24920872</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>4509657</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>4332884.44</BUDGET>
<GROSS_PROFIT>3838370.46</GROSS_PROFIT>
<EXPENSES>4087982.28</EXPENSES>
<NET_INCOME>621674.72</NET_INCOME>
<REVENUE_M>4.509657</REVENUE_M>
<PROFIT_M>3.83837046</PROFIT_M>
<INCOME_M>0.62167472</INCOME_M>
<PHARMA_REV_M>4.509657</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.83837046</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62167472</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>1609654.66</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>1480882.28</BUDGET>
<GROSS_PROFIT>1310258.89</GROSS_PROFIT>
<EXPENSES>1321526.47</EXPENSES>
<NET_INCOME>288128.18</NET_INCOME>
<REVENUE_M>1.60965466</REVENUE_M>
<PROFIT_M>1.31025889</PROFIT_M>
<INCOME_M>0.28812818</INCOME_M>
<PHARMA_REV_M>1.60965466</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.31025889</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28812818</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7985412.72</REVENUE>
<PREV_YEAR_REV>7479305.06</PREV_YEAR_REV>
<BUDGET>8266579.7</BUDGET>
<GROSS_PROFIT>6981367.41</GROSS_PROFIT>
<EXPENSES>8329477.59</EXPENSES>
<NET_INCOME>655935.13</NET_INCOME>
<REVENUE_M>7.98541272</REVENUE_M>
<PROFIT_M>6.98136741</PROFIT_M>
<INCOME_M>0.65593513</INCOME_M>
<PHARMA_REV_M>7.98541272</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.98136741</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65593513</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9646646.38</REVENUE>
<PREV_YEAR_REV>1.342326989E7</PREV_YEAR_REV>
<BUDGET>8874914.67</BUDGET>
<GROSS_PROFIT>7227363.465</GROSS_PROFIT>
<EXPENSES>8213922.16</EXPENSES>
<NET_INCOME>1432724.22</NET_INCOME>
<REVENUE_M>9.64664638</REVENUE_M>
<PROFIT_M>7.227363465</PROFIT_M>
<INCOME_M>1.43272422</INCOME_M>
<PHARMA_REV_M>9.64664638</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.227363465</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.43272422</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>12047903</REVENUE>
<PREV_YEAR_REV>9836950.1</PREV_YEAR_REV>
<BUDGET>1.108407076E7</BUDGET>
<GROSS_PROFIT>1.007204691E7</GROSS_PROFIT>
<EXPENSES>1.073468157E7</EXPENSES>
<NET_INCOME>1313221.43</NET_INCOME>
<REVENUE_M>12.047903</REVENUE_M>
<PROFIT_M>10.07204691</PROFIT_M>
<INCOME_M>1.31322143</INCOME_M>
<PHARMA_REV_M>12.047903</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.07204691</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.31322143</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>4472018.59</REVENUE>
<PREV_YEAR_REV>8717385.17</PREV_YEAR_REV>
<BUDGET>4114257.11</BUDGET>
<GROSS_PROFIT>3449267.937</GROSS_PROFIT>
<EXPENSES>3868296.08</EXPENSES>
<NET_INCOME>603722.51</NET_INCOME>
<REVENUE_M>4.47201859</REVENUE_M>
<PROFIT_M>3.449267937</PROFIT_M>
<INCOME_M>0.60372251</INCOME_M>
<PHARMA_REV_M>4.47201859</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.449267937</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60372251</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8977458.97</REVENUE>
<PREV_YEAR_REV>1.503362404E7</PREV_YEAR_REV>
<BUDGET>8259262.26</BUDGET>
<GROSS_PROFIT>7725046.04</GROSS_PROFIT>
<EXPENSES>7787869.74</EXPENSES>
<NET_INCOME>1189589.23</NET_INCOME>
<REVENUE_M>8.97745897</REVENUE_M>
<PROFIT_M>7.72504604</PROFIT_M>
<INCOME_M>1.18958923</INCOME_M>
<PHARMA_REV_M>8.97745897</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.72504604</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.18958923</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3557334.42</REVENUE>
<PREV_YEAR_REV>3152760.98</PREV_YEAR_REV>
<BUDGET>3572587.5</BUDGET>
<GROSS_PROFIT>3090185.04</GROSS_PROFIT>
<EXPENSES>3084771.56</EXPENSES>
<NET_INCOME>672562.86</NET_INCOME>
<REVENUE_M>3.55733442</REVENUE_M>
<PROFIT_M>3.09018504</PROFIT_M>
<INCOME_M>0.67256286</INCOME_M>
<PHARMA_REV_M>3.55733442</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.09018504</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67256286</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2444710.77</REVENUE>
<PREV_YEAR_REV>2266298.54</PREV_YEAR_REV>
<BUDGET>2137700.43</BUDGET>
<GROSS_PROFIT>2105363.71</GROSS_PROFIT>
<EXPENSES>2115610.94</EXPENSES>
<NET_INCOME>329099.84</NET_INCOME>
<REVENUE_M>2.44471077</REVENUE_M>
<PROFIT_M>2.10536371</PROFIT_M>
<INCOME_M>0.32909984</INCOME_M>
<PHARMA_REV_M>2.44471077</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.10536371</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32909984</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1158591.7</REVENUE>
<PREV_YEAR_REV>1082593.63</PREV_YEAR_REV>
<BUDGET>1009638.11</BUDGET>
<GROSS_PROFIT>893621.781</GROSS_PROFIT>
<EXPENSES>1002181.82</EXPENSES>
<NET_INCOME>156409.88</NET_INCOME>
<REVENUE_M>1.1585917</REVENUE_M>
<PROFIT_M>0.893621781</PROFIT_M>
<INCOME_M>0.15640988</INCOME_M>
<PHARMA_REV_M>1.1585917</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.893621781</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15640988</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2747760.32</REVENUE>
<PREV_YEAR_REV>2562229.86</PREV_YEAR_REV>
<BUDGET>2170225.65</BUDGET>
<GROSS_PROFIT>2334498.59</GROSS_PROFIT>
<EXPENSES>2381430.21</EXPENSES>
<NET_INCOME>366330.11</NET_INCOME>
<REVENUE_M>2.74776032</REVENUE_M>
<PROFIT_M>2.33449859</PROFIT_M>
<INCOME_M>0.36633011</INCOME_M>
<PHARMA_REV_M>2.74776032</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.33449859</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36633011</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7394910.19</REVENUE>
<PREV_YEAR_REV>7037141.9</PREV_YEAR_REV>
<BUDGET>7099113.79</BUDGET>
<GROSS_PROFIT>5701475.76</GROSS_PROFIT>
<EXPENSES>6418782.05</EXPENSES>
<NET_INCOME>976128.15</NET_INCOME>
<REVENUE_M>7.39491019</REVENUE_M>
<PROFIT_M>5.70147576</PROFIT_M>
<INCOME_M>0.97612815</INCOME_M>
<PHARMA_REV_M>7.39491019</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.70147576</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.97612815</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5759408.42</REVENUE>
<PREV_YEAR_REV>5458534.03</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>3410721.666</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>742963.69</NET_INCOME>
<REVENUE_M>5.75940842</REVENUE_M>
<PROFIT_M>3.410721666</PROFIT_M>
<INCOME_M>0.74296369</INCOME_M>
<PHARMA_REV_M>5.75940842</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.410721666</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74296369</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5739645.54</REVENUE>
<PREV_YEAR_REV>5329240.71</PREV_YEAR_REV>
<BUDGET>5510059.72</BUDGET>
<GROSS_PROFIT>4115899.813</GROSS_PROFIT>
<EXPENSES>4982012.33</EXPENSES>
<NET_INCOME>757633.21</NET_INCOME>
<REVENUE_M>5.73964554</REVENUE_M>
<PROFIT_M>4.115899813</PROFIT_M>
<INCOME_M>0.75763321</INCOME_M>
<PHARMA_REV_M>5.73964554</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.115899813</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75763321</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.335084729E7</REVENUE>
<PREV_YEAR_REV>1.249227218E7</PREV_YEAR_REV>
<BUDGET>1.28168134E7</BUDGET>
<GROSS_PROFIT>8744912.949</GROSS_PROFIT>
<EXPENSES>1.173801145E7</EXPENSES>
<NET_INCOME>1612835.84</NET_INCOME>
<REVENUE_M>13.35084729</REVENUE_M>
<PROFIT_M>8.744912949</PROFIT_M>
<INCOME_M>1.61283584</INCOME_M>
<PHARMA_REV_M>13.35084729</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.744912949</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.61283584</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.026024747E7</REVENUE>
<PREV_YEAR_REV>9618582.2</PREV_YEAR_REV>
<BUDGET>9849837.57</BUDGET>
<GROSS_PROFIT>7298397.225</GROSS_PROFIT>
<EXPENSES>8735019.29</EXPENSES>
<NET_INCOME>1525228.18</NET_INCOME>
<REVENUE_M>10.26024747</REVENUE_M>
<PROFIT_M>7.298397225</PROFIT_M>
<INCOME_M>1.52522818</INCOME_M>
<PHARMA_REV_M>10.26024747</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.298397225</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.52522818</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.547283482E7</REVENUE>
<PREV_YEAR_REV>1.460785023E7</PREV_YEAR_REV>
<BUDGET>1.485392143E7</BUDGET>
<GROSS_PROFIT>1.135240959E7</GROSS_PROFIT>
<EXPENSES>1.397132832E7</EXPENSES>
<NET_INCOME>1501506.49</NET_INCOME>
<REVENUE_M>15.47283482</REVENUE_M>
<PROFIT_M>11.35240959</PROFIT_M>
<INCOME_M>1.50150649</INCOME_M>
<PHARMA_REV_M>15.47283482</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.35240959</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.50150649</PHARMA_INCOME_M>
<FRANCE_REV_M>15.47283482</FRANCE_REV_M>
<FRANCE_PROFIT_M>11.35240959</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>1.50150649</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6672719.67</REVENUE>
<PREV_YEAR_REV>6319162.52</PREV_YEAR_REV>
<BUDGET>6405810.88</BUDGET>
<GROSS_PROFIT>4973711.781</GROSS_PROFIT>
<EXPENSES>5478302.85</EXPENSES>
<NET_INCOME>1194416.82</NET_INCOME>
<REVENUE_M>6.67271967</REVENUE_M>
<PROFIT_M>4.973711781</PROFIT_M>
<INCOME_M>1.19441682</INCOME_M>
<PHARMA_REV_M>6.67271967</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.973711781</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.19441682</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5002466.77</REVENUE>
<PREV_YEAR_REV>4761487.87</PREV_YEAR_REV>
<BUDGET>4802368.1</BUDGET>
<GROSS_PROFIT>3156056.289</GROSS_PROFIT>
<EXPENSES>4327133.76</EXPENSES>
<NET_INCOME>675333.01</NET_INCOME>
<REVENUE_M>5.00246677</REVENUE_M>
<PROFIT_M>3.156056289</PROFIT_M>
<INCOME_M>0.67533301</INCOME_M>
<PHARMA_REV_M>5.00246677</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.156056289</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67533301</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3989298.94</REVENUE>
<PREV_YEAR_REV>3691975.06</PREV_YEAR_REV>
<BUDGET>3692895.11</BUDGET>
<GROSS_PROFIT>2731359.113</GROSS_PROFIT>
<EXPENSES>3549493.15</EXPENSES>
<NET_INCOME>439805.79</NET_INCOME>
<REVENUE_M>3.98929894</REVENUE_M>
<PROFIT_M>2.731359113</PROFIT_M>
<INCOME_M>0.43980579</INCOME_M>
<PHARMA_REV_M>3.98929894</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.731359113</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43980579</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4099344.07</REVENUE>
<PREV_YEAR_REV>3853177.83</PREV_YEAR_REV>
<BUDGET>3764724.06</BUDGET>
<GROSS_PROFIT>2416479.002</GROSS_PROFIT>
<EXPENSES>3603112.34</EXPENSES>
<NET_INCOME>496231.72</NET_INCOME>
<REVENUE_M>4.09934407</REVENUE_M>
<PROFIT_M>2.416479002</PROFIT_M>
<INCOME_M>0.49623172</INCOME_M>
<PHARMA_REV_M>4.09934407</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.416479002</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49623172</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1774707.33</REVENUE>
<PREV_YEAR_REV>1670941.84</PREV_YEAR_REV>
<BUDGET>1621107.17</BUDGET>
<GROSS_PROFIT>1362265.346</GROSS_PROFIT>
<EXPENSES>1540445.96</EXPENSES>
<NET_INCOME>234261.37</NET_INCOME>
<REVENUE_M>1.77470733</REVENUE_M>
<PROFIT_M>1.362265346</PROFIT_M>
<INCOME_M>0.23426137</INCOME_M>
<PHARMA_REV_M>1.77470733</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.362265346</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23426137</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2076703.23</REVENUE>
<PREV_YEAR_REV>1969297.73</PREV_YEAR_REV>
<BUDGET>1901782.74</BUDGET>
<GROSS_PROFIT>1487106.416</GROSS_PROFIT>
<EXPENSES>1850342.58</EXPENSES>
<NET_INCOME>226360.65</NET_INCOME>
<REVENUE_M>2.07670323</REVENUE_M>
<PROFIT_M>1.487106416</PROFIT_M>
<INCOME_M>0.22636065</INCOME_M>
<PHARMA_REV_M>2.07670323</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.487106416</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22636065</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1459348.12</REVENUE>
<PREV_YEAR_REV>1387094.38</PREV_YEAR_REV>
<BUDGET>1740546.74</BUDGET>
<GROSS_PROFIT>955873.02</GROSS_PROFIT>
<EXPENSES>1225852.42</EXPENSES>
<NET_INCOME>233495.7</NET_INCOME>
<REVENUE_M>1.45934812</REVENUE_M>
<PROFIT_M>0.95587302</PROFIT_M>
<INCOME_M>0.2334957</INCOME_M>
<PHARMA_REV_M>1.45934812</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.95587302</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2334957</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2848549.19</REVENUE>
<PREV_YEAR_REV>2676341.59</PREV_YEAR_REV>
<BUDGET>3355054.59</BUDGET>
<GROSS_PROFIT>1823851.116</GROSS_PROFIT>
<EXPENSES>2532719.65</EXPENSES>
<NET_INCOME>315829.55</NET_INCOME>
<REVENUE_M>2.84854919</REVENUE_M>
<PROFIT_M>1.823851116</PROFIT_M>
<INCOME_M>0.31582955</INCOME_M>
<PHARMA_REV_M>2.84854919</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.823851116</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31582955</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1455829.55</REVENUE>
<PREV_YEAR_REV>1335635.69</PREV_YEAR_REV>
<BUDGET>1693351.73</BUDGET>
<GROSS_PROFIT>1076003.621</GROSS_PROFIT>
<EXPENSES>1222896.82</EXPENSES>
<NET_INCOME>232932.73</NET_INCOME>
<REVENUE_M>1.45582955</REVENUE_M>
<PROFIT_M>1.076003621</PROFIT_M>
<INCOME_M>0.23293273</INCOME_M>
<PHARMA_REV_M>1.45582955</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.076003621</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23293273</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1532631.61</REVENUE>
<PREV_YEAR_REV>1455158.95</PREV_YEAR_REV>
<BUDGET>1693351.73</BUDGET>
<GROSS_PROFIT>985298.2132</GROSS_PROFIT>
<EXPENSES>1420749.51</EXPENSES>
<NET_INCOME>111882.11</NET_INCOME>
<REVENUE_M>1.53263161</REVENUE_M>
<PROFIT_M>0.985298213</PROFIT_M>
<INCOME_M>0.11188211</INCOME_M>
<PHARMA_REV_M>1.53263161</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.985298213</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11188211</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.554372681E7</REVENUE>
<PREV_YEAR_REV>1.437122258E7</PREV_YEAR_REV>
<BUDGET>1.70980995E7</BUDGET>
<GROSS_PROFIT>1.177390243E7</GROSS_PROFIT>
<EXPENSES>1.36465364E7</EXPENSES>
<NET_INCOME>1897190.41</NET_INCOME>
<REVENUE_M>15.54372681</REVENUE_M>
<PROFIT_M>11.77390243</PROFIT_M>
<INCOME_M>1.89719041</INCOME_M>
<PHARMA_REV_M>15.54372681</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.77390243</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.89719041</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.896319531E7</REVENUE>
<PREV_YEAR_REV>1.746682569E7</PREV_YEAR_REV>
<BUDGET>2.085951485E7</BUDGET>
<GROSS_PROFIT>1.616649293E7</GROSS_PROFIT>
<EXPENSES>1.715078894E7</EXPENSES>
<NET_INCOME>1812406.37</NET_INCOME>
<REVENUE_M>18.96319531</REVENUE_M>
<PROFIT_M>16.16649293</PROFIT_M>
<INCOME_M>1.81240637</INCOME_M>
<PHARMA_REV_M>18.96319531</PHARMA_REV_M>
<PHARMA_PROFIT_M>16.16649293</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.81240637</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2959772.9</REVENUE>
<PREV_YEAR_REV>2772877.91</PREV_YEAR_REV>
<BUDGET>3394090.35</BUDGET>
<GROSS_PROFIT>2121088.42</GROSS_PROFIT>
<EXPENSES>2561635.85</EXPENSES>
<NET_INCOME>398137.06</NET_INCOME>
<REVENUE_M>2.9597729</REVENUE_M>
<PROFIT_M>2.12108842</PROFIT_M>
<INCOME_M>0.39813706</INCOME_M>
<PHARMA_REV_M>2.9597729</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.12108842</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39813706</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1689746.3</REVENUE>
<PREV_YEAR_REV>1557240.69</PREV_YEAR_REV>
<BUDGET>1732419.94</BUDGET>
<GROSS_PROFIT>1198030.12</GROSS_PROFIT>
<EXPENSES>1505563.95</EXPENSES>
<NET_INCOME>184182.35</NET_INCOME>
<REVENUE_M>1.6897463</REVENUE_M>
<PROFIT_M>1.19803012</PROFIT_M>
<INCOME_M>0.18418235</INCOME_M>
<PHARMA_REV_M>1.6897463</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.19803012</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18418235</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1063995.29</REVENUE>
<PREV_YEAR_REV>986633.37</PREV_YEAR_REV>
<BUDGET>1119253.54</BUDGET>
<GROSS_PROFIT>709578.4555</GROSS_PROFIT>
<EXPENSES>893756.04</EXPENSES>
<NET_INCOME>170239.25</NET_INCOME>
<REVENUE_M>1.06399529</REVENUE_M>
<PROFIT_M>0.709578456</PROFIT_M>
<INCOME_M>0.17023925</INCOME_M>
<PHARMA_REV_M>1.06399529</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.709578456</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17023925</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1216630.46</REVENUE>
<PREV_YEAR_REV>1132560.49</PREV_YEAR_REV>
<BUDGET>1214588.19</BUDGET>
<GROSS_PROFIT>902678.9705</GROSS_PROFIT>
<EXPENSES>998853.61</EXPENSES>
<NET_INCOME>217776.85</NET_INCOME>
<REVENUE_M>1.21663046</REVENUE_M>
<PROFIT_M>0.902678971</PROFIT_M>
<INCOME_M>0.21777685</INCOME_M>
<PHARMA_REV_M>1.21663046</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.902678971</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21777685</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.014449995E7</REVENUE>
<PREV_YEAR_REV>9368837.39</PREV_YEAR_REV>
<BUDGET>9738719.95</BUDGET>
<GROSS_PROFIT>6872232.348</GROSS_PROFIT>
<EXPENSES>8639684.22</EXPENSES>
<NET_INCOME>1504815.73</NET_INCOME>
<REVENUE_M>10.14449995</REVENUE_M>
<PROFIT_M>6.872232348</PROFIT_M>
<INCOME_M>1.50481573</INCOME_M>
<PHARMA_REV_M>10.14449995</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.872232348</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.50481573</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1122077.54</REVENUE>
<PREV_YEAR_REV>1055228.8</PREV_YEAR_REV>
<BUDGET>1145792.72</BUDGET>
<GROSS_PROFIT>824726.99</GROSS_PROFIT>
<EXPENSES>999771.09</EXPENSES>
<NET_INCOME>122306.45</NET_INCOME>
<REVENUE_M>1.12207754</REVENUE_M>
<PROFIT_M>0.82472699</PROFIT_M>
<INCOME_M>0.12230645</INCOME_M>
<PHARMA_REV_M>1.12207754</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.82472699</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12230645</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5964644.15</REVENUE>
<PREV_YEAR_REV>5541392.59</PREV_YEAR_REV>
<BUDGET>5726058.39</BUDGET>
<GROSS_PROFIT>4138687.635</GROSS_PROFIT>
<EXPENSES>4896972.85</EXPENSES>
<NET_INCOME>1067671.3</NET_INCOME>
<REVENUE_M>5.96464415</REVENUE_M>
<PROFIT_M>4.138687635</PROFIT_M>
<INCOME_M>1.0676713</INCOME_M>
<PHARMA_REV_M>5.96464415</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.138687635</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.0676713</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>1959207.7</REVENUE>
<PREV_YEAR_REV>1769803.34</PREV_YEAR_REV>
<BUDGET>2016221.44</BUDGET>
<GROSS_PROFIT>1466897.986</GROSS_PROFIT>
<EXPENSES>1608509.52</EXPENSES>
<NET_INCOME>350698.18</NET_INCOME>
<REVENUE_M>1.9592077</REVENUE_M>
<PROFIT_M>1.466897986</PROFIT_M>
<INCOME_M>0.35069818</INCOME_M>
<PHARMA_REV_M>1.9592077</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.466897986</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35069818</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2063426.99</REVENUE>
<PREV_YEAR_REV>1895835.16</PREV_YEAR_REV>
<BUDGET>2055147.09</BUDGET>
<GROSS_PROFIT>1480933.933</GROSS_PROFIT>
<EXPENSES>1852957.44</EXPENSES>
<NET_INCOME>210469.55</NET_INCOME>
<REVENUE_M>2.06342699</REVENUE_M>
<PROFIT_M>1.480933933</PROFIT_M>
<INCOME_M>0.21046955</INCOME_M>
<PHARMA_REV_M>2.06342699</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.480933933</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21046955</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4056768.32</REVENUE>
<PREV_YEAR_REV>3715787.04</PREV_YEAR_REV>
<BUDGET>4171057.45</BUDGET>
<GROSS_PROFIT>2867224.779</GROSS_PROFIT>
<EXPENSES>3517456.39</EXPENSES>
<NET_INCOME>539311.93</NET_INCOME>
<REVENUE_M>4.05676832</REVENUE_M>
<PROFIT_M>2.867224779</PROFIT_M>
<INCOME_M>0.53931193</INCOME_M>
<PHARMA_REV_M>4.05676832</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.867224779</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53931193</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1447705.64</REVENUE>
<PREV_YEAR_REV>1309216.69</PREV_YEAR_REV>
<BUDGET>1820808.31</BUDGET>
<GROSS_PROFIT>1101703.99</GROSS_PROFIT>
<EXPENSES>1342023.13</EXPENSES>
<NET_INCOME>105682.51</NET_INCOME>
<REVENUE_M>1.44770564</REVENUE_M>
<PROFIT_M>1.10170399</PROFIT_M>
<INCOME_M>0.10568251</INCOME_M>
<PHARMA_REV_M>1.44770564</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.10170399</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10568251</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1325135.38</REVENUE>
<PREV_YEAR_REV>1199543.21</PREV_YEAR_REV>
<BUDGET>1820808.31</BUDGET>
<GROSS_PROFIT>925275.7845</GROSS_PROFIT>
<EXPENSES>1228400.5</EXPENSES>
<NET_INCOME>96734.88</NET_INCOME>
<REVENUE_M>1.32513538</REVENUE_M>
<PROFIT_M>0.925275785</PROFIT_M>
<INCOME_M>0.09673488</INCOME_M>
<PHARMA_REV_M>1.32513538</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.925275785</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.09673488</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1474617.81</REVENUE>
<PREV_YEAR_REV>1369152.03</PREV_YEAR_REV>
<BUDGET>1802925.43</BUDGET>
<GROSS_PROFIT>951202.2155</GROSS_PROFIT>
<EXPENSES>1210661.22</EXPENSES>
<NET_INCOME>263956.59</NET_INCOME>
<REVENUE_M>1.47461781</REVENUE_M>
<PROFIT_M>0.951202216</PROFIT_M>
<INCOME_M>0.26395659</INCOME_M>
<PHARMA_REV_M>1.47461781</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.951202216</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26395659</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2726307.45</REVENUE>
<PREV_YEAR_REV>2502006.92</PREV_YEAR_REV>
<BUDGET>3601622.46</BUDGET>
<GROSS_PROFIT>1851788.042</GROSS_PROFIT>
<EXPENSES>2364919.85</EXPENSES>
<NET_INCOME>361387.6</NET_INCOME>
<REVENUE_M>2.72630745</REVENUE_M>
<PROFIT_M>1.851788042</PROFIT_M>
<INCOME_M>0.3613876</INCOME_M>
<PHARMA_REV_M>2.72630745</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.851788042</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3613876</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1248845.2</REVENUE>
<PREV_YEAR_REV>1150468.63</PREV_YEAR_REV>
<BUDGET>1306008.8</BUDGET>
<GROSS_PROFIT>898107.029</GROSS_PROFIT>
<EXPENSES>1083997.64</EXPENSES>
<NET_INCOME>164847.57</NET_INCOME>
<REVENUE_M>1.2488452</REVENUE_M>
<PROFIT_M>0.898107029</PROFIT_M>
<INCOME_M>0.16484757</INCOME_M>
<PHARMA_REV_M>1.2488452</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.898107029</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16484757</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>823107.54</REVENUE>
<PREV_YEAR_REV>751511.08</PREV_YEAR_REV>
<BUDGET>992184.29</BUDGET>
<GROSS_PROFIT>561441.6495</GROSS_PROFIT>
<EXPENSES>739150.57</EXPENSES>
<NET_INCOME>83956.97</NET_INCOME>
<REVENUE_M>0.82310754</REVENUE_M>
<PROFIT_M>0.56144165</PROFIT_M>
<INCOME_M>0.08395697</INCOME_M>
<PHARMA_REV_M>0.82310754</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.56144165</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.08395697</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6135113.1</REVENUE>
<PREV_YEAR_REV>5696642.53</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>4527713.466</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>791429.59</NET_INCOME>
<REVENUE_M>6.1351131</REVENUE_M>
<PROFIT_M>4.527713466</PROFIT_M>
<INCOME_M>0.79142959</INCOME_M>
<PHARMA_REV_M>6.1351131</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.527713466</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.79142959</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5771040.14</REVENUE>
<PREV_YEAR_REV>5431056.03</PREV_YEAR_REV>
<BUDGET>5540198.54</BUDGET>
<GROSS_PROFIT>4668829.182</GROSS_PROFIT>
<EXPENSES>5009262.84</EXPENSES>
<NET_INCOME>761777.3</NET_INCOME>
<REVENUE_M>5.77104014</REVENUE_M>
<PROFIT_M>4.668829182</PROFIT_M>
<INCOME_M>0.7617773</INCOME_M>
<PHARMA_REV_M>5.77104014</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.668829182</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.7617773</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.971481859E7</REVENUE>
<PREV_YEAR_REV>1.870258506E7</PREV_YEAR_REV>
<BUDGET>1.892622585E7</BUDGET>
<GROSS_PROFIT>1.603183047E7</GROSS_PROFIT>
<EXPENSES>1.777225832E7</EXPENSES>
<NET_INCOME>1942560.28</NET_INCOME>
<REVENUE_M>19.71481859</REVENUE_M>
<PROFIT_M>16.03183047</PROFIT_M>
<INCOME_M>1.94256028</INCOME_M>
<PHARMA_REV_M>19.71481859</PHARMA_REV_M>
<PHARMA_PROFIT_M>16.03183047</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.94256028</PHARMA_INCOME_M>
<FRANCE_REV_M>19.71481859</FRANCE_REV_M>
<FRANCE_PROFIT_M>16.03183047</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>1.94256028</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7736703.79</REVENUE>
<PREV_YEAR_REV>7333090.49</PREV_YEAR_REV>
<BUDGET>7427235.63</BUDGET>
<GROSS_PROFIT>6638091.85</GROSS_PROFIT>
<EXPENSES>6893403.07</EXPENSES>
<NET_INCOME>843300.71</NET_INCOME>
<REVENUE_M>7.73670379</REVENUE_M>
<PROFIT_M>6.63809185</PROFIT_M>
<INCOME_M>0.84330071</INCOME_M>
<PHARMA_REV_M>7.73670379</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.63809185</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.84330071</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>7145165.98</REVENUE>
<PREV_YEAR_REV>6706487.54</PREV_YEAR_REV>
<BUDGET>5367183.9</BUDGET>
<GROSS_PROFIT>6128864.456</GROSS_PROFIT>
<EXPENSES>6455940.57</EXPENSES>
<NET_INCOME>689225.41</NET_INCOME>
<REVENUE_M>7.14516598</REVENUE_M>
<PROFIT_M>6.128864456</PROFIT_M>
<INCOME_M>0.68922541</INCOME_M>
<PHARMA_REV_M>7.14516598</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.128864456</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68922541</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2290032.37</REVENUE>
<PREV_YEAR_REV>2163244.6</PREV_YEAR_REV>
<BUDGET>1747506.56</BUDGET>
<GROSS_PROFIT>1954725.826</GROSS_PROFIT>
<EXPENSES>1880116.57</EXPENSES>
<NET_INCOME>409915.79</NET_INCOME>
<REVENUE_M>2.29003237</REVENUE_M>
<PROFIT_M>1.954725826</PROFIT_M>
<INCOME_M>0.40991579</INCOME_M>
<PHARMA_REV_M>2.29003237</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.954725826</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40991579</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1345948.03</REVENUE>
<PREV_YEAR_REV>1249197.67</PREV_YEAR_REV>
<BUDGET>1291814.49</BUDGET>
<GROSS_PROFIT>1090837.04</GROSS_PROFIT>
<EXPENSES>1130596.34</EXPENSES>
<NET_INCOME>215351.68</NET_INCOME>
<REVENUE_M>1.34594803</REVENUE_M>
<PROFIT_M>1.09083704</PROFIT_M>
<INCOME_M>0.21535168</INCOME_M>
<PHARMA_REV_M>1.34594803</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.09083704</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21535168</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1861082.13</REVENUE>
<PREV_YEAR_REV>1759372.79</PREV_YEAR_REV>
<BUDGET>1622121.31</BUDGET>
<GROSS_PROFIT>1632169.02</GROSS_PROFIT>
<EXPENSES>1563308.99</EXPENSES>
<NET_INCOME>297773.14</NET_INCOME>
<REVENUE_M>1.86108213</REVENUE_M>
<PROFIT_M>1.63216902</PROFIT_M>
<INCOME_M>0.29777314</INCOME_M>
<PHARMA_REV_M>1.86108213</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.63216902</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29777314</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1693889.74</REVENUE>
<PREV_YEAR_REV>1579207.68</PREV_YEAR_REV>
<BUDGET>1544313.61</BUDGET>
<GROSS_PROFIT>1273034.363</GROSS_PROFIT>
<EXPENSES>1475377.96</EXPENSES>
<NET_INCOME>218511.78</NET_INCOME>
<REVENUE_M>1.69388974</REVENUE_M>
<PROFIT_M>1.273034363</PROFIT_M>
<INCOME_M>0.21851178</INCOME_M>
<PHARMA_REV_M>1.69388974</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.273034363</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21851178</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1681412.75</REVENUE>
<PREV_YEAR_REV>1554258.83</PREV_YEAR_REV>
<BUDGET>1562637.89</BUDGET>
<GROSS_PROFIT>1316546.181</GROSS_PROFIT>
<EXPENSES>1464510.5</EXPENSES>
<NET_INCOME>216902.24</NET_INCOME>
<REVENUE_M>1.68141275</REVENUE_M>
<PROFIT_M>1.316546181</PROFIT_M>
<INCOME_M>0.21690224</INCOME_M>
<PHARMA_REV_M>1.68141275</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.316546181</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21690224</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3253147.67</REVENUE>
<PREV_YEAR_REV>3018537.6</PREV_YEAR_REV>
<BUDGET>3146413.54</BUDGET>
<GROSS_PROFIT>2415069.733</GROSS_PROFIT>
<EXPENSES>2769450.38</EXPENSES>
<NET_INCOME>483697.29</NET_INCOME>
<REVENUE_M>3.25314767</REVENUE_M>
<PROFIT_M>2.415069733</PROFIT_M>
<INCOME_M>0.48369729</INCOME_M>
<PHARMA_REV_M>3.25314767</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.415069733</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48369729</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3323805.91</REVENUE>
<PREV_YEAR_REV>3093187.55</PREV_YEAR_REV>
<BUDGET>3125275.78</BUDGET>
<GROSS_PROFIT>2673729.818</GROSS_PROFIT>
<EXPENSES>2876605.3</EXPENSES>
<NET_INCOME>447200.61</NET_INCOME>
<REVENUE_M>3.32380591</REVENUE_M>
<PROFIT_M>2.673729818</PROFIT_M>
<INCOME_M>0.44720061</INCOME_M>
<PHARMA_REV_M>3.32380591</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.673729818</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44720061</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4854711.41</REVENUE>
<PREV_YEAR_REV>4507647.47</PREV_YEAR_REV>
<BUDGET>4754433.62</BUDGET>
<GROSS_PROFIT>3875862.725</GROSS_PROFIT>
<EXPENSES>4382976.73</EXPENSES>
<NET_INCOME>471734.67</NET_INCOME>
<REVENUE_M>4.85471141</REVENUE_M>
<PROFIT_M>3.875862725</PROFIT_M>
<INCOME_M>0.47173467</INCOME_M>
<PHARMA_REV_M>4.85471141</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.875862725</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47173467</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7524698.4</REVENUE>
<PREV_YEAR_REV>6453927.32</PREV_YEAR_REV>
<BUDGET>7374204.44</BUDGET>
<GROSS_PROFIT>6079956.307</GROSS_PROFIT>
<EXPENSES>6531438.21</EXPENSES>
<NET_INCOME>993260.19</NET_INCOME>
<REVENUE_M>7.5246984</REVENUE_M>
<PROFIT_M>6.079956307</PROFIT_M>
<INCOME_M>0.99326019</INCOME_M>
<PHARMA_REV_M>7.5246984</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.079956307</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.99326019</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.571171026E7</REVENUE>
<PREV_YEAR_REV>1.337982338E7</PREV_YEAR_REV>
<BUDGET>1.539747605E7</BUDGET>
<GROSS_PROFIT>1.234295758E7</GROSS_PROFIT>
<EXPENSES>1.36015854E7</EXPENSES>
<NET_INCOME>2110124.86</NET_INCOME>
<REVENUE_M>15.71171026</REVENUE_M>
<PROFIT_M>12.34295758</PROFIT_M>
<INCOME_M>2.11012486</INCOME_M>
<PHARMA_REV_M>15.71171026</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.34295758</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.11012486</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6500681.08</REVENUE>
<PREV_YEAR_REV>5644814.33</PREV_YEAR_REV>
<BUDGET>6370667.46</BUDGET>
<GROSS_PROFIT>5245984.622</GROSS_PROFIT>
<EXPENSES>5337059.17</EXPENSES>
<NET_INCOME>1163621.91</NET_INCOME>
<REVENUE_M>6.50068108</REVENUE_M>
<PROFIT_M>5.245984622</PROFIT_M>
<INCOME_M>1.16362191</INCOME_M>
<PHARMA_REV_M>6.50068108</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.245984622</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.16362191</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>9589122.73</REVENUE>
<PREV_YEAR_REV>8508840.36</PREV_YEAR_REV>
<BUDGET>9397340.28</BUDGET>
<GROSS_PROFIT>7728641.144</GROSS_PROFIT>
<EXPENSES>7939793.62</EXPENSES>
<NET_INCOME>1649329.11</NET_INCOME>
<REVENUE_M>9.58912273</REVENUE_M>
<PROFIT_M>7.728641144</PROFIT_M>
<INCOME_M>1.64932911</INCOME_M>
<PHARMA_REV_M>9.58912273</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.728641144</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.64932911</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5618883.72</REVENUE>
<PREV_YEAR_REV>4954641.91</PREV_YEAR_REV>
<BUDGET>5167496.25</BUDGET>
<GROSS_PROFIT>4357476.293</GROSS_PROFIT>
<EXPENSES>5000167.14</EXPENSES>
<NET_INCOME>618716.58</NET_INCOME>
<REVENUE_M>5.61888372</REVENUE_M>
<PROFIT_M>4.357476293</PROFIT_M>
<INCOME_M>0.61871658</INCOME_M>
<PHARMA_REV_M>5.61888372</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.357476293</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61871658</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3006281.78</REVENUE>
<PREV_YEAR_REV>2687107.19</PREV_YEAR_REV>
<BUDGET>2699215.31</BUDGET>
<GROSS_PROFIT>2298885.637</GROSS_PROFIT>
<EXPENSES>2618471.43</EXPENSES>
<NET_INCOME>387810.35</NET_INCOME>
<REVENUE_M>3.00628178</REVENUE_M>
<PROFIT_M>2.298885637</PROFIT_M>
<INCOME_M>0.38781035</INCOME_M>
<PHARMA_REV_M>3.00628178</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.298885637</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38781035</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5927192.09</REVENUE>
<PREV_YEAR_REV>5229799.26</PREV_YEAR_REV>
<BUDGET>5344079.54</BUDGET>
<GROSS_PROFIT>4672346.373</GROSS_PROFIT>
<EXPENSES>5129793.3</EXPENSES>
<NET_INCOME>797398.8</NET_INCOME>
<REVENUE_M>5.92719209</REVENUE_M>
<PROFIT_M>4.672346373</PROFIT_M>
<INCOME_M>0.7973988</INCOME_M>
<PHARMA_REV_M>5.92719209</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.672346373</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.7973988</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3671718.85</REVENUE>
<PREV_YEAR_REV>3212886.62</PREV_YEAR_REV>
<BUDGET>3561567.28</BUDGET>
<GROSS_PROFIT>3115063.88</GROSS_PROFIT>
<EXPENSES>3177773.01</EXPENSES>
<NET_INCOME>493945.85</NET_INCOME>
<REVENUE_M>3.67171885</REVENUE_M>
<PROFIT_M>3.11506388</PROFIT_M>
<INCOME_M>0.49394585</INCOME_M>
<PHARMA_REV_M>3.67171885</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.11506388</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49394585</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1673550.11</REVENUE>
<PREV_YEAR_REV>1466932.65</PREV_YEAR_REV>
<BUDGET>1623343.61</BUDGET>
<GROSS_PROFIT>1462682.8</GROSS_PROFIT>
<EXPENSES>1491133.15</EXPENSES>
<NET_INCOME>182416.96</NET_INCOME>
<REVENUE_M>1.67355011</REVENUE_M>
<PROFIT_M>1.4626828</PROFIT_M>
<INCOME_M>0.18241696</INCOME_M>
<PHARMA_REV_M>1.67355011</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.4626828</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18241696</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1784278.62</REVENUE>
<PREV_YEAR_REV>1606488.53</PREV_YEAR_REV>
<BUDGET>1730750.26</BUDGET>
<GROSS_PROFIT>1238753.275</GROSS_PROFIT>
<EXPENSES>1543401.01</EXPENSES>
<NET_INCOME>240877.61</NET_INCOME>
<REVENUE_M>1.78427862</REVENUE_M>
<PROFIT_M>1.238753275</PROFIT_M>
<INCOME_M>0.24087761</INCOME_M>
<PHARMA_REV_M>1.78427862</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.238753275</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24087761</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2657231.85</REVENUE>
<PREV_YEAR_REV>2319569.2</PREV_YEAR_REV>
<BUDGET>2577514.9</BUDGET>
<GROSS_PROFIT>2016971.847</GROSS_PROFIT>
<EXPENSES>2363171.66</EXPENSES>
<NET_INCOME>294060.2</NET_INCOME>
<REVENUE_M>2.65723185</REVENUE_M>
<PROFIT_M>2.016971847</PROFIT_M>
<INCOME_M>0.2940602</INCOME_M>
<PHARMA_REV_M>2.65723185</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.016971847</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2940602</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5764301.29</REVENUE>
<PREV_YEAR_REV>5023004.64</PREV_YEAR_REV>
<BUDGET>5324395.79</BUDGET>
<GROSS_PROFIT>4793618.621</GROSS_PROFIT>
<EXPENSES>4988372.33</EXPENSES>
<NET_INCOME>775928.96</NET_INCOME>
<REVENUE_M>5.76430129</REVENUE_M>
<PROFIT_M>4.793618621</PROFIT_M>
<INCOME_M>0.77592896</INCOME_M>
<PHARMA_REV_M>5.76430129</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.793618621</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.77592896</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5934547.41</REVENUE>
<PREV_YEAR_REV>5100955.12</PREV_YEAR_REV>
<BUDGET>5348168.44</BUDGET>
<GROSS_PROFIT>4427719.839</GROSS_PROFIT>
<EXPENSES>5052566.74</EXPENSES>
<NET_INCOME>881980.66</NET_INCOME>
<REVENUE_M>5.93454741</REVENUE_M>
<PROFIT_M>4.427719839</PROFIT_M>
<INCOME_M>0.88198066</INCOME_M>
<PHARMA_REV_M>5.93454741</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.427719839</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.88198066</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>6012033.15</REVENUE>
<PREV_YEAR_REV>5297809.94</PREV_YEAR_REV>
<BUDGET>5421510.48</BUDGET>
<GROSS_PROFIT>4819618.508</GROSS_PROFIT>
<EXPENSES>5220455.1</EXPENSES>
<NET_INCOME>791578.05</NET_INCOME>
<REVENUE_M>6.01203315</REVENUE_M>
<PROFIT_M>4.819618508</PROFIT_M>
<INCOME_M>0.79157805</INCOME_M>
<PHARMA_REV_M>6.01203315</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.819618508</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.79157805</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2868124.34</REVENUE>
<PREV_YEAR_REV>2583290.7</PREV_YEAR_REV>
<BUDGET>2623822.03</BUDGET>
<GROSS_PROFIT>2229636.836</GROSS_PROFIT>
<EXPENSES>2575575.66</EXPENSES>
<NET_INCOME>292548.68</NET_INCOME>
<REVENUE_M>2.86812434</REVENUE_M>
<PROFIT_M>2.229636836</PROFIT_M>
<INCOME_M>0.29254868</INCOME_M>
<PHARMA_REV_M>2.86812434</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.229636836</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29254868</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4320140.36</REVENUE>
<PREV_YEAR_REV>3872761.93</PREV_YEAR_REV>
<BUDGET>4769101.38</BUDGET>
<GROSS_PROFIT>3301314.75</GROSS_PROFIT>
<EXPENSES>3799279.88</EXPENSES>
<NET_INCOME>520860.48</NET_INCOME>
<REVENUE_M>4.32014036</REVENUE_M>
<PROFIT_M>3.30131475</PROFIT_M>
<INCOME_M>0.52086048</INCOME_M>
<PHARMA_REV_M>4.32014036</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.30131475</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52086048</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2123549.19</REVENUE>
<PREV_YEAR_REV>1889446.74</PREV_YEAR_REV>
<BUDGET>2346247.97</BUDGET>
<GROSS_PROFIT>1681511.185</GROSS_PROFIT>
<EXPENSES>1743433.88</EXPENSES>
<NET_INCOME>380115.3</NET_INCOME>
<REVENUE_M>2.12354919</REVENUE_M>
<PROFIT_M>1.681511185</PROFIT_M>
<INCOME_M>0.3801153</INCOME_M>
<PHARMA_REV_M>2.12354919</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.681511185</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3801153</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2043502.1</REVENUE>
<PREV_YEAR_REV>1793568.35</PREV_YEAR_REV>
<BUDGET>2346247.97</BUDGET>
<GROSS_PROFIT>1626627.67</GROSS_PROFIT>
<EXPENSES>1677715.22</EXPENSES>
<NET_INCOME>365786.88</NET_INCOME>
<REVENUE_M>2.0435021</REVENUE_M>
<PROFIT_M>1.62662767</PROFIT_M>
<INCOME_M>0.36578688</INCOME_M>
<PHARMA_REV_M>2.0435021</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.62662767</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36578688</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2007753.57</REVENUE>
<PREV_YEAR_REV>1754845.27</PREV_YEAR_REV>
<BUDGET>2371390.88</BUDGET>
<GROSS_PROFIT>1734699.08</GROSS_PROFIT>
<EXPENSES>1861187.56</EXPENSES>
<NET_INCOME>146566.01</NET_INCOME>
<REVENUE_M>2.00775357</REVENUE_M>
<PROFIT_M>1.73469908</PROFIT_M>
<INCOME_M>0.14656601</INCOME_M>
<PHARMA_REV_M>2.00775357</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.73469908</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14656601</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2007930.7</REVENUE>
<PREV_YEAR_REV>1706031.39</PREV_YEAR_REV>
<BUDGET>2291636.22</BUDGET>
<GROSS_PROFIT>1448962.951</GROSS_PROFIT>
<EXPENSES>1736860.06</EXPENSES>
<NET_INCOME>271070.64</NET_INCOME>
<REVENUE_M>2.0079307</REVENUE_M>
<PROFIT_M>1.448962951</PROFIT_M>
<INCOME_M>0.27107064</INCOME_M>
<PHARMA_REV_M>2.0079307</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.448962951</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27107064</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2039093.87</REVENUE>
<PREV_YEAR_REV>1738950.94</PREV_YEAR_REV>
<BUDGET>2302548.41</BUDGET>
<GROSS_PROFIT>1545837.062</GROSS_PROFIT>
<EXPENSES>1831106.3</EXPENSES>
<NET_INCOME>207987.57</NET_INCOME>
<REVENUE_M>2.03909387</REVENUE_M>
<PROFIT_M>1.545837062</PROFIT_M>
<INCOME_M>0.20798757</INCOME_M>
<PHARMA_REV_M>2.03909387</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.545837062</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20798757</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2047685.05</REVENUE>
<PREV_YEAR_REV>1836307.68</PREV_YEAR_REV>
<BUDGET>2340745.31</BUDGET>
<GROSS_PROFIT>1567912.443</GROSS_PROFIT>
<EXPENSES>1695483.22</EXPENSES>
<NET_INCOME>352201.83</NET_INCOME>
<REVENUE_M>2.04768505</REVENUE_M>
<PROFIT_M>1.567912443</PROFIT_M>
<INCOME_M>0.35220183</INCOME_M>
<PHARMA_REV_M>2.04768505</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.567912443</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35220183</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1489911.48</REVENUE>
<PREV_YEAR_REV>1280740.88</PREV_YEAR_REV>
<BUDGET>1528537.5</BUDGET>
<GROSS_PROFIT>1183287.7</GROSS_PROFIT>
<EXPENSES>1327511.13</EXPENSES>
<NET_INCOME>162400.35</NET_INCOME>
<REVENUE_M>1.48991148</REVENUE_M>
<PROFIT_M>1.1832877</PROFIT_M>
<INCOME_M>0.16240035</INCOME_M>
<PHARMA_REV_M>1.48991148</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.1832877</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16240035</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3510951.56</REVENUE>
<PREV_YEAR_REV>3058939.94</PREV_YEAR_REV>
<BUDGET>3258520.44</BUDGET>
<GROSS_PROFIT>2907969.29</GROSS_PROFIT>
<EXPENSES>3042909.13</EXPENSES>
<NET_INCOME>468042.44</NET_INCOME>
<REVENUE_M>3.51095156</REVENUE_M>
<PROFIT_M>2.90796929</PROFIT_M>
<INCOME_M>0.46804244</INCOME_M>
<PHARMA_REV_M>3.51095156</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.90796929</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46804244</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>883027.06</REVENUE>
<PREV_YEAR_REV>779790.58</PREV_YEAR_REV>
<BUDGET>1603316.48</BUDGET>
<GROSS_PROFIT>758520.24</GROSS_PROFIT>
<EXPENSES>786777.11</EXPENSES>
<NET_INCOME>96249.95</NET_INCOME>
<REVENUE_M>0.88302706</REVENUE_M>
<PROFIT_M>0.75852024</PROFIT_M>
<INCOME_M>0.09624995</INCOME_M>
<PHARMA_REV_M>0.88302706</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.75852024</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.09624995</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.896841062E7</REVENUE>
<PREV_YEAR_REV>1.657294174E7</PREV_YEAR_REV>
<BUDGET>1.745093777E7</BUDGET>
<GROSS_PROFIT>1.50772324E7</GROSS_PROFIT>
<EXPENSES>1.687542481E7</EXPENSES>
<NET_INCOME>2092985.81</NET_INCOME>
<REVENUE_M>18.96841062</REVENUE_M>
<PROFIT_M>15.0772324</PROFIT_M>
<INCOME_M>2.09298581</INCOME_M>
<PHARMA_REV_M>18.96841062</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.0772324</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.09298581</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>9358648.65</REVENUE>
<PREV_YEAR_REV>8239334.99</PREV_YEAR_REV>
<BUDGET>8609956.76</BUDGET>
<GROSS_PROFIT>8104589.73</GROSS_PROFIT>
<EXPENSES>8123307.03</EXPENSES>
<NET_INCOME>1235341.62</NET_INCOME>
<REVENUE_M>9.35864865</REVENUE_M>
<PROFIT_M>8.10458973</PROFIT_M>
<INCOME_M>1.23534162</INCOME_M>
<PHARMA_REV_M>9.35864865</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.10458973</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.23534162</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8292149.53</REVENUE>
<PREV_YEAR_REV>7480986.2</PREV_YEAR_REV>
<BUDGET>7628777.57</BUDGET>
<GROSS_PROFIT>7236061.372</GROSS_PROFIT>
<EXPENSES>6807854.77</EXPENSES>
<NET_INCOME>1484294.77</NET_INCOME>
<REVENUE_M>8.29214953</REVENUE_M>
<PROFIT_M>7.236061372</PROFIT_M>
<INCOME_M>1.48429477</INCOME_M>
<PHARMA_REV_M>8.29214953</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.236061372</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.48429477</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6178909.36</REVENUE>
<PREV_YEAR_REV>5285275.05</PREV_YEAR_REV>
<BUDGET>5684596.61</BUDGET>
<GROSS_PROFIT>5079063.49</GROSS_PROFIT>
<EXPENSES>5505408.24</EXPENSES>
<NET_INCOME>673501.12</NET_INCOME>
<REVENUE_M>6.17890936</REVENUE_M>
<PROFIT_M>5.07906349</PROFIT_M>
<INCOME_M>0.67350112</INCOME_M>
<PHARMA_REV_M>6.17890936</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.07906349</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67350112</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2448023.49</REVENUE>
<PREV_YEAR_REV>2115635.93</PREV_YEAR_REV>
<BUDGET>2374582.79</BUDGET>
<GROSS_PROFIT>1895259.789</GROSS_PROFIT>
<EXPENSES>2056339.73</EXPENSES>
<NET_INCOME>391683.76</NET_INCOME>
<REVENUE_M>2.44802349</REVENUE_M>
<PROFIT_M>1.895259789</PROFIT_M>
<INCOME_M>0.39168376</INCOME_M>
<PHARMA_REV_M>2.44802349</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.895259789</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39168376</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5083004.75</REVENUE>
<PREV_YEAR_REV>4374092.17</PREV_YEAR_REV>
<BUDGET>4930514.6</BUDGET>
<GROSS_PROFIT>3805928.722</GROSS_PROFIT>
<EXPENSES>4472090.8</EXPENSES>
<NET_INCOME>610913.95</NET_INCOME>
<REVENUE_M>5.08300475</REVENUE_M>
<PROFIT_M>3.805928722</PROFIT_M>
<INCOME_M>0.61091395</INCOME_M>
<PHARMA_REV_M>5.08300475</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.805928722</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61091395</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2595406.64</REVENUE>
<PREV_YEAR_REV>2278631.31</PREV_YEAR_REV>
<BUDGET>2517544.44</BUDGET>
<GROSS_PROFIT>1959860.327</GROSS_PROFIT>
<EXPENSES>2330675.16</EXPENSES>
<NET_INCOME>264731.48</NET_INCOME>
<REVENUE_M>2.59540664</REVENUE_M>
<PROFIT_M>1.959860327</PROFIT_M>
<INCOME_M>0.26473148</INCOME_M>
<PHARMA_REV_M>2.59540664</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.959860327</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26473148</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1589361.17</REVENUE>
<PREV_YEAR_REV>1406116.11</PREV_YEAR_REV>
<BUDGET>2082054.09</BUDGET>
<GROSS_PROFIT>1198696.194</GROSS_PROFIT>
<EXPENSES>1374797.41</EXPENSES>
<NET_INCOME>214563.76</NET_INCOME>
<REVENUE_M>1.58936117</REVENUE_M>
<PROFIT_M>1.198696194</PROFIT_M>
<INCOME_M>0.21456376</INCOME_M>
<PHARMA_REV_M>1.58936117</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.198696194</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21456376</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1553530.55</REVENUE>
<PREV_YEAR_REV>1342189.41</PREV_YEAR_REV>
<BUDGET>2012030.41</BUDGET>
<GROSS_PROFIT>1085195.463</GROSS_PROFIT>
<EXPENSES>1343803.93</EXPENSES>
<NET_INCOME>209726.62</NET_INCOME>
<REVENUE_M>1.55353055</REVENUE_M>
<PROFIT_M>1.085195463</PROFIT_M>
<INCOME_M>0.20972662</INCOME_M>
<PHARMA_REV_M>1.55353055</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.085195463</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20972662</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2746751.04</REVENUE>
<PREV_YEAR_REV>2446926.78</PREV_YEAR_REV>
<BUDGET>3003594.07</BUDGET>
<GROSS_PROFIT>2053540.215</GROSS_PROFIT>
<EXPENSES>2444033.45</EXPENSES>
<NET_INCOME>302717.6</NET_INCOME>
<REVENUE_M>2.74675104</REVENUE_M>
<PROFIT_M>2.053540215</PROFIT_M>
<INCOME_M>0.3027176</INCOME_M>
<PHARMA_REV_M>2.74675104</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.053540215</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3027176</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1307861.52</REVENUE>
<PREV_YEAR_REV>1182942.77</PREV_YEAR_REV>
<BUDGET>1478109.12</BUDGET>
<GROSS_PROFIT>1025036.472</GROSS_PROFIT>
<EXPENSES>1212387.63</EXPENSES>
<NET_INCOME>95473.89</NET_INCOME>
<REVENUE_M>1.30786152</REVENUE_M>
<PROFIT_M>1.025036472</PROFIT_M>
<INCOME_M>0.09547389</INCOME_M>
<PHARMA_REV_M>1.30786152</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.025036472</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.09547389</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2488290.25</REVENUE>
<PREV_YEAR_REV>2167356.46</PREV_YEAR_REV>
<BUDGET>2818066.7</BUDGET>
<GROSS_PROFIT>2046215.13</GROSS_PROFIT>
<EXPENSES>2152881.4</EXPENSES>
<NET_INCOME>335408.85</NET_INCOME>
<REVENUE_M>2.48829025</REVENUE_M>
<PROFIT_M>2.04621513</PROFIT_M>
<INCOME_M>0.33540885</INCOME_M>
<PHARMA_REV_M>2.48829025</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.04621513</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33540885</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2328864.17</REVENUE>
<PREV_YEAR_REV>2044844.5</PREV_YEAR_REV>
<BUDGET>2657509.94</BUDGET>
<GROSS_PROFIT>1668626.964</GROSS_PROFIT>
<EXPENSES>1983243.8</EXPENSES>
<NET_INCOME>345620.37</NET_INCOME>
<REVENUE_M>2.32886417</REVENUE_M>
<PROFIT_M>1.668626964</PROFIT_M>
<INCOME_M>0.34562037</INCOME_M>
<PHARMA_REV_M>2.32886417</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.668626964</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34562037</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2435866.83</REVENUE>
<PREV_YEAR_REV>2146463.13</PREV_YEAR_REV>
<BUDGET>2816856.5</BUDGET>
<GROSS_PROFIT>1903372.415</GROSS_PROFIT>
<EXPENSES>2111856.49</EXPENSES>
<NET_INCOME>324010.35</NET_INCOME>
<REVENUE_M>2.43586683</REVENUE_M>
<PROFIT_M>1.903372415</PROFIT_M>
<INCOME_M>0.32401035</INCOME_M>
<PHARMA_REV_M>2.43586683</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.903372415</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32401035</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8047318.38</REVENUE>
<PREV_YEAR_REV>6922424.41</PREV_YEAR_REV>
<BUDGET>7805898.83</BUDGET>
<GROSS_PROFIT>6276908.34</GROSS_PROFIT>
<EXPENSES>6985072.36</EXPENSES>
<NET_INCOME>1062246.03</NET_INCOME>
<REVENUE_M>8.04731838</REVENUE_M>
<PROFIT_M>6.27690834</PROFIT_M>
<INCOME_M>1.06224603</INCOME_M>
<PHARMA_REV_M>8.04731838</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.27690834</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.06224603</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>2.081036594E7</REVENUE>
<PREV_YEAR_REV>1.838093415E7</PREV_YEAR_REV>
<BUDGET>2.018605496E7</BUDGET>
<GROSS_PROFIT>1.687034057E7</GROSS_PROFIT>
<EXPENSES>1.872976735E7</EXPENSES>
<NET_INCOME>2080598.6</NET_INCOME>
<REVENUE_M>20.81036594</REVENUE_M>
<PROFIT_M>16.87034057</PROFIT_M>
<INCOME_M>2.0805986</INCOME_M>
<PHARMA_REV_M>20.81036594</PHARMA_REV_M>
<PHARMA_PROFIT_M>16.87034057</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.0805986</PHARMA_INCOME_M>
<FRANCE_REV_M>20.81036594</FRANCE_REV_M>
<FRANCE_PROFIT_M>16.87034057</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>2.0805986</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6172395.94</REVENUE>
<PREV_YEAR_REV>5367674.22</PREV_YEAR_REV>
<BUDGET>5987224.06</BUDGET>
<GROSS_PROFIT>4857675.61</GROSS_PROFIT>
<EXPENSES>5721811.04</EXPENSES>
<NET_INCOME>450584.9</NET_INCOME>
<REVENUE_M>6.17239594</REVENUE_M>
<PROFIT_M>4.85767561</PROFIT_M>
<INCOME_M>0.4505849</INCOME_M>
<PHARMA_REV_M>6.17239594</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.85767561</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4505849</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.130518945E7</REVENUE>
<PREV_YEAR_REV>9743246.15</PREV_YEAR_REV>
<BUDGET>1.096603377E7</BUDGET>
<GROSS_PROFIT>9790656.321</GROSS_PROFIT>
<EXPENSES>9816308.98</EXPENSES>
<NET_INCOME>1488880.47</NET_INCOME>
<REVENUE_M>11.30518945</REVENUE_M>
<PROFIT_M>9.790656321</PROFIT_M>
<INCOME_M>1.48888047</INCOME_M>
<PHARMA_REV_M>11.30518945</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.790656321</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.48888047</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2998252.96</REVENUE>
<PREV_YEAR_REV>2682304.33</PREV_YEAR_REV>
<BUDGET>2420784.81</BUDGET>
<GROSS_PROFIT>2453930.634</GROSS_PROFIT>
<EXPENSES>2692431.16</EXPENSES>
<NET_INCOME>305821.8</NET_INCOME>
<REVENUE_M>2.99825296</REVENUE_M>
<PROFIT_M>2.453930634</PROFIT_M>
<INCOME_M>0.3058218</INCOME_M>
<PHARMA_REV_M>2.99825296</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.453930634</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3058218</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1312464.8</REVENUE>
<PREV_YEAR_REV>1137199.6</PREV_YEAR_REV>
<BUDGET>1273090.86</BUDGET>
<GROSS_PROFIT>1156281.49</GROSS_PROFIT>
<EXPENSES>1077533.6</EXPENSES>
<NET_INCOME>234931.2</NET_INCOME>
<REVENUE_M>1.3124648</REVENUE_M>
<PROFIT_M>1.15628149</PROFIT_M>
<INCOME_M>0.2349312</INCOME_M>
<PHARMA_REV_M>1.3124648</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.15628149</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2349312</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.706932474E7</REVENUE>
<PREV_YEAR_REV>1.331782725E7</PREV_YEAR_REV>
<BUDGET>1.621585851E7</BUDGET>
<GROSS_PROFIT>1.239817238E7</GROSS_PROFIT>
<EXPENSES>1.518310131E7</EXPENSES>
<NET_INCOME>1886223.43</NET_INCOME>
<REVENUE_M>17.06932474</REVENUE_M>
<PROFIT_M>12.39817238</PROFIT_M>
<INCOME_M>1.88622343</INCOME_M>
<PHARMA_REV_M>17.06932474</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.39817238</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.88622343</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.033453621E7</REVENUE>
<PREV_YEAR_REV>8321083.61</PREV_YEAR_REV>
<BUDGET>9817809.4</BUDGET>
<GROSS_PROFIT>8205621.75</GROSS_PROFIT>
<EXPENSES>8681010.42</EXPENSES>
<NET_INCOME>1653525.79</NET_INCOME>
<REVENUE_M>10.33453621</REVENUE_M>
<PROFIT_M>8.20562175</PROFIT_M>
<INCOME_M>1.65352579</INCOME_M>
<PHARMA_REV_M>10.33453621</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.20562175</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.65352579</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.015940125E7</REVENUE>
<PREV_YEAR_REV>8545570.3</PREV_YEAR_REV>
<BUDGET>9651431.19</BUDGET>
<GROSS_PROFIT>7682539.23</GROSS_PROFIT>
<EXPENSES>9123142.32</EXPENSES>
<NET_INCOME>1036258.93</NET_INCOME>
<REVENUE_M>10.15940125</REVENUE_M>
<PROFIT_M>7.68253923</PROFIT_M>
<INCOME_M>1.03625893</INCOME_M>
<PHARMA_REV_M>10.15940125</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.68253923</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03625893</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.019880662E7</REVENUE>
<PREV_YEAR_REV>8048427.7</PREV_YEAR_REV>
<BUDGET>9688866.29</BUDGET>
<GROSS_PROFIT>8668985.62</GROSS_PROFIT>
<EXPENSES>9087136.69</EXPENSES>
<NET_INCOME>1111669.92</NET_INCOME>
<REVENUE_M>10.19880662</REVENUE_M>
<PROFIT_M>8.66898562</PROFIT_M>
<INCOME_M>1.11166992</INCOME_M>
<PHARMA_REV_M>10.19880662</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.66898562</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.11166992</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7295293.84</REVENUE>
<PREV_YEAR_REV>5934547.41</PREV_YEAR_REV>
<BUDGET>6938962.5</BUDGET>
<GROSS_PROFIT>5388856.971</GROSS_PROFIT>
<EXPENSES>6211926.77</EXPENSES>
<NET_INCOME>1083367.07</NET_INCOME>
<REVENUE_M>7.29529384</REVENUE_M>
<PROFIT_M>5.388856971</PROFIT_M>
<INCOME_M>1.08336707</INCOME_M>
<PHARMA_REV_M>7.29529384</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.388856971</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.08336707</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3611065.67</REVENUE>
<PREV_YEAR_REV>3031121.25</PREV_YEAR_REV>
<BUDGET>3435094.88</BUDGET>
<GROSS_PROFIT>3022281.417</GROSS_PROFIT>
<EXPENSES>3217459.52</EXPENSES>
<NET_INCOME>393606.16</NET_INCOME>
<REVENUE_M>3.61106567</REVENUE_M>
<PROFIT_M>3.022281417</PROFIT_M>
<INCOME_M>0.39360616</INCOME_M>
<PHARMA_REV_M>3.61106567</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.022281417</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39360616</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3648190.67</REVENUE>
<PREV_YEAR_REV>2841734.77</PREV_YEAR_REV>
<BUDGET>3469992.38</BUDGET>
<GROSS_PROFIT>3048882.33</GROSS_PROFIT>
<EXPENSES>3276075.23</EXPENSES>
<NET_INCOME>372115.45</NET_INCOME>
<REVENUE_M>3.64819067</REVENUE_M>
<PROFIT_M>3.04888233</PROFIT_M>
<INCOME_M>0.37211545</INCOME_M>
<PHARMA_REV_M>3.64819067</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.04888233</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37211545</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5185440.72</REVENUE>
<PREV_YEAR_REV>4065491.35</PREV_YEAR_REV>
<BUDGET>4955700.57</BUDGET>
<GROSS_PROFIT>4130649.239</GROSS_PROFIT>
<EXPENSES>4612772.38</EXPENSES>
<NET_INCOME>572668.34</NET_INCOME>
<REVENUE_M>5.18544072</REVENUE_M>
<PROFIT_M>4.130649239</PROFIT_M>
<INCOME_M>0.57266834</INCOME_M>
<PHARMA_REV_M>5.18544072</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.130649239</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57266834</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5135753.22</REVENUE>
<PREV_YEAR_REV>4091059.28</PREV_YEAR_REV>
<BUDGET>4908994.32</BUDGET>
<GROSS_PROFIT>4329646.14</GROSS_PROFIT>
<EXPENSES>4444852.67</EXPENSES>
<NET_INCOME>690900.56</NET_INCOME>
<REVENUE_M>5.13575322</REVENUE_M>
<PROFIT_M>4.32964614</PROFIT_M>
<INCOME_M>0.69090056</INCOME_M>
<PHARMA_REV_M>5.13575322</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.32964614</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69090056</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2367054.9</REVENUE>
<PREV_YEAR_REV>1857825.05</PREV_YEAR_REV>
<BUDGET>2343384.35</BUDGET>
<GROSS_PROFIT>1950831.968</GROSS_PROFIT>
<EXPENSES>2054603.65</EXPENSES>
<NET_INCOME>312451.25</NET_INCOME>
<REVENUE_M>2.3670549</REVENUE_M>
<PROFIT_M>1.950831968</PROFIT_M>
<INCOME_M>0.31245125</INCOME_M>
<PHARMA_REV_M>2.3670549</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.950831968</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31245125</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2632283.33</REVENUE>
<PREV_YEAR_REV>2182674.26</PREV_YEAR_REV>
<BUDGET>2605960.49</BUDGET>
<GROSS_PROFIT>1991480.275</GROSS_PROFIT>
<EXPENSES>2211117.99</EXPENSES>
<NET_INCOME>421165.33</NET_INCOME>
<REVENUE_M>2.63228333</REVENUE_M>
<PROFIT_M>1.991480275</PROFIT_M>
<INCOME_M>0.42116533</INCOME_M>
<PHARMA_REV_M>2.63228333</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.991480275</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42116533</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5576430.83</REVENUE>
<PREV_YEAR_REV>4604251.33</PREV_YEAR_REV>
<BUDGET>5520666.52</BUDGET>
<GROSS_PROFIT>4321927.834</GROSS_PROFIT>
<EXPENSES>4826681.62</EXPENSES>
<NET_INCOME>749749.21</NET_INCOME>
<REVENUE_M>5.57643083</REVENUE_M>
<PROFIT_M>4.321927834</PROFIT_M>
<INCOME_M>0.74974921</INCOME_M>
<PHARMA_REV_M>5.57643083</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.321927834</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74974921</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2820825</REVENUE>
<PREV_YEAR_REV>2209292.76</PREV_YEAR_REV>
<BUDGET>2792616.75</BUDGET>
<GROSS_PROFIT>2146506.789</GROSS_PROFIT>
<EXPENSES>2614904.78</EXPENSES>
<NET_INCOME>205920.23</NET_INCOME>
<REVENUE_M>2.820825</REVENUE_M>
<PROFIT_M>2.146506789</PROFIT_M>
<INCOME_M>0.20592023</INCOME_M>
<PHARMA_REV_M>2.820825</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.146506789</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20592023</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2907292.5</REVENUE>
<PREV_YEAR_REV>2361463.77</PREV_YEAR_REV>
<BUDGET>2878219.58</BUDGET>
<GROSS_PROFIT>2484165.155</GROSS_PROFIT>
<EXPENSES>2695060.15</EXPENSES>
<NET_INCOME>212232.35</NET_INCOME>
<REVENUE_M>2.9072925</REVENUE_M>
<PROFIT_M>2.484165155</PROFIT_M>
<INCOME_M>0.21223235</INCOME_M>
<PHARMA_REV_M>2.9072925</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.484165155</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21223235</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5657228.33</REVENUE>
<PREV_YEAR_REV>4573930.77</PREV_YEAR_REV>
<BUDGET>5600656.04</BUDGET>
<GROSS_PROFIT>4352040.858</GROSS_PROFIT>
<EXPENSES>4909767.15</EXPENSES>
<NET_INCOME>747461.17</NET_INCOME>
<REVENUE_M>5.65722833</REVENUE_M>
<PROFIT_M>4.352040858</PROFIT_M>
<INCOME_M>0.74746117</INCOME_M>
<PHARMA_REV_M>5.65722833</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.352040858</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74746117</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5696932.5</REVENUE>
<PREV_YEAR_REV>4609606.48</PREV_YEAR_REV>
<BUDGET>5639963.18</BUDGET>
<GROSS_PROFIT>4603359.123</GROSS_PROFIT>
<EXPENSES>4944500.82</EXPENSES>
<NET_INCOME>752431.68</NET_INCOME>
<REVENUE_M>5.6969325</REVENUE_M>
<PROFIT_M>4.603359123</PROFIT_M>
<INCOME_M>0.75243168</INCOME_M>
<PHARMA_REV_M>5.6969325</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.603359123</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75243168</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2776882.5</REVENUE>
<PREV_YEAR_REV>2168389.14</PREV_YEAR_REV>
<BUDGET>2749113.68</BUDGET>
<GROSS_PROFIT>2266158.271</GROSS_PROFIT>
<EXPENSES>2474202.31</EXPENSES>
<NET_INCOME>302680.19</NET_INCOME>
<REVENUE_M>2.7768825</REVENUE_M>
<PROFIT_M>2.266158271</PROFIT_M>
<INCOME_M>0.30268019</INCOME_M>
<PHARMA_REV_M>2.7768825</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.266158271</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30268019</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5664032.33</REVENUE>
<PREV_YEAR_REV>4666722.3</PREV_YEAR_REV>
<BUDGET>5607392.01</BUDGET>
<GROSS_PROFIT>4470295.794</GROSS_PROFIT>
<EXPENSES>4911856.53</EXPENSES>
<NET_INCOME>752175.79</NET_INCOME>
<REVENUE_M>5.66403233</REVENUE_M>
<PROFIT_M>4.470295794</PROFIT_M>
<INCOME_M>0.75217579</INCOME_M>
<PHARMA_REV_M>5.66403233</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.470295794</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75217579</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3909819.38</REVENUE>
<PREV_YEAR_REV>3121762.05</PREV_YEAR_REV>
<BUDGET>3870721.18</BUDGET>
<GROSS_PROFIT>2789901.716</GROSS_PROFIT>
<EXPENSES>3478037.89</EXPENSES>
<NET_INCOME>431781.49</NET_INCOME>
<REVENUE_M>3.90981938</REVENUE_M>
<PROFIT_M>2.789901716</PROFIT_M>
<INCOME_M>0.43178149</INCOME_M>
<PHARMA_REV_M>3.90981938</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.789901716</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43178149</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1990871.66</REVENUE>
<PREV_YEAR_REV>1561541.45</PREV_YEAR_REV>
<BUDGET>1970962.95</BUDGET>
<GROSS_PROFIT>1505098.98</GROSS_PROFIT>
<EXPENSES>1728076.6</EXPENSES>
<NET_INCOME>262795.06</NET_INCOME>
<REVENUE_M>1.99087166</REVENUE_M>
<PROFIT_M>1.50509898</PROFIT_M>
<INCOME_M>0.26279506</INCOME_M>
<PHARMA_REV_M>1.99087166</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.50509898</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26279506</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3935688.76</REVENUE>
<PREV_YEAR_REV>3047966.47</PREV_YEAR_REV>
<BUDGET>3896331.86</BUDGET>
<GROSS_PROFIT>2899087.983</GROSS_PROFIT>
<EXPENSES>3351178.73</EXPENSES>
<NET_INCOME>584510.03</NET_INCOME>
<REVENUE_M>3.93568876</REVENUE_M>
<PROFIT_M>2.899087983</PROFIT_M>
<INCOME_M>0.58451003</INCOME_M>
<PHARMA_REV_M>3.93568876</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.899087983</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58451003</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1985350.5</REVENUE>
<PREV_YEAR_REV>1589361.17</PREV_YEAR_REV>
<BUDGET>1965497</BUDGET>
<GROSS_PROFIT>1402650.126</GROSS_PROFIT>
<EXPENSES>1717328.18</EXPENSES>
<NET_INCOME>268022.32</NET_INCOME>
<REVENUE_M>1.9853505</REVENUE_M>
<PROFIT_M>1.402650126</PROFIT_M>
<INCOME_M>0.26802232</INCOME_M>
<PHARMA_REV_M>1.9853505</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.402650126</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26802232</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1927714.95</REVENUE>
<PREV_YEAR_REV>1503326.02</PREV_YEAR_REV>
<BUDGET>1908437.8</BUDGET>
<GROSS_PROFIT>1421386.157</GROSS_PROFIT>
<EXPENSES>1731088.03</EXPENSES>
<NET_INCOME>196626.92</NET_INCOME>
<REVENUE_M>1.92771495</REVENUE_M>
<PROFIT_M>1.421386157</PROFIT_M>
<INCOME_M>0.19662692</INCOME_M>
<PHARMA_REV_M>1.92771495</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.421386157</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19662692</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3203323.2</REVENUE>
<PREV_YEAR_REV>2592669.83</PREV_YEAR_REV>
<BUDGET>3171289.97</BUDGET>
<GROSS_PROFIT>2165223.016</GROSS_PROFIT>
<EXPENSES>2815996.52</EXPENSES>
<NET_INCOME>387326.68</NET_INCOME>
<REVENUE_M>3.2033232</REVENUE_M>
<PROFIT_M>2.165223016</PROFIT_M>
<INCOME_M>0.38732668</INCOME_M>
<PHARMA_REV_M>3.2033232</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.165223016</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38732668</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1310668.13</REVENUE>
<PREV_YEAR_REV>1088350.73</PREV_YEAR_REV>
<BUDGET>1297561.45</BUDGET>
<GROSS_PROFIT>1002661.12</GROSS_PROFIT>
<EXPENSES>1100961.23</EXPENSES>
<NET_INCOME>209706.9</NET_INCOME>
<REVENUE_M>1.31066813</REVENUE_M>
<PROFIT_M>1.00266112</PROFIT_M>
<INCOME_M>0.2097069</INCOME_M>
<PHARMA_REV_M>1.31066813</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.00266112</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2097069</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.071211016E7</REVENUE>
<PREV_YEAR_REV>8712786.94</PREV_YEAR_REV>
<BUDGET>1.060498906E7</BUDGET>
<GROSS_PROFIT>8837490.88</GROSS_PROFIT>
<EXPENSES>8998172.53</EXPENSES>
<NET_INCOME>1713937.63</NET_INCOME>
<REVENUE_M>10.71211016</REVENUE_M>
<PROFIT_M>8.83749088</PROFIT_M>
<INCOME_M>1.71393763</INCOME_M>
<PHARMA_REV_M>10.71211016</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.83749088</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.71393763</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>2.109929979E7</REVENUE>
<PREV_YEAR_REV>1.682701338E7</PREV_YEAR_REV>
<BUDGET>2.08883068E7</BUDGET>
<GROSS_PROFIT>1.558624066E7</GROSS_PROFIT>
<EXPENSES>1.877169757E7</EXPENSES>
<NET_INCOME>2327602.23</NET_INCOME>
<REVENUE_M>21.09929979</REVENUE_M>
<PROFIT_M>15.58624066</PROFIT_M>
<INCOME_M>2.32760223</INCOME_M>
<PHARMA_REV_M>21.09929979</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.58624066</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.32760223</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8454711.98</REVENUE>
<PREV_YEAR_REV>6868779.48</PREV_YEAR_REV>
<BUDGET>8370164.86</BUDGET>
<GROSS_PROFIT>6983592.09</GROSS_PROFIT>
<EXPENSES>7101958.06</EXPENSES>
<NET_INCOME>1352753.92</NET_INCOME>
<REVENUE_M>8.45471198</REVENUE_M>
<PROFIT_M>6.98359209</PROFIT_M>
<INCOME_M>1.35275392</INCOME_M>
<PHARMA_REV_M>8.45471198</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.98359209</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.35275392</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>2.101701416E7</REVENUE>
<PREV_YEAR_REV>1.690539642E7</PREV_YEAR_REV>
<BUDGET>2.080684402E7</BUDGET>
<GROSS_PROFIT>1.707713461E7</GROSS_PROFIT>
<EXPENSES>1.823167672E7</EXPENSES>
<NET_INCOME>2785337.44</NET_INCOME>
<REVENUE_M>21.01701416</REVENUE_M>
<PROFIT_M>17.07713461</PROFIT_M>
<INCOME_M>2.78533744</INCOME_M>
<PHARMA_REV_M>21.01701416</PHARMA_REV_M>
<PHARMA_PROFIT_M>17.07713461</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.78533744</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7203376.52</REVENUE>
<PREV_YEAR_REV>6039807.59</PREV_YEAR_REV>
<BUDGET>7131342.75</BUDGET>
<GROSS_PROFIT>5501665.258</GROSS_PROFIT>
<EXPENSES>6468632.11</EXPENSES>
<NET_INCOME>734744.4</NET_INCOME>
<REVENUE_M>7.20337652</REVENUE_M>
<PROFIT_M>5.501665258</PROFIT_M>
<INCOME_M>0.7347444</INCOME_M>
<PHARMA_REV_M>7.20337652</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.501665258</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.7347444</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>7674760.25</REVENUE>
<PREV_YEAR_REV>6224329.15</PREV_YEAR_REV>
<BUDGET>7291022.24</BUDGET>
<GROSS_PROFIT>6200264.184</GROSS_PROFIT>
<EXPENSES>6641794.98</EXPENSES>
<NET_INCOME>1032965.27</NET_INCOME>
<REVENUE_M>7.67476025</REVENUE_M>
<PROFIT_M>6.200264184</PROFIT_M>
<INCOME_M>1.03296527</INCOME_M>
<PHARMA_REV_M>7.67476025</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.200264184</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03296527</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3959302</REVENUE>
<PREV_YEAR_REV>3121517.83</PREV_YEAR_REV>
<BUDGET>3761336.9</BUDGET>
<GROSS_PROFIT>3107972.882</GROSS_PROFIT>
<EXPENSES>3527738.08</EXPENSES>
<NET_INCOME>431563.92</NET_INCOME>
<REVENUE_M>3.959302</REVENUE_M>
<PROFIT_M>3.107972882</PROFIT_M>
<INCOME_M>0.43156392</INCOME_M>
<PHARMA_REV_M>3.959302</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.107972882</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43156392</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5886676.81</REVENUE>
<PREV_YEAR_REV>4636919.21</PREV_YEAR_REV>
<BUDGET>5298009.14</BUDGET>
<GROSS_PROFIT>4431077.295</GROSS_PROFIT>
<EXPENSES>5172793.53</EXPENSES>
<NET_INCOME>713883.28</NET_INCOME>
<REVENUE_M>5.88667681</REVENUE_M>
<PROFIT_M>4.431077295</PROFIT_M>
<INCOME_M>0.71388328</INCOME_M>
<PHARMA_REV_M>5.88667681</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.431077295</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.71388328</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5739760.25</REVENUE>
<PREV_YEAR_REV>4599290.67</PREV_YEAR_REV>
<BUDGET>5165784.23</BUDGET>
<GROSS_PROFIT>4465791.474</GROSS_PROFIT>
<EXPENSES>5103143.7</EXPENSES>
<NET_INCOME>636616.55</NET_INCOME>
<REVENUE_M>5.73976025</REVENUE_M>
<PROFIT_M>4.465791474</PROFIT_M>
<INCOME_M>0.63661655</INCOME_M>
<PHARMA_REV_M>5.73976025</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.465791474</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.63661655</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5813861.19</REVENUE>
<PREV_YEAR_REV>4767474.48</PREV_YEAR_REV>
<BUDGET>5232475.07</BUDGET>
<GROSS_PROFIT>4120615.341</GROSS_PROFIT>
<EXPENSES>5110684.98</EXPENSES>
<NET_INCOME>703176.21</NET_INCOME>
<REVENUE_M>5.81386119</REVENUE_M>
<PROFIT_M>4.120615341</PROFIT_M>
<INCOME_M>0.70317621</INCOME_M>
<PHARMA_REV_M>5.81386119</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.120615341</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.70317621</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2900387.31</REVENUE>
<PREV_YEAR_REV>2321219.77</PREV_YEAR_REV>
<BUDGET>2610348.58</BUDGET>
<GROSS_PROFIT>2427624.18</GROSS_PROFIT>
<EXPENSES>2517536.19</EXPENSES>
<NET_INCOME>382851.13</NET_INCOME>
<REVENUE_M>2.90038731</REVENUE_M>
<PROFIT_M>2.42762418</PROFIT_M>
<INCOME_M>0.38285113</INCOME_M>
<PHARMA_REV_M>2.90038731</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.42762418</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38285113</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5769142.44</REVENUE>
<PREV_YEAR_REV>4773301.43</PREV_YEAR_REV>
<BUDGET>5192228.19</BUDGET>
<GROSS_PROFIT>4226616.099</GROSS_PROFIT>
<EXPENSES>4912155.91</EXPENSES>
<NET_INCOME>856986.53</NET_INCOME>
<REVENUE_M>5.76914244</REVENUE_M>
<PROFIT_M>4.226616099</PROFIT_M>
<INCOME_M>0.85698653</INCOME_M>
<PHARMA_REV_M>5.76914244</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.226616099</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.85698653</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>8705811</REVENUE>
<PREV_YEAR_REV>6961207.67</PREV_YEAR_REV>
<BUDGET>7835229.9</BUDGET>
<GROSS_PROFIT>6922364.763</GROSS_PROFIT>
<EXPENSES>7861603.03</EXPENSES>
<NET_INCOME>844207.96</NET_INCOME>
<REVENUE_M>8.705811</REVENUE_M>
<PROFIT_M>6.922364763</PROFIT_M>
<INCOME_M>0.84420796</INCOME_M>
<PHARMA_REV_M>8.705811</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.922364763</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.84420796</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2814324.81</REVENUE>
<PREV_YEAR_REV>2256731.57</PREV_YEAR_REV>
<BUDGET>2532892.33</BUDGET>
<GROSS_PROFIT>2291282.542</GROSS_PROFIT>
<EXPENSES>2527263.68</EXPENSES>
<NET_INCOME>287061.13</NET_INCOME>
<REVENUE_M>2.81432481</REVENUE_M>
<PROFIT_M>2.291282542</PROFIT_M>
<INCOME_M>0.28706113</INCOME_M>
<PHARMA_REV_M>2.81432481</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.291282542</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28706113</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2451298</REVENUE>
<PREV_YEAR_REV>1914418.48</PREV_YEAR_REV>
<BUDGET>2402272.04</BUDGET>
<GROSS_PROFIT>1641058.212</GROSS_PROFIT>
<EXPENSES>2135080.56</EXPENSES>
<NET_INCOME>316217.44</NET_INCOME>
<REVENUE_M>2.451298</REVENUE_M>
<PROFIT_M>1.641058212</PROFIT_M>
<INCOME_M>0.31621744</INCOME_M>
<PHARMA_REV_M>2.451298</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.641058212</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31621744</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2277302</REVENUE>
<PREV_YEAR_REV>1895603.32</PREV_YEAR_REV>
<BUDGET>2231755.96</BUDGET>
<GROSS_PROFIT>1741566.705</GROSS_PROFIT>
<EXPENSES>2029076.08</EXPENSES>
<NET_INCOME>248225.92</NET_INCOME>
<REVENUE_M>2.277302</REVENUE_M>
<PROFIT_M>1.741566705</PROFIT_M>
<INCOME_M>0.24822592</INCOME_M>
<PHARMA_REV_M>2.277302</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.741566705</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24822592</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2262802</REVENUE>
<PREV_YEAR_REV>1903017.51</PREV_YEAR_REV>
<BUDGET>2217545.96</BUDGET>
<GROSS_PROFIT>1671984.396</GROSS_PROFIT>
<EXPENSES>1957323.73</EXPENSES>
<NET_INCOME>305478.27</NET_INCOME>
<REVENUE_M>2.262802</REVENUE_M>
<PROFIT_M>1.671984396</PROFIT_M>
<INCOME_M>0.30547827</INCOME_M>
<PHARMA_REV_M>2.262802</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.671984396</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30547827</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>5868347.2</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>5398879.42</BUDGET>
<GROSS_PROFIT>4782702.96</GROSS_PROFIT>
<EXPENSES>5093725.37</EXPENSES>
<NET_INCOME>774621.83</NET_INCOME>
<REVENUE_M>5.8683472</REVENUE_M>
<PROFIT_M>4.78270296</PROFIT_M>
<INCOME_M>0.77462183</INCOME_M>
<PHARMA_REV_M>5.8683472</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.78270296</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.77462183</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6146947</REVENUE>
<PREV_YEAR_REV>9413395.1</PREV_YEAR_REV>
<BUDGET>5655191.24</BUDGET>
<GROSS_PROFIT>5255639.69</GROSS_PROFIT>
<EXPENSES>5335550</EXPENSES>
<NET_INCOME>811397</NET_INCOME>
<REVENUE_M>6.146947</REVENUE_M>
<PROFIT_M>5.25563969</PROFIT_M>
<INCOME_M>0.811397</INCOME_M>
<PHARMA_REV_M>6.146947</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.25563969</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.811397</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6520832.88</REVENUE>
<PREV_YEAR_REV>1.200890032E7</PREV_YEAR_REV>
<BUDGET>5999166.25</BUDGET>
<GROSS_PROFIT>4923880.902</GROSS_PROFIT>
<EXPENSES>5679645.43</EXPENSES>
<NET_INCOME>841187.44</NET_INCOME>
<REVENUE_M>6.52083288</REVENUE_M>
<PROFIT_M>4.923880902</PROFIT_M>
<INCOME_M>0.84118744</INCOME_M>
<PHARMA_REV_M>6.52083288</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.923880902</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.84118744</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>5238612</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>4819523.04</BUDGET>
<GROSS_PROFIT>4232798.5</GROSS_PROFIT>
<EXPENSES>4400434.08</EXPENSES>
<NET_INCOME>838177.92</NET_INCOME>
<REVENUE_M>5.238612</REVENUE_M>
<PROFIT_M>4.2327985</PROFIT_M>
<INCOME_M>0.83817792</INCOME_M>
<PHARMA_REV_M>5.238612</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.2327985</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83817792</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>2.462269888E7</REVENUE>
<PREV_YEAR_REV>2.06315345E7</PREV_YEAR_REV>
<BUDGET>2.265288297E7</BUDGET>
<GROSS_PROFIT>1.842944955E7</GROSS_PROFIT>
<EXPENSES>2.092922932E7</EXPENSES>
<NET_INCOME>3693469.56</NET_INCOME>
<REVENUE_M>24.62269888</REVENUE_M>
<PROFIT_M>18.42944955</PROFIT_M>
<INCOME_M>3.69346956</INCOME_M>
<PHARMA_REV_M>24.62269888</PHARMA_REV_M>
<PHARMA_PROFIT_M>18.42944955</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>3.69346956</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>8597352.13</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>7909563.96</BUDGET>
<GROSS_PROFIT>7048497.49</GROSS_PROFIT>
<EXPENSES>7420676.4</EXPENSES>
<NET_INCOME>1176675.73</NET_INCOME>
<REVENUE_M>8.59735213</REVENUE_M>
<PROFIT_M>7.04849749</PROFIT_M>
<INCOME_M>1.17667573</INCOME_M>
<PHARMA_REV_M>8.59735213</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.04849749</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.17667573</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>2805996.38</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>2581516.67</BUDGET>
<GROSS_PROFIT>2244797.1</GROSS_PROFIT>
<EXPENSES>2601158.64</EXPENSES>
<NET_INCOME>204837.74</NET_INCOME>
<REVENUE_M>2.80599638</REVENUE_M>
<PROFIT_M>2.2447971</PROFIT_M>
<INCOME_M>0.20483774</INCOME_M>
<PHARMA_REV_M>2.80599638</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.2447971</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20483774</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>2040633.25</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>2061382.59</BUDGET>
<GROSS_PROFIT>1730553.089</GROSS_PROFIT>
<EXPENSES>2012088.66</EXPENSES>
<NET_INCOME>228544.59</NET_INCOME>
<REVENUE_M>2.04063325</REVENUE_M>
<PROFIT_M>1.730553089</PROFIT_M>
<INCOME_M>0.22854459</INCOME_M>
<PHARMA_REV_M>2.04063325</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.730553089</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22854459</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>4472956</REVENUE>
<PREV_YEAR_REV>7833548.16</PREV_YEAR_REV>
<BUDGET>4115119.52</BUDGET>
<GROSS_PROFIT>3467435.495</GROSS_PROFIT>
<EXPENSES>3703607.57</EXPENSES>
<NET_INCOME>769348.43</NET_INCOME>
<REVENUE_M>4.472956</REVENUE_M>
<PROFIT_M>3.467435495</PROFIT_M>
<INCOME_M>0.76934843</INCOME_M>
<PHARMA_REV_M>4.472956</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.467435495</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76934843</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>6450324.5</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>5934298.54</BUDGET>
<GROSS_PROFIT>5361832.243</GROSS_PROFIT>
<EXPENSES>5340868.69</EXPENSES>
<NET_INCOME>1109455.81</NET_INCOME>
<REVENUE_M>6.4503245</REVENUE_M>
<PROFIT_M>5.361832243</PROFIT_M>
<INCOME_M>1.10945581</INCOME_M>
<PHARMA_REV_M>6.4503245</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.361832243</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.10945581</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7045918.84</REVENUE>
<PREV_YEAR_REV>5618883.72</PREV_YEAR_REV>
<BUDGET>6704550</BUDGET>
<GROSS_PROFIT>5472639.327</GROSS_PROFIT>
<EXPENSES>6268002.95</EXPENSES>
<NET_INCOME>777915.91</NET_INCOME>
<REVENUE_M>7.04591884</REVENUE_M>
<PROFIT_M>5.472639327</PROFIT_M>
<INCOME_M>0.77791591</INCOME_M>
<PHARMA_REV_M>7.04591884</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.472639327</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.77791591</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2293465.41</REVENUE>
<PREV_YEAR_REV>2129145.19</PREV_YEAR_REV>
<BUDGET>1982255.86</BUDGET>
<GROSS_PROFIT>1802011.908</GROSS_PROFIT>
<EXPENSES>2040751.84</EXPENSES>
<NET_INCOME>252713.56</NET_INCOME>
<REVENUE_M>2.29346541</REVENUE_M>
<PROFIT_M>1.802011908</PROFIT_M>
<INCOME_M>0.25271356</INCOME_M>
<PHARMA_REV_M>2.29346541</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.802011908</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25271356</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>979492.2</REVENUE>
<PREV_YEAR_REV>911164.01</PREV_YEAR_REV>
<BUDGET>815397.38</BUDGET>
<GROSS_PROFIT>720220.608</GROSS_PROFIT>
<EXPENSES>853137.7</EXPENSES>
<NET_INCOME>126354.49</NET_INCOME>
<REVENUE_M>0.9794922</REVENUE_M>
<PROFIT_M>0.720220608</PROFIT_M>
<INCOME_M>0.12635449</INCOME_M>
<PHARMA_REV_M>0.9794922</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.720220608</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12635449</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3912373.03</REVENUE>
<PREV_YEAR_REV>3663516.97</PREV_YEAR_REV>
<BUDGET>3238437.97</BUDGET>
<GROSS_PROFIT>3185496.851</GROSS_PROFIT>
<EXPENSES>3537829.88</EXPENSES>
<NET_INCOME>374543.16</NET_INCOME>
<REVENUE_M>3.91237303</REVENUE_M>
<PROFIT_M>3.185496851</PROFIT_M>
<INCOME_M>0.37454316</INCOME_M>
<PHARMA_REV_M>3.91237303</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.185496851</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37454316</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1440797.33</REVENUE>
<PREV_YEAR_REV>1348707.58</PREV_YEAR_REV>
<BUDGET>1125717.65</BUDGET>
<GROSS_PROFIT>1101370.694</GROSS_PROFIT>
<EXPENSES>1192980.19</EXPENSES>
<NET_INCOME>247817.14</NET_INCOME>
<REVENUE_M>1.44079733</REVENUE_M>
<PROFIT_M>1.101370694</PROFIT_M>
<INCOME_M>0.24781714</INCOME_M>
<PHARMA_REV_M>1.44079733</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.101370694</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24781714</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1033782.75</REVENUE>
<PREV_YEAR_REV>983094.4</PREV_YEAR_REV>
<BUDGET>859949.47</BUDGET>
<GROSS_PROFIT>813173.514</GROSS_PROFIT>
<EXPENSES>928336.91</EXPENSES>
<NET_INCOME>105445.84</NET_INCOME>
<REVENUE_M>1.03378275</REVENUE_M>
<PROFIT_M>0.813173514</PROFIT_M>
<INCOME_M>0.10544584</INCOME_M>
<PHARMA_REV_M>1.03378275</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.813173514</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10544584</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5893616.05</REVENUE>
<PREV_YEAR_REV>5506302.71</PREV_YEAR_REV>
<BUDGET>5657871.41</BUDGET>
<GROSS_PROFIT>4303695.244</GROSS_PROFIT>
<EXPENSES>4950637.48</EXPENSES>
<NET_INCOME>942978.57</NET_INCOME>
<REVENUE_M>5.89361605</REVENUE_M>
<PROFIT_M>4.303695244</PROFIT_M>
<INCOME_M>0.94297857</INCOME_M>
<PHARMA_REV_M>5.89361605</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.303695244</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.94297857</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6649839.36</REVENUE>
<PREV_YEAR_REV>6317356.87</PREV_YEAR_REV>
<BUDGET>6383845.79</BUDGET>
<GROSS_PROFIT>4751137.33</GROSS_PROFIT>
<EXPENSES>5792010.09</EXPENSES>
<NET_INCOME>857829.28</NET_INCOME>
<REVENUE_M>6.64983936</REVENUE_M>
<PROFIT_M>4.75113733</PROFIT_M>
<INCOME_M>0.85782928</INCOME_M>
<PHARMA_REV_M>6.64983936</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.75113733</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.85782928</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.503510438E7</REVENUE>
<PREV_YEAR_REV>1.395420905E7</PREV_YEAR_REV>
<BUDGET>1.443370019E7</BUDGET>
<GROSS_PROFIT>1.036649176E7</GROSS_PROFIT>
<EXPENSES>1.334652986E7</EXPENSES>
<NET_INCOME>1688574.51</NET_INCOME>
<REVENUE_M>15.03510438</REVENUE_M>
<PROFIT_M>10.36649176</PROFIT_M>
<INCOME_M>1.68857451</INCOME_M>
<PHARMA_REV_M>15.03510438</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.36649176</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.68857451</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.714381189E7</REVENUE>
<PREV_YEAR_REV>1.610548558E7</PREV_YEAR_REV>
<BUDGET>1.645805941E7</BUDGET>
<GROSS_PROFIT>1.099521574E7</GROSS_PROFIT>
<EXPENSES>1.507634359E7</EXPENSES>
<NET_INCOME>2067468.31</NET_INCOME>
<REVENUE_M>17.14381189</REVENUE_M>
<PROFIT_M>10.99521574</PROFIT_M>
<INCOME_M>2.06746831</INCOME_M>
<PHARMA_REV_M>17.14381189</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.99521574</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.06746831</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3959405.72</REVENUE>
<PREV_YEAR_REV>3732303.32</PREV_YEAR_REV>
<BUDGET>3725785.57</BUDGET>
<GROSS_PROFIT>2579219.879</GROSS_PROFIT>
<EXPENSES>3521428.48</EXPENSES>
<NET_INCOME>437977.23</NET_INCOME>
<REVENUE_M>3.95940572</REVENUE_M>
<PROFIT_M>2.579219879</PROFIT_M>
<INCOME_M>0.43797723</INCOME_M>
<PHARMA_REV_M>3.95940572</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.579219879</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43797723</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2087361.34</REVENUE>
<PREV_YEAR_REV>1977079.83</PREV_YEAR_REV>
<BUDGET>1991095.66</BUDGET>
<GROSS_PROFIT>1245716.37</GROSS_PROFIT>
<EXPENSES>1805567.56</EXPENSES>
<NET_INCOME>281793.78</NET_INCOME>
<REVENUE_M>2.08736134</REVENUE_M>
<PROFIT_M>1.24571637</PROFIT_M>
<INCOME_M>0.28179378</INCOME_M>
<PHARMA_REV_M>2.08736134</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.24571637</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28179378</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2103450.56</REVENUE>
<PREV_YEAR_REV>1972866.53</PREV_YEAR_REV>
<BUDGET>1916830.02</BUDGET>
<GROSS_PROFIT>1340245.08</GROSS_PROFIT>
<EXPENSES>1741657.06</EXPENSES>
<NET_INCOME>361793.5</NET_INCOME>
<REVENUE_M>2.10345056</REVENUE_M>
<PROFIT_M>1.34024508</PROFIT_M>
<INCOME_M>0.3617935</INCOME_M>
<PHARMA_REV_M>2.10345056</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.34024508</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3617935</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1505499.12</REVENUE>
<PREV_YEAR_REV>1405996.73</PREV_YEAR_REV>
<BUDGET>1755066.43</BUDGET>
<GROSS_PROFIT>1123102.34</GROSS_PROFIT>
<EXPENSES>1306773.23</EXPENSES>
<NET_INCOME>198725.88</NET_INCOME>
<REVENUE_M>1.50549912</REVENUE_M>
<PROFIT_M>1.12310234</PROFIT_M>
<INCOME_M>0.19872588</INCOME_M>
<PHARMA_REV_M>1.50549912</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.12310234</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19872588</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2991879.37</REVENUE>
<PREV_YEAR_REV>2813490.24</PREV_YEAR_REV>
<BUDGET>3408186.54</BUDGET>
<GROSS_PROFIT>1953910.017</GROSS_PROFIT>
<EXPENSES>2630336.88</EXPENSES>
<NET_INCOME>361542.48</NET_INCOME>
<REVENUE_M>2.99187937</REVENUE_M>
<PROFIT_M>1.953910017</PROFIT_M>
<INCOME_M>0.36154248</INCOME_M>
<PHARMA_REV_M>2.99187937</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.953910017</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36154248</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1486544.14</REVENUE>
<PREV_YEAR_REV>1399192.55</PREV_YEAR_REV>
<BUDGET>1672788.23</BUDGET>
<GROSS_PROFIT>970193.029</GROSS_PROFIT>
<EXPENSES>1290320.31</EXPENSES>
<NET_INCOME>196223.83</NET_INCOME>
<REVENUE_M>1.48654414</REVENUE_M>
<PROFIT_M>0.970193029</PROFIT_M>
<INCOME_M>0.19622383</INCOME_M>
<PHARMA_REV_M>1.48654414</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.970193029</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19622383</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1412993.42</REVENUE>
<PREV_YEAR_REV>1337074.34</PREV_YEAR_REV>
<BUDGET>1676720.65</BUDGET>
<GROSS_PROFIT>913076.352</GROSS_PROFIT>
<EXPENSES>1230717.27</EXPENSES>
<NET_INCOME>182276.15</NET_INCOME>
<REVENUE_M>1.41299342</REVENUE_M>
<PROFIT_M>0.913076352</PROFIT_M>
<INCOME_M>0.18227615</INCOME_M>
<PHARMA_REV_M>1.41299342</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.913076352</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18227615</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1494061.73</REVENUE>
<PREV_YEAR_REV>1372537.28</PREV_YEAR_REV>
<BUDGET>1693351.73</BUDGET>
<GROSS_PROFIT>1068254.14</GROSS_PROFIT>
<EXPENSES>1384995.22</EXPENSES>
<NET_INCOME>109066.51</NET_INCOME>
<REVENUE_M>1.49406173</REVENUE_M>
<PROFIT_M>1.06825414</PROFIT_M>
<INCOME_M>0.10906651</INCOME_M>
<PHARMA_REV_M>1.49406173</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.06825414</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10906651</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6293254.87</REVENUE>
<PREV_YEAR_REV>5740083.07</PREV_YEAR_REV>
<BUDGET>6922580.36</BUDGET>
<GROSS_PROFIT>5021388.064</GROSS_PROFIT>
<EXPENSES>5462545.23</EXPENSES>
<NET_INCOME>830709.64</NET_INCOME>
<REVENUE_M>6.29325487</REVENUE_M>
<PROFIT_M>5.021388064</PROFIT_M>
<INCOME_M>0.83070964</INCOME_M>
<PHARMA_REV_M>6.29325487</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.021388064</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83070964</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.653964679E7</REVENUE>
<PREV_YEAR_REV>1.499246211E7</PREV_YEAR_REV>
<BUDGET>1.819361146E7</BUDGET>
<GROSS_PROFIT>1.354908305E7</GROSS_PROFIT>
<EXPENSES>1.493426364E7</EXPENSES>
<NET_INCOME>1605383.16</NET_INCOME>
<REVENUE_M>16.53964679</REVENUE_M>
<PROFIT_M>13.54908305</PROFIT_M>
<INCOME_M>1.60538316</INCOME_M>
<PHARMA_REV_M>16.53964679</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.54908305</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.60538316</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2894136.32</REVENUE>
<PREV_YEAR_REV>2708441.71</PREV_YEAR_REV>
<BUDGET>3350343.76</BUDGET>
<GROSS_PROFIT>1927334.33</GROSS_PROFIT>
<EXPENSES>2507373.68</EXPENSES>
<NET_INCOME>386762.64</NET_INCOME>
<REVENUE_M>2.89413632</REVENUE_M>
<PROFIT_M>1.92733433</PROFIT_M>
<INCOME_M>0.38676264</INCOME_M>
<PHARMA_REV_M>2.89413632</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.92733433</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38676264</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2372084.99</REVENUE>
<PREV_YEAR_REV>2204089.7</PREV_YEAR_REV>
<BUDGET>2376342.74</BUDGET>
<GROSS_PROFIT>1622769.228</GROSS_PROFIT>
<EXPENSES>2084822.58</EXPENSES>
<NET_INCOME>287262.41</NET_INCOME>
<REVENUE_M>2.37208499</REVENUE_M>
<PROFIT_M>1.622769228</PROFIT_M>
<INCOME_M>0.28726241</INCOME_M>
<PHARMA_REV_M>2.37208499</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.622769228</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28726241</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.666808953E7</REVENUE>
<PREV_YEAR_REV>1.565841709E7</PREV_YEAR_REV>
<BUDGET>1.600136595E7</BUDGET>
<GROSS_PROFIT>1.192736076E7</GROSS_PROFIT>
<EXPENSES>1.504323172E7</EXPENSES>
<NET_INCOME>1624857.82</NET_INCOME>
<REVENUE_M>16.66808953</REVENUE_M>
<PROFIT_M>11.92736076</PROFIT_M>
<INCOME_M>1.62485782</INCOME_M>
<PHARMA_REV_M>16.66808953</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.92736076</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.62485782</PHARMA_INCOME_M>
<FRANCE_REV_M>16.66808953</FRANCE_REV_M>
<FRANCE_PROFIT_M>11.92736076</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>1.62485782</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.115852124E7</REVENUE>
<PREV_YEAR_REV>1.018817879E7</PREV_YEAR_REV>
<BUDGET>1.071218039E7</BUDGET>
<GROSS_PROFIT>7280997.642</GROSS_PROFIT>
<EXPENSES>9500323.86</EXPENSES>
<NET_INCOME>1658197.38</NET_INCOME>
<REVENUE_M>11.15852124</REVENUE_M>
<PROFIT_M>7.280997642</PROFIT_M>
<INCOME_M>1.65819738</INCOME_M>
<PHARMA_REV_M>11.15852124</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.280997642</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.65819738</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8819149.66</REVENUE>
<PREV_YEAR_REV>7988989.63</PREV_YEAR_REV>
<BUDGET>8466383.68</BUDGET>
<GROSS_PROFIT>5882879.158</GROSS_PROFIT>
<EXPENSES>7656291.19</EXPENSES>
<NET_INCOME>1162858.47</NET_INCOME>
<REVENUE_M>8.81914966</REVENUE_M>
<PROFIT_M>5.882879158</PROFIT_M>
<INCOME_M>1.16285847</INCOME_M>
<PHARMA_REV_M>8.81914966</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.882879158</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.16285847</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6939153.4</REVENUE>
<PREV_YEAR_REV>6418723.31</PREV_YEAR_REV>
<BUDGET>6661587.26</BUDGET>
<GROSS_PROFIT>4476100.902</GROSS_PROFIT>
<EXPENSES>5745619.01</EXPENSES>
<NET_INCOME>1193534.38</NET_INCOME>
<REVENUE_M>6.9391534</REVENUE_M>
<PROFIT_M>4.476100902</PROFIT_M>
<INCOME_M>1.19353438</INCOME_M>
<PHARMA_REV_M>6.9391534</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.476100902</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.19353438</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7089689.05</REVENUE>
<PREV_YEAR_REV>6528379.02</PREV_YEAR_REV>
<BUDGET>6806101.49</BUDGET>
<GROSS_PROFIT>5395253.37</GROSS_PROFIT>
<EXPENSES>6316912.95</EXPENSES>
<NET_INCOME>772776.11</NET_INCOME>
<REVENUE_M>7.08968905</REVENUE_M>
<PROFIT_M>5.39525337</PROFIT_M>
<INCOME_M>0.77277611</INCOME_M>
<PHARMA_REV_M>7.08968905</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.39525337</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.77277611</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1923678.3</REVENUE>
<PREV_YEAR_REV>1743093.78</PREV_YEAR_REV>
<BUDGET>1971857.26</BUDGET>
<GROSS_PROFIT>1231731.212</GROSS_PROFIT>
<EXPENSES>1615889.77</EXPENSES>
<NET_INCOME>307788.53</NET_INCOME>
<REVENUE_M>1.9236783</REVENUE_M>
<PROFIT_M>1.231731212</PROFIT_M>
<INCOME_M>0.30778853</INCOME_M>
<PHARMA_REV_M>1.9236783</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.231731212</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30778853</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1892057.63</REVENUE>
<PREV_YEAR_REV>1727338.62</PREV_YEAR_REV>
<BUDGET>1978120.44</BUDGET>
<GROSS_PROFIT>1376850.333</GROSS_PROFIT>
<EXPENSES>1642306.02</EXPENSES>
<NET_INCOME>249751.61</NET_INCOME>
<REVENUE_M>1.89205763</REVENUE_M>
<PROFIT_M>1.376850333</PROFIT_M>
<INCOME_M>0.24975161</INCOME_M>
<PHARMA_REV_M>1.89205763</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.376850333</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24975161</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1955202.75</REVENUE>
<PREV_YEAR_REV>1790642.68</PREV_YEAR_REV>
<BUDGET>2075189.26</BUDGET>
<GROSS_PROFIT>1195264.316</GROSS_PROFIT>
<EXPENSES>1702981.59</EXPENSES>
<NET_INCOME>252221.15</NET_INCOME>
<REVENUE_M>1.95520275</REVENUE_M>
<PROFIT_M>1.195264316</PROFIT_M>
<INCOME_M>0.25222115</INCOME_M>
<PHARMA_REV_M>1.95520275</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.195264316</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25222115</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3241134.94</REVENUE>
<PREV_YEAR_REV>2987932.84</PREV_YEAR_REV>
<BUDGET>3505051.97</BUDGET>
<GROSS_PROFIT>2290608.025</GROSS_PROFIT>
<EXPENSES>2850665.06</EXPENSES>
<NET_INCOME>390469.88</NET_INCOME>
<REVENUE_M>3.24113494</REVENUE_M>
<PROFIT_M>2.290608025</PROFIT_M>
<INCOME_M>0.39046988</INCOME_M>
<PHARMA_REV_M>3.24113494</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.290608025</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39046988</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2050006.31</REVENUE>
<PREV_YEAR_REV>1888032.04</PREV_YEAR_REV>
<BUDGET>2140963.07</BUDGET>
<GROSS_PROFIT>1349970.151</GROSS_PROFIT>
<EXPENSES>1900355.85</EXPENSES>
<NET_INCOME>149650.46</NET_INCOME>
<REVENUE_M>2.05000631</REVENUE_M>
<PROFIT_M>1.349970151</PROFIT_M>
<INCOME_M>0.14965046</INCOME_M>
<PHARMA_REV_M>2.05000631</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.349970151</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14965046</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1548987.04</REVENUE>
<PREV_YEAR_REV>1434672.34</PREV_YEAR_REV>
<BUDGET>1559183.41</BUDGET>
<GROSS_PROFIT>1061052.247</GROSS_PROFIT>
<EXPENSES>1390990.36</EXPENSES>
<NET_INCOME>157996.68</NET_INCOME>
<REVENUE_M>1.54898704</REVENUE_M>
<PROFIT_M>1.061052247</PROFIT_M>
<INCOME_M>0.15799668</INCOME_M>
<PHARMA_REV_M>1.54898704</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.061052247</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15799668</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1348027.4</REVENUE>
<PREV_YEAR_REV>1255298.5</PREV_YEAR_REV>
<BUDGET>1827313.55</BUDGET>
<GROSS_PROFIT>1070333.75</GROSS_PROFIT>
<EXPENSES>1170087.78</EXPENSES>
<NET_INCOME>177939.62</NET_INCOME>
<REVENUE_M>1.3480274</REVENUE_M>
<PROFIT_M>1.07033375</PROFIT_M>
<INCOME_M>0.17793962</INCOME_M>
<PHARMA_REV_M>1.3480274</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.07033375</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17793962</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1456664.89</REVENUE>
<PREV_YEAR_REV>1307669.07</PREV_YEAR_REV>
<BUDGET>1802925.43</BUDGET>
<GROSS_PROFIT>895411.908</GROSS_PROFIT>
<EXPENSES>1268755.11</EXPENSES>
<NET_INCOME>187909.77</NET_INCOME>
<REVENUE_M>1.45666489</REVENUE_M>
<PROFIT_M>0.895411908</PROFIT_M>
<INCOME_M>0.18790977</INCOME_M>
<PHARMA_REV_M>1.45666489</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.895411908</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18790977</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4130831.04</REVENUE>
<PREV_YEAR_REV>3775693.59</PREV_YEAR_REV>
<BUDGET>5475435.41</BUDGET>
<GROSS_PROFIT>2963662.992</GROSS_PROFIT>
<EXPENSES>3729870.93</EXPENSES>
<NET_INCOME>400960.1</NET_INCOME>
<REVENUE_M>4.13083104</REVENUE_M>
<PROFIT_M>2.963662992</PROFIT_M>
<INCOME_M>0.4009601</INCOME_M>
<PHARMA_REV_M>4.13083104</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.963662992</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4009601</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2890442.11</REVENUE>
<PREV_YEAR_REV>2657084.43</PREV_YEAR_REV>
<BUDGET>3605850.86</BUDGET>
<GROSS_PROFIT>1981387.308</GROSS_PROFIT>
<EXPENSES>2501730.66</EXPENSES>
<NET_INCOME>388711.45</NET_INCOME>
<REVENUE_M>2.89044211</REVENUE_M>
<PROFIT_M>1.981387308</PROFIT_M>
<INCOME_M>0.38871145</INCOME_M>
<PHARMA_REV_M>2.89044211</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.981387308</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38871145</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1426359.42</REVENUE>
<PREV_YEAR_REV>1321388.33</PREV_YEAR_REV>
<BUDGET>1809430.66</BUDGET>
<GROSS_PROFIT>1089738.6</GROSS_PROFIT>
<EXPENSES>1171041.09</EXPENSES>
<NET_INCOME>255318.34</NET_INCOME>
<REVENUE_M>1.42635942</REVENUE_M>
<PROFIT_M>1.0897386</PROFIT_M>
<INCOME_M>0.25531834</INCOME_M>
<PHARMA_REV_M>1.42635942</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.0897386</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25531834</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1139807.87</REVENUE>
<PREV_YEAR_REV>1043436.11</PREV_YEAR_REV>
<BUDGET>1291630.73</BUDGET>
<GROSS_PROFIT>644168.115</GROSS_PROFIT>
<EXPENSES>992772.66</EXPENSES>
<NET_INCOME>147035.22</NET_INCOME>
<REVENUE_M>1.13980787</REVENUE_M>
<PROFIT_M>0.644168115</PROFIT_M>
<INCOME_M>0.14703522</INCOME_M>
<PHARMA_REV_M>1.13980787</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.644168115</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14703522</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3229036.87</REVENUE>
<PREV_YEAR_REV>2942066.91</PREV_YEAR_REV>
<BUDGET>3736414.05</BUDGET>
<GROSS_PROFIT>2197273.212</GROSS_PROFIT>
<EXPENSES>2917494.81</EXPENSES>
<NET_INCOME>311542.05</NET_INCOME>
<REVENUE_M>3.22903687</REVENUE_M>
<PROFIT_M>2.197273212</PROFIT_M>
<INCOME_M>0.31154205</INCOME_M>
<PHARMA_REV_M>3.22903687</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.197273212</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31154205</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>992962.25</REVENUE>
<PREV_YEAR_REV>903736.36</PREV_YEAR_REV>
<BUDGET>1174572.83</BUDGET>
<GROSS_PROFIT>722578.626</GROSS_PROFIT>
<EXPENSES>884729.36</EXPENSES>
<NET_INCOME>108232.89</NET_INCOME>
<REVENUE_M>0.99296225</REVENUE_M>
<PROFIT_M>0.722578626</PROFIT_M>
<INCOME_M>0.10823289</INCOME_M>
<PHARMA_REV_M>0.99296225</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.722578626</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10823289</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.175147731E7</REVENUE>
<PREV_YEAR_REV>1.101113255E7</PREV_YEAR_REV>
<BUDGET>1.128141822E7</BUDGET>
<GROSS_PROFIT>8894837.214</GROSS_PROFIT>
<EXPENSES>1.032995753E7</EXPENSES>
<NET_INCOME>1421519.77</NET_INCOME>
<REVENUE_M>11.75147731</REVENUE_M>
<PROFIT_M>8.894837214</PROFIT_M>
<INCOME_M>1.42151977</INCOME_M>
<PHARMA_REV_M>11.75147731</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.894837214</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.42151977</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7143877.68</REVENUE>
<PREV_YEAR_REV>6568780.91</PREV_YEAR_REV>
<BUDGET>6858122.57</BUDGET>
<GROSS_PROFIT>5297899.689</GROSS_PROFIT>
<EXPENSES>6179454.19</EXPENSES>
<NET_INCOME>964423.49</NET_INCOME>
<REVENUE_M>7.14387768</REVENUE_M>
<PROFIT_M>5.297899689</PROFIT_M>
<INCOME_M>0.96442349</INCOME_M>
<PHARMA_REV_M>7.14387768</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.297899689</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.96442349</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.661667565E7</REVENUE>
<PREV_YEAR_REV>1.543015355E7</PREV_YEAR_REV>
<BUDGET>1.595200863E7</BUDGET>
<GROSS_PROFIT>1.390379266E7</GROSS_PROFIT>
<EXPENSES>1.440999504E7</EXPENSES>
<NET_INCOME>2206680.61</NET_INCOME>
<REVENUE_M>16.61667565</REVENUE_M>
<PROFIT_M>13.90379266</PROFIT_M>
<INCOME_M>2.20668061</INCOME_M>
<PHARMA_REV_M>16.61667565</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.90379266</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.20668061</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1996677.67</REVENUE>
<PREV_YEAR_REV>1858671.33</PREV_YEAR_REV>
<BUDGET>1498250.51</BUDGET>
<GROSS_PROFIT>1629448.716</GROSS_PROFIT>
<EXPENSES>1677209.24</EXPENSES>
<NET_INCOME>319468.43</NET_INCOME>
<REVENUE_M>1.99667767</REVENUE_M>
<PROFIT_M>1.629448716</PROFIT_M>
<INCOME_M>0.31946843</INCOME_M>
<PHARMA_REV_M>1.99667767</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.629448716</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31946843</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1907423.68</REVENUE>
<PREV_YEAR_REV>1763797.64</PREV_YEAR_REV>
<BUDGET>1510012.14</BUDGET>
<GROSS_PROFIT>1439093.94</GROSS_PROFIT>
<EXPENSES>1661366.02</EXPENSES>
<NET_INCOME>246057.65</NET_INCOME>
<REVENUE_M>1.90742368</REVENUE_M>
<PROFIT_M>1.43909394</PROFIT_M>
<INCOME_M>0.24605765</INCOME_M>
<PHARMA_REV_M>1.90742368</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.43909394</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24605765</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2247833.27</REVENUE>
<PREV_YEAR_REV>2134228.29</PREV_YEAR_REV>
<BUDGET>1680094.34</BUDGET>
<GROSS_PROFIT>1936328.531</GROSS_PROFIT>
<EXPENSES>1888179.94</EXPENSES>
<NET_INCOME>359653.32</NET_INCOME>
<REVENUE_M>2.24783327</REVENUE_M>
<PROFIT_M>1.936328531</PROFIT_M>
<INCOME_M>0.35965332</INCOME_M>
<PHARMA_REV_M>2.24783327</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.936328531</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35965332</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4720254.88</REVENUE>
<PREV_YEAR_REV>4366941.81</PREV_YEAR_REV>
<BUDGET>3559240.67</BUDGET>
<GROSS_PROFIT>3861723.581</GROSS_PROFIT>
<EXPENSES>4084922.6</EXPENSES>
<NET_INCOME>635332.28</NET_INCOME>
<REVENUE_M>4.72025488</REVENUE_M>
<PROFIT_M>3.861723581</PROFIT_M>
<INCOME_M>0.63533228</INCOME_M>
<PHARMA_REV_M>4.72025488</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.861723581</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.63533228</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2448028.04</REVENUE>
<PREV_YEAR_REV>2279398.17</PREV_YEAR_REV>
<BUDGET>1786410.41</BUDGET>
<GROSS_PROFIT>1895618.274</GROSS_PROFIT>
<EXPENSES>2026967.22</EXPENSES>
<NET_INCOME>421060.82</NET_INCOME>
<REVENUE_M>2.44802804</REVENUE_M>
<PROFIT_M>1.895618274</PROFIT_M>
<INCOME_M>0.42106082</INCOME_M>
<PHARMA_REV_M>2.44802804</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.895618274</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42106082</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2269448.58</REVENUE>
<PREV_YEAR_REV>2087636.33</PREV_YEAR_REV>
<BUDGET>1781244.34</BUDGET>
<GROSS_PROFIT>1770336.692</GROSS_PROFIT>
<EXPENSES>2037964.82</EXPENSES>
<NET_INCOME>231483.75</NET_INCOME>
<REVENUE_M>2.26944858</REVENUE_M>
<PROFIT_M>1.770336692</PROFIT_M>
<INCOME_M>0.23148375</INCOME_M>
<PHARMA_REV_M>2.26944858</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.770336692</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23148375</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2343745.6</REVENUE>
<PREV_YEAR_REV>2167906.69</PREV_YEAR_REV>
<BUDGET>1772386.93</BUDGET>
<GROSS_PROFIT>1967129.116</GROSS_PROFIT>
<EXPENSES>2088277.33</EXPENSES>
<NET_INCOME>255468.27</NET_INCOME>
<REVENUE_M>2.3437456</REVENUE_M>
<PROFIT_M>1.967129116</PROFIT_M>
<INCOME_M>0.25546827</INCOME_M>
<PHARMA_REV_M>2.3437456</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.967129116</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25546827</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2343567.21</REVENUE>
<PREV_YEAR_REV>2153499.36</PREV_YEAR_REV>
<BUDGET>1747506.56</BUDGET>
<GROSS_PROFIT>1797853.523</GROSS_PROFIT>
<EXPENSES>2104523.36</EXPENSES>
<NET_INCOME>239043.86</NET_INCOME>
<REVENUE_M>2.34356721</REVENUE_M>
<PROFIT_M>1.797853523</PROFIT_M>
<INCOME_M>0.23904386</INCOME_M>
<PHARMA_REV_M>2.34356721</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.797853523</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23904386</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2600409.96</REVENUE>
<PREV_YEAR_REV>2423043.2</PREV_YEAR_REV>
<BUDGET>1838433</BUDGET>
<GROSS_PROFIT>2079495.839</GROSS_PROFIT>
<EXPENSES>2316965.28</EXPENSES>
<NET_INCOME>283444.69</NET_INCOME>
<REVENUE_M>2.60040996</REVENUE_M>
<PROFIT_M>2.079495839</PROFIT_M>
<INCOME_M>0.28344469</INCOME_M>
<PHARMA_REV_M>2.60040996</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.079495839</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28344469</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3277549.81</REVENUE>
<PREV_YEAR_REV>3022203.97</PREV_YEAR_REV>
<BUDGET>3110334.45</BUDGET>
<GROSS_PROFIT>2470371.194</GROSS_PROFIT>
<EXPENSES>2917190.29</EXPENSES>
<NET_INCOME>360359.51</NET_INCOME>
<REVENUE_M>3.27754981</REVENUE_M>
<PROFIT_M>2.470371194</PROFIT_M>
<INCOME_M>0.36035951</INCOME_M>
<PHARMA_REV_M>3.27754981</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.470371194</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36035951</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3387843.46</REVENUE>
<PREV_YEAR_REV>3144942.7</PREV_YEAR_REV>
<BUDGET>3183907.83</BUDGET>
<GROSS_PROFIT>2437561.823</GROSS_PROFIT>
<EXPENSES>2977825.5</EXPENSES>
<NET_INCOME>410017.94</NET_INCOME>
<REVENUE_M>3.38784346</REVENUE_M>
<PROFIT_M>2.437561823</PROFIT_M>
<INCOME_M>0.41001794</INCOME_M>
<PHARMA_REV_M>3.38784346</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.437561823</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41001794</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3244879.61</REVENUE>
<PREV_YEAR_REV>3060971.58</PREV_YEAR_REV>
<BUDGET>3163159.11</BUDGET>
<GROSS_PROFIT>2691248.76</GROSS_PROFIT>
<EXPENSES>2808364.67</EXPENSES>
<NET_INCOME>436514.94</NET_INCOME>
<REVENUE_M>3.24487961</REVENUE_M>
<PROFIT_M>2.69124876</PROFIT_M>
<INCOME_M>0.43651494</INCOME_M>
<PHARMA_REV_M>3.24487961</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.69124876</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43651494</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1578595.12</REVENUE>
<PREV_YEAR_REV>1454658.24</PREV_YEAR_REV>
<BUDGET>1579383.46</BUDGET>
<GROSS_PROFIT>1363906.19</GROSS_PROFIT>
<EXPENSES>1463357.68</EXPENSES>
<NET_INCOME>115237.44</NET_INCOME>
<REVENUE_M>1.57859512</REVENUE_M>
<PROFIT_M>1.36390619</PROFIT_M>
<INCOME_M>0.11523744</INCOME_M>
<PHARMA_REV_M>1.57859512</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.36390619</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11523744</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1587964.65</REVENUE>
<PREV_YEAR_REV>1459030.15</PREV_YEAR_REV>
<BUDGET>1562637.89</BUDGET>
<GROSS_PROFIT>1224955.926</GROSS_PROFIT>
<EXPENSES>1314834.73</EXPENSES>
<NET_INCOME>273129.92</NET_INCOME>
<REVENUE_M>1.58796465</REVENUE_M>
<PROFIT_M>1.224955926</PROFIT_M>
<INCOME_M>0.27312992</INCOME_M>
<PHARMA_REV_M>1.58796465</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.224955926</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27312992</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1516508.55</REVENUE>
<PREV_YEAR_REV>1433400.02</PREV_YEAR_REV>
<BUDGET>1431548.84</BUDGET>
<GROSS_PROFIT>1229888.44</GROSS_PROFIT>
<EXPENSES>1351209.12</EXPENSES>
<NET_INCOME>165299.43</NET_INCOME>
<REVENUE_M>1.51650855</REVENUE_M>
<PROFIT_M>1.22988844</PROFIT_M>
<INCOME_M>0.16529943</INCOME_M>
<PHARMA_REV_M>1.51650855</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.22988844</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16529943</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1597097.19</REVENUE>
<PREV_YEAR_REV>1474438.64</PREV_YEAR_REV>
<BUDGET>1526265.61</BUDGET>
<GROSS_PROFIT>1227449.049</GROSS_PROFIT>
<EXPENSES>1434193.28</EXPENSES>
<NET_INCOME>162903.91</NET_INCOME>
<REVENUE_M>1.59709719</REVENUE_M>
<PROFIT_M>1.227449049</PROFIT_M>
<INCOME_M>0.16290391</INCOME_M>
<PHARMA_REV_M>1.59709719</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.227449049</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16290391</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1305425.42</REVENUE>
<PREV_YEAR_REV>1220468.6</PREV_YEAR_REV>
<BUDGET>1043100.41</BUDGET>
<GROSS_PROFIT>998324.087</GROSS_PROFIT>
<EXPENSES>1096557.35</EXPENSES>
<NET_INCOME>208868.07</NET_INCOME>
<REVENUE_M>1.30542542</REVENUE_M>
<PROFIT_M>0.998324087</PROFIT_M>
<INCOME_M>0.20886807</INCOME_M>
<PHARMA_REV_M>1.30542542</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.998324087</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20886807</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.28829307E7</REVENUE>
<PREV_YEAR_REV>1.223878416E7</PREV_YEAR_REV>
<BUDGET>1.249644278E7</BUDGET>
<GROSS_PROFIT>9219476.114</GROSS_PROFIT>
<EXPENSES>1.085847016E7</EXPENSES>
<NET_INCOME>1314058.93</NET_INCOME>
<REVENUE_M>12.8829307</REVENUE_M>
<PROFIT_M>9.219476114</PROFIT_M>
<INCOME_M>1.31405893</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.117126909E7</REVENUE>
<PREV_YEAR_REV>1.061270563E7</PREV_YEAR_REV>
<BUDGET>1.083613101E7</BUDGET>
<GROSS_PROFIT>7994551.153</GROSS_PROFIT>
<EXPENSES>9415783.95</EXPENSES>
<NET_INCOME>1921458.28</NET_INCOME>
<REVENUE_M>11.17126909</REVENUE_M>
<PROFIT_M>7.994551153</PROFIT_M>
<INCOME_M>1.92145828</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.269710418E7</REVENUE>
<PREV_YEAR_REV>1.206224897E7</PREV_YEAR_REV>
<BUDGET>1.231619106E7</BUDGET>
<GROSS_PROFIT>9564728.583</GROSS_PROFIT>
<EXPENSES>1.070184495E7</EXPENSES>
<NET_INCOME>1383984.36</NET_INCOME>
<REVENUE_M>12.69710418</REVENUE_M>
<PROFIT_M>9.564728583</PROFIT_M>
<INCOME_M>1.38398436</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.131648559E7</REVENUE>
<PREV_YEAR_REV>2.975066132E7</PREV_YEAR_REV>
<BUDGET>3.037699102E7</BUDGET>
<GROSS_PROFIT>2.35907086E7</GROSS_PROFIT>
<EXPENSES>2.754678005E7</EXPENSES>
<NET_INCOME>3068964.83</NET_INCOME>
<REVENUE_M>31.31648559</REVENUE_M>
<PROFIT_M>23.5907086</PROFIT_M>
<INCOME_M>3.06896483</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>7794639.33</REVENUE>
<PREV_YEAR_REV>7404907.36</PREV_YEAR_REV>
<BUDGET>7560800.15</BUDGET>
<GROSS_PROFIT>5871701.81</GROSS_PROFIT>
<EXPENSES>6586261.79</EXPENSES>
<NET_INCOME>1395240.44</NET_INCOME>
<REVENUE_M>7.79463933</REVENUE_M>
<PROFIT_M>5.87170181</PROFIT_M>
<INCOME_M>1.39524044</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.330618291E7</REVENUE>
<PREV_YEAR_REV>3.164087377E7</PREV_YEAR_REV>
<BUDGET>3.230699742E7</BUDGET>
<GROSS_PROFIT>2.258059283E7</GROSS_PROFIT>
<EXPENSES>4.282223517E7</EXPENSES>
<NET_INCOME>4031210.56</NET_INCOME>
<REVENUE_M>33.30618291</REVENUE_M>
<PROFIT_M>22.58059283</PROFIT_M>
<INCOME_M>4.03121056</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.629948721E7</REVENUE>
<PREV_YEAR_REV>2.498451285E7</PREV_YEAR_REV>
<BUDGET>2.551050259E7</BUDGET>
<GROSS_PROFIT>1.783026335E7</GROSS_PROFIT>
<EXPENSES>3.381362642E7</EXPENSES>
<NET_INCOME>3876963.96</NET_INCOME>
<REVENUE_M>26.29948721</REVENUE_M>
<PROFIT_M>17.83026335</PROFIT_M>
<INCOME_M>3.87696396</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.149944796E7</REVENUE>
<PREV_YEAR_REV>1.092447556E7</PREV_YEAR_REV>
<BUDGET>1.115446452E7</BUDGET>
<GROSS_PROFIT>8229407.443</GROSS_PROFIT>
<EXPENSES>1.478500452E7</EXPENSES>
<NET_INCOME>1977905.05</NET_INCOME>
<REVENUE_M>11.49944796</REVENUE_M>
<PROFIT_M>8.229407443</PROFIT_M>
<INCOME_M>1.97790505</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.482679598E7</REVENUE>
<PREV_YEAR_REV>1.408545618E7</PREV_YEAR_REV>
<BUDGET>1.43819921E7</BUDGET>
<GROSS_PROFIT>1.005212288E7</GROSS_PROFIT>
<EXPENSES>1.906302341E7</EXPENSES>
<NET_INCOME>2001617.46</NET_INCOME>
<REVENUE_M>14.82679598</REVENUE_M>
<PROFIT_M>10.05212288</PROFIT_M>
<INCOME_M>2.00161746</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.904487441E7</REVENUE>
<PREV_YEAR_REV>1.809263069E7</PREV_YEAR_REV>
<BUDGET>1.847352818E7</BUDGET>
<GROSS_PROFIT>1.29118535E7</GROSS_PROFIT>
<EXPENSES>2.332025438E7</EXPENSES>
<NET_INCOME>2830842.74</NET_INCOME>
<REVENUE_M>19.04487441</REVENUE_M>
<PROFIT_M>12.9118535</PROFIT_M>
<INCOME_M>2.83084274</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.207442036E7</REVENUE>
<PREV_YEAR_REV>1.147069934E7</PREV_YEAR_REV>
<BUDGET>1.171218775E7</BUDGET>
<GROSS_PROFIT>8186094.77</GROSS_PROFIT>
<EXPENSES>1.478500452E7</EXPENSES>
<NET_INCOME>1630046.75</NET_INCOME>
<REVENUE_M>12.07442036</REVENUE_M>
<PROFIT_M>8.18609477</PROFIT_M>
<INCOME_M>1.63004675</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.359511117E7</REVENUE>
<PREV_YEAR_REV>2.855584449E7</PREV_YEAR_REV>
<BUDGET>3.258725783E7</BUDGET>
<GROSS_PROFIT>2.530719725E7</GROSS_PROFIT>
<EXPENSES>3.099964894E7</EXPENSES>
<NET_INCOME>4464328.96</NET_INCOME>
<REVENUE_M>33.59511117</REVENUE_M>
<PROFIT_M>25.30719725</PROFIT_M>
<INCOME_M>4.46432896</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.507588352E7</REVENUE>
<PREV_YEAR_REV>3.831450099E7</PREV_YEAR_REV>
<BUDGET>4.372360701E7</BUDGET>
<GROSS_PROFIT>3.395566305E7</GROSS_PROFIT>
<EXPENSES>4.050986252E7</EXPENSES>
<NET_INCOME>7212141.36</NET_INCOME>
<REVENUE_M>45.07588352</REVENUE_M>
<PROFIT_M>33.95566305</PROFIT_M>
<INCOME_M>7.21214136</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.384521079E7</REVENUE>
<PREV_YEAR_REV>3.726842917E7</PREV_YEAR_REV>
<BUDGET>4.252985446E7</BUDGET>
<GROSS_PROFIT>2.972573756E7</GROSS_PROFIT>
<EXPENSES>3.908718466E7</EXPENSES>
<NET_INCOME>5306800.76</NET_INCOME>
<REVENUE_M>43.84521079</REVENUE_M>
<PROFIT_M>29.72573756</PROFIT_M>
<INCOME_M>5.30680076</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.187734934E7</REVENUE>
<PREV_YEAR_REV>1.859574694E7</PREV_YEAR_REV>
<BUDGET>2.122102886E7</BUDGET>
<GROSS_PROFIT>1.483218654E7</GROSS_PROFIT>
<EXPENSES>1.928620997E7</EXPENSES>
<NET_INCOME>3150145.01</NET_INCOME>
<REVENUE_M>21.87734934</REVENUE_M>
<PROFIT_M>14.83218654</PROFIT_M>
<INCOME_M>3.15014501</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.208377541E7</REVENUE>
<PREV_YEAR_REV>1.02712091E7</PREV_YEAR_REV>
<BUDGET>1.172126215E7</BUDGET>
<GROSS_PROFIT>8765570.683</GROSS_PROFIT>
<EXPENSES>1.087539787E7</EXPENSES>
<NET_INCOME>2162995.8</NET_INCOME>
<REVENUE_M>12.08377541</REVENUE_M>
<PROFIT_M>8.765570683</PROFIT_M>
<INCOME_M>2.1629958</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.64277828E7</REVENUE>
<PREV_YEAR_REV>1.396361538E7</PREV_YEAR_REV>
<BUDGET>1.593494932E7</BUDGET>
<GROSS_PROFIT>1.132087796E7</GROSS_PROFIT>
<EXPENSES>1.478500452E7</EXPENSES>
<NET_INCOME>2825578.64</NET_INCOME>
<REVENUE_M>16.4277828</REVENUE_M>
<PROFIT_M>11.32087796</PROFIT_M>
<INCOME_M>2.82557864</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.118113712E7</REVENUE>
<PREV_YEAR_REV>1.800396655E7</PREV_YEAR_REV>
<BUDGET>2.054570301E7</BUDGET>
<GROSS_PROFIT>1.382831718E7</GROSS_PROFIT>
<EXPENSES>1.906302341E7</EXPENSES>
<NET_INCOME>2859453.51</NET_INCOME>
<REVENUE_M>21.18113712</REVENUE_M>
<PROFIT_M>13.82831718</PROFIT_M>
<INCOME_M>2.85945351</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.384521079E7</REVENUE>
<PREV_YEAR_REV>3.726842917E7</PREV_YEAR_REV>
<BUDGET>4.252985446E7</BUDGET>
<GROSS_PROFIT>2.972573756E7</GROSS_PROFIT>
<EXPENSES>3.908718466E7</EXPENSES>
<NET_INCOME>5306800.76</NET_INCOME>
<REVENUE_M>43.84521079</REVENUE_M>
<PROFIT_M>29.72573756</PROFIT_M>
<INCOME_M>5.30680076</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.074386641E7</REVENUE>
<PREV_YEAR_REV>9132286.45</PREV_YEAR_REV>
<BUDGET>1.042155042E7</BUDGET>
<GROSS_PROFIT>8093354.565</GROSS_PROFIT>
<EXPENSES>9577955.78</EXPENSES>
<NET_INCOME>784302.25</NET_INCOME>
<REVENUE_M>10.74386641</REVENUE_M>
<PROFIT_M>8.093354565</PROFIT_M>
<INCOME_M>0.78430225</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.513820185E7</REVENUE>
<PREV_YEAR_REV>1.286747157E7</PREV_YEAR_REV>
<BUDGET>1.468405579E7</BUDGET>
<GROSS_PROFIT>1.026324671E7</GROSS_PROFIT>
<EXPENSES>1.349542357E7</EXPENSES>
<NET_INCOME>2043657.25</NET_INCOME>
<REVENUE_M>15.13820185</REVENUE_M>
<PROFIT_M>10.26324671</PROFIT_M>
<INCOME_M>2.04365725</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.020667309E7</REVENUE>
<PREV_YEAR_REV>1.859013924E7</PREV_YEAR_REV>
<BUDGET>1.041080655E7</BUDGET>
<GROSS_PROFIT>1.522168684E7</GROSS_PROFIT>
<EXPENSES>1.908393905E7</EXPENSES>
<NET_INCOME>1475087.14</NET_INCOME>
<REVENUE_M>20.20667309</REVENUE_M>
<PROFIT_M>15.22168684</PROFIT_M>
<INCOME_M>1.47508714</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.865844184E7</REVENUE>
<PREV_YEAR_REV>2.63657665E7</PREV_YEAR_REV>
<BUDGET>2.923161068E7</BUDGET>
<GROSS_PROFIT>2.158840425E7</GROSS_PROFIT>
<EXPENSES>2.550601324E7</EXPENSES>
<NET_INCOME>3798006.5</NET_INCOME>
<REVENUE_M>28.65844184</REVENUE_M>
<PROFIT_M>21.58840425</PROFIT_M>
<INCOME_M>3.7980065</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.113342471E7</REVENUE>
<PREV_YEAR_REV>2.864275074E7</PREV_YEAR_REV>
<BUDGET>2.461609321E7</BUDGET>
<GROSS_PROFIT>2.110752795E7</GROSS_PROFIT>
<EXPENSES>2.851449637E7</EXPENSES>
<NET_INCOME>3789423.55</NET_INCOME>
<REVENUE_M>31.13342471</REVENUE_M>
<PROFIT_M>21.10752795</PROFIT_M>
<INCOME_M>3.78942355</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.50638415E7</REVENUE>
<PREV_YEAR_REV>1.385873418E7</PREV_YEAR_REV>
<BUDGET>1.536511833E7</BUDGET>
<GROSS_PROFIT>1.13475918E7</GROSS_PROFIT>
<EXPENSES>1.342913271E7</EXPENSES>
<NET_INCOME>1641958.72</NET_INCOME>
<REVENUE_M>15.0638415</REVENUE_M>
<PROFIT_M>11.3475918</PROFIT_M>
<INCOME_M>1.64195872</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.154099869E7</REVENUE>
<PREV_YEAR_REV>2.901771879E7</PREV_YEAR_REV>
<BUDGET>1.965238753E7</BUDGET>
<GROSS_PROFIT>2.375983431E7</GROSS_PROFIT>
<EXPENSES>2.737758686E7</EXPENSES>
<NET_INCOME>4163411.83</NET_INCOME>
<REVENUE_M>31.54099869</REVENUE_M>
<PROFIT_M>23.75983431</PROFIT_M>
<INCOME_M>4.16341183</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.728205777E7</REVENUE>
<PREV_YEAR_REV>1.589949315E7</PREV_YEAR_REV>
<BUDGET>1.560639366E7</BUDGET>
<GROSS_PROFIT>1.17167167E7</GROSS_PROFIT>
<EXPENSES>1.494897997E7</EXPENSES>
<NET_INCOME>2333077.8</NET_INCOME>
<REVENUE_M>17.28205777</REVENUE_M>
<PROFIT_M>11.7167167</PROFIT_M>
<INCOME_M>2.3330778</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.728205777E7</REVENUE>
<PREV_YEAR_REV>1.589949315E7</PREV_YEAR_REV>
<BUDGET>1.560639366E7</BUDGET>
<GROSS_PROFIT>1.236764541E7</GROSS_PROFIT>
<EXPENSES>1.430954383E7</EXPENSES>
<NET_INCOME>2972513.94</NET_INCOME>
<REVENUE_M>17.28205777</REVENUE_M>
<PROFIT_M>12.36764541</PROFIT_M>
<INCOME_M>2.97251394</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.787741997E7</REVENUE>
<PREV_YEAR_REV>2.012722637E7</PREV_YEAR_REV>
<BUDGET>1.997198775E7</BUDGET>
<GROSS_PROFIT>1.565624744E7</GROSS_PROFIT>
<EXPENSES>1.964592313E7</EXPENSES>
<NET_INCOME>2231496.84</NET_INCOME>
<REVENUE_M>17.87741997</REVENUE_M>
<PROFIT_M>15.65624744</PROFIT_M>
<INCOME_M>2.23149684</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>4966055.63</REVENUE>
<PREV_YEAR_REV>4591949.5</PREV_YEAR_REV>
<BUDGET>5462661.19</BUDGET>
<GROSS_PROFIT>3530865.546</GROSS_PROFIT>
<EXPENSES>4295638.12</EXPENSES>
<NET_INCOME>670417.51</NET_INCOME>
<REVENUE_M>4.96605563</REVENUE_M>
<PROFIT_M>3.530865546</PROFIT_M>
<INCOME_M>0.67041751</INCOME_M>
<PHARMA_REV_M>4.96605563</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.530865546</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67041751</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5300977.25</REVENUE>
<PREV_YEAR_REV>4927316.34</PREV_YEAR_REV>
<BUDGET>3873233.66</BUDGET>
<GROSS_PROFIT>4134666.173</GROSS_PROFIT>
<EXPENSES>4714046.36</EXPENSES>
<NET_INCOME>586930.89</NET_INCOME>
<REVENUE_M>5.30097725</REVENUE_M>
<PROFIT_M>4.134666173</PROFIT_M>
<INCOME_M>0.58693089</INCOME_M>
<PHARMA_REV_M>5.30097725</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.134666173</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58693089</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5253903.74</REVENUE>
<PREV_YEAR_REV>4738008.1</PREV_YEAR_REV>
<BUDGET>3907730.29</BUDGET>
<GROSS_PROFIT>4065521.244</GROSS_PROFIT>
<EXPENSES>4671581.86</EXPENSES>
<NET_INCOME>582321.87</NET_INCOME>
<REVENUE_M>5.25390374</REVENUE_M>
<PROFIT_M>4.065521244</PROFIT_M>
<INCOME_M>0.58232187</INCOME_M>
<PHARMA_REV_M>5.25390374</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.065521244</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58232187</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2726517.33</REVENUE>
<PREV_YEAR_REV>2502999.48</PREV_YEAR_REV>
<BUDGET>2023163.85</BUDGET>
<GROSS_PROFIT>2007998.218</GROSS_PROFIT>
<EXPENSES>2374796.6</EXPENSES>
<NET_INCOME>351720.74</NET_INCOME>
<REVENUE_M>2.72651733</REVENUE_M>
<PROFIT_M>2.007998218</PROFIT_M>
<INCOME_M>0.35172074</INCOME_M>
<PHARMA_REV_M>2.72651733</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.007998218</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35172074</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4526049.99</REVENUE>
<PREV_YEAR_REV>4072165.35</PREV_YEAR_REV>
<BUDGET>3430384.44</BUDGET>
<GROSS_PROFIT>3536848.316</GROSS_PROFIT>
<EXPENSES>3859717.41</EXPENSES>
<NET_INCOME>666332.58</NET_INCOME>
<REVENUE_M>4.52604999</REVENUE_M>
<PROFIT_M>3.536848316</PROFIT_M>
<INCOME_M>0.66633258</INCOME_M>
<PHARMA_REV_M>4.52604999</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.536848316</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.66633258</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2564365.67</REVENUE>
<PREV_YEAR_REV>2107380.26</PREV_YEAR_REV>
<BUDGET>2451196.88</BUDGET>
<GROSS_PROFIT>2089958.02</GROSS_PROFIT>
<EXPENSES>2105344.22</EXPENSES>
<NET_INCOME>459021.46</NET_INCOME>
<REVENUE_M>2.56436567</REVENUE_M>
<PROFIT_M>2.08995802</PROFIT_M>
<INCOME_M>0.45902146</INCOME_M>
<PHARMA_REV_M>2.56436567</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.08995802</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45902146</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2337021.92</REVENUE>
<PREV_YEAR_REV>1888609.4</PREV_YEAR_REV>
<BUDGET>2237493.75</BUDGET>
<GROSS_PROFIT>1701585.666</GROSS_PROFIT>
<EXPENSES>2021523.96</EXPENSES>
<NET_INCOME>315497.96</NET_INCOME>
<REVENUE_M>2.33702192</REVENUE_M>
<PROFIT_M>1.701585666</PROFIT_M>
<INCOME_M>0.31549796</INCOME_M>
<PHARMA_REV_M>2.33702192</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.701585666</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31549796</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1945509.42</REVENUE>
<PREV_YEAR_REV>1601097.37</PREV_YEAR_REV>
<BUDGET>1869472</BUDGET>
<GROSS_PROFIT>1493373.03</GROSS_PROFIT>
<EXPENSES>1634227.92</EXPENSES>
<NET_INCOME>311281.51</NET_INCOME>
<REVENUE_M>1.94550942</REVENUE_M>
<PROFIT_M>1.49337303</PROFIT_M>
<INCOME_M>0.31128151</INCOME_M>
<PHARMA_REV_M>1.94550942</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.49337303</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31128151</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1690397.42</REVENUE>
<PREV_YEAR_REV>1318953.69</PREV_YEAR_REV>
<BUDGET>1629666.72</BUDGET>
<GROSS_PROFIT>1394577.88</GROSS_PROFIT>
<EXPENSES>1566998.41</EXPENSES>
<NET_INCOME>123399.01</NET_INCOME>
<REVENUE_M>1.69039742</REVENUE_M>
<PROFIT_M>1.39457788</PROFIT_M>
<INCOME_M>0.12339901</INCOME_M>
<PHARMA_REV_M>1.69039742</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.39457788</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12339901</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1882000</REVENUE>
<PREV_YEAR_REV>1482800.46</PREV_YEAR_REV>
<BUDGET>1810203.12</BUDGET>
<GROSS_PROFIT>1389377.09</GROSS_PROFIT>
<EXPENSES>1690036</EXPENSES>
<NET_INCOME>191964</NET_INCOME>
<REVENUE_M>1.882</REVENUE_M>
<PROFIT_M>1.38937709</PROFIT_M>
<INCOME_M>0.191964</INCOME_M>
<PHARMA_REV_M>1.882</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.38937709</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.191964</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2091149.42</REVENUE>
<PREV_YEAR_REV>1636766.64</PREV_YEAR_REV>
<BUDGET>2006373.6</BUDGET>
<GROSS_PROFIT>1603179.711</GROSS_PROFIT>
<EXPENSES>1731471.72</EXPENSES>
<NET_INCOME>359677.7</NET_INCOME>
<REVENUE_M>2.09114942</REVENUE_M>
<PROFIT_M>1.603179711</PROFIT_M>
<INCOME_M>0.3596777</INCOME_M>
<PHARMA_REV_M>2.09114942</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.603179711</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3596777</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.181256116E7</REVENUE>
<PREV_YEAR_REV>1.063130504E7</PREV_YEAR_REV>
<BUDGET>1.12219331E7</BUDGET>
<GROSS_PROFIT>8898402.322</GROSS_PROFIT>
<EXPENSES>1.947125466E7</EXPENSES>
<NET_INCOME>1890009.79</NET_INCOME>
<REVENUE_M>11.81256116</REVENUE_M>
<PROFIT_M>8.898402322</PROFIT_M>
<INCOME_M>1.89000979</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.414762099E7</REVENUE>
<PREV_YEAR_REV>1.273285889E7</PREV_YEAR_REV>
<BUDGET>1.344023994E7</BUDGET>
<GROSS_PROFIT>9591662.601</GROSS_PROFIT>
<EXPENSES>2.332025438E7</EXPENSES>
<NET_INCOME>2102911.75</NET_INCOME>
<REVENUE_M>14.14762099</REVENUE_M>
<PROFIT_M>9.591662601</PROFIT_M>
<INCOME_M>2.10291175</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.156490087E7</REVENUE>
<PREV_YEAR_REV>1.040841078E7</PREV_YEAR_REV>
<BUDGET>1.098665582E7</BUDGET>
<GROSS_PROFIT>7840655.839</GROSS_PROFIT>
<EXPENSES>1.906302341E7</EXPENSES>
<NET_INCOME>1561261.62</NET_INCOME>
<REVENUE_M>11.56490087</REVENUE_M>
<PROFIT_M>7.840655839</PROFIT_M>
<INCOME_M>1.56126162</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.202912297E7</REVENUE>
<PREV_YEAR_REV>1.082621068E7</PREV_YEAR_REV>
<BUDGET>1.073020359E7</BUDGET>
<GROSS_PROFIT>9061538.337</GROSS_PROFIT>
<EXPENSES>1.861805134E7</EXPENSES>
<NET_INCOME>1587844.23</NET_INCOME>
<REVENUE_M>12.02912297</REVENUE_M>
<PROFIT_M>9.061538337</PROFIT_M>
<INCOME_M>1.58784423</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>9530364.6</REVENUE>
<PREV_YEAR_REV>8577328.14</PREV_YEAR_REV>
<BUDGET>8501264.2</BUDGET>
<GROSS_PROFIT>6820262.474</GROSS_PROFIT>
<EXPENSES>1.475060301E7</EXPENSES>
<NET_INCOME>972097.19</NET_INCOME>
<REVENUE_M>9.5303646</REVENUE_M>
<PROFIT_M>6.820262474</PROFIT_M>
<INCOME_M>0.97209719</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.231661942E7</REVENUE>
<PREV_YEAR_REV>1.108495748E7</PREV_YEAR_REV>
<BUDGET>1.098665582E7</BUDGET>
<GROSS_PROFIT>8350298.468</GROSS_PROFIT>
<EXPENSES>1.906302341E7</EXPENSES>
<NET_INCOME>1662743.62</NET_INCOME>
<REVENUE_M>12.31661942</REVENUE_M>
<PROFIT_M>8.350298468</PROFIT_M>
<INCOME_M>1.66274362</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>8048415.85</REVENUE>
<PREV_YEAR_REV>7243574.26</PREV_YEAR_REV>
<BUDGET>1.07474132E7</BUDGET>
<GROSS_PROFIT>6062871.661</GROSS_PROFIT>
<EXPENSES>1.864791185E7</EXPENSES>
<NET_INCOME>877277.33</NET_INCOME>
<REVENUE_M>8.04841585</REVENUE_M>
<PROFIT_M>6.062871661</PROFIT_M>
<INCOME_M>0.87727733</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.351657781E7</REVENUE>
<PREV_YEAR_REV>2.234074893E7</PREV_YEAR_REV>
<BUDGET>2.281108048E7</BUDGET>
<GROSS_PROFIT>1.771503808E7</GROSS_PROFIT>
<EXPENSES>2.092111559E7</EXPENSES>
<NET_INCOME>3125030.27</NET_INCOME>
<REVENUE_M>23.51657781</REVENUE_M>
<PROFIT_M>17.71503808</PROFIT_M>
<INCOME_M>3.12503027</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.777843731E7</REVENUE>
<PREV_YEAR_REV>2.638951545E7</PREV_YEAR_REV>
<BUDGET>2.694508419E7</BUDGET>
<GROSS_PROFIT>1.883294715E7</GROSS_PROFIT>
<EXPENSES>2.528325431E7</EXPENSES>
<NET_INCOME>4145181.43</NET_INCOME>
<REVENUE_M>27.77843731</REVENUE_M>
<PROFIT_M>18.83294715</PROFIT_M>
<INCOME_M>4.14518143</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4954641.91</REVENUE>
<PREV_YEAR_REV>4470726.62</PREV_YEAR_REV>
<BUDGET>3719792.23</BUDGET>
<GROSS_PROFIT>3747547.787</GROSS_PROFIT>
<EXPENSES>4409980.67</EXPENSES>
<NET_INCOME>544661.25</NET_INCOME>
<REVENUE_M>4.95464191</REVENUE_M>
<PROFIT_M>3.747547787</PROFIT_M>
<INCOME_M>0.54466125</INCOME_M>
<PHARMA_REV_M>4.95464191</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.747547787</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54466125</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2521266.37</REVENUE>
<PREV_YEAR_REV>2281461.91</PREV_YEAR_REV>
<BUDGET>1943982.59</BUDGET>
<GROSS_PROFIT>1761192.809</GROSS_PROFIT>
<EXPENSES>2196023.01</EXPENSES>
<NET_INCOME>325243.36</NET_INCOME>
<REVENUE_M>2.52126637</REVENUE_M>
<PROFIT_M>1.761192809</PROFIT_M>
<INCOME_M>0.32524336</INCOME_M>
<PHARMA_REV_M>2.52126637</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.761192809</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32524336</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4996952.9</REVENUE>
<PREV_YEAR_REV>4536829.89</PREV_YEAR_REV>
<BUDGET>3752922.25</BUDGET>
<GROSS_PROFIT>3869343.4</GROSS_PROFIT>
<EXPENSES>4442721.35</EXPENSES>
<NET_INCOME>554231.54</NET_INCOME>
<REVENUE_M>4.9969529</REVENUE_M>
<PROFIT_M>3.8693434</PROFIT_M>
<INCOME_M>0.55423154</INCOME_M>
<PHARMA_REV_M>4.9969529</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.8693434</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55423154</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5141560.16</REVENUE>
<PREV_YEAR_REV>4642359.07</PREV_YEAR_REV>
<BUDGET>3770445.55</BUDGET>
<GROSS_PROFIT>3883605.933</GROSS_PROFIT>
<EXPENSES>4523143.88</EXPENSES>
<NET_INCOME>618416.27</NET_INCOME>
<REVENUE_M>5.14156016</REVENUE_M>
<PROFIT_M>3.883605933</PROFIT_M>
<INCOME_M>0.61841627</INCOME_M>
<PHARMA_REV_M>5.14156016</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.883605933</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61841627</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4437116.24</REVENUE>
<PREV_YEAR_REV>3984538.19</PREV_YEAR_REV>
<BUDGET>3294486.86</BUDGET>
<GROSS_PROFIT>3402076.577</GROSS_PROFIT>
<EXPENSES>3783643.01</EXPENSES>
<NET_INCOME>653473.23</NET_INCOME>
<REVENUE_M>4.43711624</REVENUE_M>
<PROFIT_M>3.402076577</PROFIT_M>
<INCOME_M>0.65347323</INCOME_M>
<PHARMA_REV_M>4.43711624</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.402076577</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65347323</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7570208.62</REVENUE>
<PREV_YEAR_REV>6923173.8</PREV_YEAR_REV>
<BUDGET>5757855.05</BUDGET>
<GROSS_PROFIT>6218462.375</GROSS_PROFIT>
<EXPENSES>6837571.58</EXPENSES>
<NET_INCOME>732637.04</NET_INCOME>
<REVENUE_M>7.57020862</REVENUE_M>
<PROFIT_M>6.218462375</PROFIT_M>
<INCOME_M>0.73263704</INCOME_M>
<PHARMA_REV_M>7.57020862</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.218462375</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.73263704</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2592979.51</REVENUE>
<PREV_YEAR_REV>2343745.6</PREV_YEAR_REV>
<BUDGET>1915634.33</BUDGET>
<GROSS_PROFIT>2074176.168</GROSS_PROFIT>
<EXPENSES>2310344.74</EXPENSES>
<NET_INCOME>282634.77</NET_INCOME>
<REVENUE_M>2.59297951</REVENUE_M>
<PROFIT_M>2.074176168</PROFIT_M>
<INCOME_M>0.28263477</INCOME_M>
<PHARMA_REV_M>2.59297951</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.074176168</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28263477</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2495890.95</REVENUE>
<PREV_YEAR_REV>2305097.99</PREV_YEAR_REV>
<BUDGET>1908006.99</BUDGET>
<GROSS_PROFIT>1884377.697</GROSS_PROFIT>
<EXPENSES>2158945.67</EXPENSES>
<NET_INCOME>336945.28</NET_INCOME>
<REVENUE_M>2.49589095</REVENUE_M>
<PROFIT_M>1.884377697</PROFIT_M>
<INCOME_M>0.33694528</INCOME_M>
<PHARMA_REV_M>2.49589095</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.884377697</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33694528</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2583290.7</REVENUE>
<PREV_YEAR_REV>2343567.21</PREV_YEAR_REV>
<BUDGET>1888743.09</BUDGET>
<GROSS_PROFIT>2056312.315</GROSS_PROFIT>
<EXPENSES>2319795.05</EXPENSES>
<NET_INCOME>263495.65</NET_INCOME>
<REVENUE_M>2.5832907</REVENUE_M>
<PROFIT_M>2.056312315</PROFIT_M>
<INCOME_M>0.26349565</INCOME_M>
<PHARMA_REV_M>2.5832907</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.056312315</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26349565</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1505819.73</REVENUE>
<PREV_YEAR_REV>1345948.03</PREV_YEAR_REV>
<BUDGET>1396221.18</BUDGET>
<GROSS_PROFIT>1232212.29</GROSS_PROFIT>
<EXPENSES>1264888.57</EXPENSES>
<NET_INCOME>240931.16</NET_INCOME>
<REVENUE_M>1.50581973</REVENUE_M>
<PROFIT_M>1.23221229</PROFIT_M>
<INCOME_M>0.24093116</INCOME_M>
<PHARMA_REV_M>1.50581973</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.23221229</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24093116</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3787239.65</REVENUE>
<PREV_YEAR_REV>3453727.07</PREV_YEAR_REV>
<BUDGET>3383959.95</BUDGET>
<GROSS_PROFIT>2983343.22</GROSS_PROFIT>
<EXPENSES>3368542.26</EXPENSES>
<NET_INCOME>418697.39</NET_INCOME>
<REVENUE_M>3.78723965</REVENUE_M>
<PROFIT_M>2.98334322</PROFIT_M>
<INCOME_M>0.41869739</INCOME_M>
<PHARMA_REV_M>3.78723965</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.98334322</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41869739</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3872761.93</REVENUE>
<PREV_YEAR_REV>3502899.87</PREV_YEAR_REV>
<BUDGET>3433009.99</BUDGET>
<GROSS_PROFIT>2825146.845</GROSS_PROFIT>
<EXPENSES>3405800</EXPENSES>
<NET_INCOME>466961.93</NET_INCOME>
<REVENUE_M>3.87276193</REVENUE_M>
<PROFIT_M>2.825146845</PROFIT_M>
<INCOME_M>0.46696193</INCOME_M>
<PHARMA_REV_M>3.87276193</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.825146845</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46696193</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3690717.65</REVENUE>
<PREV_YEAR_REV>3387843.46</PREV_YEAR_REV>
<BUDGET>3441236.8</BUDGET>
<GROSS_PROFIT>2756263.748</GROSS_PROFIT>
<EXPENSES>3244365.4</EXPENSES>
<NET_INCOME>446352.26</NET_INCOME>
<REVENUE_M>3.69071765</REVENUE_M>
<PROFIT_M>2.756263748</PROFIT_M>
<INCOME_M>0.44635226</INCOME_M>
<PHARMA_REV_M>3.69071765</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.756263748</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44635226</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5494130.53</REVENUE>
<PREV_YEAR_REV>5013912.16</PREV_YEAR_REV>
<BUDGET>5132601.28</BUDGET>
<GROSS_PROFIT>4562628.46</GROSS_PROFIT>
<EXPENSES>4961321.56</EXPENSES>
<NET_INCOME>532808.97</NET_INCOME>
<REVENUE_M>5.49413053</REVENUE_M>
<PROFIT_M>4.56262846</PROFIT_M>
<INCOME_M>0.53280897</INCOME_M>
<PHARMA_REV_M>5.49413053</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.56262846</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53280897</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3582270.16</REVENUE>
<PREV_YEAR_REV>3233181.19</PREV_YEAR_REV>
<BUDGET>3426916.06</BUDGET>
<GROSS_PROFIT>2977246.92</GROSS_PROFIT>
<EXPENSES>3107099.47</EXPENSES>
<NET_INCOME>475170.7</NET_INCOME>
<REVENUE_M>3.58227016</REVENUE_M>
<PROFIT_M>2.97724692</PROFIT_M>
<INCOME_M>0.4751707</INCOME_M>
<PHARMA_REV_M>3.58227016</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.97724692</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4751707</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1757098.76</REVENUE>
<PREV_YEAR_REV>1587964.65</PREV_YEAR_REV>
<BUDGET>1688933.01</BUDGET>
<GROSS_PROFIT>1452242.124</GROSS_PROFIT>
<EXPENSES>1454877.77</EXPENSES>
<NET_INCOME>302220.99</NET_INCOME>
<REVENUE_M>1.75709876</REVENUE_M>
<PROFIT_M>1.452242124</PROFIT_M>
<INCOME_M>0.30222099</INCOME_M>
<PHARMA_REV_M>1.75709876</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.452242124</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30222099</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1418997.43</REVENUE>
<PREV_YEAR_REV>1305425.42</PREV_YEAR_REV>
<BUDGET>1127405.6</BUDGET>
<GROSS_PROFIT>1167409.182</GROSS_PROFIT>
<EXPENSES>1191957.84</EXPENSES>
<NET_INCOME>227039.59</NET_INCOME>
<REVENUE_M>1.41899743</REVENUE_M>
<PROFIT_M>1.167409182</PROFIT_M>
<INCOME_M>0.22703959</INCOME_M>
<PHARMA_REV_M>1.41899743</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.167409182</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22703959</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1373986</REVENUE>
<PREV_YEAR_REV>1230464.61</PREV_YEAR_REV>
<BUDGET>1100507.5</BUDGET>
<GROSS_PROFIT>1039660.857</GROSS_PROFIT>
<EXPENSES>1188497.89</EXPENSES>
<NET_INCOME>185488.11</NET_INCOME>
<REVENUE_M>1.373986</REVENUE_M>
<PROFIT_M>1.039660857</PROFIT_M>
<INCOME_M>0.18548811</INCOME_M>
<PHARMA_REV_M>1.373986</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.039660857</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18548811</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8277883.37</REVENUE>
<PREV_YEAR_REV>7385230.55</PREV_YEAR_REV>
<BUDGET>7450095.03</BUDGET>
<GROSS_PROFIT>7259703.72</GROSS_PROFIT>
<EXPENSES>6953422.03</EXPENSES>
<NET_INCOME>1324461.34</NET_INCOME>
<REVENUE_M>8.27788337</REVENUE_M>
<PROFIT_M>7.25970372</PROFIT_M>
<INCOME_M>1.32446134</INCOME_M>
<PHARMA_REV_M>8.27788337</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.25970372</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.32446134</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6279079.85</REVENUE>
<PREV_YEAR_REV>5759408.42</PREV_YEAR_REV>
<BUDGET>5651171.86</BUDGET>
<GROSS_PROFIT>4820449.599</GROSS_PROFIT>
<EXPENSES>5469078.55</EXPENSES>
<NET_INCOME>810001.3</NET_INCOME>
<REVENUE_M>6.27907985</REVENUE_M>
<PROFIT_M>4.820449599</PROFIT_M>
<INCOME_M>0.8100013</INCOME_M>
<PHARMA_REV_M>6.27907985</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.820449599</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.8100013</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6499302.97</REVENUE>
<PREV_YEAR_REV>5893616.05</PREV_YEAR_REV>
<BUDGET>5849372.67</BUDGET>
<GROSS_PROFIT>5297386.875</GROSS_PROFIT>
<EXPENSES>5459414.49</EXPENSES>
<NET_INCOME>1039888.48</NET_INCOME>
<REVENUE_M>6.49930297</REVENUE_M>
<PROFIT_M>5.297386875</PROFIT_M>
<INCOME_M>1.03988848</INCOME_M>
<PHARMA_REV_M>6.49930297</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.297386875</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03988848</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.492366282E7</REVENUE>
<PREV_YEAR_REV>1.335084729E7</PREV_YEAR_REV>
<BUDGET>1.343129654E7</BUDGET>
<GROSS_PROFIT>1.103468407E7</GROSS_PROFIT>
<EXPENSES>1.312069561E7</EXPENSES>
<NET_INCOME>1802967.22</NET_INCOME>
<REVENUE_M>14.92366282</REVENUE_M>
<PROFIT_M>11.03468407</PROFIT_M>
<INCOME_M>1.80296722</INCOME_M>
<PHARMA_REV_M>14.92366282</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.03468407</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.80296722</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.126619431E7</REVENUE>
<PREV_YEAR_REV>1.026024747E7</PREV_YEAR_REV>
<BUDGET>1.013957488E7</BUDGET>
<GROSS_PROFIT>8217087.03</GROSS_PROFIT>
<EXPENSES>9591509.06</EXPENSES>
<NET_INCOME>1674685.25</NET_INCOME>
<REVENUE_M>11.26619431</REVENUE_M>
<PROFIT_M>8.21708703</PROFIT_M>
<INCOME_M>1.67468525</INCOME_M>
<PHARMA_REV_M>11.26619431</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.21708703</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.67468525</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1615511.46</REVENUE>
<PREV_YEAR_REV>1402231.98</PREV_YEAR_REV>
<BUDGET>2082054.09</BUDGET>
<GROSS_PROFIT>1154153.695</GROSS_PROFIT>
<EXPENSES>1407110.48</EXPENSES>
<NET_INCOME>208400.98</NET_INCOME>
<REVENUE_M>1.61551146</REVENUE_M>
<PROFIT_M>1.154153695</PROFIT_M>
<INCOME_M>0.20840098</INCOME_M>
<PHARMA_REV_M>1.61551146</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.154153695</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20840098</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1688086.75</REVENUE>
<PREV_YEAR_REV>1467888.76</PREV_YEAR_REV>
<BUDGET>2138394.12</BUDGET>
<GROSS_PROFIT>1362286.01</GROSS_PROFIT>
<EXPENSES>1417992.87</EXPENSES>
<NET_INCOME>270093.88</NET_INCOME>
<REVENUE_M>1.68808675</REVENUE_M>
<PROFIT_M>1.36228601</PROFIT_M>
<INCOME_M>0.27009388</INCOME_M>
<PHARMA_REV_M>1.68808675</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.36228601</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27009388</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3233731.53</REVENUE>
<PREV_YEAR_REV>2828172.8</PREV_YEAR_REV>
<BUDGET>4197250.68</BUDGET>
<GROSS_PROFIT>2282917.742</GROSS_PROFIT>
<EXPENSES>2841373.38</EXPENSES>
<NET_INCOME>392358.15</NET_INCOME>
<REVENUE_M>3.23373153</REVENUE_M>
<PROFIT_M>2.282917742</PROFIT_M>
<INCOME_M>0.39235815</INCOME_M>
<PHARMA_REV_M>3.23373153</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.282917742</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39235815</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1620335.75</REVENUE>
<PREV_YEAR_REV>1456664.89</PREV_YEAR_REV>
<BUDGET>2059978.9</BUDGET>
<GROSS_PROFIT>1210390.803</GROSS_PROFIT>
<EXPENSES>1411312.44</EXPENSES>
<NET_INCOME>209023.31</NET_INCOME>
<REVENUE_M>1.62033575</REVENUE_M>
<PROFIT_M>1.210390803</PROFIT_M>
<INCOME_M>0.20902331</INCOME_M>
<PHARMA_REV_M>1.62033575</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.210390803</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20902331</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1653535.22</REVENUE>
<PREV_YEAR_REV>1412469.11</PREV_YEAR_REV>
<BUDGET>2059978.9</BUDGET>
<GROSS_PROFIT>1426008.77</GROSS_PROFIT>
<EXPENSES>1357552.41</EXPENSES>
<NET_INCOME>295982.8</NET_INCOME>
<REVENUE_M>1.65353522</REVENUE_M>
<PROFIT_M>1.42600877</PROFIT_M>
<INCOME_M>0.2959828</INCOME_M>
<PHARMA_REV_M>1.65353522</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.42600877</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2959828</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6818639.72</REVENUE>
<PREV_YEAR_REV>6114330.05</PREV_YEAR_REV>
<BUDGET>6136775.75</BUDGET>
<GROSS_PROFIT>5274620.131</GROSS_PROFIT>
<EXPENSES>5898123.36</EXPENSES>
<NET_INCOME>920516.36</NET_INCOME>
<REVENUE_M>6.81863972</REVENUE_M>
<PROFIT_M>5.274620131</PROFIT_M>
<INCOME_M>0.92051636</INCOME_M>
<PHARMA_REV_M>6.81863972</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.274620131</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.92051636</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1886981</REVENUE>
<PREV_YEAR_REV>1720803.05</PREV_YEAR_REV>
<BUDGET>1852870.24</BUDGET>
<GROSS_PROFIT>1430531.614</GROSS_PROFIT>
<EXPENSES>1643560.45</EXPENSES>
<NET_INCOME>243420.55</NET_INCOME>
<REVENUE_M>1.886981</REVENUE_M>
<PROFIT_M>1.430531614</PROFIT_M>
<INCOME_M>0.24342055</INCOME_M>
<PHARMA_REV_M>1.886981</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.430531614</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24342055</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3862563.88</REVENUE>
<PREV_YEAR_REV>3509909.06</PREV_YEAR_REV>
<BUDGET>3727688.5</BUDGET>
<GROSS_PROFIT>3079425.09</GROSS_PROFIT>
<EXPENSES>3394099.57</EXPENSES>
<NET_INCOME>468464.31</NET_INCOME>
<REVENUE_M>3.86256388</REVENUE_M>
<PROFIT_M>3.07942509</PROFIT_M>
<INCOME_M>0.46846431</INCOME_M>
<PHARMA_REV_M>3.86256388</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.07942509</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46846431</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4512971.66</REVENUE>
<PREV_YEAR_REV>4108945.26</PREV_YEAR_REV>
<BUDGET>4355188.71</BUDGET>
<GROSS_PROFIT>3285469.23</GROSS_PROFIT>
<EXPENSES>3841436.63</EXPENSES>
<NET_INCOME>671535.03</NET_INCOME>
<REVENUE_M>4.51297166</REVENUE_M>
<PROFIT_M>3.28546923</PROFIT_M>
<INCOME_M>0.67153503</INCOME_M>
<PHARMA_REV_M>4.51297166</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.28546923</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67153503</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2271248.79</REVENUE>
<PREV_YEAR_REV>2076703.23</PREV_YEAR_REV>
<BUDGET>2174818.94</BUDGET>
<GROSS_PROFIT>1972806.7</GROSS_PROFIT>
<EXPENSES>2023682.67</EXPENSES>
<NET_INCOME>247566.12</NET_INCOME>
<REVENUE_M>2.27124879</REVENUE_M>
<PROFIT_M>1.9728067</PROFIT_M>
<INCOME_M>0.24756612</INCOME_M>
<PHARMA_REV_M>2.27124879</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.9728067</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24756612</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2290610.52</REVENUE>
<PREV_YEAR_REV>2055004.28</PREV_YEAR_REV>
<BUDGET>2166159.63</BUDGET>
<GROSS_PROFIT>1719291.023</GROSS_PROFIT>
<EXPENSES>1981378.1</EXPENSES>
<NET_INCOME>309232.42</NET_INCOME>
<REVENUE_M>2.29061052</REVENUE_M>
<PROFIT_M>1.719291023</PROFIT_M>
<INCOME_M>0.30923242</INCOME_M>
<PHARMA_REV_M>2.29061052</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.719291023</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30923242</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2334877.4</REVENUE>
<PREV_YEAR_REV>2116324.57</PREV_YEAR_REV>
<BUDGET>2255861.19</BUDGET>
<GROSS_PROFIT>1864866.578</GROSS_PROFIT>
<EXPENSES>2080375.77</EXPENSES>
<NET_INCOME>254501.64</NET_INCOME>
<REVENUE_M>2.3348774</REVENUE_M>
<PROFIT_M>1.864866578</PROFIT_M>
<INCOME_M>0.25450164</INCOME_M>
<PHARMA_REV_M>2.3348774</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.864866578</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25450164</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1663311.04</REVENUE>
<PREV_YEAR_REV>1508644.78</PREV_YEAR_REV>
<BUDGET>1993893.75</BUDGET>
<GROSS_PROFIT>1212553.746</GROSS_PROFIT>
<EXPENSES>1448743.92</EXPENSES>
<NET_INCOME>214567.12</NET_INCOME>
<REVENUE_M>1.66331104</REVENUE_M>
<PROFIT_M>1.212553746</PROFIT_M>
<INCOME_M>0.21456712</INCOME_M>
<PHARMA_REV_M>1.66331104</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.212553746</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21456712</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3216925.55</REVENUE>
<PREV_YEAR_REV>2896067.14</PREV_YEAR_REV>
<BUDGET>3816556.16</BUDGET>
<GROSS_PROFIT>2465689.863</GROSS_PROFIT>
<EXPENSES>2860962.41</EXPENSES>
<NET_INCOME>355963.14</NET_INCOME>
<REVENUE_M>3.21692555</REVENUE_M>
<PROFIT_M>2.465689863</PROFIT_M>
<INCOME_M>0.35596314</INCOME_M>
<PHARMA_REV_M>3.21692555</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.465689863</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35596314</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3162679.51</REVENUE>
<PREV_YEAR_REV>2876432.14</PREV_YEAR_REV>
<BUDGET>3890576.52</BUDGET>
<GROSS_PROFIT>2569749.269</GROSS_PROFIT>
<EXPENSES>2813626.22</EXPENSES>
<NET_INCOME>349053.28</NET_INCOME>
<REVENUE_M>3.16267951</REVENUE_M>
<PROFIT_M>2.569749269</PROFIT_M>
<INCOME_M>0.34905328</INCOME_M>
<PHARMA_REV_M>3.16267951</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.569749269</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34905328</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1550000.49</REVENUE>
<PREV_YEAR_REV>1418492.09</PREV_YEAR_REV>
<BUDGET>1917445.01</BUDGET>
<GROSS_PROFIT>1265327.402</GROSS_PROFIT>
<EXPENSES>1272550.4</EXPENSES>
<NET_INCOME>277450.09</NET_INCOME>
<REVENUE_M>1.55000049</REVENUE_M>
<PROFIT_M>1.265327402</PROFIT_M>
<INCOME_M>0.27745009</INCOME_M>
<PHARMA_REV_M>1.55000049</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.265327402</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27745009</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6135364</REVENUE>
<PREV_YEAR_REV>1.083986572E7</PREV_YEAR_REV>
<BUDGET>5644534.88</BUDGET>
<GROSS_PROFIT>5055539.94</GROSS_PROFIT>
<EXPENSES>5153705.76</EXPENSES>
<NET_INCOME>981658.24</NET_INCOME>
<REVENUE_M>6.135364</REVENUE_M>
<PROFIT_M>5.05553994</PROFIT_M>
<INCOME_M>0.98165824</INCOME_M>
<PHARMA_REV_M>6.135364</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.05553994</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.98165824</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7055625</REVENUE>
<PREV_YEAR_REV>6386763.66</PREV_YEAR_REV>
<BUDGET>7411175</BUDGET>
<GROSS_PROFIT>6184226.88</GROSS_PROFIT>
<EXPENSES>6613668.13</EXPENSES>
<NET_INCOME>1441956.88</NET_INCOME>
<REVENUE_M>7.055625</REVENUE_M>
<PROFIT_M>6.18422688</PROFIT_M>
<INCOME_M>1.44195688</INCOME_M>
<PHARMA_REV_M>7.055625</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.18422688</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.44195688</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3438565.67</REVENUE>
<PREV_YEAR_REV>2821734.51</PREV_YEAR_REV>
<BUDGET>3272944.88</BUDGET>
<GROSS_PROFIT>2844106.441</GROSS_PROFIT>
<EXPENSES>2888395.17</EXPENSES>
<NET_INCOME>550170.51</NET_INCOME>
<REVENUE_M>3.43856567</REVENUE_M>
<PROFIT_M>2.844106441</PROFIT_M>
<INCOME_M>0.55017051</INCOME_M>
<PHARMA_REV_M>3.43856567</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.844106441</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55017051</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2668930.38</REVENUE>
<PREV_YEAR_REV>2473043.11</PREV_YEAR_REV>
<BUDGET>2222357.72</BUDGET>
<GROSS_PROFIT>1895878.351</GROSS_PROFIT>
<EXPENSES>2347699.6</EXPENSES>
<NET_INCOME>321230.79</NET_INCOME>
<REVENUE_M>2.66893038</REVENUE_M>
<PROFIT_M>1.895878351</PROFIT_M>
<INCOME_M>0.32123079</INCOME_M>
<PHARMA_REV_M>2.66893038</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.895878351</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32123079</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6114330.05</REVENUE>
<PREV_YEAR_REV>5647507.11</PREV_YEAR_REV>
<BUDGET>5869756.84</BUDGET>
<GROSS_PROFIT>3712694.575</GROSS_PROFIT>
<EXPENSES>5288895.49</EXPENSES>
<NET_INCOME>825434.56</NET_INCOME>
<REVENUE_M>6.11433005</REVENUE_M>
<PROFIT_M>3.712694575</PROFIT_M>
<INCOME_M>0.82543456</INCOME_M>
<PHARMA_REV_M>6.11433005</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.712694575</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.82543456</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2109104.49</REVENUE>
<PREV_YEAR_REV>1952350.29</PREV_YEAR_REV>
<BUDGET>1928964.93</BUDGET>
<GROSS_PROFIT>1240773.521</GROSS_PROFIT>
<EXPENSES>1837030.01</EXPENSES>
<NET_INCOME>272074.48</NET_INCOME>
<REVENUE_M>2.10910449</REVENUE_M>
<PROFIT_M>1.240773521</PROFIT_M>
<INCOME_M>0.27207448</INCOME_M>
<PHARMA_REV_M>2.10910449</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.240773521</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27207448</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1963817.04</REVENUE>
<PREV_YEAR_REV>1824684.83</PREV_YEAR_REV>
<BUDGET>1892065.1</BUDGET>
<GROSS_PROFIT>1416010.283</GROSS_PROFIT>
<EXPENSES>1749760.99</EXPENSES>
<NET_INCOME>214056.06</NET_INCOME>
<REVENUE_M>1.96381704</REVENUE_M>
<PROFIT_M>1.416010283</PROFIT_M>
<INCOME_M>0.21405606</INCOME_M>
<PHARMA_REV_M>1.96381704</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.416010283</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21405606</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2973144.17</REVENUE>
<PREV_YEAR_REV>2778653.66</PREV_YEAR_REV>
<BUDGET>3460396.9</BUDGET>
<GROSS_PROFIT>1848050.102</GROSS_PROFIT>
<EXPENSES>2612505.02</EXPENSES>
<NET_INCOME>360639.16</NET_INCOME>
<REVENUE_M>2.97314417</REVENUE_M>
<PROFIT_M>1.848050102</PROFIT_M>
<INCOME_M>0.36063916</INCOME_M>
<PHARMA_REV_M>2.97314417</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.848050102</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36063916</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>4259678.72</REVENUE>
<PREV_YEAR_REV>3857566.04</PREV_YEAR_REV>
<BUDGET>4089291.57</BUDGET>
<GROSS_PROFIT>3411704.482</GROSS_PROFIT>
<EXPENSES>3795373.74</EXPENSES>
<NET_INCOME>464304.98</NET_INCOME>
<REVENUE_M>4.25967872</REVENUE_M>
<PROFIT_M>3.411704482</PROFIT_M>
<INCOME_M>0.46430498</INCOME_M>
<PHARMA_REV_M>4.25967872</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.411704482</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46430498</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>1972515.37</REVENUE>
<PREV_YEAR_REV>1831303.55</PREV_YEAR_REV>
<BUDGET>2074155.84</BUDGET>
<GROSS_PROFIT>1263064.713</GROSS_PROFIT>
<EXPENSES>1718060.88</EXPENSES>
<NET_INCOME>254454.48</NET_INCOME>
<REVENUE_M>1.97251537</REVENUE_M>
<PROFIT_M>1.263064713</PROFIT_M>
<INCOME_M>0.25445448</INCOME_M>
<PHARMA_REV_M>1.97251537</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.263064713</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25445448</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5969324.12</REVENUE>
<PREV_YEAR_REV>5454421.21</PREV_YEAR_REV>
<BUDGET>6192498.2</BUDGET>
<GROSS_PROFIT>4275797.266</GROSS_PROFIT>
<EXPENSES>5391640.72</EXPENSES>
<NET_INCOME>577683.4</NET_INCOME>
<REVENUE_M>5.96932412</REVENUE_M>
<PROFIT_M>4.275797266</PROFIT_M>
<INCOME_M>0.5776834</INCOME_M>
<PHARMA_REV_M>5.96932412</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.275797266</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5776834</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2745743.27</REVENUE>
<PREV_YEAR_REV>2508431.89</PREV_YEAR_REV>
<BUDGET>3612356.09</BUDGET>
<GROSS_PROFIT>1837304.22</GROSS_PROFIT>
<EXPENSES>2442077.58</EXPENSES>
<NET_INCOME>303665.69</NET_INCOME>
<REVENUE_M>2.74574327</REVENUE_M>
<PROFIT_M>1.83730422</PROFIT_M>
<INCOME_M>0.30366569</INCOME_M>
<PHARMA_REV_M>2.74574327</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.83730422</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30366569</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1412469.11</REVENUE>
<PREV_YEAR_REV>1281906.9</PREV_YEAR_REV>
<BUDGET>1802925.43</BUDGET>
<GROSS_PROFIT>1100454.681</GROSS_PROFIT>
<EXPENSES>1159637.14</EXPENSES>
<NET_INCOME>252831.97</NET_INCOME>
<REVENUE_M>1.41246911</REVENUE_M>
<PROFIT_M>1.100454681</PROFIT_M>
<INCOME_M>0.25283197</INCOME_M>
<PHARMA_REV_M>1.41246911</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.100454681</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25283197</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1002655.44</REVENUE>
<PREV_YEAR_REV>936492.26</PREV_YEAR_REV>
<BUDGET>1174784.87</BUDGET>
<GROSS_PROFIT>614662.8773</GROSS_PROFIT>
<EXPENSES>867296.95</EXPENSES>
<NET_INCOME>135358.48</NET_INCOME>
<REVENUE_M>1.00265544</REVENUE_M>
<PROFIT_M>0.614662877</PROFIT_M>
<INCOME_M>0.13535848</INCOME_M>
<PHARMA_REV_M>1.00265544</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.614662877</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13535848</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8584714.14</REVENUE>
<PREV_YEAR_REV>8064853.68</PREV_YEAR_REV>
<BUDGET>8241325.58</BUDGET>
<GROSS_PROFIT>7116728.02</GROSS_PROFIT>
<EXPENSES>7211159.88</EXPENSES>
<NET_INCOME>1373554.26</NET_INCOME>
<REVENUE_M>8.58471414</REVENUE_M>
<PROFIT_M>7.11672802</PROFIT_M>
<INCOME_M>1.37355426</INCOME_M>
<PHARMA_REV_M>8.58471414</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.11672802</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.37355426</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.203067547E7</REVENUE>
<PREV_YEAR_REV>1.138964929E7</PREV_YEAR_REV>
<BUDGET>1.154944845E7</BUDGET>
<GROSS_PROFIT>1.015870962E7</GROSS_PROFIT>
<EXPENSES>1.046715069E7</EXPENSES>
<NET_INCOME>1563524.78</NET_INCOME>
<REVENUE_M>12.03067547</REVENUE_M>
<PROFIT_M>10.15870962</PROFIT_M>
<INCOME_M>1.56352478</INCOME_M>
<PHARMA_REV_M>12.03067547</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.15870962</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.56352478</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.968348187E7</REVENUE>
<PREV_YEAR_REV>3.373095959E7</PREV_YEAR_REV>
<BUDGET>3.849297742E7</BUDGET>
<GROSS_PROFIT>2.690421021E7</GROSS_PROFIT>
<EXPENSES>3.718829887E7</EXPENSES>
<NET_INCOME>5921687.76</NET_INCOME>
<REVENUE_M>39.68348187</REVENUE_M>
<PROFIT_M>26.90421021</PROFIT_M>
<INCOME_M>5.92168776</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.595895584E7</REVENUE>
<PREV_YEAR_REV>1.356511246E7</PREV_YEAR_REV>
<BUDGET>1.548018716E7</BUDGET>
<GROSS_PROFIT>1.142078736E7</GROSS_PROFIT>
<EXPENSES>1.42034707E7</EXPENSES>
<NET_INCOME>2744940.4</NET_INCOME>
<REVENUE_M>15.95895584</REVENUE_M>
<PROFIT_M>11.42078736</PROFIT_M>
<INCOME_M>2.7449404</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.16347274E7</REVENUE>
<PREV_YEAR_REV>1.838951829E7</PREV_YEAR_REV>
<BUDGET>2.098568558E7</BUDGET>
<GROSS_PROFIT>1.569383125E7</GROSS_PROFIT>
<EXPENSES>1.947125466E7</EXPENSES>
<NET_INCOME>3461556.38</NET_INCOME>
<REVENUE_M>21.6347274</REVENUE_M>
<PROFIT_M>15.69383125</PROFIT_M>
<INCOME_M>3.46155638</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.937282812E7</REVENUE>
<PREV_YEAR_REV>1.64669039E7</PREV_YEAR_REV>
<BUDGET>1.879164327E7</BUDGET>
<GROSS_PROFIT>1.459355143E7</GROSS_PROFIT>
<EXPENSES>1.727051362E7</EXPENSES>
<NET_INCOME>3467736.23</NET_INCOME>
<REVENUE_M>19.37282812</REVENUE_M>
<PROFIT_M>14.59355143</PROFIT_M>
<INCOME_M>3.46773623</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.113519904E7</REVENUE>
<PREV_YEAR_REV>1.024438312E7</PREV_YEAR_REV>
<BUDGET>1.135790302E7</BUDGET>
<GROSS_PROFIT>8388145.435</GROSS_PROFIT>
<EXPENSES>9926821.5</EXPENSES>
<NET_INCOME>1993200.63</NET_INCOME>
<REVENUE_M>11.13519904</REVENUE_M>
<PROFIT_M>8.388145435</PROFIT_M>
<INCOME_M>1.99320063</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.927924596E7</REVENUE>
<PREV_YEAR_REV>3.613690628E7</PREV_YEAR_REV>
<BUDGET>3.569216122E7</BUDGET>
<GROSS_PROFIT>2.663015039E7</GROSS_PROFIT>
<EXPENSES>3.348700635E7</EXPENSES>
<NET_INCOME>5792239.61</NET_INCOME>
<REVENUE_M>39.27924596</REVENUE_M>
<PROFIT_M>26.63015039</PROFIT_M>
<INCOME_M>5.79223961</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5601352.54</REVENUE>
<PREV_YEAR_REV>5045052.88</PREV_YEAR_REV>
<BUDGET>3994399.49</BUDGET>
<GROSS_PROFIT>4072507.99</GROSS_PROFIT>
<EXPENSES>4770409.16</EXPENSES>
<NET_INCOME>830943.38</NET_INCOME>
<REVENUE_M>5.60135254</REVENUE_M>
<PROFIT_M>4.07250799</PROFIT_M>
<INCOME_M>0.83094338</INCOME_M>
<PHARMA_REV_M>5.60135254</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.07250799</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83094338</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1690397.42</REVENUE>
<PREV_YEAR_REV>1391330.86</PREV_YEAR_REV>
<BUDGET>1629666.72</BUDGET>
<GROSS_PROFIT>1396268.27</GROSS_PROFIT>
<EXPENSES>1419933.84</EXPENSES>
<NET_INCOME>270463.59</NET_INCOME>
<REVENUE_M>1.69039742</REVENUE_M>
<PROFIT_M>1.39626827</PROFIT_M>
<INCOME_M>0.27046359</INCOME_M>
<PHARMA_REV_M>1.69039742</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.39626827</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27046359</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.147863717E7</REVENUE>
<PREV_YEAR_REV>1.033077345E7</PREV_YEAR_REV>
<BUDGET>1.090470531E7</BUDGET>
<GROSS_PROFIT>8214514.513</GROSS_PROFIT>
<EXPENSES>1.89208305E7</EXPENSES>
<NET_INCOME>1170820.99</NET_INCOME>
<REVENUE_M>11.47863717</REVENUE_M>
<PROFIT_M>8.214514513</PROFIT_M>
<INCOME_M>1.17082099</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.004348072E7</REVENUE>
<PREV_YEAR_REV>9541306.68</PREV_YEAR_REV>
<BUDGET>9742176.3</BUDGET>
<GROSS_PROFIT>7187466.322</GROSS_PROFIT>
<EXPENSES>8465219.46</EXPENSES>
<NET_INCOME>1024435.03</NET_INCOME>
<REVENUE_M>10.04348072</REVENUE_M>
<PROFIT_M>7.187466322</PROFIT_M>
<INCOME_M>1.02443503</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4314394.87</REVENUE>
<PREV_YEAR_REV>3924284.22</PREV_YEAR_REV>
<BUDGET>3283440.26</BUDGET>
<GROSS_PROFIT>3291015.747</GROSS_PROFIT>
<EXPENSES>3786970.5</EXPENSES>
<NET_INCOME>527424.37</NET_INCOME>
<REVENUE_M>4.31439487</REVENUE_M>
<PROFIT_M>3.291015747</PROFIT_M>
<INCOME_M>0.52742437</INCOME_M>
<PHARMA_REV_M>4.31439487</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.291015747</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52742437</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3642732.26</REVENUE>
<PREV_YEAR_REV>3277549.81</PREV_YEAR_REV>
<BUDGET>3361717.1</BUDGET>
<GROSS_PROFIT>2840436.761</GROSS_PROFIT>
<EXPENSES>3241718.81</EXPENSES>
<NET_INCOME>401013.44</NET_INCOME>
<REVENUE_M>3.64273226</REVENUE_M>
<PROFIT_M>2.840436761</PROFIT_M>
<INCOME_M>0.40101344</INCOME_M>
<PHARMA_REV_M>3.64273226</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.840436761</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40101344</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1631989.01</REVENUE>
<PREV_YEAR_REV>1459348.12</PREV_YEAR_REV>
<BUDGET>1990434.53</BUDGET>
<GROSS_PROFIT>1312119.16</GROSS_PROFIT>
<EXPENSES>1370870.77</EXPENSES>
<NET_INCOME>261118.24</NET_INCOME>
<REVENUE_M>1.63198901</REVENUE_M>
<PROFIT_M>1.31211916</PROFIT_M>
<INCOME_M>0.26111824</INCOME_M>
<PHARMA_REV_M>1.63198901</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.31211916</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26111824</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1673836.45</REVENUE>
<PREV_YEAR_REV>1536602.48</PREV_YEAR_REV>
<BUDGET>1936463.79</BUDGET>
<GROSS_PROFIT>1271606.853</GROSS_PROFIT>
<EXPENSES>1385936.58</EXPENSES>
<NET_INCOME>287899.87</NET_INCOME>
<REVENUE_M>1.67383645</REVENUE_M>
<PROFIT_M>1.271606853</PROFIT_M>
<INCOME_M>0.28789987</INCOME_M>
<PHARMA_REV_M>1.67383645</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.271606853</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28789987</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3706897.19</REVENUE>
<PREV_YEAR_REV>3361900.93</PREV_YEAR_REV>
<BUDGET>3890880.51</BUDGET>
<GROSS_PROFIT>3146112.55</GROSS_PROFIT>
<EXPENSES>3348918.98</EXPENSES>
<NET_INCOME>357978.19</NET_INCOME>
<REVENUE_M>3.70689719</REVENUE_M>
<PROFIT_M>3.14611255</PROFIT_M>
<INCOME_M>0.35797819</INCOME_M>
<PHARMA_REV_M>3.70689719</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.14611255</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35797819</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7899449.8</REVENUE>
<PREV_YEAR_REV>6937313.75</PREV_YEAR_REV>
<BUDGET>8057438.79</BUDGET>
<GROSS_PROFIT>6438051.59</GROSS_PROFIT>
<EXPENSES>6856722.42</EXPENSES>
<NET_INCOME>1042727.37</NET_INCOME>
<REVENUE_M>7.8994498</REVENUE_M>
<PROFIT_M>6.43805159</PROFIT_M>
<INCOME_M>1.04272737</INCOME_M>
<PHARMA_REV_M>7.8994498</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.43805159</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.04272737</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6774713.38</REVENUE>
<PREV_YEAR_REV>5914404.15</PREV_YEAR_REV>
<BUDGET>6910207.65</BUDGET>
<GROSS_PROFIT>5338474.14</GROSS_PROFIT>
<EXPENSES>6036269.62</EXPENSES>
<NET_INCOME>738443.76</NET_INCOME>
<REVENUE_M>6.77471338</REVENUE_M>
<PROFIT_M>5.33847414</PROFIT_M>
<INCOME_M>0.73844376</INCOME_M>
<PHARMA_REV_M>6.77471338</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.33847414</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.73844376</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1865487.32</REVENUE>
<PREV_YEAR_REV>1593984.02</PREV_YEAR_REV>
<BUDGET>1975098.95</BUDGET>
<GROSS_PROFIT>1582679.444</GROSS_PROFIT>
<EXPENSES>1567009.35</EXPENSES>
<NET_INCOME>298477.97</NET_INCOME>
<REVENUE_M>1.86548732</REVENUE_M>
<PROFIT_M>1.582679444</PROFIT_M>
<INCOME_M>0.29847797</INCOME_M>
<PHARMA_REV_M>1.86548732</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.582679444</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29847797</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2648002.1</REVENUE>
<PREV_YEAR_REV>2364773.21</PREV_YEAR_REV>
<BUDGET>2068982.86</BUDGET>
<GROSS_PROFIT>2146099.775</GROSS_PROFIT>
<EXPENSES>2359369.87</EXPENSES>
<NET_INCOME>288632.23</NET_INCOME>
<REVENUE_M>2.6480021</REVENUE_M>
<PROFIT_M>2.146099775</PROFIT_M>
<INCOME_M>0.28863223</INCOME_M>
<PHARMA_REV_M>2.6480021</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.146099775</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28863223</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2079045.76</REVENUE>
<PREV_YEAR_REV>1881199.96</PREV_YEAR_REV>
<BUDGET>1776044.74</BUDGET>
<GROSS_PROFIT>1728206.788</GROSS_PROFIT>
<EXPENSES>1927275.42</EXPENSES>
<NET_INCOME>151770.34</NET_INCOME>
<REVENUE_M>2.07904576</REVENUE_M>
<PROFIT_M>1.728206788</PROFIT_M>
<INCOME_M>0.15177034</INCOME_M>
<PHARMA_REV_M>2.07904576</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.728206788</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15177034</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1542908.85</REVENUE>
<PREV_YEAR_REV>1396689.43</PREV_YEAR_REV>
<BUDGET>1023328.41</BUDGET>
<GROSS_PROFIT>1262099.44</GROSS_PROFIT>
<EXPENSES>1430276.5</EXPENSES>
<NET_INCOME>112632.35</NET_INCOME>
<REVENUE_M>1.54290885</REVENUE_M>
<PROFIT_M>1.26209944</PROFIT_M>
<INCOME_M>0.11263235</INCOME_M>
<PHARMA_REV_M>1.54290885</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.26209944</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11263235</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>9067976.86</REVENUE>
<PREV_YEAR_REV>8213523.96</PREV_YEAR_REV>
<BUDGET>8886617.33</BUDGET>
<GROSS_PROFIT>7455146.502</GROSS_PROFIT>
<EXPENSES>8079567.38</EXPENSES>
<NET_INCOME>988409.48</NET_INCOME>
<REVENUE_M>9.06797686</REVENUE_M>
<PROFIT_M>7.455146502</PROFIT_M>
<INCOME_M>0.98840948</INCOME_M>
<PHARMA_REV_M>9.06797686</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.455146502</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.98840948</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2821734.51</REVENUE>
<PREV_YEAR_REV>2434313.51</PREV_YEAR_REV>
<BUDGET>2522604.85</BUDGET>
<GROSS_PROFIT>2339443.652</GROSS_PROFIT>
<EXPENSES>2370256.99</EXPENSES>
<NET_INCOME>451477.52</NET_INCOME>
<REVENUE_M>2.82173451</REVENUE_M>
<PROFIT_M>2.339443652</PROFIT_M>
<INCOME_M>0.45147752</INCOME_M>
<PHARMA_REV_M>2.82173451</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.339443652</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45147752</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1857449.48</REVENUE>
<PREV_YEAR_REV>1618466.68</PREV_YEAR_REV>
<BUDGET>1801725.99</BUDGET>
<GROSS_PROFIT>1426572.274</GROSS_PROFIT>
<EXPENSES>1537968.17</EXPENSES>
<NET_INCOME>319481.31</NET_INCOME>
<REVENUE_M>1.85744948</REVENUE_M>
<PROFIT_M>1.426572274</PROFIT_M>
<INCOME_M>0.31948131</INCOME_M>
<PHARMA_REV_M>1.85744948</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.426572274</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31948131</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3027434.61</REVENUE>
<PREV_YEAR_REV>2694813.75</PREV_YEAR_REV>
<BUDGET>2682234.84</BUDGET>
<GROSS_PROFIT>2295098.176</GROSS_PROFIT>
<EXPENSES>2506715.86</EXPENSES>
<NET_INCOME>520718.75</NET_INCOME>
<REVENUE_M>3.02743461</REVENUE_M>
<PROFIT_M>2.295098176</PROFIT_M>
<INCOME_M>0.52071875</INCOME_M>
<PHARMA_REV_M>3.02743461</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.295098176</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52071875</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4165401.13</REVENUE>
<PREV_YEAR_REV>3642732.26</PREV_YEAR_REV>
<BUDGET>4670062.03</BUDGET>
<GROSS_PROFIT>3063693.276</GROSS_PROFIT>
<EXPENSES>3705556.1</EXPENSES>
<NET_INCOME>459845.03</NET_INCOME>
<REVENUE_M>4.16540113</REVENUE_M>
<PROFIT_M>3.063693276</PROFIT_M>
<INCOME_M>0.45984503</INCOME_M>
<PHARMA_REV_M>4.16540113</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.063693276</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45984503</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2107380.26</REVENUE>
<PREV_YEAR_REV>1884517.25</PREV_YEAR_REV>
<BUDGET>2354713.59</BUDGET>
<GROSS_PROFIT>1850279.87</GROSS_PROFIT>
<EXPENSES>1730159.2</EXPENSES>
<NET_INCOME>377221.07</NET_INCOME>
<REVENUE_M>2.10738026</REVENUE_M>
<PROFIT_M>1.85027987</PROFIT_M>
<INCOME_M>0.37722107</INCOME_M>
<PHARMA_REV_M>2.10738026</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.85027987</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37722107</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7349411.8</REVENUE>
<PREV_YEAR_REV>6279079.85</PREV_YEAR_REV>
<BUDGET>6761458.85</BUDGET>
<GROSS_PROFIT>5695059.204</GROSS_PROFIT>
<EXPENSES>6401337.68</EXPENSES>
<NET_INCOME>948074.12</NET_INCOME>
<REVENUE_M>7.3494118</REVENUE_M>
<PROFIT_M>5.695059204</PROFIT_M>
<INCOME_M>0.94807412</INCOME_M>
<PHARMA_REV_M>7.3494118</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.695059204</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.94807412</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9484890.74</REVENUE>
<PREV_YEAR_REV>8620276.96</PREV_YEAR_REV>
<BUDGET>8726099.48</BUDGET>
<GROSS_PROFIT>7900913.99</GROSS_PROFIT>
<EXPENSES>8451037.65</EXPENSES>
<NET_INCOME>1033853.09</NET_INCOME>
<REVENUE_M>9.48489074</REVENUE_M>
<PROFIT_M>7.90091399</PROFIT_M>
<INCOME_M>1.03385309</INCOME_M>
<PHARMA_REV_M>9.48489074</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.90091399</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03385309</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7762266.86</REVENUE>
<PREV_YEAR_REV>6745852.06</PREV_YEAR_REV>
<BUDGET>7529398.84</BUDGET>
<GROSS_PROFIT>6134312.136</GROSS_PROFIT>
<EXPENSES>7008739.29</EXPENSES>
<NET_INCOME>753527.57</NET_INCOME>
<REVENUE_M>7.76226686</REVENUE_M>
<PROFIT_M>6.134312136</PROFIT_M>
<INCOME_M>0.75352757</INCOME_M>
<PHARMA_REV_M>7.76226686</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.134312136</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75352757</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3096695.05</REVENUE>
<PREV_YEAR_REV>2709922.28</PREV_YEAR_REV>
<BUDGET>3003794.2</BUDGET>
<GROSS_PROFIT>2609476.65</GROSS_PROFIT>
<EXPENSES>2684771.12</EXPENSES>
<NET_INCOME>411923.92</NET_INCOME>
<REVENUE_M>3.09669505</REVENUE_M>
<PROFIT_M>2.60947665</PROFIT_M>
<INCOME_M>0.41192392</INCOME_M>
<PHARMA_REV_M>3.09669505</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.60947665</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41192392</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8751032.77</REVENUE>
<PREV_YEAR_REV>6774713.38</PREV_YEAR_REV>
<BUDGET>8313481.13</BUDGET>
<GROSS_PROFIT>7105838.61</GROSS_PROFIT>
<EXPENSES>7797170.2</EXPENSES>
<NET_INCOME>953862.57</NET_INCOME>
<REVENUE_M>8.75103277</REVENUE_M>
<PROFIT_M>7.10583861</PROFIT_M>
<INCOME_M>0.95386257</INCOME_M>
<PHARMA_REV_M>8.75103277</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.10583861</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.95386257</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5112481.34</REVENUE>
<PREV_YEAR_REV>4176475.95</PREV_YEAR_REV>
<BUDGET>4887118.75</BUDGET>
<GROSS_PROFIT>3996527.811</GROSS_PROFIT>
<EXPENSES>4544915.45</EXPENSES>
<NET_INCOME>567565.91</NET_INCOME>
<REVENUE_M>5.11248134</REVENUE_M>
<PROFIT_M>3.996527811</PROFIT_M>
<INCOME_M>0.56756591</INCOME_M>
<PHARMA_REV_M>5.11248134</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.996527811</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56756591</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2580762.55</REVENUE>
<PREV_YEAR_REV>2149489.06</PREV_YEAR_REV>
<BUDGET>2466609.94</BUDGET>
<GROSS_PROFIT>2195299.852</GROSS_PROFIT>
<EXPENSES>2392366.88</EXPENSES>
<NET_INCOME>188395.67</NET_INCOME>
<REVENUE_M>2.58076255</REVENUE_M>
<PROFIT_M>2.195299852</PROFIT_M>
<INCOME_M>0.18839567</INCOME_M>
<PHARMA_REV_M>2.58076255</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.195299852</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18839567</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2737901.25</REVENUE>
<PREV_YEAR_REV>2261513.44</PREV_YEAR_REV>
<BUDGET>2710522.24</BUDGET>
<GROSS_PROFIT>2028456.283</GROSS_PROFIT>
<EXPENSES>2247816.93</EXPENSES>
<NET_INCOME>490084.32</NET_INCOME>
<REVENUE_M>2.73790125</REVENUE_M>
<PROFIT_M>2.028456283</PROFIT_M>
<INCOME_M>0.49008432</INCOME_M>
<PHARMA_REV_M>2.73790125</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.028456283</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49008432</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4570567.4</REVENUE>
<PREV_YEAR_REV>3557232.21</PREV_YEAR_REV>
<BUDGET>4524861.73</BUDGET>
<GROSS_PROFIT>3568813.9</GROSS_PROFIT>
<EXPENSES>4128389.16</EXPENSES>
<NET_INCOME>442178.24</NET_INCOME>
<REVENUE_M>4.5705674</REVENUE_M>
<PROFIT_M>3.5688139</PROFIT_M>
<INCOME_M>0.44217824</INCOME_M>
<PHARMA_REV_M>4.5705674</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.5688139</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44217824</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6139399.1</REVENUE>
<PREV_YEAR_REV>4813025.53</PREV_YEAR_REV>
<BUDGET>6078005.11</BUDGET>
<GROSS_PROFIT>4726864.575</GROSS_PROFIT>
<EXPENSES>5347416.62</EXPENSES>
<NET_INCOME>791982.48</NET_INCOME>
<REVENUE_M>6.1393991</REVENUE_M>
<PROFIT_M>4.726864575</PROFIT_M>
<INCOME_M>0.79198248</INCOME_M>
<PHARMA_REV_M>6.1393991</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.726864575</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.79198248</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>2.366701753E7</REVENUE>
<PREV_YEAR_REV>1.892575075E7</PREV_YEAR_REV>
<BUDGET>2.343034734E7</BUDGET>
<GROSS_PROFIT>1.893531037E7</GROSS_PROFIT>
<EXPENSES>2.137292809E7</EXPENSES>
<NET_INCOME>2294089.43</NET_INCOME>
<REVENUE_M>23.66701753</REVENUE_M>
<PROFIT_M>18.93531037</PROFIT_M>
<INCOME_M>2.29408943</INCOME_M>
<PHARMA_REV_M>23.66701753</PHARMA_REV_M>
<PHARMA_PROFIT_M>18.93531037</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.29408943</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1983784.16</REVENUE>
<PREV_YEAR_REV>1631723.5</PREV_YEAR_REV>
<BUDGET>1963946.32</BUDGET>
<GROSS_PROFIT>1585043.55</GROSS_PROFIT>
<EXPENSES>1838967.92</EXPENSES>
<NET_INCOME>144816.24</NET_INCOME>
<REVENUE_M>1.98378416</REVENUE_M>
<PROFIT_M>1.58504355</PROFIT_M>
<INCOME_M>0.14481624</INCOME_M>
<PHARMA_REV_M>1.98378416</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.58504355</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14481624</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1964300.63</REVENUE>
<PREV_YEAR_REV>1595008.34</PREV_YEAR_REV>
<BUDGET>1944657.62</BUDGET>
<GROSS_PROFIT>1505931.07</GROSS_PROFIT>
<EXPENSES>1626440.92</EXPENSES>
<NET_INCOME>337859.71</NET_INCOME>
<REVENUE_M>1.96430063</REVENUE_M>
<PROFIT_M>1.50593107</PROFIT_M>
<INCOME_M>0.33785971</INCOME_M>
<PHARMA_REV_M>1.96430063</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.50593107</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33785971</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3284154.72</REVENUE>
<PREV_YEAR_REV>2746751.04</PREV_YEAR_REV>
<BUDGET>3251313.17</BUDGET>
<GROSS_PROFIT>2352778.891</GROSS_PROFIT>
<EXPENSES>2921781.03</EXPENSES>
<NET_INCOME>362373.69</NET_INCOME>
<REVENUE_M>3.28415472</REVENUE_M>
<PROFIT_M>2.352778891</PROFIT_M>
<INCOME_M>0.36237369</INCOME_M>
<PHARMA_REV_M>3.28415472</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.352778891</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36237369</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2470233.02</REVENUE>
<PREV_YEAR_REV>2034996.99</PREV_YEAR_REV>
<BUDGET>2445530.69</BUDGET>
<GROSS_PROFIT>1826398.19</GROSS_PROFIT>
<EXPENSES>2138812.56</EXPENSES>
<NET_INCOME>331420.46</NET_INCOME>
<REVENUE_M>2.47023302</REVENUE_M>
<PROFIT_M>1.82639819</PROFIT_M>
<INCOME_M>0.33142046</INCOME_M>
<PHARMA_REV_M>2.47023302</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.82639819</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33142046</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.581238907E7</REVENUE>
<PREV_YEAR_REV>1.279097895E7</PREV_YEAR_REV>
<BUDGET>1.565426518E7</BUDGET>
<GROSS_PROFIT>1.268161512E7</GROSS_PROFIT>
<EXPENSES>1.368748844E7</EXPENSES>
<NET_INCOME>2124900.62</NET_INCOME>
<REVENUE_M>15.81238907</REVENUE_M>
<PROFIT_M>12.68161512</PROFIT_M>
<INCOME_M>2.12490062</INCOME_M>
<PHARMA_REV_M>15.81238907</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.68161512</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.12490062</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3717989.5</REVENUE>
<PREV_YEAR_REV>2923683.24</PREV_YEAR_REV>
<BUDGET>3532090.03</BUDGET>
<GROSS_PROFIT>2935166.807</GROSS_PROFIT>
<EXPENSES>3123111.18</EXPENSES>
<NET_INCOME>594878.32</NET_INCOME>
<REVENUE_M>3.7179895</REVENUE_M>
<PROFIT_M>2.935166807</PROFIT_M>
<INCOME_M>0.59487832</INCOME_M>
<PHARMA_REV_M>3.7179895</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.935166807</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.59487832</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3789708.25</REVENUE>
<PREV_YEAR_REV>2935096.27</PREV_YEAR_REV>
<BUDGET>3600222.84</BUDGET>
<GROSS_PROFIT>2971131.268</GROSS_PROFIT>
<EXPENSES>3111350.47</EXPENSES>
<NET_INCOME>678357.78</NET_INCOME>
<REVENUE_M>3.78970825</REVENUE_M>
<PROFIT_M>2.971131268</PROFIT_M>
<INCOME_M>0.67835778</INCOME_M>
<PHARMA_REV_M>3.78970825</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.971131268</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.67835778</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2841333.25</REVENUE>
<PREV_YEAR_REV>2250044.15</PREV_YEAR_REV>
<BUDGET>2557199.93</BUDGET>
<GROSS_PROFIT>1958047.983</GROSS_PROFIT>
<EXPENSES>2474801.26</EXPENSES>
<NET_INCOME>366531.99</NET_INCOME>
<REVENUE_M>2.84133325</REVENUE_M>
<PROFIT_M>1.958047983</PROFIT_M>
<INCOME_M>0.36653199</INCOME_M>
<PHARMA_REV_M>2.84133325</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.958047983</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36653199</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1929492.4</REVENUE>
<PREV_YEAR_REV>1601331.53</PREV_YEAR_REV>
<BUDGET>1890902.55</BUDGET>
<GROSS_PROFIT>1340611.317</GROSS_PROFIT>
<EXPENSES>1680587.88</EXPENSES>
<NET_INCOME>248904.52</NET_INCOME>
<REVENUE_M>1.9294924</REVENUE_M>
<PROFIT_M>1.340611317</PROFIT_M>
<INCOME_M>0.24890452</INCOME_M>
<PHARMA_REV_M>1.9294924</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.340611317</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24890452</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3974655.82</REVENUE>
<PREV_YEAR_REV>3338120.57</PREV_YEAR_REV>
<BUDGET>3934909.27</BUDGET>
<GROSS_PROFIT>2901171.456</GROSS_PROFIT>
<EXPENSES>3493885.48</EXPENSES>
<NET_INCOME>480770.34</NET_INCOME>
<REVENUE_M>3.97465582</REVENUE_M>
<PROFIT_M>2.901171456</PROFIT_M>
<INCOME_M>0.48077034</INCOME_M>
<PHARMA_REV_M>3.97465582</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.901171456</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48077034</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1799516.25</REVENUE>
<PREV_YEAR_REV>1444663.54</PREV_YEAR_REV>
<BUDGET>1781521.09</BUDGET>
<GROSS_PROFIT>1543984.94</GROSS_PROFIT>
<EXPENSES>1603368.98</EXPENSES>
<NET_INCOME>196147.27</NET_INCOME>
<REVENUE_M>1.79951625</REVENUE_M>
<PROFIT_M>1.54398494</PROFIT_M>
<INCOME_M>0.19614727</INCOME_M>
<PHARMA_REV_M>1.79951625</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.54398494</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19614727</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7156042.14</REVENUE>
<PREV_YEAR_REV>6036459.92</PREV_YEAR_REV>
<BUDGET>7084481.72</BUDGET>
<GROSS_PROFIT>5431543.328</GROSS_PROFIT>
<EXPENSES>6189976.45</EXPENSES>
<NET_INCOME>966065.69</NET_INCOME>
<REVENUE_M>7.15604214</REVENUE_M>
<PROFIT_M>5.431543328</PROFIT_M>
<INCOME_M>0.96606569</INCOME_M>
<PHARMA_REV_M>7.15604214</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.431543328</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.96606569</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7795399.63</REVENUE>
<PREV_YEAR_REV>6361193.68</PREV_YEAR_REV>
<BUDGET>7405629.64</BUDGET>
<GROSS_PROFIT>6077431.039</GROSS_PROFIT>
<EXPENSES>6765034.87</EXPENSES>
<NET_INCOME>1030364.76</NET_INCOME>
<REVENUE_M>7.79539963</REVENUE_M>
<PROFIT_M>6.077431039</PROFIT_M>
<INCOME_M>1.03036476</INCOME_M>
<PHARMA_REV_M>7.79539963</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.077431039</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03036476</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5760704.94</REVENUE>
<PREV_YEAR_REV>4473609.78</PREV_YEAR_REV>
<BUDGET>5184634.44</BUDGET>
<GROSS_PROFIT>4620618.84</GROSS_PROFIT>
<EXPENSES>4985762.55</EXPENSES>
<NET_INCOME>774942.38</NET_INCOME>
<REVENUE_M>5.76070494</REVENUE_M>
<PROFIT_M>4.62061884</PROFIT_M>
<INCOME_M>0.77494238</INCOME_M>
<PHARMA_REV_M>5.76070494</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.62061884</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.77494238</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2825200.75</REVENUE>
<PREV_YEAR_REV>2257974.88</PREV_YEAR_REV>
<BUDGET>2542680.68</BUDGET>
<GROSS_PROFIT>2134135.46</GROSS_PROFIT>
<EXPENSES>2537030.27</EXPENSES>
<NET_INCOME>288170.48</NET_INCOME>
<REVENUE_M>2.82520075</REVENUE_M>
<PROFIT_M>2.13413546</PROFIT_M>
<INCOME_M>0.28817048</INCOME_M>
<PHARMA_REV_M>2.82520075</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.13413546</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28817048</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2472682</REVENUE>
<PREV_YEAR_REV>1985802.86</PREV_YEAR_REV>
<BUDGET>2423228.36</BUDGET>
<GROSS_PROFIT>1820512.123</GROSS_PROFIT>
<EXPENSES>2146287.98</EXPENSES>
<NET_INCOME>326394.02</NET_INCOME>
<REVENUE_M>2.472682</REVENUE_M>
<PROFIT_M>1.820512123</PROFIT_M>
<INCOME_M>0.32639402</INCOME_M>
<PHARMA_REV_M>2.472682</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.820512123</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32639402</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>1.36650842E7</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>1.183587747E7</BUDGET>
<GROSS_PROFIT>1.047902871E7</GROSS_PROFIT>
<EXPENSES>1.130784442E7</EXPENSES>
<NET_INCOME>1557239.78</NET_INCOME>
<REVENUE_M>13.6650842</REVENUE_M>
<PROFIT_M>10.47902871</PROFIT_M>
<INCOME_M>1.55723978</INCOME_M>
<PHARMA_REV_M>13.6650842</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.47902871</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.55723978</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>9415354.13</REVENUE>
<PREV_YEAR_REV>7372795</PREV_YEAR_REV>
<BUDGET>8662125.8</BUDGET>
<GROSS_PROFIT>8064062.503</GROSS_PROFIT>
<EXPENSES>8728033.27</EXPENSES>
<NET_INCOME>687320.85</NET_INCOME>
<REVENUE_M>9.41535413</REVENUE_M>
<PROFIT_M>8.064062503</PROFIT_M>
<INCOME_M>0.68732085</INCOME_M>
<PHARMA_REV_M>9.41535413</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.064062503</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68732085</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1236107.71</REVENUE>
<PREV_YEAR_REV>1138356.99</PREV_YEAR_REV>
<BUDGET>1201216.58</BUDGET>
<GROSS_PROFIT>820132.7409</GROSS_PROFIT>
<EXPENSES>1076649.81</EXPENSES>
<NET_INCOME>159457.89</NET_INCOME>
<REVENUE_M>1.23610771</REVENUE_M>
<PROFIT_M>0.820132741</PROFIT_M>
<INCOME_M>0.15945789</INCOME_M>
<PHARMA_REV_M>1.23610771</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.820132741</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15945789</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5155986.47</REVENUE>
<PREV_YEAR_REV>4687984.93</PREV_YEAR_REV>
<BUDGET>4949747.01</BUDGET>
<GROSS_PROFIT>3728603.173</GROSS_PROFIT>
<EXPENSES>4475396.25</EXPENSES>
<NET_INCOME>680590.21</NET_INCOME>
<REVENUE_M>5.15598647</REVENUE_M>
<PROFIT_M>3.728603173</PROFIT_M>
<INCOME_M>0.68059021</INCOME_M>
<PHARMA_REV_M>5.15598647</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.728603173</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68059021</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6366586.51</REVENUE>
<PREV_YEAR_REV>5875511.28</PREV_YEAR_REV>
<BUDGET>6111923.05</BUDGET>
<GROSS_PROFIT>4711274.02</GROSS_PROFIT>
<EXPENSES>5226967.52</EXPENSES>
<NET_INCOME>1139618.98</NET_INCOME>
<REVENUE_M>6.36658651</REVENUE_M>
<PROFIT_M>4.71127402</PROFIT_M>
<INCOME_M>1.13961898</INCOME_M>
<PHARMA_REV_M>6.36658651</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.71127402</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.13961898</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1345338.11</REVENUE>
<PREV_YEAR_REV>1217137.06</PREV_YEAR_REV>
<BUDGET>1820808.31</BUDGET>
<GROSS_PROFIT>917655.122</GROSS_PROFIT>
<EXPENSES>1130084.01</EXPENSES>
<NET_INCOME>215254.1</NET_INCOME>
<REVENUE_M>1.34533811</REVENUE_M>
<PROFIT_M>0.917655122</PROFIT_M>
<INCOME_M>0.2152541</INCOME_M>
<PHARMA_REV_M>1.34533811</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.917655122</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2152541</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2747204.91</REVENUE>
<PREV_YEAR_REV>2518732.02</PREV_YEAR_REV>
<BUDGET>3630238.98</BUDGET>
<GROSS_PROFIT>1645629.624</GROSS_PROFIT>
<EXPENSES>2340002.63</EXPENSES>
<NET_INCOME>407202.28</NET_INCOME>
<REVENUE_M>2.7472049099999998</REVENUE_M>
<PROFIT_M>1.645629624</PROFIT_M>
<INCOME_M>0.40720228</INCOME_M>
<PHARMA_REV_M>2.7472049099999998</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.645629624</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40720228</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1062067</REVENUE>
<PREV_YEAR_REV>968403.06</PREV_YEAR_REV>
<BUDGET>1135810.7</BUDGET>
<GROSS_PROFIT>775308.91</GROSS_PROFIT>
<EXPENSES>921874.16</EXPENSES>
<NET_INCOME>140192.84</NET_INCOME>
<REVENUE_M>1.062067</REVENUE_M>
<PROFIT_M>0.77530891</PROFIT_M>
<INCOME_M>0.14019284</INCOME_M>
<PHARMA_REV_M>1.062067</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.77530891</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14019284</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.698833466E7</REVENUE>
<PREV_YEAR_REV>1.580646195E7</PREV_YEAR_REV>
<BUDGET>1.630880127E7</BUDGET>
<GROSS_PROFIT>1.434265706E7</GROSS_PROFIT>
<EXPENSES>1.529428459E7</EXPENSES>
<NET_INCOME>1694050.07</NET_INCOME>
<REVENUE_M>16.98833466</REVENUE_M>
<PROFIT_M>14.34265706</PROFIT_M>
<INCOME_M>1.69405007</INCOME_M>
<PHARMA_REV_M>16.98833466</PHARMA_REV_M>
<PHARMA_PROFIT_M>14.34265706</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.69405007</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8594874.76</REVENUE>
<PREV_YEAR_REV>8004689.04</PREV_YEAR_REV>
<BUDGET>8251079.77</BUDGET>
<GROSS_PROFIT>6809719.273</GROSS_PROFIT>
<EXPENSES>7718197.54</EXPENSES>
<NET_INCOME>876677.23</NET_INCOME>
<REVENUE_M>8.59487476</REVENUE_M>
<PROFIT_M>6.809719273</PROFIT_M>
<INCOME_M>0.87667723</INCOME_M>
<PHARMA_REV_M>8.59487476</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.809719273</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.87667723</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.291562303E7</REVENUE>
<PREV_YEAR_REV>2.176984188E7</PREV_YEAR_REV>
<BUDGET>2.222815434E7</BUDGET>
<GROSS_PROFIT>1.726233883E7</GROSS_PROFIT>
<EXPENSES>2.94629439E7</EXPENSES>
<NET_INCOME>3036930.12</NET_INCOME>
<REVENUE_M>22.91562303</REVENUE_M>
<PROFIT_M>17.26233883</PROFIT_M>
<INCOME_M>3.03693012</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>8569443.09</REVENUE>
<PREV_YEAR_REV>8140970.94</PREV_YEAR_REV>
<BUDGET>8312359.8</BUDGET>
<GROSS_PROFIT>6455361.486</GROSS_PROFIT>
<EXPENSES>1.049319563E7</EXPENSES>
<NET_INCOME>625569.35</NET_INCOME>
<REVENUE_M>8.56944309</REVENUE_M>
<PROFIT_M>6.455361486</PROFIT_M>
<INCOME_M>0.62556935</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.813872026E7</REVENUE>
<PREV_YEAR_REV>1.541791222E7</PREV_YEAR_REV>
<BUDGET>1.759455865E7</BUDGET>
<GROSS_PROFIT>1.366389797E7</GROSS_PROFIT>
<EXPENSES>1.614346103E7</EXPENSES>
<NET_INCOME>1977120.51</NET_INCOME>
<REVENUE_M>18.13872026</REVENUE_M>
<PROFIT_M>13.66389797</PROFIT_M>
<INCOME_M>1.97712051</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.50638415E7</REVENUE>
<PREV_YEAR_REV>1.280426527E7</PREV_YEAR_REV>
<BUDGET>1.461192625E7</BUDGET>
<GROSS_PROFIT>1.13475918E7</GROSS_PROFIT>
<EXPENSES>1.342913271E7</EXPENSES>
<NET_INCOME>1641958.72</NET_INCOME>
<REVENUE_M>15.0638415</REVENUE_M>
<PROFIT_M>11.3475918</PROFIT_M>
<INCOME_M>1.64195872</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.273660433E7</REVENUE>
<PREV_YEAR_REV>2.782611368E7</PREV_YEAR_REV>
<BUDGET>3.17545062E7</BUDGET>
<GROSS_PROFIT>2.374713277E7</GROSS_PROFIT>
<EXPENSES>2.94629439E7</EXPENSES>
<NET_INCOME>4338471.6</NET_INCOME>
<REVENUE_M>32.73660433</REVENUE_M>
<PROFIT_M>23.74713277</PROFIT_M>
<INCOME_M>4.3384716</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.193958123E7</REVENUE>
<PREV_YEAR_REV>2.018441474E7</PREV_YEAR_REV>
<BUDGET>1.931837286E7</BUDGET>
<GROSS_PROFIT>1.652708654E7</GROSS_PROFIT>
<EXPENSES>1.98562273E7</EXPENSES>
<NET_INCOME>3510333</NET_INCOME>
<REVENUE_M>21.93958123</REVENUE_M>
<PROFIT_M>16.52708654</PROFIT_M>
<INCOME_M>3.510333</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.43478296E7</REVENUE>
<PREV_YEAR_REV>1.320000323E7</PREV_YEAR_REV>
<BUDGET>1.463478619E7</BUDGET>
<GROSS_PROFIT>1.026780904E7</GROSS_PROFIT>
<EXPENSES>1.276956834E7</EXPENSES>
<NET_INCOME>1463478.62</NET_INCOME>
<REVENUE_M>14.3478296</REVENUE_M>
<PROFIT_M>10.26780904</PROFIT_M>
<INCOME_M>1.46347862</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.909338975E7</REVENUE>
<PREV_YEAR_REV>1.756591857E7</PREV_YEAR_REV>
<BUDGET>1.947525754E7</BUDGET>
<GROSS_PROFIT>1.43830505E7</GROSS_PROFIT>
<EXPENSES>1.702139954E7</EXPENSES>
<NET_INCOME>2081179.48</NET_INCOME>
<REVENUE_M>19.09338975</REVENUE_M>
<PROFIT_M>14.3830505</PROFIT_M>
<INCOME_M>2.08117948</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7509262.91</REVENUE>
<PREV_YEAR_REV>6918939.03</PREV_YEAR_REV>
<BUDGET>8260189.2</BUDGET>
<GROSS_PROFIT>5649969.411</GROSS_PROFIT>
<EXPENSES>6495512.42</EXPENSES>
<NET_INCOME>1013750.49</NET_INCOME>
<REVENUE_M>7.50926291</REVENUE_M>
<PROFIT_M>5.649969411</PROFIT_M>
<INCOME_M>1.01375049</INCOME_M>
<PHARMA_REV_M>7.50926291</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.649969411</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.01375049</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>7761037.65</REVENUE>
<PREV_YEAR_REV>6367896.91</PREV_YEAR_REV>
<BUDGET>7417454.82</BUDGET>
<GROSS_PROFIT>6361348.23</GROSS_PROFIT>
<EXPENSES>7008413.87</EXPENSES>
<NET_INCOME>752623.78</NET_INCOME>
<REVENUE_M>7.76103765</REVENUE_M>
<PROFIT_M>6.36134823</PROFIT_M>
<INCOME_M>0.75262378</INCOME_M>
<PHARMA_REV_M>7.76103765</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.36134823</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75262378</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2114909.42</REVENUE>
<PREV_YEAR_REV>1649386.56</PREV_YEAR_REV>
<BUDGET>2028708</BUDGET>
<GROSS_PROFIT>1693725.208</GROSS_PROFIT>
<EXPENSES>1835741.38</EXPENSES>
<NET_INCOME>279168.04</NET_INCOME>
<REVENUE_M>2.11490942</REVENUE_M>
<PROFIT_M>1.693725208</PROFIT_M>
<INCOME_M>0.27916804</INCOME_M>
<PHARMA_REV_M>2.11490942</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.693725208</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27916804</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.052333948E7</REVENUE>
<PREV_YEAR_REV>1.847100553E7</PREV_YEAR_REV>
<BUDGET>1.94971725E7</BUDGET>
<GROSS_PROFIT>1.546023162E7</GROSS_PROFIT>
<EXPENSES>3.382968046E7</EXPENSES>
<NET_INCOME>2774602.26</NET_INCOME>
<REVENUE_M>20.52333948</REVENUE_M>
<PROFIT_M>15.46023162</PROFIT_M>
<INCOME_M>2.77460226</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.192046075E7</REVENUE>
<PREV_YEAR_REV>1.972841468E7</PREV_YEAR_REV>
<BUDGET>1.955346265E7</BUDGET>
<GROSS_PROFIT>1.651268309E7</GROSS_PROFIT>
<EXPENSES>3.392734988E7</EXPENSES>
<NET_INCOME>2135538.88</NET_INCOME>
<REVENUE_M>21.92046075</REVENUE_M>
<PROFIT_M>16.51268309</PROFIT_M>
<INCOME_M>2.13553888</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1658546.69</REVENUE>
<PREV_YEAR_REV>1469352.82</PREV_YEAR_REV>
<BUDGET>2156232.65</BUDGET>
<GROSS_PROFIT>1457862.54</GROSS_PROFIT>
<EXPENSES>1439618.53</EXPENSES>
<NET_INCOME>218928.16</NET_INCOME>
<REVENUE_M>1.65854669</REVENUE_M>
<PROFIT_M>1.45786254</PROFIT_M>
<INCOME_M>0.21892816</INCOME_M>
<PHARMA_REV_M>1.65854669</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.45786254</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21892816</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3254485.06</REVENUE>
<PREV_YEAR_REV>2763964.31</PREV_YEAR_REV>
<BUDGET>4147823.08</BUDGET>
<GROSS_PROFIT>2392837.767</GROSS_PROFIT>
<EXPENSES>2771286.8</EXPENSES>
<NET_INCOME>483198.26</NET_INCOME>
<REVENUE_M>3.25448506</REVENUE_M>
<PROFIT_M>2.392837767</PROFIT_M>
<INCOME_M>0.48319826</INCOME_M>
<PHARMA_REV_M>3.25448506</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.392837767</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48319826</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4613814.53</REVENUE>
<PREV_YEAR_REV>4164574.86</PREV_YEAR_REV>
<BUDGET>4367389.45</BUDGET>
<GROSS_PROFIT>3714927.804</GROSS_PROFIT>
<EXPENSES>3993866.12</EXPENSES>
<NET_INCOME>619948.41</NET_INCOME>
<REVENUE_M>4.61381453</REVENUE_M>
<PROFIT_M>3.714927804</PROFIT_M>
<INCOME_M>0.61994841</INCOME_M>
<PHARMA_REV_M>4.61381453</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.714927804</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61994841</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2301322.26</REVENUE>
<PREV_YEAR_REV>2082248.86</PREV_YEAR_REV>
<BUDGET>2133187.64</BUDGET>
<GROSS_PROFIT>1782300.452</GROSS_PROFIT>
<EXPENSES>1990643.76</EXPENSES>
<NET_INCOME>310678.51</NET_INCOME>
<REVENUE_M>2.30132226</REVENUE_M>
<PROFIT_M>1.782300452</PROFIT_M>
<INCOME_M>0.31067851</INCOME_M>
<PHARMA_REV_M>2.30132226</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.782300452</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31067851</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1556299.21</REVENUE>
<PREV_YEAR_REV>1412993.42</PREV_YEAR_REV>
<BUDGET>1917445.01</BUDGET>
<GROSS_PROFIT>1197572.247</GROSS_PROFIT>
<EXPENSES>1355536.62</EXPENSES>
<NET_INCOME>200762.6</NET_INCOME>
<REVENUE_M>1.55629921</REVENUE_M>
<PROFIT_M>1.197572247</PROFIT_M>
<INCOME_M>0.2007626</INCOME_M>
<PHARMA_REV_M>1.55629921</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.197572247</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2007626</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1099613.31</REVENUE>
<PREV_YEAR_REV>985643.37</PREV_YEAR_REV>
<BUDGET>1115759.29</BUDGET>
<GROSS_PROFIT>969858.94</GROSS_PROFIT>
<EXPENSES>1019341.54</EXPENSES>
<NET_INCOME>80271.77</NET_INCOME>
<REVENUE_M>1.09961331</REVENUE_M>
<PROFIT_M>0.96985894</PROFIT_M>
<INCOME_M>0.08027177</INCOME_M>
<PHARMA_REV_M>1.09961331</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.96985894</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.08027177</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.869592435E7</REVENUE>
<PREV_YEAR_REV>1.666808953E7</PREV_YEAR_REV>
<BUDGET>1.906984285E7</BUDGET>
<GROSS_PROFIT>1.554152119E7</GROSS_PROFIT>
<EXPENSES>1.687729671E7</EXPENSES>
<NET_INCOME>1818627.64</NET_INCOME>
<REVENUE_M>18.69592435</REVENUE_M>
<PROFIT_M>15.54152119</PROFIT_M>
<INCOME_M>1.81862764</INCOME_M>
<PHARMA_REV_M>18.69592435</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.54152119</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.81862764</PHARMA_INCOME_M>
<FRANCE_REV_M>18.69592435</FRANCE_REV_M>
<FRANCE_PROFIT_M>15.54152119</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>1.81862764</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2117155.73</REVENUE>
<PREV_YEAR_REV>1892057.63</PREV_YEAR_REV>
<BUDGET>2260152.48</BUDGET>
<GROSS_PROFIT>1707591.95</GROSS_PROFIT>
<EXPENSES>1837691.17</EXPENSES>
<NET_INCOME>279464.56</NET_INCOME>
<REVENUE_M>2.11715573</REVENUE_M>
<PROFIT_M>1.70759195</PROFIT_M>
<INCOME_M>0.27946456</INCOME_M>
<PHARMA_REV_M>2.11715573</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.70759195</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27946456</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5622021.35</REVENUE>
<PREV_YEAR_REV>5168969.6</PREV_YEAR_REV>
<BUDGET>4068514.28</BUDGET>
<GROSS_PROFIT>4757328.082</GROSS_PROFIT>
<EXPENSES>4874730.22</EXPENSES>
<NET_INCOME>747291.13</NET_INCOME>
<REVENUE_M>5.62202135</REVENUE_M>
<PROFIT_M>4.757328082</PROFIT_M>
<INCOME_M>0.74729113</INCOME_M>
<PHARMA_REV_M>5.62202135</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.757328082</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74729113</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.664738475E7</REVENUE>
<PREV_YEAR_REV>1.44096337E7</PREV_YEAR_REV>
<BUDGET>1.631443706E7</BUDGET>
<GROSS_PROFIT>1.218362687E7</GROSS_PROFIT>
<EXPENSES>1.417955392E7</EXPENSES>
<NET_INCOME>2467830.85</NET_INCOME>
<REVENUE_M>16.64738475</REVENUE_M>
<PROFIT_M>12.18362687</PROFIT_M>
<INCOME_M>2.46783085</INCOME_M>
<PHARMA_REV_M>16.64738475</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.18362687</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.46783085</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5734154.71</REVENUE>
<PREV_YEAR_REV>4996952.9</PREV_YEAR_REV>
<BUDGET>5213520.11</BUDGET>
<GROSS_PROFIT>4460927.11</GROSS_PROFIT>
<EXPENSES>5099596.46</EXPENSES>
<NET_INCOME>634558.23</NET_INCOME>
<REVENUE_M>5.73415471</REVENUE_M>
<PROFIT_M>4.46092711</PROFIT_M>
<INCOME_M>0.63455823</INCOME_M>
<PHARMA_REV_M>5.73415471</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.46092711</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.63455823</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3706653.14</REVENUE>
<PREV_YEAR_REV>3222390.9</PREV_YEAR_REV>
<BUDGET>3595453.54</BUDGET>
<GROSS_PROFIT>2987680.14</GROSS_PROFIT>
<EXPENSES>3215176.9</EXPENSES>
<NET_INCOME>491476.24</NET_INCOME>
<REVENUE_M>3.70665314</REVENUE_M>
<PROFIT_M>2.98768014</PROFIT_M>
<INCOME_M>0.49147624</INCOME_M>
<PHARMA_REV_M>3.70665314</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.98768014</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49147624</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2994795.85</REVENUE>
<PREV_YEAR_REV>2562019.51</PREV_YEAR_REV>
<BUDGET>2623822.03</BUDGET>
<GROSS_PROFIT>2377268.947</GROSS_PROFIT>
<EXPENSES>2458727.39</EXPENSES>
<NET_INCOME>536068.46</NET_INCOME>
<REVENUE_M>2.99479585</REVENUE_M>
<PROFIT_M>2.377268947</PROFIT_M>
<INCOME_M>0.53606846</INCOME_M>
<PHARMA_REV_M>2.99479585</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.377268947</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53606846</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3094876.18</REVENUE>
<PREV_YEAR_REV>2813165.76</PREV_YEAR_REV>
<BUDGET>2753552.81</BUDGET>
<GROSS_PROFIT>2464712.967</GROSS_PROFIT>
<EXPENSES>2562557.48</EXPENSES>
<NET_INCOME>532318.7</NET_INCOME>
<REVENUE_M>3.09487618</REVENUE_M>
<PROFIT_M>2.464712967</PROFIT_M>
<INCOME_M>0.5323187</INCOME_M>
<PHARMA_REV_M>3.09487618</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.464712967</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5323187</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4127523.36</REVENUE>
<PREV_YEAR_REV>3624507.14</PREV_YEAR_REV>
<BUDGET>4700961.56</BUDGET>
<GROSS_PROFIT>3106206.504</GROSS_PROFIT>
<EXPENSES>3513343.4</EXPENSES>
<NET_INCOME>614179.96</NET_INCOME>
<REVENUE_M>4.12752336</REVENUE_M>
<PROFIT_M>3.106206504</PROFIT_M>
<INCOME_M>0.61417996</INCOME_M>
<PHARMA_REV_M>4.12752336</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.106206504</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61417996</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3221067.63</REVENUE>
<PREV_YEAR_REV>2899773.29</PREV_YEAR_REV>
<BUDGET>3269306.25</BUDGET>
<GROSS_PROFIT>2180778.826</GROSS_PROFIT>
<EXPENSES>2745093.69</EXPENSES>
<NET_INCOME>475973.94</NET_INCOME>
<REVENUE_M>3.22106763</REVENUE_M>
<PROFIT_M>2.180778826</PROFIT_M>
<INCOME_M>0.47597394</INCOME_M>
<PHARMA_REV_M>3.22106763</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.180778826</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47597394</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6523532.02</REVENUE>
<PREV_YEAR_REV>5540672.18</PREV_YEAR_REV>
<BUDGET>6001649.46</BUDGET>
<GROSS_PROFIT>5447149.24</GROSS_PROFIT>
<EXPENSES>6047314.18</EXPENSES>
<NET_INCOME>476217.84</NET_INCOME>
<REVENUE_M>6.52353202</REVENUE_M>
<PROFIT_M>5.44714924</PROFIT_M>
<INCOME_M>0.47621784</INCOME_M>
<PHARMA_REV_M>6.52353202</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.44714924</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47621784</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.777364135E7</REVENUE>
<PREV_YEAR_REV>1.554372681E7</PREV_YEAR_REV>
<BUDGET>1.72404321E7</BUDGET>
<GROSS_PROFIT>1.360463729E7</GROSS_PROFIT>
<EXPENSES>1.559976209E7</EXPENSES>
<NET_INCOME>2173879.25</NET_INCOME>
<REVENUE_M>17.77364135</REVENUE_M>
<PROFIT_M>13.60463729</PROFIT_M>
<INCOME_M>2.17387925</INCOME_M>
<PHARMA_REV_M>17.77364135</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.60463729</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.17387925</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6044207.12</REVENUE>
<PREV_YEAR_REV>5339877.3</PREV_YEAR_REV>
<BUDGET>5862880.91</BUDGET>
<GROSS_PROFIT>4972569.202</GROSS_PROFIT>
<EXPENSES>5427697.99</EXPENSES>
<NET_INCOME>616509.13</NET_INCOME>
<REVENUE_M>6.04420712</REVENUE_M>
<PROFIT_M>4.972569202</PROFIT_M>
<INCOME_M>0.61650913</INCOME_M>
<PHARMA_REV_M>6.04420712</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.972569202</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61650913</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>9050041.46</REVENUE>
<PREV_YEAR_REV>8089714.31</PREV_YEAR_REV>
<BUDGET>7151212.68</BUDGET>
<GROSS_PROFIT>7116557.008</GROSS_PROFIT>
<EXPENSES>8169292.16</EXPENSES>
<NET_INCOME>880749.3</NET_INCOME>
<REVENUE_M>9.05004146</REVENUE_M>
<PROFIT_M>7.116557008</PROFIT_M>
<INCOME_M>0.8807493</INCOME_M>
<PHARMA_REV_M>9.05004146</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.116557008</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.8807493</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4250627.69</REVENUE>
<PREV_YEAR_REV>3706897.19</PREV_YEAR_REV>
<BUDGET>4123108.86</BUDGET>
<GROSS_PROFIT>3581756.18</GROSS_PROFIT>
<EXPENSES>3839401.92</EXPENSES>
<NET_INCOME>411225.76</NET_INCOME>
<REVENUE_M>4.25062769</REVENUE_M>
<PROFIT_M>3.58175618</PROFIT_M>
<INCOME_M>0.41122576</INCOME_M>
<PHARMA_REV_M>4.25062769</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.58175618</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41122576</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8872654.27</REVENUE>
<PREV_YEAR_REV>6845497.19</PREV_YEAR_REV>
<BUDGET>8429021.55</BUDGET>
<GROSS_PROFIT>6717930.178</GROSS_PROFIT>
<EXPENSES>7967643.53</EXPENSES>
<NET_INCOME>905010.74</NET_INCOME>
<REVENUE_M>8.87265427</REVENUE_M>
<PROFIT_M>6.717930178</PROFIT_M>
<INCOME_M>0.90501074</INCOME_M>
<PHARMA_REV_M>8.87265427</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.717930178</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.90501074</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>7405525.09</REVENUE>
<PREV_YEAR_REV>6143982.99</PREV_YEAR_REV>
<BUDGET>7042579.88</BUDGET>
<GROSS_PROFIT>6168481.532</GROSS_PROFIT>
<EXPENSES>6422055.58</EXPENSES>
<NET_INCOME>983469.53</NET_INCOME>
<REVENUE_M>7.40552509</REVENUE_M>
<PROFIT_M>6.168481532</PROFIT_M>
<INCOME_M>0.98346953</INCOME_M>
<PHARMA_REV_M>7.40552509</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.168481532</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.98346953</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5440194.9</REVENUE>
<PREV_YEAR_REV>4383835.68</PREV_YEAR_REV>
<BUDGET>5385792.95</BUDGET>
<GROSS_PROFIT>3823292.751</GROSS_PROFIT>
<EXPENSES>4837175.71</EXPENSES>
<NET_INCOME>603019.19</NET_INCOME>
<REVENUE_M>5.4401949</REVENUE_M>
<PROFIT_M>3.823292751</PROFIT_M>
<INCOME_M>0.60301919</INCOME_M>
<PHARMA_REV_M>5.4401949</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.823292751</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60301919</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1962521.66</REVENUE>
<PREV_YEAR_REV>1589266.53</PREV_YEAR_REV>
<BUDGET>1942896.45</BUDGET>
<GROSS_PROFIT>1675993.5</GROSS_PROFIT>
<EXPENSES>1648518.2</EXPENSES>
<NET_INCOME>314003.47</NET_INCOME>
<REVENUE_M>1.96252166</REVENUE_M>
<PROFIT_M>1.6759935</PROFIT_M>
<INCOME_M>0.31400347</INCOME_M>
<PHARMA_REV_M>1.96252166</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.6759935</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31400347</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1983784.16</REVENUE>
<PREV_YEAR_REV>1547956.9</PREV_YEAR_REV>
<BUDGET>1963946.32</BUDGET>
<GROSS_PROFIT>1479407.042</GROSS_PROFIT>
<EXPENSES>1838967.92</EXPENSES>
<NET_INCOME>144816.24</NET_INCOME>
<REVENUE_M>1.98378416</REVENUE_M>
<PROFIT_M>1.479407042</PROFIT_M>
<INCOME_M>0.14481624</INCOME_M>
<PHARMA_REV_M>1.98378416</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.479407042</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14481624</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>8697373.5</REVENUE>
<PREV_YEAR_REV>7041448.59</PREV_YEAR_REV>
<BUDGET>7827636.15</BUDGET>
<GROSS_PROFIT>7082274.16</GROSS_PROFIT>
<EXPENSES>7854051.13</EXPENSES>
<NET_INCOME>843322.37</NET_INCOME>
<REVENUE_M>8.6973735</REVENUE_M>
<PROFIT_M>7.08227416</PROFIT_M>
<INCOME_M>0.84332237</INCOME_M>
<PHARMA_REV_M>8.6973735</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.08227416</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.84332237</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2210364.47</REVENUE>
<PREV_YEAR_REV>1765283.53</PREV_YEAR_REV>
<BUDGET>2166157.18</BUDGET>
<GROSS_PROFIT>1719663.56</GROSS_PROFIT>
<EXPENSES>1814709.23</EXPENSES>
<NET_INCOME>395655.24</NET_INCOME>
<REVENUE_M>2.21036447</REVENUE_M>
<PROFIT_M>1.71966356</PROFIT_M>
<INCOME_M>0.39565524</INCOME_M>
<PHARMA_REV_M>2.21036447</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.71966356</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39565524</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>1.237658866E7</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>1.138646157E7</BUDGET>
<GROSS_PROFIT>1.042553314E7</GROSS_PROFIT>
<EXPENSES>1.121203129E7</EXPENSES>
<NET_INCOME>1164557.36</NET_INCOME>
<REVENUE_M>12.37658866</REVENUE_M>
<PROFIT_M>10.42553314</PROFIT_M>
<INCOME_M>1.16455736</INCOME_M>
<PHARMA_REV_M>12.37658866</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.42553314</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.16455736</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>6375058.88</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>6233054.17</BUDGET>
<GROSS_PROFIT>5562323.34</GROSS_PROFIT>
<EXPENSES>5562323.34</EXPENSES>
<NET_INCOME>1212735.54</NET_INCOME>
<REVENUE_M>6.37505888</REVENUE_M>
<PROFIT_M>5.56232334</PROFIT_M>
<INCOME_M>1.21273554</INCOME_M>
<PHARMA_REV_M>6.37505888</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.56232334</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.21273554</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6936777.84</REVENUE>
<PREV_YEAR_REV>6082758.54</PREV_YEAR_REV>
<BUDGET>7075513.39</BUDGET>
<GROSS_PROFIT>5857137.733</GROSS_PROFIT>
<EXPENSES>5826893.38</EXPENSES>
<NET_INCOME>1109884.45</NET_INCOME>
<REVENUE_M>6.93677784</REVENUE_M>
<PROFIT_M>5.857137733</PROFIT_M>
<INCOME_M>1.10988445</INCOME_M>
<PHARMA_REV_M>6.93677784</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.857137733</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.10988445</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7101427.47</REVENUE>
<PREV_YEAR_REV>6056189.7</PREV_YEAR_REV>
<BUDGET>7243456.02</BUDGET>
<GROSS_PROFIT>5695344.83</GROSS_PROFIT>
<EXPENSES>6583023.27</EXPENSES>
<NET_INCOME>518404.21</NET_INCOME>
<REVENUE_M>7.10142747</REVENUE_M>
<PROFIT_M>5.69534483</PROFIT_M>
<INCOME_M>0.51840421</INCOME_M>
<PHARMA_REV_M>7.10142747</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.69534483</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51840421</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2182674.26</REVENUE>
<PREV_YEAR_REV>1974502.46</PREV_YEAR_REV>
<BUDGET>2214818.23</BUDGET>
<GROSS_PROFIT>1762553.118</GROSS_PROFIT>
<EXPENSES>1833446.37</EXPENSES>
<NET_INCOME>349227.88</NET_INCOME>
<REVENUE_M>2.18267426</REVENUE_M>
<PROFIT_M>1.762553118</PROFIT_M>
<INCOME_M>0.34922788</INCOME_M>
<PHARMA_REV_M>2.18267426</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.762553118</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34922788</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4450652.5</REVENUE>
<PREV_YEAR_REV>3929778.25</PREV_YEAR_REV>
<BUDGET>4695630.77</BUDGET>
<GROSS_PROFIT>3265472.215</GROSS_PROFIT>
<EXPENSES>3788835.7</EXPENSES>
<NET_INCOME>661816.8</NET_INCOME>
<REVENUE_M>4.4506525</REVENUE_M>
<PROFIT_M>3.265472215</PROFIT_M>
<INCOME_M>0.6618168</INCOME_M>
<PHARMA_REV_M>4.4506525</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.265472215</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6618168</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2753304.26</REVENUE>
<PREV_YEAR_REV>2492377.28</PREV_YEAR_REV>
<BUDGET>1994654.24</BUDGET>
<GROSS_PROFIT>2191299.798</GROSS_PROFIT>
<EXPENSES>2453194.1</EXPENSES>
<NET_INCOME>300110.16</NET_INCOME>
<REVENUE_M>2.75330426</REVENUE_M>
<PROFIT_M>2.191299798</PROFIT_M>
<INCOME_M>0.30011016</INCOME_M>
<PHARMA_REV_M>2.75330426</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.191299798</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30011016</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>6201400.52</REVENUE>
<PREV_YEAR_REV>5607031.1</PREV_YEAR_REV>
<BUDGET>5344321.09</BUDGET>
<GROSS_PROFIT>5144583.52</GROSS_PROFIT>
<EXPENSES>5599243.61</EXPENSES>
<NET_INCOME>602156.91</NET_INCOME>
<REVENUE_M>6.20140052</REVENUE_M>
<PROFIT_M>5.14458352</PROFIT_M>
<INCOME_M>0.60215691</INCOME_M>
<PHARMA_REV_M>6.20140052</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.14458352</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60215691</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2428667.05</REVENUE>
<PREV_YEAR_REV>2163893.09</PREV_YEAR_REV>
<BUDGET>2268427.61</BUDGET>
<GROSS_PROFIT>1999157.276</GROSS_PROFIT>
<EXPENSES>2108083</EXPENSES>
<NET_INCOME>320584.05</NET_INCOME>
<REVENUE_M>2.42866705</REVENUE_M>
<PROFIT_M>1.999157276</PROFIT_M>
<INCOME_M>0.32058405</INCOME_M>
<PHARMA_REV_M>2.42866705</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.999157276</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32058405</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1846375.97</REVENUE>
<PREV_YEAR_REV>1634076.72</PREV_YEAR_REV>
<BUDGET>1790984.69</BUDGET>
<GROSS_PROFIT>1525106.55</GROSS_PROFIT>
<EXPENSES>1711590.52</EXPENSES>
<NET_INCOME>134785.45</NET_INCOME>
<REVENUE_M>1.84637597</REVENUE_M>
<PROFIT_M>1.52510655</PROFIT_M>
<INCOME_M>0.13478545</INCOME_M>
<PHARMA_REV_M>1.84637597</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.52510655</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13478545</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1822515.19</REVENUE>
<PREV_YEAR_REV>1624533.31</PREV_YEAR_REV>
<BUDGET>1767839.73</BUDGET>
<GROSS_PROFIT>1419739.328</GROSS_PROFIT>
<EXPENSES>1509042.58</EXPENSES>
<NET_INCOME>313472.61</NET_INCOME>
<REVENUE_M>1.82251519</REVENUE_M>
<PROFIT_M>1.419739328</PROFIT_M>
<INCOME_M>0.31347261</INCOME_M>
<PHARMA_REV_M>1.82251519</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.419739328</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31347261</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2862489.25</REVENUE>
<PREV_YEAR_REV>2506601.91</PREV_YEAR_REV>
<BUDGET>2650583.25</BUDGET>
<GROSS_PROFIT>2207723.459</GROSS_PROFIT>
<EXPENSES>2653527.54</EXPENSES>
<NET_INCOME>208961.72</NET_INCOME>
<REVENUE_M>2.86248925</REVENUE_M>
<PROFIT_M>2.207723459</PROFIT_M>
<INCOME_M>0.20896172</INCOME_M>
<PHARMA_REV_M>2.86248925</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.207723459</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20896172</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4045445.59</REVENUE>
<PREV_YEAR_REV>3582270.16</PREV_YEAR_REV>
<BUDGET>4760635.75</BUDGET>
<GROSS_PROFIT>3351716.08</GROSS_PROFIT>
<EXPENSES>3509390.61</EXPENSES>
<NET_INCOME>536054.97</NET_INCOME>
<REVENUE_M>4.04544559</REVENUE_M>
<PROFIT_M>3.35171608</PROFIT_M>
<INCOME_M>0.53605497</INCOME_M>
<PHARMA_REV_M>4.04544559</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.35171608</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53605497</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1391330.86</REVENUE>
<PREV_YEAR_REV>1184454.1</PREV_YEAR_REV>
<BUDGET>1365279.3</BUDGET>
<GROSS_PROFIT>1120021.34</GROSS_PROFIT>
<EXPENSES>1168717.92</EXPENSES>
<NET_INCOME>222612.94</NET_INCOME>
<REVENUE_M>1.39133086</REVENUE_M>
<PROFIT_M>1.12002134</PROFIT_M>
<INCOME_M>0.22261294</INCOME_M>
<PHARMA_REV_M>1.39133086</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.12002134</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22261294</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1745846.66</REVENUE>
<PREV_YEAR_REV>1575944.12</PREV_YEAR_REV>
<BUDGET>1690227</BUDGET>
<GROSS_PROFIT>1251047.531</GROSS_PROFIT>
<EXPENSES>1445561.03</EXPENSES>
<NET_INCOME>300285.62</NET_INCOME>
<REVENUE_M>1.74584666</REVENUE_M>
<PROFIT_M>1.251047531</PROFIT_M>
<INCOME_M>0.30028562</INCOME_M>
<PHARMA_REV_M>1.74584666</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.251047531</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30028562</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4426464.25</REVENUE>
<PREV_YEAR_REV>3862563.88</PREV_YEAR_REV>
<BUDGET>4293670.32</BUDGET>
<GROSS_PROFIT>3240703.397</GROSS_PROFIT>
<EXPENSES>3890248.69</EXPENSES>
<NET_INCOME>536215.55</NET_INCOME>
<REVENUE_M>4.42646425</REVENUE_M>
<PROFIT_M>3.240703397</PROFIT_M>
<INCOME_M>0.53621555</INCOME_M>
<PHARMA_REV_M>4.42646425</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.240703397</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53621555</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5837846.69</REVENUE>
<PREV_YEAR_REV>4966055.63</PREV_YEAR_REV>
<BUDGET>5662711.29</BUDGET>
<GROSS_PROFIT>4618320.516</GROSS_PROFIT>
<EXPENSES>5049737.39</EXPENSES>
<NET_INCOME>788109.3</NET_INCOME>
<REVENUE_M>5.83784669</REVENUE_M>
<PROFIT_M>4.618320516</PROFIT_M>
<INCOME_M>0.7881093</INCOME_M>
<PHARMA_REV_M>5.83784669</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.618320516</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.7881093</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3035207.15</REVENUE>
<PREV_YEAR_REV>2696308.18</PREV_YEAR_REV>
<BUDGET>2427805.71</BUDGET>
<GROSS_PROFIT>2248944.326</GROSS_PROFIT>
<EXPENSES>2513151.52</EXPENSES>
<NET_INCOME>522055.63</NET_INCOME>
<REVENUE_M>3.03520715</REVENUE_M>
<PROFIT_M>2.248944326</PROFIT_M>
<INCOME_M>0.52205563</INCOME_M>
<PHARMA_REV_M>3.03520715</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.248944326</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52205563</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1563270.59</REVENUE>
<PREV_YEAR_REV>1479193.25</PREV_YEAR_REV>
<BUDGET>1533533.3</BUDGET>
<GROSS_PROFIT>1130092.215</GROSS_PROFIT>
<EXPENSES>1403816.99</EXPENSES>
<NET_INCOME>159453.6</NET_INCOME>
<REVENUE_M>1.56327059</REVENUE_M>
<PROFIT_M>1.130092215</PROFIT_M>
<INCOME_M>0.1594536</INCOME_M>
<PHARMA_REV_M>1.56327059</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.130092215</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1594536</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4573930.77</REVENUE>
<PREV_YEAR_REV>4024847.04</PREV_YEAR_REV>
<BUDGET>4760024.24</BUDGET>
<GROSS_PROFIT>3575236.118</GROSS_PROFIT>
<EXPENSES>3967391.59</EXPENSES>
<NET_INCOME>606539.18</NET_INCOME>
<REVENUE_M>4.57393077</REVENUE_M>
<PROFIT_M>3.575236118</PROFIT_M>
<INCOME_M>0.60653918</INCOME_M>
<PHARMA_REV_M>4.57393077</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.575236118</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60653918</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2814324.81</REVENUE>
<PREV_YEAR_REV>2230687.69</PREV_YEAR_REV>
<BUDGET>2532892.33</BUDGET>
<GROSS_PROFIT>1864841.979</GROSS_PROFIT>
<EXPENSES>2434390.96</EXPENSES>
<NET_INCOME>379933.85</NET_INCOME>
<REVENUE_M>2.81432481</REVENUE_M>
<PROFIT_M>1.864841979</PROFIT_M>
<INCOME_M>0.37993385</INCOME_M>
<PHARMA_REV_M>2.81432481</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.864841979</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37993385</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3304779.42</REVENUE>
<PREV_YEAR_REV>2964724.79</PREV_YEAR_REV>
<BUDGET>2329076.85</BUDGET>
<GROSS_PROFIT>2726318.94</GROSS_PROFIT>
<EXPENSES>2861391.62</EXPENSES>
<NET_INCOME>443387.8</NET_INCOME>
<REVENUE_M>3.30477942</REVENUE_M>
<PROFIT_M>2.72631894</PROFIT_M>
<INCOME_M>0.4433878</INCOME_M>
<PHARMA_REV_M>3.30477942</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.72631894</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4433878</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5547940.57</REVENUE>
<PREV_YEAR_REV>4869831.33</PREV_YEAR_REV>
<BUDGET>5381502.35</BUDGET>
<GROSS_PROFIT>4514806.472</GROSS_PROFIT>
<EXPENSES>5009928.75</EXPENSES>
<NET_INCOME>538011.81</NET_INCOME>
<REVENUE_M>5.54794057</REVENUE_M>
<PROFIT_M>4.514806472</PROFIT_M>
<INCOME_M>0.53801181</INCOME_M>
<PHARMA_REV_M>5.54794057</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.514806472</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53801181</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5034115.86</REVENUE>
<PREV_YEAR_REV>4437116.24</PREV_YEAR_REV>
<BUDGET>4576666.5</BUDGET>
<GROSS_PROFIT>3663676.968</GROSS_PROFIT>
<EXPENSES>4293574.51</EXPENSES>
<NET_INCOME>740541.36</NET_INCOME>
<REVENUE_M>5.03411586</REVENUE_M>
<PROFIT_M>3.663676968</PROFIT_M>
<INCOME_M>0.74054136</INCOME_M>
<PHARMA_REV_M>5.03411586</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.663676968</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74054136</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6181801.37</REVENUE>
<PREV_YEAR_REV>4943700.91</PREV_YEAR_REV>
<BUDGET>5872711.3</BUDGET>
<GROSS_PROFIT>4315589.716</GROSS_PROFIT>
<EXPENSES>5347258.18</EXPENSES>
<NET_INCOME>834543.18</NET_INCOME>
<REVENUE_M>6.18180137</REVENUE_M>
<PROFIT_M>4.315589716</PROFIT_M>
<INCOME_M>0.83454318</INCOME_M>
<PHARMA_REV_M>6.18180137</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.315589716</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83454318</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1593984.02</REVENUE>
<PREV_YEAR_REV>1488981.07</PREV_YEAR_REV>
<BUDGET>1728637.18</BUDGET>
<GROSS_PROFIT>1189733.732</GROSS_PROFIT>
<EXPENSES>1338946.58</EXPENSES>
<NET_INCOME>255037.44</NET_INCOME>
<REVENUE_M>1.59398402</REVENUE_M>
<PROFIT_M>1.189733732</PROFIT_M>
<INCOME_M>0.25503744</INCOME_M>
<PHARMA_REV_M>1.59398402</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.189733732</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25503744</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6036459.92</REVENUE>
<PREV_YEAR_REV>5343182.05</PREV_YEAR_REV>
<BUDGET>5855366.12</BUDGET>
<GROSS_PROFIT>4466533.647</GROSS_PROFIT>
<EXPENSES>5221537.83</EXPENSES>
<NET_INCOME>814922.09</NET_INCOME>
<REVENUE_M>6.03645992</REVENUE_M>
<PROFIT_M>4.466533647</PROFIT_M>
<INCOME_M>0.81492209</INCOME_M>
<PHARMA_REV_M>6.03645992</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.466533647</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.81492209</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.021082069E7</REVENUE>
<PREV_YEAR_REV>1.818973862E7</PREV_YEAR_REV>
<BUDGET>2.159650672E7</BUDGET>
<GROSS_PROFIT>1.522481123E7</GROSS_PROFIT>
<EXPENSES>3.747224994E7</EXPENSES>
<NET_INCOME>2591693.36</NET_INCOME>
<REVENUE_M>20.21082069</REVENUE_M>
<PROFIT_M>15.22481123</PROFIT_M>
<INCOME_M>2.59169336</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>4.473783656E7</REVENUE>
<PREV_YEAR_REV>3.802716108E7</PREV_YEAR_REV>
<BUDGET>4.339570147E7</BUDGET>
<GROSS_PROFIT>3.370101228E7</GROSS_PROFIT>
<EXPENSES>4.096813102E7</EXPENSES>
<NET_INCOME>4384235.47</NET_INCOME>
<REVENUE_M>44.73783656</REVENUE_M>
<PROFIT_M>33.70101228</PROFIT_M>
<INCOME_M>4.38423547</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>21023145</REVENUE>
<PREV_YEAR_REV>1.786967325E7</PREV_YEAR_REV>
<BUDGET>2.039245065E7</BUDGET>
<GROSS_PROFIT>1.525018938E7</GROSS_PROFIT>
<EXPENSES>1.89208305E7</EXPENSES>
<NET_INCOME>3763142.96</NET_INCOME>
<REVENUE_M>21.023145</REVENUE_M>
<PROFIT_M>15.25018938</PROFIT_M>
<INCOME_M>3.76314296</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>4482125.88</REVENUE>
<PREV_YEAR_REV>5724298.69</PREV_YEAR_REV>
<BUDGET>4123555.81</BUDGET>
<GROSS_PROFIT>3782914.24</GROSS_PROFIT>
<EXPENSES>3993574.15</EXPENSES>
<NET_INCOME>488551.72</NET_INCOME>
<REVENUE_M>4.48212588</REVENUE_M>
<PROFIT_M>3.78291424</PROFIT_M>
<INCOME_M>0.48855172</INCOME_M>
<PHARMA_REV_M>4.48212588</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.78291424</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48855172</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2779445.42</REVENUE>
<PREV_YEAR_REV>2601854.08</PREV_YEAR_REV>
<BUDGET>2278435.91</BUDGET>
<GROSS_PROFIT>2104077.435</GROSS_PROFIT>
<EXPENSES>2472664.6</EXPENSES>
<NET_INCOME>306780.81</NET_INCOME>
<REVENUE_M>2.77944542</REVENUE_M>
<PROFIT_M>2.104077435</PROFIT_M>
<INCOME_M>0.30678081</INCOME_M>
<PHARMA_REV_M>2.77944542</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.104077435</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30678081</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1394060.07</REVENUE>
<PREV_YEAR_REV>1283097.78</PREV_YEAR_REV>
<BUDGET>1121249.02</BUDGET>
<GROSS_PROFIT>1071404.87</GROSS_PROFIT>
<EXPENSES>1292293.69</EXPENSES>
<NET_INCOME>101766.39</NET_INCOME>
<REVENUE_M>1.39406007</REVENUE_M>
<PROFIT_M>1.07140487</PROFIT_M>
<INCOME_M>0.10176639</INCOME_M>
<PHARMA_REV_M>1.39406007</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.07140487</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.10176639</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1185048.24</REVENUE>
<PREV_YEAR_REV>1126268.3</PREV_YEAR_REV>
<BUDGET>1018029.91</BUDGET>
<GROSS_PROFIT>970436.001</GROSS_PROFIT>
<EXPENSES>1055877.98</EXPENSES>
<NET_INCOME>129170.26</NET_INCOME>
<REVENUE_M>1.18504824</REVENUE_M>
<PROFIT_M>0.970436001</PROFIT_M>
<INCOME_M>0.12917026</INCOME_M>
<PHARMA_REV_M>1.18504824</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.970436001</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12917026</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>1744126.44</REVENUE>
<PREV_YEAR_REV>1629613.5</PREV_YEAR_REV>
<BUDGET>1607632.57</BUDGET>
<GROSS_PROFIT>1372261.235</GROSS_PROFIT>
<EXPENSES>1465066.21</EXPENSES>
<NET_INCOME>279060.23</NET_INCOME>
<REVENUE_M>1.74412644</REVENUE_M>
<PROFIT_M>1.372261235</PROFIT_M>
<INCOME_M>0.27906023</INCOME_M>
<PHARMA_REV_M>1.74412644</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.372261235</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27906023</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2917182.64</REVENUE>
<PREV_YEAR_REV>2672029.72</PREV_YEAR_REV>
<BUDGET>3623733.74</BUDGET>
<GROSS_PROFIT>2160804.597</GROSS_PROFIT>
<EXPENSES>2525204.56</EXPENSES>
<NET_INCOME>391978.08</NET_INCOME>
<REVENUE_M>2.91718264</REVENUE_M>
<PROFIT_M>2.160804597</PROFIT_M>
<INCOME_M>0.39197808</INCOME_M>
<PHARMA_REV_M>2.91718264</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.160804597</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39197808</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1294786.95</REVENUE>
<PREV_YEAR_REV>1177025.54</PREV_YEAR_REV>
<BUDGET>1798697.03</BUDGET>
<GROSS_PROFIT>939756.3685</GROSS_PROFIT>
<EXPENSES>1072083.59</EXPENSES>
<NET_INCOME>222703.35</NET_INCOME>
<REVENUE_M>1.29478695</REVENUE_M>
<PROFIT_M>0.939756369</PROFIT_M>
<INCOME_M>0.22270335</INCOME_M>
<PHARMA_REV_M>1.29478695</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.939756369</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22270335</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6102856.63</REVENUE>
<PREV_YEAR_REV>5731888.79</PREV_YEAR_REV>
<BUDGET>5858742.36</BUDGET>
<GROSS_PROFIT>5362580.123</GROSS_PROFIT>
<EXPENSES>5126399.57</EXPENSES>
<NET_INCOME>976457.06</NET_INCOME>
<REVENUE_M>6.10285663</REVENUE_M>
<PROFIT_M>5.362580123</PROFIT_M>
<INCOME_M>0.97645706</INCOME_M>
<PHARMA_REV_M>6.10285663</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.362580123</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.97645706</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.208495168E7</REVENUE>
<PREV_YEAR_REV>1.136435349E7</PREV_YEAR_REV>
<BUDGET>1.160155361E7</BUDGET>
<GROSS_PROFIT>1.025040684E7</GROSS_PROFIT>
<EXPENSES>1.046213027E7</EXPENSES>
<NET_INCOME>1622821.41</NET_INCOME>
<REVENUE_M>12.08495168</REVENUE_M>
<PROFIT_M>10.25040684</PROFIT_M>
<INCOME_M>1.62282141</INCOME_M>
<PHARMA_REV_M>12.08495168</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.25040684</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.62282141</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3924284.22</REVENUE>
<PREV_YEAR_REV>3623832.28</PREV_YEAR_REV>
<BUDGET>3037911.01</BUDGET>
<GROSS_PROFIT>2937141.811</GROSS_PROFIT>
<EXPENSES>3445131.5</EXPENSES>
<NET_INCOME>479152.71</NET_INCOME>
<REVENUE_M>3.92428422</REVENUE_M>
<PROFIT_M>2.937141811</PROFIT_M>
<INCOME_M>0.47915271</INCOME_M>
<PHARMA_REV_M>3.92428422</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.937141811</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47915271</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4647809.66</REVENUE>
<PREV_YEAR_REV>4357695.54</PREV_YEAR_REV>
<BUDGET>3561963.94</BUDGET>
<GROSS_PROFIT>3559010.238</GROSS_PROFIT>
<EXPENSES>3956565.37</EXPENSES>
<NET_INCOME>691244.28</NET_INCOME>
<REVENUE_M>4.64780966</REVENUE_M>
<PROFIT_M>3.559010238</PROFIT_M>
<INCOME_M>0.69124428</INCOME_M>
<PHARMA_REV_M>4.64780966</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.559010238</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69124428</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3502899.87</REVENUE>
<PREV_YEAR_REV>3248010.77</PREV_YEAR_REV>
<BUDGET>3176296.21</BUDGET>
<GROSS_PROFIT>2632196.475</GROSS_PROFIT>
<EXPENSES>3080809.75</EXPENSES>
<NET_INCOME>422090.14</NET_INCOME>
<REVENUE_M>3.50289987</REVENUE_M>
<PROFIT_M>2.632196475</PROFIT_M>
<INCOME_M>0.42209014</INCOME_M>
<PHARMA_REV_M>3.50289987</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.632196475</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42209014</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3292148.41</REVENUE>
<PREV_YEAR_REV>3091831.07</PREV_YEAR_REV>
<BUDGET>3130914.02</BUDGET>
<GROSS_PROFIT>2529448.326</GROSS_PROFIT>
<EXPENSES>2802323.13</EXPENSES>
<NET_INCOME>489825.27</NET_INCOME>
<REVENUE_M>3.29214841</REVENUE_M>
<PROFIT_M>2.529448326</PROFIT_M>
<INCOME_M>0.48982527</INCOME_M>
<PHARMA_REV_M>3.29214841</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.529448326</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48982527</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>8881574.93</REVENUE>
<PREV_YEAR_REV>8437496.18</PREV_YEAR_REV>
<BUDGET>8615127.68</BUDGET>
<GROSS_PROFIT>6690490.392</GROSS_PROFIT>
<EXPENSES>1.087539787E7</EXPENSES>
<NET_INCOME>1589801.91</NET_INCOME>
<REVENUE_M>8.88157493</REVENUE_M>
<PROFIT_M>6.690490392</PROFIT_M>
<INCOME_M>1.58980191</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5109981.34</REVENUE>
<PREV_YEAR_REV>4080169.71</PREV_YEAR_REV>
<BUDGET>4884768.76</BUDGET>
<GROSS_PROFIT>4174854.762</GROSS_PROFIT>
<EXPENSES>4422688.86</EXPENSES>
<NET_INCOME>687292.49</NET_INCOME>
<REVENUE_M>5.10998134</REVENUE_M>
<PROFIT_M>4.174854762</PROFIT_M>
<INCOME_M>0.68729249</INCOME_M>
<PHARMA_REV_M>5.10998134</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.174854762</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.68729249</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2990140.67</REVENUE>
<PREV_YEAR_REV>2502817.15</PREV_YEAR_REV>
<BUDGET>2851425.38</BUDGET>
<GROSS_PROFIT>2553580.14</GROSS_PROFIT>
<EXPENSES>2664215.34</EXPENSES>
<NET_INCOME>325925.33</NET_INCOME>
<REVENUE_M>2.99014067</REVENUE_M>
<PROFIT_M>2.55358014</PROFIT_M>
<INCOME_M>0.32592533</INCOME_M>
<PHARMA_REV_M>2.99014067</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.55358014</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32592533</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.129495115E7</REVENUE>
<PREV_YEAR_REV>1.016545603E7</PREV_YEAR_REV>
<BUDGET>1.073020359E7</BUDGET>
<GROSS_PROFIT>8508486.7</GROSS_PROFIT>
<EXPENSES>1.861805134E7</EXPENSES>
<NET_INCOME>1490933.55</NET_INCOME>
<REVENUE_M>11.29495115</REVENUE_M>
<PROFIT_M>8.5084867</PROFIT_M>
<INCOME_M>1.49093355</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>6597741.38</REVENUE>
<PREV_YEAR_REV>5937967.24</PREV_YEAR_REV>
<BUDGET>6267854.31</BUDGET>
<GROSS_PROFIT>4970078.574</GROSS_PROFIT>
<EXPENSES>1.087539787E7</EXPENSES>
<NET_INCOME>1180995.71</NET_INCOME>
<REVENUE_M>6.59774138</REVENUE_M>
<PROFIT_M>4.970078574</PROFIT_M>
<INCOME_M>1.18099571</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.184698402E7</REVENUE>
<PREV_YEAR_REV>1.966228562E7</PREV_YEAR_REV>
<BUDGET>1.948792002E7</BUDGET>
<GROSS_PROFIT>1.481159976E7</GROSS_PROFIT>
<EXPENSES>3.381362642E7</EXPENSES>
<NET_INCOME>3220593.96</NET_INCOME>
<REVENUE_M>21.84698402</REVENUE_M>
<PROFIT_M>14.81159976</PROFIT_M>
<INCOME_M>3.22059396</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.222474859E7</REVENUE>
<PREV_YEAR_REV>1.100227373E7</PREV_YEAR_REV>
<BUDGET>1.090470531E7</BUDGET>
<GROSS_PROFIT>8748457.95</GROSS_PROFIT>
<EXPENSES>1.89208305E7</EXPENSES>
<NET_INCOME>1246924.36</NET_INCOME>
<REVENUE_M>12.22474859</REVENUE_M>
<PROFIT_M>8.74845795</PROFIT_M>
<INCOME_M>1.24692436</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.003415957E7</REVENUE>
<PREV_YEAR_REV>2.853245159E7</PREV_YEAR_REV>
<BUDGET>2.913313478E7</BUDGET>
<GROSS_PROFIT>2.26247324E7</GROSS_PROFIT>
<EXPENSES>2.641450592E7</EXPENSES>
<NET_INCOME>4017046.4</NET_INCOME>
<REVENUE_M>30.03415957</REVENUE_M>
<PROFIT_M>22.6247324</PROFIT_M>
<INCOME_M>4.0170464</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2754850.39</REVENUE>
<PREV_YEAR_REV>2528058.28</PREV_YEAR_REV>
<BUDGET>1982129.04</BUDGET>
<GROSS_PROFIT>2423469.437</GROSS_PROFIT>
<EXPENSES>2261732.17</EXPENSES>
<NET_INCOME>493118.22</NET_INCOME>
<REVENUE_M>2.75485039</REVENUE_M>
<PROFIT_M>2.423469437</PROFIT_M>
<INCOME_M>0.49311822</INCOME_M>
<PHARMA_REV_M>2.75485039</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.423469437</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49311822</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1793568.35</REVENUE>
<PREV_YEAR_REV>1618700.17</PREV_YEAR_REV>
<BUDGET>1688933.01</BUDGET>
<GROSS_PROFIT>1572959.44</GROSS_PROFIT>
<EXPENSES>1472519.61</EXPENSES>
<NET_INCOME>321048.73</NET_INCOME>
<REVENUE_M>1.79356835</REVENUE_M>
<PROFIT_M>1.57295944</PROFIT_M>
<INCOME_M>0.32104873</INCOME_M>
<PHARMA_REV_M>1.79356835</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.57295944</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32104873</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1287566.72</REVENUE>
<PREV_YEAR_REV>1166305.89</PREV_YEAR_REV>
<BUDGET>1091662.85</BUDGET>
<GROSS_PROFIT>926137.0797</GROSS_PROFIT>
<EXPENSES>1156234.91</EXPENSES>
<NET_INCOME>131331.81</NET_INCOME>
<REVENUE_M>1.28756672</REVENUE_M>
<PROFIT_M>0.92613708</PROFIT_M>
<INCOME_M>0.13133181</INCOME_M>
<PHARMA_REV_M>1.28756672</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.92613708</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13133181</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.622243234E7</REVENUE>
<PREV_YEAR_REV>1.429612748E7</PREV_YEAR_REV>
<BUDGET>1.654688098E7</BUDGET>
<GROSS_PROFIT>1.322026339E7</GROSS_PROFIT>
<EXPENSES>1.443923678E7</EXPENSES>
<NET_INCOME>1783195.55</NET_INCOME>
<REVENUE_M>16.22243234</REVENUE_M>
<PROFIT_M>13.22026339</PROFIT_M>
<INCOME_M>1.78319555</INCOME_M>
<PHARMA_REV_M>16.22243234</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.22026339</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.78319555</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2197629.33</REVENUE>
<PREV_YEAR_REV>1923678.3</PREV_YEAR_REV>
<BUDGET>2252996.32</BUDGET>
<GROSS_PROFIT>1693163.511</GROSS_PROFIT>
<EXPENSES>1846008.63</EXPENSES>
<NET_INCOME>351620.69</NET_INCOME>
<REVENUE_M>2.19762933</REVENUE_M>
<PROFIT_M>1.693163511</PROFIT_M>
<INCOME_M>0.35162069</INCOME_M>
<PHARMA_REV_M>2.19762933</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.693163511</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35162069</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2209292.76</REVENUE>
<PREV_YEAR_REV>1885593.01</PREV_YEAR_REV>
<BUDGET>2373458.27</BUDGET>
<GROSS_PROFIT>1794498.045</GROSS_PROFIT>
<EXPENSES>2048014.39</EXPENSES>
<NET_INCOME>161278.37</NET_INCOME>
<REVENUE_M>2.20929276</REVENUE_M>
<PROFIT_M>1.794498045</PROFIT_M>
<INCOME_M>0.16127837</INCOME_M>
<PHARMA_REV_M>2.20929276</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.794498045</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16127837</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4198266.09</REVENUE>
<PREV_YEAR_REV>3848127.88</PREV_YEAR_REV>
<BUDGET>3540402.7</BUDGET>
<GROSS_PROFIT>3168089.541</GROSS_PROFIT>
<EXPENSES>3574715.2</EXPENSES>
<NET_INCOME>623550.9</NET_INCOME>
<REVENUE_M>4.19826609</REVENUE_M>
<PROFIT_M>3.168089541</PROFIT_M>
<INCOME_M>0.6235509</INCOME_M>
<PHARMA_REV_M>4.19826609</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.168089541</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6235509</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3414051.55</REVENUE>
<PREV_YEAR_REV>3117602.78</PREV_YEAR_REV>
<BUDGET>2450468.55</BUDGET>
<GROSS_PROFIT>2410879.47</GROSS_PROFIT>
<EXPENSES>2910411.28</EXPENSES>
<NET_INCOME>503640.27</NET_INCOME>
<REVENUE_M>3.41405155</REVENUE_M>
<PROFIT_M>2.41087947</PROFIT_M>
<INCOME_M>0.50364027</INCOME_M>
<PHARMA_REV_M>3.41405155</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.41087947</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50364027</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.833528051E7</REVENUE>
<PREV_YEAR_REV>1.661667565E7</PREV_YEAR_REV>
<BUDGET>1.650175246E7</BUDGET>
<GROSS_PROFIT>1.572892948E7</GROSS_PROFIT>
<EXPENSES>1.589450091E7</EXPENSES>
<NET_INCOME>2440779.61</NET_INCOME>
<REVENUE_M>18.33528051</REVENUE_M>
<PROFIT_M>15.72892948</PROFIT_M>
<INCOME_M>2.44077961</INCOME_M>
<PHARMA_REV_M>18.33528051</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.72892948</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.44077961</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2394600.32</REVENUE>
<PREV_YEAR_REV>2051365.79</PREV_YEAR_REV>
<BUDGET>2123689.59</BUDGET>
<GROSS_PROFIT>2060409.898</GROSS_PROFIT>
<EXPENSES>1965966.86</EXPENSES>
<NET_INCOME>428633.46</NET_INCOME>
<REVENUE_M>2.39460032</REVENUE_M>
<PROFIT_M>2.060409898</PROFIT_M>
<INCOME_M>0.42863346</INCOME_M>
<PHARMA_REV_M>2.39460032</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.060409898</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42863346</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4524080.87</REVENUE>
<PREV_YEAR_REV>3970666.32</PREV_YEAR_REV>
<BUDGET>4242398.49</BUDGET>
<GROSS_PROFIT>3410605.089</GROSS_PROFIT>
<EXPENSES>3924095.4</EXPENSES>
<NET_INCOME>599985.47</NET_INCOME>
<REVENUE_M>4.52408087</REVENUE_M>
<PROFIT_M>3.410605089</PROFIT_M>
<INCOME_M>0.59998547</INCOME_M>
<PHARMA_REV_M>4.52408087</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.410605089</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.59998547</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3763592.4</REVENUE>
<PREV_YEAR_REV>3262273.88</PREV_YEAR_REV>
<BUDGET>2903975.77</BUDGET>
<GROSS_PROFIT>2908250.286</GROSS_PROFIT>
<EXPENSES>3261843.97</EXPENSES>
<NET_INCOME>501748.44</NET_INCOME>
<REVENUE_M>3.7635924</REVENUE_M>
<PROFIT_M>2.908250286</PROFIT_M>
<INCOME_M>0.50174844</INCOME_M>
<PHARMA_REV_M>3.7635924</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.908250286</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50174844</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.251504258E7</REVENUE>
<PREV_YEAR_REV>1.119408417E7</PREV_YEAR_REV>
<BUDGET>1.226474173E7</BUDGET>
<GROSS_PROFIT>9779984.337</GROSS_PROFIT>
<EXPENSES>1.117639792E7</EXPENSES>
<NET_INCOME>1338644.66</NET_INCOME>
<REVENUE_M>12.51504258</REVENUE_M>
<PROFIT_M>9.779984337</PROFIT_M>
<INCOME_M>1.33864466</INCOME_M>
<PHARMA_REV_M>12.51504258</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.779984337</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.33864466</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9686537.18</REVENUE>
<PREV_YEAR_REV>1.525663891E7</PREV_YEAR_REV>
<BUDGET>8911614.22</BUDGET>
<GROSS_PROFIT>7947803.76</GROSS_PROFIT>
<EXPENSES>8383697.94</EXPENSES>
<NET_INCOME>1302839.25</NET_INCOME>
<REVENUE_M>9.68653718</REVENUE_M>
<PROFIT_M>7.94780376</PROFIT_M>
<INCOME_M>1.30283925</INCOME_M>
<PHARMA_REV_M>9.68653718</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.94780376</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.30283925</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6230418.84</REVENUE>
<PREV_YEAR_REV>5034115.86</PREV_YEAR_REV>
<BUDGET>5937980</BUDGET>
<GROSS_PROFIT>4955309.938</GROSS_PROFIT>
<EXPENSES>5313701.64</EXPENSES>
<NET_INCOME>916717.2</NET_INCOME>
<REVENUE_M>6.23041884</REVENUE_M>
<PROFIT_M>4.955309938</PROFIT_M>
<INCOME_M>0.9167172</INCOME_M>
<PHARMA_REV_M>6.23041884</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.955309938</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.9167172</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6064446.88</REVENUE>
<PREV_YEAR_REV>5676195.13</PREV_YEAR_REV>
<BUDGET>5821869.01</BUDGET>
<GROSS_PROFIT>3974265.523</GROSS_PROFIT>
<EXPENSES>5445873.3</EXPENSES>
<NET_INCOME>618573.58</NET_INCOME>
<REVENUE_M>6.06444688</REVENUE_M>
<PROFIT_M>3.974265523</PROFIT_M>
<INCOME_M>0.61857358</INCOME_M>
<PHARMA_REV_M>6.06444688</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.974265523</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61857358</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7260833.19</REVENUE>
<PREV_YEAR_REV>6890535.79</PREV_YEAR_REV>
<BUDGET>6970399.86</BUDGET>
<GROSS_PROFIT>4649111.492</GROSS_PROFIT>
<EXPENSES>6011969.88</EXPENSES>
<NET_INCOME>1248863.31</NET_INCOME>
<REVENUE_M>7.26083319</REVENUE_M>
<PROFIT_M>4.649111492</PROFIT_M>
<INCOME_M>1.24886331</INCOME_M>
<PHARMA_REV_M>7.26083319</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.649111492</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.24886331</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1218134.59</REVENUE>
<PREV_YEAR_REV>1145767.89</PREV_YEAR_REV>
<BUDGET>1386125.37</BUDGET>
<GROSS_PROFIT>784308.1414</GROSS_PROFIT>
<EXPENSES>1023233.06</EXPENSES>
<NET_INCOME>194901.53</NET_INCOME>
<REVENUE_M>1.21813459</REVENUE_M>
<PROFIT_M>0.784308141</PROFIT_M>
<INCOME_M>0.19490153</INCOME_M>
<PHARMA_REV_M>1.21813459</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.784308141</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19490153</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1484877.71</REVENUE>
<PREV_YEAR_REV>1387204.63</PREV_YEAR_REV>
<BUDGET>1675202.13</BUDGET>
<GROSS_PROFIT>1109203.65</GROSS_PROFIT>
<EXPENSES>1247297.28</EXPENSES>
<NET_INCOME>237580.43</NET_INCOME>
<REVENUE_M>1.48487771</REVENUE_M>
<PROFIT_M>1.10920365</PROFIT_M>
<INCOME_M>0.23758043</INCOME_M>
<PHARMA_REV_M>1.48487771</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.10920365</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23758043</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.130727583E7</REVENUE>
<PREV_YEAR_REV>1.014690294E7</PREV_YEAR_REV>
<BUDGET>1.243800342E7</BUDGET>
<GROSS_PROFIT>9684649.45</GROSS_PROFIT>
<EXPENSES>9786091.82</EXPENSES>
<NET_INCOME>1521184.02</NET_INCOME>
<REVENUE_M>11.30727583</REVENUE_M>
<PROFIT_M>9.68464945</PROFIT_M>
<INCOME_M>1.52118402</INCOME_M>
<PHARMA_REV_M>11.30727583</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.68464945</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.52118402</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1394942.11</REVENUE>
<PREV_YEAR_REV>1314928.7</PREV_YEAR_REV>
<BUDGET>1682770.51</BUDGET>
<GROSS_PROFIT>915082.02</GROSS_PROFIT>
<EXPENSES>1145247.47</EXPENSES>
<NET_INCOME>249694.64</NET_INCOME>
<REVENUE_M>1.39494211</REVENUE_M>
<PROFIT_M>0.91508202</PROFIT_M>
<INCOME_M>0.24969464</INCOME_M>
<PHARMA_REV_M>1.39494211</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.91508202</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24969464</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6082758.54</REVENUE>
<PREV_YEAR_REV>5512990.93</PREV_YEAR_REV>
<BUDGET>5839448.2</BUDGET>
<GROSS_PROFIT>4724417.733</GROSS_PROFIT>
<EXPENSES>5109517.17</EXPENSES>
<NET_INCOME>973241.37</NET_INCOME>
<REVENUE_M>6.08275854</REVENUE_M>
<PROFIT_M>4.724417733</PROFIT_M>
<INCOME_M>0.97324137</INCOME_M>
<PHARMA_REV_M>6.08275854</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.724417733</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.97324137</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.075929299E7</REVENUE>
<PREV_YEAR_REV>1.014748527E7</PREV_YEAR_REV>
<BUDGET>1.032892127E7</BUDGET>
<GROSS_PROFIT>7931514.735</GROSS_PROFIT>
<EXPENSES>9156624.93</EXPENSES>
<NET_INCOME>1602668.06</NET_INCOME>
<REVENUE_M>10.75929299</REVENUE_M>
<PROFIT_M>7.931514735</PROFIT_M>
<INCOME_M>1.60266806</INCOME_M>
<PHARMA_REV_M>10.75929299</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.931514735</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.60266806</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4847096.92</REVENUE>
<PREV_YEAR_REV>4569193.41</PREV_YEAR_REV>
<BUDGET>3549297.56</BUDGET>
<GROSS_PROFIT>3474949.781</GROSS_PROFIT>
<EXPENSES>4126610.12</EXPENSES>
<NET_INCOME>720486.81</NET_INCOME>
<REVENUE_M>4.84709692</REVENUE_M>
<PROFIT_M>3.474949781</PROFIT_M>
<INCOME_M>0.72048681</INCOME_M>
<PHARMA_REV_M>4.84709692</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.474949781</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.72048681</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3285053.99</REVENUE>
<PREV_YEAR_REV>3098433.33</PREV_YEAR_REV>
<BUDGET>3145890.32</BUDGET>
<GROSS_PROFIT>2510370.747</GROSS_PROFIT>
<EXPENSES>2796371.88</EXPENSES>
<NET_INCOME>488682.11</NET_INCOME>
<REVENUE_M>3.28505399</REVENUE_M>
<PROFIT_M>2.510370747</PROFIT_M>
<INCOME_M>0.48868211</INCOME_M>
<PHARMA_REV_M>3.28505399</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.510370747</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48868211</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3305045.81</REVENUE>
<PREV_YEAR_REV>3088129.72</PREV_YEAR_REV>
<BUDGET>3121610.92</BUDGET>
<GROSS_PROFIT>2645117.101</GROSS_PROFIT>
<EXPENSES>2866828.99</EXPENSES>
<NET_INCOME>438216.82</NET_INCOME>
<REVENUE_M>3.30504581</REVENUE_M>
<PROFIT_M>2.645117101</PROFIT_M>
<INCOME_M>0.43821682</INCOME_M>
<PHARMA_REV_M>3.30504581</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.645117101</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43821682</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.074648376E7</REVENUE>
<PREV_YEAR_REV>1.970915957E7</PREV_YEAR_REV>
<BUDGET>2.012408924E7</BUDGET>
<GROSS_PROFIT>1.562832621E7</GROSS_PROFIT>
<EXPENSES>1.698763037E7</EXPENSES>
<NET_INCOME>2749443.57</NET_INCOME>
<REVENUE_M>20.74648376</REVENUE_M>
<PROFIT_M>15.62832621</PROFIT_M>
<INCOME_M>2.74944357</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.356025435E7</REVENUE>
<PREV_YEAR_REV>3.188224163E7</PREV_YEAR_REV>
<BUDGET>3.255344672E7</BUDGET>
<GROSS_PROFIT>2.52809396E7</GROSS_PROFIT>
<EXPENSES>41094189</EXPENSES>
<NET_INCOME>5369640.7</NET_INCOME>
<REVENUE_M>33.56025435</REVENUE_M>
<PROFIT_M>25.2809396</PROFIT_M>
<INCOME_M>5.3696407</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.060233746E7</REVENUE>
<PREV_YEAR_REV>2.907222058E7</PREV_YEAR_REV>
<BUDGET>2.968426733E7</BUDGET>
<GROSS_PROFIT>2.30527408E7</GROSS_PROFIT>
<EXPENSES>3.747224994E7</EXPENSES>
<NET_INCOME>4049449.9</NET_INCOME>
<REVENUE_M>30.60233746</REVENUE_M>
<PROFIT_M>23.0527408</PROFIT_M>
<INCOME_M>4.0494499</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.289032656E7</REVENUE>
<PREV_YEAR_REV>3.645677758E7</PREV_YEAR_REV>
<BUDGET>4.160361676E7</BUDGET>
<GROSS_PROFIT>2.90783547E7</GROSS_PROFIT>
<EXPENSES>3.927239064E7</EXPENSES>
<NET_INCOME>6418558.82</NET_INCOME>
<REVENUE_M>42.89032656</REVENUE_M>
<PROFIT_M>29.0783547</PROFIT_M>
<INCOME_M>6.41855882</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.963783393E7</REVENUE>
<PREV_YEAR_REV>2.519215884E7</PREV_YEAR_REV>
<BUDGET>2.874869891E7</BUDGET>
<GROSS_PROFIT>2.232618031E7</GROSS_PROFIT>
<EXPENSES>2.587898055E7</EXPENSES>
<NET_INCOME>3927776.53</NET_INCOME>
<REVENUE_M>29.63783393</REVENUE_M>
<PROFIT_M>22.32618031</PROFIT_M>
<INCOME_M>3.92777653</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>26952750</REVENUE>
<PREV_YEAR_REV>2.29098375E7</PREV_YEAR_REV>
<BUDGET>2.61441675E7</BUDGET>
<GROSS_PROFIT>1.955152485E7</GROSS_PROFIT>
<EXPENSES>24257475</EXPENSES>
<NET_INCOME>3626043.3</NET_INCOME>
<REVENUE_M>26.95275</REVENUE_M>
<PROFIT_M>19.55152485</PROFIT_M>
<INCOME_M>3.6260433</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2506596.92</REVENUE>
<PREV_YEAR_REV>2039093.87</PREV_YEAR_REV>
<BUDGET>2396894.25</BUDGET>
<GROSS_PROFIT>1827860.605</GROSS_PROFIT>
<EXPENSES>2250924.04</EXPENSES>
<NET_INCOME>255672.89</NET_INCOME>
<REVENUE_M>2.50659692</REVENUE_M>
<PROFIT_M>1.827860605</PROFIT_M>
<INCOME_M>0.25567289</INCOME_M>
<PHARMA_REV_M>2.50659692</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.827860605</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25567289</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.766744614E7</REVENUE>
<PREV_YEAR_REV>2.490070153E7</PREV_YEAR_REV>
<BUDGET>2.467988154E7</BUDGET>
<GROSS_PROFIT>1.875769846E7</GROSS_PROFIT>
<EXPENSES>4.282223517E7</EXPENSES>
<NET_INCOME>3348726.62</NET_INCOME>
<REVENUE_M>27.66744614</REVENUE_M>
<PROFIT_M>18.75769846</PROFIT_M>
<INCOME_M>3.34872662</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>9552591.42</REVENUE>
<PREV_YEAR_REV>8597332.28</PREV_YEAR_REV>
<BUDGET>8521090.94</BUDGET>
<GROSS_PROFIT>6836168.761</GROSS_PROFIT>
<EXPENSES>1.478500452E7</EXPENSES>
<NET_INCOME>1643045.72</NET_INCOME>
<REVENUE_M>9.55259142</REVENUE_M>
<PROFIT_M>6.836168761</PROFIT_M>
<INCOME_M>1.64304572</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.884872744E7</REVENUE>
<PREV_YEAR_REV>1.790629106E7</PREV_YEAR_REV>
<BUDGET>1.828326561E7</BUDGET>
<GROSS_PROFIT>1.277887174E7</GROSS_PROFIT>
<EXPENSES>1.632678455E7</EXPENSES>
<NET_INCOME>2215816.66</NET_INCOME>
<REVENUE_M>18.84872744</REVENUE_M>
<PROFIT_M>12.77887174</PROFIT_M>
<INCOME_M>2.21581666</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5229799.26</REVENUE>
<PREV_YEAR_REV>4720254.88</PREV_YEAR_REV>
<BUDGET>3846904.7</BUDGET>
<GROSS_PROFIT>4097769.473</GROSS_PROFIT>
<EXPENSES>4525819.84</EXPENSES>
<NET_INCOME>703979.42</NET_INCOME>
<REVENUE_M>5.22979926</REVENUE_M>
<PROFIT_M>4.097769473</PROFIT_M>
<INCOME_M>0.70397942</INCOME_M>
<PHARMA_REV_M>5.22979926</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.097769473</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.70397942</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5272222.81</REVENUE>
<PREV_YEAR_REV>4788595.84</PREV_YEAR_REV>
<BUDGET>3930032.86</BUDGET>
<GROSS_PROFIT>4374281.599</GROSS_PROFIT>
<EXPENSES>4573342.54</EXPENSES>
<NET_INCOME>698880.28</NET_INCOME>
<REVENUE_M>5.27222281</REVENUE_M>
<PROFIT_M>4.374281599</PROFIT_M>
<INCOME_M>0.69888028</INCOME_M>
<PHARMA_REV_M>5.27222281</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.374281599</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69888028</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1936070.12</REVENUE>
<PREV_YEAR_REV>1756184.18</PREV_YEAR_REV>
<BUDGET>1721230.84</BUDGET>
<GROSS_PROFIT>1521673.675</GROSS_PROFIT>
<EXPENSES>1725038.48</EXPENSES>
<NET_INCOME>211031.64</NET_INCOME>
<REVENUE_M>1.93607012</REVENUE_M>
<PROFIT_M>1.521673675</PROFIT_M>
<INCOME_M>0.21103164</INCOME_M>
<PHARMA_REV_M>1.93607012</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.521673675</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21103164</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1163745.01</REVENUE>
<PREV_YEAR_REV>1036863.97</PREV_YEAR_REV>
<BUDGET>982788.39</BUDGET>
<GROSS_PROFIT>941469.72</GROSS_PROFIT>
<EXPENSES>1078791.63</EXPENSES>
<NET_INCOME>84953.39</NET_INCOME>
<REVENUE_M>1.16374501</REVENUE_M>
<PROFIT_M>0.94146972</PROFIT_M>
<INCOME_M>0.08495339</INCOME_M>
<PHARMA_REV_M>1.16374501</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.94146972</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.08495339</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>779790.58</REVENUE>
<PREV_YEAR_REV>700992.06</PREV_YEAR_REV>
<BUDGET>1154138.08</BUDGET>
<GROSS_PROFIT>692454.04</GROSS_PROFIT>
<EXPENSES>694793.41</EXPENSES>
<NET_INCOME>84997.17</NET_INCOME>
<REVENUE_M>0.77979058</REVENUE_M>
<PROFIT_M>0.69245404</PROFIT_M>
<INCOME_M>0.08499717</INCOME_M>
<PHARMA_REV_M>0.77979058</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.69245404</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.08499717</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4609606.48</REVENUE>
<PREV_YEAR_REV>4025826.87</PREV_YEAR_REV>
<BUDGET>4793431.56</BUDGET>
<GROSS_PROFIT>3894634.892</GROSS_PROFIT>
<EXPENSES>4003997.24</EXPENSES>
<NET_INCOME>605609.24</NET_INCOME>
<REVENUE_M>4.60960648</REVENUE_M>
<PROFIT_M>3.894634892</PROFIT_M>
<INCOME_M>0.60560924</INCOME_M>
<PHARMA_REV_M>4.60960648</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.894634892</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60560924</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1509605.01</REVENUE>
<PREV_YEAR_REV>1334127.26</PREV_YEAR_REV>
<BUDGET>2055147.63</BUDGET>
<GROSS_PROFIT>1203230.68</GROSS_PROFIT>
<EXPENSES>1310337.15</EXPENSES>
<NET_INCOME>199267.86</NET_INCOME>
<REVENUE_M>1.50960501</REVENUE_M>
<PROFIT_M>1.20323068</PROFIT_M>
<INCOME_M>0.19926786</INCOME_M>
<PHARMA_REV_M>1.50960501</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.20323068</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19926786</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1955180.77</REVENUE>
<PREV_YEAR_REV>1785357.56</PREV_YEAR_REV>
<BUDGET>1776044.74</BUDGET>
<GROSS_PROFIT>1584595.8</GROSS_PROFIT>
<EXPENSES>1812452.57</EXPENSES>
<NET_INCOME>142728.2</NET_INCOME>
<REVENUE_M>1.95518077</REVENUE_M>
<PROFIT_M>1.5845958</PROFIT_M>
<INCOME_M>0.1427282</INCOME_M>
<PHARMA_REV_M>1.95518077</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.5845958</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1427282</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1980426.84</REVENUE>
<PREV_YEAR_REV>1787437.24</PREV_YEAR_REV>
<BUDGET>1758601.49</BUDGET>
<GROSS_PROFIT>1528491.454</GROSS_PROFIT>
<EXPENSES>1778423.3</EXPENSES>
<NET_INCOME>202003.54</NET_INCOME>
<REVENUE_M>1.98042684</REVENUE_M>
<PROFIT_M>1.528491454</PROFIT_M>
<INCOME_M>0.20200354</INCOME_M>
<PHARMA_REV_M>1.98042684</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.528491454</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20200354</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3327060.24</REVENUE>
<PREV_YEAR_REV>3057324.29</PREV_YEAR_REV>
<BUDGET>2492388.88</BUDGET>
<GROSS_PROFIT>2392021.872</GROSS_PROFIT>
<EXPENSES>2925978.22</EXPENSES>
<NET_INCOME>401082.01</NET_INCOME>
<REVENUE_M>3.32706024</REVENUE_M>
<PROFIT_M>2.392021872</PROFIT_M>
<INCOME_M>0.40108201</INCOME_M>
<PHARMA_REV_M>3.32706024</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.392021872</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40108201</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6024209.8</REVENUE>
<PREV_YEAR_REV>5416578.07</PREV_YEAR_REV>
<BUDGET>5421788.82</BUDGET>
<GROSS_PROFIT>4879609.94</GROSS_PROFIT>
<EXPENSES>4945876.25</EXPENSES>
<NET_INCOME>1078333.55</NET_INCOME>
<REVENUE_M>6.0242098</REVENUE_M>
<PROFIT_M>4.87960994</PROFIT_M>
<INCOME_M>1.07833355</INCOME_M>
<PHARMA_REV_M>6.0242098</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.87960994</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.07833355</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2248382.97</REVENUE>
<PREV_YEAR_REV>1967708.97</PREV_YEAR_REV>
<BUDGET>2118708.9</BUDGET>
<GROSS_PROFIT>1698091.237</GROSS_PROFIT>
<EXPENSES>1951596.42</EXPENSES>
<NET_INCOME>296786.55</NET_INCOME>
<REVENUE_M>2.24838297</REVENUE_M>
<PROFIT_M>1.698091237</PROFIT_M>
<INCOME_M>0.29678655</INCOME_M>
<PHARMA_REV_M>2.24838297</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.698091237</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29678655</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>4564964.22</REVENUE>
<PREV_YEAR_REV>4000205.01</PREV_YEAR_REV>
<BUDGET>4247379.18</BUDGET>
<GROSS_PROFIT>3731795.301</GROSS_PROFIT>
<EXPENSES>3950173.41</EXPENSES>
<NET_INCOME>614790.81</NET_INCOME>
<REVENUE_M>4.56496422</REVENUE_M>
<PROFIT_M>3.731795301</PROFIT_M>
<INCOME_M>0.61479081</INCOME_M>
<PHARMA_REV_M>4.56496422</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.731795301</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61479081</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2223117.38</REVENUE>
<PREV_YEAR_REV>1912786.84</PREV_YEAR_REV>
<BUDGET>2123689.59</BUDGET>
<GROSS_PROFIT>1797279.246</GROSS_PROFIT>
<EXPENSES>1840741.19</EXPENSES>
<NET_INCOME>382376.19</NET_INCOME>
<REVENUE_M>2.22311738</REVENUE_M>
<PROFIT_M>1.797279246</PROFIT_M>
<INCOME_M>0.38237619</INCOME_M>
<PHARMA_REV_M>2.22311738</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.797279246</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38237619</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2076464.61</REVENUE>
<PREV_YEAR_REV>1866233.41</PREV_YEAR_REV>
<BUDGET>1521428.83</BUDGET>
<GROSS_PROFIT>1731979.134</GROSS_PROFIT>
<EXPENSES>1719312.7</EXPENSES>
<NET_INCOME>357151.91</NET_INCOME>
<REVENUE_M>2.07646461</REVENUE_M>
<PROFIT_M>1.731979134</PROFIT_M>
<INCOME_M>0.35715191</INCOME_M>
<PHARMA_REV_M>2.07646461</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.731979134</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35715191</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1590677.34</REVENUE>
<PREV_YEAR_REV>1373986</PREV_YEAR_REV>
<BUDGET>1528813.44</BUDGET>
<GROSS_PROFIT>1107063.704</GROSS_PROFIT>
<EXPENSES>1375935.9</EXPENSES>
<NET_INCOME>214741.44</NET_INCOME>
<REVENUE_M>1.59067734</REVENUE_M>
<PROFIT_M>1.107063704</PROFIT_M>
<INCOME_M>0.21474144</INCOME_M>
<PHARMA_REV_M>1.59067734</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.107063704</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21474144</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.283759673E7</REVENUE>
<PREV_YEAR_REV>1.126619431E7</PREV_YEAR_REV>
<BUDGET>11810589</BUDGET>
<GROSS_PROFIT>9330039.099</GROSS_PROFIT>
<EXPENSES>1.093107495E7</EXPENSES>
<NET_INCOME>1906521.79</NET_INCOME>
<REVENUE_M>12.83759673</REVENUE_M>
<PROFIT_M>9.330039099</PROFIT_M>
<INCOME_M>1.90652179</INCOME_M>
<PHARMA_REV_M>12.83759673</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.330039099</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.90652179</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>2.158760525E7</REVENUE>
<PREV_YEAR_REV>1.886196191E7</PREV_YEAR_REV>
<BUDGET>1.986059684E7</BUDGET>
<GROSS_PROFIT>1.800777611E7</GROSS_PROFIT>
<EXPENSES>1.948936919E7</EXPENSES>
<NET_INCOME>2098236.06</NET_INCOME>
<REVENUE_M>21.58760525</REVENUE_M>
<PROFIT_M>18.00777611</PROFIT_M>
<INCOME_M>2.09823606</INCOME_M>
<PHARMA_REV_M>21.58760525</PHARMA_REV_M>
<PHARMA_PROFIT_M>18.00777611</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.09823606</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2524496.63</REVENUE>
<PREV_YEAR_REV>2170209.86</PREV_YEAR_REV>
<BUDGET>2448761.73</BUDGET>
<GROSS_PROFIT>2127645.758</GROSS_PROFIT>
<EXPENSES>2191263.07</EXPENSES>
<NET_INCOME>333233.55</NET_INCOME>
<REVENUE_M>2.52449663</REVENUE_M>
<PROFIT_M>2.127645758</PROFIT_M>
<INCOME_M>0.33323355</INCOME_M>
<PHARMA_REV_M>2.52449663</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.127645758</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33323355</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3713244.52</REVENUE>
<PREV_YEAR_REV>3252487.96</PREV_YEAR_REV>
<BUDGET>3601847.18</BUDGET>
<GROSS_PROFIT>2745364.329</GROSS_PROFIT>
<EXPENSES>3264177.06</EXPENSES>
<NET_INCOME>449067.45</NET_INCOME>
<REVENUE_M>3.71324452</REVENUE_M>
<PROFIT_M>2.745364329</PROFIT_M>
<INCOME_M>0.44906745</INCOME_M>
<PHARMA_REV_M>3.71324452</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.745364329</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44906745</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1642776.6</REVENUE>
<PREV_YEAR_REV>1470138.26</PREV_YEAR_REV>
<BUDGET>2080411.46</BUDGET>
<GROSS_PROFIT>1345894.005</GROSS_PROFIT>
<EXPENSES>1360219.02</EXPENSES>
<NET_INCOME>282557.57</NET_INCOME>
<REVENUE_M>1.6427766</REVENUE_M>
<PROFIT_M>1.345894005</PROFIT_M>
<INCOME_M>0.28255757</INCOME_M>
<PHARMA_REV_M>1.6427766</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.345894005</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28255757</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1567017.25</REVENUE>
<PREV_YEAR_REV>1331818.16</PREV_YEAR_REV>
<BUDGET>2094541.06</BUDGET>
<GROSS_PROFIT>1162499.582</GROSS_PROFIT>
<EXPENSES>1297490.28</EXPENSES>
<NET_INCOME>269526.97</NET_INCOME>
<REVENUE_M>1.56701725</REVENUE_M>
<PROFIT_M>1.162499582</PROFIT_M>
<INCOME_M>0.26952697</INCOME_M>
<PHARMA_REV_M>1.56701725</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.162499582</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26952697</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.658615585E7</REVENUE>
<PREV_YEAR_REV>1.430185902E7</PREV_YEAR_REV>
<BUDGET>1.608857117E7</BUDGET>
<GROSS_PROFIT>1.316696183E7</GROSS_PROFIT>
<EXPENSES>1.472590648E7</EXPENSES>
<NET_INCOME>1860249.37</NET_INCOME>
<REVENUE_M>16.58615585</REVENUE_M>
<PROFIT_M>13.16696183</PROFIT_M>
<INCOME_M>1.86024937</INCOME_M>
<PHARMA_REV_M>16.58615585</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.16696183</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.86024937</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5903952.94</REVENUE>
<PREV_YEAR_REV>5118161.59</PREV_YEAR_REV>
<BUDGET>5726834.35</BUDGET>
<GROSS_PROFIT>5008913.675</GROSS_PROFIT>
<EXPENSES>5260422.07</EXPENSES>
<NET_INCOME>643530.87</NET_INCOME>
<REVENUE_M>5.90395294</REVENUE_M>
<PROFIT_M>5.008913675</PROFIT_M>
<INCOME_M>0.64353087</INCOME_M>
<PHARMA_REV_M>5.90395294</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.008913675</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.64353087</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>6001479.2</REVENUE>
<PREV_YEAR_REV>5238845.47</PREV_YEAR_REV>
<BUDGET>4741014.56</BUDGET>
<GROSS_PROFIT>4272618.648</GROSS_PROFIT>
<EXPENSES>5277299.3</EXPENSES>
<NET_INCOME>724179.9</NET_INCOME>
<REVENUE_M>6.0014792</REVENUE_M>
<PROFIT_M>4.272618648</PROFIT_M>
<INCOME_M>0.7241799</INCOME_M>
<PHARMA_REV_M>6.0014792</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.272618648</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.7241799</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3970758.55</REVENUE>
<PREV_YEAR_REV>3599893.67</PREV_YEAR_REV>
<BUDGET>3500387.92</BUDGET>
<GROSS_PROFIT>3006975.51</GROSS_PROFIT>
<EXPENSES>3532964.96</EXPENSES>
<NET_INCOME>437793.58</NET_INCOME>
<REVENUE_M>3.97075855</REVENUE_M>
<PROFIT_M>3.00697551</PROFIT_M>
<INCOME_M>0.43779358</INCOME_M>
<PHARMA_REV_M>3.97075855</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.00697551</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43779358</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4051604.71</REVENUE>
<PREV_YEAR_REV>3697916.46</PREV_YEAR_REV>
<BUDGET>3568276.35</BUDGET>
<GROSS_PROFIT>3278331.83</GROSS_PROFIT>
<EXPENSES>3514306.92</EXPENSES>
<NET_INCOME>537297.79</NET_INCOME>
<REVENUE_M>4.05160471</REVENUE_M>
<PROFIT_M>3.27833183</PROFIT_M>
<INCOME_M>0.53729779</INCOME_M>
<PHARMA_REV_M>4.05160471</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.27833183</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53729779</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3146936.85</REVENUE>
<PREV_YEAR_REV>2866317.55</PREV_YEAR_REV>
<BUDGET>2230841.92</BUDGET>
<GROSS_PROFIT>2424711.211</GROSS_PROFIT>
<EXPENSES>2798654.24</EXPENSES>
<NET_INCOME>348282.62</NET_INCOME>
<REVENUE_M>3.14693685</REVENUE_M>
<PROFIT_M>2.424711211</PROFIT_M>
<INCOME_M>0.34828262</INCOME_M>
<PHARMA_REV_M>3.14693685</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.424711211</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34828262</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1587057.03</REVENUE>
<PREV_YEAR_REV>1425210.16</PREV_YEAR_REV>
<BUDGET>1101861.51</BUDGET>
<GROSS_PROFIT>1322018.51</GROSS_PROFIT>
<EXPENSES>1302973.82</EXPENSES>
<NET_INCOME>284083.21</NET_INCOME>
<REVENUE_M>1.58705703</REVENUE_M>
<PROFIT_M>1.32201851</PROFIT_M>
<INCOME_M>0.28408321</INCOME_M>
<PHARMA_REV_M>1.58705703</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.32201851</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28408321</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.281957161E7</REVENUE>
<PREV_YEAR_REV>1.175147731E7</PREV_YEAR_REV>
<BUDGET>1.153761444E7</BUDGET>
<GROSS_PROFIT>9725701.788</GROSS_PROFIT>
<EXPENSES>1.127156729E7</EXPENSES>
<NET_INCOME>1548004.32</NET_INCOME>
<REVENUE_M>12.81957161</REVENUE_M>
<PROFIT_M>9.725701788</PROFIT_M>
<INCOME_M>1.54800432</INCOME_M>
<PHARMA_REV_M>12.81957161</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.725701788</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.54800432</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.753814486E7</REVENUE>
<PREV_YEAR_REV>1.599326802E7</PREV_YEAR_REV>
<BUDGET>1.578433037E7</BUDGET>
<GROSS_PROFIT>1.501574786E7</GROSS_PROFIT>
<EXPENSES>1.520599621E7</EXPENSES>
<NET_INCOME>2332148.64</NET_INCOME>
<REVENUE_M>17.53814486</REVENUE_M>
<PROFIT_M>15.01574786</PROFIT_M>
<INCOME_M>2.33214864</INCOME_M>
<PHARMA_REV_M>17.53814486</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.01574786</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.33214864</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2246616.18</REVENUE>
<PREV_YEAR_REV>1934020.45</PREV_YEAR_REV>
<BUDGET>2121766.28</BUDGET>
<GROSS_PROFIT>1835485.42</GROSS_PROFIT>
<EXPENSES>1887157.59</EXPENSES>
<NET_INCOME>359458.59</NET_INCOME>
<REVENUE_M>2.24661618</REVENUE_M>
<PROFIT_M>1.83548542</PROFIT_M>
<INCOME_M>0.35945859</INCOME_M>
<PHARMA_REV_M>2.24661618</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.83548542</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35945859</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2424759.23</REVENUE>
<PREV_YEAR_REV>2202264.45</PREV_YEAR_REV>
<BUDGET>2159320.68</BUDGET>
<GROSS_PROFIT>1779124.657</GROSS_PROFIT>
<EXPENSES>2007700.64</EXPENSES>
<NET_INCOME>417058.59</NET_INCOME>
<REVENUE_M>2.42475923</REVENUE_M>
<PROFIT_M>1.779124657</PROFIT_M>
<INCOME_M>0.41705859</INCOME_M>
<PHARMA_REV_M>2.42475923</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.779124657</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41705859</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1892613.3</REVENUE>
<PREV_YEAR_REV>1674982.79</PREV_YEAR_REV>
<BUDGET>1523823.84</BUDGET>
<GROSS_PROFIT>1582224.715</GROSS_PROFIT>
<EXPENSES>1754452.53</EXPENSES>
<NET_INCOME>138160.77</NET_INCOME>
<REVENUE_M>1.8926133</REVENUE_M>
<PROFIT_M>1.582224715</PROFIT_M>
<INCOME_M>0.13816077</INCOME_M>
<PHARMA_REV_M>1.8926133</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.582224715</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13816077</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2146834.5</REVENUE>
<PREV_YEAR_REV>1836926.61</PREV_YEAR_REV>
<BUDGET>2346247.97</BUDGET>
<GROSS_PROFIT>1679039.262</GROSS_PROFIT>
<EXPENSES>1869892.85</EXPENSES>
<NET_INCOME>276941.65</NET_INCOME>
<REVENUE_M>2.1468345</REVENUE_M>
<PROFIT_M>1.679039262</PROFIT_M>
<INCOME_M>0.27694165</INCOME_M>
<PHARMA_REV_M>2.1468345</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.679039262</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27694165</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1985877.81</REVENUE>
<PREV_YEAR_REV>1708502.44</PREV_YEAR_REV>
<BUDGET>2346247.97</BUDGET>
<GROSS_PROFIT>1553035.882</GROSS_PROFIT>
<EXPENSES>1783318.27</EXPENSES>
<NET_INCOME>202559.54</NET_INCOME>
<REVENUE_M>1.98587781</REVENUE_M>
<PROFIT_M>1.553035882</PROFIT_M>
<INCOME_M>0.20255954</INCOME_M>
<PHARMA_REV_M>1.98587781</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.553035882</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20255954</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2943977.64</REVENUE>
<PREV_YEAR_REV>2572743.26</PREV_YEAR_REV>
<BUDGET>2976290.16</BUDGET>
<GROSS_PROFIT>2338900.865</GROSS_PROFIT>
<EXPENSES>2618992.31</EXPENSES>
<NET_INCOME>324985.33</NET_INCOME>
<REVENUE_M>2.94397764</REVENUE_M>
<PROFIT_M>2.338900865</PROFIT_M>
<INCOME_M>0.32498533</INCOME_M>
<PHARMA_REV_M>2.94397764</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.338900865</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32498533</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4425449.18</REVENUE>
<PREV_YEAR_REV>3906485.63</PREV_YEAR_REV>
<BUDGET>4292685.7</BUDGET>
<GROSS_PROFIT>3590135.349</GROSS_PROFIT>
<EXPENSES>3936419.24</EXPENSES>
<NET_INCOME>489029.93</NET_INCOME>
<REVENUE_M>4.42544918</REVENUE_M>
<PROFIT_M>3.590135349</PROFIT_M>
<INCOME_M>0.48902993</INCOME_M>
<PHARMA_REV_M>4.42544918</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.590135349</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48902993</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1912157.89</REVENUE>
<PREV_YEAR_REV>1698895.53</PREV_YEAR_REV>
<BUDGET>1854793.15</BUDGET>
<GROSS_PROFIT>1623422.05</GROSS_PROFIT>
<EXPENSES>1659753.05</EXPENSES>
<NET_INCOME>252404.84</NET_INCOME>
<REVENUE_M>1.91215789</REVENUE_M>
<PROFIT_M>1.62342205</PROFIT_M>
<INCOME_M>0.25240484</INCOME_M>
<PHARMA_REV_M>1.91215789</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.62342205</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25240484</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3678310.23</REVENUE>
<PREV_YEAR_REV>3207235.3</PREV_YEAR_REV>
<BUDGET>3567960.92</BUDGET>
<GROSS_PROFIT>2840613.552</GROSS_PROFIT>
<EXPENSES>3131871.11</EXPENSES>
<NET_INCOME>546439.11</NET_INCOME>
<REVENUE_M>3.67831023</REVENUE_M>
<PROFIT_M>2.840613552</PROFIT_M>
<INCOME_M>0.54643911</INCOME_M>
<PHARMA_REV_M>3.67831023</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.840613552</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54643911</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.311399057E7</REVENUE>
<PREV_YEAR_REV>1.130727583E7</PREV_YEAR_REV>
<BUDGET>1.272057085E7</BUDGET>
<GROSS_PROFIT>1.08260838E7</GROSS_PROFIT>
<EXPENSES>1.134916579E7</EXPENSES>
<NET_INCOME>1764824.77</NET_INCOME>
<REVENUE_M>13.11399057</REVENUE_M>
<PROFIT_M>10.8260838</PROFIT_M>
<INCOME_M>1.76482477</INCOME_M>
<PHARMA_REV_M>13.11399057</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.8260838</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.76482477</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3194658.93</REVENUE>
<PREV_YEAR_REV>2753304.26</PREV_YEAR_REV>
<BUDGET>2408747.22</BUDGET>
<GROSS_PROFIT>2716801.848</GROSS_PROFIT>
<EXPENSES>2846441.11</EXPENSES>
<NET_INCOME>348217.82</NET_INCOME>
<REVENUE_M>3.19465893</REVENUE_M>
<PROFIT_M>2.716801848</PROFIT_M>
<INCOME_M>0.34821782</INCOME_M>
<PHARMA_REV_M>3.19465893</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.716801848</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34821782</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3955172.29</REVENUE>
<PREV_YEAR_REV>3254485.06</PREV_YEAR_REV>
<BUDGET>3915620.57</BUDGET>
<GROSS_PROFIT>2882686.508</GROSS_PROFIT>
<EXPENSES>3367603.35</EXPENSES>
<NET_INCOME>587568.94</NET_INCOME>
<REVENUE_M>3.95517229</REVENUE_M>
<PROFIT_M>2.882686508</PROFIT_M>
<INCOME_M>0.58756894</INCOME_M>
<PHARMA_REV_M>3.95517229</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.882686508</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58756894</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3924972.45</REVENUE>
<PREV_YEAR_REV>3169183.93</PREV_YEAR_REV>
<BUDGET>3885722.73</BUDGET>
<GROSS_PROFIT>3305522.23</GROSS_PROFIT>
<EXPENSES>3403487.98</EXPENSES>
<NET_INCOME>521484.47</NET_INCOME>
<REVENUE_M>3.92497245</REVENUE_M>
<PROFIT_M>3.30552223</PROFIT_M>
<INCOME_M>0.52148447</INCOME_M>
<PHARMA_REV_M>3.92497245</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.30552223</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52148447</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3138534</REVENUE>
<PREV_YEAR_REV>2597128.63</PREV_YEAR_REV>
<BUDGET>3107148.66</BUDGET>
<GROSS_PROFIT>2082251.764</GROSS_PROFIT>
<EXPENSES>2675150.98</EXPENSES>
<NET_INCOME>463383.02</NET_INCOME>
<REVENUE_M>3.138534</REVENUE_M>
<PROFIT_M>2.082251764</PROFIT_M>
<INCOME_M>0.46338302</INCOME_M>
<PHARMA_REV_M>3.138534</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.082251764</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46338302</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>2.212634499E7</REVENUE>
<PREV_YEAR_REV>1.777364135E7</PREV_YEAR_REV>
<BUDGET>2.190508155E7</BUDGET>
<GROSS_PROFIT>1.698970386E7</GROSS_PROFIT>
<EXPENSES>1.942791767E7</EXPENSES>
<NET_INCOME>2698427.32</NET_INCOME>
<REVENUE_M>22.12634499</REVENUE_M>
<PROFIT_M>16.98970386</PROFIT_M>
<INCOME_M>2.69842732</INCOME_M>
<PHARMA_REV_M>22.12634499</PHARMA_REV_M>
<PHARMA_PROFIT_M>16.98970386</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.69842732</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7479854</REVENUE>
<PREV_YEAR_REV>5983500.78</PREV_YEAR_REV>
<BUDGET>7105861.31</BUDGET>
<GROSS_PROFIT>5406334.024</GROSS_PROFIT>
<EXPENSES>6653922.44</EXPENSES>
<NET_INCOME>825931.56</NET_INCOME>
<REVENUE_M>7.479854</REVENUE_M>
<PROFIT_M>5.406334024</PROFIT_M>
<INCOME_M>0.82593156</INCOME_M>
<PHARMA_REV_M>7.479854</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.406334024</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.82593156</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>7699212.13</REVENUE>
<PREV_YEAR_REV>6184011.5</PREV_YEAR_REV>
<BUDGET>7314251.52</BUDGET>
<GROSS_PROFIT>5878868.632</GROSS_PROFIT>
<EXPENSES>6664002.31</EXPENSES>
<NET_INCOME>1035209.82</NET_INCOME>
<REVENUE_M>7.69921213</REVENUE_M>
<PROFIT_M>5.878868632</PROFIT_M>
<INCOME_M>1.03520982</INCOME_M>
<PHARMA_REV_M>7.69921213</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.878868632</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.03520982</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2913473.88</REVENUE>
<PREV_YEAR_REV>2336105.42</PREV_YEAR_REV>
<BUDGET>2622126.49</BUDGET>
<GROSS_PROFIT>2375530.055</GROSS_PROFIT>
<EXPENSES>2595905.22</EXPENSES>
<NET_INCOME>317568.65</NET_INCOME>
<REVENUE_M>2.91347388</REVENUE_M>
<PROFIT_M>2.375530055</PROFIT_M>
<INCOME_M>0.31756865</INCOME_M>
<PHARMA_REV_M>2.91347388</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.375530055</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31756865</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>8274309</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>7612364.28</BUDGET>
<GROSS_PROFIT>6921571.28</GROSS_PROFIT>
<EXPENSES>7172074.13</EXPENSES>
<NET_INCOME>1102234.87</NET_INCOME>
<REVENUE_M>8.274309</REVENUE_M>
<PROFIT_M>6.92157128</PROFIT_M>
<INCOME_M>1.10223487</INCOME_M>
<PHARMA_REV_M>8.274309</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.92157128</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.10223487</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6942357.49</REVENUE>
<PREV_YEAR_REV>7468145.56</PREV_YEAR_REV>
<BUDGET>8226968.89</BUDGET>
<GROSS_PROFIT>7095818.799</GROSS_PROFIT>
<EXPENSES>8030237.03</EXPENSES>
<NET_INCOME>912120.46</NET_INCOME>
<REVENUE_M>6.94235749</REVENUE_M>
<PROFIT_M>7.095818799</PROFIT_M>
<INCOME_M>0.91212046</INCOME_M>
<PHARMA_REV_M>6.94235749</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.095818799</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.91212046</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4197719.02</REVENUE>
<PREV_YEAR_REV>3936163.06</PREV_YEAR_REV>
<BUDGET>3812098.74</BUDGET>
<GROSS_PROFIT>2976905.428</GROSS_PROFIT>
<EXPENSES>3632869.03</EXPENSES>
<NET_INCOME>564849.98</NET_INCOME>
<REVENUE_M>4.19771902</REVENUE_M>
<PROFIT_M>2.976905428</PROFIT_M>
<INCOME_M>0.56484998</INCOME_M>
<PHARMA_REV_M>4.19771902</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.976905428</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56484998</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2876432.14</REVENUE>
<PREV_YEAR_REV>2680239.32</PREV_YEAR_REV>
<BUDGET>3402136.67</BUDGET>
<GROSS_PROFIT>1891582.592</GROSS_PROFIT>
<EXPENSES>2558878.22</EXPENSES>
<NET_INCOME>317553.91</NET_INCOME>
<REVENUE_M>2.87643214</REVENUE_M>
<PROFIT_M>1.891582592</PROFIT_M>
<INCOME_M>0.31755391</INCOME_M>
<PHARMA_REV_M>2.87643214</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.891582592</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31755391</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4443170.2</REVENUE>
<PREV_YEAR_REV>4143747.23</PREV_YEAR_REV>
<BUDGET>5091904.4</BUDGET>
<GROSS_PROFIT>3146144.34</GROSS_PROFIT>
<EXPENSES>4011132.16</EXPENSES>
<NET_INCOME>432038.04</NET_INCOME>
<REVENUE_M>4.4431702</REVENUE_M>
<PROFIT_M>3.14614434</PROFIT_M>
<INCOME_M>0.43203804</INCOME_M>
<PHARMA_REV_M>4.4431702</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.14614434</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43203804</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.12572572E7</REVENUE>
<PREV_YEAR_REV>1.010431413E7</PREV_YEAR_REV>
<BUDGET>1.238298292E7</BUDGET>
<GROSS_PROFIT>9270619.411</GROSS_PROFIT>
<EXPENSES>9746406.04</EXPENSES>
<NET_INCOME>1510851.16</NET_INCOME>
<REVENUE_M>11.2572572</REVENUE_M>
<PROFIT_M>9.270619411</PROFIT_M>
<INCOME_M>1.51085116</INCOME_M>
<PHARMA_REV_M>11.2572572</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.270619411</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.51085116</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1401922.12</REVENUE>
<PREV_YEAR_REV>1286178.89</PREV_YEAR_REV>
<BUDGET>1676720.65</BUDGET>
<GROSS_PROFIT>875782.1573</GROSS_PROFIT>
<EXPENSES>1258926.07</EXPENSES>
<NET_INCOME>142996.06</NET_INCOME>
<REVENUE_M>1.40192212</REVENUE_M>
<PROFIT_M>0.875782157</PROFIT_M>
<INCOME_M>0.14299606</INCOME_M>
<PHARMA_REV_M>1.40192212</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.875782157</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14299606</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1451707.53</REVENUE>
<PREV_YEAR_REV>1361558.73</PREV_YEAR_REV>
<BUDGET>1672788.23</BUDGET>
<GROSS_PROFIT>1013654.788</GROSS_PROFIT>
<EXPENSES>1202013.84</EXPENSES>
<NET_INCOME>249693.7</NET_INCOME>
<REVENUE_M>1.45170753</REVENUE_M>
<PROFIT_M>1.013654788</PROFIT_M>
<INCOME_M>0.2496937</INCOME_M>
<PHARMA_REV_M>1.45170753</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.013654788</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2496937</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2135570.05</REVENUE>
<PREV_YEAR_REV>1990987.08</PREV_YEAR_REV>
<BUDGET>2163081.28</BUDGET>
<GROSS_PROFIT>1387770.246</GROSS_PROFIT>
<EXPENSES>1818619.3</EXPENSES>
<NET_INCOME>316950.75</NET_INCOME>
<REVENUE_M>2.13557005</REVENUE_M>
<PROFIT_M>1.387770246</PROFIT_M>
<INCOME_M>0.31695075</INCOME_M>
<PHARMA_REV_M>2.13557005</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.387770246</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31695075</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2183770.27</REVENUE>
<PREV_YEAR_REV>2031247.36</PREV_YEAR_REV>
<BUDGET>2292781.47</BUDGET>
<GROSS_PROFIT>1524578.962</GROSS_PROFIT>
<EXPENSES>1892026.53</EXPENSES>
<NET_INCOME>291743.74</NET_INCOME>
<REVENUE_M>2.18377027</REVENUE_M>
<PROFIT_M>1.524578962</PROFIT_M>
<INCOME_M>0.29174374</INCOME_M>
<PHARMA_REV_M>2.18377027</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.524578962</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29174374</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5914404.15</REVENUE>
<PREV_YEAR_REV>5346692.36</PREV_YEAR_REV>
<BUDGET>5677827.99</BUDGET>
<GROSS_PROFIT>4199226.95</GROSS_PROFIT>
<EXPENSES>5269734.1</EXPENSES>
<NET_INCOME>644670.05</NET_INCOME>
<REVENUE_M>5.91440415</REVENUE_M>
<PROFIT_M>4.19922695</PROFIT_M>
<INCOME_M>0.64467005</INCOME_M>
<PHARMA_REV_M>5.91440415</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.19922695</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.64467005</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3908618.39</REVENUE>
<PREV_YEAR_REV>3512258.86</PREV_YEAR_REV>
<BUDGET>4024927.07</BUDGET>
<GROSS_PROFIT>2550697.898</GROSS_PROFIT>
<EXPENSES>3442286.59</EXPENSES>
<NET_INCOME>466331.8</NET_INCOME>
<REVENUE_M>3.90861839</REVENUE_M>
<PROFIT_M>2.550697898</PROFIT_M>
<INCOME_M>0.4663318</INCOME_M>
<PHARMA_REV_M>3.90861839</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.550697898</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4663318</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2236659.48</REVENUE>
<PREV_YEAR_REV>2096920.68</PREV_YEAR_REV>
<BUDGET>1765329.95</BUDGET>
<GROSS_PROFIT>1874096.973</GROSS_PROFIT>
<EXPENSES>2073383.34</EXPENSES>
<NET_INCOME>163276.14</NET_INCOME>
<REVENUE_M>2.23665948</REVENUE_M>
<PROFIT_M>1.874096973</PROFIT_M>
<INCOME_M>0.16327614</INCOME_M>
<PHARMA_REV_M>2.23665948</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.874096973</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16327614</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1534625.83</REVENUE>
<PREV_YEAR_REV>1416137.59</PREV_YEAR_REV>
<BUDGET>1561222.69</BUDGET>
<GROSS_PROFIT>1327451.34</GROSS_PROFIT>
<EXPENSES>1289085.69</EXPENSES>
<NET_INCOME>245540.13</NET_INCOME>
<REVENUE_M>1.53462583</REVENUE_M>
<PROFIT_M>1.32745134</PROFIT_M>
<INCOME_M>0.24554013</INCOME_M>
<PHARMA_REV_M>1.53462583</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.32745134</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24554013</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5052751.73</REVENUE>
<PREV_YEAR_REV>4716935.04</PREV_YEAR_REV>
<BUDGET>4745455.23</BUDGET>
<GROSS_PROFIT>4175291.84</GROSS_PROFIT>
<EXPENSES>4562722.59</EXPENSES>
<NET_INCOME>490029.13</NET_INCOME>
<REVENUE_M>5.05275173</REVENUE_M>
<PROFIT_M>4.17529184</PROFIT_M>
<INCOME_M>0.49002913</INCOME_M>
<PHARMA_REV_M>5.05275173</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.17529184</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49002913</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1605493.03</REVENUE>
<PREV_YEAR_REV>1475460.68</PREV_YEAR_REV>
<BUDGET>1568276.13</BUDGET>
<GROSS_PROFIT>1268981.69</GROSS_PROFIT>
<EXPENSES>1441732.74</EXPENSES>
<NET_INCOME>163760.29</NET_INCOME>
<REVENUE_M>1.60549303</REVENUE_M>
<PROFIT_M>1.26898169</PROFIT_M>
<INCOME_M>0.16376029</INCOME_M>
<PHARMA_REV_M>1.60549303</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.26898169</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16376029</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3371393.64</REVENUE>
<PREV_YEAR_REV>3125691.41</PREV_YEAR_REV>
<BUDGET>3122389</BUDGET>
<GROSS_PROFIT>2932632.63</GROSS_PROFIT>
<EXPENSES>2922716.63</EXPENSES>
<NET_INCOME>448677.01</NET_INCOME>
<REVENUE_M>3.37139364</REVENUE_M>
<PROFIT_M>2.93263263</PROFIT_M>
<INCOME_M>0.44867701</INCOME_M>
<PHARMA_REV_M>3.37139364</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.93263263</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.44867701</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.356097968E7</REVENUE>
<PREV_YEAR_REV>1.28829307E7</PREV_YEAR_REV>
<BUDGET>1.315415029E7</BUDGET>
<GROSS_PROFIT>1.021548599E7</GROSS_PROFIT>
<EXPENSES>1.145866518E7</EXPENSES>
<NET_INCOME>2427415.36</NET_INCOME>
<REVENUE_M>13.56097968</REVENUE_M>
<PROFIT_M>10.21548599</PROFIT_M>
<INCOME_M>2.42741536</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>8458642.79</REVENUE>
<PREV_YEAR_REV>8035710.65</PREV_YEAR_REV>
<BUDGET>8204883.51</BUDGET>
<GROSS_PROFIT>6371895.614</GROSS_PROFIT>
<EXPENSES>1.087539787E7</EXPENSES>
<NET_INCOME>1514097.06</NET_INCOME>
<REVENUE_M>8.45864279</REVENUE_M>
<PROFIT_M>6.371895614</PROFIT_M>
<INCOME_M>1.51409706</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.770733572E7</REVENUE>
<PREV_YEAR_REV>2.632196894E7</PREV_YEAR_REV>
<BUDGET>2.687611565E7</BUDGET>
<GROSS_PROFIT>20871936</GROSS_PROFIT>
<EXPENSES>3.392734988E7</EXPENSES>
<NET_INCOME>2699308.81</NET_INCOME>
<REVENUE_M>27.70733572</REVENUE_M>
<PROFIT_M>20.871936</PROFIT_M>
<INCOME_M>2.69930881</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.618928346E7</REVENUE>
<PREV_YEAR_REV>2.226089094E7</PREV_YEAR_REV>
<BUDGET>2.540360496E7</BUDGET>
<GROSS_PROFIT>1.70979356E7</GROSS_PROFIT>
<EXPENSES>2.357035512E7</EXPENSES>
<NET_INCOME>3168121.05</NET_INCOME>
<REVENUE_M>26.18928346</REVENUE_M>
<PROFIT_M>17.0979356</PROFIT_M>
<INCOME_M>3.16812105</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.63895589E7</REVENUE>
<PREV_YEAR_REV>1.393112507E7</PREV_YEAR_REV>
<BUDGET>1.589787213E7</BUDGET>
<GROSS_PROFIT>1.129453672E7</GROSS_PROFIT>
<EXPENSES>1.475060301E7</EXPENSES>
<NET_INCOME>1671735.01</NET_INCOME>
<REVENUE_M>16.3895589</REVENUE_M>
<PROFIT_M>11.29453672</PROFIT_M>
<INCOME_M>1.67173501</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.934760822E7</REVENUE>
<PREV_YEAR_REV>1.644546698E7</PREV_YEAR_REV>
<BUDGET>1.876717997E7</BUDGET>
<GROSS_PROFIT>1.457455327E7</GROSS_PROFIT>
<EXPENSES>1.724803055E7</EXPENSES>
<NET_INCOME>1412375.4</NET_INCOME>
<REVENUE_M>19.34760822</REVENUE_M>
<PROFIT_M>14.57455327</PROFIT_M>
<INCOME_M>1.4123754</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2564365.67</REVENUE>
<PREV_YEAR_REV>2061983.91</PREV_YEAR_REV>
<BUDGET>2451196.88</BUDGET>
<GROSS_PROFIT>2039055.367</GROSS_PROFIT>
<EXPENSES>2302800.38</EXPENSES>
<NET_INCOME>261565.3</NET_INCOME>
<REVENUE_M>2.56436567</REVENUE_M>
<PROFIT_M>2.039055367</PROFIT_M>
<INCOME_M>0.2615653</INCOME_M>
<PHARMA_REV_M>2.56436567</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.039055367</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2615653</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>4314888.82</REVENUE>
<PREV_YEAR_REV>3510951.56</PREV_YEAR_REV>
<BUDGET>4140202.18</BUDGET>
<GROSS_PROFIT>3591020.98</GROSS_PROFIT>
<EXPENSES>3740812.02</EXPENSES>
<NET_INCOME>574076.8</NET_INCOME>
<REVENUE_M>4.31488882</REVENUE_M>
<PROFIT_M>3.59102098</PROFIT_M>
<INCOME_M>0.5740768</INCOME_M>
<PHARMA_REV_M>4.31488882</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.59102098</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5740768</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>8925509.99</REVENUE>
<PREV_YEAR_REV>8032958.99</PREV_YEAR_REV>
<BUDGET>8479234.49</BUDGET>
<GROSS_PROFIT>6723586.674</GROSS_PROFIT>
<EXPENSES>1.471237911E7</EXPENSES>
<NET_INCOME>972880.59</NET_INCOME>
<REVENUE_M>8.92550999</REVENUE_M>
<PROFIT_M>6.723586674</PROFIT_M>
<INCOME_M>0.97288059</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.570066132E7</REVENUE>
<PREV_YEAR_REV>3.391562825E7</PREV_YEAR_REV>
<BUDGET>3.462964147E7</BUDGET>
<GROSS_PROFIT>2.689330817E7</GROSS_PROFIT>
<EXPENSES>3.207055739E7</EXPENSES>
<NET_INCOME>3485316.59</NET_INCOME>
<REVENUE_M>35.70066132</REVENUE_M>
<PROFIT_M>26.89330817</PROFIT_M>
<INCOME_M>3.48531659</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2566745.31</REVENUE>
<PREV_YEAR_REV>2282139.67</PREV_YEAR_REV>
<BUDGET>1930791.21</BUDGET>
<GROSS_PROFIT>2019001.864</GROSS_PROFIT>
<EXPENSES>2107297.9</EXPENSES>
<NET_INCOME>459447.41</NET_INCOME>
<REVENUE_M>2.56674531</REVENUE_M>
<PROFIT_M>2.019001864</PROFIT_M>
<INCOME_M>0.45944741</INCOME_M>
<PHARMA_REV_M>2.56674531</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.019001864</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45944741</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2576936.23</REVENUE>
<PREV_YEAR_REV>2324139.57</PREV_YEAR_REV>
<BUDGET>1905845.92</BUDGET>
<GROSS_PROFIT>2053947.025</GROSS_PROFIT>
<EXPENSES>2296050.19</EXPENSES>
<NET_INCOME>280886.05</NET_INCOME>
<REVENUE_M>2.57693623</REVENUE_M>
<PROFIT_M>2.053947025</PROFIT_M>
<INCOME_M>0.28088605</INCOME_M>
<PHARMA_REV_M>2.57693623</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.053947025</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28088605</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5305976.8</REVENUE>
<PREV_YEAR_REV>4794276.85</PREV_YEAR_REV>
<BUDGET>5129243.52</BUDGET>
<GROSS_PROFIT>4418924.311</GROSS_PROFIT>
<EXPENSES>4792822.73</EXPENSES>
<NET_INCOME>513154.08</NET_INCOME>
<REVENUE_M>5.3059768</REVENUE_M>
<PROFIT_M>4.418924311</PROFIT_M>
<INCOME_M>0.51315408</INCOME_M>
<PHARMA_REV_M>5.3059768</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.418924311</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51315408</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3589083.68</REVENUE>
<PREV_YEAR_REV>3244879.61</PREV_YEAR_REV>
<BUDGET>3418811.13</BUDGET>
<GROSS_PROFIT>3087484.09</GROSS_PROFIT>
<EXPENSES>3106523.9</EXPENSES>
<NET_INCOME>482559.77</NET_INCOME>
<REVENUE_M>3.58908368</REVENUE_M>
<PROFIT_M>3.08748409</PROFIT_M>
<INCOME_M>0.48255977</INCOME_M>
<PHARMA_REV_M>3.58908368</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.08748409</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48255977</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2899773.29</REVENUE>
<PREV_YEAR_REV>2599607.07</PREV_YEAR_REV>
<BUDGET>2353391.16</BUDGET>
<GROSS_PROFIT>2125816.536</GROSS_PROFIT>
<EXPENSES>2471187.1</EXPENSES>
<NET_INCOME>428586.19</NET_INCOME>
<REVENUE_M>2.89977329</REVENUE_M>
<PROFIT_M>2.125816536</PROFIT_M>
<INCOME_M>0.42858619</INCOME_M>
<PHARMA_REV_M>2.89977329</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.125816536</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42858619</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1575944.12</REVENUE>
<PREV_YEAR_REV>1440797.33</PREV_YEAR_REV>
<BUDGET>1216700.11</BUDGET>
<GROSS_PROFIT>1125031.05</GROSS_PROFIT>
<EXPENSES>1304881.73</EXPENSES>
<NET_INCOME>271062.39</NET_INCOME>
<REVENUE_M>1.57594412</REVENUE_M>
<PROFIT_M>1.12503105</PROFIT_M>
<INCOME_M>0.27106239</INCOME_M>
<PHARMA_REV_M>1.57594412</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.12503105</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27106239</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2147100.85</REVENUE>
<PREV_YEAR_REV>1831450.37</PREV_YEAR_REV>
<BUDGET>2291758.83</BUDGET>
<GROSS_PROFIT>1590647.456</GROSS_PROFIT>
<EXPENSES>1857242.23</EXPENSES>
<NET_INCOME>289858.61</NET_INCOME>
<REVENUE_M>2.14710085</REVENUE_M>
<PROFIT_M>1.590647456</PROFIT_M>
<INCOME_M>0.28985861</INCOME_M>
<PHARMA_REV_M>2.14710085</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.590647456</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28985861</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.31727461E7</REVENUE>
<PREV_YEAR_REV>1.178226831E7</PREV_YEAR_REV>
<BUDGET>1.185547149E7</BUDGET>
<GROSS_PROFIT>1.124269513E7</GROSS_PROFIT>
<EXPENSES>1.140130957E7</EXPENSES>
<NET_INCOME>1771436.53</NET_INCOME>
<REVENUE_M>13.1727461</REVENUE_M>
<PROFIT_M>11.24269513</PROFIT_M>
<INCOME_M>1.77143653</INCOME_M>
<PHARMA_REV_M>13.1727461</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.24269513</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.77143653</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2434209.56</REVENUE>
<PREV_YEAR_REV>2183770.27</PREV_YEAR_REV>
<BUDGET>2621952.79</BUDGET>
<GROSS_PROFIT>1884926.16</GROSS_PROFIT>
<EXPENSES>2109231.68</EXPENSES>
<NET_INCOME>324977.87</NET_INCOME>
<REVENUE_M>2.43420956</REVENUE_M>
<PROFIT_M>1.88492616</PROFIT_M>
<INCOME_M>0.32497787</INCOME_M>
<PHARMA_REV_M>2.43420956</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.88492616</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32497787</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.979775181E7</REVENUE>
<PREV_YEAR_REV>1.696103122E7</PREV_YEAR_REV>
<BUDGET>2.019370685E7</BUDGET>
<GROSS_PROFIT>1.660381311E7</GROSS_PROFIT>
<EXPENSES>1.788385022E7</EXPENSES>
<NET_INCOME>1913901.59</NET_INCOME>
<REVENUE_M>19.79775181</REVENUE_M>
<PROFIT_M>16.60381311</PROFIT_M>
<INCOME_M>1.91390159</INCOME_M>
<PHARMA_REV_M>19.79775181</PHARMA_REV_M>
<PHARMA_PROFIT_M>16.60381311</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.91390159</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.675696076E7</REVENUE>
<PREV_YEAR_REV>1.466139865E7</PREV_YEAR_REV>
<BUDGET>1.709209997E7</BUDGET>
<GROSS_PROFIT>1.413013016E7</GROSS_PROFIT>
<EXPENSES>1.454447914E7</EXPENSES>
<NET_INCOME>2212481.61</NET_INCOME>
<REVENUE_M>16.75696076</REVENUE_M>
<PROFIT_M>14.13013016</PROFIT_M>
<INCOME_M>2.21248161</INCOME_M>
<PHARMA_REV_M>16.75696076</PHARMA_REV_M>
<PHARMA_PROFIT_M>14.13013016</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.21248161</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1941207.62</REVENUE>
<PREV_YEAR_REV>1740587.51</PREV_YEAR_REV>
<BUDGET>1777447.05</BUDGET>
<GROSS_PROFIT>1599904.498</GROSS_PROFIT>
<EXPENSES>1684968.22</EXPENSES>
<NET_INCOME>256239.41</NET_INCOME>
<REVENUE_M>1.94120762</REVENUE_M>
<PROFIT_M>1.599904498</PROFIT_M>
<INCOME_M>0.25623941</INCOME_M>
<PHARMA_REV_M>1.94120762</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.599904498</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25623941</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2012196.27</REVENUE>
<PREV_YEAR_REV>1813917</PREV_YEAR_REV>
<BUDGET>1764946.8</BUDGET>
<GROSS_PROFIT>1686019.255</GROSS_PROFIT>
<EXPENSES>1806952.25</EXPENSES>
<NET_INCOME>205244.02</NET_INCOME>
<REVENUE_M>2.01219627</REVENUE_M>
<PROFIT_M>1.686019255</PROFIT_M>
<INCOME_M>0.20524402</INCOME_M>
<PHARMA_REV_M>2.01219627</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.686019255</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20524402</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8436740.99</REVENUE>
<PREV_YEAR_REV>7535899.56</PREV_YEAR_REV>
<BUDGET>7593066.89</BUDGET>
<GROSS_PROFIT>7339964.66</GROSS_PROFIT>
<EXPENSES>7323091.18</EXPENSES>
<NET_INCOME>1113649.81</NET_INCOME>
<REVENUE_M>8.43674099</REVENUE_M>
<PROFIT_M>7.33996466</PROFIT_M>
<INCOME_M>1.11364981</INCOME_M>
<PHARMA_REV_M>8.43674099</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.33996466</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.11364981</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4599290.67</REVENUE>
<PREV_YEAR_REV>3923341.91</PREV_YEAR_REV>
<BUDGET>4249422.54</BUDGET>
<GROSS_PROFIT>3588730.507</GROSS_PROFIT>
<EXPENSES>4088678.91</EXPENSES>
<NET_INCOME>510611.75</NET_INCOME>
<REVENUE_M>4.59929067</REVENUE_M>
<PROFIT_M>3.588730507</PROFIT_M>
<INCOME_M>0.51061175</INCOME_M>
<PHARMA_REV_M>4.59929067</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.588730507</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51061175</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2336105.42</REVENUE>
<PREV_YEAR_REV>2091185.75</PREV_YEAR_REV>
<BUDGET>2164301.37</BUDGET>
<GROSS_PROFIT>1918503.213</GROSS_PROFIT>
<EXPENSES>2081469.93</EXPENSES>
<NET_INCOME>254635.49</NET_INCOME>
<REVENUE_M>2.33610542</REVENUE_M>
<PROFIT_M>1.918503213</PROFIT_M>
<INCOME_M>0.25463549</INCOME_M>
<PHARMA_REV_M>2.33610542</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.918503213</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25463549</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>5899947.01</REVENUE>
<PREV_YEAR_REV>5225433.33</PREV_YEAR_REV>
<BUDGET>4401171.29</BUDGET>
<GROSS_PROFIT>4818063.092</GROSS_PROFIT>
<EXPENSES>5331831.27</EXPENSES>
<NET_INCOME>568115.74</NET_INCOME>
<REVENUE_M>5.89994701</REVENUE_M>
<PROFIT_M>4.818063092</PROFIT_M>
<INCOME_M>0.56811574</INCOME_M>
<PHARMA_REV_M>5.89994701</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.818063092</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56811574</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.200890032E7</REVENUE>
<PREV_YEAR_REV>1.090498835E7</PREV_YEAR_REV>
<BUDGET>1.176872232E7</BUDGET>
<GROSS_PROFIT>8959840.533</GROSS_PROFIT>
<EXPENSES>1.045975218E7</EXPENSES>
<NET_INCOME>1549148.14</NET_INCOME>
<REVENUE_M>12.00890032</REVENUE_M>
<PROFIT_M>8.959840533</PROFIT_M>
<INCOME_M>1.54914814</INCOME_M>
<PHARMA_REV_M>12.00890032</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.959840533</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.54914814</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6432821.58</REVENUE>
<PREV_YEAR_REV>5489317.66</PREV_YEAR_REV>
<BUDGET>5918195.86</BUDGET>
<GROSS_PROFIT>5673748.64</GROSS_PROFIT>
<EXPENSES>5281346.52</EXPENSES>
<NET_INCOME>1151475.06</NET_INCOME>
<REVENUE_M>6.43282158</REVENUE_M>
<PROFIT_M>5.67374864</PROFIT_M>
<INCOME_M>1.15147506</INCOME_M>
<PHARMA_REV_M>6.43282158</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.67374864</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.15147506</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>7715733.79</REVENUE>
<PREV_YEAR_REV>6709625.45</PREV_YEAR_REV>
<BUDGET>7098475.09</BUDGET>
<GROSS_PROFIT>6717472.155</GROSS_PROFIT>
<EXPENSES>6874718.81</EXPENSES>
<NET_INCOME>841014.98</NET_INCOME>
<REVENUE_M>7.71573379</REVENUE_M>
<PROFIT_M>6.717472155</PROFIT_M>
<INCOME_M>0.84101498</INCOME_M>
<PHARMA_REV_M>7.71573379</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.717472155</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.84101498</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5176589.09</REVENUE>
<PREV_YEAR_REV>4599716.88</PREV_YEAR_REV>
<BUDGET>5021291.42</BUDGET>
<GROSS_PROFIT>4223355.051</GROSS_PROFIT>
<EXPENSES>4480259.62</EXPENSES>
<NET_INCOME>696329.47</NET_INCOME>
<REVENUE_M>5.17658909</REVENUE_M>
<PROFIT_M>4.223355051</PROFIT_M>
<INCOME_M>0.69632947</INCOME_M>
<PHARMA_REV_M>5.17658909</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.223355051</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69632947</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1896338.59</REVENUE>
<PREV_YEAR_REV>1631989.01</PREV_YEAR_REV>
<BUDGET>1839448.43</BUDGET>
<GROSS_PROFIT>1602406.11</GROSS_PROFIT>
<EXPENSES>1592924.41</EXPENSES>
<NET_INCOME>303414.17</NET_INCOME>
<REVENUE_M>1.89633859</REVENUE_M>
<PROFIT_M>1.60240611</PROFIT_M>
<INCOME_M>0.30341417</INCOME_M>
<PHARMA_REV_M>1.89633859</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.60240611</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30341417</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1623479.33</REVENUE>
<PREV_YEAR_REV>1421772.47</PREV_YEAR_REV>
<BUDGET>2012030.41</BUDGET>
<GROSS_PROFIT>1286282.672</GROSS_PROFIT>
<EXPENSES>1457884.43</EXPENSES>
<NET_INCOME>165594.89</NET_INCOME>
<REVENUE_M>1.62347933</REVENUE_M>
<PROFIT_M>1.286282672</PROFIT_M>
<INCOME_M>0.16559489</INCOME_M>
<PHARMA_REV_M>1.62347933</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.286282672</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16559489</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.682701338E7</REVENUE>
<PREV_YEAR_REV>1.442079731E7</PREV_YEAR_REV>
<BUDGET>1.632220298E7</BUDGET>
<GROSS_PROFIT>1.34140072E7</GROSS_PROFIT>
<EXPENSES>1.497346612E7</EXPENSES>
<NET_INCOME>1853547.25</NET_INCOME>
<REVENUE_M>16.82701338</REVENUE_M>
<PROFIT_M>13.4140072</PROFIT_M>
<INCOME_M>1.85354725</INCOME_M>
<PHARMA_REV_M>16.82701338</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.4140072</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.85354725</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2678375.96</REVENUE>
<PREV_YEAR_REV>2353767.84</PREV_YEAR_REV>
<BUDGET>2036184.48</BUDGET>
<GROSS_PROFIT>2145191.661</GROSS_PROFIT>
<EXPENSES>2249835.81</EXPENSES>
<NET_INCOME>428540.15</NET_INCOME>
<REVENUE_M>2.67837596</REVENUE_M>
<PROFIT_M>2.145191661</PROFIT_M>
<INCOME_M>0.42854015</INCOME_M>
<PHARMA_REV_M>2.67837596</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.145191661</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42854015</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3099811.31</REVENUE>
<PREV_YEAR_REV>2766354.89</PREV_YEAR_REV>
<BUDGET>2492358.66</BUDGET>
<GROSS_PROFIT>2352646.735</GROSS_PROFIT>
<EXPENSES>2566643.76</EXPENSES>
<NET_INCOME>533167.54</NET_INCOME>
<REVENUE_M>3.09981131</REVENUE_M>
<PROFIT_M>2.352646735</PROFIT_M>
<INCOME_M>0.53316754</INCOME_M>
<PHARMA_REV_M>3.09981131</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.352646735</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53316754</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7987018.63</REVENUE>
<PREV_YEAR_REV>6172395.94</PREV_YEAR_REV>
<BUDGET>7907148.44</BUDGET>
<GROSS_PROFIT>6501433.16</GROSS_PROFIT>
<EXPENSES>7403966.27</EXPENSES>
<NET_INCOME>583052.36</NET_INCOME>
<REVENUE_M>7.98701863</REVENUE_M>
<PROFIT_M>6.50143316</PROFIT_M>
<INCOME_M>0.58305236</INCOME_M>
<PHARMA_REV_M>7.98701863</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.50143316</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58305236</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2893814.5</REVENUE>
<PREV_YEAR_REV>2400250.91</PREV_YEAR_REV>
<BUDGET>2604433.05</BUDGET>
<GROSS_PROFIT>1998485.654</GROSS_PROFIT>
<EXPENSES>2520512.43</EXPENSES>
<NET_INCOME>373302.07</NET_INCOME>
<REVENUE_M>2.8938145</REVENUE_M>
<PROFIT_M>1.998485654</PROFIT_M>
<INCOME_M>0.37330207</INCOME_M>
<PHARMA_REV_M>2.8938145</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.998485654</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37330207</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>5769142.44</REVENUE>
<PREV_YEAR_REV>4712717.32</PREV_YEAR_REV>
<BUDGET>5192228.19</BUDGET>
<GROSS_PROFIT>4052022.977</GROSS_PROFIT>
<EXPENSES>4912155.91</EXPENSES>
<NET_INCOME>856986.53</NET_INCOME>
<REVENUE_M>5.76914244</REVENUE_M>
<PROFIT_M>4.052022977</PROFIT_M>
<INCOME_M>0.85698653</INCOME_M>
<PHARMA_REV_M>5.76914244</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.052022977</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.85698653</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4874084</REVENUE>
<PREV_YEAR_REV>4059567.58</PREV_YEAR_REV>
<BUDGET>4776602.32</BUDGET>
<GROSS_PROFIT>3427754.44</GROSS_PROFIT>
<EXPENSES>4284647.72</EXPENSES>
<NET_INCOME>589436.28</NET_INCOME>
<REVENUE_M>4.874084</REVENUE_M>
<PROFIT_M>3.42775444</PROFIT_M>
<INCOME_M>0.58943628</INCOME_M>
<PHARMA_REV_M>4.874084</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.42775444</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58943628</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2362664.7</REVENUE>
<PREV_YEAR_REV>1978035.66</PREV_YEAR_REV>
<BUDGET>2315411.4</BUDGET>
<GROSS_PROFIT>1894857.09</GROSS_PROFIT>
<EXPENSES>2105134.24</EXPENSES>
<NET_INCOME>257530.45</NET_INCOME>
<REVENUE_M>2.3626647</REVENUE_M>
<PROFIT_M>1.89485709</PROFIT_M>
<INCOME_M>0.25753045</INCOME_M>
<PHARMA_REV_M>2.3626647</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.89485709</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25753045</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.897522024E7</REVENUE>
<PREV_YEAR_REV>1.571171026E7</PREV_YEAR_REV>
<BUDGET>1.745720262E7</BUDGET>
<GROSS_PROFIT>1.590557819E7</GROSS_PROFIT>
<EXPENSES>1.64267899E7</EXPENSES>
<NET_INCOME>2548430.34</NET_INCOME>
<REVENUE_M>18.97522024</REVENUE_M>
<PROFIT_M>15.90557819</PROFIT_M>
<INCOME_M>2.54843034</INCOME_M>
<PHARMA_REV_M>18.97522024</PHARMA_REV_M>
<PHARMA_PROFIT_M>15.90557819</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.54843034</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>1224545.75</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>1126582.09</BUDGET>
<GROSS_PROFIT>1000453.88</GROSS_PROFIT>
<EXPENSES>1091070.26</EXPENSES>
<NET_INCOME>133475.49</NET_INCOME>
<REVENUE_M>1.22454575</REVENUE_M>
<PROFIT_M>1.00045388</PROFIT_M>
<INCOME_M>0.13347549</INCOME_M>
<PHARMA_REV_M>1.22454575</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.00045388</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13347549</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>7262481.34</REVENUE>
<PREV_YEAR_REV>5764301.29</PREV_YEAR_REV>
<BUDGET>6908118.75</BUDGET>
<GROSS_PROFIT>5927200.392</GROSS_PROFIT>
<EXPENSES>6284888.7</EXPENSES>
<NET_INCOME>977592.65</NET_INCOME>
<REVENUE_M>7.26248134</REVENUE_M>
<PROFIT_M>5.927200392</PROFIT_M>
<INCOME_M>0.97759265</INCOME_M>
<PHARMA_REV_M>7.26248134</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.927200392</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.97759265</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1230464.61</REVENUE>
<PREV_YEAR_REV>1163504.9</PREV_YEAR_REV>
<BUDGET>1018213.69</BUDGET>
<GROSS_PROFIT>855314.4092</GROSS_PROFIT>
<EXPENSES>1064351.89</EXPENSES>
<NET_INCOME>166112.72</NET_INCOME>
<REVENUE_M>1.23046461</REVENUE_M>
<PROFIT_M>0.855314409</PROFIT_M>
<INCOME_M>0.16611272</INCOME_M>
<PHARMA_REV_M>1.23046461</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.855314409</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16611272</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>904390.26</REVENUE>
<PREV_YEAR_REV>858649.98</PREV_YEAR_REV>
<BUDGET>922731.39</BUDGET>
<GROSS_PROFIT>575644.3965</GROSS_PROFIT>
<EXPENSES>812142.45</EXPENSES>
<NET_INCOME>92247.81</NET_INCOME>
<REVENUE_M>0.90439026</REVENUE_M>
<PROFIT_M>0.575644397</PROFIT_M>
<INCOME_M>0.09224781</INCOME_M>
<PHARMA_REV_M>0.90439026</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.575644397</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.09224781</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7475981.61</REVENUE>
<PREV_YEAR_REV>6742286.04</PREV_YEAR_REV>
<BUDGET>7176942.35</BUDGET>
<GROSS_PROFIT>4651929.553</GROSS_PROFIT>
<EXPENSES>6713431.49</EXPENSES>
<NET_INCOME>762550.12</NET_INCOME>
<REVENUE_M>7.47598161</REVENUE_M>
<PROFIT_M>4.651929553</PROFIT_M>
<INCOME_M>0.76255012</INCOME_M>
<PHARMA_REV_M>7.47598161</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.651929553</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.76255012</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2912874.85</REVENUE>
<PREV_YEAR_REV>2708593.62</PREV_YEAR_REV>
<BUDGET>3720856.88</BUDGET>
<GROSS_PROFIT>1790776.435</GROSS_PROFIT>
<EXPENSES>2558462.03</EXPENSES>
<NET_INCOME>354412.81</NET_INCOME>
<REVENUE_M>2.91287485</REVENUE_M>
<PROFIT_M>1.790776435</PROFIT_M>
<INCOME_M>0.35441281</INCOME_M>
<PHARMA_REV_M>2.91287485</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.790776435</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35441281</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1338206.08</REVENUE>
<PREV_YEAR_REV>1215114.93</PREV_YEAR_REV>
<BUDGET>1820808.31</BUDGET>
<GROSS_PROFIT>784898.0093</GROSS_PROFIT>
<EXPENSES>1157548.26</EXPENSES>
<NET_INCOME>180657.82</NET_INCOME>
<REVENUE_M>1.33820608</REVENUE_M>
<PROFIT_M>0.784898009</PROFIT_M>
<INCOME_M>0.18065782</INCOME_M>
<PHARMA_REV_M>1.33820608</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.784898009</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18065782</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>7882021.84</REVENUE>
<PREV_YEAR_REV>7064959.3</PREV_YEAR_REV>
<BUDGET>8670224.02</BUDGET>
<GROSS_PROFIT>6502668.02</GROSS_PROFIT>
<EXPENSES>6620898.34</EXPENSES>
<NET_INCOME>1261123.49</NET_INCOME>
<REVENUE_M>7.88202184</REVENUE_M>
<PROFIT_M>6.50266802</PROFIT_M>
<INCOME_M>1.26112349</INCOME_M>
<PHARMA_REV_M>7.88202184</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.50266802</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.26112349</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8754852.91</REVENUE>
<PREV_YEAR_REV>8229946.9</PREV_YEAR_REV>
<BUDGET>8404658.79</BUDGET>
<GROSS_PROFIT>6670322.429</GROSS_PROFIT>
<EXPENSES>7861857.91</EXPENSES>
<NET_INCOME>892995</NET_INCOME>
<REVENUE_M>8.75485291</REVENUE_M>
<PROFIT_M>6.670322429</PROFIT_M>
<INCOME_M>0.892995</INCOME_M>
<PHARMA_REV_M>8.75485291</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.670322429</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.892995</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>1831620.94</REVENUE>
<PREV_YEAR_REV>1683676.31</PREV_YEAR_REV>
<BUDGET>1351380.95</BUDGET>
<GROSS_PROFIT>1386898.798</GROSS_PROFIT>
<EXPENSES>1644795.61</EXPENSES>
<NET_INCOME>186825.34</NET_INCOME>
<REVENUE_M>1.83162094</REVENUE_M>
<PROFIT_M>1.386898798</PROFIT_M>
<INCOME_M>0.18682534</INCOME_M>
<PHARMA_REV_M>1.83162094</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.386898798</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18682534</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1739621.17</REVENUE>
<PREV_YEAR_REV>1617815.82</PREV_YEAR_REV>
<BUDGET>1624940.43</BUDGET>
<GROSS_PROFIT>1258789.878</GROSS_PROFIT>
<EXPENSES>1515210.04</EXPENSES>
<NET_INCOME>224411.13</NET_INCOME>
<REVENUE_M>1.73962117</REVENUE_M>
<PROFIT_M>1.258789878</PROFIT_M>
<INCOME_M>0.22441113</INCOME_M>
<PHARMA_REV_M>1.73962117</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.258789878</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22441113</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1692957.64</REVENUE>
<PREV_YEAR_REV>1588363.88</PREV_YEAR_REV>
<BUDGET>1578137.41</BUDGET>
<GROSS_PROFIT>1388665.429</GROSS_PROFIT>
<EXPENSES>1569371.73</EXPENSES>
<NET_INCOME>123585.91</NET_INCOME>
<REVENUE_M>1.69295764</REVENUE_M>
<PROFIT_M>1.388665429</PROFIT_M>
<INCOME_M>0.12358591</INCOME_M>
<PHARMA_REV_M>1.69295764</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.388665429</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12358591</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1313683.61</REVENUE>
<PREV_YEAR_REV>1127112.65</PREV_YEAR_REV>
<BUDGET>1291185.06</BUDGET>
<GROSS_PROFIT>1022111.536</GROSS_PROFIT>
<EXPENSES>1179687.88</EXPENSES>
<NET_INCOME>133995.73</NET_INCOME>
<REVENUE_M>1.31368361</REVENUE_M>
<PROFIT_M>1.022111536</PROFIT_M>
<INCOME_M>0.13399573</INCOME_M>
<PHARMA_REV_M>1.31368361</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.022111536</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13399573</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>9611119.27</REVENUE>
<PREV_YEAR_REV>8277883.37</PREV_YEAR_REV>
<BUDGET>8842229.72</BUDGET>
<GROSS_PROFIT>7554339.74</GROSS_PROFIT>
<EXPENSES>8073340.18</EXPENSES>
<NET_INCOME>1537779.08</NET_INCOME>
<REVENUE_M>9.61111927</REVENUE_M>
<PROFIT_M>7.55433974</PROFIT_M>
<INCOME_M>1.53777908</INCOME_M>
<PHARMA_REV_M>9.61111927</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.55433974</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.53777908</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6954429.98</REVENUE>
<PREV_YEAR_REV>5973569.81</PREV_YEAR_REV>
<BUDGET>6398075.58</BUDGET>
<GROSS_PROFIT>6147716.1</GROSS_PROFIT>
<EXPENSES>6446756.59</EXPENSES>
<NET_INCOME>507673.39</NET_INCOME>
<REVENUE_M>6.95442998</REVENUE_M>
<PROFIT_M>6.1477161</PROFIT_M>
<INCOME_M>0.50767339</INCOME_M>
<PHARMA_REV_M>6.95442998</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.1477161</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.50767339</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2572218.18</REVENUE>
<PREV_YEAR_REV>2234050.03</PREV_YEAR_REV>
<BUDGET>2495051.63</BUDGET>
<GROSS_PROFIT>2225843.277</GROSS_PROFIT>
<EXPENSES>2384446.25</EXPENSES>
<NET_INCOME>187771.93</NET_INCOME>
<REVENUE_M>2.57221818</REVENUE_M>
<PROFIT_M>2.225843277</PROFIT_M>
<INCOME_M>0.18777193</INCOME_M>
<PHARMA_REV_M>2.57221818</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.225843277</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18777193</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3047966.47</REVENUE>
<PREV_YEAR_REV>2632380.76</PREV_YEAR_REV>
<BUDGET>4127390.52</BUDGET>
<GROSS_PROFIT>2274757.407</GROSS_PROFIT>
<EXPENSES>2595194.47</EXPENSES>
<NET_INCOME>452772</NET_INCOME>
<REVENUE_M>3.04796647</REVENUE_M>
<PROFIT_M>2.274757407</PROFIT_M>
<INCOME_M>0.452772</INCOME_M>
<PHARMA_REV_M>3.04796647</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.274757407</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.452772</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1168348.05</REVENUE>
<PREV_YEAR_REV>1062067</PREV_YEAR_REV>
<BUDGET>1297749.78</BUDGET>
<GROSS_PROFIT>1009452.71</GROSS_PROFIT>
<EXPENSES>1014126.11</EXPENSES>
<NET_INCOME>154221.94</NET_INCOME>
<REVENUE_M>1.16834805</REVENUE_M>
<PROFIT_M>1.00945271</PROFIT_M>
<INCOME_M>0.15422194</INCOME_M>
<PHARMA_REV_M>1.16834805</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.00945271</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15422194</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1171144.44</REVENUE>
<PREV_YEAR_REV>993202.32</PREV_YEAR_REV>
<BUDGET>1290691.19</BUDGET>
<GROSS_PROFIT>949798.14</GROSS_PROFIT>
<EXPENSES>961509.59</EXPENSES>
<NET_INCOME>209634.86</NET_INCOME>
<REVENUE_M>1.17114444</REVENUE_M>
<PROFIT_M>0.94979814</PROFIT_M>
<INCOME_M>0.20963486</INCOME_M>
<PHARMA_REV_M>1.17114444</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.94979814</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20963486</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5098850.1</REVENUE>
<PREV_YEAR_REV>4325091.27</PREV_YEAR_REV>
<BUDGET>4945884.59</BUDGET>
<GROSS_PROFIT>4526708.122</GROSS_PROFIT>
<EXPENSES>4283034.08</EXPENSES>
<NET_INCOME>815816.02</NET_INCOME>
<REVENUE_M>5.0988501</REVENUE_M>
<PROFIT_M>4.526708122</PROFIT_M>
<INCOME_M>0.81581602</INCOME_M>
<PHARMA_REV_M>5.0988501</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.526708122</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.81581602</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2918836.62</REVENUE>
<PREV_YEAR_REV>2535673.03</PREV_YEAR_REV>
<BUDGET>2831271.53</BUDGET>
<GROSS_PROFIT>2075800.19</GROSS_PROFIT>
<EXPENSES>2487890.42</EXPENSES>
<NET_INCOME>430946.2</NET_INCOME>
<REVENUE_M>2.91883662</REVENUE_M>
<PROFIT_M>2.07580019</PROFIT_M>
<INCOME_M>0.4309462</INCOME_M>
<PHARMA_REV_M>2.91883662</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.07580019</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4309462</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1467660.9</REVENUE>
<PREV_YEAR_REV>1163701.95</PREV_YEAR_REV>
<BUDGET>1452984.29</BUDGET>
<GROSS_PROFIT>963724.8524</GROSS_PROFIT>
<EXPENSES>1269526.68</EXPENSES>
<NET_INCOME>198134.22</NET_INCOME>
<REVENUE_M>1.4676609</REVENUE_M>
<PROFIT_M>0.963724852</PROFIT_M>
<INCOME_M>0.19813422</INCOME_M>
<PHARMA_REV_M>1.4676609</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.963724852</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19813422</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>2.711678799E7</REVENUE>
<PREV_YEAR_REV>2.171819494E7</PREV_YEAR_REV>
<BUDGET>2.684562011E7</BUDGET>
<GROSS_PROFIT>2.28820849E7</GROSS_PROFIT>
<EXPENSES>2.453811111E7</EXPENSES>
<NET_INCOME>2578676.88</NET_INCOME>
<REVENUE_M>27.11678799</REVENUE_M>
<PROFIT_M>22.8820849</PROFIT_M>
<INCOME_M>2.57867688</INCOME_M>
<PHARMA_REV_M>27.11678799</PHARMA_REV_M>
<PHARMA_PROFIT_M>22.8820849</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.57867688</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3050864.5</REVENUE>
<PREV_YEAR_REV>2510111.24</PREV_YEAR_REV>
<BUDGET>2898321.28</BUDGET>
<GROSS_PROFIT>2307353.566</GROSS_PROFIT>
<EXPENSES>2739676.32</EXPENSES>
<NET_INCOME>311188.18</NET_INCOME>
<REVENUE_M>3.0508645</REVENUE_M>
<PROFIT_M>2.307353566</PROFIT_M>
<INCOME_M>0.31118818</INCOME_M>
<PHARMA_REV_M>3.0508645</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.307353566</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31118818</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2961989.5</REVENUE>
<PREV_YEAR_REV>2494285.94</PREV_YEAR_REV>
<BUDGET>2665790.55</BUDGET>
<GROSS_PROFIT>2268587.754</GROSS_PROFIT>
<EXPENSES>2579892.85</EXPENSES>
<NET_INCOME>382096.65</NET_INCOME>
<REVENUE_M>2.9619895</REVENUE_M>
<PROFIT_M>2.268587754</PROFIT_M>
<INCOME_M>0.38209665</INCOME_M>
<PHARMA_REV_M>2.9619895</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.268587754</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38209665</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2868755.13</REVENUE>
<PREV_YEAR_REV>2358766.27</PREV_YEAR_REV>
<BUDGET>2581879.61</BUDGET>
<GROSS_PROFIT>2234760.24</GROSS_PROFIT>
<EXPENSES>2355247.96</EXPENSES>
<NET_INCOME>513507.17</NET_INCOME>
<REVENUE_M>2.86875513</REVENUE_M>
<PROFIT_M>2.23476024</PROFIT_M>
<INCOME_M>0.51350717</INCOME_M>
<PHARMA_REV_M>2.86875513</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.23476024</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51350717</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2277517.36</REVENUE>
<PREV_YEAR_REV>1909691.65</PREV_YEAR_REV>
<BUDGET>2231967.01</BUDGET>
<GROSS_PROFIT>1618187.475</GROSS_PROFIT>
<EXPENSES>1970052.52</EXPENSES>
<NET_INCOME>307464.84</NET_INCOME>
<REVENUE_M>2.27751736</REVENUE_M>
<PROFIT_M>1.618187475</PROFIT_M>
<INCOME_M>0.30746484</INCOME_M>
<PHARMA_REV_M>2.27751736</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.618187475</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30746484</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8494026</REVENUE>
<PREV_YEAR_REV>7119469.94</PREV_YEAR_REV>
<BUDGET>7814503.92</BUDGET>
<GROSS_PROFIT>6323556.027</GROSS_PROFIT>
<EXPENSES>7398296.65</EXPENSES>
<NET_INCOME>1095729.35</NET_INCOME>
<REVENUE_M>8.494026</REVENUE_M>
<PROFIT_M>6.323556027</PROFIT_M>
<INCOME_M>1.09572935</INCOME_M>
<PHARMA_REV_M>8.494026</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.323556027</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.09572935</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8367091.63</REVENUE>
<PREV_YEAR_REV>6500681.08</PREV_YEAR_REV>
<BUDGET>7697724.3</BUDGET>
<GROSS_PROFIT>7200049.681</GROSS_PROFIT>
<EXPENSES>6869382.22</EXPENSES>
<NET_INCOME>1497709.4</NET_INCOME>
<REVENUE_M>8.36709163</REVENUE_M>
<PROFIT_M>7.200049681</PROFIT_M>
<INCOME_M>1.4977094</INCOME_M>
<PHARMA_REV_M>8.36709163</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.200049681</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.4977094</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>4207190.15</REVENUE>
<PREV_YEAR_REV>3799949.55</PREV_YEAR_REV>
<BUDGET>4627909.16</BUDGET>
<GROSS_PROFIT>3311874.843</GROSS_PROFIT>
<EXPENSES>3664462.62</EXPENSES>
<NET_INCOME>542727.53</NET_INCOME>
<REVENUE_M>4.20719015</REVENUE_M>
<PROFIT_M>3.311874843</PROFIT_M>
<INCOME_M>0.54272753</INCOME_M>
<PHARMA_REV_M>4.20719015</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.311874843</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.54272753</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.429612748E7</REVENUE>
<PREV_YEAR_REV>1.32227687E7</PREV_YEAR_REV>
<BUDGET>1.372428238E7</BUDGET>
<GROSS_PROFIT>9669086.14</GROSS_PROFIT>
<EXPENSES>1.272470159E7</EXPENSES>
<NET_INCOME>1571425.9</NET_INCOME>
<REVENUE_M>14.29612748</REVENUE_M>
<PROFIT_M>9.66908614</PROFIT_M>
<INCOME_M>1.5714259</INCOME_M>
<PHARMA_REV_M>14.29612748</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.66908614</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.5714259</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>4404307.95</REVENUE>
<PREV_YEAR_REV>3992845.24</PREV_YEAR_REV>
<BUDGET>4228135.63</BUDGET>
<GROSS_PROFIT>2958153.43</GROSS_PROFIT>
<EXPENSES>3646766.98</EXPENSES>
<NET_INCOME>757540.97</NET_INCOME>
<REVENUE_M>4.40430795</REVENUE_M>
<PROFIT_M>2.95815343</PROFIT_M>
<INCOME_M>0.75754097</INCOME_M>
<PHARMA_REV_M>4.40430795</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.95815343</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75754097</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3765566.26</REVENUE>
<PREV_YEAR_REV>3451983.16</PREV_YEAR_REV>
<BUDGET>3970854.96</BUDGET>
<GROSS_PROFIT>2444900.721</GROSS_PROFIT>
<EXPENSES>3350806.73</EXPENSES>
<NET_INCOME>414759.53</NET_INCOME>
<REVENUE_M>3.76556626</REVENUE_M>
<PROFIT_M>2.444900721</PROFIT_M>
<INCOME_M>0.41475953</INCOME_M>
<PHARMA_REV_M>3.76556626</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.444900721</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41475953</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>1816360.78</REVENUE>
<PREV_YEAR_REV>1691400.14</PREV_YEAR_REV>
<BUDGET>1998997.7</BUDGET>
<GROSS_PROFIT>1404446.487</GROSS_PROFIT>
<EXPENSES>1576601.16</EXPENSES>
<NET_INCOME>239759.62</NET_INCOME>
<REVENUE_M>1.81636078</REVENUE_M>
<PROFIT_M>1.404446487</PROFIT_M>
<INCOME_M>0.23975962</INCOME_M>
<PHARMA_REV_M>1.81636078</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.404446487</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23975962</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1469067.55</REVENUE>
<PREV_YEAR_REV>1331545.53</PREV_YEAR_REV>
<BUDGET>1874808.26</BUDGET>
<GROSS_PROFIT>913613.112</GROSS_PROFIT>
<EXPENSES>1279557.84</EXPENSES>
<NET_INCOME>189509.71</NET_INCOME>
<REVENUE_M>1.46906755</REVENUE_M>
<PROFIT_M>0.913613112</PROFIT_M>
<INCOME_M>0.18950971</INCOME_M>
<PHARMA_REV_M>1.46906755</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.913613112</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18950971</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1363459.69</REVENUE>
<PREV_YEAR_REV>1221311.27</PREV_YEAR_REV>
<BUDGET>1802925.43</BUDGET>
<GROSS_PROFIT>887612.26</GROSS_PROFIT>
<EXPENSES>1119400.4</EXPENSES>
<NET_INCOME>244059.28</NET_INCOME>
<REVENUE_M>1.36345969</REVENUE_M>
<PROFIT_M>0.88761226</PROFIT_M>
<INCOME_M>0.24405928</INCOME_M>
<PHARMA_REV_M>1.36345969</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.88761226</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24405928</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2286604.6</REVENUE>
<PREV_YEAR_REV>2109835.44</PREV_YEAR_REV>
<BUDGET>2555207.25</BUDGET>
<GROSS_PROFIT>1478051.406</GROSS_PROFIT>
<EXPENSES>2012654.67</EXPENSES>
<NET_INCOME>273949.93</NET_INCOME>
<REVENUE_M>2.2866046</REVENUE_M>
<PROFIT_M>1.478051406</PROFIT_M>
<INCOME_M>0.27394993</INCOME_M>
<PHARMA_REV_M>2.2866046</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.478051406</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27394993</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.297758518E7</REVENUE>
<PREV_YEAR_REV>1.207819326E7</PREV_YEAR_REV>
<BUDGET>1.245848177E7</BUDGET>
<GROSS_PROFIT>9772832.178</GROSS_PROFIT>
<EXPENSES>1.105375985E7</EXPENSES>
<NET_INCOME>1923825.33</NET_INCOME>
<REVENUE_M>12.97758518</REVENUE_M>
<PROFIT_M>9.772832178</PROFIT_M>
<INCOME_M>1.92382533</INCOME_M>
<PHARMA_REV_M>12.97758518</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.772832178</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.92382533</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.638793879E7</REVENUE>
<PREV_YEAR_REV>2.506854186E7</PREV_YEAR_REV>
<BUDGET>2.559630062E7</BUDGET>
<GROSS_PROFIT>1.987803428E7</GROSS_PROFIT>
<EXPENSES>3.392734988E7</EXPENSES>
<NET_INCOME>2570770.3</NET_INCOME>
<REVENUE_M>26.38793879</REVENUE_M>
<PROFIT_M>19.87803428</PROFIT_M>
<INCOME_M>2.5707703</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.276096649E7</REVENUE>
<PREV_YEAR_REV>1.212291816E7</PREV_YEAR_REV>
<BUDGET>1.237813749E7</BUDGET>
<GROSS_PROFIT>9132194.248</GROSS_PROFIT>
<EXPENSES>1.640695691E7</EXPENSES>
<NET_INCOME>2194886.24</NET_INCOME>
<REVENUE_M>12.76096649</REVENUE_M>
<PROFIT_M>9.132194248</PROFIT_M>
<INCOME_M>2.19488624</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.854249696E7</REVENUE>
<PREV_YEAR_REV>1.576112242E7</PREV_YEAR_REV>
<BUDGET>1.798622205E7</BUDGET>
<GROSS_PROFIT>1.257125667E7</GROSS_PROFIT>
<EXPENSES>1.65028223E7</EXPENSES>
<NET_INCOME>2503237.09</NET_INCOME>
<REVENUE_M>18.54249696</REVENUE_M>
<PROFIT_M>12.57125667</PROFIT_M>
<INCOME_M>2.50323709</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.934760822E7</REVENUE>
<PREV_YEAR_REV>1.644546698E7</PREV_YEAR_REV>
<BUDGET>1.876717997E7</BUDGET>
<GROSS_PROFIT>1.457455327E7</GROSS_PROFIT>
<EXPENSES>1.724803055E7</EXPENSES>
<NET_INCOME>1412375.4</NET_INCOME>
<REVENUE_M>19.34760822</REVENUE_M>
<PROFIT_M>14.57455327</PROFIT_M>
<INCOME_M>1.4123754</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.64277828E7</REVENUE>
<PREV_YEAR_REV>1.396361538E7</PREV_YEAR_REV>
<BUDGET>1.593494932E7</BUDGET>
<GROSS_PROFIT>1.072504228E7</GROSS_PROFIT>
<EXPENSES>1.478500452E7</EXPENSES>
<NET_INCOME>2217750.68</NET_INCOME>
<REVENUE_M>16.4277828</REVENUE_M>
<PROFIT_M>10.72504228</PROFIT_M>
<INCOME_M>2.21775068</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.188474042E7</REVENUE>
<PREV_YEAR_REV>1.860202936E7</PREV_YEAR_REV>
<BUDGET>2.122819821E7</BUDGET>
<GROSS_PROFIT>1.566148621E7</GROSS_PROFIT>
<EXPENSES>1.972687386E7</EXPENSES>
<NET_INCOME>2122819.82</NET_INCOME>
<REVENUE_M>21.88474042</REVENUE_M>
<PROFIT_M>15.66148621</PROFIT_M>
<INCOME_M>2.12281982</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.679890088E7</REVENUE>
<PREV_YEAR_REV>1.427906575E7</PREV_YEAR_REV>
<BUDGET>1.629493386E7</BUDGET>
<GROSS_PROFIT>1.202188144E7</GROSS_PROFIT>
<EXPENSES>1.497590567E7</EXPENSES>
<NET_INCOME>2889410.95</NET_INCOME>
<REVENUE_M>16.79890088</REVENUE_M>
<PROFIT_M>12.02188144</PROFIT_M>
<INCOME_M>2.88941095</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>5.886115861E7</REVENUE>
<PREV_YEAR_REV>5.415226592E7</PREV_YEAR_REV>
<BUDGET>5.493838178E7</BUDGET>
<GROSS_PROFIT>4.434011078E7</GROSS_PROFIT>
<EXPENSES>5.301621465E7</EXPENSES>
<NET_INCOME>5723733.71</NET_INCOME>
<REVENUE_M>58.86115861</REVENUE_M>
<PROFIT_M>44.34011078</PROFIT_M>
<INCOME_M>5.72373371</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.929708378E7</REVENUE>
<PREV_YEAR_REV>3.615331708E7</PREV_YEAR_REV>
<BUDGET>3.570910715E7</BUDGET>
<GROSS_PROFIT>2.960249321E7</GROSS_PROFIT>
<EXPENSES>3.398559469E7</EXPENSES>
<NET_INCOME>5311489.09</NET_INCOME>
<REVENUE_M>39.29708378</REVENUE_M>
<PROFIT_M>29.60249321</PROFIT_M>
<INCOME_M>5.31148909</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>6.334438321E7</REVENUE>
<PREV_YEAR_REV>5.827683256E7</PREV_YEAR_REV>
<BUDGET>3.95540416E7</BUDGET>
<GROSS_PROFIT>4.771732387E7</GROSS_PROFIT>
<EXPENSES>5.454854469E7</EXPENSES>
<NET_INCOME>8795838.52</NET_INCOME>
<REVENUE_M>63.34438321</REVENUE_M>
<PROFIT_M>47.71732387</PROFIT_M>
<INCOME_M>8.79583852</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>5432657.32</REVENUE>
<PREV_YEAR_REV>4878810.79</PREV_YEAR_REV>
<BUDGET>3948570.29</BUDGET>
<GROSS_PROFIT>3812820.268</GROSS_PROFIT>
<EXPENSES>4780011.3</EXPENSES>
<NET_INCOME>652646.02</NET_INCOME>
<REVENUE_M>5.43265732</REVENUE_M>
<PROFIT_M>3.812820268</PROFIT_M>
<INCOME_M>0.65264602</INCOME_M>
<PHARMA_REV_M>5.43265732</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.812820268</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.65264602</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>8583764.9</REVENUE>
<PREV_YEAR_REV>7861389.22</PREV_YEAR_REV>
<BUDGET>6040259.02</BUDGET>
<GROSS_PROFIT>7238945.528</GROSS_PROFIT>
<EXPENSES>7750951.37</EXPENSES>
<NET_INCOME>832813.53</NET_INCOME>
<REVENUE_M>8.5837649</REVENUE_M>
<PROFIT_M>7.238945528</PROFIT_M>
<INCOME_M>0.83281353</INCOME_M>
<PHARMA_REV_M>8.5837649</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.238945528</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83281353</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3919059.82</REVENUE>
<PREV_YEAR_REV>3091420.8</PREV_YEAR_REV>
<BUDGET>3831242.98</BUDGET>
<GROSS_PROFIT>3226861.52</GROSS_PROFIT>
<EXPENSES>3391270.11</EXPENSES>
<NET_INCOME>527789.72</NET_INCOME>
<REVENUE_M>3.91905982</REVENUE_M>
<PROFIT_M>3.22686152</PROFIT_M>
<INCOME_M>0.52778972</INCOME_M>
<PHARMA_REV_M>3.91905982</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.22686152</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52778972</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1779727.69</REVENUE>
<PREV_YEAR_REV>1635899.41</PREV_YEAR_REV>
<BUDGET>1688933.01</BUDGET>
<GROSS_PROFIT>1489543.086</GROSS_PROFIT>
<EXPENSES>1461156.43</EXPENSES>
<NET_INCOME>318571.26</NET_INCOME>
<REVENUE_M>1.77972769</REVENUE_M>
<PROFIT_M>1.489543086</PROFIT_M>
<INCOME_M>0.31857126</INCOME_M>
<PHARMA_REV_M>1.77972769</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.489543086</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31857126</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1738950.94</REVENUE>
<PREV_YEAR_REV>1563270.59</PREV_YEAR_REV>
<BUDGET>1657476.13</BUDGET>
<GROSS_PROFIT>1250814.37</GROSS_PROFIT>
<EXPENSES>1561577.94</EXPENSES>
<NET_INCOME>177373</NET_INCOME>
<REVENUE_M>1.73895094</REVENUE_M>
<PROFIT_M>1.25081437</PROFIT_M>
<INCOME_M>0.177373</INCOME_M>
<PHARMA_REV_M>1.73895094</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.25081437</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.177373</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.272422645E7</REVENUE>
<PREV_YEAR_REV>1.163708495E7</PREV_YEAR_REV>
<BUDGET>1.145180381E7</BUDGET>
<GROSS_PROFIT>9731316.033</GROSS_PROFIT>
<EXPENSES>1.118261106E7</EXPENSES>
<NET_INCOME>1541615.39</NET_INCOME>
<REVENUE_M>12.72422645</REVENUE_M>
<PROFIT_M>9.731316033</PROFIT_M>
<INCOME_M>1.54161539</INCOME_M>
<PHARMA_REV_M>12.72422645</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.731316033</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.54161539</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2268168.09</REVENUE>
<PREV_YEAR_REV>1951414.49</PREV_YEAR_REV>
<BUDGET>2446212.52</BUDGET>
<GROSS_PROFIT>1524277.003</GROSS_PROFIT>
<EXPENSES>1961965.4</EXPENSES>
<NET_INCOME>306202.69</NET_INCOME>
<REVENUE_M>2.26816809</REVENUE_M>
<PROFIT_M>1.524277003</PROFIT_M>
<INCOME_M>0.30620269</INCOME_M>
<PHARMA_REV_M>2.26816809</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.524277003</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30620269</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1561541.45</REVENUE>
<PREV_YEAR_REV>1348027.4</PREV_YEAR_REV>
<BUDGET>2087844.18</BUDGET>
<GROSS_PROFIT>1274217.83</GROSS_PROFIT>
<EXPENSES>1355417.98</EXPENSES>
<NET_INCOME>206123.47</NET_INCOME>
<REVENUE_M>1.56154145</REVENUE_M>
<PROFIT_M>1.27421783</PROFIT_M>
<INCOME_M>0.20612347</INCOME_M>
<PHARMA_REV_M>1.56154145</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.27421783</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20612347</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>4453275.92</REVENUE>
<PREV_YEAR_REV>4099344.07</PREV_YEAR_REV>
<BUDGET>4305220.06</BUDGET>
<GROSS_PROFIT>3072693.588</GROSS_PROFIT>
<EXPENSES>3914256.79</EXPENSES>
<NET_INCOME>539019.13</NET_INCOME>
<REVENUE_M>4.45327592</REVENUE_M>
<PROFIT_M>3.072693588</PROFIT_M>
<INCOME_M>0.53901913</INCOME_M>
<PHARMA_REV_M>4.45327592</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.072693588</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53901913</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4599716.88</REVENUE>
<PREV_YEAR_REV>4197719.02</PREV_YEAR_REV>
<BUDGET>4359396.25</BUDGET>
<GROSS_PROFIT>3587918.209</GROSS_PROFIT>
<EXPENSES>3980626.67</EXPENSES>
<NET_INCOME>619090.21</NET_INCOME>
<REVENUE_M>4.59971688</REVENUE_M>
<PROFIT_M>3.587918209</PROFIT_M>
<INCOME_M>0.61909021</INCOME_M>
<PHARMA_REV_M>4.59971688</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.587918209</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61909021</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1698895.53</REVENUE>
<PREV_YEAR_REV>1505499.12</PREV_YEAR_REV>
<BUDGET>2007038.78</BUDGET>
<GROSS_PROFIT>1379503.17</GROSS_PROFIT>
<EXPENSES>1474641.32</EXPENSES>
<NET_INCOME>224254.21</NET_INCOME>
<REVENUE_M>1.69889553</REVENUE_M>
<PROFIT_M>1.37950317</PROFIT_M>
<INCOME_M>0.22425421</INCOME_M>
<PHARMA_REV_M>1.69889553</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.37950317</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22425421</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1642502.24</REVENUE>
<PREV_YEAR_REV>1508640.56</PREV_YEAR_REV>
<BUDGET>1943382.23</BUDGET>
<GROSS_PROFIT>1378059.38</GROSS_PROFIT>
<EXPENSES>1425691.94</EXPENSES>
<NET_INCOME>216810.3</NET_INCOME>
<REVENUE_M>1.64250224</REVENUE_M>
<PROFIT_M>1.37805938</PROFIT_M>
<INCOME_M>0.2168103</INCOME_M>
<PHARMA_REV_M>1.64250224</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.37805938</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2168103</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.836742036E7</REVENUE>
<PREV_YEAR_REV>3.26123073E7</PREV_YEAR_REV>
<BUDGET>3.721639774E7</BUDGET>
<GROSS_PROFIT>2.890217776E7</GROSS_PROFIT>
<EXPENSES>3.420383703E7</EXPENSES>
<NET_INCOME>5076963.38</NET_INCOME>
<REVENUE_M>38.36742036</REVENUE_M>
<PROFIT_M>28.90217776</PROFIT_M>
<INCOME_M>5.07696338</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.289032656E7</REVENUE>
<PREV_YEAR_REV>3.945910044E7</PREV_YEAR_REV>
<BUDGET>3.354813309E7</BUDGET>
<GROSS_PROFIT>2.90783547E7</GROSS_PROFIT>
<EXPENSES>3.927239064E7</EXPENSES>
<NET_INCOME>6418558.82</NET_INCOME>
<REVENUE_M>42.89032656</REVENUE_M>
<PROFIT_M>29.0783547</PROFIT_M>
<INCOME_M>6.41855882</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.937282812E7</REVENUE>
<PREV_YEAR_REV>1.782300187E7</PREV_YEAR_REV>
<BUDGET>1.976028468E7</BUDGET>
<GROSS_PROFIT>1.386387385E7</GROSS_PROFIT>
<EXPENSES>1.727051362E7</EXPENSES>
<NET_INCOME>1976028.47</NET_INCOME>
<REVENUE_M>19.37282812</REVENUE_M>
<PROFIT_M>13.86387385</PROFIT_M>
<INCOME_M>1.97602847</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.444515427E7</REVENUE>
<PREV_YEAR_REV>3.168954193E7</PREV_YEAR_REV>
<BUDGET>3.109977412E7</BUDGET>
<GROSS_PROFIT>2.594753471E7</GROSS_PROFIT>
<EXPENSES>2.98802998E7</EXPENSES>
<NET_INCOME>4564854.46</NET_INCOME>
<REVENUE_M>34.44515427</REVENUE_M>
<PROFIT_M>25.94753471</PROFIT_M>
<INCOME_M>4.56485446</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.088562521E7</REVENUE>
<PREV_YEAR_REV>9890865.37</PREV_YEAR_REV>
<BUDGET>1.197418773E7</BUDGET>
<GROSS_PROFIT>8869933.27</GROSS_PROFIT>
<EXPENSES>9447074.99</EXPENSES>
<NET_INCOME>1438550.23</NET_INCOME>
<REVENUE_M>10.88562521</REVENUE_M>
<PROFIT_M>8.86993327</PROFIT_M>
<INCOME_M>1.43855023</INCOME_M>
<PHARMA_REV_M>10.88562521</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.86993327</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.43855023</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2849802.97</REVENUE>
<PREV_YEAR_REV>2640099.84</PREV_YEAR_REV>
<BUDGET>2026218.45</BUDGET>
<GROSS_PROFIT>2406801.098</GROSS_PROFIT>
<EXPENSES>2641767.35</EXPENSES>
<NET_INCOME>208035.62</NET_INCOME>
<REVENUE_M>2.84980297</REVENUE_M>
<PROFIT_M>2.406801098</PROFIT_M>
<INCOME_M>0.20803562</INCOME_M>
<PHARMA_REV_M>2.84980297</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.406801098</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20803562</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2604678.17</REVENUE>
<PREV_YEAR_REV>2081610.97</PREV_YEAR_REV>
<BUDGET>2489090.63</BUDGET>
<GROSS_PROFIT>1984504.305</GROSS_PROFIT>
<EXPENSES>2320768.25</EXPENSES>
<NET_INCOME>283909.92</NET_INCOME>
<REVENUE_M>2.60467817</REVENUE_M>
<PROFIT_M>1.984504305</PROFIT_M>
<INCOME_M>0.28390992</INCOME_M>
<PHARMA_REV_M>2.60467817</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.984504305</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28390992</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2094509.42</REVENUE>
<PREV_YEAR_REV>1696000.25</PREV_YEAR_REV>
<BUDGET>2009532</BUDGET>
<GROSS_PROFIT>1715193.764</GROSS_PROFIT>
<EXPENSES>1941610.24</EXPENSES>
<NET_INCOME>152899.19</NET_INCOME>
<REVENUE_M>2.09450942</REVENUE_M>
<PROFIT_M>1.715193764</PROFIT_M>
<INCOME_M>0.15289919</INCOME_M>
<PHARMA_REV_M>2.09450942</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.715193764</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15289919</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.655095551E7</REVENUE>
<PREV_YEAR_REV>2.389585996E7</PREV_YEAR_REV>
<BUDGET>2.368395093E7</BUDGET>
<GROSS_PROFIT>2.000083479E7</GROSS_PROFIT>
<EXPENSES>41094189</EXPENSES>
<NET_INCOME>4248152.88</NET_INCOME>
<REVENUE_M>26.55095551</REVENUE_M>
<PROFIT_M>20.00083479</PROFIT_M>
<INCOME_M>4.24815288</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.060053486E7</REVENUE>
<PREV_YEAR_REV>9540481.38</PREV_YEAR_REV>
<BUDGET>9455876.17</BUDGET>
<GROSS_PROFIT>7586113.768</GROSS_PROFIT>
<EXPENSES>1.640695691E7</EXPENSES>
<NET_INCOME>1823292</NET_INCOME>
<REVENUE_M>10.60053486</REVENUE_M>
<PROFIT_M>7.586113768</PROFIT_M>
<INCOME_M>1.823292</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.002322859E7</REVENUE>
<PREV_YEAR_REV>2.852206716E7</PREV_YEAR_REV>
<BUDGET>2.912253174E7</BUDGET>
<GROSS_PROFIT>2.035484829E7</GROSS_PROFIT>
<EXPENSES>2.640529267E7</EXPENSES>
<NET_INCOME>4492991.17</NET_INCOME>
<REVENUE_M>30.02322859</REVENUE_M>
<PROFIT_M>20.35484829</PROFIT_M>
<INCOME_M>4.49299117</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1712920.82</REVENUE>
<PREV_YEAR_REV>1556464.97</PREV_YEAR_REV>
<BUDGET>1684971.95</BUDGET>
<GROSS_PROFIT>1290428.9</GROSS_PROFIT>
<EXPENSES>1486815.27</EXPENSES>
<NET_INCOME>226105.55</NET_INCOME>
<REVENUE_M>1.71292082</REVENUE_M>
<PROFIT_M>1.2904289</PROFIT_M>
<INCOME_M>0.22610555</INCOME_M>
<PHARMA_REV_M>1.71292082</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.2904289</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22610555</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.686970624E7</REVENUE>
<PREV_YEAR_REV>1.52892648E7</PREV_YEAR_REV>
<BUDGET>1.518273561E7</BUDGET>
<GROSS_PROFIT>1.380836635E7</GROSS_PROFIT>
<EXPENSES>1.463586908E7</EXPENSES>
<NET_INCOME>2233837.16</NET_INCOME>
<REVENUE_M>16.86970624</REVENUE_M>
<PROFIT_M>13.80836635</PROFIT_M>
<INCOME_M>2.23383716</INCOME_M>
<PHARMA_REV_M>16.86970624</PHARMA_REV_M>
<PHARMA_PROFIT_M>13.80836635</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.23383716</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2351510.49</REVENUE>
<PREV_YEAR_REV>2103450.56</PREV_YEAR_REV>
<BUDGET>2192026.54</BUDGET>
<GROSS_PROFIT>1865447.392</GROSS_PROFIT>
<EXPENSES>1947050.68</EXPENSES>
<NET_INCOME>404459.8</NET_INCOME>
<REVENUE_M>2.35151049</REVENUE_M>
<PROFIT_M>1.865447392</PROFIT_M>
<INCOME_M>0.4044598</INCOME_M>
<PHARMA_REV_M>2.35151049</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.865447392</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4044598</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1666307.74</REVENUE>
<PREV_YEAR_REV>1532631.61</PREV_YEAR_REV>
<BUDGET>1936463.79</BUDGET>
<GROSS_PROFIT>1365172.605</GROSS_PROFIT>
<EXPENSES>1544667.28</EXPENSES>
<NET_INCOME>121640.47</NET_INCOME>
<REVENUE_M>1.66630774</REVENUE_M>
<PROFIT_M>1.365172605</PROFIT_M>
<INCOME_M>0.12164047</INCOME_M>
<PHARMA_REV_M>1.66630774</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.365172605</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12164047</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1581300.1</REVENUE>
<PREV_YEAR_REV>1412795.93</PREV_YEAR_REV>
<BUDGET>1924363.45</BUDGET>
<GROSS_PROFIT>1206294.781</GROSS_PROFIT>
<EXPENSES>1420007.49</EXPENSES>
<NET_INCOME>161292.61</NET_INCOME>
<REVENUE_M>1.5813001</REVENUE_M>
<PROFIT_M>1.206294781</PROFIT_M>
<INCOME_M>0.16129261</INCOME_M>
<PHARMA_REV_M>1.5813001</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.206294781</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16129261</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.006690423E7</REVENUE>
<PREV_YEAR_REV>9563559.02</PREV_YEAR_REV>
<BUDGET>9764897.1</BUDGET>
<GROSS_PROFIT>7204229.012</GROSS_PROFIT>
<EXPENSES>8484962.14</EXPENSES>
<NET_INCOME>1731507.53</NET_INCOME>
<REVENUE_M>10.06690423</REVENUE_M>
<PROFIT_M>7.204229012</PROFIT_M>
<INCOME_M>1.73150753</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.987650993E7</REVENUE>
<PREV_YEAR_REV>2.838268443E7</PREV_YEAR_REV>
<BUDGET>2.898021463E7</BUDGET>
<GROSS_PROFIT>2.250597493E7</GROSS_PROFIT>
<EXPENSES>2.524485193E7</EXPENSES>
<NET_INCOME>3943699.31</NET_INCOME>
<REVENUE_M>29.87650993</REVENUE_M>
<PROFIT_M>22.50597493</PROFIT_M>
<INCOME_M>3.94369931</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.248587139E7</REVENUE>
<PREV_YEAR_REV>1.186157781E7</PREV_YEAR_REV>
<BUDGET>1.211129525E7</BUDGET>
<GROSS_PROFIT>9405606.913</GROSS_PROFIT>
<EXPENSES>9790596.39</EXPENSES>
<NET_INCOME>1706879.23</NET_INCOME>
<REVENUE_M>12.48587139</REVENUE_M>
<PROFIT_M>9.405606913</PROFIT_M>
<INCOME_M>1.70687923</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.685719425E7</REVENUE>
<PREV_YEAR_REV>2.551433453E7</PREV_YEAR_REV>
<BUDGET>2.605147842E7</BUDGET>
<GROSS_PROFIT>2.023152443E7</GROSS_PROFIT>
<EXPENSES>2.269361092E7</EXPENSES>
<NET_INCOME>3553874.36</NET_INCOME>
<REVENUE_M>26.85719425</REVENUE_M>
<PROFIT_M>20.23152443</PROFIT_M>
<INCOME_M>3.55387436</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.631197369E7</REVENUE>
<PREV_YEAR_REV>24996375</PREV_YEAR_REV>
<BUDGET>2.552261448E7</BUDGET>
<GROSS_PROFIT>1.982080978E7</GROSS_PROFIT>
<EXPENSES>3.382968046E7</EXPENSES>
<NET_INCOME>3557182.39</NET_INCOME>
<REVENUE_M>26.31197369</REVENUE_M>
<PROFIT_M>19.82080978</PROFIT_M>
<INCOME_M>3.55718239</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>8161374.38</REVENUE>
<PREV_YEAR_REV>7753305.66</PREV_YEAR_REV>
<BUDGET>7916533.14</BUDGET>
<GROSS_PROFIT>6147963.313</GROSS_PROFIT>
<EXPENSES>1.049319563E7</EXPENSES>
<NET_INCOME>595780.33</NET_INCOME>
<REVENUE_M>8.16137438</REVENUE_M>
<PROFIT_M>6.147963313</PROFIT_M>
<INCOME_M>0.59578033</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.497149206E7</REVENUE>
<PREV_YEAR_REV>3.322291746E7</PREV_YEAR_REV>
<BUDGET>3.392234729E7</BUDGET>
<GROSS_PROFIT>2.370962247E7</GROSS_PROFIT>
<EXPENSES>4.282223517E7</EXPENSES>
<NET_INCOME>4232771.09</NET_INCOME>
<REVENUE_M>34.97149206</REVENUE_M>
<PROFIT_M>23.70962247</PROFIT_M>
<INCOME_M>4.23277109</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.201510961E7</REVENUE>
<PREV_YEAR_REV>1.141435413E7</PREV_YEAR_REV>
<BUDGET>1.165465632E7</BUDGET>
<GROSS_PROFIT>9050982.065</GROSS_PROFIT>
<EXPENSES>1.471237911E7</EXPENSES>
<NET_INCOME>1309646.95</NET_INCOME>
<REVENUE_M>12.01510961</REVENUE_M>
<PROFIT_M>9.050982065</PROFIT_M>
<INCOME_M>1.30964695</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.339901481E7</REVENUE>
<PREV_YEAR_REV>1.272906407E7</PREV_YEAR_REV>
<BUDGET>1.299704437E7</BUDGET>
<GROSS_PROFIT>9588803.967</GROSS_PROFIT>
<EXPENSES>1.640695691E7</EXPENSES>
<NET_INCOME>2304630.55</NET_INCOME>
<REVENUE_M>13.39901481</REVENUE_M>
<PROFIT_M>9.588803967</PROFIT_M>
<INCOME_M>2.30463055</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.054669205E7</REVENUE>
<PREV_YEAR_REV>3.446468824E7</PREV_YEAR_REV>
<BUDGET>3.933029129E7</BUDGET>
<GROSS_PROFIT>3.054382312E7</GROSS_PROFIT>
<EXPENSES>3.608655592E7</EXPENSES>
<NET_INCOME>5352163.35</NET_INCOME>
<REVENUE_M>40.54669205</REVENUE_M>
<PROFIT_M>30.54382312</PROFIT_M>
<INCOME_M>5.35216335</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.838022781E7</REVENUE>
<PREV_YEAR_REV>1.562319364E7</PREV_YEAR_REV>
<BUDGET>1.782882097E7</BUDGET>
<GROSS_PROFIT>1.38458256E7</GROSS_PROFIT>
<EXPENSES>1.635840275E7</EXPENSES>
<NET_INCOME>1341756.63</NET_INCOME>
<REVENUE_M>18.38022781</REVENUE_M>
<PROFIT_M>13.8458256</PROFIT_M>
<INCOME_M>1.34175663</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.43478296E7</REVENUE>
<PREV_YEAR_REV>1.219565516E7</PREV_YEAR_REV>
<BUDGET>1.391739471E7</BUDGET>
<GROSS_PROFIT>1.026780904E7</GROSS_PROFIT>
<EXPENSES>1.276956834E7</EXPENSES>
<NET_INCOME>1463478.62</NET_INCOME>
<REVENUE_M>14.3478296</REVENUE_M>
<PROFIT_M>10.26780904</PROFIT_M>
<INCOME_M>1.46347862</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.90628159E7</REVENUE>
<PREV_YEAR_REV>1.620339352E7</PREV_YEAR_REV>
<BUDGET>1.849093143E7</BUDGET>
<GROSS_PROFIT>1.436001922E7</GROSS_PROFIT>
<EXPENSES>1.699414353E7</EXPENSES>
<NET_INCOME>2516291.7</NET_INCOME>
<REVENUE_M>19.0628159</REVENUE_M>
<PROFIT_M>14.36001922</PROFIT_M>
<INCOME_M>2.5162917</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>3.113342471E7</REVENUE>
<PREV_YEAR_REV>2.646341101E7</PREV_YEAR_REV>
<BUDGET>3.019942197E7</BUDGET>
<GROSS_PROFIT>2.110752795E7</GROSS_PROFIT>
<EXPENSES>2.851449637E7</EXPENSES>
<NET_INCOME>3789423.55</NET_INCOME>
<REVENUE_M>31.13342471</REVENUE_M>
<PROFIT_M>21.10752795</PROFIT_M>
<INCOME_M>3.78942355</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.862139639E7</REVENUE>
<PREV_YEAR_REV>3.282818693E7</PREV_YEAR_REV>
<BUDGET>3.746275449E7</BUDGET>
<GROSS_PROFIT>2.618414811E7</GROSS_PROFIT>
<EXPENSES>3.486432678E7</EXPENSES>
<NET_INCOME>5731746.13</NET_INCOME>
<REVENUE_M>38.62139639</REVENUE_M>
<PROFIT_M>26.18414811</PROFIT_M>
<INCOME_M>5.73174613</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.513820185E7</REVENUE>
<PREV_YEAR_REV>1.286747157E7</PREV_YEAR_REV>
<BUDGET>1.468405579E7</BUDGET>
<GROSS_PROFIT>1.083342708E7</GROSS_PROFIT>
<EXPENSES>1.349542357E7</EXPENSES>
<NET_INCOME>2603770.72</NET_INCOME>
<REVENUE_M>15.13820185</REVENUE_M>
<PROFIT_M>10.83342708</PROFIT_M>
<INCOME_M>2.60377072</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.157866568E7</REVENUE>
<PREV_YEAR_REV>1.834186583E7</PREV_YEAR_REV>
<BUDGET>2.093130571E7</BUDGET>
<GROSS_PROFIT>1.487050588E7</GROSS_PROFIT>
<EXPENSES>1.942079911E7</EXPENSES>
<NET_INCOME>2093130.57</NET_INCOME>
<REVENUE_M>21.57866568</REVENUE_M>
<PROFIT_M>14.87050588</PROFIT_M>
<INCOME_M>2.09313057</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.757069602E7</REVENUE>
<PREV_YEAR_REV>3.193509162E7</PREV_YEAR_REV>
<BUDGET>3.644357514E7</BUDGET>
<GROSS_PROFIT>2.45284046E7</GROSS_PROFIT>
<EXPENSES>3.381362642E7</EXPENSES>
<NET_INCOME>5538519.95</NET_INCOME>
<REVENUE_M>37.57069602</REVENUE_M>
<PROFIT_M>24.5284046</PROFIT_M>
<INCOME_M>5.53851995</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.165910625E7</REVENUE>
<PREV_YEAR_REV>9910240.31</PREV_YEAR_REV>
<BUDGET>1.130933306E7</BUDGET>
<GROSS_PROFIT>8457515.678</GROSS_PROFIT>
<EXPENSES>1.049319563E7</EXPENSES>
<NET_INCOME>851114.76</NET_INCOME>
<REVENUE_M>11.65910625</REVENUE_M>
<PROFIT_M>8.457515678</PROFIT_M>
<INCOME_M>0.85111476</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.822995213E7</REVENUE>
<PREV_YEAR_REV>1.549545931E7</PREV_YEAR_REV>
<BUDGET>1.768305356E7</BUDGET>
<GROSS_PROFIT>1.256280691E7</GROSS_PROFIT>
<EXPENSES>1.640695691E7</EXPENSES>
<NET_INCOME>3135551.77</NET_INCOME>
<REVENUE_M>18.22995213</REVENUE_M>
<PROFIT_M>12.56280691</PROFIT_M>
<INCOME_M>3.13555177</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.19364013E7</REVENUE>
<PREV_YEAR_REV>1.86459411E7</PREV_YEAR_REV>
<BUDGET>2.127830926E7</BUDGET>
<GROSS_PROFIT>1.65246911E7</GROSS_PROFIT>
<EXPENSES>1.977292856E7</EXPENSES>
<NET_INCOME>3509824.21</NET_INCOME>
<REVENUE_M>21.9364013</REVENUE_M>
<PROFIT_M>16.5246911</PROFIT_M>
<INCOME_M>3.50982421</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.862139639E7</REVENUE>
<PREV_YEAR_REV>3.282818693E7</PREV_YEAR_REV>
<BUDGET>3.746275449E7</BUDGET>
<GROSS_PROFIT>2.618414811E7</GROSS_PROFIT>
<EXPENSES>3.486432678E7</EXPENSES>
<NET_INCOME>5731746.13</NET_INCOME>
<REVENUE_M>38.62139639</REVENUE_M>
<PROFIT_M>26.18414811</PROFIT_M>
<INCOME_M>5.73174613</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.783695913E7</REVENUE>
<PREV_YEAR_REV>1.516141525E7</PREV_YEAR_REV>
<BUDGET>1.730185035E7</BUDGET>
<GROSS_PROFIT>1.343658131E7</GROSS_PROFIT>
<EXPENSES>1.514168413E7</EXPENSES>
<NET_INCOME>2438398.9</NET_INCOME>
<REVENUE_M>17.83695913</REVENUE_M>
<PROFIT_M>13.43658131</PROFIT_M>
<INCOME_M>2.4383989</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.016678089E7</REVENUE>
<PREV_YEAR_REV>2.564176376E7</PREV_YEAR_REV>
<BUDGET>2.926177746E7</BUDGET>
<GROSS_PROFIT>2.272463604E7</GROSS_PROFIT>
<EXPENSES>2.689312046E7</EXPENSES>
<NET_INCOME>3997901.57</NET_INCOME>
<REVENUE_M>30.16678089</REVENUE_M>
<PROFIT_M>22.72463604</PROFIT_M>
<INCOME_M>3.99790157</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.010967511E7</REVENUE>
<PREV_YEAR_REV>1.85009011E7</PREV_YEAR_REV>
<BUDGET>1.847186861E7</BUDGET>
<GROSS_PROFIT>1.514861826E7</GROSS_PROFIT>
<EXPENSES>1.811761085E7</EXPENSES>
<NET_INCOME>2654477.11</NET_INCOME>
<REVENUE_M>20.10967511</REVENUE_M>
<PROFIT_M>15.14861826</PROFIT_M>
<INCOME_M>2.65447711</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.692675348E7</REVENUE>
<PREV_YEAR_REV>2.47726132E7</PREV_YEAR_REV>
<BUDGET>2.338528854E7</BUDGET>
<GROSS_PROFIT>1.825553105E7</GROSS_PROFIT>
<EXPENSES>2.44048106E7</EXPENSES>
<NET_INCOME>3165452.37</NET_INCOME>
<REVENUE_M>26.92675348</REVENUE_M>
<PROFIT_M>18.25553105</PROFIT_M>
<INCOME_M>3.16545237</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.838022781E7</REVENUE>
<PREV_YEAR_REV>1.690980958E7</PREV_YEAR_REV>
<BUDGET>1.874783236E7</BUDGET>
<GROSS_PROFIT>1.38458256E7</GROSS_PROFIT>
<EXPENSES>1.635840275E7</EXPENSES>
<NET_INCOME>1341756.63</NET_INCOME>
<REVENUE_M>18.38022781</REVENUE_M>
<PROFIT_M>13.8458256</PROFIT_M>
<INCOME_M>1.34175663</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>4.328557343E7</REVENUE>
<PREV_YEAR_REV>3.982272755E7</PREV_YEAR_REV>
<BUDGET>4.415128489E7</BUDGET>
<GROSS_PROFIT>3.097667133E7</GROSS_PROFIT>
<EXPENSES>3.858827843E7</EXPENSES>
<NET_INCOME>4198700.62</NET_INCOME>
<REVENUE_M>43.28557343</REVENUE_M>
<PROFIT_M>30.97667133</PROFIT_M>
<INCOME_M>4.19870062</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.074386641E7</REVENUE>
<PREV_YEAR_REV>9884357.1</PREV_YEAR_REV>
<BUDGET>1.095874374E7</BUDGET>
<GROSS_PROFIT>8093354.565</GROSS_PROFIT>
<EXPENSES>9577955.78</EXPENSES>
<NET_INCOME>784302.25</NET_INCOME>
<REVENUE_M>10.74386641</REVENUE_M>
<PROFIT_M>8.093354565</PROFIT_M>
<INCOME_M>0.78430225</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.185005166E7</REVENUE>
<PREV_YEAR_REV>2.010204753E7</PREV_YEAR_REV>
<BUDGET>1.994598785E7</BUDGET>
<GROSS_PROFIT>1.645964391E7</GROSS_PROFIT>
<EXPENSES>2.025499789E7</EXPENSES>
<NET_INCOME>1595053.77</NET_INCOME>
<REVENUE_M>21.85005166</REVENUE_M>
<PROFIT_M>16.45964391</PROFIT_M>
<INCOME_M>1.59505377</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.187741997E7</REVENUE>
<PREV_YEAR_REV>2.012722637E7</PREV_YEAR_REV>
<BUDGET>1.997198775E7</BUDGET>
<GROSS_PROFIT>1.648026047E7</GROSS_PROFIT>
<EXPENSES>1.79613618E7</EXPENSES>
<NET_INCOME>3916058.17</NET_INCOME>
<REVENUE_M>21.87741997</REVENUE_M>
<PROFIT_M>16.48026047</PROFIT_M>
<INCOME_M>3.91605817</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5049965.75</REVENUE>
<PREV_YEAR_REV>4535951.71</PREV_YEAR_REV>
<BUDGET>5554962.33</BUDGET>
<GROSS_PROFIT>4278525.41</GROSS_PROFIT>
<EXPENSES>4181371.64</EXPENSES>
<NET_INCOME>868594.11</NET_INCOME>
<REVENUE_M>5.04996575</REVENUE_M>
<PROFIT_M>4.27852541</PROFIT_M>
<INCOME_M>0.86859411</INCOME_M>
<PHARMA_REV_M>5.04996575</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.27852541</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.86859411</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>5118161.59</REVENUE>
<PREV_YEAR_REV>4637612.21</PREV_YEAR_REV>
<BUDGET>5629977.75</BUDGET>
<GROSS_PROFIT>4585207.423</GROSS_PROFIT>
<EXPENSES>4560281.98</EXPENSES>
<NET_INCOME>557879.61</NET_INCOME>
<REVENUE_M>5.11816159</REVENUE_M>
<PROFIT_M>4.585207423</PROFIT_M>
<INCOME_M>0.55787961</INCOME_M>
<PHARMA_REV_M>5.11816159</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.585207423</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55787961</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2644383.46</REVENUE>
<PREV_YEAR_REV>2396881.48</PREV_YEAR_REV>
<BUDGET>1923380.23</BUDGET>
<GROSS_PROFIT>2034853.07</GROSS_PROFIT>
<EXPENSES>2221282.1</EXPENSES>
<NET_INCOME>423101.35</NET_INCOME>
<REVENUE_M>2.64438346</REVENUE_M>
<PROFIT_M>2.03485307</PROFIT_M>
<INCOME_M>0.42310135</INCOME_M>
<PHARMA_REV_M>2.64438346</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.03485307</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42310135</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2788257.07</REVENUE>
<PREV_YEAR_REV>2536531.67</PREV_YEAR_REV>
<BUDGET>2024171.87</BUDGET>
<GROSS_PROFIT>1961998.912</GROSS_PROFIT>
<EXPENSES>2428571.91</EXPENSES>
<NET_INCOME>359685.16</NET_INCOME>
<REVENUE_M>2.78825707</REVENUE_M>
<PROFIT_M>1.961998912</PROFIT_M>
<INCOME_M>0.35968516</INCOME_M>
<PHARMA_REV_M>2.78825707</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.961998912</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35968516</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2799169.04</REVENUE>
<PREV_YEAR_REV>2569152.79</PREV_YEAR_REV>
<BUDGET>1949853.43</BUDGET>
<GROSS_PROFIT>2287816.84</GROSS_PROFIT>
<EXPENSES>2429678.72</EXPENSES>
<NET_INCOME>369490.31</NET_INCOME>
<REVENUE_M>2.79916904</REVENUE_M>
<PROFIT_M>2.28781684</PROFIT_M>
<INCOME_M>0.36949031</INCOME_M>
<PHARMA_REV_M>2.79916904</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.28781684</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36949031</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2554990.67</REVENUE>
<PREV_YEAR_REV>1991978.01</PREV_YEAR_REV>
<BUDGET>2442384.38</BUDGET>
<GROSS_PROFIT>2009755.666</GROSS_PROFIT>
<EXPENSES>2097647.34</EXPENSES>
<NET_INCOME>457343.33</NET_INCOME>
<REVENUE_M>2.55499067</REVENUE_M>
<PROFIT_M>2.009755666</PROFIT_M>
<INCOME_M>0.45734333</INCOME_M>
<PHARMA_REV_M>2.55499067</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.009755666</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45734333</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>5119356.34</REVENUE>
<PREV_YEAR_REV>4127523.36</PREV_YEAR_REV>
<BUDGET>4893581.26</BUDGET>
<GROSS_PROFIT>3835639.773</GROSS_PROFIT>
<EXPENSES>4359052.24</EXPENSES>
<NET_INCOME>760304.1</NET_INCOME>
<REVENUE_M>5.11935634</REVENUE_M>
<PROFIT_M>3.835639773</PROFIT_M>
<INCOME_M>0.7603041</INCOME_M>
<PHARMA_REV_M>5.11935634</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.835639773</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.7603041</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2582834.42</REVENUE>
<PREV_YEAR_REV>2073200.32</PREV_YEAR_REV>
<BUDGET>2468557.5</BUDGET>
<GROSS_PROFIT>1947973.725</GROSS_PROFIT>
<EXPENSES>2234151.78</EXPENSES>
<NET_INCOME>348682.65</NET_INCOME>
<REVENUE_M>2.58283442</REVENUE_M>
<PROFIT_M>1.947973725</PROFIT_M>
<INCOME_M>0.34868265</INCOME_M>
<PHARMA_REV_M>2.58283442</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.947973725</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34868265</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2548896.92</REVENUE>
<PREV_YEAR_REV>2047685.05</PREV_YEAR_REV>
<BUDGET>2436656.25</BUDGET>
<GROSS_PROFIT>1961376.185</GROSS_PROFIT>
<EXPENSES>2110486.65</EXPENSES>
<NET_INCOME>438410.27</NET_INCOME>
<REVENUE_M>2.54889692</REVENUE_M>
<PROFIT_M>1.961376185</PROFIT_M>
<INCOME_M>0.43841027</INCOME_M>
<PHARMA_REV_M>2.54889692</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.961376185</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43841027</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4257538.84</REVENUE>
<PREV_YEAR_REV>3548488.15</PREV_YEAR_REV>
<BUDGET>4083472.8</BUDGET>
<GROSS_PROFIT>3248889.705</GROSS_PROFIT>
<EXPENSES>3787775.79</EXPENSES>
<NET_INCOME>469763.06</NET_INCOME>
<REVENUE_M>4.25753884</REVENUE_M>
<PROFIT_M>3.248889705</PROFIT_M>
<INCOME_M>0.46976306</INCOME_M>
<PHARMA_REV_M>4.25753884</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.248889705</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46976306</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2091149.42</REVENUE>
<PREV_YEAR_REV>1757814.97</PREV_YEAR_REV>
<BUDGET>2006373.6</BUDGET>
<GROSS_PROFIT>1519742.844</GROSS_PROFIT>
<EXPENSES>1821391.15</EXPENSES>
<NET_INCOME>269758.28</NET_INCOME>
<REVENUE_M>2.09114942</REVENUE_M>
<PROFIT_M>1.519742844</PROFIT_M>
<INCOME_M>0.26975828</INCOME_M>
<PHARMA_REV_M>2.09114942</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.519742844</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26975828</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3987458.92</REVENUE>
<PREV_YEAR_REV>3260865.65</PREV_YEAR_REV>
<BUDGET>3829597.68</BUDGET>
<GROSS_PROFIT>3231151.22</GROSS_PROFIT>
<EXPENSES>3455126.4</EXPENSES>
<NET_INCOME>532332.52</NET_INCOME>
<REVENUE_M>3.98745892</REVENUE_M>
<PROFIT_M>3.23115122</PROFIT_M>
<INCOME_M>0.53233252</INCOME_M>
<PHARMA_REV_M>3.98745892</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.23115122</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53233252</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>2.528885268E7</REVENUE>
<PREV_YEAR_REV>2.275996741E7</PREV_YEAR_REV>
<BUDGET>2.402441005E7</BUDGET>
<GROSS_PROFIT>1.905009272E7</GROSS_PROFIT>
<EXPENSES>41684922</EXPENSES>
<NET_INCOME>3338128.55</NET_INCOME>
<REVENUE_M>25.28885268</REVENUE_M>
<PROFIT_M>19.05009272</PROFIT_M>
<INCOME_M>3.33812855</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>9953553.86</REVENUE>
<PREV_YEAR_REV>8958198.47</PREV_YEAR_REV>
<BUDGET>9455876.17</BUDGET>
<GROSS_PROFIT>7123111.52</GROSS_PROFIT>
<EXPENSES>1.640695691E7</EXPENSES>
<NET_INCOME>1712011.26</NET_INCOME>
<REVENUE_M>9.95355386</REVENUE_M>
<PROFIT_M>7.12311152</PROFIT_M>
<INCOME_M>1.71201126</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.522880644E7</REVENUE>
<PREV_YEAR_REV>1.37059258E7</PREV_YEAR_REV>
<BUDGET>1.358438133E7</BUDGET>
<GROSS_PROFIT>1.03246739E7</GROSS_PROFIT>
<EXPENSES>2.357035512E7</EXPENSES>
<NET_INCOME>1842230.72</NET_INCOME>
<REVENUE_M>15.22880644</REVENUE_M>
<PROFIT_M>10.3246739</PROFIT_M>
<INCOME_M>1.84223072</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.506721635E7</REVENUE>
<PREV_YEAR_REV>1.356049471E7</PREV_YEAR_REV>
<BUDGET>1.344023994E7</BUDGET>
<GROSS_PROFIT>1.021512067E7</GROSS_PROFIT>
<EXPENSES>2.332025438E7</EXPENSES>
<NET_INCOME>2239601.02</NET_INCOME>
<REVENUE_M>15.06721635</REVENUE_M>
<PROFIT_M>10.21512067</PROFIT_M>
<INCOME_M>2.23960102</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.407677258E7</REVENUE>
<PREV_YEAR_REV>1.337293395E7</PREV_YEAR_REV>
<BUDGET>1.36544694E7</BUDGET>
<GROSS_PROFIT>1.060403278E7</GROSS_PROFIT>
<EXPENSES>9679842.75</EXPENSES>
<NET_INCOME>2252283.61</NET_INCOME>
<REVENUE_M>14.07677258</REVENUE_M>
<PROFIT_M>10.60403278</PROFIT_M>
<INCOME_M>2.25228361</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.535770686E7</REVENUE>
<PREV_YEAR_REV>1.458982152E7</PREV_YEAR_REV>
<BUDGET>1.489697566E7</BUDGET>
<GROSS_PROFIT>1.156896058E7</GROSS_PROFIT>
<EXPENSES>1.327435293E7</EXPENSES>
<NET_INCOME>2457233.1</NET_INCOME>
<REVENUE_M>15.35770686</REVENUE_M>
<PROFIT_M>11.56896058</PROFIT_M>
<INCOME_M>2.4572331</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2562019.51</REVENUE>
<PREV_YEAR_REV>2290032.37</PREV_YEAR_REV>
<BUDGET>1888743.09</BUDGET>
<GROSS_PROFIT>2164291.604</GROSS_PROFIT>
<EXPENSES>2103418.02</EXPENSES>
<NET_INCOME>458601.49</NET_INCOME>
<REVENUE_M>2.56201951</REVENUE_M>
<PROFIT_M>2.164291604</PROFIT_M>
<INCOME_M>0.45860149</INCOME_M>
<PHARMA_REV_M>2.56201951</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.164291604</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45860149</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3758893.84</REVENUE>
<PREV_YEAR_REV>3434682.77</PREV_YEAR_REV>
<BUDGET>3485600.62</BUDGET>
<GROSS_PROFIT>2931997.541</GROSS_PROFIT>
<EXPENSES>3300904.53</EXPENSES>
<NET_INCOME>457989.32</NET_INCOME>
<REVENUE_M>3.75889384</REVENUE_M>
<PROFIT_M>2.931997541</PROFIT_M>
<INCOME_M>0.45798932</INCOME_M>
<PHARMA_REV_M>3.75889384</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.931997541</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45798932</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1905220.64</REVENUE>
<PREV_YEAR_REV>1704193.92</PREV_YEAR_REV>
<BUDGET>1767849.41</BUDGET>
<GROSS_PROFIT>1514650.41</GROSS_PROFIT>
<EXPENSES>1653731.51</EXPENSES>
<NET_INCOME>251489.12</NET_INCOME>
<REVENUE_M>1.90522064</REVENUE_M>
<PROFIT_M>1.51465041</PROFIT_M>
<INCOME_M>0.25148912</INCOME_M>
<PHARMA_REV_M>1.90522064</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.51465041</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25148912</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>5555125.95</REVENUE>
<PREV_YEAR_REV>5052751.73</PREV_YEAR_REV>
<BUDGET>5128991.17</BUDGET>
<GROSS_PROFIT>4540206.72</GROSS_PROFIT>
<EXPENSES>5015879.83</EXPENSES>
<NET_INCOME>539246.11</NET_INCOME>
<REVENUE_M>5.55512595</REVENUE_M>
<PROFIT_M>4.54020672</PROFIT_M>
<INCOME_M>0.53924611</INCOME_M>
<PHARMA_REV_M>5.55512595</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.54020672</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53924611</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1754845.27</REVENUE>
<PREV_YEAR_REV>1578595.12</PREV_YEAR_REV>
<BUDGET>1707031.98</BUDGET>
<GROSS_PROFIT>1553038.06</GROSS_PROFIT>
<EXPENSES>1626741.56</EXPENSES>
<NET_INCOME>128103.7</NET_INCOME>
<REVENUE_M>1.75484527</REVENUE_M>
<PROFIT_M>1.55303806</PROFIT_M>
<INCOME_M>0.1281037</INCOME_M>
<PHARMA_REV_M>1.75484527</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.55303806</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1281037</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1867022.53</REVENUE>
<PREV_YEAR_REV>1691572.62</PREV_YEAR_REV>
<BUDGET>1705685.22</BUDGET>
<GROSS_PROFIT>1460635.2</GROSS_PROFIT>
<EXPENSES>1614974.49</EXPENSES>
<NET_INCOME>252048.04</NET_INCOME>
<REVENUE_M>1.86702253</REVENUE_M>
<PROFIT_M>1.4606352</PROFIT_M>
<INCOME_M>0.25204804</INCOME_M>
<PHARMA_REV_M>1.86702253</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.4606352</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25204804</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3634519.02</REVENUE>
<PREV_YEAR_REV>3305045.81</PREV_YEAR_REV>
<BUDGET>3373904.96</BUDGET>
<GROSS_PROFIT>2879133.204</GROSS_PROFIT>
<EXPENSES>3151956.34</EXPENSES>
<NET_INCOME>482562.68</NET_INCOME>
<REVENUE_M>3.63451902</REVENUE_M>
<PROFIT_M>2.879133204</PROFIT_M>
<INCOME_M>0.48256268</INCOME_M>
<PHARMA_REV_M>3.63451902</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.879133204</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48256268</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1768371.35</REVENUE>
<PREV_YEAR_REV>1598195.49</PREV_YEAR_REV>
<BUDGET>1717269.79</BUDGET>
<GROSS_PROFIT>1418804.122</GROSS_PROFIT>
<EXPENSES>1464211.48</EXPENSES>
<NET_INCOME>304159.87</NET_INCOME>
<REVENUE_M>1.76837135</REVENUE_M>
<PROFIT_M>1.418804122</PROFIT_M>
<INCOME_M>0.30415987</INCOME_M>
<PHARMA_REV_M>1.76837135</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.418804122</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30415987</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1836307.68</REVENUE>
<PREV_YEAR_REV>1633449.57</PREV_YEAR_REV>
<BUDGET>1684971.95</BUDGET>
<GROSS_PROFIT>1479329.465</GROSS_PROFIT>
<EXPENSES>1520462.76</EXPENSES>
<NET_INCOME>315844.92</NET_INCOME>
<REVENUE_M>1.83630768</REVENUE_M>
<PROFIT_M>1.479329465</PROFIT_M>
<INCOME_M>0.31584492</INCOME_M>
<PHARMA_REV_M>1.83630768</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.479329465</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31584492</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2139562.27</REVENUE>
<PREV_YEAR_REV>1942742.98</PREV_YEAR_REV>
<BUDGET>1745037.99</BUDGET>
<GROSS_PROFIT>1713789.38</GROSS_PROFIT>
<EXPENSES>1906349.98</EXPENSES>
<NET_INCOME>233212.29</NET_INCOME>
<REVENUE_M>2.13956227</REVENUE_M>
<PROFIT_M>1.71378938</PROFIT_M>
<INCOME_M>0.23321229</INCOME_M>
<PHARMA_REV_M>2.13956227</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.71378938</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23321229</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2978296.24</REVENUE>
<PREV_YEAR_REV>2668930.38</PREV_YEAR_REV>
<BUDGET>2401972.54</BUDGET>
<GROSS_PROFIT>2126280.134</GROSS_PROFIT>
<EXPENSES>2619530.44</EXPENSES>
<NET_INCOME>358765.8</NET_INCOME>
<REVENUE_M>2.97829624</REVENUE_M>
<PROFIT_M>2.126280134</PROFIT_M>
<INCOME_M>0.3587658</INCOME_M>
<PHARMA_REV_M>2.97829624</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.126280134</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3587658</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1280740.88</REVENUE>
<PREV_YEAR_REV>1185048.24</PREV_YEAR_REV>
<BUDGET>1100308.86</BUDGET>
<GROSS_PROFIT>1032981.56</GROSS_PROFIT>
<EXPENSES>1141140.13</EXPENSES>
<NET_INCOME>139600.76</NET_INCOME>
<REVENUE_M>1.28074088</REVENUE_M>
<PROFIT_M>1.03298156</PROFIT_M>
<INCOME_M>0.13960076</INCOME_M>
<PHARMA_REV_M>1.28074088</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.03298156</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13960076</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1484622.52</REVENUE>
<PREV_YEAR_REV>1326278.17</PREV_YEAR_REV>
<BUDGET>1209965.61</BUDGET>
<GROSS_PROFIT>1143827.427</GROSS_PROFIT>
<EXPENSES>1229267.45</EXPENSES>
<NET_INCOME>255355.07</NET_INCOME>
<REVENUE_M>1.48462252</REVENUE_M>
<PROFIT_M>1.143827427</PROFIT_M>
<INCOME_M>0.25535507</INCOME_M>
<PHARMA_REV_M>1.48462252</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.143827427</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25535507</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.393339045E7</REVENUE>
<PREV_YEAR_REV>1.260253426E7</PREV_YEAR_REV>
<BUDGET>1.25400514E7</BUDGET>
<GROSS_PROFIT>1.09862632E7</GROSS_PROFIT>
<EXPENSES>5820622.37</EXPENSES>
<NET_INCOME>1553701.87</NET_INCOME>
<REVENUE_M>13.93339045</REVENUE_M>
<PROFIT_M>10.9862632</PROFIT_M>
<INCOME_M>1.55370187</INCOME_M>
<PHARMA_REV_M>13.93339045</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.9862632</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.55370187</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6258509.49</REVENUE>
<PREV_YEAR_REV>5739645.54</PREV_YEAR_REV>
<BUDGET>5632658.54</BUDGET>
<GROSS_PROFIT>5189618.653</GROSS_PROFIT>
<EXPENSES>5432386.24</EXPENSES>
<NET_INCOME>826123.25</NET_INCOME>
<REVENUE_M>6.25850949</REVENUE_M>
<PROFIT_M>5.189618653</PROFIT_M>
<INCOME_M>0.82612325</INCOME_M>
<PHARMA_REV_M>6.25850949</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.189618653</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.82612325</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2173866.99</REVENUE>
<PREV_YEAR_REV>1904044.8</PREV_YEAR_REV>
<BUDGET>2354971.54</BUDGET>
<GROSS_PROFIT>1565608.139</GROSS_PROFIT>
<EXPENSES>1799961.87</EXPENSES>
<NET_INCOME>373905.12</NET_INCOME>
<REVENUE_M>2.17386699</REVENUE_M>
<PROFIT_M>1.565608139</PROFIT_M>
<INCOME_M>0.37390512</INCOME_M>
<PHARMA_REV_M>2.17386699</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.565608139</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37390512</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2138655.14</REVENUE>
<PREV_YEAR_REV>1826146.66</PREV_YEAR_REV>
<BUDGET>2324545.95</BUDGET>
<GROSS_PROFIT>1794010.866</GROSS_PROFIT>
<EXPENSES>1905541.73</EXPENSES>
<NET_INCOME>233113.41</NET_INCOME>
<REVENUE_M>2.13865514</REVENUE_M>
<PROFIT_M>1.794010866</PROFIT_M>
<INCOME_M>0.23311341</INCOME_M>
<PHARMA_REV_M>2.13865514</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.794010866</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23311341</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2279529.7</REVENUE>
<PREV_YEAR_REV>2063426.99</PREV_YEAR_REV>
<BUDGET>2348161.26</BUDGET>
<GROSS_PROFIT>1885373.939</GROSS_PROFIT>
<EXPENSES>2047017.67</EXPENSES>
<NET_INCOME>232512.03</NET_INCOME>
<REVENUE_M>2.2795297</REVENUE_M>
<PROFIT_M>1.885373939</PROFIT_M>
<INCOME_M>0.23251203</INCOME_M>
<PHARMA_REV_M>2.2795297</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.885373939</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23251203</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2168389.14</REVENUE>
<PREV_YEAR_REV>1888511.7</PREV_YEAR_REV>
<BUDGET>2336484.8</BUDGET>
<GROSS_PROFIT>1712637.113</GROSS_PROFIT>
<EXPENSES>1932034.72</EXPENSES>
<NET_INCOME>236354.42</NET_INCOME>
<REVENUE_M>2.16838914</REVENUE_M>
<PROFIT_M>1.712637113</PROFIT_M>
<INCOME_M>0.23635442</INCOME_M>
<PHARMA_REV_M>2.16838914</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.712637113</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23635442</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>4666722.3</REVENUE>
<PREV_YEAR_REV>4056768.32</PREV_YEAR_REV>
<BUDGET>4765749.16</BUDGET>
<GROSS_PROFIT>3716522.688</GROSS_PROFIT>
<EXPENSES>4044412.1</EXPENSES>
<NET_INCOME>622310.2</NET_INCOME>
<REVENUE_M>4.6667223</REVENUE_M>
<PROFIT_M>3.716522688</PROFIT_M>
<INCOME_M>0.6223102</INCOME_M>
<PHARMA_REV_M>4.6667223</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.716522688</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.6223102</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3334451.34</REVENUE>
<PREV_YEAR_REV>2912874.85</PREV_YEAR_REV>
<BUDGET>4251360.89</BUDGET>
<GROSS_PROFIT>2523388.426</GROSS_PROFIT>
<EXPENSES>2930399.57</EXPENSES>
<NET_INCOME>404051.77</NET_INCOME>
<REVENUE_M>3.33445134</REVENUE_M>
<PROFIT_M>2.523388426</PROFIT_M>
<INCOME_M>0.40405177</INCOME_M>
<PHARMA_REV_M>3.33445134</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.523388426</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40405177</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3247173.42</REVENUE>
<PREV_YEAR_REV>2917182.64</PREV_YEAR_REV>
<BUDGET>4140390.36</BUDGET>
<GROSS_PROFIT>2577375.186</GROSS_PROFIT>
<EXPENSES>2810864.76</EXPENSES>
<NET_INCOME>436308.66</NET_INCOME>
<REVENUE_M>3.24717342</REVENUE_M>
<PROFIT_M>2.577375186</PROFIT_M>
<INCOME_M>0.43630866</INCOME_M>
<PHARMA_REV_M>3.24717342</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.577375186</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43630866</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.252101588E7</REVENUE>
<PREV_YEAR_REV>1.131422763E7</PREV_YEAR_REV>
<BUDGET>1.12689143E7</BUDGET>
<GROSS_PROFIT>9371094.003</GROSS_PROFIT>
<EXPENSES>1.065994199E7</EXPENSES>
<NET_INCOME>1861073.89</NET_INCOME>
<REVENUE_M>12.52101588</REVENUE_M>
<PROFIT_M>9.371094003</PROFIT_M>
<INCOME_M>1.86107389</INCOME_M>
<PHARMA_REV_M>12.52101588</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.371094003</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.86107389</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5973569.81</REVENUE>
<PREV_YEAR_REV>5297173.7</PREV_YEAR_REV>
<BUDGET>5376212.83</BUDGET>
<GROSS_PROFIT>4695225.87</GROSS_PROFIT>
<EXPENSES>5537499.22</EXPENSES>
<NET_INCOME>436070.6</NET_INCOME>
<REVENUE_M>5.97356981</REVENUE_M>
<PROFIT_M>4.69522587</PROFIT_M>
<INCOME_M>0.4360706</INCOME_M>
<PHARMA_REV_M>5.97356981</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.69522587</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.4360706</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5584321.47</REVENUE>
<PREV_YEAR_REV>5060966.88</PREV_YEAR_REV>
<BUDGET>5025889.32</BUDGET>
<GROSS_PROFIT>4212253.688</GROSS_PROFIT>
<EXPENSES>4623818.18</EXPENSES>
<NET_INCOME>960503.29</NET_INCOME>
<REVENUE_M>5.58432147</REVENUE_M>
<PROFIT_M>4.212253688</PROFIT_M>
<INCOME_M>0.96050329</INCOME_M>
<PHARMA_REV_M>5.58432147</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.212253688</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.96050329</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5285275.05</REVENUE>
<PREV_YEAR_REV>4740879.82</PREV_YEAR_REV>
<BUDGET>4756747.55</BUDGET>
<GROSS_PROFIT>4577048.2</GROSS_PROFIT>
<EXPENSES>4709180.07</EXPENSES>
<NET_INCOME>576094.98</NET_INCOME>
<REVENUE_M>5.28527505</REVENUE_M>
<PROFIT_M>4.5770482</PROFIT_M>
<INCOME_M>0.57609498</INCOME_M>
<PHARMA_REV_M>5.28527505</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.5770482</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57609498</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8492803.37</REVENUE>
<PREV_YEAR_REV>7767689.55</PREV_YEAR_REV>
<BUDGET>7643523.04</BUDGET>
<GROSS_PROFIT>6962824.845</GROSS_PROFIT>
<EXPENSES>7626537.43</EXPENSES>
<NET_INCOME>866265.94</NET_INCOME>
<REVENUE_M>8.49280337</REVENUE_M>
<PROFIT_M>6.962824845</PROFIT_M>
<INCOME_M>0.86626594</INCOME_M>
<PHARMA_REV_M>8.49280337</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.962824845</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.86626594</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2326236.8</REVENUE>
<PREV_YEAR_REV>2109104.49</PREV_YEAR_REV>
<BUDGET>2205903.64</BUDGET>
<GROSS_PROFIT>1791169.772</GROSS_PROFIT>
<EXPENSES>2026152.25</EXPENSES>
<NET_INCOME>300084.55</NET_INCOME>
<REVENUE_M>2.3262368</REVENUE_M>
<PROFIT_M>1.791169772</PROFIT_M>
<INCOME_M>0.30008455</INCOME_M>
<PHARMA_REV_M>2.3262368</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.791169772</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30008455</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6808265.19</REVENUE>
<PREV_YEAR_REV>6182570.89</PREV_YEAR_REV>
<BUDGET>6585837.99</BUDGET>
<GROSS_PROFIT>5826745.954</GROSS_PROFIT>
<EXPENSES>6147854.41</EXPENSES>
<NET_INCOME>660410.77</NET_INCOME>
<REVENUE_M>6.80826519</REVENUE_M>
<PROFIT_M>5.826745954</PROFIT_M>
<INCOME_M>0.66041077</INCOME_M>
<PHARMA_REV_M>6.80826519</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.826745954</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.66041077</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2331791.35</REVENUE>
<PREV_YEAR_REV>2087361.34</PREV_YEAR_REV>
<BUDGET>2276954.38</BUDGET>
<GROSS_PROFIT>1770389.266</GROSS_PROFIT>
<EXPENSES>2016999.52</EXPENSES>
<NET_INCOME>314791.83</NET_INCOME>
<REVENUE_M>2.33179135</REVENUE_M>
<PROFIT_M>1.770389266</PROFIT_M>
<INCOME_M>0.31479183</INCOME_M>
<PHARMA_REV_M>2.33179135</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.770389266</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.31479183</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3115531.07</REVENUE>
<PREV_YEAR_REV>2848549.19</PREV_YEAR_REV>
<BUDGET>3836734.94</BUDGET>
<GROSS_PROFIT>2535763.864</GROSS_PROFIT>
<EXPENSES>2769919.04</EXPENSES>
<NET_INCOME>345612.02</NET_INCOME>
<REVENUE_M>3.11553107</REVENUE_M>
<PROFIT_M>2.535763864</PROFIT_M>
<INCOME_M>0.34561202</INCOME_M>
<PHARMA_REV_M>3.11553107</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.535763864</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34561202</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3216623.79</REVENUE>
<PREV_YEAR_REV>2862209.89</PREV_YEAR_REV>
<BUDGET>3879846.02</BUDGET>
<GROSS_PROFIT>2477441.709</GROSS_PROFIT>
<EXPENSES>2828911.41</EXPENSES>
<NET_INCOME>387712.38</NET_INCOME>
<REVENUE_M>3.21662379</REVENUE_M>
<PROFIT_M>2.477441709</PROFIT_M>
<INCOME_M>0.38771238</INCOME_M>
<PHARMA_REV_M>3.21662379</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.477441709</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38771238</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3148074.24</REVENUE>
<PREV_YEAR_REV>2804661.49</PREV_YEAR_REV>
<BUDGET>3860827.24</BUDGET>
<GROSS_PROFIT>2326772.942</GROSS_PROFIT>
<EXPENSES>2680523.85</EXPENSES>
<NET_INCOME>467550.39</NET_INCOME>
<REVENUE_M>3.14807424</REVENUE_M>
<PROFIT_M>2.326772942</PROFIT_M>
<INCOME_M>0.46755039</INCOME_M>
<PHARMA_REV_M>3.14807424</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.326772942</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46755039</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3207235.3</REVENUE>
<PREV_YEAR_REV>2880552.63</PREV_YEAR_REV>
<BUDGET>3860185.22</BUDGET>
<GROSS_PROFIT>2329312.167</GROSS_PROFIT>
<EXPENSES>2731122.73</EXPENSES>
<NET_INCOME>476112.58</NET_INCOME>
<REVENUE_M>3.2072353</REVENUE_M>
<PROFIT_M>2.329312167</PROFIT_M>
<INCOME_M>0.47611258</INCOME_M>
<PHARMA_REV_M>3.2072353</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.329312167</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47611258</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1606881.75</REVENUE>
<PREV_YEAR_REV>1450149.58</PREV_YEAR_REV>
<BUDGET>1917445.01</BUDGET>
<GROSS_PROFIT>1348173.78</GROSS_PROFIT>
<EXPENSES>1319249.91</EXPENSES>
<NET_INCOME>287631.83</NET_INCOME>
<REVENUE_M>1.60688175</REVENUE_M>
<PROFIT_M>1.34817378</PROFIT_M>
<INCOME_M>0.28763183</INCOME_M>
<PHARMA_REV_M>1.60688175</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.34817378</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28763183</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3140722.86</REVENUE>
<PREV_YEAR_REV>2858204.7</PREV_YEAR_REV>
<BUDGET>3834890.02</BUDGET>
<GROSS_PROFIT>2567049.084</GROSS_PROFIT>
<EXPENSES>2718460.67</EXPENSES>
<NET_INCOME>422262.19</NET_INCOME>
<REVENUE_M>3.14072286</REVENUE_M>
<PROFIT_M>2.567049084</PROFIT_M>
<INCOME_M>0.42226219</INCOME_M>
<PHARMA_REV_M>3.14072286</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.567049084</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42226219</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1575304.16</REVENUE>
<PREV_YEAR_REV>1421664.84</PREV_YEAR_REV>
<BUDGET>1881732.03</BUDGET>
<GROSS_PROFIT>1194238.089</GROSS_PROFIT>
<EXPENSES>1414623.14</EXPENSES>
<NET_INCOME>160681.02</NET_INCOME>
<REVENUE_M>1.57530416</REVENUE_M>
<PROFIT_M>1.194238089</PROFIT_M>
<INCOME_M>0.16068102</INCOME_M>
<PHARMA_REV_M>1.57530416</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.194238089</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16068102</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2535673.03</REVENUE>
<PREV_YEAR_REV>2308669.96</PREV_YEAR_REV>
<BUDGET>2671804.11</BUDGET>
<GROSS_PROFIT>1801635.822</GROSS_PROFIT>
<EXPENSES>2161035.34</EXPENSES>
<NET_INCOME>374637.69</NET_INCOME>
<REVENUE_M>2.53567303</REVENUE_M>
<PROFIT_M>1.801635822</PROFIT_M>
<INCOME_M>0.37463769</INCOME_M>
<PHARMA_REV_M>2.53567303</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.801635822</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37463769</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1248019.53</REVENUE>
<PREV_YEAR_REV>1122077.54</PREV_YEAR_REV>
<BUDGET>1310292.53</BUDGET>
<GROSS_PROFIT>1053328.48</GROSS_PROFIT>
<EXPENSES>1111985.4</EXPENSES>
<NET_INCOME>136034.13</NET_INCOME>
<REVENUE_M>1.24801953</REVENUE_M>
<PROFIT_M>1.05332848</PROFIT_M>
<INCOME_M>0.13603413</INCOME_M>
<PHARMA_REV_M>1.24801953</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.05332848</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13603413</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.331782725E7</REVENUE>
<PREV_YEAR_REV>1.194520098E7</PREV_YEAR_REV>
<BUDGET>1.358418379E7</BUDGET>
<GROSS_PROFIT>1.047782531E7</GROSS_PROFIT>
<EXPENSES>1.184799418E7</EXPENSES>
<NET_INCOME>1469833.07</NET_INCOME>
<REVENUE_M>13.31782725</REVENUE_M>
<PROFIT_M>10.47782531</PROFIT_M>
<INCOME_M>1.46983307</INCOME_M>
<PHARMA_REV_M>13.31782725</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.47782531</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.46983307</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6602741.78</REVENUE>
<PREV_YEAR_REV>5964644.15</PREV_YEAR_REV>
<BUDGET>6734796.62</BUDGET>
<GROSS_PROFIT>5701797.672</GROSS_PROFIT>
<EXPENSES>5420851</EXPENSES>
<NET_INCOME>1181890.78</NET_INCOME>
<REVENUE_M>6.60274178</REVENUE_M>
<PROFIT_M>5.701797672</PROFIT_M>
<INCOME_M>1.18189078</INCOME_M>
<PHARMA_REV_M>6.60274178</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.701797672</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.18189078</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.293506524E7</REVENUE>
<PREV_YEAR_REV>1.115852124E7</PREV_YEAR_REV>
<BUDGET>1.319376654E7</BUDGET>
<GROSS_PROFIT>9352529.883</GROSS_PROFIT>
<EXPENSES>1.101310301E7</EXPENSES>
<NET_INCOME>1921962.22</NET_INCOME>
<REVENUE_M>12.93506524</REVENUE_M>
<PROFIT_M>9.352529883</PROFIT_M>
<INCOME_M>1.92196222</INCOME_M>
<PHARMA_REV_M>12.93506524</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.352529883</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.92196222</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8048427.7</REVENUE>
<PREV_YEAR_REV>7089689.05</PREV_YEAR_REV>
<BUDGET>8209396.26</BUDGET>
<GROSS_PROFIT>7042374.24</GROSS_PROFIT>
<EXPENSES>7171149.08</EXPENSES>
<NET_INCOME>877278.62</NET_INCOME>
<REVENUE_M>8.0484277</REVENUE_M>
<PROFIT_M>7.04237424</PROFIT_M>
<INCOME_M>0.87727862</INCOME_M>
<PHARMA_REV_M>8.0484277</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.04237424</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.87727862</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>3887811.21</REVENUE>
<PREV_YEAR_REV>3369943.6</PREV_YEAR_REV>
<BUDGET>4003869.06</BUDGET>
<GROSS_PROFIT>3039013.843</GROSS_PROFIT>
<EXPENSES>3458926.43</EXPENSES>
<NET_INCOME>428884.78</NET_INCOME>
<REVENUE_M>3.88781121</REVENUE_M>
<PROFIT_M>3.039013843</PROFIT_M>
<INCOME_M>0.42888478</INCOME_M>
<PHARMA_REV_M>3.88781121</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.039013843</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42888478</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>4368690.02</REVENUE>
<PREV_YEAR_REV>3862916.73</PREV_YEAR_REV>
<BUDGET>4674758.64</BUDGET>
<GROSS_PROFIT>3564402.312</GROSS_PROFIT>
<EXPENSES>3780231.84</EXPENSES>
<NET_INCOME>588458.17</NET_INCOME>
<REVENUE_M>4.36869002</REVENUE_M>
<PROFIT_M>3.564402312</PROFIT_M>
<INCOME_M>0.58845817</INCOME_M>
<PHARMA_REV_M>4.36869002</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.564402312</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58845817</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2361463.77</REVENUE>
<PREV_YEAR_REV>2050006.31</PREV_YEAR_REV>
<BUDGET>2446212.52</BUDGET>
<GROSS_PROFIT>2082173.449</GROSS_PROFIT>
<EXPENSES>2189076.91</EXPENSES>
<NET_INCOME>172386.85</NET_INCOME>
<REVENUE_M>2.36146377</REVENUE_M>
<PROFIT_M>2.082173449</PROFIT_M>
<INCOME_M>0.17238685</INCOME_M>
<PHARMA_REV_M>2.36146377</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.082173449</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17238685</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2434935.42</REVENUE>
<PREV_YEAR_REV>2191384.91</PREV_YEAR_REV>
<BUDGET>2417587.9</BUDGET>
<GROSS_PROFIT>1989561.388</GROSS_PROFIT>
<EXPENSES>1999081.98</EXPENSES>
<NET_INCOME>435853.44</NET_INCOME>
<REVENUE_M>2.43493542</REVENUE_M>
<PROFIT_M>1.989561388</PROFIT_M>
<INCOME_M>0.43585344</INCOME_M>
<PHARMA_REV_M>2.43493542</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.989561388</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.43585344</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2337304.58</REVENUE>
<PREV_YEAR_REV>2066454.4</PREV_YEAR_REV>
<BUDGET>2327181.8</BUDGET>
<GROSS_PROFIT>1798088.408</GROSS_PROFIT>
<EXPENSES>2166681.34</EXPENSES>
<NET_INCOME>170623.23</NET_INCOME>
<REVENUE_M>2.33730458</REVENUE_M>
<PROFIT_M>1.798088408</PROFIT_M>
<INCOME_M>0.17062323</INCOME_M>
<PHARMA_REV_M>2.33730458</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.798088408</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17062323</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>8207613.95</REVENUE>
<PREV_YEAR_REV>7544061.37</PREV_YEAR_REV>
<BUDGET>5995366.57</BUDGET>
<GROSS_PROFIT>6680083.358</GROSS_PROFIT>
<EXPENSES>7408855.89</EXPENSES>
<NET_INCOME>798758.04</NET_INCOME>
<REVENUE_M>8.20761395</REVENUE_M>
<PROFIT_M>6.680083358</PROFIT_M>
<INCOME_M>0.79875804</INCOME_M>
<PHARMA_REV_M>8.20761395</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.680083358</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.79875804</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5276788.84</REVENUE>
<PREV_YEAR_REV>4842310.03</PREV_YEAR_REV>
<BUDGET>4008654.3</BUDGET>
<GROSS_PROFIT>4057904.983</GROSS_PROFIT>
<EXPENSES>4492505.01</EXPENSES>
<NET_INCOME>784283.82</NET_INCOME>
<REVENUE_M>5.27678884</REVENUE_M>
<PROFIT_M>4.057904983</PROFIT_M>
<INCOME_M>0.78428382</INCOME_M>
<PHARMA_REV_M>5.27678884</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.057904983</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.78428382</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>4254520</REVENUE>
<PREV_YEAR_REV>3880650.3</PREV_YEAR_REV>
<BUDGET>3574621.65</BUDGET>
<GROSS_PROFIT>3209674.86</GROSS_PROFIT>
<EXPENSES>3738795.03</EXPENSES>
<NET_INCOME>515724.97</NET_INCOME>
<REVENUE_M>4.25452</REVENUE_M>
<PROFIT_M>3.20967486</PROFIT_M>
<INCOME_M>0.51572497</INCOME_M>
<PHARMA_REV_M>4.25452</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.20967486</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51572497</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1994860.58</REVENUE>
<PREV_YEAR_REV>1862771.45</PREV_YEAR_REV>
<BUDGET>1782390.04</BUDGET>
<GROSS_PROFIT>1607857.63</GROSS_PROFIT>
<EXPENSES>1731538.98</EXPENSES>
<NET_INCOME>263321.6</NET_INCOME>
<REVENUE_M>1.99486058</REVENUE_M>
<PROFIT_M>1.60785763</PROFIT_M>
<INCOME_M>0.2633216</INCOME_M>
<PHARMA_REV_M>1.99486058</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.60785763</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2633216</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3976382.42</REVENUE>
<PREV_YEAR_REV>3587645.69</PREV_YEAR_REV>
<BUDGET>3534646.23</BUDGET>
<GROSS_PROFIT>3214628.72</GROSS_PROFIT>
<EXPENSES>3441835.45</EXPENSES>
<NET_INCOME>534546.97</NET_INCOME>
<REVENUE_M>3.97638242</REVENUE_M>
<PROFIT_M>3.21462872</PROFIT_M>
<INCOME_M>0.53454697</INCOME_M>
<PHARMA_REV_M>3.97638242</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.21462872</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.53454697</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3970666.32</REVENUE>
<PREV_YEAR_REV>3697435.43</PREV_YEAR_REV>
<BUDGET>3513078.53</BUDGET>
<GROSS_PROFIT>3065986.158</GROSS_PROFIT>
<EXPENSES>3442234.65</EXPENSES>
<NET_INCOME>528431.67</NET_INCOME>
<REVENUE_M>3.97066632</REVENUE_M>
<PROFIT_M>3.065986158</PROFIT_M>
<INCOME_M>0.52843167</INCOME_M>
<PHARMA_REV_M>3.97066632</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.065986158</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52843167</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2154873.85</REVENUE>
<PREV_YEAR_REV>1984997.75</PREV_YEAR_REV>
<BUDGET>1792231.61</BUDGET>
<GROSS_PROFIT>1690929.51</GROSS_PROFIT>
<EXPENSES>1919992.6</EXPENSES>
<NET_INCOME>234881.25</NET_INCOME>
<REVENUE_M>2.15487385</REVENUE_M>
<PROFIT_M>1.69092951</PROFIT_M>
<INCOME_M>0.23488125</INCOME_M>
<PHARMA_REV_M>2.15487385</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.69092951</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23488125</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1986174.84</REVENUE>
<PREV_YEAR_REV>1775939.16</PREV_YEAR_REV>
<BUDGET>1717667.92</BUDGET>
<GROSS_PROFIT>1652894.702</GROSS_PROFIT>
<EXPENSES>1783585</EXPENSES>
<NET_INCOME>202589.83</NET_INCOME>
<REVENUE_M>1.98617484</REVENUE_M>
<PROFIT_M>1.652894702</PROFIT_M>
<INCOME_M>0.20258983</INCOME_M>
<PHARMA_REV_M>1.98617484</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.652894702</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20258983</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3905839.1</REVENUE>
<PREV_YEAR_REV>3613748.65</PREV_YEAR_REV>
<BUDGET>3513954.18</BUDGET>
<GROSS_PROFIT>3252874.02</GROSS_PROFIT>
<EXPENSES>3389024.76</EXPENSES>
<NET_INCOME>516814.34</NET_INCOME>
<REVENUE_M>3.9058391</REVENUE_M>
<PROFIT_M>3.25287402</PROFIT_M>
<INCOME_M>0.51681434</INCOME_M>
<PHARMA_REV_M>3.9058391</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.25287402</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.51681434</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3619747.37</REVENUE>
<PREV_YEAR_REV>3304329.86</PREV_YEAR_REV>
<BUDGET>2564164.62</BUDGET>
<GROSS_PROFIT>2686933.631</GROSS_PROFIT>
<EXPENSES>3219775.95</EXPENSES>
<NET_INCOME>399971.42</NET_INCOME>
<REVENUE_M>3.61974737</REVENUE_M>
<PROFIT_M>2.686933631</PROFIT_M>
<INCOME_M>0.39997142</INCOME_M>
<PHARMA_REV_M>3.61974737</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.686933631</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39997142</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1626958.76</REVENUE>
<PREV_YEAR_REV>1515946.03</PREV_YEAR_REV>
<BUDGET>1145903.43</BUDGET>
<GROSS_PROFIT>1160135.478</GROSS_PROFIT>
<EXPENSES>1407319.33</EXPENSES>
<NET_INCOME>219639.43</NET_INCOME>
<REVENUE_M>1.62695876</REVENUE_M>
<PROFIT_M>1.160135478</PROFIT_M>
<INCOME_M>0.21963943</INCOME_M>
<PHARMA_REV_M>1.62695876</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.160135478</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21963943</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1600498.18</REVENUE>
<PREV_YEAR_REV>1455712.97</PREV_YEAR_REV>
<BUDGET>1136693.94</BUDGET>
<GROSS_PROFIT>1190226.476</GROSS_PROFIT>
<EXPENSES>1437247.37</EXPENSES>
<NET_INCOME>163250.81</NET_INCOME>
<REVENUE_M>1.60049818</REVENUE_M>
<PROFIT_M>1.190226476</PROFIT_M>
<INCOME_M>0.16325081</INCOME_M>
<PHARMA_REV_M>1.60049818</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.190226476</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.16325081</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6766477.59</REVENUE>
<PREV_YEAR_REV>6135113.1</PREV_YEAR_REV>
<BUDGET>6089829.83</BUDGET>
<GROSS_PROFIT>5298151.95</GROSS_PROFIT>
<EXPENSES>5893601.98</EXPENSES>
<NET_INCOME>872875.61</NET_INCOME>
<REVENUE_M>6.76647759</REVENUE_M>
<PROFIT_M>5.29815195</PROFIT_M>
<INCOME_M>0.87287561</INCOME_M>
<PHARMA_REV_M>6.76647759</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.29815195</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.87287561</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9297502.96</REVENUE>
<PREV_YEAR_REV>8584714.14</PREV_YEAR_REV>
<BUDGET>8367752.66</BUDGET>
<GROSS_PROFIT>7261349.81</GROSS_PROFIT>
<EXPENSES>7809902.49</EXPENSES>
<NET_INCOME>1487600.47</NET_INCOME>
<REVENUE_M>9.29750296</REVENUE_M>
<PROFIT_M>7.26134981</PROFIT_M>
<INCOME_M>1.48760047</INCOME_M>
<PHARMA_REV_M>9.29750296</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.26134981</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.48760047</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.653797678E7</REVENUE>
<PREV_YEAR_REV>1.48564058E7</PREV_YEAR_REV>
<BUDGET>1.48841791E7</BUDGET>
<GROSS_PROFIT>1.283262112E7</GROSS_PROFIT>
<EXPENSES>1.467670373E7</EXPENSES>
<NET_INCOME>1861273.04</NET_INCOME>
<REVENUE_M>16.53797678</REVENUE_M>
<PROFIT_M>12.83262112</PROFIT_M>
<INCOME_M>1.86127304</INCOME_M>
<PHARMA_REV_M>16.53797678</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.83262112</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.86127304</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>6684157.66</REVENUE>
<PREV_YEAR_REV>6153198.19</PREV_YEAR_REV>
<BUDGET>6015741.89</BUDGET>
<GROSS_PROFIT>5354010.29</GROSS_PROFIT>
<EXPENSES>6196214.15</EXPENSES>
<NET_INCOME>487943.51</NET_INCOME>
<REVENUE_M>6.68415766</REVENUE_M>
<PROFIT_M>5.35401029</PROFIT_M>
<INCOME_M>0.48794351</INCOME_M>
<PHARMA_REV_M>6.68415766</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.35401029</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48794351</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5677627.93</REVENUE>
<PREV_YEAR_REV>5160307.14</PREV_YEAR_REV>
<BUDGET>5109865.14</BUDGET>
<GROSS_PROFIT>4428549.78</GROSS_PROFIT>
<EXPENSES>4661332.53</EXPENSES>
<NET_INCOME>1016295.4</NET_INCOME>
<REVENUE_M>5.67762793</REVENUE_M>
<PROFIT_M>4.42854978</PROFIT_M>
<INCOME_M>1.0162954</INCOME_M>
<PHARMA_REV_M>5.67762793</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.42854978</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.0162954</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.762950424E7</REVENUE>
<PREV_YEAR_REV>1.612985177E7</PREV_YEAR_REV>
<BUDGET>1.586655381E7</BUDGET>
<GROSS_PROFIT>1.289503564E7</GROSS_PROFIT>
<EXPENSES>1.498483547E7</EXPENSES>
<NET_INCOME>2644668.77</NET_INCOME>
<REVENUE_M>17.62950424</REVENUE_M>
<PROFIT_M>12.89503564</PROFIT_M>
<INCOME_M>2.64466877</INCOME_M>
<PHARMA_REV_M>17.62950424</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.89503564</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.64466877</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8122279.74</REVENUE>
<PREV_YEAR_REV>7448421.08</PREV_YEAR_REV>
<BUDGET>7310051.76</BUDGET>
<GROSS_PROFIT>6365836.741</GROSS_PROFIT>
<EXPENSES>6725247.62</EXPENSES>
<NET_INCOME>1397032.11</NET_INCOME>
<REVENUE_M>8.12227974</REVENUE_M>
<PROFIT_M>6.365836741</PROFIT_M>
<INCOME_M>1.39703211</INCOME_M>
<PHARMA_REV_M>8.12227974</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.365836741</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.39703211</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4794609.12</REVENUE>
<PREV_YEAR_REV>4160721.98</PREV_YEAR_REV>
<BUDGET>4297170.76</BUDGET>
<GROSS_PROFIT>3600089.028</GROSS_PROFIT>
<EXPENSES>4213064.14</EXPENSES>
<NET_INCOME>581544.98</NET_INCOME>
<REVENUE_M>4.79460912</REVENUE_M>
<PROFIT_M>3.600089028</PROFIT_M>
<INCOME_M>0.58154498</INCOME_M>
<PHARMA_REV_M>4.79460912</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.600089028</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.58154498</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>4724433.37</REVENUE>
<PREV_YEAR_REV>4183372.61</PREV_YEAR_REV>
<BUDGET>4255041.78</BUDGET>
<GROSS_PROFIT>3484384.92</GROSS_PROFIT>
<EXPENSES>4022734.8</EXPENSES>
<NET_INCOME>701698.57</NET_INCOME>
<REVENUE_M>4.72443337</REVENUE_M>
<PROFIT_M>3.48438492</PROFIT_M>
<INCOME_M>0.70169857</INCOME_M>
<PHARMA_REV_M>4.72443337</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.48438492</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.70169857</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>4827731.44</REVENUE>
<PREV_YEAR_REV>4254577.57</PREV_YEAR_REV>
<BUDGET>4276106.27</BUDGET>
<GROSS_PROFIT>3851355.9</GROSS_PROFIT>
<EXPENSES>4188588.9</EXPENSES>
<NET_INCOME>639142.53</NET_INCOME>
<REVENUE_M>4.82773144</REVENUE_M>
<PROFIT_M>3.8513559</PROFIT_M>
<INCOME_M>0.63914253</INCOME_M>
<PHARMA_REV_M>4.82773144</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.8513559</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.63914253</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1815198.78</REVENUE>
<PREV_YEAR_REV>1571832.03</PREV_YEAR_REV>
<BUDGET>1337886.37</BUDGET>
<GROSS_PROFIT>1424931.04</GROSS_PROFIT>
<EXPENSES>1575592.54</EXPENSES>
<NET_INCOME>239606.24</NET_INCOME>
<REVENUE_M>1.81519878</REVENUE_M>
<PROFIT_M>1.42493104</PROFIT_M>
<INCOME_M>0.23960624</INCOME_M>
<PHARMA_REV_M>1.81519878</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.42493104</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23960624</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>2.477158538E7</REVENUE>
<PREV_YEAR_REV>2.172346677E7</PREV_YEAR_REV>
<BUDGET>2.427615366E7</BUDGET>
<GROSS_PROFIT>2.082698098E7</GROSS_PROFIT>
<EXPENSES>2.23369888E7</EXPENSES>
<NET_INCOME>2434596.56</NET_INCOME>
<REVENUE_M>24.77158538</REVENUE_M>
<PROFIT_M>20.82698098</PROFIT_M>
<INCOME_M>2.43459656</INCOME_M>
<PHARMA_REV_M>24.77158538</PHARMA_REV_M>
<PHARMA_PROFIT_M>20.82698098</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.43459656</PHARMA_INCOME_M>
<FRANCE_REV_M>24.77158538</FRANCE_REV_M>
<FRANCE_PROFIT_M>20.82698098</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>2.43459656</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>20127060</REVENUE>
<PREV_YEAR_REV>1.753814486E7</PREV_YEAR_REV>
<BUDGET>1.97245188E7</BUDGET>
<GROSS_PROFIT>1.734601731E7</GROSS_PROFIT>
<EXPENSES>1.745211723E7</EXPENSES>
<NET_INCOME>2674942.77</NET_INCOME>
<REVENUE_M>20.12706</REVENUE_M>
<PROFIT_M>17.34601731</PROFIT_M>
<INCOME_M>2.67494277</INCOME_M>
<PHARMA_REV_M>20.12706</PHARMA_REV_M>
<PHARMA_PROFIT_M>17.34601731</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.67494277</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>1.525663891E7</REVENUE>
<PREV_YEAR_REV>1.382037436E7</PREV_YEAR_REV>
<BUDGET>1.495150613E7</BUDGET>
<GROSS_PROFIT>1.251072962E7</GROSS_PROFIT>
<EXPENSES>1.322316322E7</EXPENSES>
<NET_INCOME>2033475.69</NET_INCOME>
<REVENUE_M>15.25663891</REVENUE_M>
<PROFIT_M>12.51072962</PROFIT_M>
<INCOME_M>2.03347569</INCOME_M>
<PHARMA_REV_M>15.25663891</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.51072962</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.03347569</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>7626207.44</REVENUE>
<PREV_YEAR_REV>6712560.79</PREV_YEAR_REV>
<BUDGET>7473683.29</BUDGET>
<GROSS_PROFIT>6718688.75</GROSS_PROFIT>
<EXPENSES>7069494.3</EXPENSES>
<NET_INCOME>556713.14</NET_INCOME>
<REVENUE_M>7.62620744</REVENUE_M>
<PROFIT_M>6.71868875</PROFIT_M>
<INCOME_M>0.55671314</INCOME_M>
<PHARMA_REV_M>7.62620744</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.71868875</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55671314</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>6773802.23</REVENUE>
<PREV_YEAR_REV>6024209.8</PREV_YEAR_REV>
<BUDGET>6638326.18</BUDGET>
<GROSS_PROFIT>5534196.42</GROSS_PROFIT>
<EXPENSES>5561291.63</EXPENSES>
<NET_INCOME>1212510.6</NET_INCOME>
<REVENUE_M>6.77380223</REVENUE_M>
<PROFIT_M>5.53419642</PROFIT_M>
<INCOME_M>1.2125106</INCOME_M>
<PHARMA_REV_M>6.77380223</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.53419642</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.2125106</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8815655.18</REVENUE>
<PREV_YEAR_REV>7821260.16</PREV_YEAR_REV>
<BUDGET>8639342.07</BUDGET>
<GROSS_PROFIT>6632898.957</GROSS_PROFIT>
<EXPENSES>7625541.73</EXPENSES>
<NET_INCOME>1190113.45</NET_INCOME>
<REVENUE_M>8.81565518</REVENUE_M>
<PROFIT_M>6.632898957</PROFIT_M>
<INCOME_M>1.19011345</INCOME_M>
<PHARMA_REV_M>8.81565518</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.632898957</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.19011345</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.059425456E7</REVENUE>
<PREV_YEAR_REV>9607035.58</PREV_YEAR_REV>
<BUDGET>1.038236947E7</BUDGET>
<GROSS_PROFIT>7800443.687</GROSS_PROFIT>
<EXPENSES>9164030.19</EXPENSES>
<NET_INCOME>1430224.37</NET_INCOME>
<REVENUE_M>10.59425456</REVENUE_M>
<PROFIT_M>7.800443687</PROFIT_M>
<INCOME_M>1.43022437</INCOME_M>
<PHARMA_REV_M>10.59425456</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.800443687</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.43022437</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2464469.81</REVENUE>
<PREV_YEAR_REV>2175959.36</PREV_YEAR_REV>
<BUDGET>2249572.5</BUDGET>
<GROSS_PROFIT>1976356.92</GROSS_PROFIT>
<EXPENSES>2070154.64</EXPENSES>
<NET_INCOME>394315.17</NET_INCOME>
<REVENUE_M>2.46446981</REVENUE_M>
<PROFIT_M>1.97635692</PROFIT_M>
<INCOME_M>0.39431517</INCOME_M>
<PHARMA_REV_M>2.46446981</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.97635692</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.39431517</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5827909.44</REVENUE>
<PREV_YEAR_REV>5141560.16</PREV_YEAR_REV>
<BUDGET>5237863.31</BUDGET>
<GROSS_PROFIT>4343975.323</GROSS_PROFIT>
<EXPENSES>5130536.07</EXPENSES>
<NET_INCOME>697373.38</NET_INCOME>
<REVENUE_M>5.82790944</REVENUE_M>
<PROFIT_M>4.343975323</PROFIT_M>
<INCOME_M>0.69737338</INCOME_M>
<PHARMA_REV_M>5.82790944</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.343975323</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.69737338</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1844919.27</REVENUE>
<PREV_YEAR_REV>1569049.06</PREV_YEAR_REV>
<BUDGET>1789571.69</BUDGET>
<GROSS_PROFIT>1442450.132</GROSS_PROFIT>
<EXPENSES>1710240.16</EXPENSES>
<NET_INCOME>134679.11</NET_INCOME>
<REVENUE_M>1.8449192700000001</REVENUE_M>
<PROFIT_M>1.442450132</PROFIT_M>
<INCOME_M>0.13467911</INCOME_M>
<PHARMA_REV_M>1.8449192700000001</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.442450132</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.13467911</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1826799.58</REVENUE>
<PREV_YEAR_REV>1550539.89</PREV_YEAR_REV>
<BUDGET>1771995.59</BUDGET>
<GROSS_PROFIT>1374206.33</GROSS_PROFIT>
<EXPENSES>1640466.02</EXPENSES>
<NET_INCOME>186333.56</NET_INCOME>
<REVENUE_M>1.82679958</REVENUE_M>
<PROFIT_M>1.37420633</PROFIT_M>
<INCOME_M>0.18633356</INCOME_M>
<PHARMA_REV_M>1.82679958</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.37420633</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18633356</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1833390.96</REVENUE>
<PREV_YEAR_REV>1581300.1</PREV_YEAR_REV>
<BUDGET>1778389.23</BUDGET>
<GROSS_PROFIT>1490913.527</GROSS_PROFIT>
<EXPENSES>1646385.08</EXPENSES>
<NET_INCOME>187005.88</NET_INCOME>
<REVENUE_M>1.83339096</REVENUE_M>
<PROFIT_M>1.490913527</PROFIT_M>
<INCOME_M>0.18700588</INCOME_M>
<PHARMA_REV_M>1.83339096</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.490913527</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18700588</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>3649314.77</REVENUE>
<PREV_YEAR_REV>3194531.13</PREV_YEAR_REV>
<BUDGET>3539835.32</BUDGET>
<GROSS_PROFIT>2927593.236</GROSS_PROFIT>
<EXPENSES>3165692.74</EXPENSES>
<NET_INCOME>483622.04</NET_INCOME>
<REVENUE_M>3.64931477</REVENUE_M>
<PROFIT_M>2.927593236</PROFIT_M>
<INCOME_M>0.48362204</INCOME_M>
<PHARMA_REV_M>3.64931477</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.927593236</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48362204</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>3054263.89</REVENUE>
<PREV_YEAR_REV>2597073.01</PREV_YEAR_REV>
<BUDGET>2962635.98</BUDGET>
<GROSS_PROFIT>2255546.357</GROSS_PROFIT>
<EXPENSES>2717256.36</EXPENSES>
<NET_INCOME>337007.53</NET_INCOME>
<REVENUE_M>3.05426389</REVENUE_M>
<PROFIT_M>2.255546357</PROFIT_M>
<INCOME_M>0.33700753</INCOME_M>
<PHARMA_REV_M>3.05426389</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.255546357</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33700753</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1093047.54</REVENUE>
<PREV_YEAR_REV>932355.99</PREV_YEAR_REV>
<BUDGET>1060256.11</BUDGET>
<GROSS_PROFIT>847002.537</GROSS_PROFIT>
<EXPENSES>952044.41</EXPENSES>
<NET_INCOME>141003.13</NET_INCOME>
<REVENUE_M>1.09304754</REVENUE_M>
<PROFIT_M>0.847002537</PROFIT_M>
<INCOME_M>0.14100313</INCOME_M>
<PHARMA_REV_M>1.09304754</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.847002537</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14100313</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2930376.12</REVENUE>
<PREV_YEAR_REV>2566745.31</PREV_YEAR_REV>
<BUDGET>2682234.84</BUDGET>
<GROSS_PROFIT>2274411.426</GROSS_PROFIT>
<EXPENSES>2405838.79</EXPENSES>
<NET_INCOME>524537.33</NET_INCOME>
<REVENUE_M>2.93037612</REVENUE_M>
<PROFIT_M>2.274411426</PROFIT_M>
<INCOME_M>0.52453733</INCOME_M>
<PHARMA_REV_M>2.93037612</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.274411426</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.52453733</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>6023076.99</REVENUE>
<PREV_YEAR_REV>5272222.81</PREV_YEAR_REV>
<BUDGET>5459560.31</BUDGET>
<GROSS_PROFIT>4959727.675</GROSS_PROFIT>
<EXPENSES>5227972.06</EXPENSES>
<NET_INCOME>795104.93</NET_INCOME>
<REVENUE_M>6.02307699</REVENUE_M>
<PROFIT_M>4.959727675</PROFIT_M>
<INCOME_M>0.79510493</INCOME_M>
<PHARMA_REV_M>6.02307699</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.959727675</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.79510493</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>6260969.44</REVENUE>
<PREV_YEAR_REV>5409118.58</PREV_YEAR_REV>
<BUDGET>7138621.35</BUDGET>
<GROSS_PROFIT>4804700.725</GROSS_PROFIT>
<EXPENSES>5653721.59</EXPENSES>
<NET_INCOME>607247.85</NET_INCOME>
<REVENUE_M>6.26096944</REVENUE_M>
<PROFIT_M>4.804700725</PROFIT_M>
<INCOME_M>0.60724785</INCOME_M>
<PHARMA_REV_M>6.26096944</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.804700725</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60724785</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2060851.05</REVENUE>
<PREV_YEAR_REV>1748751.39</PREV_YEAR_REV>
<BUDGET>2369519.97</BUDGET>
<GROSS_PROFIT>1722871.474</GROSS_PROFIT>
<EXPENSES>1910408.92</EXPENSES>
<NET_INCOME>150442.13</NET_INCOME>
<REVENUE_M>2.06085105</REVENUE_M>
<PROFIT_M>1.722871474</PROFIT_M>
<INCOME_M>0.15044213</INCOME_M>
<PHARMA_REV_M>2.06085105</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.722871474</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15044213</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>2086395.25</REVENUE>
<PREV_YEAR_REV>1768371.35</PREV_YEAR_REV>
<BUDGET>2385613.13</BUDGET>
<GROSS_PROFIT>1540270.866</GROSS_PROFIT>
<EXPENSES>1727535.27</EXPENSES>
<NET_INCOME>358859.98</NET_INCOME>
<REVENUE_M>2.08639525</REVENUE_M>
<PROFIT_M>1.540270866</PROFIT_M>
<INCOME_M>0.35885998</INCOME_M>
<PHARMA_REV_M>2.08639525</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.540270866</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.35885998</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1888609.4</REVENUE>
<PREV_YEAR_REV>1693880.85</PREV_YEAR_REV>
<BUDGET>2149422.19</BUDGET>
<GROSS_PROFIT>1407391.722</GROSS_PROFIT>
<EXPENSES>1633647.13</EXPENSES>
<NET_INCOME>254962.27</NET_INCOME>
<REVENUE_M>1.8886094</REVENUE_M>
<PROFIT_M>1.407391722</PROFIT_M>
<INCOME_M>0.25496227</INCOME_M>
<PHARMA_REV_M>1.8886094</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.407391722</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25496227</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1757814.97</REVENUE>
<PREV_YEAR_REV>1590020.15</PREV_YEAR_REV>
<BUDGET>1680871.5</BUDGET>
<GROSS_PROFIT>1227895.28</GROSS_PROFIT>
<EXPENSES>1531056.84</EXPENSES>
<NET_INCOME>226758.13</NET_INCOME>
<REVENUE_M>1.75781497</REVENUE_M>
<PROFIT_M>1.22789528</PROFIT_M>
<INCOME_M>0.22675813</INCOME_M>
<PHARMA_REV_M>1.75781497</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.22789528</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22675813</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>4829510.75</REVENUE>
<PREV_YEAR_REV>4314386.23</PREV_YEAR_REV>
<BUDGET>4862405.14</BUDGET>
<GROSS_PROFIT>3838537.957</GROSS_PROFIT>
<EXPENSES>4365590.77</EXPENSES>
<NET_INCOME>463919.99</NET_INCOME>
<REVENUE_M>4.82951075</REVENUE_M>
<PROFIT_M>3.838537957</PROFIT_M>
<INCOME_M>0.46391999</INCOME_M>
<PHARMA_REV_M>4.82951075</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.838537957</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46391999</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1696000.25</REVENUE>
<PREV_YEAR_REV>1519413.96</PREV_YEAR_REV>
<BUDGET>1683517.5</BUDGET>
<GROSS_PROFIT>1272848.181</GROSS_PROFIT>
<EXPENSES>1572192.23</EXPENSES>
<NET_INCOME>123808.02</NET_INCOME>
<REVENUE_M>1.69600025</REVENUE_M>
<PROFIT_M>1.272848181</PROFIT_M>
<INCOME_M>0.12380802</INCOME_M>
<PHARMA_REV_M>1.69600025</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.272848181</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12380802</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.467347835E7</REVENUE>
<PREV_YEAR_REV>1.272422645E7</PREV_YEAR_REV>
<BUDGET>1.349960009E7</BUDGET>
<GROSS_PROFIT>1.127142832E7</GROSS_PROFIT>
<EXPENSES>1.289819581E7</EXPENSES>
<NET_INCOME>1775282.56</NET_INCOME>
<REVENUE_M>14.67347835</REVENUE_M>
<PROFIT_M>11.27142832</PROFIT_M>
<INCOME_M>1.77528256</INCOME_M>
<PHARMA_REV_M>14.67347835</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.27142832</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.77528256</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8340418.81</REVENUE>
<PREV_YEAR_REV>7243656.74</PREV_YEAR_REV>
<BUDGET>7673185.3</BUDGET>
<GROSS_PROFIT>7322887.71</GROSS_PROFIT>
<EXPENSES>7005951.8</EXPENSES>
<NET_INCOME>1334467.01</NET_INCOME>
<REVENUE_M>8.34041881</REVENUE_M>
<PROFIT_M>7.32288771</PROFIT_M>
<INCOME_M>1.33446701</INCOME_M>
<PHARMA_REV_M>8.34041881</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.32288771</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.33446701</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2200200.98</REVENUE>
<PREV_YEAR_REV>1886981</PREV_YEAR_REV>
<BUDGET>2134194.95</BUDGET>
<GROSS_PROFIT>1687985.385</GROSS_PROFIT>
<EXPENSES>1916375.05</EXPENSES>
<NET_INCOME>283825.93</NET_INCOME>
<REVENUE_M>2.20020098</REVENUE_M>
<PROFIT_M>1.687985385</PROFIT_M>
<INCOME_M>0.28382593</INCOME_M>
<PHARMA_REV_M>2.20020098</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.687985385</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28382593</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>5059381.26</REVENUE>
<PREV_YEAR_REV>4453990.48</PREV_YEAR_REV>
<BUDGET>4907599.82</BUDGET>
<GROSS_PROFIT>4029233.303</GROSS_PROFIT>
<EXPENSES>4498573.42</EXPENSES>
<NET_INCOME>560807.84</NET_INCOME>
<REVENUE_M>5.05938126</REVENUE_M>
<PROFIT_M>4.029233303</PROFIT_M>
<INCOME_M>0.56080784</INCOME_M>
<PHARMA_REV_M>5.05938126</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.029233303</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.56080784</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>7820389.6</REVENUE>
<PREV_YEAR_REV>6808265.19</PREV_YEAR_REV>
<BUDGET>7585777.92</BUDGET>
<GROSS_PROFIT>6742477.15</GROSS_PROFIT>
<EXPENSES>7063344.1</EXPENSES>
<NET_INCOME>757045.49</NET_INCOME>
<REVENUE_M>7.8203896</REVENUE_M>
<PROFIT_M>6.74247715</PROFIT_M>
<INCOME_M>0.75704549</INCOME_M>
<PHARMA_REV_M>7.8203896</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.74247715</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.75704549</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2672143.43</REVENUE>
<PREV_YEAR_REV>2321866.63</PREV_YEAR_REV>
<BUDGET>2591979.12</BUDGET>
<GROSS_PROFIT>2159091.887</GROSS_PROFIT>
<EXPENSES>2193829.75</EXPENSES>
<NET_INCOME>478313.67</NET_INCOME>
<REVENUE_M>2.67214343</REVENUE_M>
<PROFIT_M>2.159091887</PROFIT_M>
<INCOME_M>0.47831367</INCOME_M>
<PHARMA_REV_M>2.67214343</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.159091887</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.47831367</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2546248.16</REVENUE>
<PREV_YEAR_REV>2172789.16</PREV_YEAR_REV>
<BUDGET>2469860.72</BUDGET>
<GROSS_PROFIT>2148473.277</GROSS_PROFIT>
<EXPENSES>2090469.74</EXPENSES>
<NET_INCOME>455778.42</NET_INCOME>
<REVENUE_M>2.54624816</REVENUE_M>
<PROFIT_M>2.148473277</PROFIT_M>
<INCOME_M>0.45577842</INCOME_M>
<PHARMA_REV_M>2.54624816</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.148473277</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.45577842</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1822515.19</REVENUE>
<PREV_YEAR_REV>1617181.64</PREV_YEAR_REV>
<BUDGET>1767839.73</BUDGET>
<GROSS_PROFIT>1362603.478</GROSS_PROFIT>
<EXPENSES>1581943.18</EXPENSES>
<NET_INCOME>240572</NET_INCOME>
<REVENUE_M>1.82251519</REVENUE_M>
<PROFIT_M>1.362603478</PROFIT_M>
<INCOME_M>0.240572</INCOME_M>
<PHARMA_REV_M>1.82251519</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.362603478</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.240572</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1805377.61</REVENUE>
<PREV_YEAR_REV>1593673.96</PREV_YEAR_REV>
<BUDGET>1751216.28</BUDGET>
<GROSS_PROFIT>1330581.353</GROSS_PROFIT>
<EXPENSES>1572483.9</EXPENSES>
<NET_INCOME>232893.71</NET_INCOME>
<REVENUE_M>1.80537761</REVENUE_M>
<PROFIT_M>1.330581353</PROFIT_M>
<INCOME_M>0.23289371</INCOME_M>
<PHARMA_REV_M>1.80537761</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.330581353</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.23289371</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1547956.9</REVENUE>
<PREV_YEAR_REV>1325135.38</PREV_YEAR_REV>
<BUDGET>2080411.46</BUDGET>
<GROSS_PROFIT>1189682.274</GROSS_PROFIT>
<EXPENSES>1434956.04</EXPENSES>
<NET_INCOME>113000.85</NET_INCOME>
<REVENUE_M>1.5479569</REVENUE_M>
<PROFIT_M>1.189682274</PROFIT_M>
<INCOME_M>0.11300085</INCOME_M>
<PHARMA_REV_M>1.5479569</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.189682274</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.11300085</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1663590.08</REVENUE>
<PREV_YEAR_REV>1474617.81</PREV_YEAR_REV>
<BUDGET>2059978.9</BUDGET>
<GROSS_PROFIT>1245363.531</GROSS_PROFIT>
<EXPENSES>1365807.46</EXPENSES>
<NET_INCOME>297782.62</NET_INCOME>
<REVENUE_M>1.66359008</REVENUE_M>
<PROFIT_M>1.245363531</PROFIT_M>
<INCOME_M>0.29778262</INCOME_M>
<PHARMA_REV_M>1.66359008</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.245363531</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29778262</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>3178980.27</REVENUE>
<PREV_YEAR_REV>2789224.92</PREV_YEAR_REV>
<BUDGET>4147823.08</BUDGET>
<GROSS_PROFIT>2566424.813</GROSS_PROFIT>
<EXPENSES>2755445.75</EXPENSES>
<NET_INCOME>423534.52</NET_INCOME>
<REVENUE_M>3.17898027</REVENUE_M>
<PROFIT_M>2.566424813</PROFIT_M>
<INCOME_M>0.42353452</INCOME_M>
<PHARMA_REV_M>3.17898027</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.566424813</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.42353452</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1595008.34</REVENUE>
<PREV_YEAR_REV>1382407.84</PREV_YEAR_REV>
<BUDGET>2059978.9</BUDGET>
<GROSS_PROFIT>1230389.432</GROSS_PROFIT>
<EXPENSES>1320666.91</EXPENSES>
<NET_INCOME>274341.44</NET_INCOME>
<REVENUE_M>1.59500834</REVENUE_M>
<PROFIT_M>1.230389432</PROFIT_M>
<INCOME_M>0.27434144</INCOME_M>
<PHARMA_REV_M>1.59500834</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.230389432</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27434144</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1503326.02</REVENUE>
<PREV_YEAR_REV>1295289.56</PREV_YEAR_REV>
<BUDGET>2021611.19</BUDGET>
<GROSS_PROFIT>1066406.861</GROSS_PROFIT>
<EXPENSES>1349986.76</EXPENSES>
<NET_INCOME>153339.25</NET_INCOME>
<REVENUE_M>1.50332602</REVENUE_M>
<PROFIT_M>1.066406861</PROFIT_M>
<INCOME_M>0.15333925</INCOME_M>
<PHARMA_REV_M>1.50332602</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.066406861</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15333925</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1524187.09</REVENUE>
<PREV_YEAR_REV>1353677.83</PREV_YEAR_REV>
<BUDGET>1887168.12</BUDGET>
<GROSS_PROFIT>1146798.369</GROSS_PROFIT>
<EXPENSES>1318421.84</EXPENSES>
<NET_INCOME>205765.26</NET_INCOME>
<REVENUE_M>1.52418709</REVENUE_M>
<PROFIT_M>1.146798369</PROFIT_M>
<INCOME_M>0.20576526</INCOME_M>
<PHARMA_REV_M>1.52418709</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.146798369</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.20576526</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2299542.79</REVENUE>
<PREV_YEAR_REV>2009196.1</PREV_YEAR_REV>
<BUDGET>2613148.74</BUDGET>
<GROSS_PROFIT>1788871.518</GROSS_PROFIT>
<EXPENSES>2045286.04</EXPENSES>
<NET_INCOME>254256.75</NET_INCOME>
<REVENUE_M>2.29954279</REVENUE_M>
<PROFIT_M>1.788871518</PROFIT_M>
<INCOME_M>0.25425675</INCOME_M>
<PHARMA_REV_M>2.29954279</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.788871518</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25425675</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2034996.99</REVENUE>
<PREV_YEAR_REV>1814379.12</PREV_YEAR_REV>
<BUDGET>2259204.55</BUDGET>
<GROSS_PROFIT>1636339.385</GROSS_PROFIT>
<EXPENSES>1762069.63</EXPENSES>
<NET_INCOME>272927.36</NET_INCOME>
<REVENUE_M>2.03499699</REVENUE_M>
<PROFIT_M>1.636339385</PROFIT_M>
<INCOME_M>0.27292736</INCOME_M>
<PHARMA_REV_M>2.03499699</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.636339385</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27292736</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3557232.21</REVENUE>
<PREV_YEAR_REV>3086744.42</PREV_YEAR_REV>
<BUDGET>4180110.36</BUDGET>
<GROSS_PROFIT>2962434.09</GROSS_PROFIT>
<EXPENSES>3213427.41</EXPENSES>
<NET_INCOME>343804.81</NET_INCOME>
<REVENUE_M>3.55723221</REVENUE_M>
<PROFIT_M>2.96243409</PROFIT_M>
<INCOME_M>0.34380481</INCOME_M>
<PHARMA_REV_M>3.55723221</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.96243409</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34380481</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1230177.18</REVENUE>
<PREV_YEAR_REV>1064397.3</PREV_YEAR_REV>
<BUDGET>1331492.98</BUDGET>
<GROSS_PROFIT>908172.1584</GROSS_PROFIT>
<EXPENSES>1104699.11</EXPENSES>
<NET_INCOME>125478.07</NET_INCOME>
<REVENUE_M>1.23017718</REVENUE_M>
<PROFIT_M>0.908172158</PROFIT_M>
<INCOME_M>0.12547807</INCOME_M>
<PHARMA_REV_M>1.23017718</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.908172158</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12547807</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1321070.39</REVENUE>
<PREV_YEAR_REV>1186988.2</PREV_YEAR_REV>
<BUDGET>1483999.99</BUDGET>
<GROSS_PROFIT>953812.8198</GROSS_PROFIT>
<EXPENSES>1093846.28</EXPENSES>
<NET_INCOME>227224.11</NET_INCOME>
<REVENUE_M>1.32107039</REVENUE_M>
<PROFIT_M>0.95381282</PROFIT_M>
<INCOME_M>0.22722411</INCOME_M>
<PHARMA_REV_M>1.32107039</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.95381282</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.22722411</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>1153504.39</REVENUE>
<PREV_YEAR_REV>992962.25</PREV_YEAR_REV>
<BUDGET>1342038.46</BUDGET>
<GROSS_PROFIT>950083.885</GROSS_PROFIT>
<EXPENSES>1027772.41</EXPENSES>
<NET_INCOME>125731.98</NET_INCOME>
<REVENUE_M>1.15350439</REVENUE_M>
<PROFIT_M>0.950083885</PROFIT_M>
<INCOME_M>0.12573198</INCOME_M>
<PHARMA_REV_M>1.15350439</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.950083885</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.12573198</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>8712786.94</REVENUE>
<PREV_YEAR_REV>7882021.84</PREV_YEAR_REV>
<BUDGET>8451403.33</BUDGET>
<GROSS_PROFIT>7484283.98</GROSS_PROFIT>
<EXPENSES>7318741.03</EXPENSES>
<NET_INCOME>1394045.91</NET_INCOME>
<REVENUE_M>8.71278694</REVENUE_M>
<PROFIT_M>7.48428398</PROFIT_M>
<INCOME_M>1.39404591</INCOME_M>
<PHARMA_REV_M>8.71278694</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.48428398</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.39404591</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.098788659E7</REVENUE>
<PREV_YEAR_REV>9700857.33</PREV_YEAR_REV>
<BUDGET>10658250</BUDGET>
<GROSS_PROFIT>8533393.762</GROSS_PROFIT>
<EXPENSES>9788928.14</EXPENSES>
<NET_INCOME>1198958.45</NET_INCOME>
<REVENUE_M>10.98788659</REVENUE_M>
<PROFIT_M>8.533393762</PROFIT_M>
<INCOME_M>1.19895845</INCOME_M>
<PHARMA_REV_M>10.98788659</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.533393762</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.19895845</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>4813025.53</REVENUE>
<PREV_YEAR_REV>4207190.15</PREV_YEAR_REV>
<BUDGET>4668634.76</BUDGET>
<GROSS_PROFIT>3823785.138</GROSS_PROFIT>
<EXPENSES>4192145.23</EXPENSES>
<NET_INCOME>620880.29</NET_INCOME>
<REVENUE_M>4.81302553</REVENUE_M>
<PROFIT_M>3.823785138</PROFIT_M>
<INCOME_M>0.62088029</INCOME_M>
<PHARMA_REV_M>4.81302553</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.823785138</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.62088029</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>9354097</REVENUE>
<PREV_YEAR_REV>8089515.4</PREV_YEAR_REV>
<BUDGET>9073474.09</BUDGET>
<GROSS_PROFIT>6805621.533</GROSS_PROFIT>
<EXPENSES>8215533.55</EXPENSES>
<NET_INCOME>1138563.45</NET_INCOME>
<REVENUE_M>9.354097</REVENUE_M>
<PROFIT_M>6.805621533</PROFIT_M>
<INCOME_M>1.13856345</INCOME_M>
<PHARMA_REV_M>9.354097</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.805621533</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.13856345</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>9518908.11</REVENUE>
<PREV_YEAR_REV>8235845.71</PREV_YEAR_REV>
<BUDGET>9233340.87</BUDGET>
<GROSS_PROFIT>7624645.4</GROSS_PROFIT>
<EXPENSES>8262412.24</EXPENSES>
<NET_INCOME>1256495.87</NET_INCOME>
<REVENUE_M>9.51890811</REVENUE_M>
<PROFIT_M>7.6246454</PROFIT_M>
<INCOME_M>1.25649587</INCOME_M>
<PHARMA_REV_M>9.51890811</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.6246454</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.25649587</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Zylar</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Zylar.jpg</DRUG_IMG>
<REVENUE>0</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>0</BUDGET>
<GROSS_PROFIT>0</GROSS_PROFIT>
<EXPENSES>0</EXPENSES>
<NET_INCOME>0</NET_INCOME>
<REVENUE_M>0</REVENUE_M>
<PROFIT_M>0</PROFIT_M>
<INCOME_M>0</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.348365271E7</REVENUE>
<PREV_YEAR_REV>1.197686171E7</PREV_YEAR_REV>
<BUDGET>1.307914313E7</BUDGET>
<GROSS_PROFIT>1.035730004E7</GROSS_PROFIT>
<EXPENSES>1.147545676E7</EXPENSES>
<NET_INCOME>2008195.94</NET_INCOME>
<REVENUE_M>13.48365271</REVENUE_M>
<PROFIT_M>10.35730004</PROFIT_M>
<INCOME_M>2.00819594</INCOME_M>
<PHARMA_REV_M>13.48365271</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.35730004</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.00819594</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5702620.87</REVENUE>
<PREV_YEAR_REV>5014306.96</PREV_YEAR_REV>
<BUDGET>5531542.25</BUDGET>
<GROSS_PROFIT>4653338.63</GROSS_PROFIT>
<EXPENSES>5286329.55</EXPENSES>
<NET_INCOME>416291.32</NET_INCOME>
<REVENUE_M>5.70262087</REVENUE_M>
<PROFIT_M>4.65333863</PROFIT_M>
<INCOME_M>0.41629132</INCOME_M>
<PHARMA_REV_M>5.70262087</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.65333863</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.41629132</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>6039807.59</REVENUE>
<PREV_YEAR_REV>5231218.19</PREV_YEAR_REV>
<BUDGET>5858613.36</BUDGET>
<GROSS_PROFIT>4943301.657</GROSS_PROFIT>
<EXPENSES>5423747.21</EXPENSES>
<NET_INCOME>616060.37</NET_INCOME>
<REVENUE_M>6.03980759</REVENUE_M>
<PROFIT_M>4.943301657</PROFIT_M>
<INCOME_M>0.61606037</INCOME_M>
<PHARMA_REV_M>6.03980759</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.943301657</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.61606037</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>6403416.21</REVENUE>
<PREV_YEAR_REV>5601352.54</PREV_YEAR_REV>
<BUDGET>4823642.34</BUDGET>
<GROSS_PROFIT>4442661.405</GROSS_PROFIT>
<EXPENSES>5451985.59</EXPENSES>
<NET_INCOME>951430.61</NET_INCOME>
<REVENUE_M>6.40341621</REVENUE_M>
<PROFIT_M>4.442661405</PROFIT_M>
<INCOME_M>0.95143061</INCOME_M>
<PHARMA_REV_M>6.40341621</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.442661405</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.95143061</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>3270367.02</REVENUE>
<PREV_YEAR_REV>2927970.19</PREV_YEAR_REV>
<BUDGET>2427805.71</BUDGET>
<GROSS_PROFIT>2671889.858</GROSS_PROFIT>
<EXPENSES>2684971.33</EXPENSES>
<NET_INCOME>585395.7</NET_INCOME>
<REVENUE_M>3.27036702</REVENUE_M>
<PROFIT_M>2.671889858</PROFIT_M>
<INCOME_M>0.5853957</INCOME_M>
<PHARMA_REV_M>3.27036702</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.671889858</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.5853957</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>9144328.14</REVENUE>
<PREV_YEAR_REV>8207613.95</PREV_YEAR_REV>
<BUDGET>7240012.96</BUDGET>
<GROSS_PROFIT>7555176.642</GROSS_PROFIT>
<EXPENSES>8253912.58</EXPENSES>
<NET_INCOME>890415.55</NET_INCOME>
<REVENUE_M>9.14432814</REVENUE_M>
<PROFIT_M>7.555176642</PROFIT_M>
<INCOME_M>0.89041555</INCOME_M>
<PHARMA_REV_M>9.14432814</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.555176642</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.89041555</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3220998.33</REVENUE>
<PREV_YEAR_REV>2873812.98</PREV_YEAR_REV>
<BUDGET>2521868.58</BUDGET>
<GROSS_PROFIT>2650894.506</GROSS_PROFIT>
<EXPENSES>2666986.62</EXPENSES>
<NET_INCOME>554011.71</NET_INCOME>
<REVENUE_M>3.22099833</REVENUE_M>
<PROFIT_M>2.650894506</PROFIT_M>
<INCOME_M>0.55401171</INCOME_M>
<PHARMA_REV_M>3.22099833</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.650894506</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55401171</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>4867797.3</REVENUE>
<PREV_YEAR_REV>4580249.26</PREV_YEAR_REV>
<BUDGET>4673085.41</BUDGET>
<GROSS_PROFIT>3811485.29</GROSS_PROFIT>
<EXPENSES>3996461.59</EXPENSES>
<NET_INCOME>871335.72</NET_INCOME>
<REVENUE_M>4.8677973</REVENUE_M>
<PROFIT_M>3.81148529</PROFIT_M>
<INCOME_M>0.87133572</INCOME_M>
<PHARMA_REV_M>4.8677973</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.81148529</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.87133572</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>5444098.09</REVENUE>
<PREV_YEAR_REV>5152663.44</PREV_YEAR_REV>
<BUDGET>5226334.16</BUDGET>
<GROSS_PROFIT>3892530.13</GROSS_PROFIT>
<EXPENSES>4469604.53</EXPENSES>
<NET_INCOME>974493.56</NET_INCOME>
<REVENUE_M>5.44409809</REVENUE_M>
<PROFIT_M>3.89253013</PROFIT_M>
<INCOME_M>0.97449356</INCOME_M>
<PHARMA_REV_M>5.44409809</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.89253013</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.97449356</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2177043.61</REVENUE>
<PREV_YEAR_REV>2060384.63</PREV_YEAR_REV>
<BUDGET>1991095.66</BUDGET>
<GROSS_PROFIT>1655706.978</GROSS_PROFIT>
<EXPENSES>2018119.43</EXPENSES>
<NET_INCOME>158924.18</NET_INCOME>
<REVENUE_M>2.17704361</REVENUE_M>
<PROFIT_M>1.655706978</PROFIT_M>
<INCOME_M>0.15892418</INCOME_M>
<PHARMA_REV_M>2.17704361</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.655706978</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.15892418</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2207056.76</REVENUE>
<PREV_YEAR_REV>2090233.61</PREV_YEAR_REV>
<BUDGET>1967796.63</BUDGET>
<GROSS_PROFIT>1414604.206</GROSS_PROFIT>
<EXPENSES>1827443</EXPENSES>
<NET_INCOME>379613.76</NET_INCOME>
<REVENUE_M>2.20705676</REVENUE_M>
<PROFIT_M>1.414604206</PROFIT_M>
<INCOME_M>0.37961376</INCOME_M>
<PHARMA_REV_M>2.20705676</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.414604206</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.37961376</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1469922.9</REVENUE>
<PREV_YEAR_REV>1386654.31</PREV_YEAR_REV>
<BUDGET>1694688.75</BUDGET>
<GROSS_PROFIT>897158.6253</GROSS_PROFIT>
<EXPENSES>1280302.85</EXPENSES>
<NET_INCOME>189620.05</NET_INCOME>
<REVENUE_M>1.4699229</REVENUE_M>
<PROFIT_M>0.897158625</PROFIT_M>
<INCOME_M>0.18962005</INCOME_M>
<PHARMA_REV_M>1.4699229</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.897158625</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18962005</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>8752376.82</REVENUE>
<PREV_YEAR_REV>7824682.47</PREV_YEAR_REV>
<BUDGET>9627614.51</BUDGET>
<GROSS_PROFIT>6829479.639</GROSS_PROFIT>
<EXPENSES>7623320.21</EXPENSES>
<NET_INCOME>1129056.61</NET_INCOME>
<REVENUE_M>8.75237682</REVENUE_M>
<PROFIT_M>6.829479639</PROFIT_M>
<INCOME_M>1.12905661</INCOME_M>
<PHARMA_REV_M>8.75237682</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.829479639</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.12905661</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>936504.21</REVENUE>
<PREV_YEAR_REV>874444.85</PREV_YEAR_REV>
<BUDGET>975682.03</BUDGET>
<GROSS_PROFIT>706124.17</GROSS_PROFIT>
<EXPENSES>786663.53</EXPENSES>
<NET_INCOME>149840.67</NET_INCOME>
<REVENUE_M>0.93650421</REVENUE_M>
<PROFIT_M>0.70612417</PROFIT_M>
<INCOME_M>0.14984067</INCOME_M>
<PHARMA_REV_M>0.93650421</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.70612417</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.14984067</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>5458273.01</REVENUE>
<PREV_YEAR_REV>4929620.51</PREV_YEAR_REV>
<BUDGET>5239942.09</BUDGET>
<GROSS_PROFIT>3973622.75</GROSS_PROFIT>
<EXPENSES>4481242.14</EXPENSES>
<NET_INCOME>977030.87</NET_INCOME>
<REVENUE_M>5.45827301</REVENUE_M>
<PROFIT_M>3.97362275</PROFIT_M>
<INCOME_M>0.97703087</INCOME_M>
<PHARMA_REV_M>5.45827301</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.97362275</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.97703087</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1137622.04</REVENUE>
<PREV_YEAR_REV>1051280.38</PREV_YEAR_REV>
<BUDGET>1201216.58</BUDGET>
<GROSS_PROFIT>806232.738</GROSS_PROFIT>
<EXPENSES>941951.05</EXPENSES>
<NET_INCOME>195670.99</NET_INCOME>
<REVENUE_M>1.13762204</REVENUE_M>
<PROFIT_M>0.806232738</PROFIT_M>
<INCOME_M>0.19567099</INCOME_M>
<PHARMA_REV_M>1.13762204</PHARMA_REV_M>
<PHARMA_PROFIT_M>0.806232738</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.19567099</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>1.50066461E7</REVENUE>
<PREV_YEAR_REV>1.416334997E7</PREV_YEAR_REV>
<BUDGET>7157546.25</BUDGET>
<GROSS_PROFIT>1.187469636E7</GROSS_PROFIT>
<EXPENSES>6732566.94</EXPENSES>
<NET_INCOME>1659518.12</NET_INCOME>
<REVENUE_M>15.0066461</REVENUE_M>
<PROFIT_M>11.87469636</PROFIT_M>
<INCOME_M>1.65951812</INCOME_M>
<PHARMA_REV_M>15.0066461</PHARMA_REV_M>
<PHARMA_PROFIT_M>11.87469636</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.65951812</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.21069578E7</REVENUE>
<PREV_YEAR_REV>1.13510551E7</PREV_YEAR_REV>
<BUDGET>1.162267948E7</BUDGET>
<GROSS_PROFIT>1.013407822E7</GROSS_PROFIT>
<EXPENSES>1.056551422E7</EXPENSES>
<NET_INCOME>1541443.57</NET_INCOME>
<REVENUE_M>12.1069578</REVENUE_M>
<PROFIT_M>10.13407822</PROFIT_M>
<INCOME_M>1.54144357</INCOME_M>
<PHARMA_REV_M>12.1069578</PHARMA_REV_M>
<PHARMA_PROFIT_M>10.13407822</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.54144357</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2480461.23</REVENUE>
<PREV_YEAR_REV>2353624.41</PREV_YEAR_REV>
<BUDGET>1800433.89</BUDGET>
<GROSS_PROFIT>2050101.207</GROSS_PROFIT>
<EXPENSES>2299387.56</EXPENSES>
<NET_INCOME>181073.67</NET_INCOME>
<REVENUE_M>2.48046123</REVENUE_M>
<PROFIT_M>2.050101207</PROFIT_M>
<INCOME_M>0.18107367</INCOME_M>
<PHARMA_REV_M>2.48046123</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.050101207</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.18107367</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>1704193.92</REVENUE>
<PREV_YEAR_REV>1576322.63</PREV_YEAR_REV>
<BUDGET>1635653.08</BUDGET>
<GROSS_PROFIT>1371876.11</GROSS_PROFIT>
<EXPENSES>1479240.32</EXPENSES>
<NET_INCOME>224953.6</NET_INCOME>
<REVENUE_M>1.70419392</REVENUE_M>
<PROFIT_M>1.37187611</PROFIT_M>
<INCOME_M>0.2249536</INCOME_M>
<PHARMA_REV_M>1.70419392</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.37187611</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2249536</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Travestid</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Travestid.jpg</DRUG_IMG>
<REVENUE>1598195.49</REVENUE>
<PREV_YEAR_REV>1499484.43</PREV_YEAR_REV>
<BUDGET>1588855.7</BUDGET>
<GROSS_PROFIT>1188514.064</GROSS_PROFIT>
<EXPENSES>1323305.87</EXPENSES>
<NET_INCOME>274889.62</NET_INCOME>
<REVENUE_M>1.59819549</REVENUE_M>
<PROFIT_M>1.188514064</PROFIT_M>
<INCOME_M>0.27488962</INCOME_M>
<PHARMA_REV_M>1.59819549</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.188514064</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.27488962</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.00174546E7</REVENUE>
<PREV_YEAR_REV>9516581.87</PREV_YEAR_REV>
<BUDGET>9716930.96</BUDGET>
<GROSS_PROFIT>7546148.545</GROSS_PROFIT>
<EXPENSES>8443283.16</EXPENSES>
<NET_INCOME>1091902.55</NET_INCOME>
<REVENUE_M>10.0174546</REVENUE_M>
<PROFIT_M>7.546148545</PROFIT_M>
<INCOME_M>1.09190255</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>1.510506598E7</REVENUE>
<PREV_YEAR_REV>1.434981268E7</PREV_YEAR_REV>
<BUDGET>14651914</BUDGET>
<GROSS_PROFIT>1.080971389E7</GROSS_PROFIT>
<EXPENSES>1.942079911E7</EXPENSES>
<NET_INCOME>1465191.4</NET_INCOME>
<REVENUE_M>15.10506598</REVENUE_M>
<PROFIT_M>10.80971389</PROFIT_M>
<INCOME_M>1.4651914</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>3.452511825E7</REVENUE>
<PREV_YEAR_REV>3.279886234E7</PREV_YEAR_REV>
<BUDGET>3.34893647E7</BUDGET>
<GROSS_PROFIT>24707383</GROSS_PROFIT>
<EXPENSES>42275655</EXPENSES>
<NET_INCOME>3348936.47</NET_INCOME>
<REVENUE_M>34.52511825</REVENUE_M>
<PROFIT_M>24.707383</PROFIT_M>
<INCOME_M>3.34893647</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.193958123E7</REVENUE>
<PREV_YEAR_REV>1.864864405E7</PREV_YEAR_REV>
<BUDGET>2.12813938E7</BUDGET>
<GROSS_PROFIT>1.652708654E7</GROSS_PROFIT>
<EXPENSES>1.98562273E7</EXPENSES>
<NET_INCOME>3510333</NET_INCOME>
<REVENUE_M>21.93958123</REVENUE_M>
<PROFIT_M>16.52708654</PROFIT_M>
<INCOME_M>3.510333</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>2.188474042E7</REVENUE>
<PREV_YEAR_REV>1.860202936E7</PREV_YEAR_REV>
<BUDGET>2.122819821E7</BUDGET>
<GROSS_PROFIT>1.566148621E7</GROSS_PROFIT>
<EXPENSES>1.972687386E7</EXPENSES>
<NET_INCOME>2122819.82</NET_INCOME>
<REVENUE_M>21.88474042</REVENUE_M>
<PROFIT_M>15.66148621</PROFIT_M>
<INCOME_M>2.12281982</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>5.844943962E7</REVENUE>
<PREV_YEAR_REV>4.968202368E7</PREV_YEAR_REV>
<BUDGET>5.669595643E7</BUDGET>
<GROSS_PROFIT>4.23992235E7</GROSS_PROFIT>
<EXPENSES>5.260449566E7</EXPENSES>
<NET_INCOME>5571062.07</NET_INCOME>
<REVENUE_M>58.44943962</REVENUE_M>
<PROFIT_M>42.3992235</PROFIT_M>
<INCOME_M>5.57106207</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2337021.92</REVENUE>
<PREV_YEAR_REV>1836068.89</PREV_YEAR_REV>
<BUDGET>2237493.75</BUDGET>
<GROSS_PROFIT>2019186.94</GROSS_PROFIT>
<EXPENSES>2082286.53</EXPENSES>
<NET_INCOME>254735.39</NET_INCOME>
<REVENUE_M>2.33702192</REVENUE_M>
<PROFIT_M>2.01918694</PROFIT_M>
<INCOME_M>0.25473539</INCOME_M>
<PHARMA_REV_M>2.33702192</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.01918694</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25473539</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Canada</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Canada.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1833654.38</REVENUE>
<PREV_YEAR_REV>1547557.44</PREV_YEAR_REV>
<BUDGET>1764328.26</BUDGET>
<GROSS_PROFIT>1586111.04</GROSS_PROFIT>
<EXPENSES>1591612.01</EXPENSES>
<NET_INCOME>242042.38</NET_INCOME>
<REVENUE_M>1.83365438</REVENUE_M>
<PROFIT_M>1.58611104</PROFIT_M>
<INCOME_M>0.24204238</INCOME_M>
<PHARMA_REV_M>1.83365438</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.58611104</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.24204238</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>3756994.84</REVENUE>
<PREV_YEAR_REV>2953622.71</PREV_YEAR_REV>
<BUDGET>3612961.44</BUDGET>
<GROSS_PROFIT>2784493.17</GROSS_PROFIT>
<EXPENSES>3199013.79</EXPENSES>
<NET_INCOME>557981.06</NET_INCOME>
<REVENUE_M>3.75699484</REVENUE_M>
<PROFIT_M>2.78449317</PROFIT_M>
<INCOME_M>0.55798106</INCOME_M>
<PHARMA_REV_M>3.75699484</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.78449317</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.55798106</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Acne</OPERATING_SEGMENT>
<DRUG>ActiveX</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_ActiveX.jpg</DRUG_IMG>
<REVENUE>6365872.01</REVENUE>
<PREV_YEAR_REV>5729284.81</PREV_YEAR_REV>
<BUDGET>6047578.41</BUDGET>
<GROSS_PROFIT>4795411.387</GROSS_PROFIT>
<EXPENSES>1.049319563E7</EXPENSES>
<NET_INCOME>464708.66</NET_INCOME>
<REVENUE_M>6.36587201</REVENUE_M>
<PROFIT_M>4.795411387</PROFIT_M>
<INCOME_M>0.46470866</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2009</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>9552591.42</REVENUE>
<PREV_YEAR_REV>8597332.28</PREV_YEAR_REV>
<BUDGET>8521090.94</BUDGET>
<GROSS_PROFIT>6476370.405</GROSS_PROFIT>
<EXPENSES>1.478500452E7</EXPENSES>
<NET_INCOME>1289599.84</NET_INCOME>
<REVENUE_M>9.55259142</REVENUE_M>
<PROFIT_M>6.476370405</PROFIT_M>
<INCOME_M>1.28959984</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Cosmetics</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Anti-Aging</OPERATING_SEGMENT>
<DRUG>Advantax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Advantax.jpg</DRUG_IMG>
<REVENUE>1.006690423E7</REVENUE>
<PREV_YEAR_REV>9563559.02</PREV_YEAR_REV>
<BUDGET>9764897.1</BUDGET>
<GROSS_PROFIT>6825059.064</GROSS_PROFIT>
<EXPENSES>8484962.14</EXPENSES>
<NET_INCOME>1359032.07</NET_INCOME>
<REVENUE_M>10.06690423</REVENUE_M>
<PROFIT_M>6.825059064</PROFIT_M>
<INCOME_M>1.35903207</INCOME_M>
<PHARMA_REV_M>0</PHARMA_REV_M>
<PHARMA_PROFIT_M>0</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2725028.83</REVENUE>
<PREV_YEAR_REV>2504184.77</PREV_YEAR_REV>
<BUDGET>2005597.76</BUDGET>
<GROSS_PROFIT>1863919.716</GROSS_PROFIT>
<EXPENSES>2357149.94</EXPENSES>
<NET_INCOME>367878.89</NET_INCOME>
<REVENUE_M>2.72502883</REVENUE_M>
<PROFIT_M>1.863919716</PROFIT_M>
<INCOME_M>0.36787889</INCOME_M>
<PHARMA_REV_M>2.72502883</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.863919716</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.36787889</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>3623938.72</REVENUE>
<PREV_YEAR_REV>3289121.39</PREV_YEAR_REV>
<BUDGET>3379491.06</BUDGET>
<GROSS_PROFIT>2857779.645</GROSS_PROFIT>
<EXPENSES>3222598.29</EXPENSES>
<NET_INCOME>401340.43</NET_INCOME>
<REVENUE_M>3.62393872</REVENUE_M>
<PROFIT_M>2.857779645</PROFIT_M>
<INCOME_M>0.40134043</INCOME_M>
<PHARMA_REV_M>3.62393872</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.857779645</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40134043</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>1889446.74</REVENUE>
<PREV_YEAR_REV>1740944.2</PREV_YEAR_REV>
<BUDGET>1688933.01</BUDGET>
<GROSS_PROFIT>1568354.162</GROSS_PROFIT>
<EXPENSES>1551235.77</EXPENSES>
<NET_INCOME>338210.97</NET_INCOME>
<REVENUE_M>1.88944674</REVENUE_M>
<PROFIT_M>1.568354162</PROFIT_M>
<INCOME_M>0.33821097</INCOME_M>
<PHARMA_REV_M>1.88944674</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.568354162</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.33821097</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>3664088.32</REVENUE>
<PREV_YEAR_REV>3371393.64</PREV_YEAR_REV>
<BUDGET>3374745.92</BUDGET>
<GROSS_PROFIT>3130902.95</GROSS_PROFIT>
<EXPENSES>3176441.19</EXPENSES>
<NET_INCOME>487647.13</NET_INCOME>
<REVENUE_M>3.66408832</REVENUE_M>
<PROFIT_M>3.13090295</PROFIT_M>
<INCOME_M>0.48764713</INCOME_M>
<PHARMA_REV_M>3.66408832</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.13090295</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.48764713</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>2556865.42</REVENUE>
<PREV_YEAR_REV>2291163.58</PREV_YEAR_REV>
<BUDGET>2178836.03</BUDGET>
<GROSS_PROFIT>1961672.238</GROSS_PROFIT>
<EXPENSES>2176767.5</EXPENSES>
<NET_INCOME>380097.92</NET_INCOME>
<REVENUE_M>2.55686542</REVENUE_M>
<PROFIT_M>1.961672238</PROFIT_M>
<INCOME_M>0.38009792</INCOME_M>
<PHARMA_REV_M>2.55686542</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.961672238</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.38009792</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2261513.44</REVENUE>
<PREV_YEAR_REV>1959207.7</PREV_YEAR_REV>
<BUDGET>2303685.76</BUDGET>
<GROSS_PROFIT>1801838.221</GROSS_PROFIT>
<EXPENSES>1856702.54</EXPENSES>
<NET_INCOME>404810.91</NET_INCOME>
<REVENUE_M>2.26151344</REVENUE_M>
<PROFIT_M>1.801838221</PROFIT_M>
<INCOME_M>0.40481091</INCOME_M>
<PHARMA_REV_M>2.26151344</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.801838221</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.40481091</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.001282754E7</REVENUE>
<PREV_YEAR_REV>8819149.66</PREV_YEAR_REV>
<BUDGET>1.02130841E7</BUDGET>
<GROSS_PROFIT>8259940.762</GROSS_PROFIT>
<EXPENSES>8691055.51</EXPENSES>
<NET_INCOME>1321772.03</NET_INCOME>
<REVENUE_M>10.01282754</REVENUE_M>
<PROFIT_M>8.259940762</PROFIT_M>
<INCOME_M>1.32177203</INCOME_M>
<PHARMA_REV_M>10.01282754</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.259940762</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.32177203</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>6654828.69</REVENUE>
<PREV_YEAR_REV>5845212.64</PREV_YEAR_REV>
<BUDGET>6936676.31</BUDGET>
<GROSS_PROFIT>5170890.385</GROSS_PROFIT>
<EXPENSES>6007966.7</EXPENSES>
<NET_INCOME>646861.98</NET_INCOME>
<REVENUE_M>6.65482869</REVENUE_M>
<PROFIT_M>5.170890385</PROFIT_M>
<INCOME_M>0.64686198</INCOME_M>
<PHARMA_REV_M>6.65482869</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.170890385</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.64686198</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2535065.82</REVENUE>
<PREV_YEAR_REV>2263896.32</PREV_YEAR_REV>
<BUDGET>1986712.28</BUDGET>
<GROSS_PROFIT>1891595.13</GROSS_PROFIT>
<EXPENSES>2192831.93</EXPENSES>
<NET_INCOME>342233.89</NET_INCOME>
<REVENUE_M>2.53506582</REVENUE_M>
<PROFIT_M>1.89159513</PROFIT_M>
<INCOME_M>0.34223389</INCOME_M>
<PHARMA_REV_M>2.53506582</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.89159513</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.34223389</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>6262964.49</REVENUE>
<PREV_YEAR_REV>5712732.56</PREV_YEAR_REV>
<BUDGET>5340562.06</BUDGET>
<GROSS_PROFIT>5218973.42</GROSS_PROFIT>
<EXPENSES>5657868.1</EXPENSES>
<NET_INCOME>605096.39</NET_INCOME>
<REVENUE_M>6.26296449</REVENUE_M>
<PROFIT_M>5.21897342</PROFIT_M>
<INCOME_M>0.60509639</INCOME_M>
<PHARMA_REV_M>6.26296449</PHARMA_REV_M>
<PHARMA_PROFIT_M>5.21897342</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.60509639</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2437645.03</REVENUE>
<PREV_YEAR_REV>2272438.74</PREV_YEAR_REV>
<BUDGET>1817020.8</BUDGET>
<GROSS_PROFIT>2059810.05</GROSS_PROFIT>
<EXPENSES>2171941.73</EXPENSES>
<NET_INCOME>265703.31</NET_INCOME>
<REVENUE_M>2.43764503</REVENUE_M>
<PROFIT_M>2.05981005</PROFIT_M>
<INCOME_M>0.26570331</INCOME_M>
<PHARMA_REV_M>2.43764503</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.05981005</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.26570331</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1866233.41</REVENUE>
<PREV_YEAR_REV>1701867.09</PREV_YEAR_REV>
<BUDGET>1259876.69</BUDGET>
<GROSS_PROFIT>1542441.917</GROSS_PROFIT>
<EXPENSES>1545241.27</EXPENSES>
<NET_INCOME>320992.15</NET_INCOME>
<REVENUE_M>1.86623341</REVENUE_M>
<PROFIT_M>1.542441917</PROFIT_M>
<INCOME_M>0.32099215</INCOME_M>
<PHARMA_REV_M>1.86623341</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.542441917</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32099215</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2010</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>9607035.58</REVENUE>
<PREV_YEAR_REV>8585452.58</PREV_YEAR_REV>
<BUDGET>8646332.02</BUDGET>
<GROSS_PROFIT>7099762.616</GROSS_PROFIT>
<EXPENSES>8310085.78</EXPENSES>
<NET_INCOME>1296949.8</NET_INCOME>
<REVENUE_M>9.60703558</REVENUE_M>
<PROFIT_M>7.099762616</PROFIT_M>
<INCOME_M>1.2969498</INCOME_M>
<PHARMA_REV_M>9.60703558</PHARMA_REV_M>
<PHARMA_PROFIT_M>7.099762616</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.2969498</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2494285.94</REVENUE>
<PREV_YEAR_REV>2227776.98</PREV_YEAR_REV>
<BUDGET>2208361.32</BUDGET>
<GROSS_PROFIT>1777927.023</GROSS_PROFIT>
<EXPENSES>2172523.06</EXPENSES>
<NET_INCOME>321762.89</NET_INCOME>
<REVENUE_M>2.49428594</REVENUE_M>
<PROFIT_M>1.777927023</PROFIT_M>
<INCOME_M>0.32176289</INCOME_M>
<PHARMA_REV_M>2.49428594</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.777927023</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.32176289</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>2290435.61</REVENUE>
<PREV_YEAR_REV>1955180.77</PREV_YEAR_REV>
<BUDGET>2144754.08</BUDGET>
<GROSS_PROFIT>1928134.506</GROSS_PROFIT>
<EXPENSES>2123233.81</EXPENSES>
<NET_INCOME>167201.8</NET_INCOME>
<REVENUE_M>2.29043561</REVENUE_M>
<PROFIT_M>1.928134506</PROFIT_M>
<INCOME_M>0.1672018</INCOME_M>
<PHARMA_REV_M>2.29043561</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.928134506</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.1672018</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Taiwan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Taiwan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>3131617.41</REVENUE>
<PREV_YEAR_REV>2839387.64</PREV_YEAR_REV>
<BUDGET>2760345</BUDGET>
<GROSS_PROFIT>2663879.032</GROSS_PROFIT>
<EXPENSES>2790271.11</EXPENSES>
<NET_INCOME>341346.3</NET_INCOME>
<REVENUE_M>3.13161741</REVENUE_M>
<PROFIT_M>2.663879032</PROFIT_M>
<INCOME_M>0.3413463</INCOME_M>
<PHARMA_REV_M>3.13161741</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.663879032</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.3413463</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2240581.53</REVENUE>
<PREV_YEAR_REV>1928526.64</PREV_YEAR_REV>
<BUDGET>2439793.13</BUDGET>
<GROSS_PROFIT>1718077.923</GROSS_PROFIT>
<EXPENSES>1951546.52</EXPENSES>
<NET_INCOME>289035.02</NET_INCOME>
<REVENUE_M>2.24058153</REVENUE_M>
<PROFIT_M>1.718077923</PROFIT_M>
<INCOME_M>0.28903502</INCOME_M>
<PHARMA_REV_M>2.24058153</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.718077923</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.28903502</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Luvtor</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Luvtor.jpg</DRUG_IMG>
<REVENUE>2061983.91</REVENUE>
<PREV_YEAR_REV>1788984.83</PREV_YEAR_REV>
<BUDGET>2354713.59</BUDGET>
<GROSS_PROFIT>1694435.286</GROSS_PROFIT>
<EXPENSES>1851661.55</EXPENSES>
<NET_INCOME>210322.36</NET_INCOME>
<REVENUE_M>2.06198391</REVENUE_M>
<PROFIT_M>1.694435286</PROFIT_M>
<INCOME_M>0.21032236</INCOME_M>
<PHARMA_REV_M>2.06198391</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.694435286</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.21032236</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1318953.69</REVENUE>
<PREV_YEAR_REV>1163745.01</PREV_YEAR_REV>
<BUDGET>1365279.3</BUDGET>
<GROSS_PROFIT>1053844</GROSS_PROFIT>
<EXPENSES>1222670.07</EXPENSES>
<NET_INCOME>96283.62</NET_INCOME>
<REVENUE_M>1.31895369</REVENUE_M>
<PROFIT_M>1.053844</PROFIT_M>
<INCOME_M>0.09628362</INCOME_M>
<PHARMA_REV_M>1.31895369</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.053844</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.09628362</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Mexico</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Mexico.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>8328474.6</REVENUE>
<PREV_YEAR_REV>7369418.48</PREV_YEAR_REV>
<BUDGET>7662196.63</BUDGET>
<GROSS_PROFIT>6276013.654</GROSS_PROFIT>
<EXPENSES>7254101.38</EXPENSES>
<NET_INCOME>1074373.22</NET_INCOME>
<REVENUE_M>8.3284746</REVENUE_M>
<PROFIT_M>6.276013654</PROFIT_M>
<INCOME_M>1.07437322</INCOME_M>
<PHARMA_REV_M>8.3284746</PHARMA_REV_M>
<PHARMA_PROFIT_M>6.276013654</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.07437322</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Germany</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Germany.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.67481534E7</REVENUE>
<PREV_YEAR_REV>1.436143116E7</PREV_YEAR_REV>
<BUDGET>1.540830113E7</BUDGET>
<GROSS_PROFIT>1.275944838E7</GROSS_PROFIT>
<EXPENSES>1.426039941E7</EXPENSES>
<NET_INCOME>2487753.99</NET_INCOME>
<REVENUE_M>16.7481534</REVENUE_M>
<PROFIT_M>12.75944838</PROFIT_M>
<INCOME_M>2.48775399</INCOME_M>
<PHARMA_REV_M>16.7481534</PHARMA_REV_M>
<PHARMA_PROFIT_M>12.75944838</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.48775399</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Spain</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Spain.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>2602933.99</REVENUE>
<PREV_YEAR_REV>2323944.46</PREV_YEAR_REV>
<BUDGET>2524845.97</BUDGET>
<GROSS_PROFIT>1948556.381</GROSS_PROFIT>
<EXPENSES>2137008.8</EXPENSES>
<NET_INCOME>465925.18</NET_INCOME>
<REVENUE_M>2.60293399</REVENUE_M>
<PROFIT_M>1.948556381</PROFIT_M>
<INCOME_M>0.46592518</INCOME_M>
<PHARMA_REV_M>2.60293399</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.948556381</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.46592518</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2546248.16</REVENUE>
<PREV_YEAR_REV>2250548.58</PREV_YEAR_REV>
<BUDGET>2469860.72</BUDGET>
<GROSS_PROFIT>2038679.054</GROSS_PROFIT>
<EXPENSES>2286530.85</EXPENSES>
<NET_INCOME>259717.31</NET_INCOME>
<REVENUE_M>2.54624816</REVENUE_M>
<PROFIT_M>2.038679054</PROFIT_M>
<INCOME_M>0.25971731</INCOME_M>
<PHARMA_REV_M>2.54624816</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.038679054</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.25971731</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q4</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Argentina</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Argentina.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>1825145.15</REVENUE>
<PREV_YEAR_REV>1625139.26</PREV_YEAR_REV>
<BUDGET>1770390.79</BUDGET>
<GROSS_PROFIT>1587876.28</GROSS_PROFIT>
<EXPENSES>1533121.92</EXPENSES>
<NET_INCOME>292023.22</NET_INCOME>
<REVENUE_M>1.82514515</REVENUE_M>
<PROFIT_M>1.58787628</PROFIT_M>
<INCOME_M>0.29202322</INCOME_M>
<PHARMA_REV_M>1.82514515</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.58787628</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.29202322</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Fixerol</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Fixerol.jpg</DRUG_IMG>
<REVENUE>6184011.5</REVENUE>
<PREV_YEAR_REV>5311651.21</PREV_YEAR_REV>
<BUDGET>4837155.42</BUDGET>
<GROSS_PROFIT>4932204.243</GROSS_PROFIT>
<EXPENSES>5352466.61</EXPENSES>
<NET_INCOME>831544.89</NET_INCOME>
<REVENUE_M>6.1840115</REVENUE_M>
<PROFIT_M>4.932204243</PROFIT_M>
<INCOME_M>0.83154489</INCOME_M>
<PHARMA_REV_M>6.1840115</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.932204243</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.83154489</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2011</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Jupex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Jupex.jpg</DRUG_IMG>
<REVENUE>2970014.07</REVENUE>
<PREV_YEAR_REV>2576325.73</PREV_YEAR_REV>
<BUDGET>2374933.77</BUDGET>
<GROSS_PROFIT>2170590.228</GROSS_PROFIT>
<EXPENSES>2667072.63</EXPENSES>
<NET_INCOME>302941.43</NET_INCOME>
<REVENUE_M>2.97001407</REVENUE_M>
<PROFIT_M>2.170590228</PROFIT_M>
<INCOME_M>0.30294143</INCOME_M>
<PHARMA_REV_M>2.97001407</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.170590228</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.30294143</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>Brazil</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Brazil.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Tylent</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Tylent.jpg</DRUG_IMG>
<REVENUE>2.039613918E7</REVENUE>
<PREV_YEAR_REV>1.622243234E7</PREV_YEAR_REV>
<BUDGET>1.937633222E7</BUDGET>
<GROSS_PROFIT>1.618015253E7</GROSS_PROFIT>
<EXPENSES>1.814561694E7</EXPENSES>
<NET_INCOME>2250522.24</NET_INCOME>
<REVENUE_M>20.39613918</REVENUE_M>
<PROFIT_M>16.18015253</PROFIT_M>
<INCOME_M>2.25052224</INCOME_M>
<PHARMA_REV_M>20.39613918</PHARMA_REV_M>
<PHARMA_PROFIT_M>16.18015253</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>2.25052224</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>S Korea</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Korea.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Pragmay</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Pragmay.jpg</DRUG_IMG>
<REVENUE>1.23888696E7</REVENUE>
<PREV_YEAR_REV>1.001282754E7</PREV_YEAR_REV>
<BUDGET>1.176942612E7</BUDGET>
<GROSS_PROFIT>9509699.127</GROSS_PROFIT>
<EXPENSES>1.074728698E7</EXPENSES>
<NET_INCOME>1641582.62</NET_INCOME>
<REVENUE_M>12.3888696</REVENUE_M>
<PROFIT_M>9.509699127</PROFIT_M>
<INCOME_M>1.64158262</INCOME_M>
<PHARMA_REV_M>12.3888696</PHARMA_REV_M>
<PHARMA_PROFIT_M>9.509699127</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.64158262</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>Americas</REGION>
<COUNTRY>U.S.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_US.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5275721.97</REVENUE>
<PREV_YEAR_REV>4317247.73</PREV_YEAR_REV>
<BUDGET>5040564.94</BUDGET>
<GROSS_PROFIT>4053265.574</GROSS_PROFIT>
<EXPENSES>4635586.96</EXPENSES>
<NET_INCOME>640135.01</NET_INCOME>
<REVENUE_M>5.27572197</REVENUE_M>
<PROFIT_M>4.053265574</PROFIT_M>
<INCOME_M>0.64013501</INCOME_M>
<PHARMA_REV_M>5.27572197</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.053265574</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.64013501</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>U.K.</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_UK.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>5555891.25</REVENUE>
<PREV_YEAR_REV>4368690.02</PREV_YEAR_REV>
<BUDGET>5500332.34</BUDGET>
<GROSS_PROFIT>4458255.281</GROSS_PROFIT>
<EXPENSES>4808027.46</EXPENSES>
<NET_INCOME>747863.79</NET_INCOME>
<REVENUE_M>5.55589125</REVENUE_M>
<PROFIT_M>4.458255281</PROFIT_M>
<INCOME_M>0.74786379</INCOME_M>
<PHARMA_REV_M>5.55589125</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.458255281</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.74786379</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>China</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_China.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Specialty Care</OPERATING_SEGMENT>
<DRUG>Goypro</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Goypro.jpg</DRUG_IMG>
<REVENUE>2790759.83</REVENUE>
<PREV_YEAR_REV>2279529.7</PREV_YEAR_REV>
<BUDGET>2762852.23</BUDGET>
<GROSS_PROFIT>2126120.836</GROSS_PROFIT>
<EXPENSES>2506102.32</EXPENSES>
<NET_INCOME>284657.5</NET_INCOME>
<REVENUE_M>2.79075983</REVENUE_M>
<PROFIT_M>2.126120836</PROFIT_M>
<INCOME_M>0.2846575</INCOME_M>
<PHARMA_REV_M>2.79075983</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.126120836</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.2846575</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>France</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_France.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Restinoral</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Restinoral.jpg</DRUG_IMG>
<REVENUE>5965527.48</REVENUE>
<PREV_YEAR_REV>4713905.06</PREV_YEAR_REV>
<BUDGET>5905872.22</BUDGET>
<GROSS_PROFIT>4647853.595</GROSS_PROFIT>
<EXPENSES>5387020.16</EXPENSES>
<NET_INCOME>578507.33</NET_INCOME>
<REVENUE_M>5.96552748</REVENUE_M>
<PROFIT_M>4.647853595</PROFIT_M>
<INCOME_M>0.57850733</INCOME_M>
<PHARMA_REV_M>5.96552748</PHARMA_REV_M>
<PHARMA_PROFIT_M>4.647853595</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57850733</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q1</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Vorinex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Vorinex.jpg</DRUG_IMG>
<REVENUE>1310668.13</REVENUE>
<PREV_YEAR_REV>1105703.81</PREV_YEAR_REV>
<BUDGET>1297561.45</BUDGET>
<GROSS_PROFIT>1106203.9</GROSS_PROFIT>
<EXPENSES>1214989.35</EXPENSES>
<NET_INCOME>95678.77</NET_INCOME>
<REVENUE_M>1.31066813</REVENUE_M>
<PROFIT_M>1.1062039</PROFIT_M>
<INCOME_M>0.09567877</INCOME_M>
<PHARMA_REV_M>1.31066813</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.1062039</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.09567877</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Japan</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Japan.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Established Products</OPERATING_SEGMENT>
<DRUG>Viamax</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Viamax.jpg</DRUG_IMG>
<REVENUE>2863270.75</REVENUE>
<PREV_YEAR_REV>2326727.41</PREV_YEAR_REV>
<BUDGET>2576943.68</BUDGET>
<GROSS_PROFIT>2157045.015</GROSS_PROFIT>
<EXPENSES>2370788.18</EXPENSES>
<NET_INCOME>492482.57</NET_INCOME>
<REVENUE_M>2.86327075</REVENUE_M>
<PROFIT_M>2.157045015</PROFIT_M>
<INCOME_M>0.49248257</INCOME_M>
<PHARMA_REV_M>2.86327075</PHARMA_REV_M>
<PHARMA_PROFIT_M>2.157045015</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.49248257</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q2</QUARTER>
<REGION>EMEA</REGION>
<COUNTRY>Italy</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Italy.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Oncology</OPERATING_SEGMENT>
<DRUG>Lubridram</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Lubridram.jpg</DRUG_IMG>
<REVENUE>2454322</REVENUE>
<PREV_YEAR_REV>1892613.3</PREV_YEAR_REV>
<BUDGET>2405235.56</BUDGET>
<GROSS_PROFIT>1967875.382</GROSS_PROFIT>
<EXPENSES>2275156.49</EXPENSES>
<NET_INCOME>179165.51</NET_INCOME>
<REVENUE_M>2.454322</REVENUE_M>
<PROFIT_M>1.967875382</PROFIT_M>
<INCOME_M>0.17916551</INCOME_M>
<PHARMA_REV_M>2.454322</PHARMA_REV_M>
<PHARMA_PROFIT_M>1.967875382</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.17916551</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Betabrex</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Betabrex.jpg</DRUG_IMG>
<REVENUE>4055112</REVENUE>
<PREV_YEAR_REV>0</PREV_YEAR_REV>
<BUDGET>3914703.04</BUDGET>
<GROSS_PROFIT>3151761.462</GROSS_PROFIT>
<EXPENSES>3680671.88</EXPENSES>
<NET_INCOME>574440.12</NET_INCOME>
<REVENUE_M>4.055112</REVENUE_M>
<PROFIT_M>3.151761462</PROFIT_M>
<INCOME_M>0.57444012</INCOME_M>
<PHARMA_REV_M>4.055112</PHARMA_REV_M>
<PHARMA_PROFIT_M>3.151761462</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>0.57444012</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
<G_1>
<YEAR>2012</YEAR>
<QUARTER>Q3</QUARTER>
<REGION>APAC</REGION>
<COUNTRY>Australia</COUNTRY>
<COUNTRY_IMG>/analyticsRes/mad/images/oow/Flag_Australia.jpg</COUNTRY_IMG>
<LINE_OF_BUSINESS>Pharmaceuticals</LINE_OF_BUSINESS>
<OPERATING_SEGMENT>Primary Care</OPERATING_SEGMENT>
<DRUG>Croloft</DRUG>
<DRUG_IMG>/analyticsRes/mad/images/oow/Drug_Croloft.jpg</DRUG_IMG>
<REVENUE>10055625</REVENUE>
<PREV_YEAR_REV>8815655.18</PREV_YEAR_REV>
<BUDGET>10171175</BUDGET>
<GROSS_PROFIT>8517253.5</GROSS_PROFIT>
<EXPENSES>9563115.63</EXPENSES>
<NET_INCOME>1492509.38</NET_INCOME>
<REVENUE_M>10.055625</REVENUE_M>
<PROFIT_M>8.5172535</PROFIT_M>
<INCOME_M>1.49250938</INCOME_M>
<PHARMA_REV_M>10.055625</PHARMA_REV_M>
<PHARMA_PROFIT_M>8.5172535</PHARMA_PROFIT_M>
<PHARMA_INCOME_M>1.49250938</PHARMA_INCOME_M>
<FRANCE_REV_M>0</FRANCE_REV_M>
<FRANCE_PROFIT_M>0</FRANCE_PROFIT_M>
<FRANCE_INCOME_M>0</FRANCE_INCOME_M>
</G_1>
</DATA_DS>
